Page last updated: 2024-11-05

ticlopidine and Myocardial Infarction

ticlopidine has been researched along with Myocardial Infarction in 1579 studies

Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.

Myocardial Infarction: NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).

Research Excerpts

ExcerptRelevanceReference
"Pre-treatment of clopidogrel 600 mg is better than 300 mg loading for reducing periprocedural myocardial infarction (PMI)."9.34Prospective partially randomized comparison of clopidogrel loading versus maintenance dosing to prevent periprocedural myocardial infarction after stenting for stable angina pectoris: Results from the "Method of Clopidogrel Pre-treatment Undergoing Conven ( Ahn, CM; Ahn, KJ; Choi, JW; Hong, SJ; Joo, HJ; Kim, JS; Lim, DS; Park, JH; Yu, CW, 2020)
" The trial was halted after 84% of the anticipated number of patients had been enrolled because the data and safety monitoring board had determined that the combination of clopidogrel and aspirin was associated with both a lower risk of major ischemic events and a higher risk of major hemorrhage than aspirin alone at 90 days."9.27Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. ( Barsan, W; Conwit, RA; Easton, JD; Elm, JJ; Farrant, M; Johnston, SC; Kim, AS; Lindblad, AS; Palesch, YY, 2018)
"This study aimed to compare the effects of ticagrelor and clopidogrel on early neointimal healing assessed with optical coherence tomography (OCT) after drug-eluting stent (DES) implantation in patients with acute myocardial infarction (AMI)."9.27Randomized Comparison of Strut Coverage between Ticagrelor and Clopidogrel in Acute Myocardial Infarction at 3-Month Optical Coherence Tomography. ( Ahn, CM; Choi, D; Hong, MK; Hong, SJ; Jang, Y; Kim, BK; Kim, C; Kim, JS; Ko, YG, 2018)
"A dual pathway antithrombotic therapy approach combining low-dose rivaroxaban with a P2Y12 inhibitor for the treatment of patients with acute coronary syndromes had similar risk of clinically significant bleeding as aspirin and a P2Y12 inhibitor."9.24Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. ( Ardissino, D; Bahit, MC; Bode, C; Bueno, H; Claeys, MJ; Cornel, JH; Gibson, CM; Goto, S; Güray, Ü; Husted, S; James, SK; Kiss, RG; Montalescot, G; Mundl, H; Nicolau, JC; Ohman, EM; Park, DW; Plotnikov, A; Povsic, TJ; Rockhold, F; Roe, MT; Steg, PG; Strony, J; Sun, X; Tendera, M; Welsh, RC; White, J, 2017)
"The purpose of this study was to investigate outcomes of patients treated with prasugrel or clopidogrel after percutaneous coronary intervention (PCI) in a nationwide acute coronary syndrome (ACS) registry."9.22Comparison of prasugrel and clopidogrel-treated patients with acute coronary syndrome undergoing percutaneous coronary intervention: A propensity score-matched analysis of the Acute Myocardial Infarction in Switzerland (AMIS)-Plus Registry. ( Bernheim, AM; Eberli, FR; Erne, P; Kurz, DJ; Pedrazzini, G; Radovanovic, D; Roffi, M; Seifert, B; Windecker, S, 2016)
"In CHAMPION PHOENIX, cangrelor reduced ischaemic events with no significant increase in GUSTO-defined severe bleeding."9.22The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX. ( Bhatt, DL; Blankenship, JC; Deliargyris, EN; Généreux, P; Gibson, CM; Gutierrez, JA; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD, 2016)
"Medically managed patients with ACS in the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trial were randomised to clopidogrel versus prasugrel (plus aspirin), stratified by prior clopidogrel use."9.22Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients. ( Armstrong, PW; Boden, WE; Chin, CT; Corbalán, R; Dalby, AJ; Fox, KA; Gottlieb, S; Leiva-Pons, JL; Neely, B; Neely, ML; Ohman, EM; Prabhakaran, D; Roe, MT; Schiele, F; White, HD; Winters, KJ, 2016)
"Ticagrelor reduced cardiovascular events compared with clopidogrel in PLATO without increasing overall major bleeding."9.22Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. ( Bansilal, S; Becker, RC; Cannon, CP; Harrington, RA; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lopes, RD; Neely, B; Shimada, YJ; Steg, PG; Storey, RF; Wallentin, L; Wiviott, SD, 2016)
"The CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention) trial demonstrated that cangrelor significantly reduced periprocedural ischemic events in all-comer percutaneous coronary intervention with a modest increase in mild and moderate bleeding."9.22Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial. ( Abnousi, F; Abtan, J; Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD, 2016)
"The Elderly-ACS 2 study is a multicenter, randomized, parallel-group, open-label trial designed to demonstrate the superiority of a strategy of dual antiplatelet treatment using a reduced 5-mg daily dose of prasugrel over a standard strategy with a daily clopidogrel dose of 75mg in patients older than 74years with ACS (either ST- or non-ST-elevation myocardial infarction) undergoing early percutaneous revascularization."9.22A comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization: Design and rationale of the randomized Elderly-ACS 2 study. ( Bossi, I; Cacucci, M; Cavallini, C; Corrada, E; De Servi, S; Di Ascenzo, L; Ferrario, M; Ferri, LA; Gandolfo, N; Grosseto, D; Mariani, M; Moffa, N; Morici, N; Petronio, AS; Ravera, A; Savonitto, S; Sganzerla, P; Sibilio, G; Tondi, S; Tortorella, G; Toso, A, 2016)
"PLATO (n = 18,624) was a multicentre, double-blind, randomized trial in ACS, that showed a 16% reduction in cardiovascular death (CV-death), myocardial infarction (MI) and stroke with ticagrelor compared with clopidogrel, without significant increase in overall major bleeding."9.20Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial. ( Becker, RC; Emanuelsson, H; Hiatt, WR; Horrow, J; Husted, S; James, SK; Mahaffey, KW; Patel, MR; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, DM, 2015)
"MULTIPRAC demonstrated a steady increase in prasugrel use over time without an increase in bleeding rates compared to clopidogrel."9.20MULTInational non-interventional study of patients with ST-segment elevation myocardial infarction treated with PRimary Angioplasty and Concomitant use of upstream antiplatelet therapy with prasugrel or clopidogrel--the European MULTIPRAC Registry. ( Clemmensen, P; Danchin, N; Goedicke, J; Goldstein, P; Grieco, N; Ince, H; Ramos, Y; Schmitt, J, 2015)
"This study compared the timing of onset of antiplatelet action after treatment with clopidogrel and prasugrel at first medical contact in patients with ST-segment elevation myocardial infarction (STEMI) scheduled for primary percutaneous coronary intervention (PPCI)."9.20Double-blind, randomized, prospective comparison of loading doses of 600 mg clopidogrel versus 60 mg prasugrel in patients with acute ST-segment elevation myocardial infarction scheduled for primary percutaneous intervention: the ETAMI trial (early thieno ( Arntz, HR; Diller, F; Mark, B; Mochmann, HC; Montalescot, G; Thiele, H; Zahn, R; Zeymer, U, 2015)
" In this context, we aimed to compare ticagrelor versus high dose clopidogrel in patients with ST-segment elevation myocardial infarction (STEMI) who exhibit HPR post fibrinolysis."9.20Ticagrelor versus high dose clopidogrel in ST-segment elevation myocardial infarction patients with high platelet reactivity post fibrinolysis. ( Akinosoglou, K; Alexopoulos, D; Barampoutis, N; Hahalis, G; Karvounis, H; Koniari, I; Panagiotidis, T; Patsilinakos, S; Perperis, A; Xanthopoulou, I; Ziakas, A, 2015)
"In the study, 96 patients suffering from acute ST segment elevation myocardial infarction onset within 12 h undergoing primary percutaneous coronary intervention from May to October in 2013 were randomly divided into ticagrelor group (n=48) and clopidogrel group (n=48) by using the method of random number table."9.20[Midterm follow-up outcomes of ticagrelor on acute ST segment elevation myocardial infarction undergoing emergency percutaneous coronary intervention]. ( Hu, SD; Qu, Y; Xia, JG; Xu, D; Xu, J; Yin, CL, 2015)
" Direct comparison of the antiplatelet effects between ticagrelor and high-dose clopidogrel has not yet been reported in acute myocardial infarction (AMI) or coronary artery in-stent restenosis (ISR) patients with HTPR."9.20Ticagrelor overcomes high platelet reactivity in patients with acute myocardial infarction or coronary artery in-stent restenosis: a randomized controlled trial. ( Cao, A; Chen, T; Li, P; Liu, J; Liu, Y; Ma, L; Qin, Y; Wang, Z; Yang, Y; Zhao, X, 2015)
"Few data on the relative efficacy and safety of new P2Y12inhibitors such as prasugrel and ticagrelor in Japanese, Taiwanese and South Korean patients with acute coronary syndromes (ACS) exist."9.20Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome -- randomized, double-blind, phase III PHILO study. ( Emanuelsson, H; Goto, S; Huang, CH; Kimura, T; Park, SJ, 2015)
"This study aimed to compare preoperative treatment using clopidogrel and ticagrelor for patients with acute myocardial infarction (AMI) undergoing emergent percutaneous coronary intervention (PCI), and to investigate the efficacy and safety of these medications in the management of AMI."9.20Pre-PCI medication using clopidogrel and ticagrelor in the treatment of patients with acute myocardial infarction. ( Fu, Q; Huang, YJ; Zhang, N; Zhang, Q; Zhu, K, 2015)
" Using inverse probability-weighted propensity modeling, we compared 6-month adjusted risks of Bleeding Academic Research Consortium (BARC) bleeding, stratifying by whether or not bleeding was associated with rehospitalization among patients discharged on aspirin + anticoagulant + clopidogrel (triple-C), aspirin + anticoagulant + prasugrel (triple-P), aspirin + clopidogrel (dual-C), or aspirin + prasugrel (dual-P)."9.20Outcomes of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy: A Comparison of Clopidogrel Versus Prasugrel From the TRANSLATE-ACS Study. ( Baker, BA; Cohen, DJ; Effron, M; Jackson, LR; Ju, C; Messenger, JC; Peterson, ED; Stone, GW; Wang, TY; Zettler, M, 2015)
"The goal of this study was to determine whether there is a relationship between aspirin dose and the potent antiplatelet agent prasugrel in the TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) study."9.19Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibit ( Antman, EM; Braunwald, E; Cannon, CP; Kohli, P; Murphy, SA; Udell, JA; Wiviott, SD, 2014)
"Prasugrel is more potent than clopidogrel, but it is not known whether this translates into clinical benefit in patients undergoing primary percutaneous coronary intervention (PCI) with bivalirudin for ST elevation myocardial infarction."9.19Outcomes in patients with ST-segment elevation acute myocardial infarction treated with clopidogrel versus prasugrel (from the INFUSE-AMI trial). ( Brener, SJ; El-Omar, M; Gibson, CM; Maehara, A; Mehran, R; Oldroyd, KG; Stone, GW; Witzenbichler, B; Xu, K, 2014)
"The aim of this study was to assess the relationship between sex and clinical outcomes and treatment-related complications in patients with ST-elevation or non-ST-elevation acute coronary syndromes (ACS) randomized to treatment with ticagrelor or clopidogrel in the PLATelet inhibition and patient Outcomes (PLATO) trial."9.19The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial. ( Bach, RG; Becker, RC; Budaj, A; Heras, M; Himmelmann, A; Horrow, J; Husted, S; James, SK; Katus, HA; Lassila, R; Morais, J; Nicolau, JC; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, D, 2014)
" clopidogrel in the non-ST-elevation acute coronary syndrome (NSTE-ACS) subgroup of the PLATO trial, in the total cohort, and in the subgroups managed with and without revascularization within 10 days of randomization."9.19Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. ( Cannon, CP; Cornel, JH; Harrington, RA; Himmelmann, A; Husted, S; James, SK; Lindholm, D; Maya, J; Steg, PG; Stevens, SR; Storey, RF; Varenhorst, C; Wallentin, L, 2014)
"Whether prasugrel plus bivalirudin is a superior strategy to unfractionated heparin plus clopidogrel in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) has never been assessed in specifically designed randomized trials."9.19Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction. ( Abdel-Wahab, M; Anette Fiedler, K; Gershlick, AH; Hoppmann, P; Ibrahim, T; Kastrati, A; Kufner, S; Laugwitz, KL; Mehilli, J; Mehran, R; Morath, T; Neudecker, J; Richardt, G; Schneider, S; Schulz, S; Schunkert, H; Tölg, R, 2014)
"In the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38), prasugrel reduced the primary ischaemic endpoint as compared with clopidogrel in acute coronary syndrome (ACS) patients planned to undergo percutaneous coronary interventions, but increased the risk of bleeding."9.19Clinical outcomes for prasugrel versus clopidogrel in patients with unstable angina or non-ST-elevation myocardial infarction: an analysis from the TRITON-TIMI 38 trial. ( De Servi, S; Goedicke, J; Schirmer, A; Widimsky, P, 2014)
"This study sought to evaluate the efficacy of prasugrel versus clopidogrel in ST-segment elevation myocardial infarction (STEMI) by the timing of percutaneous coronary intervention (PCI)."9.19Prasugrel versus clopidogrel in patients with ST-segment elevation myocardial infarction according to timing of percutaneous coronary intervention: a TRITON-TIMI 38 subgroup analysis (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Plate ( Antman, EM; Braunwald, E; Montalescot, G; Murphy, SA; Udell, JA; Wiviott, SD, 2014)
"The direct-acting platelet P2Y12 receptor antagonist ticagrelor can reduce the incidence of major adverse cardiovascular events when administered at hospital admission to patients with ST-segment elevation myocardial infarction (STEMI)."9.19Prehospital ticagrelor in ST-segment elevation myocardial infarction. ( Baradat, C; Bolognese, L; Cantor, WJ; Cequier, A; Chettibi, M; Collet, JP; Ecollan, P; Goodman, SG; Hamm, CW; Hammett, CJ; Heutz, WM; Huber, K; Janzon, M; Lapostolle, F; Lassen, JF; Licour, M; Merkely, B; Montalescot, G; Silvain, J; Stibbe, O; Storey, RF; Swahn, E; Tsatsaris, A; van 't Hof, AW; Vicaut, E; Willems, FF; Zeymer, U, 2014)
"This study sought to investigate the relationship of polymorphisms in ABCB1 and the predictive value of thromboelastography (TEG) on bleeding risk in clopidogrel-treated patients with ST-elevation myocardial infarction (STEMI)."9.19Relationship between ABCB1 polymorphisms, thromboelastography and risk of bleeding events in clopidogrel-treated patients with ST-elevation myocardial infarction. ( Chen, J; Gao, RL; Gao, Z; Ma, YL; Meng, XM; Song, L; Tang, XF; Wang, J; Wu, Y; Xu, B; Yao, Y; Yuan, JQ; Zhang, JH; Zhang, Y, 2014)
"To detect residual platelet aggregation following the switch from generic (GC) to brand clopidogrel (BC) in male patients after ST-elevated myocardial infarction (STEMI)."9.19Switching from generic to brand clopidogrel in male patients after ST-elevated myocardial infarction. ( Franskavichene, LV; Golukhova, EZ; Serebruany, VL; Syvolap, VV, 2014)
"We observed no interaction between vorapaxar and clopidogrel after non-ST-segment elevation acute coronary syndromes on efficacy or safety outcomes, supporting a complementary role of protease-activated receptor 1 and P2Y12 antagonism."9.19Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial. ( Armstrong, PW; Aylward, PE; Chen, E; Cornel, JH; Harrington, RA; Held, C; Huang, Z; Jennings, LK; Lokhnygina, Y; Mahaffey, KW; Moliterno, DJ; Strony, J; Tricoci, P; Van de Werf, F; Wallentin, L; White, HD, 2014)
"Clopidogrel is recommended in patients with acute coronary syndrome (ACS) managed with PCI, but its effect on PCI-related myonecrosis in contemporary patients has not been quantified."9.17Quantification of the effect of clopidogrel on enzymatic infarct size related to a percutaneous coronary intervention in patients with acute coronary syndromes: insights from the CHAMPION percutaneous coronary intervention trial. ( Bhatt, DL; Dauerman, HL; Gibson, CM; Goodman, SG; Gruberg, L; Herrmann, HC; Leonardi, S; Lincoff, AM; Lokhnygina, Y; Lopes, RD; Mahaffey, KW; McLaurin, BT; Parikh, KH; Stebbins, A; Stone, GW; Todd, M; White, HD, 2013)
"Patients with a recently diagnosed ST-elevation myocardial infarction (STEMI) and implanted coronary drug-eluting stent (DES) who need urgent surgery are at increased risk of surgical bleeding unless aspirin and clopidogrel are discontinued beforehand."9.17Short-term follow-up of tirofiban as alternative therapy for urgent surgery patients with an implanted coronary drug-eluting stent after ST-elevation myocardial infarction. ( Liu, XH; Qu, Y; Shen, H; Xia, JG, 2013)
"Among patients who had angiography who took prasugrel there were fewer cardiovascular deaths, myocardial infarctions, or strokes than in those who took clopidogrel."9.17Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial. ( Armstrong, PW; Bhatt, DL; Boden, WE; Clemmensen, P; Fox, KA; Hafley, G; Hamm, C; Leiva-Pons, J; Lokhnygina, Y; Menozzi, A; Nicolau, JC; Ohman, EM; Oto, A; Pavlides, G; Prabhakaran, D; Roe, MT; Ruzyllo, W; White, HD; Widimsky, P; Winters, KJ; Wiviott, SD, 2013)
" clopidogrel in patients with acute coronary syndromes (ACS) are well documented in the PLATelet inhibition and patient Outcomes trial (PLATO)."9.17Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study. ( Hauch, O; Henriksson, M; Janzon, M; Nikolic, E; Wallentin, L, 2013)
"The aim of this subanalysis was to assess the net clinical effect of prehospital administration of tirofiban in ST-elevation myocardial infarction (STEMI) patients with high risk of bleeding."9.16Net clinical benefit of prehospital glycoprotein IIb/IIIa inhibitors in patients with ST-elevation myocardial infarction and high risk of bleeding: effect of tirofiban in patients at high risk of bleeding using CRUSADE bleeding score. ( Dambrink, JH; Gosselink, AT; Hamm, C; Hermanides, RS; Ottervanger, JP; Stella, PR; ten Berg, JM; van 't Hof, AW; van Houwelingen, G, 2012)
"The authors sought to compare the effect on inhibition of platelet aggregation (IPA) of prasugrel therapy versus tirofiban bolus with or without a post-bolus short drug infusion in ST-segment elevation myocardial infarction (STEMI) patients."9.16Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOppin ( Bristot, L; Campo, G; Ferrari, R; Gambetti, S; Monti, M; Parrinello, G; Tebaldi, M; Valgimigli, M, 2012)
"We evaluated treatment effects of ticagrelor versus clopidogrel in patients with acute coronary syndrome with and without a history of prior stroke or TIA in the PLATelet inhibition and patient Outcomes (PLATO) trial."9.16Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack. ( Becker, RC; Husted, S; James, SK; Keltai, M; Khurmi, NS; Lopes, RD; Lopez-Sendon, JL; Mahaffey, KW; Maya, J; Morais, J; Nicolau, JC; Pais, P; Raev, D; Stevens, SR; Storey, RF, 2012)
"The ISAR-REACT 4 (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment-4) platelet substudy aimed to determine the relevance of high on-clopidogrel treatment platelet reactivity (HPR) in non-ST-segment elevation myocardial infarction patients that received abciximab with unfractionated heparin (UFH) or bivalirudin during percutaneous coronary intervention (PCI)."9.16Prognostic value of a high on-clopidogrel treatment platelet reactivity in bivalirudin versus abciximab treated non-ST-segment elevation myocardial infarction patients. ISAR-REACT 4 (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action fo ( Bernlochner, I; Kastrati, A; Massberg, S; Mehilli, J; Schömig, A; Schulz, S; Sibbing, D, 2012)
"It remains unclear whether concomitant use of omeprazole attenuates platelet function as compared with that of famotidine in patients with acute coronary syndromes (ACS) who receive clopidogrel."9.16Influence of omeprazole and famotidine on the antiplatelet effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes: a prospective, randomized, multicenter study. ( Endo, T; Fukui, K; Hibi, K; Himeno, H; Kimura, K; Morita, S; Sugano, T; Tsukahara, K; Umemura, S; Yano, H, 2012)
"Among patients with unstable angina or myocardial infarction without ST-segment elevation, prasugrel did not significantly reduce the frequency of the primary end point, as compared with clopidogrel, and similar risks of bleeding were observed."9.16Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. ( Ardissino, D; Armstrong, PW; Aylward, PE; Bhatt, DL; Boden, WE; Brown, EB; Cinteză, M; Clemmensen, P; Corbalan, R; Cornel, JH; Dalby, AJ; Fox, KA; Gasparovic, V; Goodman, SG; Gottlieb, S; Goudev, AR; Gurbel, PA; Hamm, C; Hochman, JS; Huber, K; Leiva-Pons, JL; Lokhnygina, Y; Martinez, F; McGuire, DK; McLendon, RC; Merkely, B; Nicolau, JC; Ohman, EM; Oto, A; Parkhomenko, A; Pavlides, G; Prabhakaran, D; Roe, MT; Ruzyllo, W; Topacio, GO; Tseng, CD; White, HD; Winters, KJ, 2012)
"There is a paucity of data regarding the early effectiveness of the proposed 600 mg clopidogrel loading dose (LD) on platelet reactivity (PR) in ST elevation myocardial infarction (STEMI) patients."9.16Prasugrel versus high dose clopidogrel to overcome early high on clopidogrel platelet reactivity in patients with ST elevation myocardial infarction. ( Alexopoulos, D; Athanassiadou, A; Damelou, A; Davlouros, P; Hahalis, G; Kassimis, G; Stavrou, EF; Theodoropoulos, KC; Tsigkas, G; Xanthopoulou, I, 2012)
"The optimal loading dose of clopidogrel in patients with chronic kidney disease who undergo primary percutaneous coronary intervention for ST-segment elevation myocardial infarction has not been investigated."9.16Impact of Clopidogrel loading dose in patients with chronic kidney disease undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. ( Ahn, YK; Chae, IH; Chae, SC; Cho, MC; Hong, TJ; Hur, SH; Jang, YS; Jeong, MH; Kim, JY; Kim, YJ; Moon, JH; Park, SJ; Seong, IW; Seung, KB; Yoon, JH, 2012)
"In this prospective, randomized trial in patients with acute myocardial infarction (AMI) admitted for primary percutaneous coronary intervention (PPCI), loaded with 600 mg clopidogrel, we hypothesized that eptifibatide administered downstream of the coronary occlusion leads to a lower degree of microvascular obstruction compared with no additional eptifibatide."9.16Microvascular effect of intracoronary eptifibatide in acute myocardial infarction. ( Bondor, CI; Cadiş, H; Iancu, A; Ober, C, 2012)
" Patients with an episode of noncardioembolic ischemic stroke at least 8 days prior to randomization, who were aged <75 years or had a body weight >50 kg were randomized to 50 or 75 mg clopidogrel once daily for 52 weeks."9.16Clopidogrel two doses comparative 1-year assessment of safety and efficacy (COMPASS) study in Japanese patients with ischemic stroke. ( Minematsu, K; Tanahashi, N; Uchiyama, S, 2012)
"In this randomized crossover study analyzing patients after acute myocardial infarction, omeprazole coadministration showed a significant pharmacodynamic interaction with clopidogrel, whereas pantoprazole did not."9.15Omeprazole, but not pantoprazole, reduces the antiplatelet effect of clopidogrel: a randomized clinical crossover trial in patients after myocardial infarction evaluating the clopidogrel-PPIs drug interaction. ( Albuquerque, A; Araújo, C; Fontes-Carvalho, R; Pimentel-Nunes, P; Ribeiro, VG, 2011)
"The aim of this study was to assess the degree of platelet inhibition by adjunctive cilostazol in patients with acute myocardial infarction (AMI) according to hepatic cytochrome P450 2C19 (CYP2C19) genotype."9.15Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype. ( Hwang, JY; Hwang, SJ; Jeong, YH; Kim, IS; Kim, S; Koh, EH; Kwak, CH; Park, JR; Park, KS; Park, Y; Yun, SE, 2011)
"After an acute coronary syndrome, patients remain at risk of recurrent ischaemic events, despite contemporary treatment, including aspirin and clopidogrel."9.15Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. ( Budaj, A; Granger, CB; Khder, Y; Oldgren, J; Roberts, J; Siegbahn, A; Tijssen, JG; Van de Werf, F; Wallentin, L, 2011)
"Residual platelet reactivity (RPR) after clopidogrel loading, measured by the VerifyNow assay, has been shown to predict 12-month clinical events in patients with acute coronary syndromes."9.15Residual platelet reactivity after clopidogrel loading in patients with ST-elevation myocardial infarction undergoing an unexpectedly delayed primary percutaneous coronary intervention. - Impact on intracoronary thrombus burden and myocardial perfusion-. ( Archontakis, S; Gafou, A; Kalogeras, KI; Kariori, MG; Moldovan, C; Papaioannou, TG; Stefanadis, C; Tzamalis, P; Vavuranakis, M; Vrachatis, DA, 2011)
" On-clopidogrel platelet reactivity was investigated in patients with previous angiographically confirmed STh, myocardial infarction (MI), and controls."9.15Relationship between clopidogrel-induced platelet P2Y12 inhibition and stent thrombosis or myocardial infarction after percutaneous coronary intervention-a case-control study. ( Erlinge, D; James, S; Koul, S; Lagerqvist, B; Siegbahn, A; Varenhorst, C; Wallentin, L, 2011)
"The purpose of this study was to compare 600- and 300-mg clopidogrel loading doses in patients with ST-segment elevation myocardial infarction (STEMI)."9.15Outcome comparison of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results from the ARMYDA-6 MI (Antiplatelet therapy for Reduction of MYocar ( Barbato, E; Bárczi, G; Colonna, G; Di Sciascio, G; Edes, I; Mangiacapra, F; Merkely, B; Orlic, D; Ostojic, M; Pasceri, V; Patti, G; Wijns, W, 2011)
"Adding clopidogrel to aspirin therapy reduces stroke in patients with atrial fibrillation (AF) but increases hemorrhage."9.15Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable. ( Connolly, SJ; de Caterina, R; Eikelboom, JW; Hart, RG; Hirsh, J; Hohnloser, S; Ng, J; Pogue, J; Yusuf, S, 2011)
"In this large observational analysis of patients undergoing PCI, low-dose aspirin appeared to be as effective as higher doses in preventing ischaemic events but was also associated with a lower rate of major bleeding and an improved net efficacy to safety balance."9.14Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study. ( Avezum, A; Fox, KA; Gersh, BJ; Haladyn, K; Jolly, SS; Mehta, SR; Peters, RJ; Pogue, J; Rupprecht, HJ; Yusuf, S, 2009)
"Between April 1, 1996, and April 1, 2008, 259 young patients (aged <45 years) who survived a first myocardial infarction and were exposed to clopidogrel treatment for at least a month, were enrolled in a multicentre registry and underwent CYP2C19*2 determination."9.14Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. ( Bensimon, G; Beygui, F; Brugier, D; Cayla, G; Collet, JP; Esteve, JB; Funck-Brentano, C; Hulot, JS; Montalescot, G; Payot, L; Pena, A; Silvain, J; Villard, E, 2009)
"Mechanical reperfusion with stenting for ST-elevation myocardial infarction (STEMI) is supported by dual antiplatelet treatment with aspirin and clopidogrel."9.14Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. ( Antman, EM; Braunwald, E; Gibson, CM; McCabe, CH; Montalescot, G; Murphy, SA; Wiviott, SD, 2009)
"Two Phase III studies comparing the safety and efficacy of clopidogrel with ticlopidine as antiplatelet agents for the secondary prevention of vascular events in patients with prior stroke were performed in Japan."9.14The safety and efficacy of clopidogrel versus ticlopidine in Japanese stroke patients: combined results of two Phase III, multicenter, randomized clinical trials. ( Fukuuchi, Y; Uchiyama, S; Yamaguchi, T, 2009)
"A total of 800 patients with acute ST-segment-elevation myocardial infarction within 24 hours from symptom onset, all treated with 600 mg clopidogrel, were randomly assigned in a double-blind fashion to receive either abciximab (n=401) or placebo (n=399) in the intensive care unit before being sent to the catheterization laboratory."9.14Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial. ( Dirschinger, J; Dotzer, F; Früngel, S; Huber, K; Kastrati, A; Martinoff, S; Mehilli, J; Moshage, W; Nekolla, SG; Pache, J; Schömig, A; Schulz, S; Schwaiger, M; Seyfarth, M, 2009)
"Vitamin K antagonists reduce the risk of stroke in patients with atrial fibrillation but are considered unsuitable in many patients, who usually receive aspirin instead."9.14Effect of clopidogrel added to aspirin in patients with atrial fibrillation. ( Chrolavicius, S; Connolly, SJ; Hart, RG; Hohnloser, SH; Pfeffer, M; Pogue, J; Yusuf, S, 2009)
"Prasugrel is a novel thienopyridine that reduces new or recurrent myocardial infarctions (MIs) compared with clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention."9.14Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardi ( Antman, EM; Bonaca, MP; Bramucci, E; Braunwald, E; McCabe, CH; Morrow, DA; Murphy, SA; Nicolau, JC; Ruff, CT; Scirica, BM; White, HD; Wiviott, SD, 2009)
"The antiplatelet effect of standard or increased clopidogrel doses in patients with ST- segment elevation acute myocardial infarction (STEMI) has never been studied."9.14A randomised study comparing the antiplatelet and antiinflammatory effect of clopidogrel 150 mg/day versus 75 mg/day in patients with ST-segment elevation acute myocardial infarction and poor responsiveness to clopidogrel: results from the DOUBLE study. ( Alessi, L; Barozzi, C; Bassi, M; Branzi, A; De Servi, S; Lauria, G; Marzocchi, A; Ortolani, P; Palmerini, T; Reggiani, LB; Sangiorgi, D; Tomasi, L, 2010)
"The aim of this analysis was to evaluate whether routine pre-hospital administration of high-dose tirofiban in ST-segment elevation myocardial infarction (STEMI) decreases the incidence of early stent thrombosis after primary PCI."9.14Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction. ( De Boer, MJ; Dill, T; Gosselink, AT; Hamm, C; Heestermans, AA; Hoorntje, JC; Koopmans, PC; Ten Berg, JM; Van 't Hof, AW; Van Houwelingen, G; Van Werkum, JW, 2009)
"In patients who have an acute coronary syndrome with or without ST-segment elevation, treatment with ticagrelor as compared with clopidogrel significantly reduced the rate of death from vascular causes, myocardial infarction, or stroke without an increase in the rate of overall major bleeding but with an increase in the rate of non-procedure-related bleeding."9.14Ticagrelor versus clopidogrel in patients with acute coronary syndromes. ( Becker, RC; Budaj, A; Cannon, CP; Emanuelsson, H; Freij, A; Harrington, RA; Held, C; Horrow, J; Husted, S; James, S; Katus, H; Mahaffey, KW; Scirica, BM; Skene, A; Steg, PG; Storey, RF; Thorsén, M; Wallentin, L, 2009)
"Our aim was to determine whether a 600-mg loading dose of clopidogrel compared with 300 mg results in improved clinical outcomes in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI)."9.14Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: results from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. ( Aoki, J; Brodie, BR; Caixeta, A; Dangas, G; Dudek, D; Guagliumi, G; Kornowski, R; Mehran, R; Parise, H; Peruga, JZ; Rabbani, LE; Stone, GW; Witzenbichler, B, 2009)
"We randomly assigned a total of 400 patients with ST-segment elevation myocardial infarction referred for primary percutaneous coronary intervention to treatment initiated before cardiac catheterization, with either heparin plus eptifibatide (201 patients) or heparin alone (199 patients), in addition to oral aspirin (160 mg) and high-dose clopidogrel (600 mg)."9.14Primary percutaneous coronary angioplasty with and without eptifibatide in ST-segment elevation myocardial infarction: a safety and efficacy study of integrilin-facilitated versus primary percutaneous coronary intervention in ST-segment elevation myocardi ( Froeschl, M; Glover, CA; Jadhav, S; Kass, M; Labinaz, M; Le May, MR; Marquis, JF; O'Brien, ER; So, DY; Thomas, A; Turek, M; Wells, GA, 2009)
"In the current era of early revascularization and routine use of dual antiplatelet therapy, the incremental benefit of warfarin to reduce the incidence of left ventricular thrombus (LVT) in patients with impaired left ventricular ejection fraction post anterior ST-elevation myocardial infarction (aSTEMI), remains uncertain."9.14Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial. ( Ahmad, M; Eikelboom, JW; Natarajan, MK; Salehian, O; Schwalm, JD, 2010)
"This study sought to determine the efficacy of high-dose atorvastatin in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI)."9.14Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial. ( Cho, DK; Cho, JR; Cho, YH; Choi, D; Hong, MK; Jang, Y; Jeon, DW; Kim, BK; Kim, J; Kim, JS; Ko, YG; Lee, CJ; Lee, NH; Lee, SH; Oh, SJ; Yang, JY, 2010)
"ST-segment elevation myocardial infarction patients undergoing primary PCI in a regional STEMI network who received earlier pretreatment with a 600-mg loading dose of clopidogrel had less ischemic complications without increased bleeding or mortality."9.14Clopidogrel pretreatment in ST-elevation myocardial infarction patients transferred for percutaneous coronary intervention. ( Burke, MN; Duval, S; Henry, TD; Larson, DM; Lips, DL; Sharkey, SS; Solie, C; Steinhubl, S; Tschautscher, C, 2010)
"In patients with an acute coronary syndrome who were referred for an invasive strategy, there was no significant difference between a 7-day, double-dose clopidogrel regimen and the standard-dose regimen, or between higher-dose aspirin and lower-dose aspirin, with respect to the primary outcome of cardiovascular death, myocardial infarction, or stroke."9.14Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. ( Afzal, R; Bassand, JP; Chrolavicius, S; Diaz, R; Eikelboom, JW; Fox, KA; Granger, CB; Jolly, S; Joyner, CD; Mehta, SR; Pogue, J; Rupprecht, HJ; Widimsky, P; Yusuf, S, 2010)
"In the TRITON-TIMI 38 trial, greater platelet inhibition with prasugrel reduced the first occurrence of the primary endpoint (cardiovascular death, MI, or stroke) compared with clopidogrel in patients with an acute coronary syndrome (ACS) undergoing planned percutaneous coronary intervention."9.13Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. ( Antman, EM; Braunwald, E; Huber, K; Lopez-Sendon, J; McCabe, CH; Morocutti, G; Murphy, SA; Weerakkody, G; Wiviott, SD, 2008)
"The trial did not meet the predefined criteria for noninferiority but showed similar rates of recurrent stroke with ASA-ERDP and with clopidogrel."9.13Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. ( Albers, GW; Bath, P; Bornstein, N; Chan, BP; Chen, ST; Cotton, D; Cunha, L; Dahlöf, B; De Keyser, J; Diener, HC; Donnan, GA; Estol, C; Gorelick, P; Gu, V; Hermansson, K; Hilbrich, L; Kaste, M; Lawton, WA; Lu, C; Machnig, T; Martin, RH; Ounpuu, S; Pais, P; Palesch, Y; Roberts, R; Sacco, RL; Skvortsova, V; Teal, P; Toni, D; Vandermaelen, C; Voigt, T; Weber, M; Yoon, BW; Yusuf, S, 2008)
" Among a high-risk NSTEMI population not undergoing PCI within 24 hours of arrival, the nonrandomized short-term use of clopidogrel is associated with a lower risk of inhospital mortality without an increased risk of major bleeding."9.13Use of and inhospital outcomes after early clopidogrel therapy in patients not undergoing an early invasive strategy for treatment of non-ST-segment elevation myocardial infarction: results from Can Rapid risk stratification of Unstable angina patients Su ( Alexander, D; Brown, DL; Cannon, CP; Fintel, DJ; Gibler, WB; Ohman, EM; Ou, FS; Peterson, ED; Pollack, CV; Roe, MT, 2008)
"Antiplatelet therapy with clopidogrel and acetylsalicylic acid (ASA) reduces major cardiovascular events in patients with ST and non-ST-segment-elevation acute coronary syndromes (ACS)."9.13Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. ( Bassand, JP; Chrolavicius, S; Diaz, R; Fox, KA; Granger, CB; Jolly, S; Mehta, SR; Rupprecht, HJ; Widimsky, P; Yusuf, S, 2008)
"This post-hoc analysis suggests that in acute coronary syndrome patients, as long as clopidogrel is administered before or within 30 min of PCI treatment with bivalirudin alone is similarly effective to heparin plus a GP IIb/IIIa inhibitor in suppressing 30-day ischemic events with significantly less bleeding."9.13Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and U ( Bertrand, ME; Chew, D; Cox, DA; Desmet, W; Feit, F; Lincoff, AM; Manoukian, SV; Mehran, R; Ohman, EM; Pollack, CV; Steinhubl, SR; Stone, GW; Ware, JH, 2008)
"The purpose of this study was to evaluate the effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention (PCI) with glycoprotein (GP) IIb/IIIa blockade."9.13The effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention: a BRIEF-PCI (Brief Infusion of Intravenous Eptifibatide Following Successful Percutaneous Coronary Intervention) trial substudy. ( Buller, C; Densem, C; Fox, R; Fung, A; Jokhi, P; Mancini, GB; Ricci, D; Saw, J; Starovoytov, A; Walsh, S; Wong, G, 2008)
"The aim of this study is to investigate whether the benefit of abciximab in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACSs) undergoing percutaneous coronary intervention (PCI) after pre-treatment with 600 mg clopidogrel is sustained at 1 year."9.13One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: results of the ISAR-REACT 2 randomized trial. ( Berger, PB; Bruskina, O; Dirschinger, J; Dotzer, F; Kastrati, A; Mehilli, J; Ndrepepa, G; Neumann, FJ; Pache, J; Schömig, A; Seyfarth, M; ten Berg, J, 2008)
"To investigate the association between neutrophil count, outcomes, and benefit of clopidogrel therapy in ST-elevation myocardial infarction (STEMI)."9.13Association between baseline neutrophil count, clopidogrel therapy, and clinical and angiographic outcomes in patients with ST-elevation myocardial infarction receiving fibrinolytic therapy. ( Cannon, CP; Gibson, CM; Guo, W; Morrow, DA; Murphy, SA; O'Donoghue, M; Sabatine, MS, 2008)
" Whether the addition of intravenous tirofiban during this procedure produces further benefit has not been clarified in ST segment elevation myocardial infarction (STEMI) patients."9.13Effect of tirofiban plus clopidogrel and aspirin on primary percutaneous coronary intervention via transradial approach in patients with acute myocardial infarction. ( Fan, WZ; Fu, XH; Geng, W; Gu, XS; Hao, GZ; Hao, QQ; Jia, XW; Jiang, YF; Li, SQ; Wu, WL, 2008)
"The CLARITY-TIMI 28 (Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction 28) trial randomized 3,491 patients with ST-segment elevation myocardial infarction (STEMI) undergoing fibrinolysis to clopidogrel versus placebo."9.12The role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST-segment elevation myocardial infarction: the ECG CLARITY-TIMI 28 Study. ( Braunwald, E; Cannon, CP; Gibson, CM; Giugliano, RP; McCabe, CH; Morrow, DA; Murphy, SA; Sabatine, MS; Scirica, BM; Wiviott, SD, 2006)
"Efficacy of clopidogrel in acute myocardial infarction (AMI) was studied only in two trials."9.12[Effectiveness and safety of clopidogrel bisulfate in complex therapy of patients with acute coronary syndrome with ST segment elevation]. ( Giliarov, MIu; Malova, EV; Novikova, NA; Sulimov, VA; Syrkin, AL, 2006)
" Approximately 13,000 patients with moderate to high-risk ACS undergoing PCI (9500 unstable angina/non-ST-segment elevation myocardial infarction [MI], 3500 ST-segment elevation MI) will be randomized to prasugrel 60 mg loading dose followed by 10 mg daily or clopidogrel 300 mg loading dose followed by 75 mg daily for up to 15 months."9.12Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infar ( Antman, EM; Braunwald, E; Gibson, CM; McCabe, CH; Montalescot, G; Riesmeyer, J; Warmke, JW; Weerakkody, G; Winters, KJ; Wiviott, SD, 2006)
"Aspirin resistance may increase the risk of major adverse cardiac events (MACE) more than threefold in patients with stable coronary artery disease (CAD)."9.12Clinical relevance of aspirin resistance in patients with stable coronary artery disease: a prospective follow-up study (PROSPECTAR). ( Mercanoglu, F; Meric, M; Nisanci, Y; Oflaz, H; Oncul, A; Onur, I; Ozcan, M; Pamukcu, B; Umman, B, 2007)
"The Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction 28 (CLARITY-TIMI 28) trial was a randomized, double-blind, placebo-controlled study of clopidogrel in 3,491 patients receiving fibrinolytic therapy for ST-segment elevation myocardial infarction."9.12Benefits and risks of clopidogrel pretreatment before coronary artery bypass grafting in patients with ST-elevation myocardial infarction treated with fibrinolytics in CLARITY-TIMI 28. ( Cannon, CP; Guo, W; McCabe, CH; McLean, DS; Sabatine, MS, 2007)
"Sirolimus-eluting stents (SESs) recently proved to be superior to bare metal stents (BMSs) in decreasing the need for repeat revascularization in patients with ST-segment elevation myocardial infarction (STEMI) at 1 year."9.12Comparison of three-year clinical outcome of sirolimus- and paclitaxel-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction (from the RESEARCH and T-SEARCH Registries). ( Daemen, J; de Jaegere, PP; García-García, HM; Kukreja, N; Serruys, PW; Sianos, G; Tanimoto, S; van de Sande, M; van Domburg, RT, 2007)
" The aim of the study was to assess the impact of clopidogrel on safety and efficacy in patients with renal dysfunction in non-ST elevation acute coronary syndromes."9.12Renal function and outcomes in acute coronary syndrome: impact of clopidogrel. ( Hawken, S; Keltai, M; Lewis, BS; Mann, JF; Mehta, SR; Sitkei, E; Tonelli, M; Yusuf, S, 2007)
"The purpose of this study was to determine the efficacy and safety of enoxaparin (ENOX) versus unfractionated heparin (UFH) in patients with ST-segment elevation myocardial infarction (STEMI) receiving fibrinolytic therapy with and without clopidogrel."9.12Efficacy and safety of enoxaparin versus unfractionated heparin in patients with ST-segment elevation myocardial infarction also treated with clopidogrel. ( Antman, EM; Braunwald, E; Dalby, A; Duris, T; Gao, R; Lopez-Sendon, J; Morrow, DA; Murphy, SA; Pfisterer, M; Sabatine, MS, 2007)
" clopidogRel in non-ST-segment Elevation myocardial infarction)-2, we compared the antiplatelet effects of AZD6140 and clopidogrel and assessed the effects of AZD6140 in clopidogrel-pretreated patients."9.12Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. ( Cannon, CP; Emanuelsson, H; Grande, P; Gurbel, P; Harrington, RA; Heptinstall, S; Husted, S; Peters, G; Storey, RF; Wickens, M; Wilcox, RG, 2007)
"Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous coronary intervention."9.12Prasugrel versus clopidogrel in patients with acute coronary syndromes. ( Antman, EM; Ardissino, D; Braunwald, E; De Servi, S; Gibson, CM; Gottlieb, S; McCabe, CH; Montalescot, G; Murphy, SA; Neumann, FJ; Riesmeyer, J; Ruzyllo, W; Weerakkody, G; Wiviott, SD, 2007)
"The present study hypothesis was that eptifibatide offered further antiplatelet efficacy above clopidogrel in non-ST-elevation myocardial infarction (NSTEMI) patients before an expeditive coronary intervention."9.11Eptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel. Results of the platelet activity extinction in non-Q-wave myocardial infarction with aspirin, clopidogrel ( Bal dit Sollier, C; Choussat, R; Collet, JP; Dalby, M; Drobinski, G; Drouet, L; Gallois, V; Montalescot, G; Soulat, T; Thomas, D; Vicaut, E, 2004)
" The aim of the current study was to compare ticlopidine and clopidogrel in a consecutive series of patients with ST-segment elevation myocardial infarction (STEMI) treated with primary stenting."9.11Comparison between ticlopidine and clopidogrel in patients with ST-segment elevation myocardial infarction treated with coronary stenting. ( Dambrink, JH; de Boer, MJ; De Luca, G; Gosselink, AT; Hoorntje, JC; Ottervanger, JP; Suryapranata, H; van 't Hof, AW; Zijlstra, F, 2004)
"To examine efficacy of clopidogrel before thrombolytic therapy (TLT) in patients with acute myocardial infarction (AMI)."9.11[First experience of clopidogrel application in the treatment of acute myocardial infarction with ST-elevation]. ( Akinina, SA; Petrik, ES; Sereshcheva, AKh; Shalaev, SV; Vorob'eva, NM, 2004)
"In patients 75 years of age or younger who have myocardial infarction with ST-segment elevation and who receive aspirin and a standard fibrinolytic regimen, the addition of clopidogrel improves the patency rate of the infarct-related artery and reduces ischemic complications."9.11Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. ( Braunwald, E; Cannon, CP; Claeys, MJ; Cools, F; Gibson, CM; Hill, KA; López-Sendón, JL; McCabe, CH; Montalescot, G; Sabatine, MS; Skene, AM; Theroux, P, 2005)
"We sought to evaluate the long-term cost-effectiveness of clopidogrel for up to one year after an acute coronary syndrome (ACS) without ST-segment elevation."9.11Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation. ( Caro, J; Culler, S; Gabriel, S; Lamy, A; Mahoney, EM; Weintraub, WS; Yuan, Y; Yusuf, S, 2005)
"We compared the effects of ticlopidine and cilostazol on the prevention of subacute stent thrombosis (SAT) in acute myocardial infarction (AMI) patients with stenting."9.11Comparative inhibitory effects of cilostazol and ticlopidine on subacute stent thrombosis and platelet function in acute myocardial infarction patients with percutaneous coronary intervention. ( Adachi, K; Kataoka, T; Kawata, M; Kuramoto, E; Matsuura, A; Saito, A; Sakamoto, S, 2005)
"To evaluate the impact of a clopidogrel therapy on the effectiveness of myocardial reperfusion in patients with ST-segment elevation acute myocardial infarction (AMI) undergoing routine infarct-related artery (IRA) stent implantation and receiving routine abciximab therapy."9.11A randomized trial comparing clopidogrel versus ticlopidine therapy in patients undergoing infarct artery stenting for acute myocardial infarction with abciximab as adjunctive therapy. ( Antoniucci, D; Memisha, G; Migliorini, A; Moschi, G; Parodi, G; Pupi, A; Sciagrà, R; Valenti, R, 2005)
"To determine if clopidogrel pretreatment before PCI in patients with recent ST-segment elevation myocardial infarction (STEMI) is superior to clopidogrel treatment initiated at the time of PCI in preventing major adverse cardiovascular events."9.11Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. ( Braunwald, E; Cannon, CP; Gibson, CM; Lewis, BS; López-Sendón, JL; McCabe, CH; Montalescot, G; Murphy, SA; Sabatine, MS; Theroux, P, 2005)
"In patients with NSTE-ACS undergoing early invasive strategy, the adjunctive administration of upstream tirofiban did not reduce the peak values and the cumulative release of myocardial necrosis markers, compared with aspirin, heparin, and clopidogrel given on admission and associated with selective use of abciximab just before PCI."9.11Effects of tirofiban plus clopidogrel versus clopidogrel plus provisional abciximab on biomarkers of myocardial necrosis in patients with non-ST-elevation acute coronary syndromes treated with early aggressive approach. Results of the CLOpidogrel, upstrea ( Badia, T; Bellandi, F; Dabizzi, RP; De Servi, S; Leoncini, M; Maioli, M; Politi, A; Toso, A, 2005)
"Effects of thienopyridines ticlopidine (TIC) and clopidogrel (CL) on hemostasis in patients (pts) with non-ST-elevation acute coronary syndromes (NSTEACS) have not been compared."9.11[Indirect comparison of changes of parameters of hemostasis during short-term use of ticlopidine and clopidogrel in patients with non-ST elevation acute coronary syndrome]. ( Averkov, OV; Gratsianskiĭ, NA; Slavina, NN, 2005)
"We studied the benefits and risks of adding clopidogrel to different doses of aspirin in the treatment of patients with acute coronary syndrome (ACS)."9.10Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. ( Commerford, PJ; Diaz, R; Fox, KA; Kopecky, SL; Lewis, BS; Mehta, SR; Peters, RJ; Valentin, V; Yusuf, S; Zhao, F, 2003)
"The safety and tolerability of clopidogrel coadministration to patients with recent acute myocardial infarction (AMI) treated with recombinant tissue plasminogen activator (rt-PA) and heparin were assessed."9.09Clopidogrel-rt-PA-heparin combination in the treatment of acute myocardial infarction. ( Bassand, JP; Cariou, R; Grollier, G; Heyndrickx, GR; Kragten, J; Wolf, JE, 1999)
"Cilostazol, an antiplatelet drug that also may inhibit smooth muscle proliferation, was given together with aspirin after primary stenting to treat patients with acute myocardial infarction."9.09Impact of cilostazol on clinical and angiographic outcome after primary stenting for acute myocardial infarction. ( Eto, K; Isshiki, T; Kondo, K; Ochiai, M; Oshima, A; Sato, T; Takeshita, S; Yokoyama, N, 1999)
"Although antiplatelet therapy with a specific inhibitor of phosphodiesterase-3 cilostazol improves stent patency compared with use of aspirin (ASA) alone, the specific role of cilostazol on platelet aggregation in patients with acute myocardial infarction (AMI) is less well understood."9.09Increased platelet aggregability in response to shear stress in acute myocardial infarction and its inhibition by combined therapy with aspirin and cilostazol after coronary intervention. ( Ikeda, Y; Isaka, N; Ito, M; Kitai, T; Makino, K; Nakano, T; Nishikawa, M; Okinaka, T; Shiku, H; Tanigawa, T; Ueda, Y, 2000)
" We sought to determine whether clopidogrel compared with aspirin decreases the need for rehospitalization for ischemia and bleeding."9.09Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators. ( Bhatt, DL; Hacke, W; Hirsch, AT; Ringleb, PA; Topol, EJ, 2000)
"The effects of clopidogrel 75 mg or aspirin 100 (300) mg on platelet aggregation and activation by flow cytometry after stimulation with various agonists were determined in 30 patients with a past history of myocardial infarction."9.09Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: enhanced inhibitory effects of combination therapy. ( Gebauer, MU; Haeberli, A; Julmy, F; Meyer, BJ; Moshfegh, K; Redondo, M; Wuillemin, WA, 2000)
"Assessing combined anti-platelet therapy in suspected acute myocardial infarction Aspirin has been shown to be effective in the emergency treatment of acute myocardial infarction."9.09Rationale, design and organization of the Second Chinese Cardiac Study (CCS-2): a randomized trial of clopidogrel plus aspirin, and of metoprolol, among patients with suspected acute myocardial infarction. Second Chinese Cardiac Study (CCS-2) Collaborativ ( , 2000)
"We sought to compare the efficacy of aspirin and ticlopidine in survivors of acute myocardial infarction (AMI) treated with thrombolysis."9.09Ticlopidine versus aspirin after myocardial infarction (STAMI) trial. ( Cimminiello, C; Di Biase, M; Marubini, E; Pitzalis, MV; Rizzon, P; Scrutinio, D, 2001)
"The efficacy of combining antiplatelet agents with low doses of aspirin to prevent cardiac events in patients with myocardial infarction was examined."9.08Aspirin plus either dipyridamole or ticlopidine is effective in preventing recurrent myocardial infarction. Secondary Prevention Group. ( Hama, J; Ishikawa, K; Kanamasa, K; Katori, R; Kimura, A; Naito, T; Nakai, S; Ogawa, I; Oyaizu, M; Takenaka, T; Yamamoto, K; Yamamoto, T, 1997)
"Data collected to investigate the effects of ticlopidine in a subset of 489 patients with angina at rest accompanied by transient ischaemic electrocardiographic changes have been analysed."9.07Ticlopidine treatment for patients with unstable angina at rest. A further analysis of the study of ticlopidine in unstable angina. Studio della Ticlopidina nell'Angina Instabile Group. ( Lagioia, R; Rizzon, P; Scrutinio, D, 1991)
"The Swedish Ticlopidine Multicentre Study (STIMS) was a double-blind placebo-controlled trial designed to determine whether ticlopidine, a platelet antiaggregatory agent, reduces the incidence of myocardial infarction, stroke and transitory ischaemic attacks in patients with intermittent claudication."9.06Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study. ( Almgren, B; Bergqvist, D; Boberg, J; Boberg, M; Eriksson, I; Fagher, B; Janzon, L; Kjellström, T; Lindgärde, F; Persson, G, 1990)
"Prasugrel has similar effects as clopidogrel in terms of all causes of death, MI, and stroke in ACS patients."8.91Novel oral P2Y12 inhibitor prasugrel vs. clopidogrel in patients with acute coronary syndrome: evidence based on 6 studies. ( Chen, K; Chu, H; Jia, M; Li, L; Li, Z, 2015)
"Clopidogrel, prasugrel, and ticagrelor are the currently available oral P2Y12 inhibitors for the treatment of ST-segment elevation myocardial infarction (STEMI), in association with aspirin."8.91Ticagrelor, prasugrel, or clopidogrel in ST-segment elevation myocardial infarction: which one to choose? ( Guimarães, PO; Tricoci, P, 2015)
"Vorapaxar is a novel antiplatelet agent that has demonstrated efficacy in reducing atherosclerotic events in patients with a history of MI or PAD without a history of stroke, transient ischemic attack, or ICH when taken in combination with aspirin and clopidogrel."8.91Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease. ( Arif, SA; D'Souza, J; Gil, M; Gim, S, 2015)
" These P2Y12 inhibitors might be superior to clopidogrel for reducing ischemic events in patients with coronary artery disease (CAD)."8.90Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials. ( Fan, JY; Jin, C; Meng, J; Tang, XF; Yang, YJ; Yuan, JQ, 2014)
"In ST-elevation myocardial infarction patients treated with primary percutaneous coronary intervention, administration of a 600-mg LD of clopidogrel is associated with a lower risk of MACE than is administration of a 300-mg LD, without increasing the risk of major bleeding."8.90Outcome comparison of 600 mg versus 300 mg loading dose of clopidogrel for patients with ST-elevation myocardial infarction: a meta-analysis. ( Blevins, A; El Accaoui, R; Karrowni, W; Vyas, A, 2014)
" In the large Phase III trial, PLATO, ticagrelor significantly reduced the composite of cardiovascular death, myocardial infarction, or stroke as well as cardiovascular and all-cause mortality compared with clopidogrel in patients presenting with acute coronary syndromes."8.89Ticagrelor for acute coronary syndromes. ( Bansilal, S; Bonaca, MP; Sabatine, MS, 2013)
"For many years clopidogrel was the 'gold standard' ADP receptor antagonist in patients with coronary artery disease in combination with acetylsalicylic acid, i."8.88Clopidogrel in coronary artery disease: update 2012. ( Huber, K, 2012)
"To evaluate the association of clopidogrel pretreatment vs no treatment with mortality and major bleeding after PCI."8.88Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. ( Barthélémy, O; Bellemain-Appaix, A; Bernasconi, F; Beygui, F; Collet, JP; Cucherat, M; Jacq, L; Montalescot, G; O'Connor, SA; Silvain, J, 2012)
"To determine the effectiveness and safety of thienopyridine derivatives (ticlopidine and clopidogrel) versus aspirin for preventing serious vascular events (stroke, myocardial infarction (MI) or vascular death) in patients at high risk, and specifically in patients with a previous TIA or ischaemic stroke."8.85Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. ( Hankey, GJ; Mason, G; Maurice, JB; Sudlow, CL; Wedderburn, CJ, 2009)
"Clopidogrel (Plavix), a platelet aggregation inhibitor, has been shown to be effective in certain patients undergoing percutaneous coronary interventions, but its use in patients with acute myocardial infarction who receive a fibrinolytic strategy instead has been controversial."8.84Do patients with acute myocardial infarction benefit from treatment with clopidogrel? ( Keim, SM; Rosen, P; Vadera, R; Worster, A, 2008)
"Clopidogrel bisulfate (hereafter, clopidogrel), a selective inhibitor of ADP-induced platelet aggregation, is approved for the reduction of atherothrombotic events in patients with ST-segment elevation myocardial infarction (STEMI)."8.83Clopidogrel bisulfate: in ST-segment elevation myocardial infarction. ( Dickie, JS; Scott, LJ, 2006)
" This article reviews the mechanism of action and the major evidence supporting the clinical use of clopidogrel, a potent antiplatelet agent of the thienopyridines class, focusing on its role in the setting of acute coronary syndromes without persistent ST segment elevation (unstable angina and non-Q wave myocardial infarction)."8.82Clopidogrel in acute coronary syndromes (unstable angina and non-Q-wave myocardial infarction). ( Heras, M; Sionis, A, 2003)
"Clopidogrel was shown to have added benefits to aspirin in patients with acute coronary syndromes without ST-segment elevation in the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) trial."8.82CLARITY about the use of clopidogrel in patients with acute coronary syndromes and myocardial infarction. ( Doggrell, SA, 2005)
" A total of 477 patients receiving double antiaggregation therapy with aspirin and clopidogrel, after suffering a first event, were followed for 1 year to record relapse, as a surrogate end point to measure their therapeutic response, as defined by presenting with an acute coronary event (unstable angina, ST-segment-elevation myocardial infarction, or non-ST-segment-elevation myocardial infarction), stent thrombosis/restenosis, or cardiac mortality."8.12Clinical and Pharmacological Parameters Determine Relapse During Clopidogrel Treatment of Acute Coronary Syndrome. ( Martínez-Quintana, E; Medina-Gil, JM; Rodríguez-González, F; Saavedra-Santana, P; Santana-Mateos, M; Tugores, A, 2022)
"A significant number of ischemic events occur after acute myocardial infarction (MI), even when adhering to dual antiplatelet therapy including aspirin and clopidogrel."7.91The association between clopidogrel and 2-oxo-clopidogrel plasma levels and the long-term clinical outcome after acute myocardial infarction
. ( Apostolovic, S; Konstantinovic, SS; Lilic, J; Nikolic, VN; Pavlovic, M; Stokanovic, D; Zvezdanovic, JB, 2019)
"Our study shows that the recommended dose of prasugrel had significantly higher in-hospital bleeding complications without reducing ischemic events compared with clopidogrel."7.88Comparison of prasugrel versus clopidogrel in Korean patients with acute myocardial infarction undergoing successful revascularization. ( Ahn, TH; Cha, KS; Chae, JK; Chae, SC; Choi, DJ; Gwon, HC; Hwang, KK; Jeong, MH; Kim, HK; Kim, HS; Kim, KB; Kim, YJ; Oh, DJ; Oh, SK; Park, KH; Seong, IW; Seung, KB, 2018)
"The objective of this study is to evaluate the effects of cytochrome P450 2C19 (CYP2C19) polymorphism on adverse cardiovascular events (MACE) in Hakka patients with acute coronary syndrome (ACS) receiving clopidogrel who had undergone coronary drug-eluting stent placement after percutaneous coronary intervention (PCI) in southern China."7.88Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China. ( He, X; Hou, J; Li, B; Li, C; Liu, Z; Wu, H; Yang, M; Zhang, Q; Zhao, P; Zhong, M; Zhong, W; Zhong, Z, 2018)
"The clinical significance of the laboratory-based phenomenon of clopidogrel hypo-responsiveness and platelet reactivity associated with acute myocardial infarction, despite chronic clopidogrel therapy, is largely unknown."7.88Acute myocardial infarction occurring while on chronic clopidogrel therapy ('clopidogrel failure') is associated with high incidence of clopidogrel poor responsiveness and stent thrombosis. ( Asher, E; Beigel, R; Fefer, P; Matetzky, S; Mazin, I; Regev, E, 2018)
"Clopidogrel HTPR does not seem to be a major contributor to recurrent ischemic events in Danish ischemic stroke patients."7.88Secondary Stroke Prophylaxis with Clopidogrel Produces Sufficient Antiplatelet Response. ( Jørgensen, NR; Rath, CL; Wienecke, T, 2018)
"We consecutively enrolled 375 patients with IS after they received clopidogrel therapy, and venous blood samples were subjected to genotyping allelic variants of genes modulating clopidogrel absorption (ATP binding cassette subfamily B1, ABCB1), metabolic activation (cytochrome P450[CYP] 3A and CYP2C19), and biologic activity (platelet membrane receptor [ P2Y12, P2Y1)], and glycoprotein IIIa [ GPIIIa]) and statistically analyzing their interactions with clopidogrel sensitivity (CS) and adverse events, risk of IS recurrence, myocardial infarction, and death during 6 months of follow-up."7.85Interaction of CYP2C19, P2Y12, and GPIIIa Variants Associates With Efficacy of Clopidogrel and Adverse Events on Patients With Ischemic Stroke. ( Cheng, W; Lin, J; Wang, C; Wang, Y; Yi, X; Zhou, Q, 2017)
"The reasons for postdischarge adenosine diphosphate receptor inhibitor (ADPri) switching among patients with myocardial infarction (MI) are unclear."7.85Switching of adenosine diphosphate receptor inhibitor after hospital discharge among myocardial infarction patients: Insights from the Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after ( Anstrom, KJ; Baker, BA; Cohen, DJ; Effron, MB; Henry, TD; McCoy, LA; Messenger, JC; Peterson, ED; Wang, TY; Zettler, ME, 2017)
"Among patients in the CHAMPION trials with a prior cerebrovascular event at least 1 year before the percutaneous coronary intervention, the efficacy and bleeding profile of cangrelor compared with clopidogrel was similar to that in the overall trial."7.85Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention. ( Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Sawlani, NN; Steg, PG; Stone, GW; White, HD, 2017)
"Active smokers with myocardial infarction were shown to have enhanced benefit with clopidogrel compared with aspirin."7.85Clopidogrel and ischemic stroke outcomes by smoking status: Smoker's paradox? ( Cao, Q; Dong, K; Feng, W; Hou, C; Huang, X; Ji, X; Ovbiagele, B; Song, H; Wang, M; Wang, Y; Zhang, Q, 2017)
"To evaluate long-term health benefits and risks of adding vorapaxar (VOR) to the standard care antiplatelet therapy (SC) of aspirin and/or clopidogrel, among a population with a recent myocardial infarction (MI) and/or peripheral artery disease (PAD)."7.85State transition model: vorapaxar added to standard antiplatelet therapy to prevent thrombosis post myocardial infarction or peripheral artery disease. ( Chase, M; Davies, G; Du, M; Oguz, M, 2017)
"Despite the growing use of clopidogrel, limited data exist regarding the prognostic significance of chronic clopidogrel therapy in patients sustaining acute coronary syndrome (ACS)."7.83Prior chronic clopidogrel therapy is associated with increased adverse events and early stent thrombosis. ( Asher, E; Atar, S; Beigel, R; Fefer, P; Hammerman, H; Herscovici, R; Matetzky, S; Mazin, I; Polak, A; Regev, E; Sabbag, A; Shlomo, N; Zahger, D, 2016)
"The risk of bleeding and ischemic complications among patients on TT is similar between those on ticagrelor and clopidogrel."7.83Ticagrelor in Triple Antithrombotic Therapy: Predictors of Ischemic and Bleeding Complications. ( Abunassar, J; Chong, AY; Dick, A; Froeschl, M; Fu, A; Glover, C; Hibbert, B; Labinaz, M; Le May, M; Malhotra, N; Marquis, JF; Singh, K; So, DY, 2016)
" Our results suggest that this strategy is not beneficial as compared to aspirin alone in terms of ischaemic or bleeding events."7.83Clopidogrel Use as Single Antiplatelet Therapy in Outpatients with Stable Coronary Artery Disease: Prevalence, Correlates and Association with Prognosis (from the CORONOR Study). ( Bauters, C; Caudmont, S; Ketelers, R; Lamblin, N; Lemaire, N; Lemesle, G; Meurice, T; Philias, A; Schurtz, G; Tricot, O, 2016)
"Guidelines recommend prasugrel or ticagrelor instead of clopidogrel in patients with acute coronary syndromes (ACS) undergoing percutaneous coronary interventions (PCI)."7.83Clopidogrel, prasugrel or ticagrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention. ( Ajani, AE; Andrianopoulos, N; Brennan, A; Clark, DJ; Duffy, SJ; Eccleston, D; Farouque, O; Lefkovits, J; Oqueli, E; Ramchand, J; Reid, CM; Yip, T; Yudi, MB, 2016)
" Rates of discharge clopidogrel use were described for patients with no angiography, angiography without obstructive coronary artery disease (CAD; ≥50% stenosis in ≥1 vessel), and angiography with obstructive CAD."7.83Outcomes According to Cardiac Catheterization Referral and Clopidogrel Use Among Medicare Patients With Non-ST-Segment Elevation Myocardial Infarction Discharged Without In-hospital Revascularization. ( Hellkamp, AS; Hess, CN; Peng, SA; Peterson, ED; Roe, MT; Scirica, BM; Thomas, L; Wang, TY, 2016)
"To observe the relationship between ATP-binding cassette subfamily B member 1 (ABCB1) and cytochrome P450 (CYP)2C19 polymorphisms and the effect of clopidogrel post percutaneous coronary intervention in patients with coronary artery disease."7.83[Relationship between ATP-binding cassette subfamily B member 1 and cytochrome P450 2C19 polymorphisms and the effect of clopidogrel post percutaneous coronary intervention in patients with acute coronary syndrome]. ( Fu, ZH; Han, BS; Li, DY; Ren, YH; Song, YQ; Xue, Q; Yi, J; Zhou, CF, 2016)
" However, the incidences of in-hospital Thrombolysis In Myocardial Infarction (TIMI) major and minor bleeding were higher in ticagrelor than clopidogrel (2."7.83Comparison of short-term clinical outcomes between ticagrelor versus clopidogrel in patients with acute myocardial infarction undergoing successful revascularization; from Korea Acute Myocardial Infarction Registry-National Institute of Health. ( Ahn, TH; Ahn, Y; Cha, KS; Chae, JK; Chae, SC; Choi, DJ; Gwon, HC; Hwang, KK; Jeong, MH; Kim, HS; Kim, KB; Kim, YJ; Oh, DJ; Oh, SK; Park, KH; Seong, IW; Seung, KB, 2016)
"The TRA 2°P-TIMI 50 trial showed the addition of vorapaxar to standard care (SC) antiplatelet therapy reduced the combined risk of death, myocardial infarction (MI), and stroke, while exhibiting an increase in moderate, but not other bleeding events."7.83A State Transition Model for Health Outcomes Associated with Vorapaxar Treatment as an Add-on to Standard Care Antiplatelet Therapy in the Prevention of Thrombotic Events for Patients with a Recent Myocardial Infarction. ( Bash, LD; Davies, G; Du, M; Oguz, M; Ozer-Stillman, I; Whalen, JD, 2016)
"Ticagrelor reduces ischaemic events and mortality in acute coronary syndrome (ACS) vs."7.83Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registry. ( Erlinge, D; James, SK; Jernberg, T; Lagerqvist, B; Omerovic, E; Renlund, H; Sahlén, A; Varenhorst, C; Wallentin, L, 2016)
" The aim of the current study was to compare these two point-of-care platelet function tests and to analyze the consistency between the two tests for evaluating on-clopidogrel platelet reactivity in Chinese acute myocardial infarction patients undergoing percutaneous coronary intervention (PCI)."7.83Head to Head Comparison of Two Point-of-care Platelet Function Tests Used for Assessment of On-clopidogrel Platelet Reactivity in Chinese Acute Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention. ( Gao, RL; He, C; Liu, R; Ma, YL; Meng, XM; Song, L; Song, Y; Tang, XF; Wang, M; Xu, JJ; Yao, Y; Yuan, JQ; Zhang, JH, 2016)
"We examined clinical outcomes with proton pump inhibitors (PPI) use within CYP2C19 genotype groups during clopidogrel treatment following acute myocardial infarction (AMI)."7.81Clinical outcomes associated with proton pump inhibitor use among clopidogrel-treated patients within CYP2C19 genotype groups following acute myocardial infarction. ( Bach, RG; Cresci, S; Depta, JP; Lanfear, DE; Lenzini, PA; Spertus, JA; Wang, TY, 2015)
"While randomized clinical trials have compared clopidogrel with higher potency adenosine diphosphate (ADP) receptor inhibitors among patients with acute myocardial infarction, little is known about the frequency, effectiveness and safety of switching between ADP receptor inhibitors in routine clinical practice."7.81In-hospital switching between adenosine diphosphate receptor inhibitors in patients with acute myocardial infarction treated with percutaneous coronary intervention: Insights into contemporary practice from the TRANSLATE-ACS study. ( Anstrom, KJ; Bagai, A; Cohen, DJ; Effron, MB; Goodman, SG; Gupta, A; Honeycutt, E; Messenger, JC; Peterson, ED; Wang, TY, 2015)
"There are limited data about long-term outcomes for biodegradable polymer biolimus-eluting stent (BES) versus durable polymer everolimus-eluting stent (EES) in patients undergoing percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI)."7.81Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent in patients with acute myocardial infarction. ( Choi, JH; Choi, RK; Choi, SH; Choi, YJ; Gwon, HC; Hahn, JY; Jang, HJ; Kim, JS; Kim, TH; Lee, HJ; Lee, SH; Park, JS; Park, TK; Roh, YM; Shim, WH; Song, YB; Yang, JH; Yu, CW, 2015)
"We describe the case of a patient with non-ST segment elevation myocardial infarction (NSTEMI) where a limitation of oral clopidogrel loading prior to percutaneous coronary intervention (PCI) was directly visualized on angiography."7.81Delayed clopidogrel transit during myocardial infarction evident on angiography. ( Ghobrial, J; Gibson, CM; Pinto, DS, 2015)
"We sought explore the relative benefits of unfractionated heparin (UFH) compared with enoxaparin, alone or in combination with clopidogrel, in ST-segment elevation myocardial infarction (STEMI) patients not undergoing reperfusion therapy."7.81Unfractionated heparin-clopidogrel combination in ST-elevation myocardial infarction not receiving reperfusion therapy. ( Badimon, L; Bugiardini, R; Calmac, L; Cenko, E; Daullxhiu, I; Dorobantu, M; Kedev, S; Knežević, B; Koller, A; Manfrini, O; Miličić, D; Puddu, PE; Ricci, B; Trninic, D; Vasiljevic, Z, 2015)
"Early clopidogrel administration to patients with acute myocardial infarction (AMI) has been demonstrated to improve outcomes in a large Chinese trial."7.81National Quality Assessment of Early Clopidogrel Therapy in Chinese Patients With Acute Myocardial Infarction (AMI) in 2006 and 2011: Insights From the China Patient-Centered Evaluative Assessment of Cardiac Events (PEACE)-Retrospective AMI Study. ( Desai, NR; Hu, S; Jiang, L; Krumholz, HM; Li, J; Li, X; Masoudi, FA; Nuti, SV; Spertus, JA; Wang, Q; Wang, S; Zhang, L, 2015)
"The current standard of antiplatelet therapy of patients after myocardial infarction includes the P2Y12 receptor antagonists clopidogrel, prasugrel or ticagrelor."7.80Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry. ( Bode, C; Diehl, P; Moser, M; Olivier, CB; Schnabel, K; Weik, P; Zhou, Q, 2014)
" We report a case of clopidogrel non-responsiveness in a patient with HIV, latent tuberculosis and cardiovascular disease with a history of myocardial infarction."7.80A patient with HIV and tuberculosis with diminished clopidogrel response. ( Metzger, NL; Momary, KM, 2014)
"Our aim was to identify risk factors for acute gastrointestinal (GI) bleeding in patients with myocardial infarction (MI) who were prescribed clopidogrel following hospital discharge."7.80Risk factors for acute gastrointestinal bleeding following myocardial infarction in veteran patients who are prescribed clopidogrel. ( Cuschieri, JR; Drawz, P; Falck-Ytter, Y; Wong, RC, 2014)
"There was no significant difference in the incidence of major adverse cardiac events between temporary adjunctive cilostazol treatment and clopidogrel loading in ST-segment elevation acute myocardial infarction patients."7.80Temporary adjunctive cilostazol vs clopidogrel loading for ST-segment elevation acute myocardial infarction. ( Inoue, Y; Ishii, H; Jinno, Y; Murohara, T; Okada, K; Okumura, S; Sakakibara, M; Suzuki, S; Tanaka, A, 2014)
"Switching patients with ACS who have HPR to treatment with prasugrel reduces thrombotic and bleeding events to a level similar to that of those without HPR; however, there is a higher risk of both thrombotic and bleeding complications with high-dose clopidogrel."7.80Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel. ( Aradi, D; Faluközy, J; Horváth, IG; Komócsi, A; Kónyi, A; Magyari, B; Pintér, T; Tornyos, A; Veress, G; Vorobcsuk, A, 2014)
"Current ST-elevation myocardial infarction (STEMI) guidelines recommend initiation of clopidogrel treatment as early as possible before angiography, based on pharmacokinetic and positive registry data."7.80Association of upstream clopidogrel administration and myocardial reperfusion assessed by cardiac magnetic resonance imaging in patients with ST-elevation myocardial infarction. ( de Waha, S; Desch, S; Eitel, I; Fuernau, G; Lurz, P; Schuler, G; Thiele, H, 2014)
"This study sought to examine the effectiveness of clopidogrel in real-world, medically managed patients with unstable angina (UA) or non-ST-segment elevation myocardial infarction (NSTEMI)."7.80Comparative effectiveness of clopidogrel in medically managed patients with unstable angina and non-ST-segment elevation myocardial infarction. ( Boothroyd, DB; Chang, TI; Go, AS; Hlatky, MA; Kazi, DS; Leong, TK; Shilane, D; Solomon, MD, 2014)
"Clopidogrel is recommended after acute myocardial infarction but has variable efficacy and safety, in part related to the effect of cytochrome P450 (CYP) polymorphisms on its metabolism."7.80Cytochrome p450 gene variants, race, and mortality among clopidogrel-treated patients after acute myocardial infarction. ( Bach, RG; Cresci, S; Depta, JP; Lanfear, DE; Lenzini, PA; Li, AY; Province, MA; Spertus, JA, 2014)
"To compare 30 and 90 day real-world acute myocardial infarction (AMI) and bleeding related rehospitalization rates in acute coronary syndrome (ACS) patients receiving percutaneous coronary intervention (PCI; ACS-PCI) treated with clopidogrel or prasugrel."7.80Real-world observations with prasugrel compared to clopidogrel in acute coronary syndrome patients treated with percutaneous coronary intervention in the United States. ( Bae, JP; Effron, MB; Ernst, FR; Faries, DE; Lieu, HD; Lipkin, C; Moretz, C; Zhao, Z, 2014)
"Although randomized clinical trials have compared clopidogrel with higher potency ADP receptor inhibitors (ADPris) among patients with myocardial infarction, little is known about the frequency and factors associated with switching between ADPris in clinical practice."7.80In-hospital switching between clopidogrel and prasugrel among patients with acute myocardial infarction treated with percutaneous coronary intervention: insights into contemporary practice from the national cardiovascular data registry. ( Alexander, KP; Bagai, A; Bhatt, DL; Cheema, AN; Curtis, JP; Granger, CB; Gurm, HS; McNamara, RL; Peterson, ED; Roe, MT; Saucedo, JF; Shah, B; Wang, TY; Wang, Y, 2014)
"The aim of the present study was to evaluate clopidogrel treatment after incident myocardial infarction (MI) in patients with and without chronic kidney disease (CKD)."7.80Benefit of clopidogrel therapy in patients with myocardial infarction and chronic kidney disease-a Danish nation-wide cohort study. ( Blicher, TM; Hommel, K; Kamper, AL; Kristensen, SL; Madsen, M; Olesen, JB; Torp-Pedersen, C, 2014)
" The other 32 rats were subjected to induction of hypercholesterolemia by high-fat diet for 3 weeks, followed by induction of AMI by subcutaneous injections of isoproterenol (85 mg/kg/day, for 2 days)."7.80Assessment of the prophylactic role of aspirin and/or clopidogrel on experimentally induced acute myocardial infarction in hypercholesterolemic rats. ( El-Hadidy, WF; Mannaa, HF; Mohamed, AR, 2014)
"Although previous retrospective studies have suggested the clinical benefits of clopidogrel pretreatment in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI), the antiplatelet effect of thienopyridines during a narrow door-to-balloon time frame has not been evaluated."7.79Antiplatelet effect of thienopyridine (clopidogrel or prasugrel) pretreatment in patients undergoing primary percutaneous intervention for ST elevation myocardial infarction. ( Beigel, R; Elian, D; Fefer, P; Fink, N; Guetta, V; Hod, H; Matetzky, S; Novikov, I; Rosenberg, N; Segev, A, 2013)
"Clopidogrel could decrease mortality and improve cardiovascular outcomes without increasing risk of bleeding in ACS patients with CKD."7.79Effects of clopidogrel on mortality, cardiovascular and bleeding outcomes in patients with chronic kidney disease - data from Taiwan acute coronary syndrome full spectrum registry. ( Chang, SC; Chiang, FT; Hsin, HT; Hwang, JJ; Kuo, CT; Lai, WT; Li, AH; Lin, TH; Wang, CL, 2013)
"This study sought to assess the usefulness of clopidogrel-pathway genotyping and on-treatment platelet reactivity (OTR) testing in predicting major adverse cardiac events (MACE) in stable coronary artery disease (CAD) patients receiving drug-eluting stents (DES) under dual antiplatelet (clopidogrel plus aspirin) therapy."7.79Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease. ( Briguori, C; Condorelli, G; De Micco, F; Focaccio, A; Latronico, MV; Pagnotta, P; Papa, L; Roncarati, R; Visconti, G; Viviani Anselmi, C, 2013)
"Ticagrelor showed significant reductions in myocardial infarctions (MIs) compared to clopidogrel in the Platelet Inhibition and Patient Outcomes (PLATO) trial."7.79Exploring the reduction in myocardial infarctions in the PLATO trial: which patients benefited on ticagrelor vs. clopidogrel? ( DiNicolantonio, JJ; Serebruany, VL, 2013)
"The present study was performed to compare the influence of cytochrome P459 2C19 (CYP2C19) *2 and *17 genetic variants on the platelet response to clopidogrel and prasugrel maintenance therapy and to assess the relation between platelet reactivity and bleeding complications."7.79Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications. ( Alessi, MC; Beguin, S; Bonnet, JL; Camoin, L; Cohen, W; Cuisset, T; Gaborit, B; Grosdidier, C; Lambert, M; Loosveld, M; Morange, PE; Moro, PJ; Pankert, M; Quilici, J; Saut, N, 2013)
"The purpose of the present study was to evaluate the effects of different loading doses of clopidogrel on ST segment resolution on ECG, changes in cardiac enzyme levels and serum levels of high-sensitivity C-reactive protein (Hs-CRP) in patients with ST elevated myocardial infarction (STEMI) treated with fibrinolytic therapy."7.79Effects of high loading dose of clopidogrel in ST elevated myocardial infarction treated with fibrinolytic agent. ( Akbulut, M; Karadağ, MK; Kaya, OK; Korkmaz, H; Kurtoğlu, E; Kuzu, Z; Solmaz, H; Uysal, A; Yavuzkir, MF, 2013)
"Our findings suggest that concomitant use of clopidogrel with PPIs might be safer than ticlopidine with PPIs in patients undergoing primary stenting for acute myocardial infarction."7.78Comparison of early outcomes after primary stenting in Japanese patients with acute myocardial infarction between clopidogrel and ticlopidine in concomitant use with proton-pump inhibitor. ( Ishii, H; Murohara, T; Okada, K; Okumura, S; Sakakibara, M; Tanaka, A, 2012)
"High on-treatment platelet reactivity (HTPR) despite clopidogrel therapy is associated with adverse cardiac events after acute myocardial infarction (AMI)."7.78Clopidogrel response up to six months after acute myocardial infarction. ( Assali, A; Battler, A; Codner, P; Greenberg, G; Hasdai, D; Iakobishvili, Z; Kornowski, R; Lev, EI; Rechavia, E; Vaduganathan, M, 2012)
" We aimed to determine the relationship between high on-treatment platelet reactivity (HTPR) and ST-elevation myocardial infarction (STEMI) following a 600 mg loading dose (LD) of clopidogrel."7.78Biological efficacy of a 600 mg loading dose of clopidogrel in ST-elevation myocardial infarction. ( Armero, S; Barragan, P; Berbis, J; Bessereau, J; Bonello, C; Bonello, L; Camillieri, E; Camoin-Jau, L; Dignat-George, F; Jacquin, L; Laine, M; Paganelli, F, 2012)
"Clopidogrel prescription is a class I guideline recommendation for medically managed patients with non-ST-segment-elevation myocardial infarction (NSTEMI)."7.78Clopidogrel use and hospital quality in medically managed patients with non-ST-segment-elevation myocardial infarction. ( Ho, PM; Li, S; Maddox, TM; Masoudi, FA; Peng, SA; Rumsfeld, JS; Tsai, TT; Wang, TY; Wiviott, SD, 2012)
"Little is known about the antiplatelet action of the thienopyridines, clopidogrel and prasugrel, as well as the non-thienopyridine, ticagrelor, in patients suffering from ST-elevation myocardial infarction (STEMI) complicated by cardiogenic shock since systematic comparisons of these antiplatelet agents in this devastating condition are limited so far."7.78Dual thienopyridine low-response to clopidogrel and prasugrel in a patient with STEMI, cardiogenic shock and early stent thrombosis is overcome by ticagrelor. ( Hausleiter, J; Joner, M; Kastrati, A; Massberg, S; Okrojek, R; Orban, M; Riegger, J; Sibbing, D; Tada, T, 2012)
" We wanted to explore long-term variability of multiple electrode aggregometry (MEA) measurements and the agreement between MEA and light transmission aggregometry (LTA) in patients with non-ST elevation myocardial infarction (NSTEMI) treated with aspirin and clopidogrel."7.78Sequential ADP-stimulated light transmission and multiple electrode aggregometry in patients taking aspirin and clopidogrel after non ST-elevation myocardial infarction. ( Andreassen, T; Bendz, B; Brosstad, F; Erikssen, G; Kunszt, G; Liestøl, K; Meen, O; Schjelderup, NM; Wettergreen, M, 2012)
"The benefit of extending clopidogrel treatment beyond the 12-month period recommended in current guidelines after myocardial infarction (MI) is debated."7.78Clopidogrel discontinuation after myocardial infarction and risk of thrombosis: a nationwide cohort study. ( Ahlehoff, O; Charlot, M; Gislason, GH; Hansen, ML; Hansen, PR; Køber, L; Lindhardsen, J; Madsen, JK; Nielsen, LH; Olsen, AM; Torp-Pedersen, C, 2012)
"One of the foundations of the modern treatment of myocardial infarction (MI) is a combination antiplatelet therapy consisting of acetylsalicylic acid (ASA) and clopidogrel."7.78[CYP2C19 gene polymorphism in patients with myocardial infarction who use clopidogrel]. ( Akhmetov, II; Arkhipova, AA; Galiavi, RA; Galiavich, AS; Minnetdinov, RSh; Valeeva, DD, 2012)
"The optimum loading dose of clopidogrel has not been established in Asian patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI)."7.78Effects of 600 mg versus 300 mg loading dose of clopidogrel in Asian patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: long-term follow-up study. ( Ahn, KT; Choi, JH; Choi, SH; Gwon, HC; Hahn, JY; Kang, GH; Kim, HS; Lim, WH; Park, KW; Song, PS; Song, YB, 2012)
"This case report describes recurrent drug-eluting stent thrombosis with documented laboratory hyporesponsiveness to clopidogrel."7.78Failure of high-dose clopidogrel in recurrent stent thrombosis. ( Chan, MY; Li, Y, 2012)
"To estimate the clinical effectiveness associated with clopidogrel treatment after myocardial infarction (MI) in patients with diabetes."7.78Association of clopidogrel treatment with risk of mortality and cardiovascular events following myocardial infarction in patients with and without diabetes. ( Andersson, C; Gislason, GH; Køber, L; Lyngbæk, S; Nguyen, CD; Nielsen, M; Torp-Pedersen, C, 2012)
"High platelet reactivity (HPR) after clopidogrel treatment is linked to an increased risk of periprocedural myocardial infarction (PMI)."7.78Association of CYP2C19 genotype with periprocedural myocardial infarction after uneventful stent implantation in Chinese patients receiving clopidogrel pretreatment. ( Ge, J; Qian, J; Sun, A; Wang, Q; Wu, H, 2012)
"Our study showed that clopidogrel resistance may be one of the responsible mechanisms for the no-reflow phenomenon."7.78Impact of clopidogrel resistance on ST-segment resolution and no-reflow in acute myocardial infarction with ST-elevation patients treated with a primary percutaneous coronary intervention. ( Aksu, H; Bozbeyoglu, E; Nurkalem, Z; Satilmis, S; Yildirimturk, O, 2012)
"This study sought to examine the pattern of death and myocardial infarction (MI) after clopidogrel cessation in patients undergoing percutaneous coronary intervention (PCI) of the saphenous vein graft (SVG)."7.78Discontinuation of long-term clopidogrel therapy is associated with death and myocardial infarction after saphenous vein graft percutaneous coronary intervention. ( Aharonian, V; Bavisetty, S; Beckham, G; Brar, SS; Contreras, R; Hyett, R; Leon, M; Mansukhani, P; Moore, N; Moses, J; Sachdeva, A; Shen, AY; Stone, GW, 2012)
"The association between myocardial infarction (MI) and co-administration of proton pump inhibitors (PPIs) and clopidogrel remains controversial."7.77Risk of recurrent myocardial infarction with the concomitant use of clopidogrel and proton pump inhibitors. ( 't Jong, GW; Kuipers, EJ; Sturkenboom, MC; Valkhoff, VE; Van Soest, EM, 2011)
"Clopidogrel is a widely used anti-platelet agent for the prevention of arterial thrombosis."7.77Clopidogrel Resistance: case reports of CYP2C19 gene variants in suspected coronary stent thrombosis. ( Byron, KA; Dear, AE; Dick, RJ, 2011)
"The purpose of this study was to determine the risk of adverse cardiovascular events associated with concomitant use of clopidogrel and calcium-channel blockers (CCBs) in patients with myocardial infarction (MI)."7.77Calcium-channel blockers do not alter the clinical efficacy of clopidogrel after myocardial infarction: a nationwide cohort study. ( Ahlehoff, O; Andersson, C; Charlot, MG; Fosbøl, EL; Gislason, GH; Hansen, PR; Olesen, JB; Selmer, C; Torp-Pedersen, C; Weeke, P, 2011)
"The optimal loading dose of clopidogrel in Asian patients with ST-segment elevation myocardial infarction (STEMI) has not been fully investigated."7.77Standard versus high loading doses of clopidogrel in Asian ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention: insights from the Korea Acute Myocardial Infarction Registry. ( Ahn, TH; Ahn, YK; Bae, JH; Chae, IH; Chae, JK; Chae, SC; Cho, MC; Choi, CU; Choi, DH; Chung, WS; Hong, TJ; Hur, SH; Jang, YS; Jeong, MH; Kim, CJ; Kim, EJ; Kim, HS; Kim, JW; Kim, YJ; Lim, HE; Na, JO; Oh, DJ; Park, CG; Park, JS; Park, SJ; Poddar, KL; Rha, SW; Seo, HS; Seong, IW; Seung, KB; Tahk, SJ; Yoon, JH, 2011)
"The objective of this study was to examine the clinical efficacy of clopidogrel treatment on death and recurrent myocardial infarction (MI) among MI patients revascularized by coronary artery bypass graft surgery (CABG)."7.77Efficacy of post-operative clopidogrel treatment in patients revascularized with coronary artery bypass grafting after myocardial infarction. ( Abildstrøm, SZ; Andersson, C; Charlot, M; Fosbøl, EL; Gislason, GH; Hansen, PR; Hvelplund, A; Køber, L; Madsen, JK; Sørensen, R; Torp-Pedersen, C, 2011)
" Triple therapy (OAC, clopidogrel plus aspirin) was associated with four times higher risk of any bleeding than OAC plus aspirin, adj."7.77Efficacy and safety of clopidogrel after PCI with stenting in patients on oral anticoagulants with acute coronary syndrome. ( Hofman-Bang, C; Lagerqvist, B; Lindbäck, J; Persson, J; Samnegard, A; Stenestrand, U, 2011)
"While acute myocardial infarction (MI) is associated with impaired clopidogrel responsiveness, systematic evaluation is lacking due to the inability of functional aggregation-based assays to analyse clopidogrel responsiveness in the presence of glycoprotein IIb/IIIa inhibitors."7.77Early determination of clopidogrel responsiveness by platelet reactivity indexidentifies patients at risk for cardiovascular events after myocardial infarction. ( Bauersachs, J; Flierl, U; Kobsar, A; Kössler, J; Schäfer, A; Seydelmann, N; Störk, S, 2011)
"AIMS Immediate treatment with a loading dose of clopidogrel at diagnosis of ST-segment elevation myocardial infarction (STEMI) is recommended by ESC/AHA/ACC guidelines in patients eligible for primary percutaneous coronary intervention (PCI)."7.77Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. ( Erlinge, D; James, S; Koul, S; Lagerqvist, B; Scherstén, F; Smith, JG, 2011)
"Data are lacking on the efficacy and safety of a loading dose (LD) of clopidogrel in elderly patients with acute myocardial infarction (AMI)."7.77Comparison of efficacy and safety of a standard versus a loading dose of clopidogrel for acute myocardial infarction in patients ≥ 75 years of age (from the FAST-MI registry). ( Aïssaoui, N; Bataille, V; Blanchard, D; Carrié, D; Coste, P; Danchin, N; Dentan, G; Drouet, E; Mulak, G; Puymirat, E; Simon, T, 2011)
"We report a case of a 27-year-old woman who received a drug-eluting coronary stent for an acute myocardial infarction and was started on clopidogrel as treatment."7.77Clopidogrel use throughout pregnancy in a patient with a drug-eluting coronary stent. ( Hoffman, MK; Marshall, ES; Myers, GR, 2011)
"Ticagrelor has been shown to be superior to clopidogrel in patients presenting with acute myocardial infarction who undergo early invasive treatment."7.77The use of ticagrelor in a patient at increased risk of stent thrombosis resistant to multiple thienopyridines. ( Chauhan, A; More, RS; Morgan, KP, 2011)
"To test the hypothesis that HRPR after clopidogrel loading is an independent prognostic marker of risk of long-term thrombotic events in patients with acute coronary syndromes (ACS) undergoing an invasive procedure and antithrombotic treatment adjusted according to the results of platelet function tests."7.77High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. ( Abbate, R; Antoniucci, D; Buonamici, P; Gensini, GF; Giusti, B; Gori, AM; Marcucci, R; Migliorini, A; Parodi, G; Valenti, R, 2011)
" The influence of the CYP2C19 LOF alleles (*2 and *3) on clopidogrel response and clinical outcomes in East Asians with acute myocardial infarction (AMI) has not been reported."7.77Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin. ( Bliden, KP; Gurbel, PA; Hwang, JY; Hwang, SJ; Jeong, YH; Kim, IS; Koh, JS; Kwak, CH; Kwon, TJ; Park, Y; Tantry, US, 2011)
"In patients with acute coronary syndromes and planned percutaneous coronary intervention, the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38) demonstrated that treatment with prasugrel versus clopidogrel was associated with reduced rates of cardiovascular death, MI, or stroke and an increased risk of major bleeding."7.76Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasug ( Antman, E; Arnold, SV; Braunwald, E; Cohen, DJ; Mahoney, EM; Proskorovsky, I; Wang, K; Wiviott, S, 2010)
"Current guidelines recommend pretreatment with a loading dose of clopidogrel before percutaneous coronary intervention (PCI) to reduce the incidence of periprocedural myocardial infarctions in patients undergoing PCI."7.76Efficacy of high-dose clopidogrel treatment (600 mg) less than two hours before percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes. ( Bergman, G; Fakorede, F; Feldman, DN; Minutello, RM; Moussa, I; Wong, SC, 2010)
"Clopidogrel improves outcomes in patients with ST-segment elevation myocardial infarction (STEMI) and is recommended in the guidelines."7.76Cost-effectiveness analysis of short-term clopidogrel therapy for ST elevation myocardial infarction. ( Cannon, CP; Cohen, DJ; Gibler, KB; Huskamp, HA; Murphy, SA; Sabatine, MS, 2010)
"The purpose of this study was to determine the readmission rate for acute myocardial infarction (AMI) in patients discharged on clopidogrel and a proton-pump inhibitor (PPI) versus patients discharged on clopidogrel alone after experiencing an AMI and undergoing stent placement."7.76Recurrence of acute myocardial infarction in patients discharged on clopidogrel and a proton pump inhibitor after stent placement for acute myocardial infarction. ( Binkley, P; Donnally, MR; Evanchan, J; Mazzaferri, E, 2010)
"We sought to evaluate the influence of platelet reactivity after clopidogrel, as assessed by the VerifyNow point-of-care assay (Accumetrics, San Diego, California), on myonecrosis in low-to-intermediate risk patients undergoing percutaneous coronary intervention (PCI)."7.76Point-of-care assessment of platelet reactivity after clopidogrel to predict myonecrosis in patients undergoing percutaneous coronary intervention. ( Barbato, E; D'Ambrosio, A; Di Sciascio, G; Gatto, L; Mangiacapra, F; Patti, G; Ricottini, E; Vizzi, V; Wijns, W, 2010)
"We studied the association of clopidogrel with mortality in acute myocardial infarction (AMI) patients with heart failure (HF) not receiving percutaneous coronary intervention (PCI)."7.76Increased mortality associated with low use of clopidogrel in patients with heart failure and acute myocardial infarction not undergoing percutaneous coronary intervention: a nationwide study. ( Abildstrøm, SZ; Bonde, L; Bretler, DM; Fosbøl, EL; Gislason, GH; Hansen, PR; Kober, L; Olesen, J; Schramm, TK; Sorensen, R; Torp-Pedersen, C; Weeke, P, 2010)
"This was a retrospective cohort study of 2017 patients with acute coronary syndrome discharged on clopidogrel from an integrated health care delivery system."7.76Adverse events after stopping clopidogrel in post-acute coronary syndrome patients: Insights from a large integrated healthcare delivery system. ( Clarke, CL; Go, AS; Ho, PM; Magid, DJ; Peterson, ED; Rumsfeld, JS; Sedrakyan, A; Shetterly, SM; Tsai, TT; Wang, TY, 2010)
"To evaluate effect of duration of clopidogrel use on clinical follow-up outcomes in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention."7.76[Effect of duration of clopidogrel use on clinical follow-up outcomes in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention]. ( Fan, ZJ; Fang, Q; Jin, XF; Liu, ZY; Shen, ZJ; Wang, CH; Xie, HZ; Yang, J; Zhang, SY, 2010)
"The aim of the present study was to compare 600- and 300-mg clopidogrel loading doses in patients with ST-segment elevation myocardial infarctions who underwent primary percutaneous coronary intervention (PCI)."7.76Comparison of 600 versus 300-mg Clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary coronary angioplasty. ( Barbato, E; Bartunek, J; De Bruyne, B; Heyndrickx, GR; Mangiacapra, F; Muller, O; Ntalianis, A; Trana, C; Vanderheyden, M; Wijns, W, 2010)
"To assess the prognosis of patients presenting with an acute coronary syndrome (ACS) despite chronic clopidogrel therapy (CCT)."7.75Prognosis of patients suffering an acute coronary syndrome while already under chronic clopidogrel therapy. ( Bonello, L; De Labriolle, A; Kent, KM; Lemesle, G; Pichard, AD; Roy, P; Satler, LF; Steinberg, DH; Suddath, WO; Torguson, R; Waksman, R, 2009)
" As compared with the conventional 300-mg dose, pretreatment with a 600-mg loading dose of clopidogrel significantly reduced periprocedural myocardial infarction (MI) in patients undergoing percutaneous coronary intervention (PCI)."7.75Clopidogrel pretreatment before primary percutaneous coronary stenting in patients with acute ST-segment elevation myocardial infarction: comparison of high loading dose (600 mg) versus low loading dose (300 mg). ( Byun, KH; Cho, JR; Choi, S; Jung, JH; Lee, N; Lee, SH; Min, PK; Sung, CW, 2009)
"To determine the association between the discontinuation of clopidogrel therapy prior to 1 year and the risk of acute myocardial infarction (AMI) hospitalization, coronary intervention or all-cause mortality in a cohort of managed-care patients following AMI hospitalization or stent insertion."7.75Clinical impact of early clopidogrel discontinuation following acute myocardial infarction hospitalization or stent implantation: analysis in a single integrated health network. ( Berenson, K; Casciano, R; Corbelli, J; Lamerato, L; Makenbaeva, D; Mozaffari, E; Stern, L; Wiederkehr, D, 2009)
"To evaluate the association between discontinuation of clopidogrel therapy and risk of acute myocardial infarction (AMI) hospitalization or cardiac revascularization in a nationally-representative patient population following hospitalization for an AMI or coronary stent insertion."7.75Clinical impact of early clopidogrel discontinuation following acute myocardial infarction hospitalization or stent implantation: analysis in a nationally representative managed-care population. ( Casciano, R; Corbelli, J; Makenbaeva, D; Mozaffari, E; Ogbonnaya, A; Wiederkehr, D, 2009)
"We evaluated the effect and optimal dose of clopidogrel pretreatment in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention (PPCI)."7.75Usefulness of pretreatment with high-dose clopidogrel in patients undergoing primary angioplasty for ST-elevation myocardial infarction. ( Behar, S; Beinart, R; Boyko, V; Fefer, P; Hammerman, H; Hod, H; Matetzky, S; Segev, A, 2009)
"Combinations of aspirin, clopidogrel, and vitamin K antagonists are widely used in patients after myocardial infarction."7.75Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. ( Abildstrom, SZ; Andersson, C; Gislason, GH; Hansen, ML; Hansen, PR; Hvelplund, A; Jørgensen, C; Køber, L; Madsen, JK; Sørensen, R; Torp-Pedersen, C, 2009)
" This study was designed to determine the relation between responses to aspirin and clopidogrel as assessed by a point-of-care assay (Verify Now, Accumetrics, San Diego, California) and periprocedural myocardial infarction (PMI) in patients undergoing elective PCI for stable angina."7.74Relation of low response to clopidogrel assessed with point-of-care assay to periprocedural myonecrosis in patients undergoing elective coronary stenting for stable angina pectoris. ( Barbato, E; Bartunek, J; Cuisset, T; De Bruyne, B; Hamilos, M; Sarma, J; Sarno, G; Vanderheyden, M; Wijns, W; Wyffels, E, 2008)
"To identify possible underuse by analysing initiation and persistence with clopidogrel treatment in an unselected population of patients admitted with myocardial infarction (MI) with or without subsequent percutaneous coronary intervention (PCI)."7.74Initiation and persistence with clopidogrel treatment after acute myocardial infarction: a nationwide study. ( Abildstrom, SZ; Fosbøl, EL; Gislason, GH; Køber, L; Madsen, JK; Rasmussen, S; Sørensen, R; Torp-Pedersen, C, 2008)
"The aim of this article is to examine whether clopidogrel and ticlopidine treatments produce similar clinical outcomes for patients receiving primary stenting for acute myocardial infarction (AMI)."7.74Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: results from the CADILLAC trial. ( Brener, M; Carroll, JD; Cox, DA; Cristea, E; Garcia, E; Grines, CL; Guagliumi, G; Lansky, AJ; Leon, MB; Mehran, R; Moses, J; Pietras, C; Rutherford, BD; Stone, GW; Stuckey, T; Tcheng, JE; Tsuchiya, Y; Turco, M, 2008)
"The purpose of this study was to evaluate the risk of stent thrombosis (ST), clinical outcomes, and the benefits of extended clopidogrel use after drug-eluting stent (DES) implantation."7.74Stent thrombosis, clinical events, and influence of prolonged clopidogrel use after placement of drug-eluting stent data from an observational cohort study of drug-eluting versus bare-metal stents. ( Cheong, SS; Hong, MK; Kim, JJ; Kim, YH; Lee, CW; Lee, SW; Park, DW; Park, SJ; Park, SW; Yun, SC, 2008)
"Patients with acute coronary syndrome without ST-segment elevation receiving clopidogrel in addition to acetylsalicylic acid (ASA) showed a 20% risk reduction in comparison to patients receiving ASA monotherapy (CURE trial)."7.74Long-term cost-effectiveness of clopidogrel in patients with acute coronary syndrome without ST-segment elevation in Germany. ( Brüggenjürgen, B; Ehlken, B; Lindgren, P; Rupprecht, HJ; Willich, SN, 2007)
"(i) to determine the proportion of "low-responders" or "resistants" patients during coronary syndrome (ii) to identify determinants of interindividual variability response to clopidogrel (iii) to compare aggregometry and VASP phosphorylation measured by flow cytometry."7.74[Platelet responsiveness to clopidogrel in patients with coronary syndrome. Comparison of platelet aggregation induced by ADP and flow cytometric analysis of intraplatelet VASP phosphorylation]. ( Bareiss, P; Chauvin, M; Desprez, D; Faure, A; Grunebaum, L; Jesel, L; Morel, O; Ohlmann, P; Roul, G; Viellard, C, 2007)
"Several health economic studies have shown that the use of clopidogrel is cost-effective to prevent ischemic events in non-ST-segment elevation myocardial infarction (NSTEMI) and unstable angina."7.74Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: a European model based on the CLARITY and COMMIT trials. ( Berg, J; Jönsson, B; Lindgren, P; Parry, D; Spiesser, J, 2007)
"In clinical practice, early therapy with clopidogrel, in addition, to aspirin in patients with NSTEMI is associated with a significant reduction of the combined endpoint of death, non-fatal reinfarction and non-fatal stroke after one year."7.74Clopidogrel in addition to aspirin reduces one-year major adverse cardiac and cerebrovascular events in unselected patients with non-ST segment elevation myocardial infarction. ( Bauer, T; Gitt, AK; Gottwik, M; Heer, T; Jünger, C; Köth, O; Senges, J; Wienbergen, H; Zahn, R; Zeymer, U, 2008)
"Rate of all-cause mortality or acute myocardial infarction (AMI) after stopping treatment with clopidogrel."7.74Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. ( Fihn, SD; Ho, PM; Jesse, RA; Larsen, GC; Magid, DJ; Peterson, ED; Rumsfeld, JS; Wang, L, 2008)
"The superiority of clopidogrel and aspirin versus aspirin alone for up to 1 year in patients who undergo percutaneous coronary intervention (PCI) after presenting with acute coronary syndromes without ST-segment elevation was demonstrated in the PCI-CURE study."7.73Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation. ( Caro, J; Chen, R; Culler, S; Gabriel, S; Jackson, J; Lamy, A; Mahoney, EM; Mehta, S; Weintraub, WS; Yuan, Y; Yusuf, S, 2006)
"To compare the effects of an aspirin-clopidogrel combination with those of the specific glycoprotein IIb/IIIa inhibitor tirofiban on myocardial no-reflow, nitric oxide concentration and activity of nitric oxide synthase (NOS) isoforms in a mini-swine model of acute myocardial infarction and reperfusion."7.73Different effects of tirofiban and aspirin plus clopidogrel on myocardial no-reflow in a mini-swine model of acute myocardial infarction and reperfusion. ( Gao, RL; Jing, ZC; Meng, L; Wang, YW; Wu, YJ; Yang, WX; Yang, YJ; You, SJ; Zhao, JL, 2006)
"Clopidogrel added to aspirin improved outcomes after hospitalization in patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS) in the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial, regardless of in-hospital treatment approach."7.73Clopidogrel to treat patients with non-ST-segment elevation acute coronary syndromes after hospital discharge. ( Bhatt, DL; Cannon, CP; Fintel, DJ; Gibler, WB; Harrington, RA; Mulgund, J; Newby, LK; Ohman, EM; Peterson, ED; Pollack, CV; Roe, MT; Smith, SC; Tricoci, P, 2006)
" All suffered stent thrombosis after discontinuation (in three cases prematurely) of clopidogrel therapy."7.73[Thrombosis of a coronary stent after discontinuing treatment with clopidogrel]. ( de Boer, MJ; Hautvast, RW; Heestermans, AA; Jaarsma, W; ten Berg, JM; van Werkum, JW, 2006)
"We sought to characterize patterns of clopidogrel use before coronary artery bypass grafting (CABG) and examine the drug's impact on risks for postoperative transfusions among patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS)."7.73Acute clopidogrel use and outcomes in patients with non-ST-segment elevation acute coronary syndromes undergoing coronary artery bypass surgery. ( Cannon, CP; Ferguson, TB; Gibler, WB; Mehta, RH; Mulgund, J; Ohman, EM; Peterson, ED; Pollack, CV; Roe, MT; Smith, SC, 2006)
"The incidence of subacute stent thrombosis (SAT) within 30 days after stenting with a sirolimus-eluting stent (Cypher) for acute myocardial infarction (AMI) was retrospectively compared to that with bare-metal stents (BMS)."7.73Documented subacute stent thrombosis within thirty days after stenting with sirolimus-eluting stent (Cypher) for acute myocardial infarction: a Japanese single center retrospective non-randomized study. ( Enta, K; Fuda, Y; Higashitani, M; Horie, T; Imai, K; Ishikawa, T; Mochizuki, S; Mutoh, M; Nakano, Y; Okada, H; Sakamoto, H; Satoh, T; Yamaguchi, J, 2006)
"Our study demonstrates an increased risk of major bleeding in unselected patients receiving combination therapy with ASA and clopidogrel after UAP or NSTEMI."7.73[Bleeding complications after treatment with clopidogrel and acetylsalicylic acid after acute coronary syndrome]. ( Kjaer, J; Larsen, CH; Mickley, H; Møller, JE; Poulsen, TS, 2006)
"We sought to assess the effect of clopidogrel on clinical events 1 year after discharge in survivors of ST-elevation myocardial infarction (STEMI) in clinical practice."7.73Effect of clopidogrel on 1-year mortality in hospital survivors of acute ST-segment elevation myocardial infarction in clinical practice. ( Bauer, T; Gitt, AK; Gottwik, M; Heer, T; Jünger, C; Koeth, O; Mark, B; Senges, J; Wienbergen, H; Zahn, R; Zeymer, U, 2006)
"We investigated whether a combination of clopidogrel and glycoprotein (GP) IIb/IIIa inhibitors safely decreases hospital mortality, reinfarction, and major bleeding beyond either therapy alone in patients with non-ST-elevation myocardial infarction (NSTEMI)."7.73Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4). ( Bromberg-Marin, G; Canto, JG; Marin-Neto, JA; Parsons, LS; Rogers, WJ, 2006)
"Despite the beneficial effect of an aspirin-clopidogrel combination in acute coronary syndrome, the incidence of ischaemic recurrences remains significant and very probably implicates a variability in the response to anti-platelet agents."7.73[Beneficial effect of a loading dose of 600 mg of clopidogrel on platelet parameters in patients admitted for acute coronary syndrome]. ( Alessi, MC; Bonnet, JL; Carvajal, J; Cuisset, T; Frère, C; Lambert, M; Morange, PE; Mouret, JP; Quilici, J; Saidi, LN, 2006)
"This study investigated the safety and efficacy of sirolimus-eluting stents (SESs) on early and late outcomes in patients with acute myocardial infarction."7.73[Promising efficacy of the sirolimus-eluting stent in patients with acute myocardial infarction]. ( Asai, T; Gochi, T; Hiramitsu, S; Hishida, H; Katoh, T; Maekawa, H; Matsushita, T; Morimoto, S; Murakami, Y; Murohara, T; Nomura, M; Okada, T; Ozaki, Y; Shimizu, T; Tani, T; Umeda, H; Watanabe, K; Yokoya, M; Yoshida, N, 2006)
"We report a case of a 76-year-old-man who developed spontaneous hemarthrosis of his right knee following clopidogrel-aspirin treatment."7.72Spontaneous hemarthrosis of the knee associated with clopidogrel and aspirin treatment. ( Behrens, P; Bernotat, J; Böhm, S; Gille, J; Löhr, JF, 2003)
"The antiplatelet effect of clopidogrel was studied prospectively in 60 consecutive patients who underwent primary angioplasty (percutaneous coronary intervention [PCI]) with stenting for acute ST-segment-elevation myocardial infarction (STEMI) to determine whether variability in response to clopidogrel affects clinical outcomes."7.72Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. ( Beinart, R; Bienart, R; Goldenberg, I; Guetta, V; Hod, H; Matetzky, S; Novikov, I; Pres, H; Savion, N; Shechter, M; Shenkman, B; Varon, D, 2004)
"Aspirin is widely used as an antiplatelet drug in patients with coronary heart disease."7.72Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (ASpirin non-responsiveness and Clopidogrel Endpoint Trial) design. ( Abdelnoor, M; Arnesen, H; Pettersen, AA; Seljeflot, I, 2004)
" The CURE trial shows that clopidogrel in addition to aspirin achieves this double goal, with a 20% relative risk reduction in the primary composite endpoint of cardiovascular death, myocardial infarction or stroke in the first 30 days."7.71[Clopidogrel in acute coronary syndromes with non-ST elevation. Clinical implications of the CURE trial]. ( Valentín, V, 2001)
"Recently the anti-platelet drug clopidogrel has been publicized in the press as a breakthrough in the treatment of myocardial infarction."7.71Clopidogrel--a myocardial infarction CURE? ( Bradley, C, 2001)
"In a large, randomized, placebo-controlled trial in centers that use a conservative approach to acute coronary syndromes, the antiplatelet drug clopidogrel (Plavix) decreased the rate of the combined end point of cardiovascular death, nonfatal myocardial infarction, or stroke by 20% in patients presenting with acute coronary syndromes without ST-segment elevation."7.71The CURE trial: using clopidogrel in acute coronary syndromes without ST-segment elevation. ( Bhatt, DL; Gerschutz, GP, 2002)
"The thienopyridine derivatives, ticlopidine and clopidogrel, provide alternatives to aspirin for use in the prevention of recurrent ischemic events in the post-myocardial infarction patient."7.70Aspirin and newer orally active antiplatelet agents in the treatment of the post-myocardial infarction patient. ( Pepine, CJ, 1998)
"This study sought to determine whether the duration of pretreatment with the adenosine diphosphate receptor antagonist ticlopidine prior to intracoronary stenting is associated with the incidence of procedure-related non-Q-wave myocardial infarctions (MIs)."7.70The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-Q-wave myocardial infarctions. ( Ellis, SG; Lauer, MS; Lincoff, AM; Moliterno, DJ; Mukherjee, DP; Steinhubl, SR; Topol, EJ, 1998)
" To monitor platelet function in patients with myocardial infarction (n=46) who were treated with the fibrinolytic agent reteplase, the glycoprotein (GP) IIb/IIIa blocker abciximab, and the ADP receptor antagonist ticlopidine, we developed a flow cytometric assay."7.70Flow cytometric monitoring of glycoprotein IIb/IIIa blockade and platelet function in patients with acute myocardial infarction receiving reteplase, abciximab, and ticlopidine: continuous platelet inhibition by the combination of abciximab and ticlopidine ( Bode, C; Kohler, B; Kübler, W; Moser, M; Nordt, T; Ohman, ME; Olschewski, M; Peter, K; Ruef, J; Straub, A, 2000)
"We examined the antithrombotic effect of ticlopidine on occlusive thrombi of small coronary arteries in (NZWxBXSB)F1 [(WxB)F1] male mice with myocardial infarction (MI) and systemic lupus erythematosus (SLE)."7.69Antithrombotic effect of ticlopidine on occlusive thrombi of small coronary arteries in (NZWxBXSB)F1 male mice with myocardial infarction and systemic lupus erythematosus. ( Fujiwara, H; Nakamura, Y; Shibata, Y; Suzuka, H; Tanaka, M; Yoshifusa, H, 1995)
"Twenty-eight subjects, 16 with old myocardial infarction (OMI) and a control group of 12, received ticlopidine 250 mg/day for 4 weeks."7.67Effects of exercise and ticlopidine on platelet function and prostanoids in patients with old myocardial infarction. ( Chang, HC; Ding, YA; Lee, KW; Liang, YB; Lin, KC, 1989)
"Survivors after cardiac arrest (CA) due to AMI undergo PCI and then receive dual antiplatelet therapy."6.82Antiplatelet efficacy of P2Y12 inhibitors (prasugrel, ticagrelor, clopidogrel) in patients treated with mild therapeutic hypothermia after cardiac arrest due to acute myocardial infarction. ( Bednar, F; Kopa, M; Kroupa, J; Motovska, Z; Ondrakova, M; Osmancik, P, 2016)
"Treatment with cangrelor reduced the incidence of MI at 48 hours (3."6.82Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition). ( Bhatt, DL; Cavender, MA; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Leonardi, S; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD, 2016)
" The primary efficacy endpoint was the incidence of major adverse cardiovascular events (MACE) at 24 weeks, defined as a composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal ischemic stroke."6.79Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study. ( Isshiki, T; Kimura, T; Kitagawa, K; Miyazaki, S; Nakamura, M; Nanto, S; Nishikawa, M; Ogawa, H; Saito, S; Takayama, M; Yokoi, H, 2014)
" The primary end point was major adverse cardiac events (death, MI, and ischemia-driven target vessel revascularization) at 12 months."6.74Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction. ( Cheong, SS; Cho, YH; Hong, MK; Hong, TJ; Jeong, MH; Kim, JJ; Kim, KS; Kim, YH; Lee, CW; Lee, JH; Lee, NH; Lee, SG; Lee, SH; Lim, DS; Park, DW; Park, SJ; Park, SW; Seong, IW; Seung, KB; Yang, JY; Yoon, J; Yun, SC, 2009)
" A significant dose-response was also observed for the vasodilator-stimulated phosphoprotein index, a measure of P2Y(12) receptor inhibition."6.72A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) t ( Bal-dit-Sollier, C; Beygui, F; Collet, JP; Drouet, L; Henry, P; Lellouche, N; Meuleman, C; Milleron, O; Montalescot, G; Sideris, G; Slama, M; Steg, PG, 2006)
"Despite improvements in the emergency treatment of myocardial infarction (MI), early mortality and morbidity remain high."6.71Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. ( Chen, YP; Chen, ZM; Collins, R; Jiang, LX; Liu, LS; Pan, HC; Peto, R; Xie, JX, 2005)
" Combined major adverse cardiovascular event (stroke, MI, and death) was not different in the two groups (OR 1."6.47Safety of clopidogrel being continued until the time of coronary artery bypass grafting in patients with acute coronary syndrome: a meta-analysis of 34 studies. ( Athanasiou, T; Malik, IS; Nijjer, SS; Watson, G, 2011)
" Aspirin and the thienopyridines, clopidogrel, and ticlopidine, are the most widely used oral antiplatelet agents in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention."6.24Antiplatelet therapy in percutaneous coronary intervention: integration of prasugrel into clinical practice. ( Giugliano, RP; Thomas, D, 2009)
"Aspirin has been convincingly shown to reduce stroke and death in men with transient ischemic attacks (it may possibly be beneficial to women also), myocardial infarction and death in patients with unstable angina, thromboembolic complications associated with artificial heart valves in patients receiving oral anticoagulants (although gastrointestinal bleeding is prohibitive with this combination), and thrombotic occlusion of silicone rubber arteriovenous cannulae in uremic patients undergoing hemodialysis."6.15Clinical trials evaluating platelet-modifying drugs in patients with atherosclerotic cardiovascular disease and thrombosis. ( Harker, LA, 1986)
"The major result events, included: (1) recurrence of ischemic stroke; (2) hemorrhagic transformation of ischemic stroke; (3) myocardial infarction; (4) the digestive hemorrhage."5.43[Retrospective cohort study for the impact on readmission of patients with ischemic stroke after treatment of aspirin plus clopidogrel or aspirin mono-therapy]. ( Gao, P; Hu, YH; Tang, X; Wei, CL; Yang, C; Zhang, YQ, 2016)
"All ticagrelor treatments improved left ventricular ejection fraction, acute (69."5.42Ticagrelor protects the heart against reperfusion injury and improves remodeling after myocardial infarction. ( Birnbaum, GD; Birnbaum, Y; Nanhwan, MK; Nylander, S; Perez-Polo, JR; Ye, Y, 2015)
"Stent thrombosis is a morbid complication after percutaneous coronary intervention."5.40Clopidogrel resistance in diabetic patient with acute myocardial infarction due to stent thrombosis. ( Duraj, L; Fedor, M; Fedorová, J; Galajda, P; Kovář, F; Kubisz, P; Mokáň, M; Samoš, M; Šimonová, R; Staško, J, 2014)
"In a murine model of myocardial reperfusion injury caused by transient coronary artery occlusion, APT102 also decreased infarct size by 51%, whereas clopidogrel was not effective."5.40Optimizing human apyrase to treat arterial thrombosis and limit reperfusion injury without increasing bleeding risk. ( Abendschein, D; Broekman, MJ; Chen, R; Drosopoulos, JH; Jeong, SS; Marcus, AJ; Moeckel, D; Nguyen, A; Robson, SC; Sun, X, 2014)
"Diabetes mellitus is an independent predictor of adverse clinical events after drug-eluting stent implantation."5.39Clinical efficacy and safety of biodegradable polymer-based sirolimus-eluting stents in patients with diabetes mellitus insight from the 4-year results of the create study. ( Chen, X; Han, Y; Jiang, T; Jing, Q; Li, Y; Liu, H; Ma, Y; Wang, G; Wang, S; Wang, X; Yan, G; Yang, L; Zhang, L; Zhu, G, 2013)
"Patients with more extensive coronary atherosclerosis have a higher rate of HPR, which might partly account for higher risk of periprocedural MI."5.36High residual platelet reactivity after clopidogrel: extent of coronary atherosclerosis and periprocedural myocardial infarction in patients with stable angina undergoing percutaneous coronary intervention. ( Barbato, E; Bartunek, J; De Bruyne, B; Di Sciascio, G; Heyndrickx, G; Mangiacapra, F; Muller, O; Ntalianis, A; Trana, C; Wijns, W, 2010)
"In conclusion, in a dog coronary thrombosis model, ticagrelor blocks ADP-induced platelet activation and aggregation; prevents platelet-mediated thrombosis; prolongs reperfusion time and reduces re-occlusion and cyclic flow variation; and significantly decreases infarct size and rapidly restores myocardial tissue perfusion."5.36Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model. ( Huang, Y; Khalil, M; Penn, MS; van Giezen, JJ; Wang, K; Wiktor, D; Zhou, X, 2010)
"Tirofiban was administered for 24 h and the IABP was withdrawn after 60 h."5.35Reversible clopidogrel resistance due to right ventricular myocardial infarction: risk factor of recurrent stent thrombosis? ( Braun-Dullaeus, RC; Hass, N; Ibrahim, K; Kolschmann, S; Strasser, RH, 2008)
"Pre-treatment of clopidogrel 600 mg is better than 300 mg loading for reducing periprocedural myocardial infarction (PMI)."5.34Prospective partially randomized comparison of clopidogrel loading versus maintenance dosing to prevent periprocedural myocardial infarction after stenting for stable angina pectoris: Results from the "Method of Clopidogrel Pre-treatment Undergoing Conven ( Ahn, CM; Ahn, KJ; Choi, JW; Hong, SJ; Joo, HJ; Kim, JS; Lim, DS; Park, JH; Yu, CW, 2020)
"Thrombocytopenia is rapid in onset and antibody mediated."5.32Repetitive profound thrombocytopenia after treatment with tirofiban: a case report. ( Erkoc, R; Eryonucu, B; Tuncer, M, 2004)
" Because of better side-effect profile and simpler dosing regime, clopidogrel has largely replaced ticlopidine."5.31Isolated profound thrombocytopenia associated with clopidogrel. ( Elmi, F; Peacock, T; Schiavone, J, 2000)
" The trial was halted after 84% of the anticipated number of patients had been enrolled because the data and safety monitoring board had determined that the combination of clopidogrel and aspirin was associated with both a lower risk of major ischemic events and a higher risk of major hemorrhage than aspirin alone at 90 days."5.27Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. ( Barsan, W; Conwit, RA; Easton, JD; Elm, JJ; Farrant, M; Johnston, SC; Kim, AS; Lindblad, AS; Palesch, YY, 2018)
"This study aimed to compare the effects of ticagrelor and clopidogrel on early neointimal healing assessed with optical coherence tomography (OCT) after drug-eluting stent (DES) implantation in patients with acute myocardial infarction (AMI)."5.27Randomized Comparison of Strut Coverage between Ticagrelor and Clopidogrel in Acute Myocardial Infarction at 3-Month Optical Coherence Tomography. ( Ahn, CM; Choi, D; Hong, MK; Hong, SJ; Jang, Y; Kim, BK; Kim, C; Kim, JS; Ko, YG, 2018)
" Patients undergoing percutaneous coronary intervention with a biolimus A9-eluting stent for stable coronary artery disease or acute coronary syndromes were randomly assigned (1:1) to 75-100 mg aspirin daily plus 90 mg ticagrelor twice daily for 1 month, followed by 23 months of ticagrelor monotherapy, or standard dual antiplatelet therapy with 75-100 mg aspirin daily plus either 75 mg clopidogrel daily (for patients with stable coronary artery disease) or 90 mg ticagrelor twice daily (for patients with acute coronary syndromes) for 12 months, followed by aspirin monotherapy for 12 months."5.27Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la ( Benit, E; Chichareon, P; Dominici, M; Ferrario, M; Hamm, C; Heg, D; Huber, K; Janssens, L; Jüni, P; McFadden, EP; Möllmann, H; Moschovitis, A; Onuma, Y; Serruys, PW; Slagboom, T; Steg, PG; Valgimigli, M; van Es, GA; Van Geuns, RJ; van Meijeren, C; Vranckx, P; Windecker, S; Zurakowski, A, 2018)
"The purpose of this study was to test whether different results between Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON (CHAMPION) PCI/PLATFORM and PHOENIX trials are due in part to different definitions of percutaneous coronary intervention (PCI)-related myocardial infarction (MI)."5.27Implications of different criteria for percutaneous coronary intervention-related myocardial infarction on study results of three large phase III clinical trials: The CHAMPION experience. ( Abnousi, F; Bhatt, DL; Gibson, CM; Hamm, CW; Harrington, RA; Leonardi, S; Lopes, RD; Mahaffey, KW; Mangum, S; Menozzi, A; Prats, J; Price, MJ; Steg, PG; Stone, GW; Todd, M; White, HD; Wilson, M, 2018)
"A dual pathway antithrombotic therapy approach combining low-dose rivaroxaban with a P2Y12 inhibitor for the treatment of patients with acute coronary syndromes had similar risk of clinically significant bleeding as aspirin and a P2Y12 inhibitor."5.24Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. ( Ardissino, D; Bahit, MC; Bode, C; Bueno, H; Claeys, MJ; Cornel, JH; Gibson, CM; Goto, S; Güray, Ü; Husted, S; James, SK; Kiss, RG; Montalescot, G; Mundl, H; Nicolau, JC; Ohman, EM; Park, DW; Plotnikov, A; Povsic, TJ; Rockhold, F; Roe, MT; Steg, PG; Strony, J; Sun, X; Tendera, M; Welsh, RC; White, J, 2017)
"The DAPT (Dual Antiplatelet Therapy) study randomized 11,648 patients free from ischemic and bleeding events 12 months after coronary stenting to continued thienopyridine plus aspirin therapy for an additional 18 months versus aspirin therapy alone."5.24Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study. ( Apruzzese, PK; Cutlip, DE; Kereiakes, DJ; Massaro, JM; Mauri, L; Secemsky, EA; Steg, PG; Yeh, RW, 2017)
"The aim of this study was to compare aspirin plus clopidogrel with aspirin alone as antithrombotic treatment following transcatheter aortic valve replacement (TAVR) for the prevention of ischemic events, bleeding events, and death."5.24Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomi ( Al-Qoofi, F; Chamandi, C; Côté, M; Dumont, E; Garcia Del Blanco, B; Généreux, P; Maluenda, G; Masson, JB; Paradis, JM; Pelletier, M; Rodés-Cabau, J; Serra, V; Thoenes, M; Webb, JG; Welsh, RC, 2017)
"The ITALIC (Is There a Life for DES After Discontinuation of Clopidogrel) trial showed that rates of bleeding and thrombotic events at 1 year were much the same with 6 versus 12 months of DAPT after percutaneous coronary intervention with second-generation drug-eluting stents."5.246- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin: Final Results of the ITALIC Trial (Is There a Life for DES After Discontinuation of Clopidogrel). ( Armengaud, J; Barragan, P; Ben Amer, H; Berlan, J; Blanchard, D; Bressolette, E; Carrie, D; Cassat, C; Castellant, P; Cazaux, P; Champagnac, D; Darremont, O; Dauphin, R; Delarche, N; Didier, R; Druelles, P; Dupouy, P; Furber, A; Gilard, M; Gommeaux, A; Hovasse, T; Jouve, B; Kermarrec, A; Kiss, RG; Le Breton, H; Levy, G; Lyuycx-Bore, A; Maillard, L; Majwal, T; Morice, MC; Noor, HA; Noryani, AAL; Ohlmann, P; Ormezzano, O; Paganelli, F; Sainsous, J; Schneeberger, M; Ungi, I; Wojcik, J, 2017)
" However, the greatest anti-ischaemic benefit of potent antiplatelet drugs over the less potent clopidogrel occurs early, while most excess bleeding events arise during chronic treatment."5.24Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. ( Aradi, D; Dézsi, CA; Felix, SB; Geisler, T; Gross, L; Hadamitzky, M; Holdt, L; Huber, K; Huczek, Z; Jacobshagen, C; Kiss, RG; Klopotowski, M; Koltowski, L; Komócsi, A; Massberg, S; Mehilli, J; Merkely, B; Neumann, FJ; Orban, M; Parma, R; Rieber, J; Schwinger, RHG; Sibbing, D; Trenk, D, 2017)
"Thienopyridine plus aspirin beyond 1 year after coronary stenting reduces myocardial infarction (MI) risk and increases bleeding risk in comparison with aspirin alone."5.24Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy). ( Cutlip, DE; D'Agostino, RB; Hsieh, WH; Kereiakes, DJ; Massaro, JM; Mauri, L; Stefanescu Schmidt, AC; Yeh, RW, 2017)
"The purpose of this study was to investigate outcomes of patients treated with prasugrel or clopidogrel after percutaneous coronary intervention (PCI) in a nationwide acute coronary syndrome (ACS) registry."5.22Comparison of prasugrel and clopidogrel-treated patients with acute coronary syndrome undergoing percutaneous coronary intervention: A propensity score-matched analysis of the Acute Myocardial Infarction in Switzerland (AMIS)-Plus Registry. ( Bernheim, AM; Eberli, FR; Erne, P; Kurz, DJ; Pedrazzini, G; Radovanovic, D; Roffi, M; Seifert, B; Windecker, S, 2016)
"High platelet reactivity (HPR) and presence of CYP2C19 loss-of-function alleles are associated with higher risk for periprocedural myocardial infarction in clopidogrel-treated patients undergoing percutaneous coronary intervention (PCI)."5.22Study design and rationale for Optimal aNtiplatelet pharmacotherapy guided by bedSIDE genetic or functional TESTing in elective percutaneous coronary intervention patients (ONSIDE TEST): a prospective, open-label, randomised parallel-group multicentre tri ( Aradi, D; Balsam, P; Filipiak, KJ; Huczek, Z; Kochman, J; Kołtowski, Ł; Opolski, G; Sibbing, D; Tomaniak, M, 2016)
"In CHAMPION PHOENIX, cangrelor reduced ischaemic events with no significant increase in GUSTO-defined severe bleeding."5.22The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX. ( Bhatt, DL; Blankenship, JC; Deliargyris, EN; Généreux, P; Gibson, CM; Gutierrez, JA; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD, 2016)
" prasugrel plus bivalirudin in patients with ST-segment elevation myocardial infarction."5.22Platelet function and coagulation in patients with STEMI and peri-interventional clopidogrel plus heparin vs. prasugrel plus bivalirudin therapy (BRAVE 4 substudy). ( Braun, D; Braun, S; Hausleiter, J; Kastrati, A; Knipper, A; Massberg, S; Mehilli, J; Orban, M; Petzold, T; Schulz, S; Sibbing, D, 2016)
"The effects of ticagrelor in the subpopulation of patients with ST-elevation myocardial infarction (STEMI) were consistent with those observed in the overall Platelet Inhibition and Patient Outcomes (PLATO) study."5.22Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention. ( Abtan, J; Angiolillo, DJ; Ardissino, D; Gabriel Steg, P; Harrington, RA; Hellkamp, A; Himmelmann, A; Husted, S; James, SK; Katus, HA; Meier, B; Schulte, PJ; Storey, RF; Velders, MA; Wallentin, L, 2016)
"We analyzed data from the randomized TRILOGY ACS (TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medically manage Acute Coronary Syndromes) trial of aspirin plus prasugrel or clopidogrel following ACS."5.22Spontaneous MI After Non-ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization: The TRILOGY ACS Trial. ( Ardissino, D; Armstrong, PW; Bhatt, DL; Fox, KA; Goodman, SG; Hamm, CW; Leonardi, S; Lopes, RD; Martinez, F; Neely, B; Neely, ML; Nicolau, JC; Ohman, EM; Prabhakaran, D; Roe, MT; White, HD; Winters, KJ, 2016)
"Medically managed patients with ACS in the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trial were randomised to clopidogrel versus prasugrel (plus aspirin), stratified by prior clopidogrel use."5.22Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients. ( Armstrong, PW; Boden, WE; Chin, CT; Corbalán, R; Dalby, AJ; Fox, KA; Gottlieb, S; Leiva-Pons, JL; Neely, B; Neely, ML; Ohman, EM; Prabhakaran, D; Roe, MT; Schiele, F; White, HD; Winters, KJ, 2016)
" Ticagrelor, a potent, reversibly binding P2Y12 receptor antagonist, is beneficial in patients with acute coronary syndrome and prior myocardial infarction."5.22Design and rationale for the Effects of Ticagrelor and Clopidogrel in Patients with Peripheral Artery Disease (EUCLID) trial. ( Baumgartner, I; Berger, JS; Blomster, J; Fowkes, FG; Heizer, G; Held, P; Hiatt, WR; Jones, WS; Katona, BG; Mahaffey, KW; Millegård, M; Norgren, L; Patel, MR; Reist, C, 2016)
"Compared with 12-month DAPT, 6-month DAPT did not increase the composite events of cardiac death, myocardial infarction, stroke, or TIMI major bleeding at 1 year in patients who underwent everolimus-eluting stent implantation."5.226-Month Versus 12-Month Dual-Antiplatelet Therapy Following Long Everolimus-Eluting Stent Implantation: The IVUS-XPL Randomized Clinical Trial. ( Choi, D; Her, AY; Hong, MK; Hong, SJ; Jang, Y; Kim, BK; Kim, JS; Kim, YH; Ko, YG; Shin, DH, 2016)
"Ticagrelor reduced cardiovascular events compared with clopidogrel in PLATO without increasing overall major bleeding."5.22Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. ( Bansilal, S; Becker, RC; Cannon, CP; Harrington, RA; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lopes, RD; Neely, B; Shimada, YJ; Steg, PG; Storey, RF; Wallentin, L; Wiviott, SD, 2016)
"Policosanol reduced platelet reactivity to a similar extent as high maintenance dose of clopidogrel without increasing bleeding rate."5.22Safety and efficacy of policosanol in patients with high on-treatment platelet reactivity after drug-eluting stent implantation: two-year follow-up results. ( Guo, L; Han, Y; Li, Y; Liu, X; Wang, X; Wang, Y; Xu, K; Zang, H; Zhao, W, 2016)
"The CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention) trial demonstrated that cangrelor significantly reduced periprocedural ischemic events in all-comer percutaneous coronary intervention with a modest increase in mild and moderate bleeding."5.22Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial. ( Abnousi, F; Abtan, J; Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD, 2016)
"The Elderly-ACS 2 study is a multicenter, randomized, parallel-group, open-label trial designed to demonstrate the superiority of a strategy of dual antiplatelet treatment using a reduced 5-mg daily dose of prasugrel over a standard strategy with a daily clopidogrel dose of 75mg in patients older than 74years with ACS (either ST- or non-ST-elevation myocardial infarction) undergoing early percutaneous revascularization."5.22A comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization: Design and rationale of the randomized Elderly-ACS 2 study. ( Bossi, I; Cacucci, M; Cavallini, C; Corrada, E; De Servi, S; Di Ascenzo, L; Ferrario, M; Ferri, LA; Gandolfo, N; Grosseto, D; Mariani, M; Moffa, N; Morici, N; Petronio, AS; Ravera, A; Savonitto, S; Sganzerla, P; Sibilio, G; Tondi, S; Tortorella, G; Toso, A, 2016)
"PLATO (n = 18,624) was a multicentre, double-blind, randomized trial in ACS, that showed a 16% reduction in cardiovascular death (CV-death), myocardial infarction (MI) and stroke with ticagrelor compared with clopidogrel, without significant increase in overall major bleeding."5.20Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial. ( Becker, RC; Emanuelsson, H; Hiatt, WR; Horrow, J; Husted, S; James, SK; Mahaffey, KW; Patel, MR; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, DM, 2015)
"We evaluated the impact of clopidogrel 150 mg/d in patients with chronic kidney disease (CKD) having clopidogrel resistance (CR) after percutaneous coronary intervention (PCI); 1076 consecutive patients with coronary artery disease (CAD) having CKD were enrolled."5.20High clopidogrel dose in patients with chronic kidney disease having clopidogrel resistance after percutaneous coronary intervention. ( Han, H; Li, Y; Liang, J; Liu, W; Liu, Y; Shi, D; Wang, Z; Yang, L; Zhang, L; Zhao, Y; Zhou, Y, 2015)
"Dual antiplatelet treatment (DAPT) with clopidogrel and aspirin represents common approach in prevention of thromboembolic events in patients with acute coronary syndrome undergoing percutaneous coronary intervention (PCI)."5.20Monitoring the efficacy of ADP inhibitor treatment in patients with acute STEMI post-PCI by VASP-P flow cytometry assay. ( Duraj, L; Fedor, M; Fedorová, J; Kovář, F; Kubisz, P; Mokáň, M; Samoš, M; Šimonová, R; Škorňová, I; Staško, J, 2015)
"MULTIPRAC demonstrated a steady increase in prasugrel use over time without an increase in bleeding rates compared to clopidogrel."5.20MULTInational non-interventional study of patients with ST-segment elevation myocardial infarction treated with PRimary Angioplasty and Concomitant use of upstream antiplatelet therapy with prasugrel or clopidogrel--the European MULTIPRAC Registry. ( Clemmensen, P; Danchin, N; Goedicke, J; Goldstein, P; Grieco, N; Ince, H; Ramos, Y; Schmitt, J, 2015)
"This study compared the timing of onset of antiplatelet action after treatment with clopidogrel and prasugrel at first medical contact in patients with ST-segment elevation myocardial infarction (STEMI) scheduled for primary percutaneous coronary intervention (PPCI)."5.20Double-blind, randomized, prospective comparison of loading doses of 600 mg clopidogrel versus 60 mg prasugrel in patients with acute ST-segment elevation myocardial infarction scheduled for primary percutaneous intervention: the ETAMI trial (early thieno ( Arntz, HR; Diller, F; Mark, B; Mochmann, HC; Montalescot, G; Thiele, H; Zahn, R; Zeymer, U, 2015)
" In this context, we aimed to compare ticagrelor versus high dose clopidogrel in patients with ST-segment elevation myocardial infarction (STEMI) who exhibit HPR post fibrinolysis."5.20Ticagrelor versus high dose clopidogrel in ST-segment elevation myocardial infarction patients with high platelet reactivity post fibrinolysis. ( Akinosoglou, K; Alexopoulos, D; Barampoutis, N; Hahalis, G; Karvounis, H; Koniari, I; Panagiotidis, T; Patsilinakos, S; Perperis, A; Xanthopoulou, I; Ziakas, A, 2015)
"The aim of this study was to examine the efficacy and bleeding outcomes of cangrelor in patients in the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]) who underwent percutaneous coronary intervention with bivalirudin."5.20Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]). ( Bhatt, DL; Cortese, B; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Liu, T; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD; Wilensky, M, 2015)
"Between 2009 and 2012, 2286 patients invasively managed for ACS were enrolled in the multicentre Swiss ACS Bleeding Cohort, among whom 2148 patients received either prasugrel or clopidogrel according to current guidelines."5.20Safety profile of prasugrel and clopidogrel in patients with acute coronary syndromes in Switzerland. ( Auer, R; Carballo, D; Gencer, B; Heg, D; Jaguszewski, M; Jakob, P; Jüni, P; Klingenberg, R; Landmesser, U; Lüscher, TF; Mach, F; Maier, W; Matter, CM; Meier, B; Nanchen, D; Räber, L; Rodondi, N; Roffi, M; Stähli, BE; Stefanini, GG; Templin, C; Vogt, P; Windecker, S, 2015)
"In the study, 96 patients suffering from acute ST segment elevation myocardial infarction onset within 12 h undergoing primary percutaneous coronary intervention from May to October in 2013 were randomly divided into ticagrelor group (n=48) and clopidogrel group (n=48) by using the method of random number table."5.20[Midterm follow-up outcomes of ticagrelor on acute ST segment elevation myocardial infarction undergoing emergency percutaneous coronary intervention]. ( Hu, SD; Qu, Y; Xia, JG; Xu, D; Xu, J; Yin, CL, 2015)
" Direct comparison of the antiplatelet effects between ticagrelor and high-dose clopidogrel has not yet been reported in acute myocardial infarction (AMI) or coronary artery in-stent restenosis (ISR) patients with HTPR."5.20Ticagrelor overcomes high platelet reactivity in patients with acute myocardial infarction or coronary artery in-stent restenosis: a randomized controlled trial. ( Cao, A; Chen, T; Li, P; Liu, J; Liu, Y; Ma, L; Qin, Y; Wang, Z; Yang, Y; Zhao, X, 2015)
"Few data on the relative efficacy and safety of new P2Y12inhibitors such as prasugrel and ticagrelor in Japanese, Taiwanese and South Korean patients with acute coronary syndromes (ACS) exist."5.20Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome -- randomized, double-blind, phase III PHILO study. ( Emanuelsson, H; Goto, S; Huang, CH; Kimura, T; Park, SJ, 2015)
"This study aimed to compare preoperative treatment using clopidogrel and ticagrelor for patients with acute myocardial infarction (AMI) undergoing emergent percutaneous coronary intervention (PCI), and to investigate the efficacy and safety of these medications in the management of AMI."5.20Pre-PCI medication using clopidogrel and ticagrelor in the treatment of patients with acute myocardial infarction. ( Fu, Q; Huang, YJ; Zhang, N; Zhang, Q; Zhu, K, 2015)
" Using inverse probability-weighted propensity modeling, we compared 6-month adjusted risks of Bleeding Academic Research Consortium (BARC) bleeding, stratifying by whether or not bleeding was associated with rehospitalization among patients discharged on aspirin + anticoagulant + clopidogrel (triple-C), aspirin + anticoagulant + prasugrel (triple-P), aspirin + clopidogrel (dual-C), or aspirin + prasugrel (dual-P)."5.20Outcomes of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy: A Comparison of Clopidogrel Versus Prasugrel From the TRANSLATE-ACS Study. ( Baker, BA; Cohen, DJ; Effron, M; Jackson, LR; Ju, C; Messenger, JC; Peterson, ED; Stone, GW; Wang, TY; Zettler, M, 2015)
"The goal of this study was to determine whether there is a relationship between aspirin dose and the potent antiplatelet agent prasugrel in the TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) study."5.19Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibit ( Antman, EM; Braunwald, E; Cannon, CP; Kohli, P; Murphy, SA; Udell, JA; Wiviott, SD, 2014)
"The relationships between Q waves that appear during the acute phase of ST-elevation myocardial infarction (STEMI), clinical characteristics, ST-segment resolution (STRes), and clopidogrel therapy in patients treated with fibrinolysis are not well described."5.19Clinical implications and correlates of Q waves in patients with ST-elevation myocardial infarction treated with fibrinolysis: observations from the CLARITY-TIMI 28 trial. ( Cannon, CP; Gibson, CM; Giugliano, RP; Morrow, DA; Sabatine, MS; Scirica, BM; Sloan, S; Waks, JW; Wiviott, SD, 2014)
"Prasugrel is more potent than clopidogrel, but it is not known whether this translates into clinical benefit in patients undergoing primary percutaneous coronary intervention (PCI) with bivalirudin for ST elevation myocardial infarction."5.19Outcomes in patients with ST-segment elevation acute myocardial infarction treated with clopidogrel versus prasugrel (from the INFUSE-AMI trial). ( Brener, SJ; El-Omar, M; Gibson, CM; Maehara, A; Mehran, R; Oldroyd, KG; Stone, GW; Witzenbichler, B; Xu, K, 2014)
"The aim of this study was to assess the relationship between sex and clinical outcomes and treatment-related complications in patients with ST-elevation or non-ST-elevation acute coronary syndromes (ACS) randomized to treatment with ticagrelor or clopidogrel in the PLATelet inhibition and patient Outcomes (PLATO) trial."5.19The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial. ( Bach, RG; Becker, RC; Budaj, A; Heras, M; Himmelmann, A; Horrow, J; Husted, S; James, SK; Katus, HA; Lassila, R; Morais, J; Nicolau, JC; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, D, 2014)
" clopidogrel in the non-ST-elevation acute coronary syndrome (NSTE-ACS) subgroup of the PLATO trial, in the total cohort, and in the subgroups managed with and without revascularization within 10 days of randomization."5.19Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. ( Cannon, CP; Cornel, JH; Harrington, RA; Himmelmann, A; Husted, S; James, SK; Lindholm, D; Maya, J; Steg, PG; Stevens, SR; Storey, RF; Varenhorst, C; Wallentin, L, 2014)
" Perioperative bleeding and composite of morbidity endpoints including myocardial infarction were compared in relation to the tertile distribution of the fibrinogen concentration."5.19Impact of preoperative fibrinogen concentration on postoperative outcome in patients who received dual antiplatelet therapy in proximity to off-pump coronary bypass surgery. ( Kim, EK; Kim, NY; Kwak, YL; Shim, JK; Song, JW, 2014)
"Whether prasugrel plus bivalirudin is a superior strategy to unfractionated heparin plus clopidogrel in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) has never been assessed in specifically designed randomized trials."5.19Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction. ( Abdel-Wahab, M; Anette Fiedler, K; Gershlick, AH; Hoppmann, P; Ibrahim, T; Kastrati, A; Kufner, S; Laugwitz, KL; Mehilli, J; Mehran, R; Morath, T; Neudecker, J; Richardt, G; Schneider, S; Schulz, S; Schunkert, H; Tölg, R, 2014)
"In the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38), prasugrel reduced the primary ischaemic endpoint as compared with clopidogrel in acute coronary syndrome (ACS) patients planned to undergo percutaneous coronary interventions, but increased the risk of bleeding."5.19Clinical outcomes for prasugrel versus clopidogrel in patients with unstable angina or non-ST-elevation myocardial infarction: an analysis from the TRITON-TIMI 38 trial. ( De Servi, S; Goedicke, J; Schirmer, A; Widimsky, P, 2014)
"This study sought to evaluate the efficacy of prasugrel versus clopidogrel in ST-segment elevation myocardial infarction (STEMI) by the timing of percutaneous coronary intervention (PCI)."5.19Prasugrel versus clopidogrel in patients with ST-segment elevation myocardial infarction according to timing of percutaneous coronary intervention: a TRITON-TIMI 38 subgroup analysis (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Plate ( Antman, EM; Braunwald, E; Montalescot, G; Murphy, SA; Udell, JA; Wiviott, SD, 2014)
"In TRITON-TIMI 38, patients with acute coronary syndromes were treated with prasugrel or clopidogrel, with aspirin, for a median of 14."5.19An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel. ( Costigan, T; Iqbal, K; Lopez-Sendon, J; Ramos, Y; Widimsky, P; Wilcox, R, 2014)
"The direct-acting platelet P2Y12 receptor antagonist ticagrelor can reduce the incidence of major adverse cardiovascular events when administered at hospital admission to patients with ST-segment elevation myocardial infarction (STEMI)."5.19Prehospital ticagrelor in ST-segment elevation myocardial infarction. ( Baradat, C; Bolognese, L; Cantor, WJ; Cequier, A; Chettibi, M; Collet, JP; Ecollan, P; Goodman, SG; Hamm, CW; Hammett, CJ; Heutz, WM; Huber, K; Janzon, M; Lapostolle, F; Lassen, JF; Licour, M; Merkely, B; Montalescot, G; Silvain, J; Stibbe, O; Storey, RF; Swahn, E; Tsatsaris, A; van 't Hof, AW; Vicaut, E; Willems, FF; Zeymer, U, 2014)
"This study sought to investigate the relationship of polymorphisms in ABCB1 and the predictive value of thromboelastography (TEG) on bleeding risk in clopidogrel-treated patients with ST-elevation myocardial infarction (STEMI)."5.19Relationship between ABCB1 polymorphisms, thromboelastography and risk of bleeding events in clopidogrel-treated patients with ST-elevation myocardial infarction. ( Chen, J; Gao, RL; Gao, Z; Ma, YL; Meng, XM; Song, L; Tang, XF; Wang, J; Wu, Y; Xu, B; Yao, Y; Yuan, JQ; Zhang, JH; Zhang, Y, 2014)
"To detect residual platelet aggregation following the switch from generic (GC) to brand clopidogrel (BC) in male patients after ST-elevated myocardial infarction (STEMI)."5.19Switching from generic to brand clopidogrel in male patients after ST-elevated myocardial infarction. ( Franskavichene, LV; Golukhova, EZ; Serebruany, VL; Syvolap, VV, 2014)
"Definite/probable ST and MB (TIMI major and Bleeding Academic Research Consortium (BARC) ≥ 3) were compared in 2 subsequent trials with similar inclusion criteria but different DAPT duration, that is, BASKET (6 months; n = 557) and BASKET-PROVE (12 months; n = 2,314), between months 0 to 6 (DAPT in both trials), 7 to 12 (DAPT in BASKET-PROVE only), and 13 to 24 (aspirin in both trials) using propensity score-adjusted, time-stratified Cox proportional hazard models."5.19Tradeoff between bleeding and stent thrombosis in different dual antiplatelet therapy regimes: Importance of case fatality rates and effective treatment durations. ( Alber, H; Bonetti, PO; Eberli, F; Erne, P; Galatius, S; Jeger, RV; Kaiser, CA; Pedrazzini, G; Pfisterer, ME; Rickli, H; Sørensen, R; von Felten, S, 2014)
"We observed no interaction between vorapaxar and clopidogrel after non-ST-segment elevation acute coronary syndromes on efficacy or safety outcomes, supporting a complementary role of protease-activated receptor 1 and P2Y12 antagonism."5.19Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial. ( Armstrong, PW; Aylward, PE; Chen, E; Cornel, JH; Harrington, RA; Held, C; Huang, Z; Jennings, LK; Lokhnygina, Y; Mahaffey, KW; Moliterno, DJ; Strony, J; Tricoci, P; Van de Werf, F; Wallentin, L; White, HD, 2014)
" Then, patients with no MACCE or major bleeding will be randomized to receive either 36 additional months of clopidogrel plus aspirin or aspirin only."5.17Efficacy and safety of 12 versus 48 months of dual antiplatelet therapy after implantation of a drug-eluting stent: the OPTImal DUAL antiplatelet therapy (OPTIDUAL) trial: study protocol for a randomized controlled trial. ( Carrie, D; Cattan, S; Cayla, G; Eltchaninoff, H; Furber, A; Georges, JL; Helft, G; Le Feuvre, C; Leclercq, F; Metzger, JP; Prunier, F; Sebagh, L; Vicaut, E, 2013)
"Clopidogrel is recommended in patients with acute coronary syndrome (ACS) managed with PCI, but its effect on PCI-related myonecrosis in contemporary patients has not been quantified."5.17Quantification of the effect of clopidogrel on enzymatic infarct size related to a percutaneous coronary intervention in patients with acute coronary syndromes: insights from the CHAMPION percutaneous coronary intervention trial. ( Bhatt, DL; Dauerman, HL; Gibson, CM; Goodman, SG; Gruberg, L; Herrmann, HC; Leonardi, S; Lincoff, AM; Lokhnygina, Y; Lopes, RD; Mahaffey, KW; McLaurin, BT; Parikh, KH; Stebbins, A; Stone, GW; Todd, M; White, HD, 2013)
"The results indicate that tirofiban and warfarin combined with aspirin and clopidogrel could reduce the rates of MACCE and bleeding, and it could prevent non-acute stent thrombosis safely and effectively after percutaneous coronary intervention with DES."5.17[Prevention of non-acute stent thrombosis after drug-eluting stent implantation]. ( Gao, YX; Li, L; Li, Y; Sun, TW; Yu, XZ; Yuan, YQ; Zhao, XY, 2013)
"High residual platelet reactivity (RPR) on clopidogrel treatment has been associated with increased risk for ischemic events during follow-up in patients with acute coronary syndromes."5.17Incidence and outcome of high on-treatment platelet reactivity in patients with non-ST elevation acute coronary syndromes undergoing percutaneous coronary intervention (from the VIP [VerifyNow and Inhibition of Platelet Reactivity] study). ( Campo, G; De Palma, R; Guastaroba, P; Guiducci, V; Magnavacchi, P; Manari, A; Marino, M; Marzocchi, A; Saia, F; Sangiorgio, P; Taglieri, N; Tondi, S; Valgimigli, M; Varani, E, 2013)
" Across the baseline ST-segment depression strata, there was a consistent treatment benefit with ticagrelor versus clopidogrel on vascular death/myocardial infarction."5.17Quantitative ST-depression in acute coronary syndromes: the PLATO electrocardiographic substudy. ( Armstrong, PW; Fu, Y; Harrington, RA; James, S; Katus, H; Storey, RF; Wallentin, L; Westerhout, CM, 2013)
"Patients with a recently diagnosed ST-elevation myocardial infarction (STEMI) and implanted coronary drug-eluting stent (DES) who need urgent surgery are at increased risk of surgical bleeding unless aspirin and clopidogrel are discontinued beforehand."5.17Short-term follow-up of tirofiban as alternative therapy for urgent surgery patients with an implanted coronary drug-eluting stent after ST-elevation myocardial infarction. ( Liu, XH; Qu, Y; Shen, H; Xia, JG, 2013)
"Among patients who had angiography who took prasugrel there were fewer cardiovascular deaths, myocardial infarctions, or strokes than in those who took clopidogrel."5.17Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial. ( Armstrong, PW; Bhatt, DL; Boden, WE; Clemmensen, P; Fox, KA; Hafley, G; Hamm, C; Leiva-Pons, J; Lokhnygina, Y; Menozzi, A; Nicolau, JC; Ohman, EM; Oto, A; Pavlides, G; Prabhakaran, D; Roe, MT; Ruzyllo, W; White, HD; Widimsky, P; Winters, KJ; Wiviott, SD, 2013)
" Eligible patients were those with stable coronary artery disease or history of low-risk acute coronary syndrome (ACS) undergoing PCI with zotarolimus-eluting stents."5.17Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. ( Abizaid, A; Abizaid, AS; Bhatt, DL; Botelho, RV; Castello, HJ; Costa, JR; Costa, RA; de Castro, JP; de Paula, JE; Devito, FS; Feres, F; Gusmão, M; King, SB; Labrunie, A; Leon, MB; Liu, M; Mangione, JA; Marin-Neto, JA; Meireles, GX; Negoita, M; Nicolela, EL; Perin, MA; Salvadori, D; Staico, R, 2013)
"The TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38) enrolled 13,608 patients with an acute coronary syndrome (ACS) and planned percutaneous coronary intervention (PCI), and randomized them to clopidogrel or prasugrel."5.17Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarctio ( Antman, EM; Bates, ER; Mega, JL; Murphy, SA; O'Donoghue, ML; Ojeifo, O; Sabatine, MS; Udell, JA; Wiviott, SD, 2013)
" clopidogrel in patients with acute coronary syndromes (ACS) are well documented in the PLATelet inhibition and patient Outcomes trial (PLATO)."5.17Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study. ( Hauch, O; Henriksson, M; Janzon, M; Nikolic, E; Wallentin, L, 2013)
"105 patients with ST elevation myocardial infarction (STEMI), treated with percutaneous coronary angioplasty (PCI) and who received dual antiplatelet therapy, were randomized between pantoprazole (n=54) or ranitidine (n=51)."5.17Pantoprazole significantly interferes with antiplatelet effect of clopidogrel: results of a pilot randomized trial. ( Berti, S; Della Pina, F; Dushpanova, A; Gianetti, J; Giusti, B; Marcucci, R; Parri, MS; Saracini, C, 2013)
"Low dose aspirin reduces the secondary incidence of myocardial infarction and stroke."5.17Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin. ( FitzGerald, GA; Fries, S; Grant, GR; Grosser, T; Kapoor, SC; Lawson, JA, 2013)
"In the PLATelet inhibition and patient Outcomes (PLATO) study, 18 624 patients presenting with acute coronary syndromes randomly received ticagrelor (n=9333) or clopidogrel (n=9291)."5.17Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study. ( Angiolillo, DJ; Ardissino, D; Cannon, CP; Horrow, J; Husted, S; James, SK; Kohli, P; Maurer, G; Morais, J; Nicolau, JC; Oto, A; Reyes, E; Storey, RF; Wallentin, L, 2013)
"The purpose of this pre-specified analysis of the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY) was to assess device-specific outcomes relative to different duration of dual antiplatelet therapy (DAPT) after Everolimus- (EES), Paclitaxel (PES), Zotarolimus- (ZES-S) eluting, or bare metal stents (BMS)."5.17Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY). ( Borghesi, M; Ferrari, R; Parrinello, G; Tebaldi, M; Valgimigli, M; Vranckx, P, 2013)
"Ticagrelor, when compared with clopidogrel, reduced the 12-month risk of vascular death/myocardial infarction and stroke in patients with ST-elevation acute coronary syndromes intended to undergo primary percutaneous coronary intervention in the PLATelet inhibition and patient Outcomes (PLATO) trial."5.16ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial: insights from the ECG substudy. ( Armstrong, PW; Clemmensen, P; Fu, Y; Harrington, RA; Horrow, J; James, SK; Katus, H; Siha, H; Steg, PG; Storey, RF; Wallentin, L; Westerhout, CM, 2012)
"We examined the relationship between PPI use and 1-year cardiovascular events (cardiovascular death, myocardial infarction, or stroke) in patients with acute coronary syndrome randomized to clopidogrel or ticagrelor in a prespecified, nonrandomized subgroup analysis of the Platelet Inhibition and Patient Outcomes (PLATO) trial."5.16Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial. ( Angiolillo, DJ; Cannon, CP; Cantor, WJ; Clare, R; Goodman, SG; Harrington, RA; Husted, S; James, SK; Kilhamn, J; Mahaffey, KW; Nicolau, JC; Pieper, KS; Steg, PG; Storey, RF; Wallentin, L, 2012)
"The aim of this subanalysis was to assess the net clinical effect of prehospital administration of tirofiban in ST-elevation myocardial infarction (STEMI) patients with high risk of bleeding."5.16Net clinical benefit of prehospital glycoprotein IIb/IIIa inhibitors in patients with ST-elevation myocardial infarction and high risk of bleeding: effect of tirofiban in patients at high risk of bleeding using CRUSADE bleeding score. ( Dambrink, JH; Gosselink, AT; Hamm, C; Hermanides, RS; Ottervanger, JP; Stella, PR; ten Berg, JM; van 't Hof, AW; van Houwelingen, G, 2012)
"A regimen of 24 months of clopidogrel therapy in patients who had received a balanced mixture of drug-eluting or bare-metal stents was not significantly more effective than a 6-month clopidogrel regimen in reducing the composite of death due to any cause, myocardial infarction, or cerebrovascular accident."5.16Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. ( Borghesi, M; Campo, G; Cangiano, E; Castriota, F; Cavazza, C; Colombo, F; Ferrari, R; Frangione, A; Fucà, G; Kubbajeh, M; Marchesini, J; Minarelli, M; Monti, M; Parrinello, G; Percoco, G; Scalone, A; Tebaldi, M; Tumscitz, C; Valgimigli, M; Vranckx, P, 2012)
"The authors sought to compare the effect on inhibition of platelet aggregation (IPA) of prasugrel therapy versus tirofiban bolus with or without a post-bolus short drug infusion in ST-segment elevation myocardial infarction (STEMI) patients."5.16Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOppin ( Bristot, L; Campo, G; Ferrari, R; Gambetti, S; Monti, M; Parrinello, G; Tebaldi, M; Valgimigli, M, 2012)
"The main findings were a significant reduction of the primary outcome (death from vascular causes/myocardial infarction/stroke) with ticagrelor versus clopidogrel [9."5.16Lessons from platelet inhibition and patient outcomes. ( Held, C, 2012)
"We evaluated treatment effects of ticagrelor versus clopidogrel in patients with acute coronary syndrome with and without a history of prior stroke or TIA in the PLATelet inhibition and patient Outcomes (PLATO) trial."5.16Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack. ( Becker, RC; Husted, S; James, SK; Keltai, M; Khurmi, NS; Lopes, RD; Lopez-Sendon, JL; Mahaffey, KW; Maya, J; Morais, J; Nicolau, JC; Pais, P; Raev, D; Stevens, SR; Storey, RF, 2012)
"In patients undergoing nonurgent percutaneous coronary intervention and in comparison with clopidogrel, intravenous and oral elinogrel therapy did not significantly increase thrombolysis in myocardial infarction major or minor bleeding, although bleeding requiring medical attention was more common."5.16A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PC ( Angiolillo, DJ; Berdan, LG; Bhatt, DL; French, WJ; Gibson, CM; Gretler, DD; Gurbel, PA; Harrington, RA; Huber, K; Kochman, J; Leonardi, S; Madan, M; McClure, MW; Paynter, G; Rao, SV; Thompson, VP; Welsh, RC; Zeymer, U, 2012)
"The ISAR-REACT 4 (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment-4) platelet substudy aimed to determine the relevance of high on-clopidogrel treatment platelet reactivity (HPR) in non-ST-segment elevation myocardial infarction patients that received abciximab with unfractionated heparin (UFH) or bivalirudin during percutaneous coronary intervention (PCI)."5.16Prognostic value of a high on-clopidogrel treatment platelet reactivity in bivalirudin versus abciximab treated non-ST-segment elevation myocardial infarction patients. ISAR-REACT 4 (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action fo ( Bernlochner, I; Kastrati, A; Massberg, S; Mehilli, J; Schömig, A; Schulz, S; Sibbing, D, 2012)
"Thrombolysis, as reperfusion therapy for ST segment elevation myocardial infarction (STEMI), induces a pro-thrombotic status with enhanced platelet activity; this study aims to evaluate P2Y12 platelet reactivity and response to clopidogrel in the post-thrombolysis scenario."5.16P2Y12 platelet reactivity after thrombolytic therapy for ST-segment elevation myocardial infarction. ( Alonso-Rodríguez, D; Bangueses, R; Cuellas, C; de Miguel, A; de Prado, AP; Diego, A; Fernandez-Vazquez, F; Martín, J; Samaniego, B; Vega, B, 2012)
"It remains unclear whether concomitant use of omeprazole attenuates platelet function as compared with that of famotidine in patients with acute coronary syndromes (ACS) who receive clopidogrel."5.16Influence of omeprazole and famotidine on the antiplatelet effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes: a prospective, randomized, multicenter study. ( Endo, T; Fukui, K; Hibi, K; Himeno, H; Kimura, K; Morita, S; Sugano, T; Tsukahara, K; Umemura, S; Yano, H, 2012)
"Among patients with unstable angina or myocardial infarction without ST-segment elevation, prasugrel did not significantly reduce the frequency of the primary end point, as compared with clopidogrel, and similar risks of bleeding were observed."5.16Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. ( Ardissino, D; Armstrong, PW; Aylward, PE; Bhatt, DL; Boden, WE; Brown, EB; Cinteză, M; Clemmensen, P; Corbalan, R; Cornel, JH; Dalby, AJ; Fox, KA; Gasparovic, V; Goodman, SG; Gottlieb, S; Goudev, AR; Gurbel, PA; Hamm, C; Hochman, JS; Huber, K; Leiva-Pons, JL; Lokhnygina, Y; Martinez, F; McGuire, DK; McLendon, RC; Merkely, B; Nicolau, JC; Ohman, EM; Oto, A; Parkhomenko, A; Pavlides, G; Prabhakaran, D; Roe, MT; Ruzyllo, W; Topacio, GO; Tseng, CD; White, HD; Winters, KJ, 2012)
"There is a paucity of data regarding the early effectiveness of the proposed 600 mg clopidogrel loading dose (LD) on platelet reactivity (PR) in ST elevation myocardial infarction (STEMI) patients."5.16Prasugrel versus high dose clopidogrel to overcome early high on clopidogrel platelet reactivity in patients with ST elevation myocardial infarction. ( Alexopoulos, D; Athanassiadou, A; Damelou, A; Davlouros, P; Hahalis, G; Kassimis, G; Stavrou, EF; Theodoropoulos, KC; Tsigkas, G; Xanthopoulou, I, 2012)
"The optimal loading dose of clopidogrel in patients with chronic kidney disease who undergo primary percutaneous coronary intervention for ST-segment elevation myocardial infarction has not been investigated."5.16Impact of Clopidogrel loading dose in patients with chronic kidney disease undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. ( Ahn, YK; Chae, IH; Chae, SC; Cho, MC; Hong, TJ; Hur, SH; Jang, YS; Jeong, MH; Kim, JY; Kim, YJ; Moon, JH; Park, SJ; Seong, IW; Seung, KB; Yoon, JH, 2012)
"In this prospective, randomized trial in patients with acute myocardial infarction (AMI) admitted for primary percutaneous coronary intervention (PPCI), loaded with 600 mg clopidogrel, we hypothesized that eptifibatide administered downstream of the coronary occlusion leads to a lower degree of microvascular obstruction compared with no additional eptifibatide."5.16Microvascular effect of intracoronary eptifibatide in acute myocardial infarction. ( Bondor, CI; Cadiş, H; Iancu, A; Ober, C, 2012)
" Patients with an episode of noncardioembolic ischemic stroke at least 8 days prior to randomization, who were aged <75 years or had a body weight >50 kg were randomized to 50 or 75 mg clopidogrel once daily for 52 weeks."5.16Clopidogrel two doses comparative 1-year assessment of safety and efficacy (COMPASS) study in Japanese patients with ischemic stroke. ( Minematsu, K; Tanahashi, N; Uchiyama, S, 2012)
"Patients with medically managed unstable angina or non-ST-segment elevation myocardial infarction were enrolled in the TRILOGY ACS trial (2008 to 2011) comparing clopidogrel vs prasugrel."5.16Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. ( Armstrong, PW; Brown, E; Chan, MY; Cornel, JH; Erlinge, D; Fox, KA; Goodman, SG; Gurbel, PA; Huber, K; Jakubowski, JA; Neely, B; Neely, M; Ohman, EM; Prabhakaran, D; Roe, MT; Tantry, US; White, HD; Zhou, C, 2012)
"Presentation with an acute coronary syndrome (ACS) on chronic aspirin therapy is an independent predictor of adverse short-term outcomes."5.15Impact of chronic antiplatelet therapy before hospitalization on ischemic and bleeding events in invasively managed patients with acute coronary syndromes: the ACUITY trial. ( Ambrosio, G; Bertrand, ME; Gresele, P; Lincoff, AM; Mehran, R; Moses, JW; Ohman, EM; Steinhubl, S; Stone, GW; Tritto, I; White, HD; Zuchi, C, 2011)
"Any bleeding and TIMI major bleeding complications increase in patients aged ≥75 years treated with clopidogrel in addition to aspirin."5.15Safety of clopidogrel in older patients: a nonrandomized, parallel-group, controlled, two-centre study. ( Aydogdu, S; Balbay, Y; Cagirci, G; Cay, S; Demir, AD; Erbay, AR; Maden, O; Sen, N, 2011)
" We explored the relationship between GFR and angiographic and clinical outcomes in ST-segment elevation myocardial infarction (STEMI) patients receiving pharamacologic reperfusion, with or without clopidogrel."5.15Impact of reduced glomerular filtration rate on outcomes in patients with ST-segment elevation myocardial infarction undergoing fibrinolysis: a CLARITY-TIMI 28 analysis. ( Ahmed, S; Cannon, CP; Michael Gibson, C; Murphy, SA; Sabatine, MS, 2011)
"Among patients with high on-treatment reactivity after PCI with drug-eluting stents, the use of high-dose clopidogrel compared with standard-dose clopidogrel did not reduce the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or stent thrombosis."5.15Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. ( Angiolillo, DJ; Aragon, JR; Berger, PB; Bertrand, OF; Cannon, CP; Garratt, KN; Kandzari, DE; Lee, MS; Manoukian, SV; Price, MJ; Puri, S; Robbins, M; Schork, NJ; Spriggs, D; Stillablower, ME; Stillabower, ME; Stinis, CT; Tanguay, JF; Teirstein, PS; Topol, EJ, 2011)
"In this randomized crossover study analyzing patients after acute myocardial infarction, omeprazole coadministration showed a significant pharmacodynamic interaction with clopidogrel, whereas pantoprazole did not."5.15Omeprazole, but not pantoprazole, reduces the antiplatelet effect of clopidogrel: a randomized clinical crossover trial in patients after myocardial infarction evaluating the clopidogrel-PPIs drug interaction. ( Albuquerque, A; Araújo, C; Fontes-Carvalho, R; Pimentel-Nunes, P; Ribeiro, VG, 2011)
"The Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial included 3602 patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention who were randomized to heparin plus a glycoprotein IIb/IIIa inhibitor (GPI) (n=1802) versus bivalirudin monotherapy (n=1800)."5.15Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction. ( Brodie, BR; Caixeta, A; Cristea, E; Dangas, GD; Dudek, D; Guagliumi, G; Lansky, AJ; Mehran, R; Möeckel, M; Parise, H; Peruga, JZ; Stone, GW; Witzenbichler, B, 2011)
"The aim of this study was to assess the degree of platelet inhibition by adjunctive cilostazol in patients with acute myocardial infarction (AMI) according to hepatic cytochrome P450 2C19 (CYP2C19) genotype."5.15Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype. ( Hwang, JY; Hwang, SJ; Jeong, YH; Kim, IS; Kim, S; Koh, EH; Kwak, CH; Park, JR; Park, KS; Park, Y; Yun, SE, 2011)
"After an acute coronary syndrome, patients remain at risk of recurrent ischaemic events, despite contemporary treatment, including aspirin and clopidogrel."5.15Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. ( Budaj, A; Granger, CB; Khder, Y; Oldgren, J; Roberts, J; Siegbahn, A; Tijssen, JG; Van de Werf, F; Wallentin, L, 2011)
" The lowest risk of cardiovascular death, myocardial infarction, or stroke with ticagrelor compared with clopidogrel is associated with a low maintenance dose of concomitant aspirin."5.15Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. ( Angiolillo, DJ; Becker, RC; Cannon, CP; Carroll, K; Harrington, RA; Held, C; Horrow, J; James, S; Mahaffey, KW; Pieper, KS; Storey, RF; Wallentin, L; Wojdyla, DM, 2011)
"Residual platelet reactivity (RPR) after clopidogrel loading, measured by the VerifyNow assay, has been shown to predict 12-month clinical events in patients with acute coronary syndromes."5.15Residual platelet reactivity after clopidogrel loading in patients with ST-elevation myocardial infarction undergoing an unexpectedly delayed primary percutaneous coronary intervention. - Impact on intracoronary thrombus burden and myocardial perfusion-. ( Archontakis, S; Gafou, A; Kalogeras, KI; Kariori, MG; Moldovan, C; Papaioannou, TG; Stefanadis, C; Tzamalis, P; Vavuranakis, M; Vrachatis, DA, 2011)
" On-clopidogrel platelet reactivity was investigated in patients with previous angiographically confirmed STh, myocardial infarction (MI), and controls."5.15Relationship between clopidogrel-induced platelet P2Y12 inhibition and stent thrombosis or myocardial infarction after percutaneous coronary intervention-a case-control study. ( Erlinge, D; James, S; Koul, S; Lagerqvist, B; Siegbahn, A; Varenhorst, C; Wallentin, L, 2011)
"In the Gauging Responsiveness With A VerifyNow P2Y12 Assay: Impact on Thrombosis and Safety (GRAVITAS) trial, 6 months of high-dose clopidogrel did not reduce cardiovascular events compared with standard-dose clopidogrel in patients with high on-treatment platelet reactivity (OTR) after percutaneous coronary intervention, defined as OTR ≥230 P2Y12 reaction units according to the VerifyNow P2Y12 platelet function test."5.15Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial. ( Angiolillo, DJ; Berger, PB; Cannon, CP; Lillie, E; Manoukian, SV; Price, MJ; Tanguay, JF; Teirstein, PS; Topol, EJ, 2011)
" The elderly have an increased risk of (temporary) discontinuation of clopidogrel, which is associated with a higher risk of developing stent thrombosis (ST)."5.15Coronary stenting with the Genous™ Bio-Engineered R Stent™ in elderly patients. ( Beijk, M; Damman, P; de Winter, RJ; Iñiguez, A; Klomp, M; Ribeiro, EE; Silber, S; Sim, KH; Suryapranata, H; Tijssen, JG; Woudstra, P, 2011)
"The purpose of this study was to compare 600- and 300-mg clopidogrel loading doses in patients with ST-segment elevation myocardial infarction (STEMI)."5.15Outcome comparison of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results from the ARMYDA-6 MI (Antiplatelet therapy for Reduction of MYocar ( Barbato, E; Bárczi, G; Colonna, G; Di Sciascio, G; Edes, I; Mangiacapra, F; Merkely, B; Orlic, D; Ostojic, M; Pasceri, V; Patti, G; Wijns, W, 2011)
"Adding clopidogrel to aspirin therapy reduces stroke in patients with atrial fibrillation (AF) but increases hemorrhage."5.15Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable. ( Connolly, SJ; de Caterina, R; Eikelboom, JW; Hart, RG; Hirsh, J; Hohnloser, S; Ng, J; Pogue, J; Yusuf, S, 2011)
"In this large observational analysis of patients undergoing PCI, low-dose aspirin appeared to be as effective as higher doses in preventing ischaemic events but was also associated with a lower rate of major bleeding and an improved net efficacy to safety balance."5.14Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study. ( Avezum, A; Fox, KA; Gersh, BJ; Haladyn, K; Jolly, SS; Mehta, SR; Peters, RJ; Pogue, J; Rupprecht, HJ; Yusuf, S, 2009)
"Between April 1, 1996, and April 1, 2008, 259 young patients (aged <45 years) who survived a first myocardial infarction and were exposed to clopidogrel treatment for at least a month, were enrolled in a multicentre registry and underwent CYP2C19*2 determination."5.14Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. ( Bensimon, G; Beygui, F; Brugier, D; Cayla, G; Collet, JP; Esteve, JB; Funck-Brentano, C; Hulot, JS; Montalescot, G; Payot, L; Pena, A; Silvain, J; Villard, E, 2009)
"In 111 patients with acute ST segment elevation myocardial infarction (STEMI), duplo measurements of iron (Fe)-induced platelet aggregation (FIPA) were performed after clopidogrel, acetylsalicylic acid and/or tirofiban treatment."5.14Iron-induced platelet aggregation measurement: a novel method to measure platelet function in stenting for ST segment elevation myocardial infarction. ( Ottervanger, JP; Remijn, JA; Slingerland, RJ; Smit, JJ; van 't Hof, AW; van Oeveren, W; Zijlstra, F, 2009)
"Mechanical reperfusion with stenting for ST-elevation myocardial infarction (STEMI) is supported by dual antiplatelet treatment with aspirin and clopidogrel."5.14Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. ( Antman, EM; Braunwald, E; Gibson, CM; McCabe, CH; Montalescot, G; Murphy, SA; Wiviott, SD, 2009)
"Two Phase III studies comparing the safety and efficacy of clopidogrel with ticlopidine as antiplatelet agents for the secondary prevention of vascular events in patients with prior stroke were performed in Japan."5.14The safety and efficacy of clopidogrel versus ticlopidine in Japanese stroke patients: combined results of two Phase III, multicenter, randomized clinical trials. ( Fukuuchi, Y; Uchiyama, S; Yamaguchi, T, 2009)
"A total of 800 patients with acute ST-segment-elevation myocardial infarction within 24 hours from symptom onset, all treated with 600 mg clopidogrel, were randomly assigned in a double-blind fashion to receive either abciximab (n=401) or placebo (n=399) in the intensive care unit before being sent to the catheterization laboratory."5.14Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial. ( Dirschinger, J; Dotzer, F; Früngel, S; Huber, K; Kastrati, A; Martinoff, S; Mehilli, J; Moshage, W; Nekolla, SG; Pache, J; Schömig, A; Schulz, S; Schwaiger, M; Seyfarth, M, 2009)
"Vitamin K antagonists reduce the risk of stroke in patients with atrial fibrillation but are considered unsuitable in many patients, who usually receive aspirin instead."5.14Effect of clopidogrel added to aspirin in patients with atrial fibrillation. ( Chrolavicius, S; Connolly, SJ; Hart, RG; Hohnloser, SH; Pfeffer, M; Pogue, J; Yusuf, S, 2009)
"The aim of this study was to examine the interaction between cigarette smoking and the clinical efficacy of clopidogrel in ST-segment elevation myocardial infarction (STEMI)."5.14Interaction between cigarette smoking and clinical benefit of clopidogrel. ( Cannon, CP; Desai, NR; Jiang, S; Mega, JL; Sabatine, MS, 2009)
"TRITON-TIMI 38 randomized acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) to prasugrel or standard dose clopidogrel."5.14Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. ( Angiolillo, DJ; Antman, EM; Braunwald, E; Downey, WE; Frelinger, AL; Jakubowski, JA; Li, Y; McCabe, CH; Michelson, AD; Murphy, SA; Qin, J; Wiviott, SD; Xenopoulos, NP, 2009)
"Prasugrel is a novel thienopyridine that reduces new or recurrent myocardial infarctions (MIs) compared with clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention."5.14Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardi ( Antman, EM; Bonaca, MP; Bramucci, E; Braunwald, E; McCabe, CH; Morrow, DA; Murphy, SA; Nicolau, JC; Ruff, CT; Scirica, BM; White, HD; Wiviott, SD, 2009)
"We screened 1277 patients to enroll 93 aspirin, 147 clopidogrel, and 23 dual poor responders, based on a point-of-care assay, who underwent elective coronary angioplasty at 10 European sites for stable or low-risk unstable coronary artery disease."5.14Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho ( Angiolillo, DJ; Brugaletta, S; Campo, G; Colangelo, S; de Cesare, N; Ferrari, R; Furgieri, A; Hamon, M; Meliga, E; Parrinello, G; Percoco, G; Repetto, A; Sabatè, M; Valgimigli, M; Vranckx, P, 2009)
"The antiplatelet effect of standard or increased clopidogrel doses in patients with ST- segment elevation acute myocardial infarction (STEMI) has never been studied."5.14A randomised study comparing the antiplatelet and antiinflammatory effect of clopidogrel 150 mg/day versus 75 mg/day in patients with ST-segment elevation acute myocardial infarction and poor responsiveness to clopidogrel: results from the DOUBLE study. ( Alessi, L; Barozzi, C; Bassi, M; Branzi, A; De Servi, S; Lauria, G; Marzocchi, A; Ortolani, P; Palmerini, T; Reggiani, LB; Sangiorgi, D; Tomasi, L, 2010)
"Prasugrel reduced cardiovascular events as compared with clopidogrel in TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38) but with increased bleeding."5.14The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Pla ( Antman, EM; Braunwald, E; Finkelstein, A; Fridrich, V; McCabe, CH; Murphy, SA; O'Donoghue, M; Penny, WF; Sabatine, MS; Steg, PG; Wiviott, SD, 2009)
"The aim of this analysis was to evaluate whether routine pre-hospital administration of high-dose tirofiban in ST-segment elevation myocardial infarction (STEMI) decreases the incidence of early stent thrombosis after primary PCI."5.14Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction. ( De Boer, MJ; Dill, T; Gosselink, AT; Hamm, C; Heestermans, AA; Hoorntje, JC; Koopmans, PC; Ten Berg, JM; Van 't Hof, AW; Van Houwelingen, G; Van Werkum, JW, 2009)
"In patients who have an acute coronary syndrome with or without ST-segment elevation, treatment with ticagrelor as compared with clopidogrel significantly reduced the rate of death from vascular causes, myocardial infarction, or stroke without an increase in the rate of overall major bleeding but with an increase in the rate of non-procedure-related bleeding."5.14Ticagrelor versus clopidogrel in patients with acute coronary syndromes. ( Becker, RC; Budaj, A; Cannon, CP; Emanuelsson, H; Freij, A; Harrington, RA; Held, C; Horrow, J; Husted, S; James, S; Katus, H; Mahaffey, KW; Scirica, BM; Skene, A; Steg, PG; Storey, RF; Thorsén, M; Wallentin, L, 2009)
"Our aim was to determine whether a 600-mg loading dose of clopidogrel compared with 300 mg results in improved clinical outcomes in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI)."5.14Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: results from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. ( Aoki, J; Brodie, BR; Caixeta, A; Dangas, G; Dudek, D; Guagliumi, G; Kornowski, R; Mehran, R; Parise, H; Peruga, JZ; Rabbani, LE; Stone, GW; Witzenbichler, B, 2009)
"Cangrelor, when administered intravenously 30 minutes before PCI and continued for 2 hours after PCI, was not superior to an oral loading dose of 600 mg of clopidogrel, administered 30 minutes before PCI, in reducing the composite end point of death from any cause, myocardial infarction, or ischemia-driven revascularization at 48 hours."5.14Platelet inhibition with cangrelor in patients undergoing PCI. ( Amine, M; Angiolillo, DJ; Becker, RC; Bhatt, DL; Chew, DP; French, WJ; Gibson, CM; Goodman, SG; Harrington, RA; Kleiman, NS; Leisch, F; Lincoff, AM; Mahaffey, KW; McNulty, S; Montalescot, G; Parikh, KH; Pollack, CV; Skerjanec, S; Stone, GW; White, HD, 2009)
"We randomly assigned a total of 400 patients with ST-segment elevation myocardial infarction referred for primary percutaneous coronary intervention to treatment initiated before cardiac catheterization, with either heparin plus eptifibatide (201 patients) or heparin alone (199 patients), in addition to oral aspirin (160 mg) and high-dose clopidogrel (600 mg)."5.14Primary percutaneous coronary angioplasty with and without eptifibatide in ST-segment elevation myocardial infarction: a safety and efficacy study of integrilin-facilitated versus primary percutaneous coronary intervention in ST-segment elevation myocardi ( Froeschl, M; Glover, CA; Jadhav, S; Kass, M; Labinaz, M; Le May, MR; Marquis, JF; O'Brien, ER; So, DY; Thomas, A; Turek, M; Wells, GA, 2009)
"In the current era of early revascularization and routine use of dual antiplatelet therapy, the incremental benefit of warfarin to reduce the incidence of left ventricular thrombus (LVT) in patients with impaired left ventricular ejection fraction post anterior ST-elevation myocardial infarction (aSTEMI), remains uncertain."5.14Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial. ( Ahmad, M; Eikelboom, JW; Natarajan, MK; Salehian, O; Schwalm, JD, 2010)
"The use of dual antiplatelet therapy for a period longer than 12 months in patients who had received drug-eluting stents was not significantly more effective than aspirin monotherapy in reducing the rate of myocardial infarction or death from cardiac causes."5.14Duration of dual antiplatelet therapy after implantation of drug-eluting stents. ( Chae, JK; Cheong, SS; Choi, YJ; Chung, WS; Han, KH; Hur, SH; Jang, JS; Jeon, DS; Jeong, MH; Kang, SJ; Kim, KS; Kim, YH; Lee, BK; Lee, CW; Lee, K; Lee, NH; Lee, SG; Lee, SW; Lim, DS; Nah, DY; Park, DW; Park, HS; Park, SJ; Park, SW; Rha, SW; Seong, IW; Seung, KB; Yang, JY; Yoon, J; Yun, SC, 2010)
"This study sought to determine the efficacy of high-dose atorvastatin in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI)."5.14Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial. ( Cho, DK; Cho, JR; Cho, YH; Choi, D; Hong, MK; Jang, Y; Jeon, DW; Kim, BK; Kim, J; Kim, JS; Ko, YG; Lee, CJ; Lee, NH; Lee, SH; Oh, SJ; Yang, JY, 2010)
"In a double-blind randomized controlled trial, 108 patients undergoing infrainguinal revascularization or amputation for critical limb ischemia were maintained on aspirin (75 mg daily) and randomized to clopidogrel (600 mg prior to surgery, and 75 mg daily for 3 days; n = 50) or matched placebo (n = 58)."5.14Randomized controlled trial of dual antiplatelet therapy in patients undergoing surgery for critical limb ischemia. ( Burdess, A; Dawson, AR; Fox, KA; Garden, OJ; Murie, JA; Newby, DE; Nimmo, AF, 2010)
"In the Bavarian Reperfusion Alternatives Evaluation (BRAVE)-3 study upstream administration of abciximab additional to 600 mg clopidogrel loading did not reduce the infarct size in patients with acute ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary interventions."5.14One-year clinical outcomes with abciximab in acute myocardial infarction: results of the BRAVE-3 randomized trial. ( Birkmeier, KA; Dirschinger, J; Dotzer, F; Huber, K; Kastrati, A; Mehilli, J; Moshage, W; Ndrepepa, G; Schömig, A; Schulz, S; Seyfarth, M, 2010)
"ST-segment elevation myocardial infarction patients undergoing primary PCI in a regional STEMI network who received earlier pretreatment with a 600-mg loading dose of clopidogrel had less ischemic complications without increased bleeding or mortality."5.14Clopidogrel pretreatment in ST-elevation myocardial infarction patients transferred for percutaneous coronary intervention. ( Burke, MN; Duval, S; Henry, TD; Larson, DM; Lips, DL; Sharkey, SS; Solie, C; Steinhubl, S; Tschautscher, C, 2010)
"In a multicentre, controlled, randomized study, 320 patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention received a high-dose bolus of tirofiban given either in the ambulance (prehospital group) or in the catheterization laboratory."5.14Prehospital high-dose tirofiban in patients undergoing primary percutaneous intervention. The AGIR-2 study. ( Belle, L; Bonnefoy, E; Capel, O; Debaty, G; Dubien, PY; El Khoury, C; Mercier, C; Perret, T; Savary, D; Serre, P, 2010)
"In patients with an acute coronary syndrome who were referred for an invasive strategy, there was no significant difference between a 7-day, double-dose clopidogrel regimen and the standard-dose regimen, or between higher-dose aspirin and lower-dose aspirin, with respect to the primary outcome of cardiovascular death, myocardial infarction, or stroke."5.14Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. ( Afzal, R; Bassand, JP; Chrolavicius, S; Diaz, R; Eikelboom, JW; Fox, KA; Granger, CB; Jolly, S; Joyner, CD; Mehta, SR; Pogue, J; Rupprecht, HJ; Widimsky, P; Yusuf, S, 2010)
"Prespecified two-centre substudy of the prospective, international, multicentre, placebo controlled Ongoing Tirofiban in Myocardial Infarction Evaluation trial 2 (On-TIME-2 trial)."5.14Prehospital triple antiplatelet therapy in patients with acute ST elevation myocardial infarction leads to better platelet aggregation inhibition and clinical outcome than dual antiplatelet therapy. ( Dill, T; Hamm, C; Heestermans, T; Ottervanger, JP; Slingerland, R; Smit, JJ; ten Berg, J; van 't Hof, AW; van Werkum, JW, 2010)
"Poor response to clopidogrel is an independent predictor of periprocedural myocardial infarction and worse 1-year outcome in low-risk patients undergoing PCI, whereas poor response to aspirin failed to predict a worse outcome."5.14Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) tr ( Brugaletta, S; Campo, G; Colangelo, S; de Cesare, N; Ferrari, R; Fileti, L; Furgieri, A; Meliga, E; Russo, F; Valgimigli, M, 2010)
"To assess whether glycoprotein IIb/IIIa inhibition using tirofiban in low risk patients undergoing percutaneous coronary intervention (PCI) may reduce the risk of periprocedural myocardial infarction compared to standard care in poor responders to aspirin and/or clopidogrel."5.13Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel (3T/2R). Rationale for the study and protocol design. ( Angiolillo, DJ; Campo, G; Colangelo, S; de Cesare, N; Ferrari, F; Ferrari, R; Furgieri, A; Hamon, M; Kubbajeh, M; Meliga, E; Parrinello, G; Percoco, G; Repetto, A; Sabatè, M; Tumscitz, C; Valgimigli, M; Vranckx, P, 2008)
"In the TRITON-TIMI 38 trial, greater platelet inhibition with prasugrel reduced the first occurrence of the primary endpoint (cardiovascular death, MI, or stroke) compared with clopidogrel in patients with an acute coronary syndrome (ACS) undergoing planned percutaneous coronary intervention."5.13Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. ( Antman, EM; Braunwald, E; Huber, K; Lopez-Sendon, J; McCabe, CH; Morocutti, G; Murphy, SA; Weerakkody, G; Wiviott, SD, 2008)
"The trial did not meet the predefined criteria for noninferiority but showed similar rates of recurrent stroke with ASA-ERDP and with clopidogrel."5.13Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. ( Albers, GW; Bath, P; Bornstein, N; Chan, BP; Chen, ST; Cotton, D; Cunha, L; Dahlöf, B; De Keyser, J; Diener, HC; Donnan, GA; Estol, C; Gorelick, P; Gu, V; Hermansson, K; Hilbrich, L; Kaste, M; Lawton, WA; Lu, C; Machnig, T; Martin, RH; Ounpuu, S; Pais, P; Palesch, Y; Roberts, R; Sacco, RL; Skvortsova, V; Teal, P; Toni, D; Vandermaelen, C; Voigt, T; Weber, M; Yoon, BW; Yusuf, S, 2008)
" The Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38) showed an overall reduction in ischemic events with more intensive antiplatelet therapy with prasugrel than with clopidogrel but with more bleeding."5.13Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial I ( Angiolillo, DJ; Antman, EM; Braunwald, E; Corbalan, R; Dalby, AJ; Goodman, SG; McCabe, CH; Meisel, S; Murphy, SA; Purdy, DA; Verheugt, FW; Wiviott, SD, 2008)
" Among a high-risk NSTEMI population not undergoing PCI within 24 hours of arrival, the nonrandomized short-term use of clopidogrel is associated with a lower risk of inhospital mortality without an increased risk of major bleeding."5.13Use of and inhospital outcomes after early clopidogrel therapy in patients not undergoing an early invasive strategy for treatment of non-ST-segment elevation myocardial infarction: results from Can Rapid risk stratification of Unstable angina patients Su ( Alexander, D; Brown, DL; Cannon, CP; Fintel, DJ; Gibler, WB; Ohman, EM; Ou, FS; Peterson, ED; Pollack, CV; Roe, MT, 2008)
"Antiplatelet therapy with clopidogrel and acetylsalicylic acid (ASA) reduces major cardiovascular events in patients with ST and non-ST-segment-elevation acute coronary syndromes (ACS)."5.13Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. ( Bassand, JP; Chrolavicius, S; Diaz, R; Fox, KA; Granger, CB; Jolly, S; Mehta, SR; Rupprecht, HJ; Widimsky, P; Yusuf, S, 2008)
"This post-hoc analysis suggests that in acute coronary syndrome patients, as long as clopidogrel is administered before or within 30 min of PCI treatment with bivalirudin alone is similarly effective to heparin plus a GP IIb/IIIa inhibitor in suppressing 30-day ischemic events with significantly less bleeding."5.13Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and U ( Bertrand, ME; Chew, D; Cox, DA; Desmet, W; Feit, F; Lincoff, AM; Manoukian, SV; Mehran, R; Ohman, EM; Pollack, CV; Steinhubl, SR; Stone, GW; Ware, JH, 2008)
"The purpose of this study was to evaluate the effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention (PCI) with glycoprotein (GP) IIb/IIIa blockade."5.13The effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention: a BRIEF-PCI (Brief Infusion of Intravenous Eptifibatide Following Successful Percutaneous Coronary Intervention) trial substudy. ( Buller, C; Densem, C; Fox, R; Fung, A; Jokhi, P; Mancini, GB; Ricci, D; Saw, J; Starovoytov, A; Walsh, S; Wong, G, 2008)
"The aim of this study is to investigate whether the benefit of abciximab in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACSs) undergoing percutaneous coronary intervention (PCI) after pre-treatment with 600 mg clopidogrel is sustained at 1 year."5.13One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: results of the ISAR-REACT 2 randomized trial. ( Berger, PB; Bruskina, O; Dirschinger, J; Dotzer, F; Kastrati, A; Mehilli, J; Ndrepepa, G; Neumann, FJ; Pache, J; Schömig, A; Seyfarth, M; ten Berg, J, 2008)
" The association of hypoglycemia and mild hyperglycemia with angiographic outcomes and the effect of clopidogrel on these outcomes have not been extensively evaluated."5.13Association of blood glucose with angiographic and clinical outcomes among patients with ST-segment elevation myocardial infarction (from the CLARITY-TIMI-28 study). ( Cannon, CP; Gibson, CM; Kirtane, AJ; Murphy, SA; Pinto, DS; Pride, YB; Sabatine, MS, 2008)
"In the CLARITY-TIMI 28 (Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis In Myocardial Infarction 28) study, 3,491 patients underwent angiography a median of 3."5.13Association of impaired thrombolysis in myocardial infarction myocardial perfusion grade with ventricular tachycardia and ventricular fibrillation following fibrinolytic therapy for ST-segment elevation myocardial infarction. ( Buros, JL; Cannon, CP; Gibson, CM; Josephson, ME; Lord, E; Murphy, SA; Pinto, DS; Pride, YB; Sabatine, MS; Shui, A; Zimetbaum, PJ, 2008)
"To investigate the association between neutrophil count, outcomes, and benefit of clopidogrel therapy in ST-elevation myocardial infarction (STEMI)."5.13Association between baseline neutrophil count, clopidogrel therapy, and clinical and angiographic outcomes in patients with ST-elevation myocardial infarction receiving fibrinolytic therapy. ( Cannon, CP; Gibson, CM; Guo, W; Morrow, DA; Murphy, SA; O'Donoghue, M; Sabatine, MS, 2008)
" Seventeen patients with acute myocardial infarction were divided into 2 groups: (A) clopidogrel plus tirofiban infusion administered together during inclusion (n = 10); (B) clopidogrel administered at inclusion and followed 2 hours after by tirofiban (n = 7)."5.13Effects of coronary prestenting platelet inhibition on coronary poststenting inflammation. ( Azcona, L; Farré, J; Fernández-Ortiz, A; López-Farré, AJ; Macaya, C; Romero, J; Sacristán, D; Zamorano-León, JJ, 2008)
" Whether the addition of intravenous tirofiban during this procedure produces further benefit has not been clarified in ST segment elevation myocardial infarction (STEMI) patients."5.13Effect of tirofiban plus clopidogrel and aspirin on primary percutaneous coronary intervention via transradial approach in patients with acute myocardial infarction. ( Fan, WZ; Fu, XH; Geng, W; Gu, XS; Hao, GZ; Hao, QQ; Jia, XW; Jiang, YF; Li, SQ; Wu, WL, 2008)
"Clopidogrel in mild or moderate CKD patients may not have the same beneficial effect as it does in patients with normal renal function, but was not associated with a greater relative risk of bleeding based on renal function."5.13The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. ( Berger, PB; Best, PJ; Brennan, DM; Califf, RM; Dasgupta, A; Steinhubl, SR; Szczech, LA; Topol, EJ, 2008)
"Intensive antiplatelet therapy with prasugrel resulted in fewer ischaemic outcomes including stent thrombosis than with standard clopidogrel."5.13Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomi ( Antman, EM; Braunwald, E; Downey, WE; Herrman, JP; Horvath, I; Keltai, M; McCabe, CH; Murphy, SA; Scirica, BM; Van de Werf, F; Wiviott, SD, 2008)
"Prasugrel is superior to clopidogrel in preventing ischemic events in patients with an acute coronary syndrome who are undergoing percutaneous coronary intervention, but it is associated with an increased risk of major bleeding."5.13Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolys ( Antman, EM; Braunwald, E; Chandna, H; Hasin, Y; Macias, W; McCabe, CH; Murphy, SA; Voitk, J; Widimsky, P; Wiviott, SD, 2008)
"Aspirin can inhibit inflammatory reactions and platelet aggregation, but little is known about the effects of the combination of aspirin plus clopidogrel, a new antiplatelet agent, on inflammation."5.12Effect of aspirin plus clopidogrel on inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome. ( Chen, YG; Ji, QS; Li, RJ; Lü, RJ; Sun, Y; Xu, F; Zhang, Y, 2006)
" Overall, clopidogrel plus aspirin was not significantly more effective than aspirin alone in reducing the rate of myocardial infarction, stroke, or death from cardiovascular causes."5.12Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. ( Berger, PB; Bhatt, DL; Black, HR; Boden, WE; Booth, J; Brennan, DM; Cacoub, P; Cohen, EA; Creager, MA; Easton, JD; Fabry-Ribaudo, L; Flather, MD; Fox, KA; Hacke, W; Haffner, SM; Hamm, CW; Hankey, GJ; Johnston, SC; Mak, KH; Mas, JL; Montalescot, G; Pearson, TA; Steg, PG; Steinhubl, SR; Topol, EJ; Weber, MA, 2006)
" We sought to determine the efficacy and safety of single high-dose bolus (HDB) tirofiban with high-dose clopidogrel loading in primary PCI in acute ST elevation myocardial infarction."5.12Single high-dose bolus tirofiban with high-loading-dose clopidogrel in primary coronary angioplasty. ( Akbulut, T; Akgoz, H; Bilsel, T; Ciloglu, F; Dayi, SU; Ergelen, M; Sayar, N; Terzi, S; Yesilcimen, K, 2006)
"The CLARITY-TIMI 28 (Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction 28) trial randomized 3,491 patients with ST-segment elevation myocardial infarction (STEMI) undergoing fibrinolysis to clopidogrel versus placebo."5.12The role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST-segment elevation myocardial infarction: the ECG CLARITY-TIMI 28 Study. ( Braunwald, E; Cannon, CP; Gibson, CM; Giugliano, RP; McCabe, CH; Morrow, DA; Murphy, SA; Sabatine, MS; Scirica, BM; Wiviott, SD, 2006)
"Efficacy of clopidogrel in acute myocardial infarction (AMI) was studied only in two trials."5.12[Effectiveness and safety of clopidogrel bisulfate in complex therapy of patients with acute coronary syndrome with ST segment elevation]. ( Giliarov, MIu; Malova, EV; Novikova, NA; Sulimov, VA; Syrkin, AL, 2006)
" Approximately 13,000 patients with moderate to high-risk ACS undergoing PCI (9500 unstable angina/non-ST-segment elevation myocardial infarction [MI], 3500 ST-segment elevation MI) will be randomized to prasugrel 60 mg loading dose followed by 10 mg daily or clopidogrel 300 mg loading dose followed by 75 mg daily for up to 15 months."5.12Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infar ( Antman, EM; Braunwald, E; Gibson, CM; McCabe, CH; Montalescot, G; Riesmeyer, J; Warmke, JW; Weerakkody, G; Winters, KJ; Wiviott, SD, 2006)
"Aspirin resistance may increase up to more then threefold the risk of major cardiovascular events (MACE) in patients with stable coronary artery disease."5.12The role of aspirin resistance on outcome in patients with acute coronary syndrome and the effect of clopidogrel therapy in the prevention of major cardiovascular events. ( Mercanoglu, F; Meric, M; Nisanci, Y; Oflaz, H; Oncul, A; Ozcan, M; Pamukcu, B; Umman, B, 2006)
"Addition of clopidogrel to medical reperfusion of STEMI with fibrinolysis, heparin, and aspirin before reaching the hospital is feasible in medically equipped ambulances without an apparent increase in bleeding."5.12Prehospital fibrinolysis with dual antiplatelet therapy in ST-elevation acute myocardial infarction: a substudy of the randomized double blind CLARITY-TIMI 28 trial. ( Adgey, J; Cannon, CP; Lambert, Y; Lapostolle, F; Montalescot, G; Sabatine, MS; Soulat, L; Verheugt, FW, 2007)
"Aspirin resistance may increase the risk of major adverse cardiac events (MACE) more than threefold in patients with stable coronary artery disease (CAD)."5.12Clinical relevance of aspirin resistance in patients with stable coronary artery disease: a prospective follow-up study (PROSPECTAR). ( Mercanoglu, F; Meric, M; Nisanci, Y; Oflaz, H; Oncul, A; Onur, I; Ozcan, M; Pamukcu, B; Umman, B, 2007)
"The Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction 28 (CLARITY-TIMI 28) trial was a randomized, double-blind, placebo-controlled study of clopidogrel in 3,491 patients receiving fibrinolytic therapy for ST-segment elevation myocardial infarction."5.12Benefits and risks of clopidogrel pretreatment before coronary artery bypass grafting in patients with ST-elevation myocardial infarction treated with fibrinolytics in CLARITY-TIMI 28. ( Cannon, CP; Guo, W; McCabe, CH; McLean, DS; Sabatine, MS, 2007)
"Impaired antiplatelet response to clopidogrel but not to aspirin may contribute to smaller anti-inflammatory response in patients with ST-elevation myocardial infarction."5.12Relation between impaired antiplatelet response to clopidogrel and possible pleiotropic effects. ( Bobilewicz, D; Filipiak, KJ; Grabowski, M; Huczek, Z; Imiela, T; Malek, LA; Opolski, G; Spiewak, M; Szpotanska, M, 2007)
"Sirolimus-eluting stents (SESs) recently proved to be superior to bare metal stents (BMSs) in decreasing the need for repeat revascularization in patients with ST-segment elevation myocardial infarction (STEMI) at 1 year."5.12Comparison of three-year clinical outcome of sirolimus- and paclitaxel-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction (from the RESEARCH and T-SEARCH Registries). ( Daemen, J; de Jaegere, PP; García-García, HM; Kukreja, N; Serruys, PW; Sianos, G; Tanimoto, S; van de Sande, M; van Domburg, RT, 2007)
" The aim of the study was to assess the impact of clopidogrel on safety and efficacy in patients with renal dysfunction in non-ST elevation acute coronary syndromes."5.12Renal function and outcomes in acute coronary syndrome: impact of clopidogrel. ( Hawken, S; Keltai, M; Lewis, BS; Mann, JF; Mehta, SR; Sitkei, E; Tonelli, M; Yusuf, S, 2007)
" The rate of cardiovascular death, MI, or stroke was significantly lower in the clopidogrel plus aspirin arm than in the placebo plus aspirin arm: 7."5.12Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. ( Berger, PB; Bhatt, DL; Black, HR; Boden, WE; Cacoub, P; Cohen, EA; Creager, MA; Easton, JD; Fabry-Ribaudo, L; Flather, MD; Fox, KA; Hacke, W; Hamm, CW; Hankey, GJ; Hu, T; Johnston, SC; Mak, KH; Mas, JL; Montalescot, G; Pearson, TA; Steg, PG; Steinhubl, SR; Topol, EJ; Weber, MA, 2007)
"The purpose of this study was to determine the efficacy and safety of enoxaparin (ENOX) versus unfractionated heparin (UFH) in patients with ST-segment elevation myocardial infarction (STEMI) receiving fibrinolytic therapy with and without clopidogrel."5.12Efficacy and safety of enoxaparin versus unfractionated heparin in patients with ST-segment elevation myocardial infarction also treated with clopidogrel. ( Antman, EM; Braunwald, E; Dalby, A; Duris, T; Gao, R; Lopez-Sendon, J; Morrow, DA; Murphy, SA; Pfisterer, M; Sabatine, MS, 2007)
"To assess the efficacy and safety of a treatment with clopidogrel when associated or not to the treatment with tirofiban and aspirin for high-risk non-ST segment elevation myocardial infarction (non-STEMI), without early angioplasty."5.12[Absence of benefit with triple antiaggregation in acute non persistent ST segment elevation myocardial infarction in patients not subjected to early interventionism]. ( Blancas Gómez-Casero, R; Chana García, M; González Manzanares, JL; López Matamala, B; Martín Delgado, C; Martínez Díaz, C; Nevado Losada, E; Serrano Castañeda, J; Yáñez Parareda, E, 2007)
" clopidogRel in non-ST-segment Elevation myocardial infarction)-2, we compared the antiplatelet effects of AZD6140 and clopidogrel and assessed the effects of AZD6140 in clopidogrel-pretreated patients."5.12Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. ( Cannon, CP; Emanuelsson, H; Grande, P; Gurbel, P; Harrington, RA; Heptinstall, S; Husted, S; Peters, G; Storey, RF; Wickens, M; Wilcox, RG, 2007)
"Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous coronary intervention."5.12Prasugrel versus clopidogrel in patients with acute coronary syndromes. ( Antman, EM; Ardissino, D; Braunwald, E; De Servi, S; Gibson, CM; Gottlieb, S; McCabe, CH; Montalescot, G; Murphy, SA; Neumann, FJ; Riesmeyer, J; Ruzyllo, W; Weerakkody, G; Wiviott, SD, 2007)
"Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 (PRINCIPLE-TIMI 44) was a randomized, double-blind, 2-phase crossover study of prasugrel compared with high-dose clopidogrel in patients undergoing cardiac catheterization for planned percutaneous coronary intervention."5.12Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial ( Angiolillo, DJ; Antman, EM; Braunwald, E; Cairns, R; Frelinger, AL; Hod, H; Jakubowski, JA; McCabe, CH; Michelson, AD; Miller, DL; Montalescot, G; Murphy, SA; Neumann, FJ; O'Donoghue, M; Trenk, D; Wiviott, SD, 2007)
"The present study hypothesis was that eptifibatide offered further antiplatelet efficacy above clopidogrel in non-ST-elevation myocardial infarction (NSTEMI) patients before an expeditive coronary intervention."5.11Eptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel. Results of the platelet activity extinction in non-Q-wave myocardial infarction with aspirin, clopidogrel ( Bal dit Sollier, C; Choussat, R; Collet, JP; Dalby, M; Drobinski, G; Drouet, L; Gallois, V; Montalescot, G; Soulat, T; Thomas, D; Vicaut, E, 2004)
"We studied 18 558 patients with ischemic stroke, myocardial infarction, or peripheral arterial disease who participated in the trial of Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE), a study that compared the occurrence of ischemic stroke, myocardial infarction, or vascular death under randomized treatment with aspirin or clopidogrel."5.11Leukocyte count as an independent predictor of recurrent ischemic events. ( Boddy, AW; Brandt, T; Buggle, F; Dukovic, DA; Grau, AJ; Hacke, W; Lichy, C, 2004)
" The aim of the current study was to compare ticlopidine and clopidogrel in a consecutive series of patients with ST-segment elevation myocardial infarction (STEMI) treated with primary stenting."5.11Comparison between ticlopidine and clopidogrel in patients with ST-segment elevation myocardial infarction treated with coronary stenting. ( Dambrink, JH; de Boer, MJ; De Luca, G; Gosselink, AT; Hoorntje, JC; Ottervanger, JP; Suryapranata, H; van 't Hof, AW; Zijlstra, F, 2004)
"To examine efficacy of clopidogrel before thrombolytic therapy (TLT) in patients with acute myocardial infarction (AMI)."5.11[First experience of clopidogrel application in the treatment of acute myocardial infarction with ST-elevation]. ( Akinina, SA; Petrik, ES; Sereshcheva, AKh; Shalaev, SV; Vorob'eva, NM, 2004)
"This study (Intracoronary Stenting and Antithrombotic Regimen: Is Abciximab a Superior Way to Eliminate Elevated Thrombotic Risk in Diabetics [ISAR-SWEET] Study) enrolled 701 diabetic patients with coronary artery disease who underwent an elective percutaneous coronary intervention after pretreatment with a 600-mg dose of clopidogrel >2 hours before the procedure: 351 patients were randomly assigned to abciximab and 350 patients to placebo."5.11Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. ( Berger, PP; Bollwein, H; Dibra, A; Dirschinger, J; Dotzer, F; Kastrati, A; Mehilli, J; Pache, J; Schömig, A; Schühlen, H; von Beckerath, N, 2004)
"Among 2,159 patients with coronary disease who underwent percutaneous coronary intervention (PCI) in the ISAR-REACT trial, we examined clinical outcomes relative to the duration of pretreatment with a 600-mg dose of clopidogrel: (2 to 3 h, 3 to 6 h, 6 to 12 h, or >12 h)."5.11Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization. ( Berger, PB; Bollwein, H; Dirschinger, J; Dotzer, F; Kandzari, DE; Kastrati, A; Mehilli, J; Neumann, FJ; Schömig, A; Steinhubl, SR; Ten Berg, JM, 2004)
"In elective stenting without clopidogrel pretreatment, use of a GPIIb/IIIa inhibitor produces superior platelet inhibition and lower myocardial necrosis compared with high-dose (600 mg) or standard-dose (300 mg) clopidogrel loading alone."5.11Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. ( Bliden, KP; Gurbel, PA; Hayes, KM; Tantry, US; Yoho, JA; Zaman, KA, 2005)
"In patients 75 years of age or younger who have myocardial infarction with ST-segment elevation and who receive aspirin and a standard fibrinolytic regimen, the addition of clopidogrel improves the patency rate of the infarct-related artery and reduces ischemic complications."5.11Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. ( Braunwald, E; Cannon, CP; Claeys, MJ; Cools, F; Gibson, CM; Hill, KA; López-Sendón, JL; McCabe, CH; Montalescot, G; Sabatine, MS; Skene, AM; Theroux, P, 2005)
"We sought to evaluate the long-term cost-effectiveness of clopidogrel for up to one year after an acute coronary syndrome (ACS) without ST-segment elevation."5.11Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation. ( Caro, J; Culler, S; Gabriel, S; Lamy, A; Mahoney, EM; Weintraub, WS; Yuan, Y; Yusuf, S, 2005)
"We compared the effects of ticlopidine and cilostazol on the prevention of subacute stent thrombosis (SAT) in acute myocardial infarction (AMI) patients with stenting."5.11Comparative inhibitory effects of cilostazol and ticlopidine on subacute stent thrombosis and platelet function in acute myocardial infarction patients with percutaneous coronary intervention. ( Adachi, K; Kataoka, T; Kawata, M; Kuramoto, E; Matsuura, A; Saito, A; Sakamoto, S, 2005)
"To evaluate the impact of a clopidogrel therapy on the effectiveness of myocardial reperfusion in patients with ST-segment elevation acute myocardial infarction (AMI) undergoing routine infarct-related artery (IRA) stent implantation and receiving routine abciximab therapy."5.11A randomized trial comparing clopidogrel versus ticlopidine therapy in patients undergoing infarct artery stenting for acute myocardial infarction with abciximab as adjunctive therapy. ( Antoniucci, D; Memisha, G; Migliorini, A; Moschi, G; Parodi, G; Pupi, A; Sciagrà, R; Valenti, R, 2005)
"The Clopidogrel for the Reduction of Events During Observation (CREDO) trial, a randomized trial of 2,116 patients, showed the effectiveness of antiplatelet therapy with clopidogrel 300 mg before PCI and 75 mg daily for one year afterward compared with placebo load and placebo days 29 to 365 in reducing the combined risk of death, myocardial infarction, and stroke."5.11Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) tria ( Beinart, SC; Bouin, O; Caro, J; Chen, R; Gabriel, S; Jackson, J; Kolm, P; Mahoney, EM; Steinhubl, S; Topol, E; Veledar, E; Weintraub, WS; Zhang, Z, 2005)
"To determine if clopidogrel pretreatment before PCI in patients with recent ST-segment elevation myocardial infarction (STEMI) is superior to clopidogrel treatment initiated at the time of PCI in preventing major adverse cardiovascular events."5.11Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. ( Braunwald, E; Cannon, CP; Gibson, CM; Lewis, BS; López-Sendón, JL; McCabe, CH; Montalescot, G; Murphy, SA; Sabatine, MS; Theroux, P, 2005)
"In patients with NSTE-ACS undergoing early invasive strategy, the adjunctive administration of upstream tirofiban did not reduce the peak values and the cumulative release of myocardial necrosis markers, compared with aspirin, heparin, and clopidogrel given on admission and associated with selective use of abciximab just before PCI."5.11Effects of tirofiban plus clopidogrel versus clopidogrel plus provisional abciximab on biomarkers of myocardial necrosis in patients with non-ST-elevation acute coronary syndromes treated with early aggressive approach. Results of the CLOpidogrel, upstrea ( Badia, T; Bellandi, F; Dabizzi, RP; De Servi, S; Leoncini, M; Maioli, M; Politi, A; Toso, A, 2005)
"Effects of thienopyridines ticlopidine (TIC) and clopidogrel (CL) on hemostasis in patients (pts) with non-ST-elevation acute coronary syndromes (NSTEACS) have not been compared."5.11[Indirect comparison of changes of parameters of hemostasis during short-term use of ticlopidine and clopidogrel in patients with non-ST elevation acute coronary syndrome]. ( Averkov, OV; Gratsianskiĭ, NA; Slavina, NN, 2005)
"We studied the benefits and risks of adding clopidogrel to different doses of aspirin in the treatment of patients with acute coronary syndrome (ACS)."5.10Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. ( Commerford, PJ; Diaz, R; Fox, KA; Kopecky, SL; Lewis, BS; Mehta, SR; Peters, RJ; Valentin, V; Yusuf, S; Zhao, F, 2003)
"The 30-day primary composite end point (death, myocardial infarction [MI], or urgent target vessel revascularization [TVR]) was lower among clopidogrel-pretreated patients (6."5.10Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET). ( Berger, PB; Bhatt, DL; Chan, AW; DiBattiste, PM; Moliterno, DJ; Sapp, SK; Stone, GW; Topol, EJ; Wolski, K; Yakubov, SL, 2003)
"In patients receiving intracoronary stents, stent thrombosis is reduced when ticlopidine therapy is combined with aspirin after the procedure."5.09Safety and efficacy of ticlopidine for only 2 weeks after successful intracoronary stent placement. ( Bell, MR; Berger, PB; Grill, DE; Hasdai, D; Holmes, DR; Melby, S, 1999)
"The safety and tolerability of clopidogrel coadministration to patients with recent acute myocardial infarction (AMI) treated with recombinant tissue plasminogen activator (rt-PA) and heparin were assessed."5.09Clopidogrel-rt-PA-heparin combination in the treatment of acute myocardial infarction. ( Bassand, JP; Cariou, R; Grollier, G; Heyndrickx, GR; Kragten, J; Wolf, JE, 1999)
"Compared with aspirin, clopidogrel reduced the combined risk of ischaemic stroke, myocardial infarction or vascular death by 8."5.09Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events. ( Boissel, JP; Gent, M; Harker, LA; Pilgrim, AJ, 1999)
"Cilostazol, an antiplatelet drug that also may inhibit smooth muscle proliferation, was given together with aspirin after primary stenting to treat patients with acute myocardial infarction."5.09Impact of cilostazol on clinical and angiographic outcome after primary stenting for acute myocardial infarction. ( Eto, K; Isshiki, T; Kondo, K; Ochiai, M; Oshima, A; Sato, T; Takeshita, S; Yokoyama, N, 1999)
"Although antiplatelet therapy with a specific inhibitor of phosphodiesterase-3 cilostazol improves stent patency compared with use of aspirin (ASA) alone, the specific role of cilostazol on platelet aggregation in patients with acute myocardial infarction (AMI) is less well understood."5.09Increased platelet aggregability in response to shear stress in acute myocardial infarction and its inhibition by combined therapy with aspirin and cilostazol after coronary intervention. ( Ikeda, Y; Isaka, N; Ito, M; Kitai, T; Makino, K; Nakano, T; Nishikawa, M; Okinaka, T; Shiku, H; Tanigawa, T; Ueda, Y, 2000)
" We sought to determine whether clopidogrel compared with aspirin decreases the need for rehospitalization for ischemia and bleeding."5.09Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators. ( Bhatt, DL; Hacke, W; Hirsch, AT; Ringleb, PA; Topol, EJ, 2000)
"The effects of clopidogrel 75 mg or aspirin 100 (300) mg on platelet aggregation and activation by flow cytometry after stimulation with various agonists were determined in 30 patients with a past history of myocardial infarction."5.09Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: enhanced inhibitory effects of combination therapy. ( Gebauer, MU; Haeberli, A; Julmy, F; Meyer, BJ; Moshfegh, K; Redondo, M; Wuillemin, WA, 2000)
"Assessing combined anti-platelet therapy in suspected acute myocardial infarction Aspirin has been shown to be effective in the emergency treatment of acute myocardial infarction."5.09Rationale, design and organization of the Second Chinese Cardiac Study (CCS-2): a randomized trial of clopidogrel plus aspirin, and of metoprolol, among patients with suspected acute myocardial infarction. Second Chinese Cardiac Study (CCS-2) Collaborativ ( , 2000)
"We sought to compare the efficacy of aspirin and ticlopidine in survivors of acute myocardial infarction (AMI) treated with thrombolysis."5.09Ticlopidine versus aspirin after myocardial infarction (STAMI) trial. ( Cimminiello, C; Di Biase, M; Marubini, E; Pitzalis, MV; Rizzon, P; Scrutinio, D, 2001)
"One hundred twenty-three patients with successful stenting after acute myocardial infarction were randomized to receive aspirin plus ticlopidine (n = 61) or intense anticoagulant therapy (n = 62)."5.08Coronary stent placement in patients with acute myocardial infarction: comparison of clinical and angiographic outcome after randomization to antiplatelet or anticoagulant therapy. ( Alt, E; Blasini, R; Dirschinger, J; Hadamitzky, M; Hausleiter, J; Kastrati, A; Neumann, FJ; Schmitt, C; Schömig, A; Schühlen, H; Walter, H; Zitzmann-Roth, EM, 1997)
"The efficacy of combining antiplatelet agents with low doses of aspirin to prevent cardiac events in patients with myocardial infarction was examined."5.08Aspirin plus either dipyridamole or ticlopidine is effective in preventing recurrent myocardial infarction. Secondary Prevention Group. ( Hama, J; Ishikawa, K; Kanamasa, K; Katori, R; Kimura, A; Naito, T; Nakai, S; Ogawa, I; Oyaizu, M; Takenaka, T; Yamamoto, K; Yamamoto, T, 1997)
"The mortality in patients with intermittent claudication can be reduced by treatment with ticlopidine."5.08The STIMS trial: the ticlopidine experience and its clinical applications. Swedish Ticlopidine Multicenter Study. ( Janzon, L, 1996)
"Data collected to investigate the effects of ticlopidine in a subset of 489 patients with angina at rest accompanied by transient ischaemic electrocardiographic changes have been analysed."5.07Ticlopidine treatment for patients with unstable angina at rest. A further analysis of the study of ticlopidine in unstable angina. Studio della Ticlopidina nell'Angina Instabile Group. ( Lagioia, R; Rizzon, P; Scrutinio, D, 1991)
"The Swedish Ticlopidine Multicentre Study (STIMS) was a double-blind placebo-controlled trial designed to determine whether ticlopidine, a platelet antiaggregatory agent, reduces the incidence of myocardial infarction, stroke and transitory ischaemic attacks in patients with intermittent claudication."5.06Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study. ( Almgren, B; Bergqvist, D; Boberg, J; Boberg, M; Eriksson, I; Fagher, B; Janzon, L; Kjellström, T; Lindgärde, F; Persson, G, 1990)
"The Canadian American Ticlopidine Study (CATS) is a randomised, double-blind, placebo-controlled trial to assess the effect of ticlopidine (250 mg twice daily) in reducing the rate of subsequent occurrence of stroke, myocardial infarction, or vascular death in patients who have had a recent thromboembolic stroke."5.06The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. ( Blakely, JA; Easton, JD; Ellis, DJ; Gent, M; Hachinski, VC; Harbison, JW; Panak, E; Roberts, RS; Sicurella, J; Turpie, AG, 1989)
"Despite the demonstrated benefits of Prasugrel, a new generation thienopyridine, in the prevention of thrombotic complications after percutaneous coronary interventions (PCI) for Acute Coronary Syndromes (ACS), its use is still precluded to those many patients arriving to the cath lab pre-treated with Clopidogrel."4.93Switching from Clopidogrel to Prasugrel in patients undergoing PCI: A meta-analytic overview. ( Barbieri, L; De Luca, G; Suryapranata, H; Verdoia, M, 2016)
"Dual antithrombotic regimen of warfarin and clopidogrel is comparable to the recommended triple therapy in respect to the prevention of thromboembolic outcomes of MI/ death and ischemic stroke, while the risk of bleeding is similar in those patients with indications for chronic oral anticoagulation undergoing percutaneous coronary intervention with stent implantation."4.93[Meta-analysis of the combination of warfarin and clopidogrel after coronary stenting in patients with indications for chronic oral anticoagulation]. ( Du, M; Ma, G; Shi, Y; Zhang, D, 2016)
"To complete a systematic review evaluating the currently available evidence regarding the pharmacokinetic and pharmacodynamic activity of orally administered clopidogrel, prasugrel and ticagrelor during the acute phase of a myocardial infarction in relation to mechanical reperfusion with primary percutaneous coronary angioplasty."4.93Pharmacokinetics and pharmacodynamics of oral P2Y12 inhibitors during the acute phase of a myocardial infarction: A systematic review. ( Cotton, JM; Cox, AR; Khan, N, 2016)
"Physicians considering prescription of P2Y12-receptor antagonist for long-term (>1 year) protection of patients post-myocardial infarction face the trilemma of selecting between clopidogrel, prasugrel, or ticagrelor."4.93Long-Term P2Y12-Receptor Antagonists in Post-Myocardial Infarction Patients: Facing a New Trilemma? ( Alexopoulos, D; Lekakis, J; Moulias, A; Xanthopoulou, I, 2016)
"Prasugrel has similar effects as clopidogrel in terms of all causes of death, MI, and stroke in ACS patients."4.91Novel oral P2Y12 inhibitor prasugrel vs. clopidogrel in patients with acute coronary syndrome: evidence based on 6 studies. ( Chen, K; Chu, H; Jia, M; Li, L; Li, Z, 2015)
" We present a case of profound thrombocytopenia due to administration of a glycoprotein IIb/IIIa receptor antagonist, eptifibatide, after percutaneous coronary intervention for an inferior ST-elevation myocardial infarction."4.91Thrombocytopenia in acute coronary syndromes: etiologies and proposed management. ( Bainey, KR; Ferguson, C; Sharma, A, 2015)
"Clopidogrel, prasugrel, and ticagrelor are the currently available oral P2Y12 inhibitors for the treatment of ST-segment elevation myocardial infarction (STEMI), in association with aspirin."4.91Ticagrelor, prasugrel, or clopidogrel in ST-segment elevation myocardial infarction: which one to choose? ( Guimarães, PO; Tricoci, P, 2015)
" Ticagrelor or prasugrel in addition to aspirin should be used preferentially for patients with ST-elevation myocardial infarction because of significant anti-ischemic benefits."4.91Current Evidence on Platelet P2Y12 Receptor Inhibitors: Is There Still a Role for Clopidogrel in 2015? ( Chong, AY; Qutub, MA; So, DY, 2015)
"Vorapaxar is a novel antiplatelet agent that has demonstrated efficacy in reducing atherosclerotic events in patients with a history of MI or PAD without a history of stroke, transient ischemic attack, or ICH when taken in combination with aspirin and clopidogrel."4.91Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease. ( Arif, SA; D'Souza, J; Gil, M; Gim, S, 2015)
"New P2Y12 inhibitors decreased death in patients undergoing PCI compared with clopidogrel with a considerable safety and tolerability profile; however, the risk/benefit ratio of ischemic and bleeding events should be further investigated."4.91Efficacy and safety analysis of new P2Y12 inhibitors versus clopidogrel in patients with percutaneous coronary intervention: a meta-analysis. ( Ding, SL; Fang, D; Fang, Q; Gan, XD; Li, KY; Peng, S; Wan, J; Wei, BZ, 2015)
"Based on this meta-analysis, we did not find any difference in the risk of the primary composite efficacy endpoint of all-cause death, ischaemia-driven revascularisation, and myocardial infarction at 48hours between cangrelor and clopidogrel use."4.90Cangrelor versus clopidogrel in percutaneous coronary intervention: a systematic review and meta-analysis. ( Aryal Pandit, A; Aryal, MR; Hakim, FA; Jalota, L; Lee, HR; Mookadam, F; Pandit, A; Tleyjeh, IM, 2014)
"The association between DAPT interruption and the rates of stent thrombosis (ST) and cardiac death/target-vessel myocardial infarction (CD/TVMI) in patients receiving a Resolute zotarolimus-eluting stent (R-ZES) was analysed in 4896 patients from the pooled RESOLUTE clinical programme."4.90Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. ( Belardi, JA; Brar, S; Kirtane, AJ; Liu, M; Rothman, M; Silber, S; Windecker, S, 2014)
" These P2Y12 inhibitors might be superior to clopidogrel for reducing ischemic events in patients with coronary artery disease (CAD)."4.90Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials. ( Fan, JY; Jin, C; Meng, J; Tang, XF; Yang, YJ; Yuan, JQ, 2014)
"The two new drugs prasugrel and ticagrelor were included in the current guidelines for the treatment of patients with acute coronary syndrome."4.90[Dual platelet inhibitors in intensive care units]. ( Delle Karth, G; Siller-Matula, JM, 2014)
"In ST-elevation myocardial infarction patients treated with primary percutaneous coronary intervention, administration of a 600-mg LD of clopidogrel is associated with a lower risk of MACE than is administration of a 300-mg LD, without increasing the risk of major bleeding."4.90Outcome comparison of 600 mg versus 300 mg loading dose of clopidogrel for patients with ST-elevation myocardial infarction: a meta-analysis. ( Blevins, A; El Accaoui, R; Karrowni, W; Vyas, A, 2014)
" In the second part of the review is discussed higher incidence of myocardial infarction in controlled group in the trial comparing treatment of dabigatran with warfarin."4.90[Anticoagulant therapy in secondary prevention of coronary events]. ( Bultas, J, 2014)
"The impact of PPI use on the 1-year primary end point (ischemic stroke, myocardial infarction [MI], or vascular death) in the Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) trial and the 28-day (all-cause death, MI, or urgent target vessel revascularization) and 1-year (all-cause death, MI, or stroke) primary end points in the Clopidogrel for Reduction of Events During Observation (CREDO) trial were examined."4.89Impact of proton pump inhibitor therapy on the efficacy of clopidogrel in the CAPRIE and CREDO trials. ( Bauer, D; Berger, PB; Charnigo, RJ; Dunn, SP; Steinhubl, SR; Topol, EJ, 2013)
" As part of a planned re-evaluation within 2 years, we conducted an extensive literature search encompassing all topics included in the 2010 CCS Guidelines, and concluded that there were sufficient new data to merit revisiting the guidance on antiplatelet therapy for secondary prevention in the first year after acute coronary syndrome (ACS), percutaneous coronary intervention, or coronary artery bypass grafting, and the interaction between clopidogrel and proton pump inhibitors."4.89Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy. ( Ackman, ML; Bauer, RD; Bell, AD; Cartier, R; Chan, WS; Douketis, J; Mehta, SR; Roussin, A; Schnell, G; Tanguay, JF; Verma, S; Wong, G, 2013)
" In the large Phase III trial, PLATO, ticagrelor significantly reduced the composite of cardiovascular death, myocardial infarction, or stroke as well as cardiovascular and all-cause mortality compared with clopidogrel in patients presenting with acute coronary syndromes."4.89Ticagrelor for acute coronary syndromes. ( Bansilal, S; Bonaca, MP; Sabatine, MS, 2013)
"Contrary to the findings of post hoc analyses of randomized trials, observational studies showed that recent exposure to clopidogrel before coronary artery bypass grafting is associated with increased risk of postoperative death, reoperations for bleeding, blood loss, and need of blood transfusions."4.88Benefits and risks of using clopidogrel before coronary artery bypass surgery: systematic review and meta-analysis of randomized trials and observational studies. ( Airaksinen, KE; Biancari, F; Lip, GY, 2012)
"Although the addition of aspirin to clopidogrel resulted in small relative reductions in major cardiovascular events, myocardial infarction, and stroke, it also resulted in a relative increase in major bleeding events."4.88Effects of combined aspirin and clopidogrel therapy on cardiovascular outcomes: a systematic review and meta-analysis. ( He, J; Lu, J; Qin, YY; Wei, X; Wu, MJ; Xu, JF; Ye, XF; Zhou, YH, 2012)
"Since its first approval in 1997, clopidogrel has revolutionized interventional cardiology and transformed therapy for non‑ST‑segment elevation myocardial infarction (NSTEMI), STEMI, and percutaneous coronary intervention‑treated patients."4.88Antiplatelet therapy beyond 2012: role of personalized medicine. ( Budaj, A; Gurbel, PA; Tantry, US, 2012)
" Addition of clopidogrel was associated with an increase in fatal hemorrhage (OR, 1."4.88Effect of addition of clopidogrel to aspirin on mortality: systematic review of randomized trials. ( Benavente, OR; Hart, RG; Palacio, S; Pearce, LA, 2012)
"For many years clopidogrel was the 'gold standard' ADP receptor antagonist in patients with coronary artery disease in combination with acetylsalicylic acid, i."4.88Clopidogrel in coronary artery disease: update 2012. ( Huber, K, 2012)
"In those who have already survived myocardial infarction (MI) or stroke, or have had a transient ischaemic episode (TIA), daily low dose aspirin (ASA) reduces the risk of recurrences by an amount that greatly exceeds the risk of serious bleeding (secondary prevention)."4.88Primary prevention of ischaemic cardiovascular disorders with antiplatelet agents. ( Meade, T, 2012)
"To evaluate the association of clopidogrel pretreatment vs no treatment with mortality and major bleeding after PCI."4.88Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. ( Barthélémy, O; Bellemain-Appaix, A; Bernasconi, F; Beygui, F; Collet, JP; Cucherat, M; Jacq, L; Montalescot, G; O'Connor, SA; Silvain, J, 2012)
"Enhanced platelet inhibition by clopidogrel decreases the risk of ischemic events but carries a risk for a concomitant increase in bleeding."4.87Impact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. ( Christ, G; Herkner, H; Huber, K; Jilma, B; Kubica, J; Schrör, K; Siller-Matula, JM, 2011)
"To assess the clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole (MRD) alone or with aspirin (ASA) compared with ASA (and each other where appropriate) in the prevention of occlusive vascular events in patients with a history of MI, ischaemic stroke/TIA or established peripheral arterial disease."4.87Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis. ( Bagust, A; Blundell, M; Boland, A; Dickson, R; Dundar, Y; Fisher, M; Greenhalgh, J; Martin Saborido, C; Oyee, J; Proudlove, C, 2011)
"Patients should be placed on the following medications: antiplatelet agents, (meta-analysis for aspirin, multiple randomized controlled trials [RCTs] for aspirin plus clopidogrel); a statin; atorvastatin has the best evidence (a single RCT); a beta-blocker (meta-analysis); renin-angiotensin-aldosterone system blockers, whether or not the ejection fraction is diminished after myocardial infarction (MI) (SOR: A, meta-analysis for angiotensin-converting enzyme [ACE] inhibitor; B, single RCT for ACE inhibitor plus aldosterone blocker)."4.86Clinical Inquiries: Which drugs should post-MI patients routinely receive? ( Holman, JR; Jamieson, B; Lin, V, 2010)
"Dual antiplatelet therapy with a thienopyridine (ticlopidine or clopidogrel) and aspirin is used to reduce the risk of late stent thrombosis and complications (myocardial infarction [MI] and death) after placement of a drug-eluting stent (DES)."4.86Antiplatelet therapy after placement of a drug-eluting stent: a review of efficacy and safety studies. ( Cheng, JW; Dorsch, MP; Goldberg, T; Mohammad, RA, 2010)
" Monotherapy with either aspirin or clopidogrel, reduces the rate of stroke, myocardial infarction, and cardiovascular death in patients suffering from peripheral arterial disease."4.85Antiplatelet therapy after endovascular intervention: does combination therapy really work and what is the optimum duration of therapy? ( Milani, RV, 2009)
" This review examines the role of clopidogrel in decreasing periprocedural myonecrosis following percutaneous coronary intervention (PCI)."4.85Use of clopidogrel in the reduction of myocardial damage during percutaneous coronary intervention. ( Dasgupta, A; Mukherjee, D, 2009)
"Since the development and market entry of clopidogrel, a platelet ADP blocker, physicians have had few new antiplatelet options available to them for the treatment of acute and chronic coronary disease, specifically in the setting of acute coronary syndromes, percutaneous coronary intervention, and chronic stent management."4.85A new generation of antiplatelet agents. ( Harrington, RA; Sellers, MB; Tricoci, P, 2009)
"Clopidogrel is recommended with aspirin for patients who undergo coronary artery bypass grafting (CABG) after non-ST elevation myocardial infarctions."4.85Evidence for using clopidogrel alone or in addition to aspirin in post coronary artery bypass surgery patients. ( Mathew, ST; Owora, A; Patel, JH; Stoner, JA; Thadani, U, 2009)
" The Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial demonstrated a similar ischemic event rate to 30 days with a significantly lower bleeding event rate (enhanced net clinical benefit) in favor of bivalirudin monotherapy (with provisional platelet glycoprotein [GP] IIb/IIIa receptor blockade) in comparison with unfractionated heparin plus GP IIb/IIIa blockade in patients undergoing primary PCI for STEMI."4.85Improving adjunctive pharmacotherapy for primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: beyond the HORIZONS-AMI trial. ( Kereiakes, DJ, 2009)
"To determine the effectiveness and safety of thienopyridine derivatives (ticlopidine and clopidogrel) versus aspirin for preventing serious vascular events (stroke, myocardial infarction (MI) or vascular death) in patients at high risk, and specifically in patients with a previous TIA or ischaemic stroke."4.85Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. ( Hankey, GJ; Mason, G; Maurice, JB; Sudlow, CL; Wedderburn, CJ, 2009)
"Current guidelines support dual antiplatelet therapy with aspirin and clopidogrel (Plavix) in a number of clinical scenarios, ie, in ST-segment-elevation myocardial infarction (MI), non-ST-elevation MI, and percutaneous coronary intervention."4.85Dual antiplatelet therapy in coronary artery disease: a case-based approach. ( Menon, V; Raymond, C, 2009)
"To quantify the impact of clopidogrel plus aspirin on the individual outcomes of death, myocardial infarction, or stroke in patients with established cardiovascular disease, or in patients with multiple risk factors for vascular disease."4.84Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: a meta-analysis of randomized trials. ( Bavry, AA; Bhatt, DL; Duggal, S; Helton, TJ; Kumbhani, DJ; Roukoz, H, 2007)
"Clopidogrel (Plavix), a platelet aggregation inhibitor, has been shown to be effective in certain patients undergoing percutaneous coronary interventions, but its use in patients with acute myocardial infarction who receive a fibrinolytic strategy instead has been controversial."4.84Do patients with acute myocardial infarction benefit from treatment with clopidogrel? ( Keim, SM; Rosen, P; Vadera, R; Worster, A, 2008)
"Clopidogrel bisulfate (hereafter, clopidogrel), a selective inhibitor of ADP-induced platelet aggregation, is approved for the reduction of atherothrombotic events in patients with ST-segment elevation myocardial infarction (STEMI)."4.83Clopidogrel bisulfate: in ST-segment elevation myocardial infarction. ( Dickie, JS; Scott, LJ, 2006)
" This article reviews the mechanism of action and the major evidence supporting the clinical use of clopidogrel, a potent antiplatelet agent of the thienopyridines class, focusing on its role in the setting of acute coronary syndromes without persistent ST segment elevation (unstable angina and non-Q wave myocardial infarction)."4.82Clopidogrel in acute coronary syndromes (unstable angina and non-Q-wave myocardial infarction). ( Heras, M; Sionis, A, 2003)
" The CURE study evaluated the efficacy and safety of clopidogrel on top of acetylsalicylic acid (ASA) versus standard therapy (including ASA) in over 12,000 patients with unstable angina or non-ST-segment elevation myocardial infarction (MI)."4.82Recent clinical trial results with antiplatelet therapy: implications in stroke prevention. ( Teal, PA, 2004)
"Clopidogrel was shown to have added benefits to aspirin in patients with acute coronary syndromes without ST-segment elevation in the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) trial."4.82CLARITY about the use of clopidogrel in patients with acute coronary syndromes and myocardial infarction. ( Doggrell, SA, 2005)
" Beta-blockers, nitrates, and calcium-channel blockers are useful for antiischemic therapy in patients with acute coronary syndromes."4.81[Acute coronary syndromes: an update. I. Pathogenesis and drug therapy]. ( Auer, J; Berent, R; Eber, B; Maurer, E; Mayr, H; Weber, T, 2001)
" coronary angioplasty (PTCA) with or without stent implantation), and in unstable angina/non-ST-segment elevation myocardial infarction, the risk of acute vessel occlusion by thrombosis is high in spite of treatment with aspirin and heparin."4.81Platelet glycoprotein IIb/IIIa blockers for percutaneous coronary revascularization, and unstable angina and non-ST-segment elevation myocardial infarction. ( Bosch, X; Marrugat, J, 2001)
" In the CAPRIE (Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events) Trial, clopidogrel (clopidogrel bisulphate) was superior to acetylsalicylic acid (ASA) in reducing the combined risk of ischaemic stroke (IS), myocardial infarction (MI) or vascular death in patients with symptomatic atherosclerosis."4.81From CURE to MATCH: ADP receptor antagonists as the treatment of choice for high-risk atherothrombotic patients. ( Hacke, W, 2002)
" On the contrary, the initial treatment with clopidogrel in addition to aspirin and anticoagulation led to a 20% relative risk reduction for an endpoint of death, myocardial infarction and stroke in the CURE trial."4.81[Modern therapy in acute coronary syndrome]. ( Blankenberg, S; Espinola-Klein, C; Meyer, J; Rupprecht, HJ, 2002)
" Strategies used for plaque stabilisation resulting in a reduction in cardiovascular mortality and morbidity are: smoking cessation; aspirin (acetylsalicylic acid); blood pressure control; lipid lowering agents when low density lipoprotein cholesterol is elevated despite dietary therapy; coronary bypass surgery in patients with left main stem disease or triple vessel coronary disease and diminished left ventricular function; and use of estrogen in postmenopausal women."4.80Choosing the most appropriate treatment for stable angina. Safety considerations. ( Asirvatham, S; Sebastian, C; Thadani, U, 1998)
"English-language articles published after 1977 and indexed in MEDLINE under the following Medical Subject Heading terms: anticoagulants, aspirin, dipyridamole, ticlopidine, or sulfinpyrazone, combined with cerebrovascular disorders."4.79Medical treatment for stroke prevention. ( Barnett, HJ; Feussner, JR; Matchar, DB; McCrory, DC, 1994)
" A total of 477 patients receiving double antiaggregation therapy with aspirin and clopidogrel, after suffering a first event, were followed for 1 year to record relapse, as a surrogate end point to measure their therapeutic response, as defined by presenting with an acute coronary event (unstable angina, ST-segment-elevation myocardial infarction, or non-ST-segment-elevation myocardial infarction), stent thrombosis/restenosis, or cardiac mortality."4.12Clinical and Pharmacological Parameters Determine Relapse During Clopidogrel Treatment of Acute Coronary Syndrome. ( Martínez-Quintana, E; Medina-Gil, JM; Rodríguez-González, F; Saavedra-Santana, P; Santana-Mateos, M; Tugores, A, 2022)
"A significant number of ischemic events occur after acute myocardial infarction (MI), even when adhering to dual antiplatelet therapy including aspirin and clopidogrel."3.91The association between clopidogrel and 2-oxo-clopidogrel plasma levels and the long-term clinical outcome after acute myocardial infarction
. ( Apostolovic, S; Konstantinovic, SS; Lilic, J; Nikolic, VN; Pavlovic, M; Stokanovic, D; Zvezdanovic, JB, 2019)
"Our study shows that the recommended dose of prasugrel had significantly higher in-hospital bleeding complications without reducing ischemic events compared with clopidogrel."3.88Comparison of prasugrel versus clopidogrel in Korean patients with acute myocardial infarction undergoing successful revascularization. ( Ahn, TH; Cha, KS; Chae, JK; Chae, SC; Choi, DJ; Gwon, HC; Hwang, KK; Jeong, MH; Kim, HK; Kim, HS; Kim, KB; Kim, YJ; Oh, DJ; Oh, SK; Park, KH; Seong, IW; Seung, KB, 2018)
"The objective of this study is to evaluate the effects of cytochrome P450 2C19 (CYP2C19) polymorphism on adverse cardiovascular events (MACE) in Hakka patients with acute coronary syndrome (ACS) receiving clopidogrel who had undergone coronary drug-eluting stent placement after percutaneous coronary intervention (PCI) in southern China."3.88Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China. ( He, X; Hou, J; Li, B; Li, C; Liu, Z; Wu, H; Yang, M; Zhang, Q; Zhao, P; Zhong, M; Zhong, W; Zhong, Z, 2018)
"Among 1469 patients with incident ST-elevation myocardial infarction (STEMI, 14%) or non-STEMI (86%), 390 patients were prescribed DAPT, 549 aspirin only, and 530 clopidogrel only."3.88Single and dual antiplatelet therapy in elderly patients of medically managed myocardial infarction. ( Chan, KA; Lai, CL; Lai, HY; Lai, MS; Lin, TT; Yang, YY, 2018)
"The clinical significance of the laboratory-based phenomenon of clopidogrel hypo-responsiveness and platelet reactivity associated with acute myocardial infarction, despite chronic clopidogrel therapy, is largely unknown."3.88Acute myocardial infarction occurring while on chronic clopidogrel therapy ('clopidogrel failure') is associated with high incidence of clopidogrel poor responsiveness and stent thrombosis. ( Asher, E; Beigel, R; Fefer, P; Matetzky, S; Mazin, I; Regev, E, 2018)
"Clopidogrel HTPR does not seem to be a major contributor to recurrent ischemic events in Danish ischemic stroke patients."3.88Secondary Stroke Prophylaxis with Clopidogrel Produces Sufficient Antiplatelet Response. ( Jørgensen, NR; Rath, CL; Wienecke, T, 2018)
"Clopidogrel plus aspirin is associated with a reduced risk for myocardial infarction and ischemic stroke and an increased risk for major bleeding compared with aspirin alone among patients at high risk for or with an established cardiovascular disease but without a coronary stent."3.88Aspirin Plus Clopidogrel vs Aspirin Alone for Preventing Cardiovascular Events Among Patients at High Risk for Cardiovascular Events. ( Bellesini, M; Donadini, MP; Squizzato, A, 2018)
"We studied 671 myocardial infarction (MI) patients treated with percutaneous coronary intervention in the TRANSLATE-ACS Registry who had VerifyNow platelet function testing performed while on clopidogrel treatment during their index hospitalization (April 2010-October 2012)."3.85Association of measured platelet reactivity with changes in P2Y ( Anstrom, KJ; Bagai, A; Cohen, DJ; Effron, MB; Henry, TD; McCoy, LA; Peterson, ED; Schulte, PJ; Stone, GW; Wang, TY; Zettler, ME, 2017)
"Among 33,943 post-MI continuous clopidogrel users without history of stroke, TIA, or bleeding, 22% had diabetes, whereas angina and renal impairment were less prevalent (5% and 7%, respectively)."3.85Antiplatelet Therapy and Clinical Outcomes Following Myocardial Infarction Among Patients in a U.S. Employer-Based Insurance Database. ( Chase, MR; Hanson, ME; Heithoff, K; Mavros, P; Patel, MD; Simpson, RJ; Wu, D, 2017)
"The present study confirms the strong relationship of high platelet reactivity on clopidogrel to 2-year ischemic and bleeding outcomes after DES."3.85Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents: 2-Year Results of a Prospective, Multicenter Registry Study. ( Ben-Yehuda, O; Brodie, BR; Cox, DA; Duffy, PL; Généreux, P; Gurbel, PA; Henry, TD; Kirtane, AJ; Litherland, C; Mazzaferri, EL; Mehran, R; Metzger, DC; Neumann, FJ; Rinaldi, MJ; Simonton, CA; Stone, GW; Stuckey, TD; Weisz, G; Witzenbichler, B, 2017)
"The present study indicated that long-term oral low-dose aspirin was safe for patients with both TBAD and coronary heart disease who underwent EVAR."3.85Safety and Necessity of Antiplatelet Therapy on Patients Underwent Endovascular Aortic Repair with Both Stanford Type B Aortic Dissection and Coronary Heart Disease. ( Fu, WX; He, RX; Jing, QM; Liu, HW; Liu, YJ; Wang, XZ; Yuan, WJ; Zhang, L; Zhou, TN, 2017)
"Dual anti-platelet treatment with clopidogrel and aspirin is indicated for most patients after myocardial infarction."3.85Risk and benefit of dual antiplatelet treatment among non-revascularized myocardial infarction patients in different age groups. ( Christiansen, CB; Gislason, G; Hansen, ML; Juul, N; Karasoy, D; Lamberts, M; Olesen, JB; Sorensen, R; Torp-Pedersen, C, 2017)
"We consecutively enrolled 375 patients with IS after they received clopidogrel therapy, and venous blood samples were subjected to genotyping allelic variants of genes modulating clopidogrel absorption (ATP binding cassette subfamily B1, ABCB1), metabolic activation (cytochrome P450[CYP] 3A and CYP2C19), and biologic activity (platelet membrane receptor [ P2Y12, P2Y1)], and glycoprotein IIIa [ GPIIIa]) and statistically analyzing their interactions with clopidogrel sensitivity (CS) and adverse events, risk of IS recurrence, myocardial infarction, and death during 6 months of follow-up."3.85Interaction of CYP2C19, P2Y12, and GPIIIa Variants Associates With Efficacy of Clopidogrel and Adverse Events on Patients With Ischemic Stroke. ( Cheng, W; Lin, J; Wang, C; Wang, Y; Yi, X; Zhou, Q, 2017)
"In clopidogrel treated PCI patients, the 2-year adjusted risk of MACE and NACE was significantly higher in PPI users driven by higher TLR compared to non-PPI users, without a difference in bleeding."3.85Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry. ( Aquino, M; Ariti, C; Baber, U; Bansilal, S; Chandrasekhar, J; Chieffo, A; Cohen, D; Colombo, A; Dangas, G; Faggioni, M; Farhan, S; Gabriel Steg, P; Giustino, G; Henry, T; Kini, A; Mehran, R; Michael Gibson, C; Moliterno, D; Pocock, S; Saporito, R; Sartori, S; Stuckey, T; Vogel, B; Witzenbichler, B, 2017)
"Scarce and conflicting evidence exists on whether clopidogrel is effective and whether dual antiplatelet treatment (DAPT) is safe in patients with acute coronary syndrome and chronic kidney disease (CKD)."3.85Long-term versus short-term dual antiplatelet therapy was similarly associated with a lower risk of death, stroke, or infarction in patients with acute coronary syndrome regardless of underlying kidney disease. ( Carrero, JJ; Evans, M; Held, C; James, S; Jensevik, K; Jernberg, T; Lagerqvist, B; Spaak, J; Szummer, K; Varenhorst, C, 2017)
"The reasons for postdischarge adenosine diphosphate receptor inhibitor (ADPri) switching among patients with myocardial infarction (MI) are unclear."3.85Switching of adenosine diphosphate receptor inhibitor after hospital discharge among myocardial infarction patients: Insights from the Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after ( Anstrom, KJ; Baker, BA; Cohen, DJ; Effron, MB; Henry, TD; McCoy, LA; Messenger, JC; Peterson, ED; Wang, TY; Zettler, ME, 2017)
"Among patients in the CHAMPION trials with a prior cerebrovascular event at least 1 year before the percutaneous coronary intervention, the efficacy and bleeding profile of cangrelor compared with clopidogrel was similar to that in the overall trial."3.85Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention. ( Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Sawlani, NN; Steg, PG; Stone, GW; White, HD, 2017)
"Active smokers with myocardial infarction were shown to have enhanced benefit with clopidogrel compared with aspirin."3.85Clopidogrel and ischemic stroke outcomes by smoking status: Smoker's paradox? ( Cao, Q; Dong, K; Feng, W; Hou, C; Huang, X; Ji, X; Ovbiagele, B; Song, H; Wang, M; Wang, Y; Zhang, Q, 2017)
"To evaluate long-term health benefits and risks of adding vorapaxar (VOR) to the standard care antiplatelet therapy (SC) of aspirin and/or clopidogrel, among a population with a recent myocardial infarction (MI) and/or peripheral artery disease (PAD)."3.85State transition model: vorapaxar added to standard antiplatelet therapy to prevent thrombosis post myocardial infarction or peripheral artery disease. ( Chase, M; Davies, G; Du, M; Oguz, M, 2017)
"Despite the growing use of clopidogrel, limited data exist regarding the prognostic significance of chronic clopidogrel therapy in patients sustaining acute coronary syndrome (ACS)."3.83Prior chronic clopidogrel therapy is associated with increased adverse events and early stent thrombosis. ( Asher, E; Atar, S; Beigel, R; Fefer, P; Hammerman, H; Herscovici, R; Matetzky, S; Mazin, I; Polak, A; Regev, E; Sabbag, A; Shlomo, N; Zahger, D, 2016)
" Compared to patients treated with aspirin+clopidogrel, patients treated with aspirin+prasugrel had fewer BARC 3 or 5 bleedings (two [0."3.83Safety of prasugrel in real-world patients with ST-segment elevation myocardial infarction: 1-year results from a prospective observational study (Bleeding and Myocardial Infarction Study). ( Auffret, V; Avez, B; Bacquelin, R; Bedossa, M; Boulanger, B; Boulmier, D; Castellant, P; Coudert, I; Druelles, P; Filippi, E; Gilard, M; Hacot, JP; Le Breton, H; Le Guellec, M; Leurent, G; Moquet, B; Oger, E; Rialan, A; Rouault, G; Treuil, J, 2016)
"The risk of bleeding and ischemic complications among patients on TT is similar between those on ticagrelor and clopidogrel."3.83Ticagrelor in Triple Antithrombotic Therapy: Predictors of Ischemic and Bleeding Complications. ( Abunassar, J; Chong, AY; Dick, A; Froeschl, M; Fu, A; Glover, C; Hibbert, B; Labinaz, M; Le May, M; Malhotra, N; Marquis, JF; Singh, K; So, DY, 2016)
" Our results suggest that this strategy is not beneficial as compared to aspirin alone in terms of ischaemic or bleeding events."3.83Clopidogrel Use as Single Antiplatelet Therapy in Outpatients with Stable Coronary Artery Disease: Prevalence, Correlates and Association with Prognosis (from the CORONOR Study). ( Bauters, C; Caudmont, S; Ketelers, R; Lamblin, N; Lemaire, N; Lemesle, G; Meurice, T; Philias, A; Schurtz, G; Tricot, O, 2016)
"Using the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (n = 10,135), we analyzed outcomes in patients with coronary artery disease (n = 1827) according to treatment with triple antithrombotic therapy (defined as concurrent therapy with an oral anticoagulant, a thienopyridine, and aspirin) or dual antithrombotic therapy (comprising either an oral anticoagulant and one antiplatelet agent [OAC plus AA] or 2 antiplatelet drugs and no anticoagulant [DAP])."3.83Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease. ( Ansell, J; Chang, P; Fonarow, GC; Gersh, BJ; Go, AS; Hylek, EM; Kowey, P; Lopes, RD; Mahaffey, KW; Peterson, ED; Piccini, JP; Rao, M; Simon, DN; Singer, DE; Thomas, L, 2016)
"Guidelines recommend prasugrel or ticagrelor instead of clopidogrel in patients with acute coronary syndromes (ACS) undergoing percutaneous coronary interventions (PCI)."3.83Clopidogrel, prasugrel or ticagrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention. ( Ajani, AE; Andrianopoulos, N; Brennan, A; Clark, DJ; Duffy, SJ; Eccleston, D; Farouque, O; Lefkovits, J; Oqueli, E; Ramchand, J; Reid, CM; Yip, T; Yudi, MB, 2016)
"Sarpogrelate-containing triple antiplatelet therapy demonstrated comparable rates of MACCE prevention to the conventional dual antiplatelet therapy after PCI without significantly increasing bleeding risk during the two-year follow-up period."3.83Antiplatelet Therapy of Cilostazol or Sarpogrelate with Aspirin and Clopidogrel after Percutaneous Coronary Intervention: A Retrospective Cohort Study Using the Korean National Health Insurance Claim Database. ( Bae, SK; Kim, GJ; Kim, JH; Lee, J; Lee, S; Lim, HS; Noh, Y; Oh, E; Shin, S, 2016)
" Rates of discharge clopidogrel use were described for patients with no angiography, angiography without obstructive coronary artery disease (CAD; ≥50% stenosis in ≥1 vessel), and angiography with obstructive CAD."3.83Outcomes According to Cardiac Catheterization Referral and Clopidogrel Use Among Medicare Patients With Non-ST-Segment Elevation Myocardial Infarction Discharged Without In-hospital Revascularization. ( Hellkamp, AS; Hess, CN; Peng, SA; Peterson, ED; Roe, MT; Scirica, BM; Thomas, L; Wang, TY, 2016)
"To observe the relationship between ATP-binding cassette subfamily B member 1 (ABCB1) and cytochrome P450 (CYP)2C19 polymorphisms and the effect of clopidogrel post percutaneous coronary intervention in patients with coronary artery disease."3.83[Relationship between ATP-binding cassette subfamily B member 1 and cytochrome P450 2C19 polymorphisms and the effect of clopidogrel post percutaneous coronary intervention in patients with acute coronary syndrome]. ( Fu, ZH; Han, BS; Li, DY; Ren, YH; Song, YQ; Xue, Q; Yi, J; Zhou, CF, 2016)
" However, the incidences of in-hospital Thrombolysis In Myocardial Infarction (TIMI) major and minor bleeding were higher in ticagrelor than clopidogrel (2."3.83Comparison of short-term clinical outcomes between ticagrelor versus clopidogrel in patients with acute myocardial infarction undergoing successful revascularization; from Korea Acute Myocardial Infarction Registry-National Institute of Health. ( Ahn, TH; Ahn, Y; Cha, KS; Chae, JK; Chae, SC; Choi, DJ; Gwon, HC; Hwang, KK; Jeong, MH; Kim, HS; Kim, KB; Kim, YJ; Oh, DJ; Oh, SK; Park, KH; Seong, IW; Seung, KB, 2016)
" Vorapaxar, a novel platelet thrombin receptor (PAR-1/4) blocker, is currently approved for post-myocardial infarction and peripheral artery disease indications on top of clopidogrel or/and aspirin."3.83Continued vorapaxar versus withdrawed clopidogrel both on top of low dose aspirin in patients undergoing heart surgery: A call for randomized trial. ( Bekbossynova, M; Cattaneo, M; Golukhova, E; Kim, MH; Marciniak, TA; Pya, Y; Serebruany, VL, 2016)
"The TRA 2°P-TIMI 50 trial showed the addition of vorapaxar to standard care (SC) antiplatelet therapy reduced the combined risk of death, myocardial infarction (MI), and stroke, while exhibiting an increase in moderate, but not other bleeding events."3.83A State Transition Model for Health Outcomes Associated with Vorapaxar Treatment as an Add-on to Standard Care Antiplatelet Therapy in the Prevention of Thrombotic Events for Patients with a Recent Myocardial Infarction. ( Bash, LD; Davies, G; Du, M; Oguz, M; Ozer-Stillman, I; Whalen, JD, 2016)
"Ticagrelor reduces ischaemic events and mortality in acute coronary syndrome (ACS) vs."3.83Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registry. ( Erlinge, D; James, SK; Jernberg, T; Lagerqvist, B; Omerovic, E; Renlund, H; Sahlén, A; Varenhorst, C; Wallentin, L, 2016)
" The aim of the current study was to compare these two point-of-care platelet function tests and to analyze the consistency between the two tests for evaluating on-clopidogrel platelet reactivity in Chinese acute myocardial infarction patients undergoing percutaneous coronary intervention (PCI)."3.83Head to Head Comparison of Two Point-of-care Platelet Function Tests Used for Assessment of On-clopidogrel Platelet Reactivity in Chinese Acute Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention. ( Gao, RL; He, C; Liu, R; Ma, YL; Meng, XM; Song, L; Song, Y; Tang, XF; Wang, M; Xu, JJ; Yao, Y; Yuan, JQ; Zhang, JH, 2016)
"Proton pump inhibitors (PPIs) reduce gastrointestinal bleeding events but may alter clopidogrel metabolism."3.83Impact of Proton Pump Inhibitor Use on the Comparative Effectiveness and Safety of Prasugrel Versus Clopidogrel: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acu ( Baker, BA; Cohen, DJ; Effron, MB; Faries, DE; Jackson, LR; Ju, C; McCoy, LA; Messenger, JC; Peterson, ED; Wang, TY; Zettler, M, 2016)
"We examined clinical outcomes with proton pump inhibitors (PPI) use within CYP2C19 genotype groups during clopidogrel treatment following acute myocardial infarction (AMI)."3.81Clinical outcomes associated with proton pump inhibitor use among clopidogrel-treated patients within CYP2C19 genotype groups following acute myocardial infarction. ( Bach, RG; Cresci, S; Depta, JP; Lanfear, DE; Lenzini, PA; Spertus, JA; Wang, TY, 2015)
"While randomized clinical trials have compared clopidogrel with higher potency adenosine diphosphate (ADP) receptor inhibitors among patients with acute myocardial infarction, little is known about the frequency, effectiveness and safety of switching between ADP receptor inhibitors in routine clinical practice."3.81In-hospital switching between adenosine diphosphate receptor inhibitors in patients with acute myocardial infarction treated with percutaneous coronary intervention: Insights into contemporary practice from the TRANSLATE-ACS study. ( Anstrom, KJ; Bagai, A; Cohen, DJ; Effron, MB; Goodman, SG; Gupta, A; Honeycutt, E; Messenger, JC; Peterson, ED; Wang, TY, 2015)
"There are limited data about long-term outcomes for biodegradable polymer biolimus-eluting stent (BES) versus durable polymer everolimus-eluting stent (EES) in patients undergoing percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI)."3.81Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent in patients with acute myocardial infarction. ( Choi, JH; Choi, RK; Choi, SH; Choi, YJ; Gwon, HC; Hahn, JY; Jang, HJ; Kim, JS; Kim, TH; Lee, HJ; Lee, SH; Park, JS; Park, TK; Roh, YM; Shim, WH; Song, YB; Yang, JH; Yu, CW, 2015)
"We describe the case of a patient with non-ST segment elevation myocardial infarction (NSTEMI) where a limitation of oral clopidogrel loading prior to percutaneous coronary intervention (PCI) was directly visualized on angiography."3.81Delayed clopidogrel transit during myocardial infarction evident on angiography. ( Ghobrial, J; Gibson, CM; Pinto, DS, 2015)
"We conducted a nested case-control study of Ontarians aged 66 years and older treated with clopidogrel between September 1 2003 and March 31 2013 following acute myocardial infarction."3.81A population-based study of the drug interaction between clopidogrel and angiotensin converting enzyme inhibitors. ( Cressman, AM; Fernandes, KA; Gomes, T; Juurlink, DN; Macdonald, EM; Mamdani, MM; Paterson, JM, 2015)
"We sought explore the relative benefits of unfractionated heparin (UFH) compared with enoxaparin, alone or in combination with clopidogrel, in ST-segment elevation myocardial infarction (STEMI) patients not undergoing reperfusion therapy."3.81Unfractionated heparin-clopidogrel combination in ST-elevation myocardial infarction not receiving reperfusion therapy. ( Badimon, L; Bugiardini, R; Calmac, L; Cenko, E; Daullxhiu, I; Dorobantu, M; Kedev, S; Knežević, B; Koller, A; Manfrini, O; Miličić, D; Puddu, PE; Ricci, B; Trninic, D; Vasiljevic, Z, 2015)
"The objective of this study is to investigate the interaction of Panax quinquefolius saponin (PQS) and dual antiplatelets (aspirin and clopidogrel) on antiplatelet activity and vascular endothelial function in rats with acute myocardial infarction (AMI)."3.81Interaction of Panax quinquefolius Saponin and Dual Antiplatelets on Vascular Endothelial Function in Rats with Acute Myocardial Infarction. ( Liu, J; Liu, Y; Shang, Q; Shi, D; Wang, B; Zhang, L; Zhang, Q, 2015)
"Early clopidogrel administration to patients with acute myocardial infarction (AMI) has been demonstrated to improve outcomes in a large Chinese trial."3.81National Quality Assessment of Early Clopidogrel Therapy in Chinese Patients With Acute Myocardial Infarction (AMI) in 2006 and 2011: Insights From the China Patient-Centered Evaluative Assessment of Cardiac Events (PEACE)-Retrospective AMI Study. ( Desai, NR; Hu, S; Jiang, L; Krumholz, HM; Li, J; Li, X; Masoudi, FA; Nuti, SV; Spertus, JA; Wang, Q; Wang, S; Zhang, L, 2015)
"This observational, nonrandomized study of ST-segment elevation myocardial infarction patients suggests that the administration of a loading dose of prasugrel in patients pre-treated with a loading dose of clopidogrel is not associated with an excess of major bleeding events."3.81Safety of Prasugrel Loading Doses in Patients Pre-Loaded With Clopidogrel in the Setting of Primary Percutaneous Coronary Intervention: Results of a Nonrandomized Observational Study. ( Auer, R; Baumbach, A; Carballo, D; Engstrøm, T; Gencer, B; Heg, D; Jüni, P; Kelbæk, H; Klingenberg, R; Lüscher, TF; Mach, F; Matter, CM; Meier, B; Moschovitis, A; Ostojic, M; Räber, L; Rodondi, N; Roffi, M; Stefanini, GG; Tüller, D; von Birgelen, C; Windecker, S; Zanchin, T, 2015)
"Patients on prasugrel had fewer cardiovascular events as compared to patients on clopidogrel twice daily with no difference in bleeding events."3.81Comparing prasugrel to twice daily clopidogrel post percutaneous coronary intervention in a Veterans Affairs population. ( Khatri, S; Pierce, T, 2015)
"High on treatment platelet reactivity (HTPR) is common in patients receiving clopidogrel following an acute coronary syndrome (ACS); it's also associated with increased morbidity and mortality."3.81Changes in platelet function independent of pharmacotherapy following coronary intervention in non-ST-elevation myocardial infarction patients. ( Anderson, RA; Freeman, PM; Hinz, C; James, PE; Kinnaird, TD; Moschonas, KE; O'Donnell, VB, 2015)
"The aim of this study was a) To identify predictors of the use of aspirin in the pre-hospital setting in acute myocardial infarction (AMI) and b) To analyze whether the use of any of the recommended medications was associated with outcome."3.81Determinants of pre-hospital pharmacological intervention and its association with outcome in acute myocardial infarction. ( Axelsson, C; Bremer, A; Claesson, A; Herlitz, J; Jimenez-Herrera, M; Karlsson, T; Ravn-Fischer, A; Strandmark, R, 2015)
" Meta-analyses evaluated effectiveness and adverse side effects for one-month administrations of aspirin plus cilostazol or aspirin plus ticlopidine therapy after coronary stenting."3.81Comparison of cilostazol and ticlopidine for one-month effectiveness and safety after elective coronary stenting. ( Hashiguchi, M; Kishino, S; Mochizuki, M; Nakazawa, R; Ohno, K; Shiga, T, 2004)
" The odds of an adverse incidence of death/myocardial infarction/stroke 1 year after discharge was significantly reduced in patients receiving aspirin and clopidogrel for ≥9 months and was consequently higher in patients in whom dual antiplatelet therapy was discontinued or prescribed for <9 months."3.80Predictors of 1-year outcomes in the Taiwan Acute Coronary Syndrome Full Spectrum Registry. ( Chiang, FT; Hou, CJ; Hwang, JJ; Kuo, C; Kuo, CT; Lai, WT; Li, AH; Li, YH; Lin, SJ; Mar, GY; Shyu, KG; Wen, MS; Wu, CJ, 2014)
"The current standard of antiplatelet therapy of patients after myocardial infarction includes the P2Y12 receptor antagonists clopidogrel, prasugrel or ticagrelor."3.80Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry. ( Bode, C; Diehl, P; Moser, M; Olivier, CB; Schnabel, K; Weik, P; Zhou, Q, 2014)
"The recently published, largest trial with cangrelor, the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION)-PHOENIX, suggested that the experimental agent significantly reduced the rate of stent thrombosis (ST) and myocardial infarction (MI) during PCI at 48 hours (h) and 30 days."3.80Disbalance between mortality and non-fatal vascular events in the CHAMPION-PHOENIX trial: the cangrelor efficacy challenge. ( DiNicolantonio, JJ; Fortmann, SD; Pokov, AN; Serebruany, VL, 2014)
" We report a case of clopidogrel non-responsiveness in a patient with HIV, latent tuberculosis and cardiovascular disease with a history of myocardial infarction."3.80A patient with HIV and tuberculosis with diminished clopidogrel response. ( Metzger, NL; Momary, KM, 2014)
"Patients with acute myocardial infarction undergoing percutaneous coronary intervention may benefit from prospective platelet function testing, because of higher platelet reactivity and much higher ratio of clopidogrel real non-response."3.80High on clopidogrel treatment platelet reactivity is frequent in acute and rare in elective stenting and can be functionally overcome by switch of therapy. ( Apró, A; Gulácsi-Bárdos, P; Hizoh, I; Horváth, Z; Kiss, RG; Kovács, A; Leé, S; Préda, I; Sztupinszki, Z; Tóth-Zsámboki, E; Vargová, K, 2014)
" This investigation aimed to evaluate the effect of hypothermia on the pharmacodynamic response of aspirin and clopidogrel in patients (n = 20) with ST elevation myocardial infarction undergoing primary PCI."3.80Impact of mild hypothermia on platelet responsiveness to aspirin and clopidogrel: an in vitro pharmacodynamic investigation. ( Angiolillo, DJ; Ariza, A; Cequier, A; Ferreiro, JL; Gómez-Hospital, JA; Gómez-Lara, J; Gracida, M; Homs, S; Lorente, V; Marcano, AL; Rivera, K; Romaguera, R; Roura, G; Sánchez-Elvira, G; Sánchez-Salado, JC; Sosa, SG; Teruel, L, 2014)
"Our aim was to identify risk factors for acute gastrointestinal (GI) bleeding in patients with myocardial infarction (MI) who were prescribed clopidogrel following hospital discharge."3.80Risk factors for acute gastrointestinal bleeding following myocardial infarction in veteran patients who are prescribed clopidogrel. ( Cuschieri, JR; Drawz, P; Falck-Ytter, Y; Wong, RC, 2014)
" Optimal use of 4 oral drugs (aspirin, β-blockers, statins, and angiotensin-converting enzyme inhibitors) in all eligible patients with AMI or unfractionated heparin in non-ST-segment-elevation myocardial infarction was a highly cost-effective strategy (incremental cost-effectiveness ratios approximately US $3100 or less)."3.80Cost-effectiveness of optimal use of acute myocardial infarction treatments and impact on coronary heart disease mortality in China. ( Coxson, PG; Goldman, L; Gu, D; He, J; Heidenreich, PA; Liu, J; Moran, AE; Wang, M; Zhao, D, 2014)
"There was no significant difference in the incidence of major adverse cardiac events between temporary adjunctive cilostazol treatment and clopidogrel loading in ST-segment elevation acute myocardial infarction patients."3.80Temporary adjunctive cilostazol vs clopidogrel loading for ST-segment elevation acute myocardial infarction. ( Inoue, Y; Ishii, H; Jinno, Y; Murohara, T; Okada, K; Okumura, S; Sakakibara, M; Suzuki, S; Tanaka, A, 2014)
"Switching patients with ACS who have HPR to treatment with prasugrel reduces thrombotic and bleeding events to a level similar to that of those without HPR; however, there is a higher risk of both thrombotic and bleeding complications with high-dose clopidogrel."3.80Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel. ( Aradi, D; Faluközy, J; Horváth, IG; Komócsi, A; Kónyi, A; Magyari, B; Pintér, T; Tornyos, A; Veress, G; Vorobcsuk, A, 2014)
"Current ST-elevation myocardial infarction (STEMI) guidelines recommend initiation of clopidogrel treatment as early as possible before angiography, based on pharmacokinetic and positive registry data."3.80Association of upstream clopidogrel administration and myocardial reperfusion assessed by cardiac magnetic resonance imaging in patients with ST-elevation myocardial infarction. ( de Waha, S; Desch, S; Eitel, I; Fuernau, G; Lurz, P; Schuler, G; Thiele, H, 2014)
" We applied this method in examining the effect of an antiplatelet agent, clopidogrel, on events, including bleeding, myocardial infarction, and death after a drug-eluting stent was implanted in coronary artery."3.80Estimating the effects of time-varying exposures in observational studies using Cox models with stabilized weights adjustment. ( Ho, PM; Magid, D; Raebel, MA; Shetterly, S; Tsai, TT; Xu, S, 2014)
"This study sought to examine the effectiveness of clopidogrel in real-world, medically managed patients with unstable angina (UA) or non-ST-segment elevation myocardial infarction (NSTEMI)."3.80Comparative effectiveness of clopidogrel in medically managed patients with unstable angina and non-ST-segment elevation myocardial infarction. ( Boothroyd, DB; Chang, TI; Go, AS; Hlatky, MA; Kazi, DS; Leong, TK; Shilane, D; Solomon, MD, 2014)
"Clopidogrel is recommended after acute myocardial infarction but has variable efficacy and safety, in part related to the effect of cytochrome P450 (CYP) polymorphisms on its metabolism."3.80Cytochrome p450 gene variants, race, and mortality among clopidogrel-treated patients after acute myocardial infarction. ( Bach, RG; Cresci, S; Depta, JP; Lanfear, DE; Lenzini, PA; Li, AY; Province, MA; Spertus, JA, 2014)
"To compare 30 and 90 day real-world acute myocardial infarction (AMI) and bleeding related rehospitalization rates in acute coronary syndrome (ACS) patients receiving percutaneous coronary intervention (PCI; ACS-PCI) treated with clopidogrel or prasugrel."3.80Real-world observations with prasugrel compared to clopidogrel in acute coronary syndrome patients treated with percutaneous coronary intervention in the United States. ( Bae, JP; Effron, MB; Ernst, FR; Faries, DE; Lieu, HD; Lipkin, C; Moretz, C; Zhao, Z, 2014)
"Although randomized clinical trials have compared clopidogrel with higher potency ADP receptor inhibitors (ADPris) among patients with myocardial infarction, little is known about the frequency and factors associated with switching between ADPris in clinical practice."3.80In-hospital switching between clopidogrel and prasugrel among patients with acute myocardial infarction treated with percutaneous coronary intervention: insights into contemporary practice from the national cardiovascular data registry. ( Alexander, KP; Bagai, A; Bhatt, DL; Cheema, AN; Curtis, JP; Granger, CB; Gurm, HS; McNamara, RL; Peterson, ED; Roe, MT; Saucedo, JF; Shah, B; Wang, TY; Wang, Y, 2014)
"The aim of the present study was to evaluate clopidogrel treatment after incident myocardial infarction (MI) in patients with and without chronic kidney disease (CKD)."3.80Benefit of clopidogrel therapy in patients with myocardial infarction and chronic kidney disease-a Danish nation-wide cohort study. ( Blicher, TM; Hommel, K; Kamper, AL; Kristensen, SL; Madsen, M; Olesen, JB; Torp-Pedersen, C, 2014)
" Data were obtained from the national VA Clinical Assessment, Reporting, and Tracking Program, including post-PCI clopidogrel prescription fill date and outcomes of myocardial infarction and death within 90 days of discharge."3.80Clopidogrel prescription filling delays and cardiovascular outcomes in a pharmacy system integrating inpatient and outpatient care: insights from the Veterans Affairs CART Program. ( Bhatt, DL; Byrd, JB; Grunwald, GK; Ho, PM; Maddox, TM; O'Donnell, CI; Rumsfeld, JS; Tsai, TT, 2014)
" The other 32 rats were subjected to induction of hypercholesterolemia by high-fat diet for 3 weeks, followed by induction of AMI by subcutaneous injections of isoproterenol (85 mg/kg/day, for 2 days)."3.80Assessment of the prophylactic role of aspirin and/or clopidogrel on experimentally induced acute myocardial infarction in hypercholesterolemic rats. ( El-Hadidy, WF; Mannaa, HF; Mohamed, AR, 2014)
"A total of 2141 patients with coronary artery disease treated exclusively with Cypher sirolimus-eluting stents (SES) or Endeavor zotarolimus-eluting stents (ZES) were considered for retrospective analysis."3.79Duration of dual antiplatelet therapy after implantation of the first-generation and second-generation drug-eluting stents. ( Chen, F; Gao, Y; He, J; Luo, Y; Lv, S; Ren, X; Wu, C; Yu, X; Zhang, X; Zhang, Y, 2013)
"A 36 year-old man, who had undergone a paclitaxel-eluting stent deployment into the left main (LM) coronary artery three years before, was admitted after successful resuscitation following out-of-hospital cardiac arrest due to an acute ST-segment elevation myocardial infarction."3.79Thrombocytosis as a potential cause of a very late stent thrombosis in the left main coronary artery. ( Janus, M; Lesiak, M; Lukawski, K; Prech, M, 2013)
"To date, there is limited data on levels of platelet inhibition achieved in patients with ST-elevation myocardial infarction (STEMI) who are loaded with clopidogrel and aspirin (ASA) prior to undergoing primary percutaneous coronary intervention (P-PCI)."3.79Clopidogrel pretreatment in primary percutaneous coronary intervention: prevalence of high on-treatment platelet reactivity and impact on preprocedural patency of the infarct-related artery. ( Angiolillo, DJ; Berdejo, J; Cequier, Á; Ferreiro, JL; Gómez-Hospital, JA; Gómez-Lara, J; Homs, S; Marcano, AL; Romaguera, R; Roura, G; Sánchez-Elvira, G; Teruel, L, 2013)
" Whether the bolus dose alone is sufficient for ST-elevation myocardial infarction patients receiving a high loading dose of clopidogrel is unknown."3.79Abciximab bolus with optional infusion in intervention for ST-elevation myocardial infarction. ( Berglund, U; Janzon, M; Nilsson, L, 2013)
"The current study sought to evaluate the clinical impact of newly reported genetic variations and their association with clopidogrel high on-treatment platelet reactivity (HTPR) in acute coronary syndrome (ACS) patients after drug-eluting stent (DES) implantation."3.79The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation. ( Han, YL; Kang, J; Li, Y; Liang, ZY; Yan, CH; Zhang, XL, 2013)
"Consecutive patients with acute ST-segment elevation myocardial infarction who were treated by primary angioplasty within 12 hours of the onset of symptoms received bivalirudin plus clopidogrel (Group A) or bivalirudin plus prasugrel (Group B)."3.79A comparative study of bivalirudin plus clopidogrel versus bivalirudin plus prasugrel in primary angioplasty using propensity score matching. ( Acosta, J; Benezet, J; Cubero Gómez, JM; Díaz DE LA Llera, LS; Fernández-Cisnal, A; Parejo, J; Rangel, D; Zafra, F, 2013)
"Although previous retrospective studies have suggested the clinical benefits of clopidogrel pretreatment in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI), the antiplatelet effect of thienopyridines during a narrow door-to-balloon time frame has not been evaluated."3.79Antiplatelet effect of thienopyridine (clopidogrel or prasugrel) pretreatment in patients undergoing primary percutaneous intervention for ST elevation myocardial infarction. ( Beigel, R; Elian, D; Fefer, P; Fink, N; Guetta, V; Hod, H; Matetzky, S; Novikov, I; Rosenberg, N; Segev, A, 2013)
"Clopidogrel could decrease mortality and improve cardiovascular outcomes without increasing risk of bleeding in ACS patients with CKD."3.79Effects of clopidogrel on mortality, cardiovascular and bleeding outcomes in patients with chronic kidney disease - data from Taiwan acute coronary syndrome full spectrum registry. ( Chang, SC; Chiang, FT; Hsin, HT; Hwang, JJ; Kuo, CT; Lai, WT; Li, AH; Lin, TH; Wang, CL, 2013)
"This study sought to assess the usefulness of clopidogrel-pathway genotyping and on-treatment platelet reactivity (OTR) testing in predicting major adverse cardiac events (MACE) in stable coronary artery disease (CAD) patients receiving drug-eluting stents (DES) under dual antiplatelet (clopidogrel plus aspirin) therapy."3.79Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease. ( Briguori, C; Condorelli, G; De Micco, F; Focaccio, A; Latronico, MV; Pagnotta, P; Papa, L; Roncarati, R; Visconti, G; Viviani Anselmi, C, 2013)
"In Non-ST elevation myocardial infarction (NSTEMI) patients (n = 132) undergoing percutaneous coronary intervention (PCI) on dual antiplatelet therapy blood samples were collected within 24 h from 600 mg clopidogrel loading dose."3.79Platelet and leukocyte ROS production and lipoperoxidation are associated with high platelet reactivity in Non-ST elevation myocardial infarction (NSTEMI) patients on dual antiplatelet treatment. ( Abbate, R; Becatti, M; Fiorillo, C; Gensini, GF; Giusti, B; Gori, AM; Marcucci, R; Paniccia, R; Pignatelli, P; Violi, F, 2013)
" We examined the influence of previously described polymorphisms, related to aspirin and clopidogrel resistance, on treatment outcome in a real life unselected population of patients presenting with ST-segment elevation myocardial infarction (STEMI) treated with percutaneous coronary intervention."3.79Value of platelet pharmacogenetics in common clinical practice of patients with ST-segment elevation myocardial infarction. ( Boden, H; Guchelaar, HJ; Heijmans, BT; Jukema, JW; Putter, H; Schalij, MJ; Trompet, S; van der Hoeven, BL; Verschuren, JJ; Wessels, JA, 2013)
"The CYP2C19 genotype is a predictor of adverse cardiovascular events in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) treated with clopidogrel."3.79Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis. ( Berger, JS; Hochman, JS; Ladapo, JA; Lala, A; Scott Braithwaite, R; Sharma, G, 2013)
" QIs for acute myocardial infarction were defined by an expert consensus group as appropriate prescription at discharge of aspirin, clopidogrel, β-blocker, statin, and an angiotensin-converting enzyme inhibitor in patients with left ventricular ejection fraction <0."3.79Hospital case volume and appropriate prescriptions at hospital discharge after acute myocardial infarction: a nationwide assessment. ( Capuano, F; Derumeaux, G; Desplanques-Leperre, A; Gardel, C; Grenier, C; Loirat, P; Schiele, F; Thebaut, JF, 2013)
"Ticagrelor showed significant reductions in myocardial infarctions (MIs) compared to clopidogrel in the Platelet Inhibition and Patient Outcomes (PLATO) trial."3.79Exploring the reduction in myocardial infarctions in the PLATO trial: which patients benefited on ticagrelor vs. clopidogrel? ( DiNicolantonio, JJ; Serebruany, VL, 2013)
"The present study was performed to compare the influence of cytochrome P459 2C19 (CYP2C19) *2 and *17 genetic variants on the platelet response to clopidogrel and prasugrel maintenance therapy and to assess the relation between platelet reactivity and bleeding complications."3.79Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications. ( Alessi, MC; Beguin, S; Bonnet, JL; Camoin, L; Cohen, W; Cuisset, T; Gaborit, B; Grosdidier, C; Lambert, M; Loosveld, M; Morange, PE; Moro, PJ; Pankert, M; Quilici, J; Saut, N, 2013)
"The purpose of the present study was to evaluate the effects of different loading doses of clopidogrel on ST segment resolution on ECG, changes in cardiac enzyme levels and serum levels of high-sensitivity C-reactive protein (Hs-CRP) in patients with ST elevated myocardial infarction (STEMI) treated with fibrinolytic therapy."3.79Effects of high loading dose of clopidogrel in ST elevated myocardial infarction treated with fibrinolytic agent. ( Akbulut, M; Karadağ, MK; Kaya, OK; Korkmaz, H; Kurtoğlu, E; Kuzu, Z; Solmaz, H; Uysal, A; Yavuzkir, MF, 2013)
" These results indicate that clopidogrel is more effective and safer than aspirin in reducing adverse cardiovascular events in patients with atherosclerosis."3.79Results of the CAPRIE trial: efficacy and safety of clopidogrel. Clopidogrel versus aspirin in patients at risk of ischaemic events. ( Creager, MA, 1998)
"Variants in ABCB1 and CYP2C19 have been identified as predictors of cardiac events during clopidogrel therapy initiated after myocardial infarction (MI) or percutaneous coronary intervention (PCI)."3.78Predicting clopidogrel response using DNA samples linked to an electronic health record. ( Basford, MA; Bowton, E; Cleator, JH; Crawford, DC; Delaney, JT; Denny, JC; Jahangir, E; Masys, DR; Oetjens, M; Pulley, JM; Ramirez, AH; Ritchie, MD; Roden, DM; Schildcrout, JS; Shi, Y; Xu, H; Zink, R, 2012)
" We applied these new methods in examining the effect of an anti-platelet agent, clopidogrel, on subsequent events, including bleeding, myocardial infarction, and death after a drug-eluting stent was implanted into a coronary artery."3.78Extension of Kaplan-Meier methods in observational studies with time-varying treatment. ( Ho, PM; Magid, D; Powers, D; Raebel, MA; Shetterly, S; Tsai, TT; Xu, S, 2012)
"Increased residual platelet reactivity remains a burden for coronary artery disease (CAD) patients who received a coronary stent and do not respond sufficiently to treatment with acetylsalicylic acid and clopidogrel."3.78Serotonin antagonism improves platelet inhibition in clopidogrel low-responders after coronary stent placement: an in vitro pilot study. ( Ahrens, I; Bode, C; Brandt, C; Duerschmied, D; Mauler, M; Moser, M; Weidner, S, 2012)
"We sought to determine whether a 600-mg loading dose of clopidogrel reduces myocardial infarct size compared with a 300-mg dose using contrast-enhanced magnetic resonance imaging in patients undergoing primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI)."3.78A high loading dose of clopidogrel reduces myocardial infarct size in patients undergoing primary percutaneous coronary intervention: a magnetic resonance imaging study. ( Chang, SA; Choe, YH; Choi, JH; Choi, SH; Gwon, HC; Hahn, JY; Lee, SC; Lee, SH; Oh, JK; Song, YB, 2012)
"Our findings suggest that concomitant use of clopidogrel with PPIs might be safer than ticlopidine with PPIs in patients undergoing primary stenting for acute myocardial infarction."3.78Comparison of early outcomes after primary stenting in Japanese patients with acute myocardial infarction between clopidogrel and ticlopidine in concomitant use with proton-pump inhibitor. ( Ishii, H; Murohara, T; Okada, K; Okumura, S; Sakakibara, M; Tanaka, A, 2012)
"Simulated cohort of patients with acute coronary syndrome scheduled to undergo percutaneous coronary intervention (PCI), consisting of three arms: those receiving genotype-guided antiplatelet therapy with clopidogrel or prasugrel, those receiving clopidogrel regardless of genotype, and those receiving prasugrel regardless of genotype."3.78Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel. ( Beitelshees, AL; Daniel Mullins, C; Onukwugha, E; Reese, ES, 2012)
"Current guidelines recommend the use of dual antiplatelet therapy (DAT) (aspirin+clopidogrel) for patients after acute myocardial infarction (MI)."3.78Dual antiplatelet therapy after myocardial infarction and percutaneous coronary intervention: analysis of patient adherence using a French health insurance reimbursement database. ( Couffinhal, T; Lafitte, M; Latry, P; Martin-Latry, K; Peter, C, 2012)
"High on-treatment platelet reactivity (HTPR) despite clopidogrel therapy is associated with adverse cardiac events after acute myocardial infarction (AMI)."3.78Clopidogrel response up to six months after acute myocardial infarction. ( Assali, A; Battler, A; Codner, P; Greenberg, G; Hasdai, D; Iakobishvili, Z; Kornowski, R; Lev, EI; Rechavia, E; Vaduganathan, M, 2012)
" We aimed to determine the relationship between high on-treatment platelet reactivity (HTPR) and ST-elevation myocardial infarction (STEMI) following a 600 mg loading dose (LD) of clopidogrel."3.78Biological efficacy of a 600 mg loading dose of clopidogrel in ST-elevation myocardial infarction. ( Armero, S; Barragan, P; Berbis, J; Bessereau, J; Bonello, C; Bonello, L; Camillieri, E; Camoin-Jau, L; Dignat-George, F; Jacquin, L; Laine, M; Paganelli, F, 2012)
"Clopidogrel prescription is a class I guideline recommendation for medically managed patients with non-ST-segment-elevation myocardial infarction (NSTEMI)."3.78Clopidogrel use and hospital quality in medically managed patients with non-ST-segment-elevation myocardial infarction. ( Ho, PM; Li, S; Maddox, TM; Masoudi, FA; Peng, SA; Rumsfeld, JS; Tsai, TT; Wang, TY; Wiviott, SD, 2012)
"The early administration of the anti-platelet agent clopidogrel in patients with acute coronary syndromes with or without ST-segment elevation has a beneficial effect on mortality and major adverse cardiac events."3.78Dramatic effect of early clopidogrel administration in reducing mortality and MACE rates in ACS patients. Data from the Swiss registry AMIS-Plus. ( Duvoisin, N; Erne, P; Goy, JJ; Radovanovic, D; Rickli, H; Stauffer, JC, 2012)
" The majority of patients had stable coronary artery disease (73%) and received sirolimus-eluting stents (93%), and approximately 90% of thienopyridine was ticlopidine."3.78Duration of dual antiplatelet therapy and long-term clinical outcome after coronary drug-eluting stent implantation: landmark analyses from the CREDO-Kyoto PCI/CABG Registry Cohort-2. ( Abe, M; Araki, M; Byrne, RA; Ehara, N; Eizawa, H; Fujiwara, H; Furukawa, Y; Inada, T; Iwabuchi, M; Kaburagi, S; Kadota, K; Kastrati, A; Kimura, T; Kita, T; Mitsudo, K; Mitsuoka, H; Mizoguchi, T; Morimoto, T; Nakagawa, Y; Nakano, A; Natsuaki, M; Nobuyoshi, M; Nohara, R; Shiomi, H; Shizuta, S; Suwa, S; Tada, T; Takizawa, A; Taniguchi, R; Tazaki, J, 2012)
"Patients receiving clopidogrel beyond 12 months had a lower risk of death or myocardial infarction compared patients receiving clopidogrel ≤12 months."3.78Prolonged clopidogrel use after bare metal and drug-eluting stent placement: the Veterans Administration drug-eluting stent study. ( Faxon, DP; Gaziano, M; Kinlay, S; Lawler, E; Young, M, 2012)
"Little is known about the antiplatelet action of the thienopyridines, clopidogrel and prasugrel, as well as the non-thienopyridine, ticagrelor, in patients suffering from ST-elevation myocardial infarction (STEMI) complicated by cardiogenic shock since systematic comparisons of these antiplatelet agents in this devastating condition are limited so far."3.78Dual thienopyridine low-response to clopidogrel and prasugrel in a patient with STEMI, cardiogenic shock and early stent thrombosis is overcome by ticagrelor. ( Hausleiter, J; Joner, M; Kastrati, A; Massberg, S; Okrojek, R; Orban, M; Riegger, J; Sibbing, D; Tada, T, 2012)
" We wanted to explore long-term variability of multiple electrode aggregometry (MEA) measurements and the agreement between MEA and light transmission aggregometry (LTA) in patients with non-ST elevation myocardial infarction (NSTEMI) treated with aspirin and clopidogrel."3.78Sequential ADP-stimulated light transmission and multiple electrode aggregometry in patients taking aspirin and clopidogrel after non ST-elevation myocardial infarction. ( Andreassen, T; Bendz, B; Brosstad, F; Erikssen, G; Kunszt, G; Liestøl, K; Meen, O; Schjelderup, NM; Wettergreen, M, 2012)
"The pharmacodynamic analysis end point was clopidogrel on-treatment platelet reactivity (OPR) and the clinical analysis end point was the composite of cardiac death, non-fatal myocardial infarction, ischaemic stroke and stent thrombosis at 12 months post-PCI."3.78Amlodipine, clopidogrel and CYP3A5 genetic variability: effects on platelet reactivity and clinical outcomes after percutaneous coronary intervention. ( Kang, HJ; Kang, J; Kim, HS; Koo, BK; Lee, HY; Oh, BH; Park, JJ; Park, KW; Park, YB; Yang, HM, 2012)
"Use of warfarin at discharge in patients with atrial fibrillation is greater among those with higher stroke and bleeding risks, but despite higher-risk profiles, less than half received warfarin at discharge."3.78Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes. ( Alexander, KP; Foody, JM; Funk, M; Granger, CB; Li, L; Lopes, RD; Peterson, ED; Wang, TY, 2012)
"The benefit of extending clopidogrel treatment beyond the 12-month period recommended in current guidelines after myocardial infarction (MI) is debated."3.78Clopidogrel discontinuation after myocardial infarction and risk of thrombosis: a nationwide cohort study. ( Ahlehoff, O; Charlot, M; Gislason, GH; Hansen, ML; Hansen, PR; Køber, L; Lindhardsen, J; Madsen, JK; Nielsen, LH; Olsen, AM; Torp-Pedersen, C, 2012)
"On July 20, 2011, the Food and Drug Administration (FDA) approved ticagrelor (Brilinta™) for use during acute coronary syndromes."3.78Ticagrelor FDA approval issues revisited. ( Serebruany, VL, 2012)
"One of the foundations of the modern treatment of myocardial infarction (MI) is a combination antiplatelet therapy consisting of acetylsalicylic acid (ASA) and clopidogrel."3.78[CYP2C19 gene polymorphism in patients with myocardial infarction who use clopidogrel]. ( Akhmetov, II; Arkhipova, AA; Galiavi, RA; Galiavich, AS; Minnetdinov, RSh; Valeeva, DD, 2012)
"The optimum loading dose of clopidogrel has not been established in Asian patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI)."3.78Effects of 600 mg versus 300 mg loading dose of clopidogrel in Asian patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: long-term follow-up study. ( Ahn, KT; Choi, JH; Choi, SH; Gwon, HC; Hahn, JY; Kang, GH; Kim, HS; Lim, WH; Park, KW; Song, PS; Song, YB, 2012)
" Fatal or nonfatal (requiring hospitalization) bleeding was determined according to antithrombotic treatment regimen: triple therapy (TT) with vitamin K antagonist (VKA)+aspirin+clopidogrel, VKA+antiplatelet, and dual antiplatelet therapy with aspirin+clopidogrel."3.78Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. ( Gislason, GH; Hansen, CM; Hansen, ML; Karasoy, D; Kristensen, SL; Køber, L; Lamberts, M; Olesen, JB; Ruwald, MH; Torp-Pedersen, C, 2012)
"This case report describes recurrent drug-eluting stent thrombosis with documented laboratory hyporesponsiveness to clopidogrel."3.78Failure of high-dose clopidogrel in recurrent stent thrombosis. ( Chan, MY; Li, Y, 2012)
"To estimate the clinical effectiveness associated with clopidogrel treatment after myocardial infarction (MI) in patients with diabetes."3.78Association of clopidogrel treatment with risk of mortality and cardiovascular events following myocardial infarction in patients with and without diabetes. ( Andersson, C; Gislason, GH; Køber, L; Lyngbæk, S; Nguyen, CD; Nielsen, M; Torp-Pedersen, C, 2012)
"High platelet reactivity (HPR) after clopidogrel treatment is linked to an increased risk of periprocedural myocardial infarction (PMI)."3.78Association of CYP2C19 genotype with periprocedural myocardial infarction after uneventful stent implantation in Chinese patients receiving clopidogrel pretreatment. ( Ge, J; Qian, J; Sun, A; Wang, Q; Wu, H, 2012)
"Our study showed that clopidogrel resistance may be one of the responsible mechanisms for the no-reflow phenomenon."3.78Impact of clopidogrel resistance on ST-segment resolution and no-reflow in acute myocardial infarction with ST-elevation patients treated with a primary percutaneous coronary intervention. ( Aksu, H; Bozbeyoglu, E; Nurkalem, Z; Satilmis, S; Yildirimturk, O, 2012)
"We conducted a population-based nested case-control study among patients aged 66 years or older who commenced clopidogrel between April 1, 2002 and December 31, 2009, following hospital discharge for acute myocardial infarction (AMI)."3.78Antidepressant use, serotonin transporter affinity, and reinfarction among patients receiving clopidogrel: a population-based study. ( Alshaikh, M; Fnais, N; Gomes, T; Juurlink, D; Mamdani, M; Yao, Z, 2012)
"This study sought to examine the pattern of death and myocardial infarction (MI) after clopidogrel cessation in patients undergoing percutaneous coronary intervention (PCI) of the saphenous vein graft (SVG)."3.78Discontinuation of long-term clopidogrel therapy is associated with death and myocardial infarction after saphenous vein graft percutaneous coronary intervention. ( Aharonian, V; Bavisetty, S; Beckham, G; Brar, SS; Contreras, R; Hyett, R; Leon, M; Mansukhani, P; Moore, N; Moses, J; Sachdeva, A; Shen, AY; Stone, GW, 2012)
"In this study, clopidogrel use during CEA resulted in a significant risk for developing a neck hematoma, particularly when using a Dacron-patch."3.77Outcomes related to antiplatelet or anticoagulation use in patients undergoing carotid endarterectomy. ( Alden, PB; Goldman, JA; Graber, JN; Rizvi, AZ; Rosenbaum, A; Sullivan, TM; Tretinyak, AS, 2011)
"The association between myocardial infarction (MI) and co-administration of proton pump inhibitors (PPIs) and clopidogrel remains controversial."3.77Risk of recurrent myocardial infarction with the concomitant use of clopidogrel and proton pump inhibitors. ( 't Jong, GW; Kuipers, EJ; Sturkenboom, MC; Valkhoff, VE; Van Soest, EM, 2011)
"Among patients receiving clopidogrel for coronary artery disease, concomitant therapy with proton pump inhibitors (PPIs) has been associated with an increased risk for recurrent coronary events."3.77Concomitant use of proton pump inhibitors and clopidogrel in patients with coronary, cerebrovascular, or peripheral artery disease in the factores de Riesgo y ENfermedad Arterial (FRENA) registry. ( Escudero, D; Monreal, M; Muñoz-Torrero, JF; Pascual, MT; Sanclemente, C; Suárez, C; Trujillo-Santos, J; Zamorano, J, 2011)
"Clopidogrel is a widely used anti-platelet agent for the prevention of arterial thrombosis."3.77Clopidogrel Resistance: case reports of CYP2C19 gene variants in suspected coronary stent thrombosis. ( Byron, KA; Dear, AE; Dick, RJ, 2011)
"The purpose of this study was to determine the risk of adverse cardiovascular events associated with concomitant use of clopidogrel and calcium-channel blockers (CCBs) in patients with myocardial infarction (MI)."3.77Calcium-channel blockers do not alter the clinical efficacy of clopidogrel after myocardial infarction: a nationwide cohort study. ( Ahlehoff, O; Andersson, C; Charlot, MG; Fosbøl, EL; Gislason, GH; Hansen, PR; Olesen, JB; Selmer, C; Torp-Pedersen, C; Weeke, P, 2011)
"The optimal loading dose of clopidogrel in Asian patients with ST-segment elevation myocardial infarction (STEMI) has not been fully investigated."3.77Standard versus high loading doses of clopidogrel in Asian ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention: insights from the Korea Acute Myocardial Infarction Registry. ( Ahn, TH; Ahn, YK; Bae, JH; Chae, IH; Chae, JK; Chae, SC; Cho, MC; Choi, CU; Choi, DH; Chung, WS; Hong, TJ; Hur, SH; Jang, YS; Jeong, MH; Kim, CJ; Kim, EJ; Kim, HS; Kim, JW; Kim, YJ; Lim, HE; Na, JO; Oh, DJ; Park, CG; Park, JS; Park, SJ; Poddar, KL; Rha, SW; Seo, HS; Seong, IW; Seung, KB; Tahk, SJ; Yoon, JH, 2011)
"From April 2003 to June 2010, 1424 consecutive patients with acute myocardial infarction who underwent primary or rescue percutaneous coronary intervention with drug-eluting stent and clopidogrel were enrolled."3.77Impact of smoking on acute phase outcomes of myocardial infarction. ( Ben-Dor, I; Delhaye, C; Gaglia, MA; Gonzalez, MA; Kent, KM; Laynez-Carnicero, A; Lindsay, J; Mahmoudi, M; Maluenda, G; Pichard, AD; Romaguera, R; Sardi, G; Satler, LF; Suddath, WO; Torguson, R; Wakabayashi, K; Waksman, R; Xue, Z, 2011)
"The objective of this study was to examine the clinical efficacy of clopidogrel treatment on death and recurrent myocardial infarction (MI) among MI patients revascularized by coronary artery bypass graft surgery (CABG)."3.77Efficacy of post-operative clopidogrel treatment in patients revascularized with coronary artery bypass grafting after myocardial infarction. ( Abildstrøm, SZ; Andersson, C; Charlot, M; Fosbøl, EL; Gislason, GH; Hansen, PR; Hvelplund, A; Køber, L; Madsen, JK; Sørensen, R; Torp-Pedersen, C, 2011)
" Triple therapy (OAC, clopidogrel plus aspirin) was associated with four times higher risk of any bleeding than OAC plus aspirin, adj."3.77Efficacy and safety of clopidogrel after PCI with stenting in patients on oral anticoagulants with acute coronary syndrome. ( Hofman-Bang, C; Lagerqvist, B; Lindbäck, J; Persson, J; Samnegard, A; Stenestrand, U, 2011)
"Clopidogrel discontinuation after percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation has been reported to correlate with stent thrombosis."3.77Relation between clopidogrel discontinuation and early cardiovascular events after percutaneous coronary intervention with drug-eluting stents. ( Ben-Dor, I; Bonello, L; Collins, SD; de Labriolle, A; Lemesle, G; Maluenda, G; Pichard, AD; Satler, LF; Syed, AI; Torguson, R; Waksman, R; Xue, Z, 2011)
"One possible cause of stent thrombosis is an insufficient effect of clopidogrel."3.77Optimizing of thienopyridine therapy by multiple electrode platelet aggregometry in clopidogrel low responders undergoing PCI. ( Behr, T; Behr, W; Kuch, B; von Scheidt, W, 2011)
"Although clopidogrel pretreatment benefits patients undergoing percutaneous coronary intervention (PCI) for acute coronary syndromes, these benefits are less well established among patients undergoing elective PCI--in particular, when they are treated with the direct thrombin inhibitor, bivalirudin."3.77Effect of clopidogrel pretreatment on ischemic complications of percutaneous coronary intervention among bivalirudin-treated patients (from the EVENT registry). ( Amin, AP; Berger, P; Cohen, DJ; Kennedy, KF; Kleiman, N; Lopez, J; Pencina, M; Piana, RN, 2011)
"While acute myocardial infarction (MI) is associated with impaired clopidogrel responsiveness, systematic evaluation is lacking due to the inability of functional aggregation-based assays to analyse clopidogrel responsiveness in the presence of glycoprotein IIb/IIIa inhibitors."3.77Early determination of clopidogrel responsiveness by platelet reactivity indexidentifies patients at risk for cardiovascular events after myocardial infarction. ( Bauersachs, J; Flierl, U; Kobsar, A; Kössler, J; Schäfer, A; Seydelmann, N; Störk, S, 2011)
"AIMS Immediate treatment with a loading dose of clopidogrel at diagnosis of ST-segment elevation myocardial infarction (STEMI) is recommended by ESC/AHA/ACC guidelines in patients eligible for primary percutaneous coronary intervention (PCI)."3.77Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. ( Erlinge, D; James, S; Koul, S; Lagerqvist, B; Scherstén, F; Smith, JG, 2011)
"Data are lacking on the efficacy and safety of a loading dose (LD) of clopidogrel in elderly patients with acute myocardial infarction (AMI)."3.77Comparison of efficacy and safety of a standard versus a loading dose of clopidogrel for acute myocardial infarction in patients ≥ 75 years of age (from the FAST-MI registry). ( Aïssaoui, N; Bataille, V; Blanchard, D; Carrié, D; Coste, P; Danchin, N; Dentan, G; Drouet, E; Mulak, G; Puymirat, E; Simon, T, 2011)
"We report a case of a 27-year-old woman who received a drug-eluting coronary stent for an acute myocardial infarction and was started on clopidogrel as treatment."3.77Clopidogrel use throughout pregnancy in a patient with a drug-eluting coronary stent. ( Hoffman, MK; Marshall, ES; Myers, GR, 2011)
"Thienopyridines, specifically clopidogrel, are the standard of care for prevention of coronary stent thrombosis; however, there are few data available on cross-hypersensitivity between these agents."3.77Use of prasugrel in a patient with clopidogrel hypersensitivity. ( Beddingfield, R; Held-Godgluck, BM; Peppard, SR, 2011)
"Ticagrelor has been shown to be superior to clopidogrel in patients presenting with acute myocardial infarction who undergo early invasive treatment."3.77The use of ticagrelor in a patient at increased risk of stent thrombosis resistant to multiple thienopyridines. ( Chauhan, A; More, RS; Morgan, KP, 2011)
"To test the hypothesis that HRPR after clopidogrel loading is an independent prognostic marker of risk of long-term thrombotic events in patients with acute coronary syndromes (ACS) undergoing an invasive procedure and antithrombotic treatment adjusted according to the results of platelet function tests."3.77High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. ( Abbate, R; Antoniucci, D; Buonamici, P; Gensini, GF; Giusti, B; Gori, AM; Marcucci, R; Migliorini, A; Parodi, G; Valenti, R, 2011)
" The influence of the CYP2C19 LOF alleles (*2 and *3) on clopidogrel response and clinical outcomes in East Asians with acute myocardial infarction (AMI) has not been reported."3.77Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin. ( Bliden, KP; Gurbel, PA; Hwang, JY; Hwang, SJ; Jeong, YH; Kim, IS; Koh, JS; Kwak, CH; Kwon, TJ; Park, Y; Tantry, US, 2011)
"We report a 50-year-old man who presented with acute myocardial infarction and received clopidogrel therapy."3.77[Clopidogrel induced thrombotic thrombocytopenic purpura]. ( Coppérré, B; Hot, A; Karkowski, L; Lescampf, J; Ninet, J; Veyradier, A; Wolf, M, 2011)
"To assess the long-term cost effectiveness of treatment for 1 month, and for 1 year with clopidogrel in addition to standard therapy (including aspirin) compared with standard therapy alone, in patients diagnosed with ST elevation acute myocardial infarction (STEMI) in the UK."3.76A cost-utility analysis of clopidogrel in patients with ST elevation acute coronary syndromes in the UK. ( Bakhai, A; Brennan, A; Holmes, MW; Karnon, J; Williams, R, 2010)
"In patients with acute coronary syndromes and planned percutaneous coronary intervention, the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38) demonstrated that treatment with prasugrel versus clopidogrel was associated with reduced rates of cardiovascular death, MI, or stroke and an increased risk of major bleeding."3.76Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasug ( Antman, E; Arnold, SV; Braunwald, E; Cohen, DJ; Mahoney, EM; Proskorovsky, I; Wang, K; Wiviott, S, 2010)
"This study assesses the costs and effects of combination treatment with clopidogrel and aspirin in comparison to aspirin alone in patients with an ST-segment elevation myocardial infarction (STEMI) in a Dutch setting."3.76Cost-effectiveness of clopidogrel in STEMI patients in the Netherlands: a model based on the CLARITY trial. ( de Charro, F; Heeg, B; Thurston, SJ; van Hout, B, 2010)
"Current guidelines recommend pretreatment with a loading dose of clopidogrel before percutaneous coronary intervention (PCI) to reduce the incidence of periprocedural myocardial infarctions in patients undergoing PCI."3.76Efficacy of high-dose clopidogrel treatment (600 mg) less than two hours before percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes. ( Bergman, G; Fakorede, F; Feldman, DN; Minutello, RM; Moussa, I; Wong, SC, 2010)
" This study sought to evaluate procedural major bleeding and myocardial infarction in patients undergoing stent implantation with adjunctive clopidogrel compared with ticlopidine."3.76Safety and efficacy of clopidogrel treatment in Japanese patients undergoing drug-eluting stent implantation. ( Hayashi, F; Iijima, R; Nakamura, M; Sugi, K, 2010)
" An increased risk of thrombosis after coronary stenting for ACS patients treated with aspirin and clopidogrel has been linked to high platelet reactivity and, for certain patients, poor drug response."3.76VerifyNow and VASP phosphorylation assays give similar results for patients receiving clopidogrel, but they do not always correlate with platelet aggregation. ( Bidet, A; Coste, P; Jais, C; Jakubowski, J; Nurden, A; Nurden, P; Puymirat, E, 2010)
"Higher clopidogrel use 12 months after drug-eluting stent implantation was associated with a greater risk of subsequent bleeding events."3.76Clopidogrel use and clinical events after drug-eluting stent implantation: findings from the HealthCore Integrated Research Database. ( Anstrom, KJ; Barron, JJ; Califf, RM; Curtis, LH; Cziraky, MJ; Eisenstein, EL; Hammill, BG; Krucoff, MW; Petersen, JL; Schulman, KA; Wahl, PM, 2010)
"Clopidogrel improves outcomes in patients with ST-segment elevation myocardial infarction (STEMI) and is recommended in the guidelines."3.76Cost-effectiveness analysis of short-term clopidogrel therapy for ST elevation myocardial infarction. ( Cannon, CP; Cohen, DJ; Gibler, KB; Huskamp, HA; Murphy, SA; Sabatine, MS, 2010)
"The purpose of this study was to determine the readmission rate for acute myocardial infarction (AMI) in patients discharged on clopidogrel and a proton-pump inhibitor (PPI) versus patients discharged on clopidogrel alone after experiencing an AMI and undergoing stent placement."3.76Recurrence of acute myocardial infarction in patients discharged on clopidogrel and a proton pump inhibitor after stent placement for acute myocardial infarction. ( Binkley, P; Donnally, MR; Evanchan, J; Mazzaferri, E, 2010)
"We sought to evaluate the influence of platelet reactivity after clopidogrel, as assessed by the VerifyNow point-of-care assay (Accumetrics, San Diego, California), on myonecrosis in low-to-intermediate risk patients undergoing percutaneous coronary intervention (PCI)."3.76Point-of-care assessment of platelet reactivity after clopidogrel to predict myonecrosis in patients undergoing percutaneous coronary intervention. ( Barbato, E; D'Ambrosio, A; Di Sciascio, G; Gatto, L; Mangiacapra, F; Patti, G; Ricottini, E; Vizzi, V; Wijns, W, 2010)
"We studied the association of clopidogrel with mortality in acute myocardial infarction (AMI) patients with heart failure (HF) not receiving percutaneous coronary intervention (PCI)."3.76Increased mortality associated with low use of clopidogrel in patients with heart failure and acute myocardial infarction not undergoing percutaneous coronary intervention: a nationwide study. ( Abildstrøm, SZ; Bonde, L; Bretler, DM; Fosbøl, EL; Gislason, GH; Hansen, PR; Kober, L; Olesen, J; Schramm, TK; Sorensen, R; Torp-Pedersen, C; Weeke, P, 2010)
"This was a retrospective cohort study of 2017 patients with acute coronary syndrome discharged on clopidogrel from an integrated health care delivery system."3.76Adverse events after stopping clopidogrel in post-acute coronary syndrome patients: Insights from a large integrated healthcare delivery system. ( Clarke, CL; Go, AS; Ho, PM; Magid, DJ; Peterson, ED; Rumsfeld, JS; Sedrakyan, A; Shetterly, SM; Tsai, TT; Wang, TY, 2010)
"Studies suggest that extended clopidogrel use after drug-eluting stent (DES) implantation may decrease the risk of myocardial infarction (MI) and death."3.76Increased risk of bleeding in patients on clopidogrel therapy after drug-eluting stents implantation: insights from the HMO Research Network-Stent Registry (HMORN-stent). ( Carroll, NM; Go, AS; Ho, PM; Maddox, TM; Magid, DJ; Margolis, K; Powers, JD; Rumsfeld, JS; Shetterly, SM; Tsai, TT; Xu, S, 2010)
"A database of deidentified electronic medical records from hospitals and hospital-affiliated outpatient facilities throughout the United States was analyzed for PCI patients with or without a diagnosis of acute coronary syndrome (ACS) who received clopidogrel loading doses of > or =300 mg between 48 hours before and 6 hours after PCI."3.76Pattern of clopidogrel use in hospitalized patients receiving percutaneous coronary interventions. ( Bae, JP; Dean, BB; Emons, MF; Fiske, S; Meadows, E; Xiong, Y; Yu, HT, 2010)
"To examine the risk for adverse cardiovascular outcomes related to concomitant use of PPIs and clopidogrel compared with that of PPIs alone in adults hospitalized for myocardial infarction."3.76Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study. ( Abildstrøm, SZ; Ahlehoff, O; Charlot, M; Gislason, G; Hansen, PR; Jørgensen, CH; Køber, L; Madsen, JK; Norgaard, ML; Sørensen, R; Torp-Pedersen, C, 2010)
"To determine whether the 681 G>A (*2) polymorphism of cytochrome P450 (CYP2C19) is related to suboptimal reperfusion and mortality in patients with acute myocardial infarction (AMI) pretreated with clopidogrel."3.76Cytochrome P450 2C19 polymorphism, suboptimal reperfusion and all-cause mortality in patients with acute myocardial infarction. ( Kostrzewa, G; Kruk, M; Kłopotowski, M; Małek, LA; Przyłuski, J; Płoski, R; Rużyłło, W; Spiewak, M; Witkowski, A, 2010)
"To evaluate effect of duration of clopidogrel use on clinical follow-up outcomes in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention."3.76[Effect of duration of clopidogrel use on clinical follow-up outcomes in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention]. ( Fan, ZJ; Fang, Q; Jin, XF; Liu, ZY; Shen, ZJ; Wang, CH; Xie, HZ; Yang, J; Zhang, SY, 2010)
"The aim of the present study was to compare 600- and 300-mg clopidogrel loading doses in patients with ST-segment elevation myocardial infarctions who underwent primary percutaneous coronary intervention (PCI)."3.76Comparison of 600 versus 300-mg Clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary coronary angioplasty. ( Barbato, E; Bartunek, J; De Bruyne, B; Heyndrickx, GR; Mangiacapra, F; Muller, O; Ntalianis, A; Trana, C; Vanderheyden, M; Wijns, W, 2010)
" Our algorithm, which is in the process of being implemented, is consistent with published and generally accepted standards of care and is based on data from the pivotal Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction (TRITON-TIMI) 38, which compared clopidogrel with prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention."3.76An algorithm for use of prasugrel (effient) in patients undergoing cardiac catheterization and percutaneous coronary intervention. ( Cannon, C; Croce, K; Kirshenbaum, J; Manica, A; Marchini, J; Morrow, D; Resnic, F, 2010)
"We consecutively enrolled 2208 patients presenting with an acute myocardial infarction in a nationwide French registry and receiving clopidogrel therapy."3.75Genetic determinants of response to clopidogrel and cardiovascular events. ( Becquemont, L; Danchin, N; Drouet, E; Ferrières, J; Mary-Krause, M; Méneveau, N; Quteineh, L; Simon, T; Steg, PG; Verstuyft, C, 2009)
"Among 13 636 patients prescribed clopidogrel following acute myocardial infarction, we identified 734 cases readmitted with myocardial infarction and 2057 controls."3.75A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. ( Austin, PC; Gomes, T; Henry, DA; Juurlink, DN; Ko, DT; Kopp, A; Mamdani, MM; Szmitko, PE; Tu, JV, 2009)
"To assess the prognosis of patients presenting with an acute coronary syndrome (ACS) despite chronic clopidogrel therapy (CCT)."3.75Prognosis of patients suffering an acute coronary syndrome while already under chronic clopidogrel therapy. ( Bonello, L; De Labriolle, A; Kent, KM; Lemesle, G; Pichard, AD; Roy, P; Satler, LF; Steinberg, DH; Suddath, WO; Torguson, R; Waksman, R, 2009)
" As compared with the conventional 300-mg dose, pretreatment with a 600-mg loading dose of clopidogrel significantly reduced periprocedural myocardial infarction (MI) in patients undergoing percutaneous coronary intervention (PCI)."3.75Clopidogrel pretreatment before primary percutaneous coronary stenting in patients with acute ST-segment elevation myocardial infarction: comparison of high loading dose (600 mg) versus low loading dose (300 mg). ( Byun, KH; Cho, JR; Choi, S; Jung, JH; Lee, N; Lee, SH; Min, PK; Sung, CW, 2009)
"To determine the association between the discontinuation of clopidogrel therapy prior to 1 year and the risk of acute myocardial infarction (AMI) hospitalization, coronary intervention or all-cause mortality in a cohort of managed-care patients following AMI hospitalization or stent insertion."3.75Clinical impact of early clopidogrel discontinuation following acute myocardial infarction hospitalization or stent implantation: analysis in a single integrated health network. ( Berenson, K; Casciano, R; Corbelli, J; Lamerato, L; Makenbaeva, D; Mozaffari, E; Stern, L; Wiederkehr, D, 2009)
"To evaluate the association between discontinuation of clopidogrel therapy and risk of acute myocardial infarction (AMI) hospitalization or cardiac revascularization in a nationally-representative patient population following hospitalization for an AMI or coronary stent insertion."3.75Clinical impact of early clopidogrel discontinuation following acute myocardial infarction hospitalization or stent implantation: analysis in a nationally representative managed-care population. ( Casciano, R; Corbelli, J; Makenbaeva, D; Mozaffari, E; Ogbonnaya, A; Wiederkehr, D, 2009)
"We evaluated the effect and optimal dose of clopidogrel pretreatment in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention (PPCI)."3.75Usefulness of pretreatment with high-dose clopidogrel in patients undergoing primary angioplasty for ST-elevation myocardial infarction. ( Behar, S; Beinart, R; Boyko, V; Fefer, P; Hammerman, H; Hod, H; Matetzky, S; Segev, A, 2009)
"(1) For patients with acute coronary syndromes who have undergone percutaneous angioplasty and stenting, the best-assessed treatment for preventing relapses is a combination of aspirin and clopidogrel; (2) Prasugrel, an antiplatelet drug belonging the same chemical class as clopidogrel, is authorized in the EU for use in this indication; (3) Clinical evaluation is based on a randomized double-blind trial comparing prasugrel + aspirin versus clopidogrel + aspirin in 13 608 patients with acute coronary syndromes, half of whom were treated for at least 15 months."3.75Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel. ( , 2009)
"Combinations of aspirin, clopidogrel, and vitamin K antagonists are widely used in patients after myocardial infarction."3.75Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. ( Abildstrom, SZ; Andersson, C; Gislason, GH; Hansen, ML; Hansen, PR; Hvelplund, A; Jørgensen, C; Køber, L; Madsen, JK; Sørensen, R; Torp-Pedersen, C, 2009)
" This study was designed to determine the relation between responses to aspirin and clopidogrel as assessed by a point-of-care assay (Verify Now, Accumetrics, San Diego, California) and periprocedural myocardial infarction (PMI) in patients undergoing elective PCI for stable angina."3.74Relation of low response to clopidogrel assessed with point-of-care assay to periprocedural myonecrosis in patients undergoing elective coronary stenting for stable angina pectoris. ( Barbato, E; Bartunek, J; Cuisset, T; De Bruyne, B; Hamilos, M; Sarma, J; Sarno, G; Vanderheyden, M; Wijns, W; Wyffels, E, 2008)
"To identify possible underuse by analysing initiation and persistence with clopidogrel treatment in an unselected population of patients admitted with myocardial infarction (MI) with or without subsequent percutaneous coronary intervention (PCI)."3.74Initiation and persistence with clopidogrel treatment after acute myocardial infarction: a nationwide study. ( Abildstrom, SZ; Fosbøl, EL; Gislason, GH; Køber, L; Madsen, JK; Rasmussen, S; Sørensen, R; Torp-Pedersen, C, 2008)
"The rate of clopidogrel use within 30 days after hospital discharge following myocardial infarction increased from 35% in the prior-authorization period to 88% in the limited-use period."3.74Cardiovascular outcomes after a change in prescription policy for clopidogrel. ( Behlouli, H; Cox, J; Demers, V; Jackevicius, CA; Johansen, H; Kalavrouziotis, D; Melo, M; Newman, A; Pilote, L; Rinfret, S; Tu, JV, 2008)
"We sought to determine the usage patterns and impact of upstream glycoprotein IIb/IIIa inhibitor and clopidogrel in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI)."3.74Patterns of upstream antiplatelet therapy use before primary percutaneous coronary intervention for acute ST-elevation myocardial infarction (from the CRUSADE National Quality Improvement Initiative). ( Alexander, D; Gibler, WB; Mann, N; Ohman, EM; Ou, FS; Peterson, ED; Roe, MT, 2008)
"The aim of this article is to examine whether clopidogrel and ticlopidine treatments produce similar clinical outcomes for patients receiving primary stenting for acute myocardial infarction (AMI)."3.74Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: results from the CADILLAC trial. ( Brener, M; Carroll, JD; Cox, DA; Cristea, E; Garcia, E; Grines, CL; Guagliumi, G; Lansky, AJ; Leon, MB; Mehran, R; Moses, J; Pietras, C; Rutherford, BD; Stone, GW; Stuckey, T; Tcheng, JE; Tsuchiya, Y; Turco, M, 2008)
"In patients undergoing coronary stenting, long-term dual antiplatelet therapy with aspirin and clopidogrel reduces atherothrombotic events but also increases the risk of bleeding."3.74Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy. ( Angiolillo, DJ; Bass, TA; Della Rovere, F; Gavazzi, A; Lettieri, C; Mantovani, P; Mihalcsik, L; Molfese, M; Musumeci, G; Rossini, R; Sirbu, V, 2008)
"The purpose of this study was to evaluate the risk of stent thrombosis (ST), clinical outcomes, and the benefits of extended clopidogrel use after drug-eluting stent (DES) implantation."3.74Stent thrombosis, clinical events, and influence of prolonged clopidogrel use after placement of drug-eluting stent data from an observational cohort study of drug-eluting versus bare-metal stents. ( Cheong, SS; Hong, MK; Kim, JJ; Kim, YH; Lee, CW; Lee, SW; Park, DW; Park, SJ; Park, SW; Yun, SC, 2008)
"To assess the association between clopidogrel use and long-term clinical outcomes of patients receiving drug-eluting stents (DES) and bare-metal stents (BMS) for treatment of coronary artery disease."3.74Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. ( Anstrom, KJ; Califf, RM; Eisenstein, EL; Harrington, RA; Kandzari, DE; Kong, DF; Kramer, JM; Mark, DB; Matchar, DB; Peterson, ED; Schulman, KA; Shaw, LK; Tuttle, RH, 2007)
"Patients with acute coronary syndrome without ST-segment elevation receiving clopidogrel in addition to acetylsalicylic acid (ASA) showed a 20% risk reduction in comparison to patients receiving ASA monotherapy (CURE trial)."3.74Long-term cost-effectiveness of clopidogrel in patients with acute coronary syndrome without ST-segment elevation in Germany. ( Brüggenjürgen, B; Ehlken, B; Lindgren, P; Rupprecht, HJ; Willich, SN, 2007)
"High post-treatment platelet reactivity (HPPR=adenosine diphosphate [ADP] 10 microM-induced platelet aggregation >70%) identifies low responders to dual antiplatelet therapy with increased risk of recurrent cardiovascular (CV) events after stenting for non-ST elevation acute coronary syndromes (NSTE-ACS)."3.74High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes. ( Alessi, MC; Bali, L; Bonnet, JL; Cuisset, T; Frere, C; Lambert, M; Mielot, C; Morange, PE; Nait-Saidi, L; Quilici, J, 2007)
"(i) to determine the proportion of "low-responders" or "resistants" patients during coronary syndrome (ii) to identify determinants of interindividual variability response to clopidogrel (iii) to compare aggregometry and VASP phosphorylation measured by flow cytometry."3.74[Platelet responsiveness to clopidogrel in patients with coronary syndrome. Comparison of platelet aggregation induced by ADP and flow cytometric analysis of intraplatelet VASP phosphorylation]. ( Bareiss, P; Chauvin, M; Desprez, D; Faure, A; Grunebaum, L; Jesel, L; Morel, O; Ohlmann, P; Roul, G; Viellard, C, 2007)
"To describe data and insights from a national quality improvement initiative known as Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the American College of Cardiology (ACC)/American Heart Association (AHA) Guidelines (CRUSADE), for managing non-ST-segment elevation acute coronary syndrome (ACS), as well as the findings and implications of Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY), a study of bivalirudin with or without a glycoprotein (GP) IIb/IIIa inhibitor in patients with non-ST-segment elevation ACS who were undergoing an invasive intervention, and the results of two recent studies of clopidogrel in patients with ST-segment elevation myocardial infarction (MI) that are not reflected in current ACC/AHA guidelines for managing ST-segment elevation MI."3.74Managing acute coronary syndrome: evidence-based approaches. ( Spinler, SA, 2007)
"Several health economic studies have shown that the use of clopidogrel is cost-effective to prevent ischemic events in non-ST-segment elevation myocardial infarction (NSTEMI) and unstable angina."3.74Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: a European model based on the CLARITY and COMMIT trials. ( Berg, J; Jönsson, B; Lindgren, P; Parry, D; Spiesser, J, 2007)
"We describe a case of an 81-year-old man with acute ST-elevation myocardial infarction (STEMI), who received a loading dose of clopidogrel (300 mg) and aspirin (ASA) (300 mg) prior to primary coronary intervention of critical left anterior descending coronary artery stenosis."3.74[Suspected clopidogrel resistance associated with recurrent coronary stent thrombosis--a case report]. ( Knapp, M; Musiał, WJ; Prokop, JB; Sawicki, R; Sobkowicz, B; Tomaszuk-Kazberuk, A; Usowicz-Szaryńska, M, 2007)
"In patients with myocardial infarction who are not eligible for angioplasty, adding clopidogrel to aspirin reduces the overall 15-day mortality rate, but the subsequent outcome is not known."3.74Clopidogrel: new indication. In combination with aspirin: marginal additional benefits. ( , 2007)
"The authors present a fatal case of late thrombosis of paclitaxel-eluting stent implanted in the left main stem occurring 6 months after the procedure and 3 weeks after the cessation of clopidogrel."3.74The lack of endothelization after drug-eluting stent implantation as a cause of fatal late stent thrombosis. ( Bystron, M; Cervinka, P; Jakabcin, J; Kala, P; Kvasnak, M; Malý, J; Spacek, R; Veselka, J, 2008)
"Aspirin resistance is a well-documented laboratory finding, but the effects of clinical aspirin (ASA) failure on patients with acute coronary syndrome (ACS) have been debated."3.74Dual antiplatelet agent failure: a new syndrome or clinical nonentity? ( Armstrong, DF; Barnes, GD; Eagle, KA; Froehlich, JB; Gurm, HS; Kline-Rogers, E; Li, J; Vedre, A, 2007)
"In clinical practice, early therapy with clopidogrel, in addition, to aspirin in patients with NSTEMI is associated with a significant reduction of the combined endpoint of death, non-fatal reinfarction and non-fatal stroke after one year."3.74Clopidogrel in addition to aspirin reduces one-year major adverse cardiac and cerebrovascular events in unselected patients with non-ST segment elevation myocardial infarction. ( Bauer, T; Gitt, AK; Gottwik, M; Heer, T; Jünger, C; Köth, O; Senges, J; Wienbergen, H; Zahn, R; Zeymer, U, 2008)
"Platelet function analyses, which included measures of platelet aggregation and activation, were performed in 173 T2DM patients with coronary artery disease on chronic treatment with aspirin and clopidogrel."3.74Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. ( Alfonso, F; Angiolillo, DJ; Bañuelos, C; Bass, TA; Bernardo, E; Costa, MA; Escaned, J; Fernandez-Ortiz, A; Guzman, LA; Hernández-Antolin, R; Jimenez-Quevedo, P; Macaya, C; Moreno, R; Palazuelos, J; Sabaté, M, 2007)
"To model the 2-year cost-effectiveness of secondary prevention with clopidogrel versus aspirin (acetylsalicylic acid) (ASS) in German patients with myocardial infarction (MI), ischaemic stroke (IS) or diagnosed with peripheral arterial disease (PAD), based on CAPRIE trial data and from the perspective of German third party payers (TPP)."3.74Clopidogrel versus aspirin in patients with atherothrombosis: CAPRIE-based calculation of cost-effectiveness for Germany. ( Berger, K; Diener, HC; Hessel, F; Kreuzer, J; Smala, A, 2008)
"The aim of the study was to investigate the effects of clopidogrel with or without abciximab on the expression of platelet surface receptors and platelet function in patients with ST-segment elevation myocardial infarction (STEMI) undergoing PCI."3.74Expression of platelet surface receptors and early changes in platelet function in patients with STEMI treated with abciximab and clopidogrel versus clopidogrel alone. ( Konopka, A; Pilichowska, I; Piotrowski, W; Sitkiewicz, D; Spychalska, J; Stepińska, J; Zdebska, E, 2007)
"We sought to assess the effect of clopidogrel on in-hospital events in unselected patients with acute ST elevation myocardial infarction (STEMI)."3.74Clopidogrel in addition to aspirin reduces in-hospital major cardiac and cerebrovascular events in unselected patients with acute ST segment elevation myocardial. ( Bauer, T; Gitt, A; Gottwik, M; Heer, T; Jünger, C; Koeth, O; Mark, B; Senges, J; Zahn, R; Zeymer, U, 2008)
"Rate of all-cause mortality or acute myocardial infarction (AMI) after stopping treatment with clopidogrel."3.74Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. ( Fihn, SD; Ho, PM; Jesse, RA; Larsen, GC; Magid, DJ; Peterson, ED; Rumsfeld, JS; Wang, L, 2008)
"The current standard of care for anti-thrombotic therapy with primary PCI for acute ST elevation myocardial infarction (STEMI) is aspirin, clopidogrel, unfractionated heparin and platelet glycoprotein IIb/IIIa inhibitors."3.74What anti-thrombotic therapy is best with primary PCI for acute ST elevation myocardial infarction: how should the HORIZONS trial change current practice? ( Brodie, BR, 2008)
"The case is reported of a patient presenting with recurrent acute myocardial infarction due to stent thrombosis resulting from possible clopidogrel resistance caused by interaction between clopidogrel and anti-tuberculosis drugs."3.74Drug interaction with anti-mycobacterial treatment as a cause of clopidogrel resistance. ( Smith, D; Srinivasan, M, 2008)
" The cost-effectiveness of longer combination therapy depends critically on the balance of thrombotic event rates, durable efficacy, and the increased bleeding rate in patients taking clopidogrel."3.73A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone. ( Heidenreich, PA; Schleinitz, MD, 2005)
"Utilizing data from the Global Registry of Acute Coronary Events, we studied 15 693 patients admitted with non-ST-segment elevation myocardial infarction (MI) or unstable angina, dividing them according to discharge medications: aspirin alone (group I); aspirin + clopidogrel (group II); aspirin + statin (group III); aspirin + clopidogrel + statin (group IV)."3.73Impact of combined pharmacologic treatment with clopidogrel and a statin on outcomes of patients with non-ST-segment elevation acute coronary syndromes: perspectives from a large multinational registry. ( Agnelli, G; Dabbous, OH; Dibenedetto, D; Eagle, KA; Gore, JM; Kline-Rogers, EM; Lim, MJ; Mehta, RH; Spencer, FA, 2005)
"The CREDO trial demonstrated the clinical efficacy of 12-month antiplatelet therapy with clopidogrel compared to standard 28-day treatment with a 27% relative reduction in the combined risk of death, myocardial infarction, or stroke in patients undergoing percutaneous coronary intervention (PCI) and being treated with aspirin."3.73The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention: a Swedish analysis of the CREDO trial. ( Jönsson, B; Lindgren, P; Ringborg, A, 2005)
"The superiority of clopidogrel and aspirin versus aspirin alone for up to 1 year in patients who undergo percutaneous coronary intervention (PCI) after presenting with acute coronary syndromes without ST-segment elevation was demonstrated in the PCI-CURE study."3.73Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation. ( Caro, J; Chen, R; Culler, S; Gabriel, S; Jackson, J; Lamy, A; Mahoney, EM; Mehta, S; Weintraub, WS; Yuan, Y; Yusuf, S, 2006)
"To compare the effects of an aspirin-clopidogrel combination with those of the specific glycoprotein IIb/IIIa inhibitor tirofiban on myocardial no-reflow, nitric oxide concentration and activity of nitric oxide synthase (NOS) isoforms in a mini-swine model of acute myocardial infarction and reperfusion."3.73Different effects of tirofiban and aspirin plus clopidogrel on myocardial no-reflow in a mini-swine model of acute myocardial infarction and reperfusion. ( Gao, RL; Jing, ZC; Meng, L; Wang, YW; Wu, YJ; Yang, WX; Yang, YJ; You, SJ; Zhao, JL, 2006)
"Clopidogrel added to aspirin improved outcomes after hospitalization in patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS) in the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial, regardless of in-hospital treatment approach."3.73Clopidogrel to treat patients with non-ST-segment elevation acute coronary syndromes after hospital discharge. ( Bhatt, DL; Cannon, CP; Fintel, DJ; Gibler, WB; Harrington, RA; Mulgund, J; Newby, LK; Ohman, EM; Peterson, ED; Pollack, CV; Roe, MT; Smith, SC; Tricoci, P, 2006)
" All suffered stent thrombosis after discontinuation (in three cases prematurely) of clopidogrel therapy."3.73[Thrombosis of a coronary stent after discontinuing treatment with clopidogrel]. ( de Boer, MJ; Hautvast, RW; Heestermans, AA; Jaarsma, W; ten Berg, JM; van Werkum, JW, 2006)
"Although drug-eluting stents (DES) significantly reduce restenosis, they require 3 to 6 months of thienopyridine therapy to prevent stent thrombosis."3.73Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. ( Bach, RG; Cohen, DJ; Decker, C; Jones, PG; Kettelkamp, R; Khanal, S; Krumholz, HM; Messenger, JC; Peterson, ED; Rumsfeld, JS; Spertus, JA; Vance, C, 2006)
"We sought to characterize patterns of clopidogrel use before coronary artery bypass grafting (CABG) and examine the drug's impact on risks for postoperative transfusions among patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS)."3.73Acute clopidogrel use and outcomes in patients with non-ST-segment elevation acute coronary syndromes undergoing coronary artery bypass surgery. ( Cannon, CP; Ferguson, TB; Gibler, WB; Mehta, RH; Mulgund, J; Ohman, EM; Peterson, ED; Pollack, CV; Roe, MT; Smith, SC, 2006)
"The incidence of subacute stent thrombosis (SAT) within 30 days after stenting with a sirolimus-eluting stent (Cypher) for acute myocardial infarction (AMI) was retrospectively compared to that with bare-metal stents (BMS)."3.73Documented subacute stent thrombosis within thirty days after stenting with sirolimus-eluting stent (Cypher) for acute myocardial infarction: a Japanese single center retrospective non-randomized study. ( Enta, K; Fuda, Y; Higashitani, M; Horie, T; Imai, K; Ishikawa, T; Mochizuki, S; Mutoh, M; Nakano, Y; Okada, H; Sakamoto, H; Satoh, T; Yamaguchi, J, 2006)
"Our study demonstrates an increased risk of major bleeding in unselected patients receiving combination therapy with ASA and clopidogrel after UAP or NSTEMI."3.73[Bleeding complications after treatment with clopidogrel and acetylsalicylic acid after acute coronary syndrome]. ( Kjaer, J; Larsen, CH; Mickley, H; Møller, JE; Poulsen, TS, 2006)
"We sought to assess the effect of clopidogrel on clinical events 1 year after discharge in survivors of ST-elevation myocardial infarction (STEMI) in clinical practice."3.73Effect of clopidogrel on 1-year mortality in hospital survivors of acute ST-segment elevation myocardial infarction in clinical practice. ( Bauer, T; Gitt, AK; Gottwik, M; Heer, T; Jünger, C; Koeth, O; Mark, B; Senges, J; Wienbergen, H; Zahn, R; Zeymer, U, 2006)
"We investigated whether a combination of clopidogrel and glycoprotein (GP) IIb/IIIa inhibitors safely decreases hospital mortality, reinfarction, and major bleeding beyond either therapy alone in patients with non-ST-elevation myocardial infarction (NSTEMI)."3.73Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4). ( Bromberg-Marin, G; Canto, JG; Marin-Neto, JA; Parsons, LS; Rogers, WJ, 2006)
"Despite the beneficial effect of an aspirin-clopidogrel combination in acute coronary syndrome, the incidence of ischaemic recurrences remains significant and very probably implicates a variability in the response to anti-platelet agents."3.73[Beneficial effect of a loading dose of 600 mg of clopidogrel on platelet parameters in patients admitted for acute coronary syndrome]. ( Alessi, MC; Bonnet, JL; Carvajal, J; Cuisset, T; Frère, C; Lambert, M; Morange, PE; Mouret, JP; Quilici, J; Saidi, LN, 2006)
"A 73-year-old female treated with clopidogrel for vascular disease presented with sudden onset of back pain, urinary retention and paraplegia."3.73Nontraumatic spinal epidural hematoma associated with clopidogrel. ( Das, K; Karabatsou, K; Rainov, NG; Sinha, A, 2006)
"This study investigated the safety and efficacy of sirolimus-eluting stents (SESs) on early and late outcomes in patients with acute myocardial infarction."3.73[Promising efficacy of the sirolimus-eluting stent in patients with acute myocardial infarction]. ( Asai, T; Gochi, T; Hiramitsu, S; Hishida, H; Katoh, T; Maekawa, H; Matsushita, T; Morimoto, S; Murakami, Y; Murohara, T; Nomura, M; Okada, T; Ozaki, Y; Shimizu, T; Tani, T; Umeda, H; Watanabe, K; Yokoya, M; Yoshida, N, 2006)
"We report a case of a 76-year-old-man who developed spontaneous hemarthrosis of his right knee following clopidogrel-aspirin treatment."3.72Spontaneous hemarthrosis of the knee associated with clopidogrel and aspirin treatment. ( Behrens, P; Bernotat, J; Böhm, S; Gille, J; Löhr, JF, 2003)
"Aspirin is used in percutaneous coronary interventions (PCI) for acute myocardial infarction (AMI) to prevent thrombosis."3.72Timing of anti-platelet effect after oral aspirin administration in patients with sympathetic excitement. ( Mohri, H; Niikawa, O; Nishiyama, A; Tsushima, M, 2003)
"5% in the ticlopidine group, and myocardial infarction (MI) was also reduced in the clopidogrel group (4."3.72Clopidogrel is associated with better in-hospital and 30-day outcomes than ticlopidine after coronary stenting. ( Albirini, A; Aronow, HD; Bhatt, DL; Cura, FA; Ellis, SG; L'Allier, PL; Schneider, JP; Topol, EJ, 2003)
"Using the CAPRIE database, we performed multivariate analyses for patients who had symptomatic atherosclerotic disease (ischemic stroke [IS] or myocardial infarction [MI]) in their medical history before enrollment in the Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) trial."3.72Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. ( Bhatt, DL; Hacke, W; Hirsch, AT; Ringleb, PA; Topol, EJ, 2004)
"We performed a retrospective analysis of the Mayo Clinic PCI database and identified 66 consecutive patients who were discharged from hospital after PCI between January 2000 and August 2002 (inclusive) receiving a combination of dual antiplatelet therapy (aspirin and clopidogrel) and systemic anticoagulation (warfarin) to determine the incidence of bleeding and other clinical events during the treatment period."3.72Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation. ( Berger, PB; Burger, K; Fasseas, P; Holmes, DR; Melby, S; Orford, JL; Steinhubl, SR, 2004)
"The antiplatelet effect of clopidogrel was studied prospectively in 60 consecutive patients who underwent primary angioplasty (percutaneous coronary intervention [PCI]) with stenting for acute ST-segment-elevation myocardial infarction (STEMI) to determine whether variability in response to clopidogrel affects clinical outcomes."3.72Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. ( Beinart, R; Bienart, R; Goldenberg, I; Guetta, V; Hod, H; Matetzky, S; Novikov, I; Pres, H; Savion, N; Shechter, M; Shenkman, B; Varon, D, 2004)
" One week later, he developed symptomatic autoimmune thrombocytopenia likely related to clopidogrel use."3.72Clopidogrel-associated autoimmune thrombocytopenic purpura. ( Best, PJ; Markovic, SN; Mathew, V, 2004)
"1% was seen for the clopidogrel/ASA combination for the first primary outcome (death from cardiovascular causes, non-fatal myocardial infarction (MI), or stroke), compared to ASA alone."3.72A critical appraisal of the CURE trial: role of clopidogrel in non-ST-segment elevation acute coronary syndromes. ( Boucher, M; Pharand, C; Skidmore, B, 2004)
" Thus, we assessed whether platelet function under high shear rates (collagen adenosine diphosphate closure times [CADP-CTs]) measured with the platelet function analyzer (PFA-100) may be enhanced in patients with myocardial infarction (MI) and whether it may predict the extent of myocardial damage as measured by creatine kinase (CK-MB) or troponin T (TnT) levels."3.72Platelet function predicts myocardial damage in patients with acute myocardial infarction. ( Domanovits, H; Frossard, M; Fuchs, I; Hsieh, K; Jilma, B; Laggner, AN; Leitner, JM; Losert, H; Schreiber, W; Vlcek, M, 2004)
"Aspirin is widely used as an antiplatelet drug in patients with coronary heart disease."3.72Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (ASpirin non-responsiveness and Clopidogrel Endpoint Trial) design. ( Abdelnoor, M; Arnesen, H; Pettersen, AA; Seljeflot, I, 2004)
" The main findings are related to the developing role of Chest Pain Units in the management and early risk stratification of acute coronary syndromes in the emergency department; new information concerning the efficacy of glycoprotein IIb/IIIa inhibitors, clopidogrel and low-molecular-weight heparins in the pharmacological treatment of acute coronary syndromes without ST-segment elevation; and the role of early invasive strategy in improving the prognosis of these patients."3.71[2002 Update of the Guidelines of the Spanish Society of Cardiology for Unstable Angina/Without ST-Segment Elevation Myocardial Infarction]. ( Alonso, JJ; Arós Borau, F; Bayón Fernández, J; Bueno, H; Cequier Fillat, A; Coma Canella, I; Fernández-Ortiz, A; Lidón Corbi, RM; Loma-Osorio, A; López Bescós, L; Marrugat De La Iglesia, J; Masiá Martorell, R; Palencia Pérez, M; Tuñón Fernández, J, 2002)
"ASPIRIN AND HEPARIN: In several studies aspirin has been found to be very effective in unstable angina pectoris reducing fatal and non-fatal myocardial infarction by 50-70%."3.71[Optimal platelet inhibition therapy in unstable angina pectoris and after coronary interventions]. ( Huber, K; Niessner, A; Niessner, H, 2001)
" The CURE trial shows that clopidogrel in addition to aspirin achieves this double goal, with a 20% relative risk reduction in the primary composite endpoint of cardiovascular death, myocardial infarction or stroke in the first 30 days."3.71[Clopidogrel in acute coronary syndromes with non-ST elevation. Clinical implications of the CURE trial]. ( Valentín, V, 2001)
"Recently the anti-platelet drug clopidogrel has been publicized in the press as a breakthrough in the treatment of myocardial infarction."3.71Clopidogrel--a myocardial infarction CURE? ( Bradley, C, 2001)
"In a large, randomized, placebo-controlled trial in centers that use a conservative approach to acute coronary syndromes, the antiplatelet drug clopidogrel (Plavix) decreased the rate of the combined end point of cardiovascular death, nonfatal myocardial infarction, or stroke by 20% in patients presenting with acute coronary syndromes without ST-segment elevation."3.71The CURE trial: using clopidogrel in acute coronary syndromes without ST-segment elevation. ( Bhatt, DL; Gerschutz, GP, 2002)
"The thienopyridine derivatives, ticlopidine and clopidogrel, provide alternatives to aspirin for use in the prevention of recurrent ischemic events in the post-myocardial infarction patient."3.70Aspirin and newer orally active antiplatelet agents in the treatment of the post-myocardial infarction patient. ( Pepine, CJ, 1998)
"Aspirin is an established therapy for the management of acute myocardial infarction (AMI) and unstable angina."3.70New antiplatelet agents. ( Ellis, CJ; French, JK; White, HD, 1998)
"This study sought to determine whether the duration of pretreatment with the adenosine diphosphate receptor antagonist ticlopidine prior to intracoronary stenting is associated with the incidence of procedure-related non-Q-wave myocardial infarctions (MIs)."3.70The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-Q-wave myocardial infarctions. ( Ellis, SG; Lauer, MS; Lincoff, AM; Moliterno, DJ; Mukherjee, DP; Steinhubl, SR; Topol, EJ, 1998)
"Ischemic event rates were estimated for 12,931 aspirin users drawn from the Saskatchewan Health population between 1990 and 1995 who had an index diagnosis of myocardial infarction, ischemic stroke, or peripheral arterial disease."3.70Generalizing the results of clinical trials to actual practice: the example of clopidogrel therapy for the prevention of vascular events. CAPRA (CAPRIE Actual Practice Rates Analysis) Study Group. Clopidogrel versus Aspirin in Patients at Risk of Ischaemi ( Caro, JJ; Migliaccio-Walle, K, 1999)
" To monitor platelet function in patients with myocardial infarction (n=46) who were treated with the fibrinolytic agent reteplase, the glycoprotein (GP) IIb/IIIa blocker abciximab, and the ADP receptor antagonist ticlopidine, we developed a flow cytometric assay."3.70Flow cytometric monitoring of glycoprotein IIb/IIIa blockade and platelet function in patients with acute myocardial infarction receiving reteplase, abciximab, and ticlopidine: continuous platelet inhibition by the combination of abciximab and ticlopidine ( Bode, C; Kohler, B; Kübler, W; Moser, M; Nordt, T; Ohman, ME; Olschewski, M; Peter, K; Ruef, J; Straub, A, 2000)
"(1) Aspirin reduces acute-phase mortality after myocardial infarction, and also reduces the risk of myocardial infarction and death in patients with unstable angina."3.70Antiplatelet drugs in cardiovascular prevention: coronary events: acute phase and secondary prevention. ( , 2000)
"(1) Aspirin reduces the risk of myocardial infarction in men over 40 with no history of cardiovascular disease, and in hypertensive patients of both sexes over that age."3.70Antiplatelet drugs in cardiovascular prevention: coronary events and stroke: primary prevention. ( , 2000)
"(1) Clopidogrel, an antiplatelet drug chemically similar to ticlopidine, is marketed in France for secondary prevention of thrombotic complications in patients with a history of myocardial infarction, ischaemic stroke or peripheral arterial disease."3.70Clopidogrel: new preparation. An alternative to aspirin. ( , 1999)
"We examined the antithrombotic effect of ticlopidine on occlusive thrombi of small coronary arteries in (NZWxBXSB)F1 [(WxB)F1] male mice with myocardial infarction (MI) and systemic lupus erythematosus (SLE)."3.69Antithrombotic effect of ticlopidine on occlusive thrombi of small coronary arteries in (NZWxBXSB)F1 male mice with myocardial infarction and systemic lupus erythematosus. ( Fujiwara, H; Nakamura, Y; Shibata, Y; Suzuka, H; Tanaka, M; Yoshifusa, H, 1995)
"1) Myocardial infarction (MI): Aspirin (160-300 mg/day) therapy started immediately after the onset, with or without simultaneous coronary arterial thrombolytic therapy, reduces the mortality rate in vascular diseases, including MI, and prevents reinfarction."3.68[Antiplatelet therapy in cardiac diseases]. ( Aosaki, M; Hosoda, S; Iwade, K; Kimata, S, 1992)
"Twenty-eight subjects, 16 with old myocardial infarction (OMI) and a control group of 12, received ticlopidine 250 mg/day for 4 weeks."3.67Effects of exercise and ticlopidine on platelet function and prostanoids in patients with old myocardial infarction. ( Chang, HC; Ding, YA; Lee, KW; Liang, YB; Lin, KC, 1989)
"The authors compared the action of small doses of aspirin (100-200 mg/day) and ticlopidine (500 mg/day) in multimodality therapy of acute myocardial infarction."3.67[Advantages and shortcomings of platelet antiaggregants in the treatment of myocardial infarction]. ( Bochko, II; Kuz'mina, LF; Martynov, IV; Nechaev, DD, 1988)
" Point-of-care genetic testing for CYP2C19*2, ABCB1 TT and CYP2C19*17 was performed with carriers of either the CYP2C19*2 allele or ABCB1 TT genotype randomly assigned to a strategy of prasugrel 10 mg daily or an augmented dosing strategy of clopidogrel (150 mg daily for 6 days then 75 mg daily)."2.82A prospective randomized evaluation of a pharmacogenomic approach to antiplatelet therapy among patients with ST-elevation myocardial infarction: the RAPID STEMI study. ( Bernick, J; Dick, AJ; Froeschl, M; Glover, C; Gollob, MH; Hibbert, B; Labinaz, M; Le May, MR; Marquis, JF; McPherson, R; Roberts, JD; So, DY; Tran, L; Wells, GA, 2016)
"Survivors after cardiac arrest (CA) due to AMI undergo PCI and then receive dual antiplatelet therapy."2.82Antiplatelet efficacy of P2Y12 inhibitors (prasugrel, ticagrelor, clopidogrel) in patients treated with mild therapeutic hypothermia after cardiac arrest due to acute myocardial infarction. ( Bednar, F; Kopa, M; Kroupa, J; Motovska, Z; Ondrakova, M; Osmancik, P, 2016)
" Therefore, the ABCB1 C3435T genotyping should be one of the parameters taken into account when deciding about the dosing regimen of clopidogrel."2.82P-Glycoprotein Polymorphism C3435T Is Associated with Dose-Adjusted Clopidogrel and 2-Oxo-Clopidogrel Concentration. ( Apostolovic, SR; Jankovic, SM; Jevtovic-Stoimenov, T; Konstantinovic, SS; Lilic, J; Nikolic, VN; Pavlovic, M; Stokanovic, D; Zivkovic, VS; Zvezdanovic, JB, 2016)
"Myocardial infarction was assessed using the third universal definition."2.82Effectiveness of platelet inhibition on major adverse cardiac events in non-cardiac surgery after percutaneous coronary intervention: a prospective cohort study. ( Beattie, WS; Carroll, J; Grewal, D; Harsha, P; Karkouti, K; Ragoonanan, T; Starzyk, Ł; Syed, S; Travis, G; Wąsowicz, M; Wijeysundera, DN, 2016)
"Randomized patients with available aspirin dosing information in COGENT (N = 3,752) were divided into "low-dose" (≤ 100 mg) and "high-dose" (>100 mg) aspirin groups."2.82Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy. ( Bhatt, DL; Cannon, CP; Cohen, M; Cryer, BL; Doros, G; Goldsmith, MA; Hsieh, WH; Laine, L; Lanas, A; Lapuerta, P; Liu, Y; Schnitzer, TJ; Shook, TL; Vaduganathan, M, 2016)
"Treatment with cangrelor reduced the incidence of MI at 48 hours (3."2.82Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition). ( Bhatt, DL; Cavender, MA; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Leonardi, S; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD, 2016)
" Major adverse cardiovascular events, comprising all-cause death, nonfatal infarction, nonfatal stroke, and ischaemia-driven target vessel revascularization, was the primary efficacy end point."2.79Efficacy and safety of tirofiban-supported primary percutaneous coronary intervention in patients pretreated with 600 mg clopidogrel: results of propensity analysis using the Clinical Center of Serbia STEMI Register. ( Asanin, M; Brdar, N; Djuricic, N; Krljanac, G; Lasica, R; Marinkovic, J; Mrdovic, I; Perunicic, J; Savic, L, 2014)
" The primary efficacy endpoint was the incidence of major adverse cardiovascular events (MACE) at 24 weeks, defined as a composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal ischemic stroke."2.79Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study. ( Isshiki, T; Kimura, T; Kitagawa, K; Miyazaki, S; Nakamura, M; Nanto, S; Nishikawa, M; Ogawa, H; Saito, S; Takayama, M; Yokoi, H, 2014)
" The PRASugrel For Japanese PatIenTs with Coronary Artery Diseases Undergoing Elective PCI (PRASFIT-Elective) study investigated the efficacy and safety of different prasugrel dosing regimens in Japanese patients undergoing elective PCI."2.79Prasugrel, a third-generation P2Y12 receptor antagonist, in patients with coronary artery disease undergoing elective percutaneous coronary intervention. ( Ikeda, Y; Isshiki, T; Kimura, T; Kitagawa, K; Miyazaki, S; Nakamura, M; Nanto, S; Nishikawa, M; Ogawa, H; Saito, S; Takayama, M; Yokoi, H, 2014)
" Following this randomized pilot study, it may be justified to perform a large-scale randomized study comparing 50- and 75-mg dosing of clopidogrel in Japanese patients undergoing coronary stent implantation."2.79Efficacy and safety of low-dose clopidogrel in Japanese patients after drug-eluting stent implantation: a randomized pilot trial. ( Fujimoto, Y; Iwata, Y; Kadohira, T; Kitahara, H; Kobayashi, Y; Morino, T; Ohkubo, K; Sugimoto, K, 2014)
"Cangrelor is an intravenous, potent, and reversible P2Y(12) inhibitor with fast onset and offset of action."2.77Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial. ( Bhatt, DL; Dietrich, M; Gallup, D; Gibson, CM; Hamm, CW; Harrington, RA; Leonardi, S; Liu, T; Mahaffey, KW; Price, MJ; Skerjanec, S; Steg, GW; Stone, GW; Todd, M; White, HD, 2012)
"Serious bleeding was associated with a significantly increased adjusted hazard ratio of 5."2.76Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel--Thrombolysis in Myocardial Infarction 38 (TRITON- ( Antman, EM; Braunwald, E; Contant, CF; Dalby, AJ; Giugliano, RP; Guo, J; Hochholzer, W; Montalescot, G; Wiviott, SD, 2011)
"The primary endpoint was a composite of cardiac death, non-fatal myocardial infarction and ischemic stroke at 6 months after PCI."2.76Inhibitory interaction between calcium channel blocker and clopidogrel. -Efficacy of cilostazol to overcome it-. ( Bae, JH; Bae, JW; Chae, IH; Cho, MC; Kim, HS; Lee, SP; Park, KW; Rha, SW; Suh, JW, 2011)
"Even very short-term dual antiplatelet therapy seems safe after coronary stenting with Genous in de novo coronary artery lesions located in secondary branch vessels."2.76Evaluating the safety of very short-term (10 days) dual antiplatelet therapy after Genous™ bio-engineered R stent™ implantation: the multicentre pilot Genous trial. ( Biondi-Zoccai, G; Bramucci, E; Colombo, A; Ferlini, M; Grinfeld, L; Iadanza, A; Morice, MC; Petronio, AS; Pierli, C; Sangiorgi, GM, 2011)
" A low postoperative dose of aprotinin in patients receiving clopidogrel is safe and has comparable effects regarding postoperative bleeding complications as a high dose."2.75Low postoperative dose of aprotinin reduces bleeding and is safe in patients receiving clopidogrel before coronary artery bypass surgery. A prospective randomized study. ( Istad, R; Ringdal, MA; Tangen, G; Tølløfsrud, S; Øvrum, E; Øystese, R, 2010)
" Monafram was introduced intravenously to 284 patients just before angioplasty at standard dosage - 0."2.75[Glycoprotein IIb-IIIa antagonist Monafram in primary angioplasty of patients with acute coronary syndrome without st segment elevation]. ( Frolova, NS; Mazurov, AV; Pevzner, DV; Ruda, MY; Samko, AN; Staroverov, II, 2010)
"The field of acute coronary syndromes is characterised by an increasing tendency towards early invasive catheter-based diagnostics and therapeutics-a practice based on observational and retrospective data."2.74Immediate versus deferred coronary angioplasty in non-ST-segment elevation acute coronary syndromes. ( Amoroso, G; Kiemeneij, F; Laarman, GJ; Patterson, MS; Riezebos, RK; Ronner, E; Slagboom, T; Smits, PC; Suttorp, MJ; ten Berg, JM; Ter Bals, E; Tijssen, JG, 2009)
" The primary end point was major adverse cardiac events (death, MI, and ischemia-driven target vessel revascularization) at 12 months."2.74Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction. ( Cheong, SS; Cho, YH; Hong, MK; Hong, TJ; Jeong, MH; Kim, JJ; Kim, KS; Kim, YH; Lee, CW; Lee, JH; Lee, NH; Lee, SG; Lee, SH; Lim, DS; Park, DW; Park, SJ; Park, SW; Seong, IW; Seung, KB; Yang, JY; Yoon, J; Yun, SC, 2009)
"Although appropriate anticoagulation is essential to maximize the efficacy and safety of primary PCI, the optimal dosing of enoxaparin in this setting is unclear."2.73A novel enoxaparin regime for ST elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: a WEST sub-study. ( Armstrong, PW; Buller, CE; Gordon, P; O'Neill, B; Welsh, RC; Westerhout, CM, 2007)
" Elderly patients (> or = 75 years of age) received a novel enoxaparin dosing regimen and when compared with UFH, benefited from a lower relative bleeding risk than younger patients without compromising efficacy in preventing death or MI."2.73ExTRACT-TIMI 25 trial: clarifying the role of enoxaparin in patients with ST-elevation myocardial infarction receiving fibrinolysis. ( Gabriel, RS; White, HD, 2007)
" A significant dose-response was also observed for the vasodilator-stimulated phosphoprotein index, a measure of P2Y(12) receptor inhibition."2.72A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) t ( Bal-dit-Sollier, C; Beygui, F; Collet, JP; Drouet, L; Henry, P; Lellouche, N; Meuleman, C; Milleron, O; Montalescot, G; Sideris, G; Slama, M; Steg, PG, 2006)
"Prospective, randomized, double-blind study (POLENOX) proved that administration of low molecular weight heparin (LMWH)--enoxaparin for elective percutaneous coronary interventions (PCI) is as safe and as effective like unfractionated heparin (UFH)."2.71[Safety and efficacy of dalteparin administration for elective percutaneous interventions in patients pre-treated with aspirin and ticlopidine]. ( Bartuś, S; Chyrchel, M; Dubiel, JS; Dudek, D; Legutko, J; Rzeszutko, L, 2004)
"Despite improvements in the emergency treatment of myocardial infarction (MI), early mortality and morbidity remain high."2.71Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. ( Chen, YP; Chen, ZM; Collins, R; Jiang, LX; Liu, LS; Pan, HC; Peto, R; Xie, JX, 2005)
"Cilostazol is a potent antiplatelet agent with less serious side effects."2.69Comparison of cilostazol versus ticlopidine therapy after stent implantation. ( Hong, MK; Kim, HS; Kim, JJ; Lee, CW; Lee, HJ; Park, HK; Park, SJ; Park, SW, 1999)
" A new therapeutic regimen of ticlopidine and aspirin without further heparin after coronary stenting in patients without AMI has been shown to be safe and reduce the incidence of stent thrombosis."2.69A safe and effective regimen without heparin therapy after successful primary coronary stenting in patients with acute myocardial infarction. ( Chang, HW; Chen, MC; Fang, CY; Hang, CL; Hsieh, KY; Wu, CJ; Yip, HK, 2000)
"ST-elevation myocardial infarction (STEMI), which constitutes nearly 25-40 % of current acute myocardial infarction (AMI) cases, is a medical emergency that requires prompt recognition and treatment."2.53Contemporary management of ST-segment elevation myocardial infarction. ( Flaherty, JD; Gajjar, M; Ricciardi, MJ; Schimmel, DR; Yadlapati, A, 2016)
" Cilostazol-based TAPT compared with DAPT is associated with improved angiographic outcomes and decreased risk of TLR and TVR but does not reduce major cardiovascular events and is associated with an increase in minor adverse events."2.52Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials. ( Bai, J; Chen, J; Chen, P; Eikelboom, JW; Gong, X; Kong, D; Li, C; Liu, J; Meng, H; Xu, L; Yang, Z; Zou, F, 2015)
" The included end-points were major adverse cardiovascular event (MACE), target lesion revascularization (TLR), target vessel revascularization (TVR), death, myocardial infarction (MI), stent thrombosis, bleeding and other drug adverse events."2.50Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy for patients undergoing PCI: a meta-analysis of randomized trials with adjusted indirect comparisons. ( Chen, Y; Huang, X; Tang, Y; Xie, Y; Zhang, Y, 2014)
"This article focuses on the pharmacokinetics of prasugrel and recently published pharmacodynamic and clinical studies."2.50Pharmacokinetic evaluation of prasugrel for the treatment of myocardial infarction. ( Coons, JC; Harris, J; Schwier, N; Seybert, AL, 2014)
"In the peripheral arteries, a thrombus superimposed on atherosclerosis contributes to the progression of peripheral artery disease (PAD), producing intermittent claudication (IC), ischemic necrosis, and, potentially, loss of the limb."2.50Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease. ( Cafaro, G; de Gaetano, G; Di Minno, A; Di Minno, G; Lupoli, R; Petitto, M; Spadarella, G; Tremoli, E, 2014)
"Non-ST elevation acute coronary syndromes are responsible for approximately 1 million admissions to U."2.48Unstable angina and non-ST elevation myocardial infarction. ( Braunwald, E, 2012)
" Proton pump inhibitors cause few adverse effects with short-term use; however, long-term use has been scrutinized for appropriateness, drug-drug interactions, and the potential for adverse effects (e."2.48Reducing adverse effects of proton pump inhibitors. ( Ament, PW; Dicola, DB; James, ME, 2012)
"Cangrelor is an intravenous direct and reversible inhibitor of the P2Y(12) receptor providing the highest level of inhibition and elinogrel is an intravenous and oral P2Y(12) antagonist with a direct and reversible action."2.47[Myocardial infarction: Role of new antiplatelet agents]. ( Bellemain, A; Collet, JP; Ecollan, P; Montalescot, G; Silvain, J, 2011)
" Combined major adverse cardiovascular event (stroke, MI, and death) was not different in the two groups (OR 1."2.47Safety of clopidogrel being continued until the time of coronary artery bypass grafting in patients with acute coronary syndrome: a meta-analysis of 34 studies. ( Athanasiou, T; Malik, IS; Nijjer, SS; Watson, G, 2011)
" Thus, two major paradoxes in cardiovascular medicine today are: 1) despite the overwhelming evidence that platelet reactivity strongly influences the development of potentially catastrophic events including myocardial infarction and stent thrombosis in the PCI patient, no measurement is made in clinical practice to assess the presence of blood vulnerability (platelet reactivity) and 2) despite the overwhelming evidence that the effect of dual antiplatelet therapy with aspirin and P2Y12 receptor blockers is variable, the guidelines largely recommend a uniform, "one size fits all" dosing of these agents in the PCI patient without any confirmation of an adequate antiplatelet effect."2.45Platelet monitoring for PCI: is it really necessary? ( Gurbel, PA; Tantry, US, 2009)
" If planned immediate PCI after thrombolytic therapy is not indicated, PCI immediately after high dosage of glycoprotein IIb/IIIa-Inhibitors in combination with a high dose of clopidogrel may give good results."2.44[Acute intervention for ST-elevation myocardial infarction]. ( Heintzen, MP, 2008)
" Recent studies have left clinicians with many questions regarding the role and dosing regimens of clopidogrel in STEMI, PCI, and primary or secondary prevention."2.44Contemporary issues in clopidogrel therapy: new evidence shaping clinical practice. ( Emmons, KL; Taylor, NR, 2007)
"Atherothrombosis is a progressive and generalized pathologic process that affects the vascular system."2.44Antiplatelet therapy for atherothrombotic disease: an update for the primary care physician. ( Brown, MT; Kikano, GE, 2007)
"Despite many recent advancements in the treatment of coronary heart disease, it continues to be an important source of patient morbidity and mortality as well as a significant source of healthcare-related expenditures."2.44The role of clopidogrel in revascularized and nonrevascularized patients with acute coronary syndromes. ( Collins, JS; Gurm, HS, 2007)
"As well as initiating thrombus formation at the site of a ruptured atherosclerotic plaque, platelets play a key role in vascular inflammation, through release of their own pro-inflammatory mediators and interactions with other relevant cell types (endothelial cells, leukocytes, and smooth muscle cells)."2.44Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease. ( Badimon, JJ; Bhatt, DL; Herbert, JM; Lüscher, TF; Steinhubl, SR, 2007)
" If the international normalized ratio (INR) was kept > 2 for a long period, by means of frequent check-ups and effective dosage adjustment, the chance of death, recurrent myocardial infarction or stroke was 30-50% lower than when acetylsalicylic acid only was used."2.43[Antithrombotic therapy after myocardial infarction: arguments for the use of acetylsalicylic acid and coumarin derivatives]. ( Brouwer, A; Verheugt, FW; Waskowsky, WM, 2005)
"Elderly patients with unstable angina pectoris/non-ST-segment elevation myocardial infarction should be hospitalized."2.42Treatment of unstable angina pectoris/non-ST-segment elevation myocardial infarction in elderly patients. ( Aronow, WS, 2003)
"Aspirin has been studied and used most extensively."2.42Role of antiplatelet drugs in the prevention of cardiovascular events. ( Tendera, M; Wojakowski, W, 2003)
"and aspirin 325 mg o."2.40Antiplatelet drugs in secondary prevention after acute myocardial infarction. ( Thizon-de-Gaulle, I, 1998)
"Previous studies have found that Panax quinquefolius saponins (PQS) combined with dual antiplatelet therapy (DAPT) of aspirin and clopidogrel enhances antithrombotic effects while reducing gastric mucosal injury induced by DAPT."1.48Panax quinquefolius saponins combined with dual antiplatelet drug therapy alleviate gastric mucosal injury and thrombogenesis through the COX/PG pathway in a rat model of acute myocardial infarction. ( Kou, N; Miao, Y; Qu, H; Shi, DZ; Wang, MM; Xue, M; Yang, B; Yang, L; Zang, MX, 2018)
"Evaluation of antithrombotic treatments for acute coronary syndromes (ACS) requires balancing ischemic and bleeding risks to assess net benefit."1.46Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes. ( Becker, RC; Budaj, A; Cannon, CP; Cornel, JH; Ducrocq, G; Held, C; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lopes, RD; Schulte, PJ; Sorbets, E; Steg, PG; Storey, RF; Wallentin, L, 2017)
"The major result events, included: (1) recurrence of ischemic stroke; (2) hemorrhagic transformation of ischemic stroke; (3) myocardial infarction; (4) the digestive hemorrhage."1.43[Retrospective cohort study for the impact on readmission of patients with ischemic stroke after treatment of aspirin plus clopidogrel or aspirin mono-therapy]. ( Gao, P; Hu, YH; Tang, X; Wei, CL; Yang, C; Zhang, YQ, 2016)
"Major bleeding was a significant correlate of DAPT ANA within 6 months."1.42Thrombotic complications associated with early and late nonadherence to dual antiplatelet therapy. ( Cutlip, DE; Dauerman, HL; Kereiakes, DJ; Mauri, L; Stoler, R, 2015)
"All ticagrelor treatments improved left ventricular ejection fraction, acute (69."1.42Ticagrelor protects the heart against reperfusion injury and improves remodeling after myocardial infarction. ( Birnbaum, GD; Birnbaum, Y; Nanhwan, MK; Nylander, S; Perez-Polo, JR; Ye, Y, 2015)
"CABG had similar rates of cardiac death compared with PCI group (HR=0."1.42Clinical outcomes of multiple chronic total occlusions in coronary arteries according to three therapeutic strategies: Bypass surgery, percutaneous intervention and medication. ( Choi, JH; Choi, SH; Gwon, HC; Hahn, JY; Jang, WJ; Kim, BS; Kim, WS; Lee, SH; Lee, YT; Song, YB; Yang, JH, 2015)
"Despite recent advances in stent design and constantly improving protective pharmacological strategies, complications and adverse events following percutaneous coronary interventions (PCI) are still major factors influencing morbidity and mortality."1.42Independent Predictors of Major Adverse Events following Coronary Stenting over 28 Months of Follow-Up. ( Bulaeva, NI; Fortmann, S; Golukhova, EZ; Grigorian, MV; Ryabinina, MN; Serebruany, VL, 2015)
"Stent thrombosis is a morbid complication after percutaneous coronary intervention."1.40Clopidogrel resistance in diabetic patient with acute myocardial infarction due to stent thrombosis. ( Duraj, L; Fedor, M; Fedorová, J; Galajda, P; Kovář, F; Kubisz, P; Mokáň, M; Samoš, M; Šimonová, R; Staško, J, 2014)
" Medication use was compared between transfer and direct-arrival patients to determine if these therapies were delayed or dosed in excess."1.40The quality of antiplatelet and anticoagulant medication administration among ST-segment elevation myocardial infarction patients transferred for primary percutaneous coronary intervention. ( Alexander, KP; Li, S; Magid, DJ; Peterson, ED; Roe, MT; Ting, HH; Wang, TY, 2014)
"In a murine model of myocardial reperfusion injury caused by transient coronary artery occlusion, APT102 also decreased infarct size by 51%, whereas clopidogrel was not effective."1.40Optimizing human apyrase to treat arterial thrombosis and limit reperfusion injury without increasing bleeding risk. ( Abendschein, D; Broekman, MJ; Chen, R; Drosopoulos, JH; Jeong, SS; Marcus, AJ; Moeckel, D; Nguyen, A; Robson, SC; Sun, X, 2014)
" The aim of this study was to evaluate the pharmacodynamic profile of 5 different anti-platelet treatments in the acute phase of STEMI in patients undergoing primary PCI."1.40A pharmacodynamic comparison of 5 anti-platelet protocols in patients with ST-elevation myocardial infarction undergoing primary PCI. ( Andell, P; Björnsson, S; Erlinge, D; Götberg, M; Harnek, J; Koul, S; Martinsson, A; Norström, E; Scherstén, F; Smith, JG, 2014)
" There was no significant difference in the pharmacodynamic effects of clopidogrel on platelet reactivity from baseline to 6-months follow-up (297 ± 57 vs."1.39Pharmacodynamic effect of clopidogrel in patients undergoing transcatheter aortic valve implantation. ( Bednar, F; Kocka, V; Linkova, H; Sulzenko, J; Tousek, P; Widimsky, P, 2013)
"Acute myocardial infarction is rare in pregnancy; however, the emerging trend towards advanced maternal age and the rising prevalence of obesity and diabetes suggest that more cases of myocardial infarction are likely to be encountered in pregnancy."1.39Acute myocardial infarction in pregnancy following unlicensed use of methylenedioxymethamphetamine ('Ecstasy'). ( Dutton, P; Okunoye, GO, 2013)
"Aspirin twice daily was given in 28% of patients, clopidogrel double dose in 26%, and prasugrel in 31%."1.39Monitoring persistent platelet reactivity in patients with unprotected left main stenting. ( Bal Dit Sollier, C; Dillinger, JG; Drouet, L; Henry, P; Kchaou, I; Logeart, D; Magkoutis, N; Manzo Silberman, S; Sideris, G; Voicu, S, 2013)
"Diabetes mellitus is an independent predictor of adverse clinical events after drug-eluting stent implantation."1.39Clinical efficacy and safety of biodegradable polymer-based sirolimus-eluting stents in patients with diabetes mellitus insight from the 4-year results of the create study. ( Chen, X; Han, Y; Jiang, T; Jing, Q; Li, Y; Liu, H; Ma, Y; Wang, G; Wang, S; Wang, X; Yan, G; Yang, L; Zhang, L; Zhu, G, 2013)
"Medical records of 659 patients treated for myocardial infarction at the 1st Department of Internal Medicine-Cardiology of Borsod-Abaúj-Zemplén County Hospital and University Hospital were analyzed."1.39Pharmaceutical care for patients with acute myocardial infarction in Hungary. ( Argay, M; Dormaeva, I; Hankó, B; Koós, I; Meskó, A; Takács, I; Zelkó, R, 2013)
"Fibrinogen ≥345 mg/dl was significantly associated with both CK-MB-defined (p = 0."1.39Elevated plasma fibrinogen rather than residual platelet reactivity after clopidogrel pre-treatment is associated with an increased ischemic risk during elective percutaneous coronary intervention. ( Ang, L; Ilapakurti, M; Lee, MS; Mahmud, E; Palakodeti, V; Thani, KB, 2013)
"Within a regional STEMI system of care, half-dose fibrinolysis combined with immediate transfer for PCI may be a safe and effective option for STEMI patients with expected delays due to long-distance transfer."1.38Safety and efficacy of a pharmaco-invasive reperfusion strategy in rural ST-elevation myocardial infarction patients with expected delays due to long-distance transfers. ( Dirks, TG; Duval, S; Garberich, RF; Harris, JL; Henry, TD; Larson, DM; Madison, JD; Sharkey, SW; Stokman, PJ; Westin, RK, 2012)
"Cardiogenic shock was present in 12 (11%) patients and in-hospital mortality was 6."1.38The HEART study: a real-world experience using the CID Chrono Carbostent in primary and rescue PCI. ( Buffon, A; Burzotta, F; Crea, F; De Caterina, AR; Leone, AM; Mazzari, MA; Mongiardo, R; Niccoli, G; Porto, I; Rebuzzi, AG; Sgueglia, GA; Trani, C, 2012)
"Stent thrombosis is not unusual in a post-operative setting."1.38Successful use of glycoprotein IIb/IIIa inhibitor, heparin, and IABP during PCI in a post-neurosurgical patient with STEMI and cardiogenic shock due to very late bare-metal stent thrombosis. ( Agnani, S; Akkus, NI; Rajpal, S, 2012)
"Eptifibatide was stopped for induction of labor."1.38Peripartum management of dual antiplatelet therapy and neuraxial labor analgesia after bare metal stent insertion for acute myocardial infarction. ( Bauer, ME; Bauer, ST; Mhyre, JM; Rabbani, AB, 2012)
"Left ventricular thrombus (LVT) and rupture are important mechanical complications following myocardial infarction (MI) and are believed to be due to unrelated mechanisms."1.37Role of intramural platelet thrombus in the pathogenesis of wall rupture and intra-ventricular thrombosis following acute myocardial infarction. ( Dart, AM; Du, XJ; Gao, XM; Head, GA; Kiriazis, H; Liu, Y; Lobo, A; Shan, L, 2011)
" At 1-year follow-up, major adverse cardiac events (MACE), defined as death, myocardial infarction (MI), acute coronary syndrome leading to hospitalization and nonfatal stroke, were recorded."1.37Safety of clopidogrel and proton pump inhibitors in patients undergoing drug-eluting stent implantation. ( Capodanno, D; Cicorella, N; Gavazzi, A; Guagliumi, G; Lettieri, C; Lortkipanidze, N; Musumeci, G; Nijaradze, T; Romano, M; Rosiello, R; Rossini, R; Sirbu, V; Tarantini, G; Valsecchi, O, 2011)
"Cardiogenic shock was present in 45%, and distal left main coronary artery disease was present in 71% of patients."1.37Percutaneous coronary intervention of unprotected left main coronary artery disease as culprit lesion in patients with acute myocardial infarction. ( El-Omar, M; Imola, F; Mamas, MA; Manzoli, A; Pappalardo, A; Prati, F; Ramazzotti, V, 2011)
"The primary outcome was first recurrence of stroke of any type and the secondary outcome was a composite of stroke, myocardial infarction, or death from vascular causes."1.37Level of systolic blood pressure within the normal range and risk of recurrent stroke. ( Bath, PM; Cotton, D; Diener, HC; Donnan, GA; Martin, RH; Ovbiagele, B; Vinisko, R; Yusuf, S, 2011)
"Patients with more extensive coronary atherosclerosis have a higher rate of HPR, which might partly account for higher risk of periprocedural MI."1.36High residual platelet reactivity after clopidogrel: extent of coronary atherosclerosis and periprocedural myocardial infarction in patients with stable angina undergoing percutaneous coronary intervention. ( Barbato, E; Bartunek, J; De Bruyne, B; Di Sciascio, G; Heyndrickx, G; Mangiacapra, F; Muller, O; Ntalianis, A; Trana, C; Wijns, W, 2010)
"Cilostazol has reduced restenosis and repeat intervention after drug-eluting stent (DES) implantation."1.36Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry). ( Hong, MK; Kim, JJ; Kim, WJ; Kim, YH; Lee, CW; Lee, JY; Lee, SW; Park, DW; Park, SJ; Park, SW; Yun, SC, 2010)
"The TRUE registry demonstrated that SES in the treatment of bare-metal stent ISR is efficacious (5% of target lesion revascularization [TLR]) and safe (stent thrombosis <1%) at 9 months."1.36Long-term effectiveness and safety of sirolimus stent implantation for coronary in-stent restenosis results of the TRUE (Tuscany Registry of sirolimus for unselected in-stent restenosis) registry at 4 years. ( Angioli, P; Bolognese, L; Carrera, A; Ducci, K; Falsini, G; Fineschi, M; Gori, T; Grotti, S; Liistro, F; Pierli, C, 2010)
"Chronic obstructive pulmonary disease (COPD) is associated with unfavourable short- and long-term outcome in patients with coronary artery disease undergoing revascularisation procedures."1.36Relationship between chronic obstructive pulmonary disease and in-hospital management and outcomes in patients with acute myocardial infarction. ( Brzeziński, M; Dubiel, JS; Dudek, D; Dziewierz, A; Mielecki, W; Rakowski, T; Siudak, Z; Zdzienicka, J, 2010)
"In conclusion, in a dog coronary thrombosis model, ticagrelor blocks ADP-induced platelet activation and aggregation; prevents platelet-mediated thrombosis; prolongs reperfusion time and reduces re-occlusion and cyclic flow variation; and significantly decreases infarct size and rapidly restores myocardial tissue perfusion."1.36Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model. ( Huang, Y; Khalil, M; Penn, MS; van Giezen, JJ; Wang, K; Wiktor, D; Zhou, X, 2010)
" Regarding the postoperative course, significant results could be demonstrated for: adrenaline dosage (0."1.36Mid-term outcomes of patients with PCI prior to CABG in comparison to patients with primary CABG. ( Adamczak, M; Boulesteix, AL; Eifert, S; Kilian, E; Lamm, P; Mair, H; Reichart, B, 2010)
"This is the first case of renal infarction that developed in the early hours of primary PCI, despite effective anticoagulant and antiplatelet treatment."1.36Acute myocardial infarction and renal infarction in a bodybuilder using anabolic steroids. ( Calık, AN; Demirci, D; Güvenç, TS; Ilhan, E, 2010)
" The present article reviews data on the clinical impact of enhanced P2Y12 inhibition with either higher clopidogrel dosing or new oral antiplatelet agents, including prasugrel and ticagrelor, in the setting of STEMI, focusing on results in the setting of primary PCI."1.36Clinical impact of enhanced inhibition of P2Y12-mediated platelet aggregation in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention. ( Capranzano, P; Dangas, G; Mehran, R; Stone, GW; Tamburino, C, 2010)
"Fondaparinux was found to be noninferior to enoxaparin and was associated with fewer bleeding events in the OASIS-5 study of patients who were not treated with an early invasive approach."1.352007 Guideline update for unstable angina/non-ST-segment elevation myocardial infarction: focus on antiplatelet and anticoagulant therapies. ( Battistone, S; Coons, JC, 2008)
"Tirofiban was administered for 24 h and the IABP was withdrawn after 60 h."1.35Reversible clopidogrel resistance due to right ventricular myocardial infarction: risk factor of recurrent stent thrombosis? ( Braun-Dullaeus, RC; Hass, N; Ibrahim, K; Kolschmann, S; Strasser, RH, 2008)
"Acute myocardial infarction is a rare condition in young athletes."1.35Recurrent myocardial infarction in a young football player with antithrombin III deficiency. ( Bosevski, M; Kalpak, O; Maksimovic, J; Pejkov, H; Peovska, I, 2008)
"Myocardial infarction is common in patients with a history of coronary artery disease."1.35[Severe myocardial infarction due to late and very late stent thrombosis after coronary artery stenting with drug-eluting stents]. ( Erdmann, E; Flesch, M; Krausgrill, B, 2008)
" The ExTRACT-TIMI 25 trial employed a novel dosing regimen for enoxaparin adjusted for age and renal function, which was designed to minimize bleeding risk while maintaining the beneficial effects of enoxaparin."1.35ExTRACT-TIMI 25 in perspective: key lessons regarding enoxaparin as an adjunct to fibrinolytic therapy. ( Giugliano, RP; Thomas, D, 2009)
"Antiplatelet therapies for the treatment of acute coronary syndromes (ACS) act to interrupt various pathways of platelet activation."1.35Novel antiplatelet strategies in acute coronary syndromes. ( Sabatine, MS, 2009)
"Serious allergic reactions have also been reported; (6) In most cases, especially when the risk of restenosis is low or moderate, it is better to use a bare metal stent."1.35Drug-eluting coronary stents: many meta-analyses, little benefit. ( , 2009)
"Factor XI deficiency is a rare coagulopathy occurring primarily in Ashkenazi Jews, and is associated with bleeding diathesis."1.35Percutaneous coronary intervention in a patient with factor XI deficiency. ( Levi, E; Shimony, A; Zahger, D, 2009)
"Stent thrombosis is a rare but devastating complication of coronary stent implantation."1.35Stent thrombosis: a poor man's disease? ( Danenberg, HD; Lotan, C; Marincheva, G; Nassar, H; Varshitzki, B, 2009)
"Non-ST-elevation acute coronary syndrome is associated with significant morbidity and mortality."1.35Glycoprotein IIb-IIIa inhibitors in the emergency department for patients with non-ST-elevation acute coronary syndromes: principles and practices. ( Bonaca, M; Giugliano, R; Hoekstra, JW; Lefebvre, CW, 2009)
"Warfarin treatment was an independent predictor of both primary endpoint (OR 1."1.34Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. ( Airaksinen, KE; Airaksinen, TJ; Karjalainen, PP; Niemelä, M; Nyman, K; Porela, P; Vahlberg, T; Vaittinen, MA; Vikman, S; Ylitalo, A, 2007)
" We assessed the cumulative incidence of major adverse cardiac events (death, acute myocardial infarction, and target-vessel revascularization) and angiographic stent thrombosis during 2-year follow-up."1.34Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) multicenter registry. ( Aurier, E; Benassi, A; Cremonesi, A; Grilli, R; Guastaroba, P; Magnavacchi, P; Manari, A; Maresta, A; Marzocchi, A; Percoco, G; Piovaccari, G; Saia, F; Varani, E, 2007)
"Symptom recurrence (angina and congestive heart failure), adverse cardiac events (myocardial infarction, coronary reintervention, and sudden cardiac death), and overall mortality were prospectively recorded."1.33Postoperative clopidogrel improves mid-term outcome after off-pump coronary artery bypass graft surgery: a prospective study. ( Aytac, A; Cui, H; Gurbuz, AT; Vuran, AC; Zia, AA, 2006)
" An independent endpoint review committee adjudicated all reported major adverse cardiovascular events, stent thromboses, and target-vessel revascularizations."1.33Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. ( Berge, C; Deme, M; Gershlick, AH; Guagliumi, G; Guyon, P; Lotan, C; Schofer, J; Seth, A; Sousa, JE; Stoll, HP; Urban, P; Wijns, W, 2006)
"Although obesity is a known risk factor for coronary artery disease, its impact on the presentation, treatment, and outcome of patients with acute coronary syndromes (ACS) has not been well studied."1.33The obesity paradox in non-ST-segment elevation acute coronary syndromes: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart A ( Boden, WE; Diercks, DB; Gibler, WB; Kirk, JD; Mulgund, J; Ohman, EM; Peterson, ED; Pollack, CV; Roe, MT; Smith, SC, 2006)
"Aspirin treatment for primary prevention is safe and useful at an annual coronary event risk > or = 1."1.32[Anticoagulation and antiaggregation in cardiac patients]. ( Meyer, BJ, 2003)
"Early administration of a combined regimen of clopidogrel and aspirin following off-pump CABG is safe and is associated with a relatively low incidence of major adverse cardiac events, bleeding, PE, and DVT."1.32A feasibility study of the safety and efficacy of a combined clopidogrel and aspirin regimen following off-pump coronary artery bypass grafting. ( Benhameid, O; Endo, M; Shennib, H, 2003)
"Most patients with PAD die of either heart attacks or strokes and they die of the former conditions far earlier than controls."1.32[Antiplatelet therapy in patients with peripheral arterial disease (PAD)]. ( Diehm, C; Huber, R; Lawall, H, 2004)
"Thrombocytopenia is rapid in onset and antibody mediated."1.32Repetitive profound thrombocytopenia after treatment with tirofiban: a case report. ( Erkoc, R; Eryonucu, B; Tuncer, M, 2004)
"Acute myocardial infarction is the leading cause of death in the industrialized world and the paramount goal is establishing early, complete, and sustained reperfusion at the myocardial tissue level."1.31Optimal treatment and current situation in reperfusion after thrombolysis for acute myocardial infarction. ( Dauterman, K; Topol, E, 2002)
"Myocardial infarction is rare during pregnancy."1.31[Myocardial infarction, pregnancy and anesthesia]. ( Diar, N; Rezig, K; Walcker, JL, 2000)
" Because of better side-effect profile and simpler dosing regime, clopidogrel has largely replaced ticlopidine."1.31Isolated profound thrombocytopenia associated with clopidogrel. ( Elmi, F; Peacock, T; Schiavone, J, 2000)

Research

Studies (1,579)

TimeframeStudies, this research(%)All Research%
pre-199014 (0.89)18.7374
1990's73 (4.62)18.2507
2000's641 (40.60)29.6817
2010's838 (53.07)24.3611
2020's13 (0.82)2.80

Authors

AuthorsStudies
Zheng, X1
Li, N1
Zhao, J1
Santana-Mateos, M1
Medina-Gil, JM2
Saavedra-Santana, P1
Martínez-Quintana, E2
Rodríguez-González, F2
Tugores, A2
Lee, D1
Kim, JS7
Kim, BJ1
Shin, SY1
Kim, DB2
Ahn, HS1
Piccin Padilla, M1
Macedo, LSDN1
França, ACW1
Meirelles, I1
Magliano, CADS1
Santos, MDS1
Manunga, J1
Pedersen, C1
Stanberry, L1
Pai, A1
Skeik, N1
Sullivan, TM2
Chiarito, M1
Sanz-Sánchez, J1
Cannata, F1
Cao, D1
Sturla, M1
Panico, C1
Godino, C2
Regazzoli, D1
Reimers, B2
De Caterina, R4
Condorelli, G2
Ferrante, G1
Stefanini, GG3
Silvain, J11
Cayla, G7
Beygui, F12
Range, G3
Lattuca, B1
Collet, JP21
Dillinger, JG2
Boueri, Z2
Brunel, P2
Pouillot, C2
Boccara, F1
Christiaens, L1
Labeque, JN1
Lhermusier, T2
Georges, JL2
Bellemain-Appaix, A6
Le Breton, H3
Hauguel-Moreau, M1
Saint-Etienne, C2
Caussin, C1
Jourda, F1
Motovska, Z6
Guedeney, P1
El Kasty, M1
Laredo, M1
Dumaine, R2
Ducrocq, G3
Vicaut, E5
Montalescot, G39
Park, JH2
Ahn, CM2
Hong, SJ3
Ahn, KJ1
Choi, JW2
Joo, HJ1
Yu, CW2
Lim, DS5
Pereira, NL2
Rihal, C1
Lennon, R1
Marcus, G1
Shrivastava, S1
Bell, MR3
So, D1
Geller, N1
Goodman, SG17
Hasan, A1
Lerman, A1
Rosenberg, Y1
Bailey, K1
Murad, MH1
Farkouh, ME3
Muthiah, MD1
Zheng, H1
Chew, NWS1
Xiao, J1
Lim, LG1
Tan, HC2
Lee, CH3
Low, AF1
Foo, LL1
Richards, AM1
Dan, YY1
Ho, KY1
Yip, JWL1
Chan, MY4
Patel, A1
Tan, M1
Suskin, N1
McKelvie, R1
Mathew, AL1
Lutchmedial, S2
Dehghani, P3
Lavoie, AJ1
Huynh, T1
Lavi, S2
Philipp, R1
Khan, R1
Yan, AT2
Radhakrishnan, S1
Sedlak, T1
Brunner, N1
Kim, HH2
Cieza, T2
Kassam, S1
Fordyce, CB1
Heffernan, M1
Jedrzkiewicz, S1
Madan, M4
Ahmed, S2
Barry, C1
Dery, JP4
Bagai, A5
Maret-Ouda, J1
Santoni, G1
Xie, S1
Rosengren, A1
Lagergren, J1
Ohman, EM24
Roe, MT32
Steg, PG34
James, SK13
Povsic, TJ1
White, J2
Rockhold, F1
Plotnikov, A1
Mundl, H1
Strony, J2
Sun, X2
Husted, S13
Tendera, M2
Bahit, MC2
Ardissino, D6
Bueno, H2
Claeys, MJ4
Nicolau, JC9
Cornel, JH8
Goto, S2
Kiss, RG5
Güray, Ü1
Park, DW6
Bode, C6
Welsh, RC10
Gibson, CM35
Bömicke, T2
Valina, CM5
Stratz, C5
Amann, M4
Neumann, FJ24
Hochholzer, W6
Alfonso, F3
Jiménez-Borreguero, LJ1
Liu, J6
Yan, HB1
Song, L3
Hua, YH1
Zhao, HJ1
Liu, C1
Zhou, P1
Li, JN1
Tan, Y1
Yang, YM1
Wu, Y2
Peterson, ED30
McCoy, LA3
Effron, MB7
Zettler, ME3
Stone, GW37
Henry, TD10
Cohen, DJ11
Schulte, PJ3
Anstrom, KJ6
Wang, TY19
Budaj, A8
Held, C6
Himmelmann, A5
Storey, RF20
Cannon, CP44
Becker, RC12
Katus, HA6
Lopes, RD11
Sorbets, E1
Wallentin, L21
Secemsky, EA1
Yeh, RW2
Kereiakes, DJ9
Cutlip, DE3
Massaro, JM2
Apruzzese, PK1
Mauri, L5
Rodés-Cabau, J3
Masson, JB1
Garcia Del Blanco, B1
Pelletier, M1
Webb, JG2
Al-Qoofi, F1
Généreux, P6
Maluenda, G3
Thoenes, M1
Paradis, JM1
Chamandi, C1
Serra, V1
Dumont, E1
Côté, M1
Choi, HI1
Ahn, JM1
Kang, SH2
Lee, PH1
Kang, SJ3
Lee, SW8
Kim, YH8
Lee, CW9
Park, SW9
Park, SJ15
Patel, MD1
Wu, D1
Chase, MR1
Mavros, P1
Heithoff, K1
Hanson, ME1
Simpson, RJ1
Choi, KN2
Jin, HY3
Shin, HC1
Park, YA1
Seo, JS3
Jang, JS4
Yang, TH3
Kim, DK4
Kim, DS3
Abnousi, F3
Sundaram, V1
Yong, CM1
Prats, J9
Deliargyris, EN8
Hamm, CW17
White, HD29
Price, MJ14
Desai, M1
Yang, L4
Ding, VY1
Harrington, RA31
Bhatt, DL51
Mahaffey, KW22
Piccolo, R3
Gargiulo, G3
Franzone, A2
Santucci, A2
Ariotti, S3
Baldo, A2
Tumscitz, C5
Moschovitis, A3
Windecker, S12
Valgimigli, M27
Uzu, K1
Shinke, T3
Otake, H1
Takaya, T1
Osue, T1
Iwasaki, M1
Kinutani, H1
Konishi, A1
Kuroda, M1
Takahashi, H1
Terashita, D1
Hirata, KI1
Saito, S5
Nakamura, M10
Shite, J2
Akasaka, T1
Iijima, R5
Ako, J2
Okada, H2
Ito, Y1
Ando, K1
Anzai, H1
Tanaka, H1
Ueda, Y3
Takiuchi, S1
Nishida, Y1
Ohira, H1
Kawaguchi, K1
Kadotani, M1
Niinuma, H1
Omiya, K1
Morita, T1
Zen, K1
Yasaka, Y1
Inoue, K1
Ishiwata, S2
Ochiai, M2
Hamasaki, T1
Yokoi, H5
Didier, R1
Morice, MC6
Barragan, P5
Noryani, AAL1
Noor, HA1
Majwal, T1
Hovasse, T1
Castellant, P2
Schneeberger, M1
Maillard, L2
Bressolette, E1
Wojcik, J1
Delarche, N2
Blanchard, D4
Jouve, B1
Ormezzano, O1
Paganelli, F3
Levy, G1
Sainsous, J1
Carrie, D4
Furber, A2
Berlan, J1
Darremont, O1
Lyuycx-Bore, A1
Gommeaux, A2
Cassat, C1
Kermarrec, A1
Cazaux, P2
Druelles, P2
Dauphin, R1
Armengaud, J1
Dupouy, P3
Champagnac, D1
Ohlmann, P4
Ben Amer, H1
Ungi, I1
Gilard, M6
Carrabba, N2
Bellandi, B1
Parodi, G5
Cecchi, E1
Baldereschi, G1
Giglioli, C3
Migliorini, A5
Valenti, R5
Valente, S4
Marcucci, R12
Marchionni, N1
Antoniucci, D7
Park, KH3
Jeong, MH12
Kim, HK1
Ahn, TH4
Seung, KB10
Oh, DJ5
Choi, DJ4
Kim, HS22
Gwon, HC10
Seong, IW7
Hwang, KK3
Chae, SC4
Kim, KB2
Kim, YJ6
Cha, KS3
Oh, SK3
Chae, JK5
Jiang, M1
You, JHS1
Baber, U5
Chandrasekhar, J2
Sartori, S2
Aquino, M2
Kini, AS2
Kapadia, S1
Weintraub, W1
Muhlestein, JB2
Vogel, B2
Faggioni, M2
Farhan, S2
Weiss, S1
Strauss, C1
Toma, C1
DeFranco, A1
Baker, BA5
Keller, S1
Rao, S1
Pocock, S2
Dangas, G5
Mehran, R18
Stuckey, TD4
Kirtane, AJ10
Brodie, BR7
Witzenbichler, B8
Litherland, C1
Weisz, G3
Rinaldi, MJ4
Metzger, DC4
Cox, DA6
Duffy, PL3
Mazzaferri, EL3
Gurbel, PA17
Ben-Yehuda, O3
Simonton, CA2
Harada, Y1
Michel, J1
Lohaus, R1
Mayer, K4
Emmer, R1
Lahmann, AL1
Colleran, R1
Giacoppo, D1
Wolk, A1
Ten Berg, JM20
Han, Y4
Adriaenssens, T2
Tölg, R4
Seyfarth, M9
Maeng, M5
Zrenner, B2
Jacobshagen, C3
Wöhrle, J2
Kufner, S3
Morath, T6
Ibrahim, T4
Bernlochner, I6
Fischer, M2
Schunkert, H7
Laugwitz, KL9
Mehilli, J26
Byrne, RA10
Kastrati, A30
Schulz-Schüpke, S2
Vaduganathan, M3
Hamilos, M3
Petousis, S2
Xanthopoulou, I8
Goudevenos, J2
Kanakakis, J1
Sitafidis, G2
Vavouranakis, M1
Skalidis, E1
Kochiadakis, G1
Lekakis, J3
Vardas, PE1
Alexopoulos, D11
Feres, F4
Abizaid, A3
Hong, MK14
Colombo, A8
Palmerini, T8
Sibbing, D12
Aradi, D7
Gross, L1
Trenk, D5
Geisler, T1
Orban, M7
Hadamitzky, M6
Merkely, B5
Komócsi, A7
Dézsi, CA1
Holdt, L1
Felix, SB1
Parma, R1
Klopotowski, M1
Schwinger, RHG1
Rieber, J1
Huber, K18
Koltowski, L1
Huczek, Z3
Massberg, S10
Pedersen, OH1
Larsen, ML1
Kristensen, SD5
Hvas, AM2
Grove, EL2
Spartalis, M1
Tzatzaki, E1
Athanasiou, A1
Spartalis, E1
He, RX1
Zhang, L7
Zhou, TN1
Yuan, WJ1
Liu, YJ1
Fu, WX1
Jing, QM2
Liu, HW1
Wang, XZ1
Capodanno, D5
Eisen, A1
Zocca, P1
van der Heijden, LC1
Kok, MM1
Löwik, MM1
Hartmann, M1
Stoel, MG1
Louwerenburg, JW1
de Man, FHAF1
Linssen, GCM1
Knottnerus, IL1
Doggen, CJM1
van Houwelingen, KG2
von Birgelen, C2
Kim, JB1
Choi, BG1
Rha, SW9
Seo, HS3
Choi, SY2
Byun, JK1
Na, JO2
Choi, CU2
Kim, EJ3
Park, CG4
Ye, M1
Wang, XF1
Jia, P1
Zeng, YJ1
Pappas, C1
Sfantou, D1
Zhong, Z1
Hou, J1
Zhang, Q4
Li, B1
Li, C2
Liu, Z1
Yang, M1
Zhong, W1
He, X1
Wu, H2
Zhong, M1
Zhao, P1
Merz, S1
Löffelhardt, N1
Ferenc, M2
Godschalk, TC1
Gimbel, ME1
Nolet, WW1
van Kessel, DJ1
Amoroso, G2
Dewilde, WJ2
Wykrzykowska, JJ1
Janssen, PW3
Bergmeijer, TO3
Kelder, JC5
Heestermans, T3
Nam, YH1
Brensinger, CM1
Bilker, WB1
Leonard, CE1
Kasner, SE1
Grosser, T2
Li, X3
Hennessy, S1
Kou, N1
Xue, M1
Zang, MX1
Qu, H1
Wang, MM1
Miao, Y1
Yang, B1
Shi, DZ1
Lin, TT1
Lai, HY1
Chan, KA1
Yang, YY1
Lai, CL1
Lai, MS1
Regev, E2
Asher, E2
Fefer, P5
Beigel, R3
Mazin, I2
Matetzky, S6
Johnston, SC5
Easton, JD5
Farrant, M1
Barsan, W1
Conwit, RA1
Elm, JJ1
Kim, AS1
Lindblad, AS1
Palesch, YY1
Lim, HH1
Li, S5
An, GD1
Woo, KS1
Kim, KH4
Kim, JM1
Kim, MH3
Han, JY1
Kim, C1
Kim, BK5
Ko, YG4
Choi, D4
Jang, Y8
Alfredsson, J1
Swahn, E2
Gustafsson, KM1
Janzon, M4
Jonasson, L1
Logander, E1
Nilsson, L2
Lindahl, TL1
Rath, CL1
Jørgensen, NR1
Wienecke, T1
Gao, CZ1
Ma, QQ1
Wu, J1
Liu, R3
Wang, F2
Bai, J2
Yang, XJ1
Fu, Q3
Wei, P1
Donadini, MP2
Bellesini, M1
Squizzato, A1
Vranckx, P12
Jüni, P4
Hamm, C8
Heg, D5
van Es, GA2
McFadden, EP1
Onuma, Y1
van Meijeren, C1
Chichareon, P1
Benit, E1
Möllmann, H2
Janssens, L1
Ferrario, M2
Zurakowski, A1
Dominici, M1
Van Geuns, RJ1
Slagboom, T3
Serruys, PW2
Wernly, B1
Lichtenauer, M1
Hoppe, UC1
Lauten, A1
Navarese, EP4
Jung, C1
Pavlovic, M3
Apostolovic, S2
Stokanovic, D2
Lilic, J2
Konstantinovic, SS2
Zvezdanovic, JB2
Nikolic, VN2
Chen, ZW1
Wu, CK1
Yang, YH2
Huang, JW1
Wu, VC1
Lee, JK2
Chen, PC1
Lin, YH1
Lin, LY1
Zhang, K1
Yang, W1
Zhang, M1
Sun, Y3
Zhang, T2
Zhang, J3
Luu, NM1
Dinh, AT1
Nguyen, TTH1
Nguyen, VH1
Almalla, M1
Schröder, J1
Hennings, V1
Marx, N1
Hoffmann, R1
Lanzillo, C1
Di Roma, M1
Sciahbasi, A1
Minati, M1
Maresca, L1
Pendenza, G1
Romagnoli, E2
Summaria, F1
Patrizi, R1
Di Luozzo, M1
Preziosi, P1
Lioy, E1
Romeo, F2
Yu, X1
Chen, F3
He, J3
Gao, Y1
Wu, C1
Luo, Y1
Zhang, X5
Zhang, Y4
Ren, X1
Lv, S1
Helft, G1
Le Feuvre, C1
Leclercq, F2
Eltchaninoff, H2
Prunier, F1
Sebagh, L1
Cattan, S3
Metzger, JP1
Leonardi, S10
Stebbins, A1
Lokhnygina, Y6
Todd, M3
Lincoff, AM10
Dauerman, HL3
Parikh, KH2
Gruberg, L2
Herrmann, HC2
McLaurin, BT1
Postma, S2
Van't Hof, AW2
Lichtveld, RA1
Armstrong, PW22
Gershlick, AH5
Goldstein, P5
Wilcox, R3
Danays, T2
Lambert, Y2
Sulimov, V1
Rosell Ortiz, F1
Ostojic, M7
Carvalho, AC1
Nanas, J1
Arntz, HR6
Halvorsen, S2
Grajek, S2
Fresco, C2
Bluhmki, E2
Regelin, A1
Vandenberghe, K1
Bogaerts, K1
Van de Werf, F6
Theidel, U1
Asseburg, C1
Giannitsis, E3
Katus, H4
Brendel, K1
Weigel, G1
Griesmacher, A1
Pachinger, O3
Mair, J1
Deo, SV1
Dunlay, SM1
Shah, IK1
Altarabsheh, SE1
Erwin, PJ1
Boilson, BA1
Joyce, LD1
Dunn, SP1
Steinhubl, SR22
Bauer, D1
Charnigo, RJ1
Berger, PB22
Topol, EJ27
Patti, G14
Mangiacapra, F9
Ricottini, E3
Cannatà, A1
Cavallari, I1
Vizzi, V3
D'Ambrosio, A4
Dicuonzo, G1
Di Sciascio, G14
Williams, JB1
Hafley, GE1
Ferguson, TB2
Mack, MJ2
Smith, PK1
Mehta, RH5
Alexander, JH1
Xie, X1
Ma, YT1
Yang, YN1
Li, XM1
Ma, X1
Fu, ZY1
Zheng, YY1
Chen, BD1
Liu, F1
Young, JJ1
Weinstock, BS1
Brown, A1
Prech, M1
Janus, M1
Lukawski, K1
Lesiak, M1
Ferreiro, JL2
Homs, S2
Berdejo, J1
Roura, G2
Gómez-Lara, J2
Romaguera, R3
Teruel, L2
Sánchez-Elvira, G2
Marcano, AL2
Gómez-Hospital, JA3
Angiolillo, DJ24
Cequier, Á3
Stathopoulou, MG1
Monteiro, P1
Shahabi, P1
Peñas-Lledó, E1
El Shamieh, S1
Silva Santos, L1
Thilly, N1
Siest, G1
Llerena, A1
Visvikis-Siest, S1
Gao, YX1
Li, Y12
Yu, XZ1
Li, L6
Yuan, YQ1
Zhao, XY1
Sun, TW1
Berglund, U1
Diercks, DB3
Kontos, MC2
Hollander, JE2
Mumma, BE1
Holmes, DN1
Wiviott, S3
Saucedo, JF4
de Lemos, JA4
Ageno, W1
Petricevic, M3
Biocina, B3
Safradin, I1
Milicic, D6
Saia, F2
Marino, M2
Campo, G12
Guastaroba, P2
Taglieri, N2
Tondi, S2
Manari, A2
Guiducci, V1
Sangiorgio, P2
Varani, E2
Magnavacchi, P2
De Palma, R1
Marzocchi, A4
Lamberts, M4
Gislason, GH13
Olesen, JB6
Kristensen, SL4
Schjerning Olsen, AM1
Mikkelsen, A1
Christensen, CB1
Lip, GY4
Køber, L10
Torp-Pedersen, C15
Hansen, ML7
Westerhout, CM6
Fu, Y3
James, S8
Lalor, N1
Conde, D1
Rodriguez, L1
Elissamburu, P1
Trivi, M1
Pollack, CV10
Cano, P1
Consuegra-Sánchez, L1
Conesa, P1
Torres-Moreno, D1
Jaulent, L1
Dau, D1
Picó, F2
Villegas, M1
Liang, ZY1
Han, YL2
Zhang, XL1
Yan, CH1
Kang, J2
García Rodríguez, LA1
Johansson, S1
Cea Soriano, L1
Xia, JG2
Qu, Y2
Shen, H1
Liu, XH1
Ducci, K2
Grotti, S2
Falsini, G2
Angioli, P2
Liistro, F3
Mandò, M1
Porto, I2
Bolognese, L5
Song, Y2
Song, JW2
Shim, JK2
Kwak, YL2
Park, MW2
Her, SH1
Choi, YS2
Park, CS2
Koh, YS2
Park, HJ1
Kim, PJ1
Kim, CJ3
Jeon, DS2
Shin, DI1
Seo, SM1
Yoo, KD1
Kim, HY1
Lee, JM1
Chung, WS4
Shin, JG3
Chang, K2
Díaz DE LA Llera, LS1
Cubero Gómez, JM1
Rangel, D1
Parejo, J1
Acosta, J1
Fernández-Cisnal, A1
Zafra, F1
Benezet, J1
Swaminathan, RV1
Feldman, DN2
Wiviott, SD29
Fox, KA28
Prabhakaran, D10
Hafley, G3
Boden, WE11
Clemmensen, P9
Menozzi, A2
Ruzyllo, W3
Widimsky, P11
Oto, A3
Leiva-Pons, J1
Pavlides, G3
Winters, KJ7
Tousek, P2
Kocka, V3
Sulzenko, J1
Bednar, F3
Linkova, H1
Okunoye, GO1
Dutton, P1
Rosenberg, N1
Novikov, I2
Elian, D1
Fink, N1
Segev, A2
Guetta, V2
Hod, H5
Suh, SY1
Kang, WC1
Oh, PC1
Choi, H1
Moon, CI1
Lee, K3
Han, SH1
Ahn, T2
Choi, IS2
Shin, EK2
Goudevenos, JA3
Deftereos, S1
Kanakakis, I1
Parissis, H1
Ntalas, IV3
Angelidis, C1
Vavuranakis, M4
Hahalis, G5
Stefanadis, C6
Tanguay, JF3
Bell, AD1
Ackman, ML1
Bauer, RD1
Cartier, R1
Chan, WS1
Douketis, J1
Roussin, A1
Schnell, G1
Verma, S2
Wong, G2
Mehta, SR16
Lin, TH1
Lai, WT2
Hsin, HT1
Li, AH2
Wang, CL1
Kuo, CT2
Hwang, JJ2
Chiang, FT2
Chang, SC1
Oh, M1
Kim, EY2
Shon, JH1
Kim, J4
Gaddam, S1
Wu, WC1
Behera, V1
Sharma, S1
Choudhary, G1
Park, KW9
Park, JJ2
Yang, HM3
Kang, HJ5
Koo, BK7
Park, BE1
Rhew, JY2
Jeon, HK2
Shin, ES2
Oh, JH2
Kim, S2
Yoon, JH5
Lee, SY3
Park, TH2
Moon, KW1
Kwon, HM2
Chae, IH8
Abbate, R8
Gensini, GF8
Shyu, KG2
Wu, CJ3
Mar, GY1
Hou, CJ1
Wen, MS1
Lin, SJ2
Kuo, C1
Li, YH5
Mao, L1
Jian, C1
Changzhi, L1
Dan, H1
Suihua, H1
Wenyi, T1
Wei, W1
Pandit, A2
Aryal, MR2
Aryal Pandit, A1
Jalota, L1
Hakim, FA1
Mookadam, F1
Lee, HR1
Tleyjeh, IM1
Chen, Y2
Tang, Y1
Huang, X2
Xie, Y1
Musumeci, G3
Limbruno, U2
Ebert, AG1
Casarosa, F1
Colivicchi, F1
Stevens, SR3
Nessel, CC1
Piccini, JP4
Patel, MR3
Halperin, JL1
Hacke, W12
Singer, DE2
Hankey, GJ6
Califf, RM8
Breithardt, G1
Bosch, X4
Marrugat, J4
Sanchis, J3
Kohli, P2
Udell, JA4
Murphy, SA26
Antman, EM22
Braunwald, E30
Bansilal, S3
Bonaca, MP3
Sabatine, MS27
Tebaldi, M7
Biscaglia, S4
Ferrari, R9
Meinertz, T2
Olivier, CB1
Diehl, P1
Schnabel, K1
Weik, P1
Zhou, Q3
Moser, M3
Costa, RA1
Leon, MB5
Marin-Neto, JA2
Botelho, RV1
King, SB3
Negoita, M1
Liu, M4
de Paula, JE1
Mangione, JA1
Meireles, GX1
Castello, HJ1
Nicolela, EL1
Perin, MA1
Devito, FS1
Labrunie, A1
Salvadori, D1
Gusmão, M1
Staico, R1
Costa, JR1
de Castro, JP1
Abizaid, AS1
Bally, K1
Buechel, RR1
Buser, P1
Tschudia, P1
Martinaa, B1
Zeller, A1
Sideris, G2
Kchaou, I1
Bal Dit Sollier, C2
Manzo Silberman, S1
Voicu, S1
Magkoutis, N1
Logeart, D1
Drouet, L3
Henry, P3
Ojeifo, O1
Bates, ER3
Mega, JL2
O'Donoghue, ML1
Viviani Anselmi, C1
Briguori, C1
Roncarati, R1
Papa, L1
Visconti, G1
Focaccio, A1
De Micco, F1
Latronico, MV1
Pagnotta, P1
Becatti, M1
Fiorillo, C1
Gori, AM7
Paniccia, R6
Giusti, B6
Violi, F2
Pignatelli, P1
Serebruany, VL21
Pokov, AN1
Fortmann, SD1
DiNicolantonio, JJ2
Borghesi, M3
Cangiano, E3
Minarelli, M2
Scalone, A2
Cavazza, C3
Marchesini, J2
Parrinello, G8
Metzger, NL1
Momary, KM1
Leé, S4
Vargová, K2
Hizoh, I1
Horváth, Z1
Gulácsi-Bárdos, P1
Sztupinszki, Z1
Apró, A1
Kovács, A1
Préda, I2
Tóth-Zsámboki, E2
Sánchez-Salado, JC1
Gracida, M1
Ariza, A1
Lorente, V1
Rivera, K1
Sosa, SG1
Cuschieri, JR1
Drawz, P1
Falck-Ytter, Y1
Wong, RC1
Gremmel, T1
Koppensteiner, R1
Ay, C1
Panzer, S1
Zou, JJ1
Chen, SL1
Tan, J2
Lin, L1
Zhao, YY1
Xu, HM1
Lin, S1
Fan, HW1
Xie, HG1
Wang, M3
Moran, AE1
Coxson, PG1
Heidenreich, PA2
Gu, D1
Goldman, L1
Zhao, D2
Koshy, A1
Balasubramaniam, K1
Noman, A1
Zaman, AG1
Schäfer, A3
Boudriot, E2
Garlichs, C2
Hoffmann, S2
Ince, H4
Klingenheben, T2
Weil, J2
Zugck, C2
Helms, TM2
Silber, S5
Miceli, A2
Angelini, GD3
Zaid, G1
Dawod, S1
Rosenschein, U1
Tanaka, A2
Ishii, H2
Sakakibara, M2
Okumura, S2
Jinno, Y1
Okada, K2
Suzuki, S3
Inoue, Y1
Murohara, T3
Waks, JW1
Morrow, DA8
Giugliano, RP8
Sloan, S3
Scirica, BM8
Gianetti, J2
Parri, MS2
Della Pina, F2
Marchi, F1
Koni, E1
De Caterina, A1
Maffei, S1
Berti, S3
Lassen, JF5
Mikkelsen, AP1
Sørensen, R7
Cheng, VE1
Oppermen, A1
Natarajan, D1
Haikerwal, D1
Pereira, J1
Tornyos, A1
Pintér, T2
Vorobcsuk, A4
Kónyi, A1
Faluközy, J1
Veress, G1
Magyari, B1
Horváth, IG3
Garay-Sánchez, P1
Limiñana, JM1
Saavedra, P1
Belardi, JA1
Brar, S1
Rothman, M1
Kreutz, RP1
Bitar, A1
Owens, J1
Desta, Z1
Breall, JA2
von der Lohe, E1
Sinha, A2
Vatta, M1
Nystrom, P1
Jin, Y1
Flockhart, DA1
de Waha, S1
Eitel, I2
Desch, S2
Fuernau, G2
Lurz, P1
Schuler, G2
Thiele, H3
Rubino, AS1
Della Corte, A1
Giordano, R1
Menicanti, L1
Tang, XF3
Fan, JY1
Meng, J1
Jin, C1
Yuan, JQ3
Yang, YJ3
Coons, JC2
Schwier, N1
Harris, J1
Seybert, AL1
Samoš, M2
Šimonová, R2
Kovář, F2
Duraj, L2
Fedorová, J2
Galajda, P1
Staško, J2
Fedor, M2
Kubisz, P2
Mokáň, M2
Mrdovic, I3
Savic, L3
Lasica, R1
Krljanac, G2
Asanin, M3
Brdar, N2
Djuricic, N2
Marinkovic, J3
Perunicic, J2
Adamson, P1
Cruden, NL2
Xu, S3
Shetterly, S2
Raebel, MA2
Ho, PM12
Tsai, TT8
Magid, D2
Holm, M1
Dalén, M1
Tornvall, P1
van der Linden, J1
Brener, SJ3
Oldroyd, KG1
Maehara, A2
El-Omar, M2
Xu, K4
Schulz, S15
Richardt, G4
Neudecker, J2
Hauschke, D1
Braun, D2
Song, PS2
Song, YB8
Yang, JH4
Hahn, JY8
Choi, SH9
Choi, JH8
Lee, SH13
Bach, RG4
Heras, M2
Horrow, J7
Lassila, R2
Morais, J4
Wojdyla, D1
Harskamp, RE1
Solomon, MD1
Go, AS5
Shilane, D1
Boothroyd, DB1
Leong, TK1
Kazi, DS1
Chang, TI1
Hlatky, MA1
Murray, AM1
Keville, N1
Gray, S1
Lindholm, D1
Varenhorst, C4
Maya, J2
Taylor, J1
Sherwood, MW3
Peng, SA3
Delemos, J1
Kim, NY1
Kim, EK1
Rao, SV4
Ho, HH1
Er Ching, M1
Ong, PJ1
Ooi, YW1
Isshiki, T5
Kimura, T6
Ogawa, H3
Nanto, S2
Takayama, M2
Kitagawa, K2
Nishikawa, M3
Miyazaki, S2
Cresci, S2
Depta, JP2
Lenzini, PA2
Li, AY1
Lanfear, DE2
Province, MA1
Spertus, JA7
Yayehd, K1
Belle, L3
Thuaire, C1
Richard, P1
Barbou, F1
Köning, R1
Chassaing, S1
Teiger, E1
Berthier, R1
Decomis, MP1
Claudel, JP1
De Poli, F1
Albert, F1
Lai, YS1
Yang, LT1
Kao Yang, YH1
Liu, PY1
Ayers, J1
Mandell, R1
Sanghvi, K1
Aboujaoude, R1
Hsi, DH1
Hoppmann, P3
Anette Fiedler, K1
Abdel-Wahab, M3
Schneider, S2
De Servi, S8
Goedicke, J3
Schirmer, A1
Wojdyla, DM2
Emanuelsson, H4
Hiatt, WR2
Jeong, HE1
Lee, SJ1
Cha, EY1
Song, YH1
Chen, J3
Meng, H1
Xu, L2
Kong, D1
Chen, P1
Gong, X1
Zou, F1
Yang, Z1
Eikelboom, JW6
Din, JN2
Janssen, C1
Smith, R1
Hilton, JD1
Klinke, WP1
Carere, RG1
Robinson, SD1
Siega, AD1
Park, SD1
Baek, YS1
Woo, SI1
Kim, SH2
Shin, SH1
Kim, DH1
Kwan, J2
Park, KS2
Youn, YN1
Yi, G1
Joo, HC1
Yoo, KJ1
Magid, DJ6
Ting, HH2
Alexander, KP5
Liang, J1
Wang, Z5
Shi, D2
Liu, Y7
Zhao, Y1
Han, H1
Liu, W2
Zhou, Y2
Tran, BA1
Egbers, R1
Lowe, L1
Helfrich, YR1
Juul, N1
Gislason, G2
Karasoy, D2
Christiansen, CB1
Sorensen, R2
Legrand, V2
Cuisset, T11
Chenu, P1
Vrolix, M1
Martinez, C1
Dens, J1
Gach, O1
Boland, J1
Magne, J1
Barbato, E8
Wijns, W8
Schipper, JC1
Qaderdan, K1
Ishak, M1
Ruitenbeek, RS1
Asselbergs, FW1
van 't Hof, AW12
Spanó, F1
Herrman, JP2
Postma, MJ1
de Boer, A1
Deneer, VH2
Dambrink, JH8
Ottervanger, JP8
Gosselink, AT7
Koopmans, PC2
Suryapranata, H7
Li, J5
Wang, Q3
Hu, S2
Wang, Y10
Masoudi, FA3
Krumholz, HM4
Jiang, L2
Siller-Matula, JM4
Delle Karth, G1
Škorňová, I1
Nanhwan, MK2
Ling, S1
Kodakandla, M1
Nylander, S2
Ye, Y2
Birnbaum, Y2
Bakal, JA1
Zheng, Y3
Hochman, JS6
Brown, EB2
Iqbal, K1
Costigan, T1
Lopez-Sendon, J3
Ramos, Y3
Parekh, P1
Agrawal, N1
Vasavada, A1
Vinchurkar, M1
Bae, JP2
Faries, DE2
Ernst, FR1
Lipkin, C1
Zhao, Z1
Moretz, C1
Lieu, HD1
Di Minno, G3
Spadarella, G1
Cafaro, G1
Petitto, M1
Lupoli, R1
Di Minno, A1
de Gaetano, G1
Tremoli, E1
Curtis, JP1
Gurm, HS4
Shah, B2
Cheema, AN3
Granger, CB6
McNamara, RL1
Moeckel, D1
Jeong, SS1
Broekman, MJ1
Nguyen, A1
Drosopoulos, JH1
Marcus, AJ1
Robson, SC1
Chen, R3
Abendschein, D1
Thim, T1
Johansen, MB2
Chisholm, GE1
Schmidt, M2
Kaltoft, A3
Sørensen, HT4
Thuesen, L4
Bøtker, HE3
Krusell, LR3
Thayssen, P3
Jensen, LO3
Tilsted, HH3
Kalogeras, K1
Dagres, N1
Kariori, M1
Vrachatis, D1
Moldovan, C2
Lavda, M1
Mpei, E1
Androulakis, A1
Siasos, G1
Tousoulis, D3
Chiostri, M1
Cau, V1
Lazzeri, C1
Ciolino, JD1
Carter, RE1
Blicher, TM1
Hommel, K1
Madsen, M1
Kamper, AL1
Yan, J1
Xu, LJ1
Liang, Y2
Byrd, JB1
Maddox, TM5
O'Donnell, CI2
Grunwald, GK2
Rumsfeld, JS9
Cheng, CL1
Chen, PS1
Lapostolle, F3
Cantor, WJ2
Chettibi, M1
Hammett, CJ1
Zeymer, U13
Stibbe, O1
Ecollan, P2
Heutz, WM1
Willems, FF1
Baradat, C1
Licour, M1
Tsatsaris, A1
Grieco, N2
Danchin, N8
Schmitt, J1
Braun, S5
Hausleiter, J7
Tiroch, K4
Kubica, A4
Kasprzak, M2
Siller-Matula, J1
Koziński, M6
Pio Navarese, E1
Obońska, K2
Andruszkiewicz, A1
Sztuba, B2
Fabiszak, T3
Swiątkiewicz, I4
Paciorek, P1
Kubica, J7
Zhang, JH2
Wang, J2
Yao, Y2
Ma, YL2
Xu, B2
Gao, RL5
Gao, Z1
Meng, XM2
Ramaiola, I1
Padró, T1
Peña, E1
Juan-Babot, O1
Cubedo, J1
Martin-Yuste, V2
Sabate, M7
Badimon, L3
Seo, KW1
Tahk, SJ2
Yoon, MH1
Shin, JH1
Lim, HS2
Hwang, GS1
Choi, BJ1
Park, JS5
Shin, JS1
Lee, YH1
Choi, YW1
Jin, XJ1
Kristensen, KE1
Zhu, HJ1
Wang, X4
Rasmussen, HB1
Markowitz, JS1
Hansen, PR9
Syvolap, VV1
Franskavichene, LV1
Golukhova, EZ2
Mohamed, AR1
El-Hadidy, WF1
Mannaa, HF1
Calabrò, P3
Piscione, F3
Cattaneo, M6
Maffeo, D2
Toso, A4
Bartorelli, A2
Palmieri, C2
De Carlo, M2
Barozzi, C3
Tomasi, L3
Della Riva, D3
Mariani, A1
Reggiani, LB2
Bianchi, R1
De Rosa, R1
Mariani, M2
Podda, G1
Karmacharya, P1
Hakim, F1
Pathak, R1
Mainali, NR1
Ukaigwe, A1
Mahmood, M1
Badal, M1
Fortuin, FD1
Vengoechea, F1
Pendyala, LK1
Loh, JP1
Minha, S1
Magalhaes, MA1
Torguson, R6
Satler, LF8
Pichard, AD7
Waksman, R8
Vyas, A1
El Accaoui, R1
Blevins, A1
Karrowni, W1
Abdullah, AS1
Ibrahim, H1
Kiernan, TJ1
Timmers, L1
Stella, PR2
Agostoni, P2
Ikeda, Y2
Christ, G2
Francesconi, M1
Dechant, C1
Grohs, K1
Podczeck-Schweighofer, A1
Baysal, E1
Çetin, M1
Yaylak, B1
Altntaş, B1
Altndağ, R1
Adyaman, Ş1
Altaş, Y2
Kaya, İ1
Sevuk, U1
Galløe, AM1
Kelbæk, H2
Havndrup, O1
Bligaard, N1
Saunamäki, K4
Junker, A1
Aarøe, J1
Abildgaard, U2
Jeppesen, JL1
Mendolicchio, GL1
Zavalloni, D1
Bacci, M1
Roveda, M1
Quagliuolo, V1
Anselmi, CV1
Rota, LL1
Ruggeri, ZM1
Jeger, RV2
Pfisterer, ME3
von Felten, S1
Alber, H1
Bonetti, PO1
Eberli, F1
Erne, P4
Pedrazzini, G2
Rickli, H2
Galatius, S1
Kaiser, CA3
Tricoci, P5
Huang, Z2
Chen, E1
Aylward, PE2
Moliterno, DJ9
Jennings, LK1
Merli, GJ1
Weitz, HH1
Honeycutt, E1
Gupta, A1
Messenger, JC6
Koul, S3
Andell, P1
Martinsson, A1
Smith, JG2
Scherstén, F2
Harnek, J1
Götberg, M1
Norström, E1
Björnsson, S1
Erlinge, D5
Laskowska, E1
Grześk, G2
Ma, W1
Zhu, J1
Kurz, DJ1
Radovanovic, D3
Seifert, B1
Bernheim, AM1
Roffi, M4
Eberli, FR1
Mudra, H1
von Hodenberg, E1
von Merzljak, B1
Rifatov, N1
Feuchtenberger, A1
Valina, C2
Desmet, W2
Hengstenberg, C1
Schömig, A23
Mochmann, HC1
Mark, B4
Diller, F2
Zahn, R7
Lüscher, TF6
Lee, HJ2
Park, TK2
Choi, YJ3
Choi, RK1
Kim, TH1
Jang, HJ1
Shim, WH2
Roh, YM1
Perperis, A1
Koniari, I1
Karvounis, H2
Patsilinakos, S2
Ziakas, A2
Barampoutis, N2
Panagiotidis, T1
Akinosoglou, K1
Wang, XY1
Yu, HY2
Zhang, YY1
Wang, YP1
Feng, XH1
Li, ZP1
Du, XJ2
Gao, W2
Bultas, J1
Alvarez-Contreras, L1
Kelbaek, H3
Jørgensen, E3
Stoler, R1
Cortese, B1
Wilensky, M1
Liu, T3
Costa, F4
Moscarella, E1
Ando, G1
Oreto, G1
Zijlstra, F9
Zalewski, J3
Bogaert, J1
Sadowski, M1
Woznicka, O1
Doulaptsis, K1
Ntoumpanaki, M1
Ząbczyk, M1
Nessler, J2
Undas, A2
Rosencher, J1
Gouffran, G1
Bougouin, W1
Varenne, O1
Kalantzi, KI2
Tsoumani, ME2
Vakalis, JN1
Vasilakopoulos, V2
Vardakis, K2
Vemmos, KN1
Voukelatou, M2
Giannakoulas, G2
Giatrakos, I2
Giogiakas, V2
Goumas, G2
Dimoulis, N2
Draganigos, A2
Efthimiadis, I2
Thoma, M2
Kazakos, E2
Kipouridis, N2
Konstantinou, S2
Bourdakis, A2
Nikolopoulos, D2
Peltekis, L2
Prokopakis, N2
Sinteles, I2
Stroumbis, CS1
Terzoudi, K2
Tsilias, K2
Xaraktsis, I2
Charmpas, C2
Hatziathanasiou, G2
Christogiannis, Z2
Panagiotakos, DB2
Tselepis, AD2
Klingenberg, R2
Räber, L3
Carballo, D2
Nanchen, D1
Gencer, B2
Auer, R2
Jaguszewski, M1
Stähli, BE1
Jakob, P1
Templin, C2
Meier, B3
Vogt, P1
Maier, W1
Landmesser, U1
Rodondi, N2
Mach, F2
Matter, CM2
Nührenberg, T1
Kuliczkowski, W3
Gasior, M3
Pres, D3
Kaczmarski, J3
Laszowska, A1
Szewczyk, M2
Hawranek, M2
Tajstra, M2
Zeglen, S2
Polonski, L3
Schiele, F4
Puymirat, E3
Bonello, L8
Dentan, G2
Meneveau, N2
Motreff, P2
Ravan, R1
Ennezat, PV1
Ferrières, J3
Berard, L1
Simon, T5
Angoulvant, D1
Angoulvant, TB1
Fauchier, L1
So, DY5
Wells, GA2
McPherson, R1
Labinaz, M4
Le May, MR2
Glover, C2
Dick, AJ1
Froeschl, M3
Marquis, JF4
Gollob, MH1
Tran, L1
Bernick, J1
Hibbert, B2
Roberts, JD1
Jia, M1
Li, Z3
Chu, H1
Chen, K1
Gandhi, S1
Schwalm, JD2
Velianou, JL2
Natarajan, MK3
Sharma, A1
Ferguson, C1
Bainey, KR2
Ghobrial, J1
Pinto, DS3
Verdoia, M2
Barbieri, L2
De Luca, G4
Cressman, AM1
Macdonald, EM1
Fernandes, KA1
Gomes, T3
Paterson, JM1
Mamdani, MM2
Juurlink, DN2
Mele, M1
Martimucci, M1
Maggi, A1
Villella, A1
Villella, M1
Langialonga, T1
Azzalini, L1
Al-Hawwas, M1
L'Allier, PL2
Rymer, JA1
Newby, LK3
Bugiardini, R1
Dorobantu, M1
Vasiljevic, Z2
Kedev, S1
Knežević, B1
Calmac, L1
Trninic, D1
Daullxhiu, I1
Cenko, E1
Ricci, B1
Puddu, PE1
Manfrini, O1
Koller, A1
De Backer, O1
Ratcovich, H1
Biasco, L1
Pedersen, F1
Helqvist, S2
Olivecrona, G1
Engstrøm, T3
Holmvang, L2
Yudi, MB2
Eccleston, D2
Andrianopoulos, N4
Farouque, O2
Duffy, SJ4
Brennan, A3
Reid, C1
Clark, DJ4
Ajani, AE4
Cherepanov, V1
Tomek, A1
Birnbaum, GD1
Perez-Polo, JR1
Shah, NH2
LePendu, P1
Bauer-Mehren, A1
Ghebremariam, YT1
Iyer, SV1
Marcus, J1
Nead, KT1
Cooke, JP2
Leeper, NJ2
Fu, R1
Bao, H1
Yang, F1
Luo, X1
Hu, SD1
Xu, J1
Yin, CL1
Xu, D1
Lozano, I2
Rondan, J1
Vegas, JM1
Segovia, E1
Wang, B1
Shang, Q1
Samardzic, J1
Skoric, B3
Kim, BS2
Jang, WJ1
Kim, WS1
Lee, YT1
Wei, YQ1
Wang, DG1
Yang, H1
Cao, H1
Desai, NR2
Nuti, SV1
Wang, S2
Tüller, D1
Baumbach, A1
Zanchin, T2
Siddiqi, OK1
Smoot, KJ1
Dufour, AB2
Cho, K2
Young, M2
Gagnon, DR2
Ly, S2
Temiyasathit, S1
Faxon, DP5
Gaziano, JM1
Kinlay, S3
Guimarães, PO1
Melloni, C2
Neely, ML6
Zamoryakhin, D2
Qutub, MA1
Chong, AY2
Khatri, S1
Pierce, T1
Freedberg, DE1
Yang, YX1
Abrams, JA1
Grigorian, MV1
Ryabinina, MN1
Bulaeva, NI1
Fortmann, S1
Bravo, PE1
Di Carli, MF1
Kroupa, J1
Ondrakova, M1
Osmancik, P3
Kopa, M1
Li, P1
Yang, Y2
Chen, T1
Cao, A1
Zhao, X2
Qin, Y1
Ma, L1
Pilgrim, T2
Tal, K1
Kołtowski, Ł1
Tomaniak, M1
Filipiak, KJ2
Kochman, J2
Balsam, P1
Opolski, G2
Huang, CH2
Perl, L1
Sasson, L1
Weissler-Snir, A1
Greenberg, G2
Vaknin-Assa, H2
Kornowski, R5
Assali, A3
Lev, EI4
Li-Sha, G1
Peng, C1
Yue-Chun, L1
Arif, SA1
D'Souza, J1
Gil, M1
Gim, S1
Cyr, DD2
McGuire, DK2
Gutierrez, JA1
Blankenship, JC3
Gan, XD1
Wei, BZ1
Fang, D1
Fang, Q2
Li, KY1
Ding, SL1
Peng, S1
Wan, J1
Freeman, PM1
Moschonas, KE1
Hinz, C1
O'Donnell, VB1
Kinnaird, TD1
James, PE1
Anderson, RA1
Mikkelsson, J1
Paana, T1
Lepantalo, A1
Karjalainen, PP2
Sabbag, A1
Herscovici, R1
Shlomo, N1
Zahger, D2
Atar, S1
Hammerman, H2
Polak, A1
Morino, Y1
Okuizumi, K1
Usami, M1
Koizumi, T1
Nishimura, S1
Bacquelin, R1
Oger, E1
Filippi, E1
Hacot, JP1
Auffret, V1
Le Guellec, M1
Coudert, I1
Moquet, B1
Rialan, A1
Rouault, G1
Boulanger, B1
Treuil, J1
Leurent, G1
Bedossa, M2
Boulmier, D1
Avez, B1
Pongas, D1
Rubimbura, V1
Labbe, R1
Sotirov, I1
Pernes, JM1
Lee, JH3
Ahn, SG1
Lee, JW1
Youn, YJ1
Ahn, MS1
Kim, JY3
Yoo, BS2
Yoon, J5
Choi, E1
Yoo, SY1
Hung, OY1
Samady, H1
Hoh, BL1
Gong, Y1
McDonough, CW1
Waters, MF1
Royster, AJ1
Sheehan, TO1
Burkley, B1
Langaee, TY1
Mocco, J1
Zuckerman, SL1
Mummareddy, N1
Stephens, ML1
Ingram, C1
Shaffer, CM1
Denny, JC2
Brilliant, MH1
Kitchner, TE1
Linneman, JG1
Roden, DM2
Johnson, JA1
Strandmark, R1
Herlitz, J2
Axelsson, C1
Claesson, A1
Bremer, A1
Karlsson, T1
Jimenez-Herrera, M1
Ravn-Fischer, A1
Knipper, A1
Petzold, T1
Limbourg, T1
Olbrich, HG1
Hennersdorf, M1
Empen, K1
Hambrecht, R1
Pöss, J1
Werdan, K1
Apostolovic, SR1
Zivkovic, VS1
Jevtovic-Stoimenov, T1
Jankovic, SM1
Zhu, K1
Zhang, N1
Huang, YJ1
Chan, JL1
El-Serag, HB1
Jackson, LR3
Ju, C3
Zettler, M2
Effron, M1
Fu, A1
Singh, K1
Abunassar, J1
Malhotra, N1
Le May, M1
Dick, A1
Ahn, J1
Carriere, KC1
Kontoprias, K1
Gkizas, V1
Karanikas, S1
Tsigkas, G3
Koutsogiannis, N1
Davlouros, P3
Wu, S1
Carvalho, A1
Lemesle, G5
Schurtz, G1
Meurice, T1
Tricot, O1
Lemaire, N1
Caudmont, S1
Philias, A1
Ketelers, R1
Lamblin, N1
Bauters, C2
Rao, M1
Simon, DN1
Thomas, L4
Ansell, J1
Fonarow, GC2
Gersh, BJ5
Hylek, EM2
Kowey, P1
Chang, P1
Morofuji, T1
Inaba, S1
Hitsumoto, T1
Takahashi, K1
Aisu, H1
Higashi, H1
Saito, M1
Ohshima, K1
Ikeda, S1
Hamada, M1
Sumimoto, T1
Dormuth, CR1
Filion, KB1
Platt, RW1
Sakr, HI1
Alamri, HS1
Almoghairi, AM1
Alkhudair, AA1
AlMasood, AS1
Velders, MA1
Abtan, J3
Hellkamp, A1
Gabriel Steg, P2
Parker, WA1
Miao, W1
Su, G1
Wąsowicz, M1
Syed, S1
Wijeysundera, DN1
Starzyk, Ł1
Grewal, D1
Ragoonanan, T1
Harsha, P1
Travis, G1
Carroll, J1
Karkouti, K1
Beattie, WS1
Lefkovits, J2
Ramchand, J1
Yip, T1
Oqueli, E1
Reid, CM3
Noh, Y1
Lee, J2
Shin, S1
Bae, SK1
Oh, E1
Kim, GJ1
Kim, JH2
Hess, CN1
Hellkamp, AS1
Neely, B4
Martinez, F3
Sardella, G2
Mancone, M2
Esposito, G2
Cryer, BL1
Hsieh, WH2
Doros, G1
Cohen, M2
Lanas, A1
Schnitzer, TJ1
Shook, TL1
Lapuerta, P1
Goldsmith, MA1
Laine, L1
Chin, CT2
Leiva-Pons, JL3
Corbalán, R4
Gottlieb, S3
Dalby, AJ4
Ruiz-Nodar, JM1
Hu, XW1
Zhang, SH1
Li, JM1
Zhu, H1
Li, CJ1
Milionis, H1
Stroumbis, C1
Vakalis, I1
Vemmos, K1
Geske, JB1
Mayr, M1
Shah, SH1
Rihal, CS3
Zhou, CF1
Ren, YH1
Song, YQ1
Yi, J1
Han, BS1
Xue, Q1
Fu, ZH1
Li, DY1
Ahn, Y2
Golukhova, E1
Pya, Y1
Bekbossynova, M1
Marciniak, TA1
Xu, LX1
Chen, KY2
Zheng, XT1
Jiao, ZQ1
Xu, Y1
Li, G1
Vigen, R1
Fischer, Q1
Green, A1
Pottegård, A1
Broe, A1
Diness, TG1
Emneus, M1
Hasvold, P1
Hagström, E1
Sidhu, MS1
Berger, JS3
Katona, BG1
Jones, WS1
Norgren, L1
Baumgartner, I1
Blomster, J1
Held, P1
Millegård, M1
Heizer, G1
Reist, C1
Fowkes, FG1
Ma, G1
Du, M3
Zhang, D1
Shi, Y2
Shin, DH2
Her, AY1
Yi, X2
Lin, J2
Cheng, W2
Wang, C2
Dadjou, Y1
Safavi, S1
Kojuri, J1
Khan, N2
Cox, AR1
Cotton, JM1
Whalen, JD1
Davies, G2
Oguz, M2
Bash, LD1
Ozer-Stillman, I1
Shimada, YJ1
Doll, JA1
Choudhry, NK3
Bhandary, DD1
Davidson-Ray, LD1
Anstrom, K1
Yang, C1
Zhang, YQ1
Tang, X1
Gao, P1
Wei, CL1
Hu, YH1
Crimi, G1
Abaci, A1
Tokgözoğlu, L1
Liu, X1
Zang, H1
Guo, L1
Zhao, W1
Fett, N1
Parvataneni, R1
Sahlén, A1
Lagerqvist, B5
Renlund, H1
Omerovic, E1
Jernberg, T2
Hoshi, T2
Sato, A2
Nogami, A1
Gosho, M1
Aonuma, K2
Magnus Ohman, E1
Cavender, MA1
Mangum, S1
Wilson, M1
Camaro, C1
Damen, SA1
Brouwer, MA2
Kedhi, E1
Rognoni, A1
van T Hof, AW1
Ligtenberg, E1
de Boer, MJ7
Essandoh, MK1
Dalia, AA1
George, BS1
Flores, AS1
Otey, AJ1
Broderick, TM1
Magnani, G1
Chi, L1
Bittl, JA1
Kaul, S1
Moulias, A1
He, C1
Xu, JJ1
Ren, F1
Mu, N1
Zhang, C1
Dong, M1
Giustino, G2
Ariti, C1
Chieffo, A3
Kini, A2
Saporito, R1
Michael Gibson, C2
Cohen, D1
Moliterno, D1
Stuckey, T3
Henry, T1
Yadlapati, A1
Gajjar, M1
Schimmel, DR1
Ricciardi, MJ1
Flaherty, JD1
Fosbøl, EL6
Vilahur, G2
Gutiérrez, M1
Casani, L1
Varela, L1
Capdevila, A1
Pons-Lladó, G1
Carreras, F1
Carlsson, L1
Hidalgo, A1
Russo, M1
Nardi, P1
Saitto, G1
Bovio, E1
Pellegrino, A1
Scafuri, A1
Ruvolo, G1
Ferri, LA1
Morici, N1
Grosseto, D1
Tortorella, G1
Bossi, I1
Sganzerla, P1
Cacucci, M1
Sibilio, G1
Gandolfo, N1
Ravera, A1
Corrada, E1
Di Ascenzo, L1
Petronio, AS2
Cavallini, C1
Moffa, N1
Savonitto, S2
Fisher, HN2
Zhu, YE2
Henderson, MA1
Siega, AJ1
Wong, BY1
Kokis, A1
Wimmer, NJ1
Quach, L1
Do, JM1
Ostrowski, S1
Michael Gaziano, J1
Carrero, JJ1
Jensevik, K1
Szummer, K1
Evans, M1
Spaak, J1
Kassam, SA1
Ducas, J2
Brass, N1
Fung, A2
Schampaert, E1
Quraishi, AU1
Alosh, M1
Huque, MF1
Bretz, F1
D'Agostino, RB2
Tijssen, J1
Guimarães, AH1
Wildgoose, P1
Volkl, AA1
Zazula, A1
Thomitzek, K1
Hemmrich, M1
Dangas, GD3
Bykov, K1
Schneeweiss, S3
Donneyong, MM1
Dong, YH1
Gagne, JJ1
Sawlani, NN1
van Diepen, S1
Fuster, V4
Hamza, TH1
Siami, FS1
Westman, PC1
Lipinski, MJ1
Ovbiagele, B3
Wang, A1
Wang, D1
Benedetto, U1
Bacchi Reggiani, L1
Sangiorgi, D2
Biondi-Zoccai, G3
Pufulete, M1
Song, H1
Hou, C1
Cao, Q1
Dong, K1
Feng, W1
Ji, X1
Chen, YT1
Chen, HT1
Hsu, CY1
Chao, PW1
Kuo, SC1
Ou, SM1
Shih, CJ1
Yu, J1
Ooi, SY1
Stefanescu Schmidt, AC1
Lee, H1
Lim, SW1
Bae, JW4
Jeon, DW3
Hur, SH8
Lee, NH5
Chase, M1
Gupta, R1
Ozan, MO1
van Klaveren, D1
Steyerberg, EW1
Brar, SS4
Brar, SK1
Zadegan, R1
Ree, M1
Liu, IL1
Mansukhani, P2
Aharonian, V2
Hyett, R2
Shen, AY2
Prasad, A3
Tsimikas, S1
Sarma, J1
Sarno, G1
Wyffels, E1
Vanderheyden, M2
Bartunek, J3
De Bruyne, B3
Dixon, SR2
Grines, CL4
O'Neill, WW2
de Cesare, N3
Hamon, M4
Ferrari, F1
Furgieri, A3
Repetto, A2
Colangelo, S3
Meliga, E3
Kubbajeh, M2
Percoco, G4
Battistone, S1
Zhang, Z2
Kolm, P2
Mosse, F1
Jackson, J3
Zhao, L1
Weintraub, WS5
Hansen, HH1
Bøttcher, M2
Rasmussen, K1
Pedersen, L1
Johnsen, SP1
Ibrahim, K1
Hass, N1
Kolschmann, S1
Strasser, RH1
Braun-Dullaeus, RC1
Weerakkody, G3
Morocutti, G1
McCabe, CH17
Bagatini, MD1
Martins, CC1
Battisti, V1
Spanevello, RM1
Gasparetto, D1
Rosa, CS1
Gonçalves, JF1
Schetinger, MR1
dos Santos, RB1
Morsch, VM1
Büttner, HJ3
Khattab, AA1
Pache, J7
Minners, J1
Graf, I2
Skelding, KA1
Dirschinger, J11
de la Cruz, KI1
Tsai, PI1
Cohn, WE1
Cooley, DA1
Shenkman, B2
Varon, D2
Savion, N2
Sacco, RL1
Diener, HC3
Yusuf, S16
Cotton, D2
Ounpuu, S1
Lawton, WA1
Palesch, Y1
Martin, RH2
Albers, GW1
Bath, P1
Bornstein, N1
Chan, BP1
Chen, ST1
Cunha, L1
Dahlöf, B1
De Keyser, J1
Donnan, GA2
Estol, C1
Gorelick, P1
Gu, V1
Hermansson, K1
Hilbrich, L1
Kaste, M1
Lu, C1
Machnig, T1
Pais, P2
Roberts, R1
Skvortsova, V1
Teal, P1
Toni, D1
Vandermaelen, C1
Voigt, T1
Weber, M1
Yoon, BW1
Meisel, S1
Verheugt, FW6
Purdy, DA1
Alexander, D2
Ou, FS3
Gibler, WB6
Fintel, DJ2
Brown, DL1
Tayyareci, Y1
Oh, J1
Hong, N1
Kang, SM1
Patel, RA1
White, CJ1
Gumina, RJ1
Yang, EH2
Sandhu, GS1
Bresnahan, JF1
Lennon, RJ1
Holmes, DR6
Singh, M1
Pezalla, E1
Day, D1
Pulliadath, I1
Ndrepepa, G5
Peovska, I1
Maksimovic, J1
Kalpak, O1
Pejkov, H1
Bosevski, M1
Krausgrill, B1
Erdmann, E1
Flesch, M1
Jolly, SS1
Pogue, J4
Haladyn, K1
Peters, RJ5
Avezum, A1
Rupprecht, HJ6
Rasmussen, S1
Madsen, JK6
Abildstrom, SZ3
Tanaka, N1
Terashima, M1
Kinoshita, Y1
Kimura, M1
Nasu, K1
Ehara, M1
Tsuchikane, E1
Matsubara, T1
Asakura, Y1
Katoh, O1
Suzuki, T1
Gogorishvili, I1
Archvadze, A1
Kipiani, V1
Kipshidze, N1
Ivandic, BT1
Kurz, K1
Keck, F1
Staritz, P1
Lehrke, S1
Vlaar, PJ1
Svilaas, T1
Damman, K1
de Smet, BJ1
Tijssen, JG4
Hillege, HL1
Black, A1
New, G1
Lew, R1
Shaw, JA1
Yan, BP2
Gurvitch, R1
Al-Fiadh, A1
Brennan, AL2
Thomas, D5
Jackevicius, CA1
Tu, JV2
Demers, V1
Melo, M1
Cox, J1
Rinfret, S3
Kalavrouziotis, D1
Johansen, H2
Behlouli, H1
Newman, A1
Pilote, L2
Mann, N1
Lansky, AJ3
Tsuchiya, Y1
Brener, M1
Cristea, E2
Pietras, C1
Garcia, E1
Tcheng, JE4
Guagliumi, G5
Turco, M1
Carroll, JD1
Rutherford, BD1
Moses, J2
Bassand, JP4
Chrolavicius, S5
Diaz, R3
Jolly, S2
Bielis, L2
Wiśniewska-Szmyt, J2
Sukiennik, A2
Grabczewska, Z2
Ziołkowski, M1
Rość, D2
Rossini, R2
Lettieri, C2
Molfese, M1
Mihalcsik, L1
Mantovani, P1
Sirbu, V2
Bass, TA3
Della Rovere, F1
Gavazzi, A2
Heintzen, MP1
Riezebos, RK2
Ronner, E1
Ter Bals, E1
Smits, PC1
Kiemeneij, F2
Patterson, MS1
Suttorp, MJ2
Laarman, GJ2
Karnon, J1
Holmes, MW1
Williams, R1
Bakhai, A2
Verstuyft, C3
Mary-Krause, M1
Quteineh, L1
Drouet, E4
Becquemont, L2
Hulot, JS5
Pena, A3
Villard, E1
Esteve, JB1
Payot, L2
Brugier, D1
Bensimon, G1
Funck-Brentano, C2
Freedman, JE2
Yiadom, MY1
Ko, DT1
Szmitko, PE1
Austin, PC1
Henry, DA1
Kopp, A1
De Labriolle, A2
Steinberg, DH2
Roy, P2
Suddath, WO3
Kent, KM4
Smit, JJ2
van Oeveren, W1
Slingerland, RJ2
Remijn, JA1
Milani, RV1
Bildirici, U1
Celikyurt, U1
Ural, E1
Bliden, KP3
Suarez, TA1
DiChiara, J1
Antonino, MJ1
Mahla, E1
Singla, A1
Herzog, WR1
Bassi, AK1
Hennebry, TA1
Gesheff, TB1
Tantry, US10
Kammer, RT1
Okabe, T1
Pinto Slottow, TL1
Kaneshige, K1
Xue, Z3
Lindsay, J2
Saracini, C3
Sestini, I1
Buonamici, P3
Uchiyama, S2
Fukuuchi, Y1
Yamaguchi, T2
Massie, BM1
Collins, JF1
Ammon, SE1
Cleland, JG1
Ezekowitz, M3
Jafri, SM1
Krol, WF1
O'Connor, CM3
Schulman, KA3
Teo, K1
Warren, SR1
Jung, JH1
Min, PK1
Sung, CW1
Choi, S1
Cho, JR2
Lee, N1
Byun, KH1
Stulman, J1
McGinn, T1
Korenstein, D1
Früngel, S1
Nekolla, SG1
Moshage, W2
Dotzer, F8
Martinoff, S1
Schwaiger, M1
Connolly, SJ2
Hart, RG3
Hohnloser, SH1
Pfeffer, M1
Becker, D1
Beres, BJ1
Szabó, G1
Fülöp, G1
Kerecsen, G1
Spaulding, C2
Miao, J1
Bhattacharyya, S1
Rakhit, R1
Ramaraj, R1
Jiang, S2
Akbulut, M2
Kutlu, M1
Ozbay, Y1
Polat, V1
Bilen, MN1
Baydas, A1
Chua, D4
Ignaszewski, A1
Rogacka, R1
Michev, I1
Airoldi, F1
Latib, A1
Cosgrave, J1
Montorfano, M1
Carlino, M1
Sangiorgi, GM3
Castelli, A1
Magni, V1
Aranzulla, TC1
Briasoulis, A1
Dhamrait, SS1
Antoniades, C1
Gulati, R1
Schafer, JA1
Kjesbo, NK1
Gleason, PP1
Bruskina, O3
Michelson, AD4
Frelinger, AL2
Downey, WE2
Xenopoulos, NP1
Jakubowski, JA3
Qin, J2
Cola, C1
Brugaletta, S3
Martín Yuste, V1
Campos, B1
Dasgupta, A2
Mukherjee, D4
Podolec, J1
Gajos, G2
Budziaszek, Ł1
Czaniecka, M1
Kleczkoska, A1
Zmudka', K1
Bramucci, E2
Ruff, CT1
Sadler, GJ1
Poullis, AP1
Yun, SC4
Cheong, SS3
Kim, JJ6
Manoukian, SV4
Chew, D1
Feit, F2
Ware, JH1
Bertrand, ME4
Saw, J3
Densem, C1
Walsh, S1
Jokhi, P1
Starovoytov, A1
Fox, R1
Buller, C1
Ricci, D1
Mancini, GB1
Kapoor, JR2
Floyd, J1
Wolfe, S1
Webster, MW2
Gladding, P1
Shil, AB1
Strohm, MP1
Fernández-Fernández, FJ1
Pía, G1
Sesma, P1
Barthélémy, O6
Makarov, LM1
Wilhelmsen, L1
Welin, L1
Odén, A1
Björnberg, A1
Allen, MJ1
McLean-Veysey, P1
Friesen, MH1
Sellers, MB1
Carrescia, C1
Carletti, R1
Li, YJ1
Poddar, KL2
Jin, Z1
Minami, Y1
Wang, L3
Ahn, YK4
Hong, TJ5
Cho, MC6
Bae, JH5
Choi, DH2
Jang, YS3
Campbell-Scherer, DL1
Green, LA1
Patel, JH1
Stoner, JA1
Owora, A1
Mathew, ST1
Thadani, U2
Harjai, KJ2
Shenoy, C1
Orshaw, P1
Boura, J2
Petersen, KU1
Schuster, T2
Ellert, J2
Goedel, J1
Ulm, K2
Ortolani, P2
Alessi, L1
Lauria, G1
Bassi, M1
Branzi, A2
Leibundgut, G1
Nietlispach, F1
Pittl, U1
Brunner-La Rocca, H2
Wiederkehr, D2
Berenson, K1
Casciano, R2
Stern, L1
Makenbaeva, D2
Mozaffari, E2
Lamerato, L1
Corbelli, J2
Ogbonnaya, A1
Ryding, A1
Kumar, S1
Bhindi, R1
Karakurt, O1
Akdemir, R1
Perez, G1
Rodriguez-Granillo, AM1
Mieres, J1
Llaurado, C1
Rubilar, B1
Risau, G1
Fernandez-Pereira, C1
Rodriguez, AE1
Lovric, D2
Pride, YB4
Appelbaum, E1
Lord, EE1
Beinart, R2
Boyko, V1
Behar, S1
O'Donoghue, M4
Finkelstein, A2
Penny, WF1
Fridrich, V1
Heestermans, AA4
Van Werkum, JW10
Dill, T3
Van Houwelingen, G3
Hoorntje, JC4
Arimura, T1
Mitsutake, R1
Miura, S1
Nishikawa, H1
Kawamura, A1
Saku, K1
Skene, A1
Freij, A1
Thorsén, M1
Shimony, A1
Levi, E1
Gupta, E1
Bansal, D1
Sotos, J1
Olden, K1
Ergelen, M2
Uyarel, H1
Osmonov, D1
Ayhan, E1
Akkaya, E1
Soylu, O1
Orhan, AL1
Sayar, N2
Bozbay, M1
Turer, A1
Yildirim, E1
Yekeler, I1
Ensor, CR1
Cahoon, WD1
Bagur, R2
Bertrand, OF3
Larose, E2
Nguyen, CM1
Noel, B1
Larochellière, RD1
Poirier, P1
Costerousse, O2
Roy, L2
Saikia, PK1
Chakrabarti, D1
Nikolsky, E1
McLaurin, B1
Moses, JW5
Fahy, M1
Legal, M1
Shalansky, SJ2
Sanchez-Lopez, J1
Muñoz-Cano, R1
Bartra, J1
Valero, A1
Picado, C1
Caixeta, A2
Aoki, J1
Peruga, JZ2
Dudek, D5
Rabbani, LE1
Parise, H2
Simon, DI4
Parikh, SA1
Koeth, O3
Gitt, AK4
Bauer, T4
Juenger, C2
Senges, J7
Sudlow, CL1
Mason, G1
Maurice, JB1
Wedderburn, CJ1
Liang, B1
Mei, Q1
Schrör, K2
Proulx, G1
Gleeton, O1
De Larochellière, R1
Raymond, C1
Menon, V2
Cho, YH2
Yang, JY3
Lee, SG2
Kim, KS2
Jirmar, R1
Hulikova, K1
Peroutka, Z1
Pompachova, A1
McNulty, S1
Kleiman, NS5
Amine, M1
Chew, DP3
French, WJ2
Leisch, F1
Skerjanec, S2
Kan, LP1
Chu, KM3
Lin, GM7
Kent, DM1
Trikalinos, TA1
Kremneva, LV1
Shalaev, SV2
Gilchrist, IC1
Sheng-Wen Wang, S1
Tsai, SS1
Hsu, PC1
Yang, CY1
Wu, DC1
Danenberg, HD1
Marincheva, G1
Varshitzki, B1
Nassar, H1
Lotan, C2
Aplin, R1
Tiede, D1
Lovitz, C1
Gartner, M1
Robinson, D1
Xu, H2
Martin, P1
Erickson, B1
Schmidt, W1
Pelzel, J1
Wendt, D1
Mahowald, J1
Hvelplund, A2
Andersson, C4
Jørgensen, C1
Atar, D1
Mahoney, EM4
Wang, K2
Arnold, SV1
Proskorovsky, I1
Antman, E1
Juhász, M1
Herszényi, L1
Tulassay, Z1
Chhatriwalla, AK1
Glover, CA1
O'Brien, ER1
Turek, M1
Thomas, A1
Kass, M1
Jadhav, S1
Bilodeau, ML1
Dosh, K1
Marso, S1
van Lente, F2
Brennan, DM4
Charnigo, R1
Steinhubl, S5
Carlhed, R1
Bojestig, M1
Peterson, A1
Aberg, C1
Garmo, H1
Lindahl, B1
Sielski, J1
Wałek, P1
Polewczyk, A1
Janion, M1
Øvrum, E1
Tangen, G1
Tølløfsrud, S1
Ringdal, MA1
Øystese, R1
Istad, R1
Thurston, SJ1
Heeg, B1
de Charro, F1
van Hout, B1
Han, CL5
Zafar, MU1
Paz-Yepes, M1
Shimbo, D1
Burg, MM1
Chaplin, W1
Davidson, KW1
Badimon, JJ2
Harkness, JR1
Fakorede, F1
Minutello, RM1
Bergman, G2
Moussa, I1
Wong, SC1
Ghaffari, S1
Pourafkari, L1
Weeke, P3
Folke, F1
Poulsen, HE1
Frangione, A2
Luccarelli, S1
Fileti, L2
Jeong, YH7
Hwang, JY4
Kim, IS5
Park, Y5
Hwang, SJ4
Kwak, CH4
Lønborg, J1
Vejlstrup, N1
Treiman, M1
Jensen, JS1
Hayashi, F1
Sugi, K1
Akhter, M1
Kothari, S1
Sharma, SK2
Serebruany, V3
Muller, O3
Trana, C2
Ntalianis, A2
Heyndrickx, G1
Ben-Dor, I3
Bidet, A1
Jais, C1
Coste, P3
Nurden, A1
Jakubowski, J1
Nurden, P1
Kloppenburg, G1
Zairis, MN2
Tsiaousis, GZ1
Patsourakos, NG2
Georgilas, AT1
Kontos, CF1
Adamopoulou, EN2
Vogiatzidis, K1
Argyrakis, SK2
Fakiolas, CN2
Foussas, SG2
Kim, WJ1
Lee, JY1
Ahmad, M1
Salehian, O1
Croce, K2
Rassen, JA1
Avorn, J1
Fineschi, M2
Carrera, A1
Gori, T2
Pierli, C2
Breet, NJ5
Bouman, HJ3
Ruven, HJ1
Bal, ET1
Harmsze, AM2
van der Heyden, JA2
Rensing, BJ1
Hackeng, CM4
Kharbanda, R1
Schmidt, MR1
Kaltoft, AK1
Terkelsen, CJ1
Munk, K1
Andersen, NH1
Hansen, TM1
Trautner, S1
Christiansen, EH1
Nielsen, SS1
Rehling, M1
Redington, AN1
Nielsen, TT1
Moerenhout, CM1
Haine, S1
Miljoen, H1
Bosmans, JM1
Vertessen, F1
Kluppels, K1
Van der Planken, M1
Vrints, CJ1
Petersen, JL1
Barron, JJ1
Hammill, BG1
Cziraky, MJ1
Wahl, PM1
Eisenstein, EL2
Krucoff, MW1
Curtis, LH1
Gibler, KB1
Huskamp, HA1
Balbi, M1
Fedele, M1
Bezante, GP1
Brunelli, C1
Barsotti, A1
Han, KH3
Lee, BK1
Nah, DY1
Park, HS2
Evanchan, J1
Donnally, MR1
Binkley, P1
Mazzaferri, E1
Ruparelia, N1
Spyrou, N1
Gatto, L3
Lee, CJ1
Oh, SJ1
Cho, DK1
Rotheray, K1
Bonde, L1
Abildstrøm, SZ3
Kober, L1
Schramm, TK1
Bretler, DM1
Olesen, J1
Coppola, A1
De Simone, C1
Di Capua, M1
Tufano, A2
Cimino, E1
Conca, P1
Guida, A1
Morisco, C1
Shetterly, SM2
Clarke, CL1
Sedrakyan, A1
Pasceri, V7
Colonna, G4
Montinaro, A4
Tan, JW1
Guo, KW1
Rakowski, T2
Bartus, S2
Giszterowicz, D1
Dobrowolski, W1
Zmudka, K2
Ochala, A1
Wieja, P1
Janus, B1
Dziewierz, A2
Legutko, J2
Bryniarski, L1
Dubiel, JS3
Meimoun, P1
Boulanger, J1
Luycx-Bore, A1
Zemir, H1
Elmkies, F1
Malaquin, D1
Doutrelan, L1
Tribouilloy, C1
Naidu, SS1
Turco, MA1
Coolong, A1
Popma, JJ2
Johansen, M1
Afshari, A1
Kristensen, BB1
Powers, JD2
Carroll, NM2
Jackevicius, C1
Margolis, KL1
DeFor, TA1
Siudak, Z1
Brzeziński, M1
Zdzienicka, J1
Mielecki, W1
Saidi, Y1
Guesmi, F1
Landolsi, M1
Trabelsi, S1
Khemiri, K1
Ounalli, K1
Dziri, C1
Houissa, M1
Stockl, KM1
Le, L1
Zakharyan, A1
Harada, AS1
Solow, BK1
Addiego, JE1
Ramsey, S1
Boiangiu, C1
Abidi, M1
Schwartz, RS1
Margolis, K1
Cho, JH2
Kang, MK1
Koh, JS2
Garavalia, L1
Garavalia, B1
Foody, JM4
Kruse, H1
Decker, C2
Sorich, MJ1
Vitry, A1
Ward, MB1
Horowitz, JD1
McKinnon, RA1
Ambrosio, G1
Gresele, P1
Tritto, I1
Zuchi, C1
Shames, AB1
Igonin, VA1
Krashutskiĭ, VV1
Ivanov, VA1
Terekhin, SA1
Burdess, A1
Nimmo, AF1
Garden, OJ1
Murie, JA1
Dawson, AR1
Newby, DE2
Rifai, N1
Gerszten, RE1
Logman, JF1
Heeg, BM1
van Hout, BA1
Birkmeier, KA1
Gershlick, A1
Marshall, DA1
Petitjean, H1
Brown, E2
Larson, DM3
Duval, S3
Sharkey, SS1
Solie, C1
Tschautscher, C1
Lips, DL1
Burke, MN1
Bonassin, F1
Wyss, C1
Schneemann, M1
El Khoury, C1
Dubien, PY1
Mercier, C1
Debaty, G1
Capel, O1
Perret, T1
Savary, D1
Serre, P1
Bonnefoy, E1
Pevzner, DV1
Staroverov, II1
Samko, AN1
Frolova, NS1
Mazurov, AV1
Ruda, MY1
Galiavich, AS2
Makhiianova, ÉI1
Sarafoff, N1
Sonntag, U1
Okura, H1
Zhou, X1
Huang, Y1
Khalil, M1
Wiktor, D1
van Giezen, JJ1
Penn, MS1
Dean, BB1
Yu, HT1
Fiske, S1
Meadows, E1
Xiong, Y1
Emons, MF1
Peace, A1
Gitt, A2
Eifert, S1
Mair, H1
Boulesteix, AL1
Kilian, E1
Adamczak, M1
Reichart, B1
Lamm, P1
Lee, SP3
Suh, JW3
Lee, HY3
Kwon, TG2
Herkner, H1
Jilma, B3
Cerfolio, RJ1
Minnich, DJ1
Bryant, AS1
Nusca, A3
Melfi, R1
Joyner, CD2
Afzal, R1
Lin, V1
Holman, JR1
Jamieson, B1
Gandhi, NK1
Abdel-Karim, AR1
Banerjee, S1
Brilakis, ES1
van Kuijk, JP1
Voute, MT1
Flu, WJ1
Schouten, O1
Chonchol, M1
Hoeks, SE1
Boersma, EE1
Verhagen, HJ1
Bax, JJ1
Poldermans, D1
Tiroch, KA1
Koch, W1
Roosen-Runge, T1
Rideg, O1
Tokés-Füzesi, M2
Magyarlaki, T1
Memtsoudis, SG1
Sharrock, NE1
Preobrazhenskiĭ, DV1
Sidorenko, BA1
Fettser, DV1
Batyraliev, TA2
Niiazova-Karben, ZA1
Besnili, F1
Zwart, B1
Koolen, JJ1
Brueren, BR1
Legal, MG1
Jung, J1
Jin, B1
Ni, HC1
Shen, W1
Shi, HM1
Charlot, M3
Ahlehoff, O3
Norgaard, ML1
Jørgensen, CH1
de Aquino Lima, JP1
Brophy, JM1
Blackburn, DF1
Lamb, DA1
Mcleod, MM1
Eurich, DT1
Rosenbaum, A1
Rizvi, AZ1
Alden, PB1
Tretinyak, AS1
Graber, JN1
Goldman, JA1
ten Berg, J4
Slingerland, R1
Małek, LA1
Przyłuski, J1
Spiewak, M2
Kłopotowski, M1
Kostrzewa, G1
Kruk, M1
Płoski, R1
Witkowski, A1
Rużyłło, W1
Ilhan, E1
Demirci, D1
Güvenç, TS1
Calık, AN1
Tran, M1
Tafreshi, J1
Pai, RG1
Han, KR2
Cho, BR1
Russo, F1
Fernández-Cimadevilla, OC1
Barriales, V1
Yokoyama, N2
Takada, K1
Ishikawa, S1
Wang, CH1
Yang, J1
Shen, ZJ1
Zhang, SY1
Fan, ZJ1
Jin, XF1
Xie, HZ1
Liu, ZY1
Solheim, S1
Seljeflot, I2
Lunde, K1
Bjørnerheim, R1
Aakhus, S1
Forfang, K1
Arnesen, H2
Heyndrickx, GR2
Shan, L1
Gao, XM1
Kiriazis, H1
Lobo, A1
Head, GA1
Dart, AM1
Capranzano, P1
Tamburino, C3
Valkhoff, VE1
't Jong, GW1
Van Soest, EM1
Kuipers, EJ1
Sturkenboom, MC1
Small, GR1
Chow, BJ1
Chen, A1
Sawada, T1
Honjo, T1
Haraguchi, Y1
Nishio, R1
Shinohara, M1
Toh, R1
Ishida, T1
Kawamori, H1
Kozuki, A1
Inoue, T1
Hariki, H1
Hirata, K1
Marchini, J1
Morrow, D1
Resnic, F1
Manica, A1
Kirshenbaum, J1
Cannon, C1
Menown, IB1
Delhaye, C3
Sudre, A1
Vanesson, L1
Koussa, M1
Fayad, G1
Lablanche, JM1
Modine, T1
Lee, MG1
Ko, JS1
Sim, DS2
Yoon, NS1
Yoon, HJ1
Hong, YJ1
Park, HW1
Cho, JG2
Park, JC3
Kang, JC2
Oberhänsli, M1
Stauffer, JC2
Togni, M1
Ribordy, V1
Chabanel, D1
Hayoz, D1
Cook, S1
Merella, P1
Casu, G1
Meloni, I1
Muñoz-Torrero, JF1
Escudero, D1
Suárez, C1
Sanclemente, C1
Pascual, MT1
Zamorano, J1
Trujillo-Santos, J1
Monreal, M1
Kozuma, K1
Ota, Y1
Nagai, Y1
Katsuta, Y1
Nozaki, E1
Onodera, T1
Ikari, Y2
Kotani, J1
Kyo, E1
Masumura, Y1
Matsuo, K1
Akazawa, Y1
Nishio, M1
Hirata, A1
Kashiwase, K1
Nemoto, T1
Kashiyama, T1
Wada, M1
Muller, JE1
Kodama, K1
Dick, RJ1
Dear, AE1
Byron, KA1
Cho, YS1
Youn, TJ1
Charlot, MG1
Selmer, C1
Hanssen, M1
Lardoux, H1
Lefèvre, T3
Mulak, G2
Bataille, V2
Cay, S1
Cagirci, G1
Aydogdu, S1
Balbay, Y1
Sen, N1
Maden, O1
Demir, AD1
Erbay, AR1
Jung, HJ1
Sir, JJ1
Edwards, J1
Yan, RT1
Kornder, JM1
Deyoung, JP1
Chauret, D1
Picard, JP1
Eagle, KA5
Kim, JW1
Lim, HE1
Wakabayashi, K1
Laynez-Carnicero, A1
Sardi, G1
Gaglia, MA1
Mahmoudi, M1
Gonzalez, MA1
Caruso, M1
Bracale, UM1
Incalcaterra, E1
Vitale, G2
Bajardi, G1
Assennato, P1
Hoffmann, E1
Novo, S2
Mohammad, RA1
Goldberg, T1
Dorsch, MP1
Cheng, JW2
Lortkipanidze, N1
Romano, M1
Nijaradze, T1
Tarantini, G1
Cicorella, N1
Rosiello, R1
Valsecchi, O1
Teirstein, PS4
Spriggs, D1
Puri, S1
Robbins, M1
Garratt, KN1
Stillabower, ME1
Stillablower, ME1
Aragon, JR1
Kandzari, DE3
Stinis, CT1
Lee, MS3
Schork, NJ1
Inglese, L1
Fantoni, C1
Steiger, H1
Fontes-Carvalho, R1
Albuquerque, A1
Araújo, C1
Pimentel-Nunes, P1
Ribeiro, VG1
Don, CW1
Fraulo, E1
Pomerantsev, E1
Palacios, I1
Lengenfelder, B1
Stoerk, S1
Boes, L1
Strotmann, J1
Ertl, G1
Voelker, W1
Bonz, AW2
Möeckel, M1
Yun, SE1
Park, JR1
Koh, EH1
Anzaha, G1
Chastre, T1
Caron, C1
Vignalou, JB1
Galier, S1
Gallois, V3
Bellemain, A1
Persson, J1
Lindbäck, J1
Hofman-Bang, C1
Stenestrand, U1
Samnegard, A1
Collins, SD1
Syed, AI1
El Ghannudi, S2
Jesel, L3
Radulescu, B2
El Adraa, E1
Crimizade, U2
Wiesel, ML2
Gachet, C3
Morel, O3
Chua, SK1
Liao, CS1
Hung, HF1
Cheng, JJ1
Chiu, CZ1
Chang, CM1
Lin, SC1
Liou, JY1
Lo, HM1
Kuan, P1
Behr, T1
Kuch, B1
Behr, W1
von Scheidt, W2
Oldgren, J1
Khder, Y1
Roberts, J1
Siegbahn, A3
Contant, CF1
Guo, J1
Nijjer, SS1
Watson, G1
Athanasiou, T1
Malik, IS1
Boinska, J1
Stolarek, W1
Marciniak, A1
Andreotti, F1
Amin, AP1
Kennedy, KF1
Pencina, M1
Berger, P2
Piana, RN1
Lopez, J2
Kleiman, N1
Flierl, U1
Kössler, J1
Seydelmann, N1
Kobsar, A1
Störk, S1
Bauersachs, J2
Greif, M2
Pappalardo, A1
Mamas, MA1
Imola, F1
Ramazzotti, V1
Manzoli, A1
Prati, F2
Biancari, F1
Airaksinen, KE2
Niccoli, G2
Minelli, S1
Cosentino, N1
Crea, F2
Carroll, K1
Pieper, KS4
Vrachatis, DA1
Papaioannou, TG1
Archontakis, S1
Kalogeras, KI1
Kariori, MG1
Gafou, A1
Tzamalis, P1
Burkard, T1
Osswald, S2
Aïssaoui, N1
Yazıcı, HU1
Birdane, A1
Nadiradze, A1
Ünalır, A1
Cassese, S1
Villari, B1
Bellone, P1
Alfieri, A1
Quaranta, G1
Marraccini, P1
Grdinic, A1
Vojvodic, D1
Djukanovic, N1
Colic, M1
Grdinic, AG1
Ignjatovic, V1
Majstorovic, I1
Ilic, V1
Magic, Z1
Obradovic, S1
Dolijanovic, SP1
Mosterd, A1
Koopmans, P1
Myers, GR1
Hoffman, MK1
Marshall, ES1
Khemasuwan, D1
Chae, YK1
Gupta, S1
Carpio, A1
Yun, JH1
Neagu, S1
Lucca, AB1
Valsecchi, ME1
Mora, JI1
Albaladejo, P1
Marret, E1
Samama, CM1
Abhay, K1
Loutrel, O1
Charbonneau, H1
Jaber, S1
Thoret, S1
Bosson, JL1
Piriou, V1
Alber, HF2
Frick, M1
Loane, P1
Clough, JD1
Martin, SS1
Cope, MW1
Kulik, A1
Ruel, M1
Bisdas, T1
Haverich, A1
Teebken, OE1
Boggon, R1
van Staa, TP1
Timmis, A2
Hemingway, H2
Ray, KK1
Begg, A1
Emmas, C1
Lillie, E1
Shelton, RJ1
Chitkara, K1
Singh, R1
Dorsch, MF1
Somers, K1
McLenachan, JM1
Blaxill, JM1
Wheatcroft, SB1
Blackman, DJ1
Greenwood, JP1
Chen, M1
Wei, JF1
Xu, YN1
Liu, XJ1
Huang, DJ1
Greenhalgh, J1
Bagust, A1
Boland, A1
Martin Saborido, C1
Oyee, J1
Blundell, M1
Dundar, Y1
Dickson, R1
Proudlove, C1
Fisher, M1
Hussain, F1
Golian, M1
Peppard, SR1
Held-Godgluck, BM1
Beddingfield, R1
Hnid, K1
Chtioui, M1
Morgan, KP1
More, RS1
Chauhan, A1
Damman, P1
Iñiguez, A1
Klomp, M1
Beijk, M1
Woudstra, P1
Ribeiro, EE1
Sim, KH1
de Winter, RJ1
Kotti, S1
Ferrari, E1
Grollier, G3
Dörler, J1
Edlinger, M1
Altenberger, J1
Benzer, W1
Grimm, G1
Schuchlenz, H1
Siostrzonek, P1
Zenker, G1
Weidinger, F1
Chiu, FC1
Wang, TD1
Shih, FY1
Lin, JW1
Chen, WJ1
Chen, MF1
Stankovic, I1
Vlahovic-Stipac, A1
Ilic, I1
Putnikovic, B1
Neskovic, AN1
Labos, C1
Dasgupta, K1
Nedjar, H1
Turecki, G1
Rahme, E1
Bárczi, G1
Orlic, D2
Edes, I1
Allanic, F1
Scott, SA1
Chen, AY3
Narancic-Skoric, K1
Gornik, I1
Sertic, J1
Snoep, JD1
DiSciascio, G1
Erpolat, S1
Nazli, Y1
Colak, N1
Yenidunya, S1
Sharkey, SW1
Garberich, RF1
Madison, JD1
Stokman, PJ1
Dirks, TG1
Westin, RK1
Harris, JL1
Ng, J1
Hirsh, J2
Hohnloser, S1
Fang, MC1
Kwon, TJ1
Leone, AM1
Sgueglia, GA1
Burzotta, F2
Trani, C1
De Caterina, AR1
Buffon, A1
Mazzari, MA1
Mongiardo, R1
Rebuzzi, AG1
Robertson, DJ1
Baron, JA1
Finzi, J1
Kerneis, M2
O'Connor, SA3
Ferlini, M1
Grinfeld, L1
Iadanza, A1
Talameh, JA1
McLeod, HL1
Bonello, N1
Grosdidier, C2
Camoin-Jau, L3
Vinisko, R1
Bath, PM1
Karkowski, L1
Wolf, M1
Lescampf, J1
Coppérré, B1
Veyradier, A1
Ninet, J1
Hot, A1
Akerblom, Å1
Buck, K1
Åsenblad, N1
Chitose, T1
Hokimoto, S1
Oshima, S1
Nakao, K1
Fujimoto, K1
Miyao, Y1
Shimomura, H1
Tsunoda, R1
Maruyama, H1
Hirose, T1
Yamamoto, K2
Mizobe, M1
Kaikita, K1
Nakamura, S1
Rudež, G1
Leebeek, FW1
ten Cate, H1
de Maat, MP1
Felmeden, DC1
Dwivedi, G1
Hermanides, RS2
Brieger, D1
Mercadier, A1
Lancar, R1
Costagliola, D1
Leontiadis, GI1
Howden, CW1
Siha, H2
Chung, WY1
Kim, BO1
Park, SH1
Wouter Jukema, J1
De Luca, L1
Fichtlscherer, S1
Werner, G1
Schöller, R1
Darius, H2
Morange, PE6
Alessi, MC7
Delaney, JT1
Ramirez, AH1
Bowton, E1
Pulley, JM1
Basford, MA1
Schildcrout, JS1
Zink, R1
Oetjens, M1
Cleator, JH1
Jahangir, E1
Ritchie, MD1
Masys, DR1
Crawford, DC1
Krasznai, Z1
Toth, P1
Aihara, H1
Takeyasu, N1
Nishina, H1
Akiyama, D1
Kakefuda, Y1
Watabe, H1
Calvi, V1
Conti, G1
Canali, E1
Stio, R1
Lucisano, L1
Calcagno, S1
de Carlo, C1
Fedele, F1
Clare, R1
Kilhamn, J1
Shuldiner, AR1
Powers, D1
Akkus, NI1
Rajpal, S1
Agnani, S1
Rollini, F1
Wiesemann, S1
Passlick, B1
Zhou, YH1
Wei, X1
Lu, J1
Ye, XF1
Wu, MJ1
Xu, JF1
Qin, YY1
Perera, M1
Suarez, A1
Luzardo, H1
Molero, T1
Duerschmied, D1
Ahrens, I1
Mauler, M1
Brandt, C1
Weidner, S1
Stankovic, S2
Trifunovic, D1
Majkic-Singh, N1
Ignjatovic, S1
Matic, D1
Chang, SA1
Lee, SC1
Choe, YH1
Oh, JK1
Monti, M2
Castriota, F1
Colombo, F1
Fucà, G1
Smith, LG1
Tannenbaum, MA1
Johnson Brown, S1
Poulose, AK1
Iannone, LA1
Ghali, MG1
Gambetti, S1
Bristot, L1
Magielski, P1
Gierach, J1
Odrowaz-Sypniewska, G1
Paré, G1
Simonsen, KL1
Emison, ES1
Bhakta, N1
Flather, MD5
Mak, KH5
Cacoub, P4
Creager, MA5
Murugesan, G1
Kottke-Marchant, K1
Reese, ES1
Daniel Mullins, C1
Beitelshees, AL1
Onukwugha, E1
Jia, XQ1
Dong, CM1
Häuptle, R1
Weilenmann, D1
Schneider, T1
Haile, SR1
Ammann, P1
Knellwolf, C1
Borovicka, J1
Fosbol, EL1
Mills, RM1
Klaskala, W1
Latry, P1
Martin-Latry, K1
Lafitte, M1
Peter, C1
Couffinhal, T1
Codner, P1
Rechavia, E1
Iakobishvili, Z1
Hasdai, D2
Battler, A2
Berbis, J1
Laine, M1
Armero, S1
Bessereau, J1
Jacquin, L1
Bonello, C1
Camillieri, E1
Dignat-George, F2
Das, D1
Łaszewska, A1
Doğan, A2
Icli, A1
Varol, E1
Erdogan, D1
Subban, V1
Kalidoss, L1
Sankardas, MA1
Khurmi, NS1
Keltai, M5
Raev, D1
Lopez-Sendon, JL3
Goy, JJ1
Duvoisin, N1
Bauer, ME1
Bauer, ST1
Rabbani, AB1
Mhyre, JM1
Steg, GW1
Dietrich, M1
Gallup, D1
Tada, T2
Natsuaki, M1
Morimoto, T1
Furukawa, Y1
Nakagawa, Y1
Kadota, K1
Iwabuchi, M1
Shizuta, S1
Tazaki, J1
Shiomi, H1
Abe, M1
Ehara, N1
Mizoguchi, T1
Mitsuoka, H1
Inada, T1
Araki, M1
Kaburagi, S1
Taniguchi, R1
Eizawa, H1
Nakano, A1
Suwa, S1
Takizawa, A1
Nohara, R1
Fujiwara, H2
Mitsudo, K1
Nobuyoshi, M1
Kita, T1
Thompson, VP1
McClure, MW1
Gretler, DD1
Berdan, LG1
Paynter, G1
Damelou, A2
Theodoropoulos, KC2
Kassimis, G2
Chouchoulis, K1
Chiladakis, J1
Lawler, E1
Gaziano, M1
Riegger, J1
Joner, M2
Okrojek, R1
Kim, DI1
Chung, SR2
Seol, SH1
Nam, CW1
Kim, W1
Ueno, T2
Igarashi, K1
Kobayashi, M1
Diego, A1
de Prado, AP1
Cuellas, C1
de Miguel, A1
Samaniego, B1
Alonso-Rodríguez, D1
Bangueses, R1
Vega, B1
Martín, J1
Fernandez-Vazquez, F1
Konosic, S1
Roubille, F1
Lairez, O1
Mewton, N1
Rioufol, G1
Ranc, S1
Sanchez, I1
Cung, TT1
Elbaz, M1
Piot, C1
Ovize, M1
Nikolic, E1
Hauch, O1
Henriksson, M1
Meen, O1
Brosstad, F2
Liestøl, K1
Kunszt, G1
Bendz, B1
Wettergreen, M1
Schjelderup, NM1
Andreassen, T1
Erikssen, G1
Peace, AJ1
Dushpanova, A1
Duggan, SM1
Aresu, G1
de Siena, PM1
Glauber, M1
Caputo, M1
Barn, K1
Oh, BH1
Park, YB1
Hess, S1
Reydel, A1
Douglas, IJ1
Evans, SJ1
Hingorani, AD1
Grosso, AM1
Smeeth, L1
Choi, YH1
Suh, SH1
Choi, JS1
Kim, CS1
Bae, EH1
Lim, SY1
Ma, SK1
Kim, SW1
Funk, M1
Nolin, TD1
Nielsen, LH1
Lindhardsen, J1
Olsen, AM1
Durak, M1
Lech, P1
Rosławiecka, A1
Palacio, S1
Pearce, LA1
Benavente, OR1
Geng, DF1
Jin, DM1
Wu, W1
Deng, J1
Wang, JF1
Valeeva, DD1
Minnetdinov, RSh1
Arkhipova, AA1
Akhmetov, II1
Galiavi, RA1
Jiang, J2
Xiang, MX1
Dong, L1
Liu, XB1
Hu, XY1
Feng, Y1
Wang, JA1
Tai, BC1
Sia, W1
Phua, QH1
Richards, MA1
Low, A1
Chan, KH1
Teo, SG1
Sim, TB1
Yeo, TC1
Colantonio, R1
Rotolo, F1
Monti, F1
Boggi, A1
Serdoz, R2
Yano, H1
Tsukahara, K1
Morita, S1
Endo, T1
Sugano, T2
Hibi, K1
Himeno, H1
Fukui, K1
Umemura, S1
Kimura, K1
Kang, GH1
Ahn, KT1
Lim, WH1
Ruwald, MH1
Hansen, CM1
Menees, DS1
Renda, G3
Vavalle, JP1
Meade, T1
Parkhomenko, A1
Topacio, GO1
Goudev, AR1
Tseng, CD1
Gasparovic, V1
Cinteză, M1
McLendon, RC1
Stavrou, EF1
Athanassiadou, A1
Moon, JH1
Verschuren, JJ1
Boden, H1
Wessels, JA1
van der Hoeven, BL2
Trompet, S1
Heijmans, BT1
Putter, H2
Guchelaar, HJ1
Schalij, MJ3
Jukema, JW2
Jing, Q1
Yan, G1
Ma, Y1
Wang, G1
Chen, X1
Zhu, G1
Liu, H1
Jiang, T1
Lyngbæk, S1
Nguyen, CD1
Nielsen, M1
Ament, PW1
Dicola, DB1
James, ME1
Fort, JG1
Plachetka, JR1
Qian, J1
Sun, A1
Ge, J1
Iversen, AZ1
Iancu, A1
Ober, C1
Bondor, CI1
Cadiş, H1
Zuckerman, IH1
Yin, X1
Rattinger, GB1
Gottlieb, SS1
Simoni-Wastila, L1
Pierce, SA1
Huang, TY1
Shenolikar, R1
Stuart, B1
Bozbeyoglu, E1
Satilmis, S1
Aksu, H1
Yildirimturk, O1
Nurkalem, Z1
Tanahashi, N1
Minematsu, K1
Fischer, MA1
Avorn, JL1
Lee, JL1
Solomon, DH1
Berman, C1
Jan, S1
Lii, J1
Mahoney, JJ1
Shrank, WH1
Paulu, P1
Minarik, M1
Benesova, L1
Gharacholou, SM1
Brodie, B1
Pokharel, Y1
Garg, A1
Kissling, G1
Hansen, C1
Milks, S1
Cooper, M1
McAlhany, C1
Fnais, N1
Alshaikh, M1
Yao, Z1
Juurlink, D1
Mamdani, M1
Do, U1
Kim, HJ1
Meyer, S1
Neely, M1
Zhou, C1
Elhadad, S1
Van Belle, E1
Rousseau, H1
Aubry, P3
Monségu, J1
Sabouret, P1
Lala, A1
Sharma, G1
Scott Braithwaite, R1
Ladapo, JA1
Sachdeva, A1
Bavisetty, S1
Beckham, G1
Leon, M1
Moore, N1
Contreras, R1
Yang, LX1
Liu, HL1
Qu, P1
Li, WM1
Jiang, TM1
Li, SM1
Zhang, QY1
Svetina, L1
Fihn, SD3
Gardin, JM1
Abrams, J1
Berra, K1
Dallas, AP1
Douglas, PS1
Gerber, TC1
Hinderliter, AL1
Kligfield, PD1
Kwong, RY1
Lim, MJ2
Linderbaum, JA1
Munger, MA2
Prager, RL1
Sabik, JF1
Shaw, LJ1
Sikkema, JD1
Smith, CR1
Smith, SC6
Williams, SV1
Argay, M1
Koós, I1
Takács, I1
Dormaeva, I1
Meskó, A1
Zelkó, R1
Hankó, B1
Fries, S1
Lawson, JA1
Kapoor, SC1
Grant, GR1
FitzGerald, GA3
Nührenberg, TG1
Leggewie, S1
Ristau, I1
Funck-Jensen, KL1
Dalsgaard, J1
Yamagishi, M1
Hara, K1
Itoh, T1
Hamanaka, I1
Wakatsuki, T2
Kawai, K1
Yang, XM1
Cui, L1
Yang, X1
Tandon, N1
Kambayashi, J1
Downey, JM1
Cohen, MV1
Capuano, F1
Loirat, P1
Desplanques-Leperre, A1
Derumeaux, G1
Thebaut, JF1
Gardel, C1
Grenier, C1
Ohkubo, K1
Fujimoto, Y1
Iwata, Y1
Kitahara, H1
Kadohira, T1
Sugimoto, K1
Morino, T1
Kobayashi, Y1
Reyes, E1
Maurer, G1
Ang, L1
Thani, KB1
Ilapakurti, M1
Palakodeti, V1
Mahmud, E1
Cucherat, M1
Jacq, L1
Bernasconi, F1
Ziegelstein, RC2
Han, JL1
Li, HY1
Qiao, R1
Zeng, H1
Andrade, C1
Lynch, DR1
Dantzler, DM1
Sumaya, W1
Daly, RL1
Mehra, S1
Dhutia, AJ1
Howgego, KE1
Ecob, R1
Judge, HM1
Morton, AC1
Park, JB1
Choi, WG1
Kim, SY1
Park, J1
Quilici, J6
Loosveld, M1
Camoin, L1
Moro, PJ1
Saut, N1
Gaborit, B1
Pankert, M1
Cohen, W1
Lambert, M4
Beguin, S1
Bonnet, JL6
Bacci, MR1
Santos, JA1
Nogueira, LF1
Namura, JJ1
Mahabaleshwarkar, RK1
Datar, MV1
Bentley, JP1
Strum, MW1
Banahan, BF1
Null, KD1
Carlquist, JF1
Knight, S1
Horne, BD1
Huntinghouse, JA1
Rollo, JS1
May, H1
Anderson, JL1
Cvetinovic, N1
Stojanovic, M1
Solmaz, H1
Korkmaz, H1
Yavuzkir, MF1
Kaya, OK1
Kurtoğlu, E1
Kuzu, Z1
Karadağ, MK1
Uysal, A1
Itagaki, BK1
López Bescós, L1
Arós Borau, F1
Lidón Corbi, RM1
Cequier Fillat, A1
Alonso, JJ1
Coma Canella, I1
Loma-Osorio, A1
Bayón Fernández, J1
Masiá Martorell, R1
Tuñón Fernández, J1
Fernández-Ortiz, A3
Marrugat De La Iglesia, J1
Palencia Pérez, M1
Malinin, AI1
Callahan, KP1
Moschi, G2
Trapani, M1
Cerisano, G1
Santoro, GM1
Marso, SP1
Hirsch, AT3
Ringleb, PA3
Beasley, JW1
Cheitlin, MD1
Jones, RH1
Kereiakes, D1
Kupersmith, J1
Levin, TN1
Pepine, CJ4
Schaeffer, JW1
Smith, EE1
Steward, DE1
Theroux, P4
Gibbons, RJ1
Alpert, JS1
Gregoratos, G1
Hiratzka, LF1
Jacobs, AK1
Sabatier, R1
Boccanelli, A2
Talbert, RL1
Spinler, SA3
Nappi, JM2
Bottorff, MB1
Davidson, CJ1
Valentín Segura, V1
Howard, PA2
Mann, JT1
Fry, ET1
DeLago, A1
Wilmer, C1
Kübler, W2
Jagroop, IA1
Mikhailidis, DP1
Dauterman, K1
Topol, E2
Zaliūnas, R1
Armstrong, EC1
Hughes, K1
Zhao, F5
Commerford, PJ2
Blumenthal, M1
Wittlinger, T1
Gille, J1
Bernotat, J1
Böhm, S1
Behrens, P1
Löhr, JF1
Meyer, BJ2
Dörffler-Melly, J1
Schmidli, J1
Mahler, F1
Flather, M1
Popma, J1
Bartolozzi, JJ1
Price, WF1
Sauls, FC1
Tani, S1
Kanmatsuse, K1
Ishikawa, K2
Sionis, A1
Ziegler, BK1
Rasmussen, LH1
Hildebrandt, PR1
Nielsen, HK1
Husted, SE1
Schroeder, WS1
Gandhi, PJ1
Fries, R1
Böhm, M1
Valettas, N1
Nishiyama, A1
Niikawa, O1
Mohri, H1
Tsushima, M1
Rogan, SV1
Arablinskiĭ, AV1
Solov'ev, OP1
Aronow, HD1
Cura, FA1
Albirini, A1
Schneider, JP2
Ellis, SG4
Brennan, D2
Mathew, V2
Pasternak, R1
Martín, M1
Romero, E1
Morís, C1
Averkov, OV3
Di Chiara, A1
Chiarella, F1
Lucci, D1
Greco, C2
Zonzin, P1
Coccolini, S1
Maggioni, AP2
Lewis, BS5
Kopecky, SL1
Valentin, V2
Chan, AW1
DiBattiste, PM1
Yakubov, SL1
Sapp, SK2
Wolski, K1
Campbell, ME2
Aronow, WS1
Wojakowski, W1
Slavina, NN2
Gratsianskiĭ, NA2
Gaiba, W1
Neri, S1
Marrozzini, C1
Aquilina, M1
Igaki, N1
Matsuda, T1
Yatani, H1
Kawaguchi, T1
Kida, A1
Yanase, K1
Moriguchi, R1
Sakai, M1
Tamada, F1
Goto, T1
Shennib, H1
Endo, M1
Benhameid, O1
Schühlen, H6
Bollwein, H4
Volmer, C2
Gawaz, M2
Lange, RA2
Hillis, LD2
Teal, PA1
Dalby, M1
Soulat, T1
Choussat, R4
Drobinski, G2
Mintz, GS1
Song, JM1
Kang, DH1
Song, JK1
Orford, JL1
Fasseas, P1
Melby, S2
Burger, K1
Grau, AJ1
Boddy, AW1
Dukovic, DA1
Buggle, F1
Lichy, C1
Brandt, T1
Chen, WH2
Lee, PY1
Ng, W1
Tse, HF1
Lau, CP1
Rodgers, JE1
Rozenman, Y1
Golmard, JL1
Tanguy, ML2
Ankri, A2
Vignolles, N1
Taylor, AJ1
Al-Saadi, N1
Abdel-Aty, H1
Schulz-Menger, J1
Messroghli, DR1
Friedrich, MG1
Steimle, AE1
Xiao, Z1
Bennett, SK1
Redberg, RF1
Shechter, M1
Bienart, R1
Goldenberg, I1
Pres, H1
Banas, JS1
Wienbergen, H3
Schiele, R1
Heer, T4
Vogel, C1
Gottwik, M4
Herbert, JM2
Savi, P1
Müller, I1
Besta, F1
Otterstad, JE1
Bergovec, M1
Best, PJ2
Markovic, SN1
SoRelle, R1
Hashiguchi, M1
Ohno, K1
Nakazawa, R1
Kishino, S1
Mochizuki, M1
Shiga, T1
van der Heijden, DJ1
Westendorp, IC1
van der Wieken, LR1
Stadius, ML1
Sawhney, N1
Kuntz, RE3
Bachinsky, W1
Bass, T1
DeMaio, S1
Fry, E1
Aghababian, RV1
Boucher, M1
Pharand, C1
Skidmore, B1
Wolski, KE1
Frossard, M1
Fuchs, I1
Leitner, JM1
Hsieh, K1
Vlcek, M1
Losert, H1
Domanovits, H1
Schreiber, W1
Laggner, AN1
Hagymási, K1
Vorob'eva, NM1
Sereshcheva, AKh1
Petrik, ES1
Akinina, SA1
Schwaab, B1
Ernst, NM1
Miedema, K2
Meade, TW1
Vorchheimer, DA1
Guyatt, GH1
Goodman, SD1
Wilcox, RG2
Schünemann, HJ2
Stein, PD1
Dalen, JE2
Gutterman, D1
Choudhury, A1
Kim, MC1
Fisher, E1
Steinheimer, AM1
Schwimmbeck, PL1
Diehm, C1
Lawall, H1
Huber, R1
Füessl, HS1
Dibra, A2
von Beckerath, N3
Berger, PP1
Schnell, O1
Standl, E1
Woodward, M1
Lowe, GD1
Francis, LM1
Rumley, A1
Cobbe, SM1
Nicholls, C1
Sani, M1
Garcia, S1
Canoniero, MJ1
Chirinos, JA1
de Marchena, E1
Salerno, T1
Ferreira, A1
Lamy, A3
Jönsson, B3
Culler, S3
Gafni, A1
Lindgren, P4
Mahoney, E1
Kline-Rogers, E2
Fang, J1
Munir, K1
Feldmann, C1
Deutsch, HJ1
Schellinger, PD1
Rajagopal, V1
Danna, P1
Piccaluga, E1
Viecca, M1
Katayama, T2
Nakashima, H2
Takagi, C2
Honda, Y2
Yano, K2
Denardo, SJ1
Davis, KE1
Cowper, PA1
Udayakumar, K1
Sketch, MH1
Waskowsky, WM1
Brouwer, A1
Schleinitz, MD1
Spencer, FA1
Gore, JM1
Dabbous, OH1
Agnelli, G1
Kline-Rogers, EM1
Dibenedetto, D1
Schmitt, C2
Zaman, KA1
Yoho, JA1
Hayes, KM1
Pepe, LL1
Cools, F1
Hill, KA1
Skene, AM1
Yuan, Y2
Caro, J3
Gabriel, S3
Eryonucu, B1
Tuncer, M1
Erkoc, R1
Pettersen, AA1
Abdelnoor, M1
Buresly, K1
Eisenberg, MJ1
Chyrchel, M1
Rzeszutko, L1
Kawata, M1
Kuramoto, E1
Kataoka, T1
Saito, A1
Adachi, K1
Matsuura, A1
Sakamoto, S1
Dieker, H1
Aengevaeren, WR1
Kunz, I1
Spada, S1
Sütsch, G1
Ruggieri, F1
Elsässer, A1
Nef, H1
Gluckman, TJ1
Rade, JJ1
Schulman, SP1
Hansen, DB1
O'Neill, W1
Lo, C1
Babor, EM1
Akowuah, E1
Shrivastava, V1
Jamnadas, B1
Hopkinson, D1
Sarkar, P1
Storey, R1
Braidley, P1
Cooper, G1
Fathi, RB1
Ozgul, M1
Ozaydin, M1
Aslan, SM1
Gedikli, O1
Altinbas, A1
McCollam, P1
Etemad, L1
Rubboli, A1
Milandri, M1
Castelvetri, C1
Cosmi, B1
Doggrell, SA2
Sciagrà, R1
Memisha, G1
Pupi, A1
Beinart, SC1
Veledar, E1
Bouin, O1
Michowitz, Y1
Blatt, A1
Frimmerman, A1
Massachi, R1
Herz, I1
Krakover, R1
Miller, H1
Keren, G1
George, J1
Iwasaki, Y1
Leoncini, M1
Maioli, M1
Bellandi, F1
Badia, T1
Politi, A1
Dabizzi, RP1
Black, HR3
Cohen, EA4
Haffner, SM2
Mas, JL4
Pearson, TA4
Weber, MA3
Booth, J2
Eriksson, P1
Rothberg, M1
Kaneda, H1
Suzuki, J1
Hosokawa, G1
Tanaka, S2
Hiroe, Y1
Ouriel, K2
Wholey, MH1
Fayad, P1
Katzen, BT1
Whitlow, P1
Frentzko, M1
Wechsler, L1
Hopkins, N1
Satler, L1
Mishkel, G1
Yadav, JS1
Blann, A1
Di Nisio, M1
Bijsterveld, NR1
Meijers, JC1
Levi, M1
Büller, HR1
Palabrica, TM1
Burton, PB1
Altman, R1
Gulec, S2
Ozdol, C2
Rahimov, U2
Atmaca, Y2
Kumbasar, D1
Erol, C2
Ringborg, A1
Chen, ZM1
Jiang, LX1
Chen, YP1
Xie, JX1
Pan, HC1
Peto, R1
Collins, R2
Liu, LS1
Gill, SS1
Dellborg, M1
Zhao, JL2
Wu, YJ2
Jing, ZC2
You, SJ2
Yang, WX2
Meng, L3
Tian, Y1
Chen, JL1
Chen, ZJ1
Maslow, A1
Bert, A1
Ng, T1
Halon, DA1
Mehta, S1
Biondi-Zoccai, GG1
Abbate, A1
Garcia-Pavia, P1
Aguiar-Souto, P1
Silva-Melchor, L1
Wang, YW1
Gurbuz, AT1
Zia, AA1
Vuran, AC1
Cui, H1
Aytac, A1
Chen, YG1
Xu, F1
Ji, QS1
Lü, RJ1
Li, RJ1
Tulsyan, N1
Kashyap, VS1
Borja, J1
García, O1
Donado, E1
Izquierdo, I1
Bhala, N1
Taggar, J1
Karthikeyan, G1
Asaro, PV1
Sheldahl, AL1
Char, DM1
Fabry-Ribaudo, L2
Ibrahim, M1
Urban, P1
Guyon, P1
Schofer, J1
Seth, A1
Sousa, JE1
Berge, C1
Deme, M1
Stoll, HP1
Bilsel, T1
Akbulut, T1
Yesilcimen, K1
Terzi, S1
Dayi, SU1
Akgoz, H1
Ciloglu, F1
Casella, G1
Di Pasquale, G1
Schaefer, A1
Stumme, B1
Drexler, H1
von Depka, M1
Mulgund, J3
Ikeda, U1
Calvet, D1
Touzé, E1
Di Pasquale, P1
Cannizzaro, S1
Giambanco, F1
Fasullo, S1
Scalzo, S1
Ganci, F1
La Manna, N1
Sarullo, F1
La Rocca, G1
Paterna, S1
Jaarsma, W1
Hautvast, RW2
Drozdz, J1
Rasoul, S1
Gosselink, M1
Buller, CE2
Pate, GE1
O'Neill, BJ1
Gallo, R1
Kettelkamp, R1
Vance, C1
Jones, PG1
Khanal, S1
Kaya, D1
Celik, A1
Avsar, A1
Kirk, JD1
Vafai, JJ1
Aroesty, JM2
Latsios, G1
Aggelis, D1
Bosinakou, I1
Karambelas, I1
Toutouzas, K1
Ishikawa, T1
Mutoh, M1
Fuda, Y1
Sakamoto, H1
Higashitani, M1
Nakano, Y1
Yamaguchi, J1
Enta, K1
Satoh, T1
Imai, K1
Horie, T1
Mochizuki, S1
Hamdalla, H1
Sulimov, VA1
Malova, EV1
Syrkin, AL1
Giliarov, MIu1
Novikova, NA1
Mannini, L1
Antonucci, E1
Prisco, D1
Garton, M1
Fesmire, FM1
Decker, WW1
Ghaemmaghami, CA1
Nazarian, D1
Brady, WJ1
Hahn, S1
Jagoda, AS1
Meuleman, C1
Bal-dit-Sollier, C1
Lellouche, N1
Slama, M1
Milleron, O1
Ly, HQ1
Ciaglo, LN2
Southard, MC2
Stein, EB2
Buros, JL2
Beyar, R1
Riesmeyer, J2
Warmke, JW1
Pamukcu, B2
Oflaz, H2
Oncul, A2
Umman, B3
Mercanoglu, F2
Ozcan, M2
Meric, M2
Nisanci, Y3
Frere, C4
Nait-Saidi, L2
Carvajal, J2
Lehmann, A1
Kjaer, J1
Larsen, CH1
Poulsen, TS1
Møller, JE1
Mickley, H1
Lytle, BL1
Brindis, RG1
Fintel, D1
Fraulo, ES1
Mayr, FB1
Jünger, C3
Bromberg-Marin, G1
Parsons, LS1
Canto, JG1
Rogers, WJ1
Chrissoheris, MP1
Mruthyunjayanna, V1
Donohue, TJ1
Cheng, X1
Saidi, LN2
Mouret, JP1
Karabatsou, K1
Das, K1
Rainov, NG1
Radke, PW1
Sharifkazemi, MB1
Zamirian, M1
Aslani, A1
Jabaren, M1
Desai, DM1
Arabi, A1
Kareti, G1
Chen-Scarabelli, C1
Rosman, HS1
Gochi, T1
Umeda, H1
Yoshida, N1
Maekawa, H1
Watanabe, K1
Okada, T1
Katoh, T1
Asai, T1
Tani, T1
Yokoya, M1
Murakami, Y1
Matsushita, T1
Shimizu, T1
Ozaki, Y1
Hiramitsu, S1
Nomura, M1
Morimoto, S1
Hishida, H1
Kong, DF1
Shaw, LK1
Tuttle, RH1
Mark, DB1
Kramer, JM1
Matchar, DB2
Turhan, S1
Soulat, L1
Adgey, J1
Köster, R1
Bochenek, A1
Wilczyński, M1
Pfisterer, M2
Brunner-La Rocca, HP1
Buser, PT1
Rickenbacher, P1
Hunziker, P1
Mueller, C1
Jeger, R1
Bader, F1
Kaiser, C1
Tang, WH1
McErlean, E1
Maroo, A1
Francis, GS1
Alviar, CL1
Arikan, ME1
Dave, BP1
Granada, JF1
DeLao, T1
Tellez, A1
Maresh, K1
Boulé, S1
Gongora, A1
Randriamora, M1
Adala, D1
Courteaux, C1
Taghipour, K1
Rifaï, A1
Bearez, E1
Hannebicque, G1
Brüggenjürgen, B1
Ehlken, B1
Willich, SN1
Dickie, JS1
Scott, LJ1
Mathias, J1
Tolleson, TR1
O'Shea, JC1
Ornato, JP1
Mielot, C1
Bali, L2
Porela, P1
Ylitalo, A1
Vikman, S1
Nyman, K1
Vaittinen, MA1
Airaksinen, TJ1
Niemelä, M1
Vahlberg, T1
Onur, I1
Dániel, A1
Gordon, P1
O'Neill, B1
McLean, DS1
Guo, W2
Tran, H1
Stellbaum, C1
Willich, T1
Boltzen, U1
Ayral, Y1
Szotowski, B1
Piorkowski, M1
Schultheiss, HP1
Rauch, U1
Viellard, C1
Faure, A1
Desprez, D1
Chauvin, M1
Roul, G1
Grunebaum, L1
Bareiss, P1
Radojković, DD1
Perisić, Z1
Tomasević, M1
Janković, R1
Damjanović, M1
Martinović, SS1
Bozinović, N1
Milenković, D1
Emmons, KL1
Taylor, NR1
Aleil, B1
Rochoux, G1
Monassier, JP2
Cazenave, JP1
Malek, LA1
Grabowski, M1
Szpotanska, M1
Imiela, T1
Bobilewicz, D1
Szabo, S1
Oikonomopoulos, T1
Hoffmeister, HM1
Daemen, J1
Tanimoto, S1
García-García, HM1
Kukreja, N1
van de Sande, M1
Sianos, G1
de Jaegere, PP1
van Domburg, RT1
Bartorelli, AL1
Trabattoni, D1
Galassi, A1
Sheiban, I2
Piovaccari, G2
Zimarino, M2
Benassi, A2
Di Mario, C1
Chierchia, S1
Finn, AV1
Nakazawa, G1
Kolodgie, F1
Newell, J1
John, MC1
Gold, HK1
Virmani, R1
Liu, QZ1
Hong, T1
Liu, ZP1
Shi, LB1
Sheng, QH1
Gong, YJ1
Huo, Y1
Tonelli, M1
Mann, JF1
Sitkei, E1
Hawken, S1
Catineau, J1
Lapandry, C1
Adnet, F1
von Beckerath, O1
Eigenthaler, M1
Karlsson, G1
Rehman, J1
Kalaria, V1
Hu, T1
Kikano, GE1
Brown, MT1
Majdoub, MA1
Sauguet, A1
Tchetche, D1
Benamer, H1
Himbert, D1
Feldman, LJ1
Juliard, JM3
Dalby, A1
Duris, T1
Gao, R1
Blancas Gómez-Casero, R1
Nevado Losada, E1
López Matamala, B1
Martínez Díaz, C1
Serrano Castañeda, J1
Yáñez Parareda, E1
González Manzanares, JL1
Chana García, M1
Martín Delgado, C1
Jiménez-Quevedo, P2
Hernández-Antolín, R2
SanMartín, M1
Bañuelos, C2
Escaned, J2
Moreno, R2
Fernández, C1
Fernández-Avilés, F1
Macaya, C3
Aurier, E1
Cremonesi, A1
Grilli, R1
Maresta, A1
Kupferwasser, LI1
Amorn, AM1
Kapoor, N1
Kar, S1
Cercek, B1
Dohad, S1
Mirocha, J1
Forrester, JS1
Shah, PK1
Makkar, RR1
Yip, HK2
Youssef, AA1
Chang, LT1
Yang, CH1
Sheu, JJ1
Chua, S1
Yeh, KH1
Lee, FY1
Hang, CL2
Chappell, LT1
Collins, JS1
El-Shahed, G1
Awadalla, H1
Amin, M1
El-Hammady, W1
Ayoub, A1
Mardikar, HM1
Hiremath, MS1
Mathew, R1
Arora, R1
Deo, D1
Hiremath, JS1
Deshpande, NV1
Khan, A1
Joseph, J1
Baglini, R1
Mezzapelle, G1
Baldari, D1
Boztosun, B1
Olcay, A1
Avci, A1
Kirma, C1
Stiefelhagen, P1
Wang, TH1
Berg, J1
Spiesser, J1
Parry, D1
Tomaszuk-Kazberuk, A1
Sobkowicz, B1
Usowicz-Szaryńska, M1
Prokop, JB1
Knapp, M1
Sawicki, R1
Musiał, WJ1
Helton, TJ1
Bavry, AA1
Kumbhani, DJ1
Duggal, S1
Roukoz, H1
Unverdorben, M1
Degenhardt, R1
Wiemer, M1
Horstkotte, D1
Schneider, H1
Nienaber, C1
Bocksch, W1
Gross, M1
Boxberger, M1
Vallbracht, C1
Jakabcin, J1
Bystron, M1
Spacek, R1
Veselka, J1
Kvasnak, M1
Kala, P2
Malý, J1
Cervinka, P1
Gabriel, RS1
Sezer, M1
Okcular, I1
Umman, S1
Kalyanasundaram, A1
Makrygiannis, SS1
Handanis, SM1
Prekates, AA1
Pissimissis, EG1
Olympios, CD1
Barnes, GD1
Vedre, A1
Armstrong, DF1
Froehlich, JB1
Ferguson, JJ4
Wilson, JM1
Diez, J1
Köth, O1
Richard Conti, C1
Bernardo, E1
Costa, MA1
Palazuelos, J1
Guzman, LA1
Schmaier, AH1
Motivala, AA1
Tamhane, U1
Saab, F1
Rogers, EK1
Froehlich, J1
Moscucci, M1
Bryson, CL1
Lowy, E1
Maynard, C1
Jesse, RL1
Mann, KG1
Heptinstall, S1
Peters, G1
Wickens, M1
Gurbel, P2
Grande, P1
Recio-Mayoral, A1
Kaski, JC1
McMurray, JJ1
Horowitz, J1
van Veldhuisen, DJ1
Remme, WJ1
Shin, M1
Ahn, M1
Choe, H1
Choe, KH1
Berger, K1
Hessel, F1
Kreuzer, J1
Smala, A1
Miller, DL1
Cairns, R1
Konopka, A1
Spychalska, J1
Sitkiewicz, D1
Zdebska, E1
Pilichowska, I1
Piotrowski, W1
Stepińska, J1
Conroy, M1
Bolsin, SN1
Black, SA1
Orford, N1
Simmons, BB1
Salzman, BE1
Johnson, SG1
Rogers, K1
Delate, T1
Witt, DM1
Arnaud, B1
Cornily, JC1
Le Gal, G1
Lacut, K1
Le Calvez, G1
Mansourati, J1
Mottier, D1
Abgrall, JF1
Boschat, J1
Sacchetta, D1
White, H1
Aylward, PG1
Fares, RR1
Lansing, LS1
Gallati, CA1
Mousa, SA1
Decalf, V1
Sabbah, L1
Lafont, A1
Durand, E1
Worster, A1
Keim, SM1
Vadera, R1
Rosen, P1
Lord, E1
Shui, A1
Zimetbaum, PJ1
Josephson, ME1
Peels, JO1
de Swart, JB1
Huybregts, MA1
Umans, VA1
Arnold, AE1
Jessurun, GA1
Larsen, GC1
Jesse, RA1
Pershukov, IV1
Liem, SS1
Suraphakdee, N1
Dijkstra, J1
Atsma, DE1
Bootsma, M1
Zeppenfeld, K1
Oemrawsingh, PV2
van der Wall, EE2
Hoekstra, J1
Miller, CD1
Vik-Mo, H1
Slette, M1
Hegbom, K1
Brosh, D1
Fuchs, S1
Schaerlig, E1
Iqbal, MB1
Westwood, MA1
Swanton, RH1
Lefebvre, CW1
Hoekstra, JW1
Bonaca, M1
Giugliano, R1
Sacristán, D1
López-Farré, AJ1
Zamorano-León, JJ1
Azcona, L1
Romero, J1
Farré, J1
von Lewinski, F1
Riggert, J1
Paulus, W1
Fu, XH1
Hao, QQ1
Jia, XW1
Fan, WZ1
Gu, XS1
Wu, WL1
Hao, GZ1
Li, SQ1
Jiang, YF1
Geng, W1
Paska, T1
Szczech, LA1
Horvath, I1
Atiemo, AD1
Williams, MS1
Arques, S1
Boyer, C1
Panagides, D1
Wittenberg, O1
Simeoni, MC1
Andrade, J1
Al Ali, A1
Wong, GC1
Nielsen, AA1
Veien, KT1
Jørgensen, LG1
Buck, TC1
Brandslund, I1
Christensen, C1
Nagarakanti, R1
Sodhi, S1
Lee, R1
Srinivasan, M1
Smith, D1
Simek, S1
Pudil, R1
Holm, F1
Petr, R1
Bílková, D1
Skalická, H1
Kuchynka, P1
Poloczek, M1
Miklík, R1
Maly, M1
Aschermann, M1
Taubert, D1
Seesing, TH1
Schömig, E1
Al-Aqeedi, RF1
Al-Nabti, AD1
Angiolillo, D1
Bates, E1
Bhatt, D1
Furman, MI1
Peterson, E1
Fromm, MF1
Chialda, LE1
Pahl, A1
Schmiebusch, P1
Bestehorn, HP1
Voitk, J1
Hasin, Y1
Chandna, H1
Macias, W1
Alvarez, W1
Offerhaus, L1
Numano, F1
Avellone, G1
Mandalà, V1
Pinto, A1
Riolo, FP1
Davì, G1
Raneli, G1
Kawai, C1
Verstraete, M1
Suzuka, H1
Tanaka, M1
Yoshifusa, H1
Nakamura, Y1
Shibata, Y1
Hirata, Y1
Umemura, K1
Uematsu, T1
Nakashima, M1
McCrory, DC1
Barnett, HJ1
Feussner, JR1
Kanter, MC1
Sherman, DG1
Hosokawa, FG1
Kim, K1
Miyake, S1
Walter, H3
Zitzmann-Roth, EM1
Blasini, R1
Alt, E1
Toplak, H1
Bahadori, B1
Wascher, TC1
Catella-Lawson, F1
Kanamasa, K1
Hama, J1
Ogawa, I1
Takenaka, T1
Naito, T1
Yamamoto, T1
Nakai, S1
Oyaizu, M1
Kimura, A1
Katori, R1
Born, GV1
Patrono, C1
Elias, J1
Raynaud, P1
Cribier, A1
Faugier, JP1
Masquet, C1
Rioux, P1
Joly, P1
Petiteau, PY1
Royer, T1
Roriz, R1
Meyer, P1
Khalifé, K1
Sternon, J1
Anzuini, A1
Rosanio, S1
Tocchi, M1
Coppi, R1
Bonnier, H1
Kulbertus, HE1
Chierchia, SL1
Noth, J1
Janzon, L3
Gonzalez, ER1
Kannel, WB1
Olin, JW1
Raps, EC1
Udayachalerm, W1
Bruschke, AV1
Martínez Elbal, L1
López Mínguez, JR1
Alonso, M1
Calvo, I1
Insa, L1
Lezaun, R1
Colman, T1
Esplugas, E1
Vázquez, N1
Amaro, A1
Chabrillat, Y1
Amor, M1
Dumas, P1
Benveniste, E1
Asirvatham, S1
Sebastian, C2
Alvarez, JM1
Harper, RW1
Peverill, RE1
French, JK1
Ellis, CJ1
de May, MR1
Laramee, LA1
Leddy, D1
O'Brien, E1
Williams, WL1
Higginson, LA1
Jelley, J1
Reid, F1
Dippel, DW1
Lauer, MS1
Mukherjee, DP1
Scherlag, M1
Kugelmass, A1
Schechter, E1
Saucedo, J1
Greenberg, A1
Elezi, S1
Müller, A1
Grill, DE2
Chassany, O1
Narboux, S1
Cosson, S1
Caulin, C1
Thizon-de-Gaulle, I1
D'Sa, S1
Machin, SJ1
Kramer, JH1
Booth, JE1
Cabot, CF1
Cariou, R1
Kragten, J1
Wolf, JE1
Park, HK1
Jauhar, R1
Savino, S1
Deutsch, E2
Shaknovich, A1
Parikh, M1
Sanborn, TA1
Harker, LA2
Boissel, JP1
Pilgrim, AJ1
Gent, M2
Quinn, MJ1
Fitzgerald, DJ1
Meyer, MI1
Kuhn, M1
Bühler, H1
Bertschinger, P1
Eto, K1
Takeshita, S1
Oshima, A2
Kondo, K1
Sato, T1
Mitsuo, K1
Matsuda, K1
Holm, J1
Hillarp, A1
Erhardt, L1
Berntorp, E1
Avran, A1
Fourcade, L1
Bory, M1
Yoon, Y1
Lee, DH1
Pyun, WB1
Kim, IJ1
Cho, SY1
Algra, A1
van Gijn, J1
Kappelle, LJ1
Koudstaal, PJ1
Stam, J1
Vermeulen, M1
Caro, JJ1
Migliaccio-Walle, K1
Vyshlov, EV1
Panfilova, EV1
Markov, VA1
Weitz, JI1
Bates, SM1
Foussas, S1
Olympios, C1
Voudris, V1
Hatzimiltiadis, S1
Sionis, D1
Vavouranakis, E1
Vrahatis, A1
Fakiolas, C1
Pissimisis, E1
Stefanidis, A1
Zairis, M1
Vitakis, S1
Louridas, G1
Cokkinos, D1
Toutouzas, P1
Tanigawa, T1
Kitai, T1
Okinaka, T1
Makino, K1
Ito, M1
Isaka, N1
Shiku, H1
Nakano, T1
Oomen, PH1
Tulleken, JE1
Zijlstra, JG1
Fitzgerald, PJ1
Hayase, M1
Metz, JA1
Bailey, SR1
Baim, DS1
Cleman, MW1
Diver, DJ1
Oesterle, SN1
Overlie, PA1
Safian, RD1
Shani, J1
Smalling, RW1
Zidar, JP1
Yeung, AC1
Yock, PG1
Hohlfeld, T1
Rezig, K1
Diar, N1
Walcker, JL1
Moshfegh, K1
Redondo, M1
Julmy, F1
Wuillemin, WA1
Gebauer, MU1
Haeberli, A1
Peter, K1
Kohler, B1
Straub, A1
Ruef, J1
Nordt, T1
Olschewski, M1
Ohman, ME1
Elmi, F1
Peacock, T1
Schiavone, J1
Wilson, SH1
Reeder, GS1
Caplice, NM1
Kang, KT1
Kim, NH1
Bae, Y1
Chang, HW1
Chen, MC1
Fang, CY1
Hsieh, KY1
Son, JW1
Sohn, MS1
Jin, DK1
Park, GS1
Koh, KK1
Scrutinio, D2
Cimminiello, C1
Marubini, E1
Pitzalis, MV1
Di Biase, M1
Rizzon, P2
Mitka, M1
Einecke, D1
Hilleman, DE1
Mauro, VF1
Lopez, LM1
Gardner, SF1
Auer, J1
Berent, R1
Maurer, E1
Mayr, H1
Weber, T1
Eber, B1
Niessner, A1
Niessner, H1
Jackson, G1
Olson, J1
Huntington, J1
Malmberg, K1
Rupprecht, H1
Copland, I1
Haldemann, R1
Szucs, TD1
Robbins, MA1
Wehrmacher, WH1
Lowe, HC1
Kumar, RK1
Chesterman, CN1
Fahmy, RG1
Khachigian, LM1
Teuma, X1
Botosezzy, I1
Bouvier, JL1
Comet, B1
Commeau, P1
Macaluso, G1
Roquebert, PO1
Klinzing, P1
Markert, UR1
Liesaus, K1
Peiker, G1
Cerbone, AM1
Bradley, C1
Vera, M1
Pou, M1
Botey, A1
Cases, A1
Blankenberg, S1
Espinola-Klein, C1
Meyer, J1
Gerschutz, GP1
Haberl, R1
Harker, LB1
Salzman, EW1
Hattori, A1
Aosaki, M1
Iwade, K1
Kimata, S1
Hosoda, S1
Fazio, S1
Santomauro, M1
Cittadini, A1
Ferraro, S1
Lucariello, A1
Maddalena, G1
Sacca, L1
Lagioia, R1
Hayakawa, M1
Kuzuya, F1
Warlow, C1
Bergqvist, D1
Boberg, J1
Boberg, M1
Eriksson, I1
Lindgärde, F1
Persson, G1
Almgren, B1
Fagher, B1
Kjellström, T1
Blakely, JA1
Ellis, DJ1
Hachinski, VC1
Harbison, JW1
Panak, E1
Roberts, RS1
Sicurella, J1
Turpie, AG1
Ding, YA1
Lee, KW1
Liang, YB1
Chang, HC1
Lin, KC1
Hayashida, N1
Nechaev, DD1
Bochko, II1
Martynov, IV1
Kuz'mina, LF1
Tomoda, H1
Yokota, I1
Yamazaki, H1
Kawagoe, S1
Yamaguchi, A1
Munakata, J1
Kuroki, S1
Tanoue, K1
David, JL1
Knudsen, JB1
Kjøller, E1
Skagen, K1
Gormsen, J1

Clinical Trials (271)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Assessment of Loading With the P2Y12 Inhibitor Ticagrelor or Clopidogrel to Halt Ischemic Events in Patients Undergoing Elective Coronary Stenting: The ALPHEUS Study[NCT02617290]Phase 31,900 participants (Actual)Interventional2017-01-09Completed
A Randomized, Double-Blind, Double-Dummy, Active-controlled, Parallel-group, Multicenter Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Subjects With Acute Coronary Syndrom[NCT02293395]Phase 23,037 participants (Actual)Interventional2015-04-20Completed
Aspirin Versus Aspirin + ClopidogRel as Antithrombotic Treatment Following Transcatheter Aortic Valve Implantation With the Edwards Valve. A Randomized Study (the ARTE Trial)[NCT02640794]Phase 4222 participants (Actual)Interventional2015-01-31Completed
Aspirin Versus Aspirin + ClopidogRel as Antithrombotic Treatment Following Transcatheter Aortic Valve Implantation With the Edwards SAPIEN XT Valve. A Randomized Pilot Study (the ARTE Trial)[NCT01559298]Phase 4178 participants (Actual)Interventional2012-03-31Completed
PROlonging Dual Antiplatelet Treatment In Patients With Coronary Artery Disease After Graded Stent-induced Intimal Hyperplasia studY[NCT00611286]Phase 41,700 participants (Anticipated)Interventional2006-12-31Completed
Randomized 2x2 Factorial Trial Comparing the Cre8 Amphilimus-sirolimus Eluting Stent vs. the Synergy Everolimus-eluting Stent and a Personalized vs. Standard Duration of Dual Antiplatelet Therapy in All-comers Patients Undergoing Percutaneous Coronary Int[NCT04135989]Phase 42,106 participants (Anticipated)Interventional2020-01-01Active, not recruiting
Nobori Dual Antiplatelet Therapy as Appropriate Duration.[NCT01514227]Phase 43,773 participants (Actual)Interventional2011-12-31Completed
Correlation Between Bleeding Complication and Treatment Failure on P2Y12 Inhibitors and Its Predictions Based on Cipherome's Pharmacogenomic Technology[NCT04580602]200 participants (Actual)Observational2020-10-07Completed
Intensified Antiplatelet Therapy in Post-PCI Patients With High On-treatment Platelet Reactivity: the OPTIMA-2 Trial[NCT01955200]Phase 41,724 participants (Actual)Interventional2013-10-05Completed
Platelet Function Guided Prasugrel Therapy in ACS Patients Undergoing PCI[NCT01959451]Phase 42,600 participants (Actual)Interventional2013-09-30Completed
VerifyNow to Optimise Platelet Inhibition in Coronary Acute Syndrome (VERONICA Trial)[NCT04654052]Phase 4634 participants (Anticipated)Interventional2021-07-02Recruiting
Clopidogrel or Ticagrelor in Acute Coronary Syndrome Patients Treated With Newer-Generation Drug-Eluting Stents: CHANGE DAPT[NCT03197298]2,062 participants (Actual)Observational [Patient Registry]2012-12-21Completed
Impact of the Degree of Peri-Interventional Platelet Inhibition After Loading With Clopidogrel on Early Clinical Outcome of Elective Coronary Stent Placement[NCT00457236]800 participants Observational2003-03-31Active, not recruiting
Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial[NCT00991029]Phase 34,881 participants (Actual)Interventional2010-05-28Terminated (stopped due to The trial was halted by the DSMB.)
Trial of PCSK9 Inhibition in Patients With Acute Stroke and Symptomatic Intracranial Atherosclerosis - a Prospective, Randomized, Open-label, Blinded End-point Study With High-resolution MR Vessel Wall Imaging[NCT05001984]Phase 260 participants (Anticipated)Interventional2021-08-01Recruiting
Early Intensive Medical Therapy for the Prevention of Early Neurological Deterioration in Branch Atheromatous Disease[NCT04824911]Phase 2424 participants (Anticipated)Interventional2021-03-23Recruiting
Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin as Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKE (APS-STROKE)[NCT05995600]Phase 4400 participants (Anticipated)Interventional2023-12-31Not yet recruiting
Genotype Guided Antiplatelet Therapy In Ischemic Stroke[NCT05763862]350 participants (Anticipated)Interventional2023-04-24Recruiting
A REAl-life Study on Short-term Dual Antiplatelet Treatment in Patients With Ischemic Stroke or Transient Ischemic Attack[NCT05476081]1,067 participants (Anticipated)Observational [Patient Registry]2021-02-03Recruiting
The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin[NCT03869268]Phase 472 participants (Actual)Interventional2019-04-24Completed
PercutaNEOus Coronary Intervention Followed by Monotherapy INstead of Dual Antiplatelet Therapy in the SETting of Acute Coronary Syndromes: The NEO-MINDSET Trial A Drug Reduction Study for Patients With Acute Coronary Syndrome in the Unified Health System[NCT04360720]Phase 33,400 participants (Anticipated)Interventional2020-10-15Recruiting
GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation[NCT01813435]Phase 315,991 participants (Actual)Interventional2013-07-01Completed
Efficacy and Safety of Sequential Monotherapy of Ticagrelor and Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention With Acute Coronary Syndrome[NCT04937699]Phase 42,690 participants (Anticipated)Interventional2023-03-28Recruiting
Optimal Duration of Dual Antiplatelet Therapy After Drug Eluting Stent (DES) Implantation[NCT00822536]Phase 41,798 participants (Actual)Interventional2009-01-31Completed
STREAM (Strategic Reperfusion Early After Myocardial Infarction). Comparison of the Efficacy and Safety of a Strategy of Early Fibrinolytic Treatment With Tenecteplase and Additional Antiplatelet and Antithrombin Therapy Followed by Catheterisation Within[NCT00623623]Phase 31,899 participants (Actual)Interventional2008-03-01Completed
STrategic Reperfusion in Elderly Patients Early After Myocardial Infarction[NCT02777580]Phase 4609 participants (Actual)Interventional2017-08-01Active, not recruiting
Dapagliflozin Effects on Mayor Adverse Cardiovascular Events in Patients With Acute Myocardial Infarction (DAPA-AMI). Randomized Clinical Trial[NCT04717986]188 participants (Actual)Interventional2021-01-26Completed
Reperfusion Strategies in ST Elevation Myocardial Infarction Network - Sao Paulo Registry.[NCT02090712]3,000 participants (Anticipated)Observational [Patient Registry]2010-01-31Enrolling by invitation
REACTIC-TAVI Trial: Platelet REACtivity According to TICagrelor Dose After Transcatheter AorticValve Implantation. A Pilot Study.[NCT04331145]Phase 440 participants (Actual)Interventional2020-06-23Completed
A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects With Unstable Angina/Non-ST-Elevation Myocardial Infarction Who Are Medically Managed[NCT00699998]Phase 39,326 participants (Actual)Interventional2008-06-30Completed
Assessment of Platelet REACtivity After Transcatheter Aortic Valve Implantation[NCT02224066]Phase 465 participants (Actual)Interventional2016-01-31Completed
The GReek AntiPlatElet (GRAPE) Registry: A Multicenter Observational Prospective Investigation of Antiplatelet Treatment in Patients With Acute Coronary Syndrome Subjected to Percutaneous Coronary Intervention[NCT01774955]2,047 participants (Actual)Observational [Patient Registry]2012-02-29Completed
CathOlic Medical Center percutAneous Coronary inTervention Registry (COACT)[NCT01239914]11,719 participants (Actual)Observational2005-01-31Completed
Comparison of the Efficacy and Safety of New Platform Everolimus-eluting Coronary Stent System (Promus Element) With Zotarolimus-eluting Coronary Stent System (Endeavor Resolute) and Triple Anti-platelet Therapy With Double-dose Clopidogrel Anti-platelet [NCT01267734]Phase 43,750 participants (Anticipated)Interventional2010-06-30Recruiting
Study of the Efficacy and Safety of Cilostazol in the Prevention of Ischemic Vascular Events in Diabetic Patients With Symptomatic Peripheral Artery Disease.[NCT02983214]Phase 4826 participants (Actual)Interventional2016-11-30Completed
A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention[NCT00097591]Phase 313,619 participants (Actual)Interventional2004-11-30Completed
The Use of BRILInta to Optimize ANTiplatelet Therapy (BRILIANT) Registry: The BRILIANT KOREA Registry[NCT02521038]2,000 participants (Anticipated)Observational [Patient Registry]2015-07-31Recruiting
Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention[NCT02270242]Phase 49,006 participants (Actual)Interventional2015-07-31Completed
Optimized Duration of Clopidogrel Therapy Following Treatment With the Endeavor Zotarolimus - Eluting Stent in the Real World Clinical Practice - Optimize Trial[NCT01113372]Phase 43,119 participants (Actual)Interventional2010-04-30Completed
Short-term Outcomes of Elective High-risk PCI With Extracorporeal Membrane Oxygenation Support: a Single-centre Registry[NCT05387902]25 participants (Actual)Observational [Patient Registry]2022-02-03Completed
A Pilot Study of Edoxaban in Patients With Non-Valvular Atrial Fibrillation and Left Atrial Appendage Closure[NCT03088072]Phase 475 participants (Anticipated)Interventional2017-03-23Recruiting
RESOLUTE International Registry: Evaluation of the Resolute Zotarolimus-Eluting Stent System in a 'Real-World' Patient Population[NCT00752128]2,349 participants (Actual)Observational2008-08-31Completed
Management of Antiplatelet Regimen During Surgical Procedures (MARS Registry)[NCT03981835]1,492 participants (Anticipated)Observational [Patient Registry]2019-08-01Recruiting
A Clinical Evaluation of the Medtronic Resolute Zotarolimus-Eluting Coronary Stent System in the Treatment of De Novo Lesions in Native Coronary Arteries With a Reference Vessel Diameter of 2.25 mm to 4.2mm[NCT00726453]1,516 participants (Actual)Interventional2008-07-31Completed
The Clinical Evaluation of the MDT-4107 Drug-Eluting Coronary Stent in De Novo Lesions in Native Coronary Arteries[NCT00927940]100 participants (Actual)Interventional2009-03-31Completed
RESOLUTE-III All-comers Trial: A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention[NCT00617084]Phase 42,292 participants (Actual)Interventional2008-04-30Completed
Randomized Trial of Prasugrel Plus Bivalirudin vs. Clopidogrel Plus Heparin in Patients With Acute STEMI[NCT00976092]Phase 4548 participants (Actual)Interventional2009-09-30Active, not recruiting
A Randomised, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of Ticagrelor Compared With Clopidogrel for Prevention of Vascular Events in Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS) [PLATO- a Study of PLATelet Inh[NCT00391872]Phase 318,624 participants (Actual)Interventional2006-10-31Completed
Evaluation of the Occurence of Thrombotic and Bleeding Events After Coronary Angioplasty With Stent According to Aspirin and Clopidogrel Platelet Reactivity Assessed by a Point of Care Assay in the Cathlab (the Verifynow French Registry)[NCT00753753]1,001 participants (Actual)Observational2008-02-29Completed
Comparison of Clopidogrel and Ticagrelor on Microvascular Dysfunction in Acute Coronary Syndrome Patients: The Index of MIcrocirculatory Resistance After PCI in STEMI Patients (TIME Study)[NCT02026219]Phase 476 participants (Actual)Interventional2013-10-31Completed
Cost-effectiveness of CYP2C19 Genotype Guided Treatment With Antiplatelet Drugs in Patients With ST-segment-elevation Myocardial Infarction Undergoing Immediate PCI With Stent Implantation: Optimization of Treatment (POPular Genetics).[NCT01761786]Phase 42,700 participants (Actual)Interventional2011-06-30Completed
Cardioprotective Effect of Dexmedetomidine in Patients With ST-segment Elevation Myocardial Infarction: a Double-Blind, Multicenter, Randomized, Placebo-Controlled Clinical Trial[NCT04912518]250 participants (Anticipated)Interventional2021-05-27Recruiting
Thyroid Hormone Replacement for Hypothyroidism and Acute Myocardial Infarction[NCT02512978]Phase 4160 participants (Anticipated)Interventional2015-08-31Recruiting
Chinese People's Liberation Army General Hospital[NCT02826616]240 participants (Anticipated)Interventional2016-07-31Enrolling by invitation
A Multi-Centre, Prospective Cohort, Non-Interventional Study About Evaluation on the Safety of Ticagrelor Among Chinese ACS Patients[NCT02430493]1,066 participants (Actual)Observational [Patient Registry]2015-05-28Completed
The China PEACE (Patient-centered Evaluative Assessment of Cardiac Events Retrospective Study of Acute Myocardial Infarction[NCT01624883]18,000 participants (Actual)Observational2012-04-30Completed
WilL LOWer Dose Aspirin be More Effective Following ACS? (WILLOW-ACS)[NCT02741817]Phase 420 participants (Actual)Interventional2016-06-26Completed
A Single-center, Randomized, Open-label, Controlled, Dose-escalating, Parallel-group Study to Assess the Anti-platelet Effect of Berberine in Patients Receiving Aspirin and Clopidogrel After Percutaneous Coronary Intervention[NCT03378934]Phase 464 participants (Anticipated)Interventional2018-09-26Recruiting
A 30 Day International, Randomized, Parallel-group, Double-blind, Placebo-controlled Phase IV Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for PCI.[NCT01347580]Phase 41,875 participants (Actual)Interventional2011-09-30Completed
Cangrelor vs. Ticagrelor for Early Platelet Inhibition in ST-elevation Myocardial Infarction[NCT03182855]Phase 480 participants (Anticipated)Interventional2018-09-01Not yet recruiting
Reversal of the Anti-platelet Effects of Ticagrelor in Healthy Persons and Patients With Coronary Artery Disease[NCT02383771]Phase 464 participants (Actual)Interventional2015-03-31Completed
Point-of-Care Measurements of Platelet Inhibition After Clopidogrel Loading in Patients With Acute Coronary Syndrome: Comparison of Generic Clopidogrel Bisulfate (Plavitor®) With Original Clopidogrel Bisulfate (Plavix®)[NCT02060786]Phase 490 participants (Actual)Interventional2010-10-31Completed
Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI Registry[NCT01515345]Phase 31,008 participants (Actual)Interventional2011-07-31Completed
The TRANSLATE-ACS Study: Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome[NCT01088503]12,227 participants (Actual)Observational2010-03-31Completed
Randomized, Double-Blind, Placebo-controlled Trial of 6 vs. 12 Months Clopidogrel Therapy After Implantation of a Drug-Eluting Stent[NCT00661206]Phase 44,005 participants (Actual)Interventional2008-09-30Active, not recruiting
ETAMI-Study: Early Thienopyridine Treatment to Improve Primary Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction[NCT01327534]Phase 363 participants (Actual)Interventional2011-05-31Completed
EDUCATE: a Prospective, Multi-center Study Designed to Collect Real-world Safety and Clinical Outcomes in Subjects Receiving One or More Endeavor Zotarolimus-Eluting Stents and Either Clopidogrel and Aspirin or Prasugrel and Aspirin as Part of a Dual Anti[NCT01069003]Phase 42,272 participants (Actual)Interventional2010-04-30Completed
Platelet Function in Resuscitated Patients-2[NCT03445546]25 participants (Actual)Observational2016-05-01Completed
CAOCT Study is a Prospective, Multi-centre, Single Cohort, Diagnostic Accuracy Study, Planned to Include 131 Patients in About 3 European Countries After Successful Return of Spontaneous Circulation After Out of Hospital Cardiac Arrest[NCT04431661]28 participants (Actual)Observational2021-01-29Terminated (stopped due to Low patient recruitment rate and change of hopsital procedures for handling cardiac arrest patients during emergency)
Comparative Study of Clinical Efficacy and Safety of Different Clopidogrel Salts in Patients With Cardiovascular Disease. A Multi-center Non-interventional Clinical Trial.[NCT02126982]1,500 participants (Actual)Observational2012-10-31Completed
Study of the Effect of Eicosapentaenoic Acid (EPA) on Markers of Atherothrombosis in Patients With Type-2 Diabetes[NCT06129526]Phase 4450 participants (Anticipated)Interventional2023-12-31Not yet recruiting
Comparison of Biolimus Eluted From an Erodable Stent Coating With Bare-Metal Stents in Acute ST-Elevation Myocardial Infarction and In Vivo 3-Vessel Assessment of Time-Related Changes of Culprit and Non-Culprit Lesions by IVUS/OCT in AMI[NCT00962416]Phase 41,161 participants (Actual)Interventional2009-09-30Completed
Inflammation and Acute Coronary Syndromes (ACS) - Novel Strategies for Prevention and Clinical Management[NCT01000701]4,000 participants (Anticipated)Observational2009-10-31Recruiting
International Survey of Acute Coronary Syndromes in Transitional Countries[NCT01218776]36,000 participants (Anticipated)Observational2010-09-28Recruiting
Definite Stent Thrombosis in Comatose Out of Hospital Cardiac Arrest Survivors Treated With Percutaneous Coronary Intervention and Hypothermia[NCT03312296]151 participants (Actual)Observational2016-08-01Completed
Optimal P2Y12-receptor treatmeNt Guided by bedSIDe Genetic or Pharmacodynamic TESTing to Prevent Periprocedural Myonecrosis During Elective Percutaneous Coronary Intervention.[NCT01930773]Phase 3150 participants (Anticipated)Interventional2013-03-31Recruiting
An Open-label, Randomized, Prospective Study Exploring Half Dose of Prasugrel and Ticagrelor in Platelet Response After Acute Coronary Syndromes[NCT02944123]Phase 3120 participants (Actual)Interventional2016-09-30Completed
A Prospective, Randomized, Open-Label, Multicenter Study Assessing Efficacy and Safety of Ticagrelor De-escalation Strategy in East Asian Acute Myocardial Infarction With Coronary Intervention: EASTYLE Trial[NCT04755387]Phase 42,000 participants (Anticipated)Interventional2021-02-15Recruiting
A Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention (CHAMPION PHOENIX)[NCT01156571]Phase 311,145 participants (Actual)Interventional2010-09-30Completed
Comparison of The Influence of Ticagrelor And Clopidogrel on Inflammatory Biomarkers And Vascular Endothelial Function For Patients With ST-Segment Elevation Myocardial Infarction Receiving Emergency Percutaneous Coronary Intervention[NCT02123004]Phase 4350 participants (Anticipated)Interventional2014-04-30Not yet recruiting
The Association Between Platelet Inhibition and Perioperative Major Adverse Cardiac Events In Post-Percutaneous Coronary Intervention (PCI) Patients Undergoing Non-Cardiac Surgery[NCT01707459]201 participants (Actual)Observational2010-03-31Completed
A Randomized, Double-Blind, Double-Dummy, Parallel Group, Phase 3 Efficacy and Safety Study of CGT-2168 Compared With Clopidogrel to Reduce Upper Gastrointestinal Events Including Bleeding and Symptomatic Ulcer Disease[NCT00557921]Phase 35,000 participants (Anticipated)Interventional2007-12-31Terminated (stopped due to Terminated by Sponsor)
Impact of IntraVascular UltraSound Guidance on Outcomes of Xience Prime Stents in Long Lesions (IVUS-XPL Study)[NCT01308281]1,079 participants (Actual)Interventional2010-10-31Completed
Phase IV: A Comparison of Reduced-dose Prasugrel and Clopidogrel in Elderly Patients With Acute Coronary Syndrome Undergoing Early Percutaneous Coronary Intervention (PCI)[NCT01777503]Phase 42,000 participants (Anticipated)Interventional2012-11-30Recruiting
Global Multicenter, Open-label, Randomized, Event-driven, Active-controlled Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement (TAVR) to Optimize Clinical Outcomes[NCT02556203]Phase 31,653 participants (Actual)Interventional2015-12-16Terminated (stopped due to Imbalance in the efficacy and safety endpoints between treatment arms in favor of comparator)
Future Revascularization Evaluation in Patients With Diabetes Mellitus: Optimal Management of Multivessel Disease (FREEDOM)[NCT00086450]Phase 31,900 participants (Actual)Interventional2004-04-30Active, not recruiting
Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents[NCT00638794]8,575 participants (Actual)Observational2008-01-31Completed
A Prospective, Multi-center, Randomized, Double-blind Trial to Assess the Effectiveness and Safety of 12 Versus 30 Months of Dual Antiplatelet Therapy in Subjects Undergoing Percutaneous Coronary Intervention With Either Drug-eluting Stent or Bare Metal S[NCT00977938]Phase 425,682 participants (Actual)Interventional2009-10-31Completed
"Prospective Registry of Patients Over 75 Years Old Treated With Xience Sierra Stents. Sierra 75 Study"[NCT03567733]1,000 participants (Actual)Observational [Patient Registry]2018-06-18Completed
Reduced Antithrombotic Strategy for High Bleeding Risk Patients With Myocardial Infarction Treated With Percutaneous Coronary Intervention - The Dan-DAPT Trial[NCT05262803]Phase 42,808 participants (Anticipated)Interventional2022-06-17Recruiting
The Predictive Value of PRECISE DAPT Score in Patients With ST Segment Elevation Myocardial Infarction (STEMI) After Primary Percutaneous Coronary Intervention (PPCI)[NCT04549766]150 participants (Anticipated)Observational2020-09-30Not yet recruiting
Effect of Tailored Use of Tirofiban in Patients With Non-ST-elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention[NCT03114995]Phase 4140 participants (Actual)Interventional2012-02-01Completed
Prospective, Randomized, Double-Blind, Active-Controlled, Multicenter Trial of Bivalirudin and Un-fractionated Heparin in Patients Undergoing Percutaneous Coronary Interventions. ISAR-REACT-3[NCT00262054]Phase 44,570 participants (Actual)Interventional2005-11-30Completed
Non-randomized, Open-label, Historical Control, Single Group Assignment Trial of a Reduced Dose of Unfractionated Heparin in Patients Undergoing Percutaneous Coronary Interventions[NCT00735280]Phase 42,505 participants (Actual)Interventional2008-08-31Completed
PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes: A Double-blind, Active and Placebo Controlled Study of Aggrenox vs. Clopidogrel, With and Without Micardis[NCT00153062]Phase 420,332 participants (Actual)Interventional2003-08-31Completed
Randomized, Multinational, Double-blind Study, Comparing a High Loading Dose Regimen of Clopidogrel Versus Standard Dose in Patients With Unstable Angina or Myocardial Infarction Managed With an Early Invasive Strategy.[NCT00335452]Phase 325,086 participants (Actual)Interventional2006-06-30Completed
Stent For Life Observatory[NCT01251198]460 participants (Actual)Observational2010-11-30Completed
French Registry of Acute Coronary Syndrome With or Without ST Elevation[NCT00673036]3,750 participants (Actual)Observational2005-10-31Active, not recruiting
Genotype Guided Versus Conventional Approach in Selection of Oral P2Y12 Receptor Blocker in Chinese Patients Suffering From Acute Coronary Syndrome[NCT01994941]Phase 4133 participants (Actual)Interventional2013-08-31Completed
ReAssessment of Anti-Platelet Therapy Using an InDividualized Strategy in Patients With ST-segment Elevation Myocardial Infarction[NCT01452139]Phase 2/Phase 3102 participants (Actual)Interventional2011-09-30Completed
French Cohort of Myocardial Infarction Evaluation[NCT04050956]15,000 participants (Anticipated)Observational2019-03-11Recruiting
A Multicenter Prospective observationaL Study to evAluate the effecT of Clopidogrel on the prEvention of Major vascuLar Events According to the gEnotype of Cytochrome P450 2C19 in Ischemic Stroke paTients; PLATELET Study[NCT04072705]2,927 participants (Actual)Observational2019-09-20Completed
French Registry of Acute Coronary Syndrome With or Without ST Elevation 2010[NCT01237418]3,700 participants (Anticipated)Observational2010-10-31Active, not recruiting
Prospective Multi-center Registry of Genotyping Related Clopidogrel in Percutaneous Coronary Intervention Patients[NCT02707445]5,000 participants (Actual)Interventional2011-09-30Completed
PPD Trial Pilot Study: Plavix, Prasugrel and Drug Eluting Stents[NCT01103843]1,000 participants (Anticipated)Interventional2010-04-30Recruiting
Genotype Guided Comparison of Clopidogrel and Prasugrel Outcomes Study[NCT00995514]4,471 participants (Actual)Observational2009-10-31Terminated (stopped due to Administrative reasons)
The Effect of Inducing the Cytochrome P450 System on the Pharmacodynamic Efficacy of Clopidogrel[NCT01330589]0 participants (Actual)Interventional2011-04-30Withdrawn (stopped due to Inability to enroll subjects and changes in standard of care for PCI)
Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer[NCT02418312]228 participants (Actual)Interventional2012-01-31Completed
Can Pharmacogenomic Testing Improve Response and Avoid Adverse Effects With Clopidogrel Therapy? A Biospecimen Bank for Genetic and Genomic Investigation of Clopidogrel.[NCT01611545]130 participants (Actual)Observational2012-06-30Completed
Pantoprazole Versus Famotidine for the Prevention of Recurrent Peptic Ulcers in Thienopyridine Users - a Double-blind Randomized Controlled Trial[NCT02551744]101 participants (Actual)Interventional2012-07-31Completed
Comparison of Platelet Inhibitory Effect With Adjunctive Cilostazol Versus High Maintenance-dose ClopidogrEL in Acute Myocardial Infarction Patients According to CYP2C19 Polymorphism[NCT00915733]Phase 480 participants (Actual)Interventional2009-05-31Completed
Clopidogrel and Proton Pump Inhibitors: A Propensity Score Adjusted Cohort Study to Examine a Possible Interaction: A CALIBER Study[NCT01231867]24,471 participants (Actual)Observational2010-12-31Completed
Peri-Procedural Myocardial Infarction, Platelet Reactivity, Thrombin Generation, and Clot Strength: Differential Effects of Eptifibatide + Bivalirudin Versus Bivalirudin -The CLEAR PLATELETS-2 Study[NCT00370045]Phase 4200 participants Interventional2006-03-31Recruiting
Bivalirudin Plus Prasugrel vs Abciximab Plus Clopidogrel. Optimizing Ischemic Protection and Bleeding Risk in Patients With ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention[NCT01158846]Phase 4800 participants (Anticipated)Interventional2010-08-31Not yet recruiting
Quantitative Fractional Ratio-guided Non-culprit-vessel Revascularization in STEMI Patients With Multi-vessel Disease: a Prospective Multi-center Randomized Controlled Trial[NCT04259853]1,016 participants (Anticipated)Interventional2020-01-30Enrolling by invitation
CSP #442 - Warfarin and Antiplatelet Therapy Study in Patients With Congestive Heart Failure (WATCH)[NCT00007683]Phase 31,587 participants (Anticipated)Interventional1998-10-31Completed
Value of Abciximab in Patients With AMI Undergoing PCI After High Dose Clopidogrel Pretreatment (BRAVE 3)[NCT00133250]Phase 4800 participants (Actual)Interventional2003-06-30Completed
A Parallel Randomized Controlled Evaluation of Clopidogrel Plus Aspirin, With Factorial Evaluation of Irbesartan, for the Prevention of Vascular Events, in Patients With Atrial Fibrillation[NCT00249873]Phase 37,554 participants (Actual)Interventional2003-06-30Completed
Prospective, Randomized Trial of the Sirolimus-Eluting Stent and Paclitaxel-Eluting Stent for the Treatment of Unprotected Left Main Coronary Artery Disease(ISAR-LEFT-MAIN)[NCT00133237]Phase 4607 participants (Actual)Interventional2005-07-31Completed
A Multicenter, Randomized, Controlled, Double-Blind Trial to Investigate the Clinical Efficacy and Tolerability of Early Treatment With Simvastatin 40 mg Daily for 30 Days, Followed by Simvastatin 80 mg Daily Thereafter in Tirofiban-Treated Acute Coronary[NCT00251576]Phase 34,497 participants (Actual)Interventional1999-11-01Completed
The Role of Multiple Electrode Aggregometry in Detection of Clopidogrel Resistance in Diabetic Patients With Coronary Artery Disease and Prediction of Clinical Outcomes. A Comparative-method, Non Interventional, Single Center Study.[NCT01991093]280 participants (Actual)Observational2014-06-30Completed
The ACUITY Trial: A Randomized Comparison of Angiomax (Bivalirudin) Versus Heparin (Unfractionated Heparin or Enoxaparin) in Patients Undergoing Early Invasive Management for Acute Coronary Syndromes Without ST-Segment Elevation[NCT00093158]Phase 313,800 participants Interventional2003-08-31Completed
Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention[NCT00111566]Phase 4624 participants (Actual)Interventional2004-12-31Completed
Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel[NCT00398463]Phase 4263 participants (Actual)Interventional2006-05-31Completed
A Randomized, Multicenter, Double-Blind, Study to Evaluate the Efficacy of Tirofiban HCl Versus Placebo in the Setting of Standard Therapies Among Subjects Undergoing Percutaneous Coronary Intervention[NCT01245725]Phase 30 participants (Actual)InterventionalWithdrawn (stopped due to Study was not initiated, change in clinical development)
Customized Choice of P2Y12 Oral Receptor Blocker Based on Phenotype Assessment Via Point of Care Testing[NCT01477775]Phase 44,000 participants (Anticipated)Interventional2012-01-31Recruiting
Randomized, Prospective , Open Label, Phase 4 Trial of Efficacy and Safety of Adjunctive Cilostazol in Acute Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention With Drug-eluting Stent[NCT01261832]Phase 4951 participants (Anticipated)Interventional2011-07-31Active, not recruiting
Intra-patient Randomized Study With Polymer Free Drug Eluting Stent Versus Abluminal Biodegradable Polymer Drug Eluting Stent With Early OCT Follow up[NCT02785237]70 participants (Actual)Interventional2016-06-30Completed
The Effect of Ticagrelor on Acute Coronary Syndrome Patients With Clopidogrel Resistance Undergoing Percutaneous Coronary Intervention[NCT01812330]Phase 3180 participants (Anticipated)Interventional2013-01-31Recruiting
Dual Antiplatelet Therapy to Inhibit Coronary Atherosclerosis and Myocardial Injury in Patients With Necrotic High-Risk Coronary Plaque Disease[NCT02110303]Phase 2/Phase 3220 participants (Actual)Interventional2015-03-31Completed
Effects of Prolonged Dual Antiplatelet Therapy With Clopidogrel Plus Acetylsalicylic Acid (ASA) After Percutaneous Lower Extremity Revascularization in Patients With Peripheral Arterial Disease[NCT02798913]Phase 3300 participants (Anticipated)Interventional2016-01-31Recruiting
MULTIcentric Study About RESistance to CLOpidogrel in Dual Antiplatelet Therapy for Carotid Stenting[NCT05566301]1,140 participants (Anticipated)Observational2021-09-02Recruiting
A Randomized, Open-label, Active-controlled, Parallel-group Study to Investigate the Platelet Inhibition of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease and Type 2 Diabetes Mellitus After Recent Elective Percutaneous Coron[NCT02748330]Phase 440 participants (Actual)Interventional2016-06-30Completed
A Randomized, Single Center Trial to Assess the Endothelial Function With Ticagrelor Monotherapy Compared to Aspirin Monotherapy in Patients With History of Acute Coronary Syndrome[NCT03881943]Phase 4200 participants (Actual)Interventional2017-01-31Completed
Ticagrelor Compared to Clopidogrel in Acute Coronary Syndromes - the TC4 Comparative Effectiveness Study[NCT04057300]Phase 41,038 participants (Actual)Interventional2018-10-01Completed
Prospective, Randomized Study of the Platelet Inhibitory Efficacy of Ticagrelor Versus Prasugrel in Clopidogrel Low Responders After Percutaneous Coronary Intervention[NCT01456364]Phase 470 participants (Anticipated)Interventional2011-09-30Recruiting
CARDIOBASE Bern PCI Registry[NCT02241291]10,000 participants (Anticipated)Observational2009-03-31Recruiting
A Non-interventional Study to Estimate the Rates of Outcomes in ACS Patients in Moscow[NCT03654157]1,576 participants (Actual)Observational2018-03-25Completed
Efficacy and Safety of Tirofiban in Patients With Acute Branch Atheromatous Disease (BAD)- Related Stroke (BRANT)[NCT06037889]Phase 3516 participants (Anticipated)Interventional2023-11-09Recruiting
Evaluation of a Strategy Guided by Imaging Versus Systematic Coronary Angiography in Elderly Patients With Ischemia: a Multicentric Randomized Non Inferiority Trial.[NCT03289728]1,756 participants (Anticipated)Interventional2018-04-04Recruiting
Pharmacogenetics of Clopidogrel in Acute Coronary Syndromes[NCT03347435]889 participants (Actual)Interventional2013-06-30Terminated (stopped due to Ethics Committe decision)
Aspirin Impact on Platelet Reactivity in Acute Coronary Syndrome Patients on Novel P2Y12 Inhibitors Therapy[NCT02049762]Phase 429 participants (Actual)Interventional2015-06-30Completed
Antiplatelet Therapy in Elderly Patients Undergoing Percutaneous Coronary Intervention[NCT04999293]1,505 participants (Actual)Observational2021-07-20Completed
Follow up of Ticagrelor Treatment Patterns in Chinese Acute Coronary Syndromes Patients- A Database Retrospective Study[NCT04861363]20,000 participants (Anticipated)Observational2019-06-19Enrolling by invitation
Evaluation of Platelet Aggregation and Adenosine Levels in Patients With Coronary Artery Disease and Chronic Kidney Dysfunction Taking Dual Antiplatelet Therapy With Aspirin and Clopidogrel or Ticagrelor[NCT03039205]Phase 290 participants (Actual)Interventional2017-11-07Completed
An Open Label, Randomized Study to Determine the Rate of Cardiovascular Events at 1 yr for Patients With Elevated Troponins Post Major Non-cardiac Surgery and the Impact of Ticagrelor vs Aspirin on the Occurrence of Cardiovascular Events[NCT02291419]Phase 46 participants (Actual)Interventional2015-07-31Terminated (stopped due to Enrollment expectations were not met)
"Evaluation of Antiplatelet Effects and Safety of Intraoperative Administration of Ticagrelor Versus Clopidogrel in Patients Undergoing One-stop Hybrid Coronary Revascularization"[NCT02513004]Phase 460 participants (Anticipated)Interventional2015-06-30Recruiting
Ticagrelor vs. Tirofiban, Comparison of Anti-platelet Effects in Patients With Non-ST Elevation Acute Coronary Syndrome(TE-CLOT Trial : Ticagrelor's Effect for CLOT Prevention) ; A Single Center, Open-label Randomized Controlled Study[NCT01660373]Phase 3100 participants (Anticipated)Interventional2012-08-31Recruiting
Role of Innate and Adaptive Immunity After Acute Myocardial Infarction BATTLE-AMI Study (B And T Types of Lymphocytes Evaluation in Acute Myocardial Infarction)[NCT02428374]Phase 4300 participants (Anticipated)Interventional2015-05-31Recruiting
Dual Arm Factorial Randomized Trial in Patients w/ST Segment Elevation AMI to Compare the Results of Using Anticoagulation With Either Unfractionated Heparin + Routine GP IIb/IIIa Inhibition or Bivalirudin + Bail-out GP IIb/IIIa Inhibition; and Primary An[NCT00433966]Phase 33,602 participants (Actual)Interventional2005-03-31Completed
A Clinical Trial Comparing Cangrelor to Clopidogrel in Subjects Who Require Percutaneous Coronary Intervention (PCI).[NCT00305162]Phase 38,882 participants (Actual)Interventional2006-04-30Terminated (stopped due to Insufficient evidence of the clinical effectiveness of cangrelor)
CHoosing Triple or Double therApy in the Era of nOac for patientS Undergoing PCI: the CHAOS a Multicenter Study.[NCT03558295]1,000 participants (Anticipated)Observational [Patient Registry]2018-05-01Recruiting
Sclerotherapy With Polidocanol Foam In The Management Of First, Second And Third-Grade Hemorrhoidal Disease In Patients With Bleeding Disorders: A Prospective Cohort Study[NCT04188171]Phase 2/Phase 3150 participants (Anticipated)Interventional2018-08-01Active, not recruiting
A Randomized, Double-Blind, Placebo-Controlled Trial Comparing Clopidogrel Plus Acetylsalicylic Acid (ASA) Versus ASA Alone in Subjects With Acute ST Elevation Myocardial Infarction (STEMI) Treated With Fibrinolytic Therapy[NCT00714961]Phase 33,491 participants (Actual)Interventional2003-02-28Completed
ACCELerated Inhibition of Platelet Aggregation, Inflammation and Ischemia-reperfusion Injury by Adjunctive Cilostazol Loading in Patients With Acute Coronary Syndrome[NCT01354808]Phase 4220 participants (Anticipated)Interventional2010-07-31Completed
Effect of Conditioning on Myocardial Damage in ST-elevation Myocardial Infarction - Comparison of Combined Intrahospital Preconditioning Plus Postconditioning Versus Postconditioning Versus Control.[NCT02158468]600 participants (Actual)Interventional2011-10-31Completed
Postconditioning Used to Limit Final Infarct Size in Patients With Acute ST-segment Elevation Myocardial Infarction[NCT00507156]Phase 4200 participants (Anticipated)Interventional2007-07-31Completed
Do Point-of-care Platelet Function Assays Predict Clinical Outcomes in Clopidogrel Pre-treated Patients Undergoing Elective PCI. (The POPular Study)[NCT00352014]1,000 participants (Anticipated)Observational2006-01-31Completed
Effect of Low Dose of Colchicine on Platelet Reactivty in Patients With Chronic Coronary Disease[NCT05956145]Phase 380 participants (Anticipated)Interventional2021-06-17Recruiting
[NCT03018873]400 participants (Anticipated)Interventional2016-12-31Not yet recruiting
Cardiopulmonary Protection of Modified Remote Ischaemic Preconditioning in Mitral Valve Replacement Surgery[NCT03010839]86 participants (Actual)Interventional2016-11-05Completed
The Effect of Remote Preconditioning in Primary Percutaneous Intervention of Acute ST Elevation Myocardial Infarction[NCT00435266]Phase 2/Phase 3250 participants (Anticipated)Interventional2007-02-28Completed
Evaluation of Remote Ischemic Conditioning in ST-elevation Myocardial Infarction as Adjuvant to Primary Angioplasty[NCT02313961]516 participants (Actual)Interventional2013-03-31Completed
Remote Ischemic Preconditioning in Head and Neck Cancer Reconstruction - A Randomized Controlled Trial[NCT02548377]60 participants (Actual)Interventional2015-09-29Completed
[NCT02843464]220 participants (Anticipated)Interventional2016-12-31Not yet recruiting
The Effect of Remote Ischemic Conditioning on the Metabolomic Profile of NSTEMI Patients[NCT03097419]300 participants (Anticipated)Interventional2012-11-28Active, not recruiting
A Single Centre Double-blinded Randomized Placebo Controlled Pilot Study Investigating the Effect of Remote Ischaemic preConditioning in ONCology Patients Undergoing Chemotherapy (ERIC-ONC)[NCT02471885]128 participants (Anticipated)Interventional2015-12-16Recruiting
Effects of Remote Limb Ischemic Conditioning to Enhance Muscle Power, Dynamic Balance, and Walking Performance in Children With Cerebral Palsy[NCT04598711]24 participants (Actual)Interventional2021-06-15Completed
The Effect of Remote Ischemic Preconditioning on Myocardial Injury After Noncardiac Surgery in Patients at a High Risk of Cardiac Events[NCT05733208]766 participants (Anticipated)Interventional2023-05-06Recruiting
COMBinAtion Therapy in Myocardial Infarction: The COMBAT-MI Trial[NCT02404376]Phase 3378 participants (Actual)Interventional2016-03-31Completed
Remote Ischemic Conditioning as a Treatment for Traumatic Brain Injury: a Prospective Randomized Controlled Trial.[NCT03176823]40 participants (Anticipated)Interventional2019-05-03Recruiting
Qvanteq Bioactive Coronary Stent System First in Man (FIM) Clinical Investigation[NCT02176265]31 participants (Actual)Interventional2014-09-30Completed
Correlation of Clopidogrel Therapy Discontinuation in REAL-world Patients Treated With Drug-Eluting Stent Implantation and Late Coronary Arterial Thrombotic Events[NCT00484926]Phase 42,000 participants (Actual)Interventional2007-03-31Completed
Evaluation of the Long-term Safety After Zotarolimus-Eluting Stent, Sirolimus-Eluting Stent, or PacliTaxel-Eluting Stent Implantation for Coronary Lesions - Late Coronary Arterial Thrombotic Events[NCT00590174]Phase 41,175 participants (Actual)Interventional2007-10-31Completed
Effects of Ticagrelor Versus Prasugrel on Coronary Microcirculation in Patients Undergoing Elective Percutaneous Coronary Intervention: Results of the PROtecting MICROcirculation During Coronary Angioplasty (PROMICRO)-3 Randomised Study[NCT05643586]Phase 450 participants (Actual)Interventional2017-12-01Completed
Efficacy of High Dose Atorvastatin Loading in ST Elevation Myocardial Infarction[NCT00808717]Phase 4170 participants (Anticipated)Interventional2007-07-31Completed
Clopidogrel Reloading in Patients With Non-ST Elevation Acute Coronary Syndrome Undergoing PCI on Chronic Clopidogrel Therapy. Results of the ARMYDA RELOAD ACS (Antiplatelet Therapy for Reduction of MYocardial Damage During Angioplasty in Acute Coronary S[NCT01572129]Phase 4240 participants (Anticipated)Interventional2011-11-30Recruiting
A Prospective Single Arm Clinical Trial Evaluating the MitraClip System in Australia and New Zealand[NCT01301625]78 participants (Actual)Observational2011-11-30Terminated (stopped due to As recruitment rate was lower than anticipated)
Multicenter Open Label Randomized Comparative Study of Efficacy and Safety of Single Bolus Injection of Recombinant Nonimmunogenic Staphylokinase (Fortelyzin) and Bolus Infusion Alteplase (Actilyse) in Patients With Acute Ischemic Stroke[NCT03151993]Phase 3336 participants (Actual)Interventional2017-03-18Completed
Multicenter Open Lable Randomized Comparative Study of Efficacy and Safety of Single Bolus Injection of Recombinant Nonimmunogenic Staphylokinase (Fortelyzin) and Tenecteplase (Metalyse) in STEMI Patients[NCT02301910]Phase 3392 participants (Anticipated)Interventional2014-10-31Recruiting
Comparison of Administration of Tirofiban in the Ambulance or in the Cathlab in Patients With Acute Myocardial Infarction Treated With Primary Angioplasty[NCT00538317]Phase 4320 participants (Actual)Interventional2007-07-31Completed
Influence of CILostazol-based Triple Anti-platelet Therapy ON Ischemic Complication After Drug-eluting stenT Implantation[NCT00776828]Phase 4960 participants (Actual)Interventional2006-11-30Completed
A Randomized Controlled Trial of Influenza Vaccine to Prevent Adverse Vascular Events: A Pilot Study[NCT01945268]Phase 4107 participants (Actual)Interventional2015-04-30Completed
A Randomized Controlled Trial of Influenza Vaccine to Prevent Adverse Vascular Events[NCT02762851]Phase 45,000 participants (Anticipated)Interventional2016-06-30Recruiting
Optimal Strategy for Side Branch Stenting in Coronary Bifurcation Lesion[NCT00794014]258 participants (Actual)Interventional2007-11-30Completed
Efficacy and Safety of Anticoagulant on Early Treatment of Post-STEMI Left Ventricular Thrombus: an Open, Prospective, Randomized and Multi-centers Trial.[NCT03764241]Phase 3280 participants (Anticipated)Interventional2020-02-01Recruiting
Efficacy and Safety of Anticoagulant on Early Prevention of Post-STEMI Left Ventricular Thrombus: an Open, Prospective, Randomized and Multi-centers Trial.[NCT03786757]Phase 3200 participants (Anticipated)Interventional2019-04-01Not yet recruiting
GRAVITAS: Gauging Responsiveness With A VerifyNow Assay-Impact On Thrombosis And Safety[NCT00645918]2,800 participants (Actual)Interventional2008-06-30Completed
Laboratory Implications of Non Obstructive Atherosclerotic Plaques Identified by Multiple Detector Coronary Angiotomography[NCT03632785]90 participants (Actual)Observational2017-03-27Completed
Effect of Modifying Anti-platelet Treatment to Ticagrelor in Patients With Diabetes and Low Response to Clopidogrel[NCT01643031]Phase 4500 participants (Anticipated)Interventional2012-08-31Not yet recruiting
Effect of the Genetic Variant 2C19*2 on Clopidogrel Biological Response in Patients With Premature Coronary Artery Disease[NCT00822666]Phase 3109 participants (Actual)Interventional2008-10-31Completed
MONET BRIDGE(Maintenance Of aNtiplatElet Therapy in Patients With Coronary Stenting Undergoing Surgery) - (Mantenimento Della Terapia Antiaggregante Nei Pazienti Portatori di Stent Coronarico Candidati a Chirurgia)[NCT03862651]Phase 2140 participants (Anticipated)Interventional2019-06-01Not yet recruiting
Multicenter, Prospective Cohort of Patient With Coronary Stents Undergoing Non Cardiac Surgery or Invasive Procedures.[NCT01045850]1,312 participants (Actual)Observational2006-02-28Completed
REsponsiveness to CLOpidogrel and Stent-related Events in Acute Coronary. Reclose 2-ACS Registry[NCT01231035]1,789 participants (Actual)Observational2008-09-30Completed
EValuation of REsidual Platelet REactivity After Acute Coronary Syndrome in HIV-infected Patients. The EVERE2ST-HIV Study.[NCT02380391]260 participants (Actual)Observational2013-12-31Completed
A Randomized Comparison of Excimer LASER vs Manual Thrombus Aspiration for the Prevention of No-reflow During Primary Percutaneous Coronary Intervention of St-elevation Myocardial Infarction(LASER-AMI Study)[NCT01826006]194 participants (Anticipated)Interventional2014-04-30Recruiting
"PGDT With the Hypotension Prediction Index to Reduce the Number and Duration of Intraoperative Hypotension and the Incidence of Renal Failure in Patients Undergoing Lung Surgery"[NCT04149314]142 participants (Actual)Interventional2019-11-20Completed
Comparison of the Efficacy of Everolimus-Eluting Versus Sirolimus-Eluting Stent for Coronary Lesions[NCT00698607]Phase 41,466 participants (Anticipated)Interventional2008-06-30Active, not recruiting
LAte Stent Strut APPosition and COverage After Drug-Eluting Stent ImplantaTIOn by Optical Coherence Tomography in PatieNts With Acute Myocardial Infarction II(APPOSITION-AMI II)[NCT02770651]69 participants (Anticipated)Observational2016-05-31Enrolling by invitation
The Electronic Medical Records and GEnomics (eMERGE) Network Genomic Risk Assessment[NCT05277116]25,000 participants (Anticipated)Interventional2022-02-16Recruiting
Risk Stratification for Subclinical Leaflet Thrombosis Post TAVI Using Thromboelastography[NCT03649594]100 participants (Anticipated)Observational2020-10-01Recruiting
Comparison of Multiple Oral and/or Intravenous Anti-platelet Strategies in Patients With ST-segment Elevation Myocardial Infarction Undergoing Primary PCI[NCT01336348]Phase 3100 participants (Anticipated)Interventional2010-04-30Completed
A Phase III, Multicenter, Multinational, Randomized, Parallel Group, Double-blind Trial of Clopidogrel Versus Placebo in High-risk Patients Aged 45 Years and Older, at Risk of Atherothrombotic Events, and Who Are Receiving Background Therapy Including Low[NCT00050817]Phase 315,603 participants (Actual)Interventional2002-10-31Completed
A Randomized, Double-Blind, Active-Controlled Trial to Evaluate Intravenous and Oral PRT060128, a Selective and Reversible P2Y12 Inhibitor, vs Clopidogrel, as a Novel Antiplatelet Therapy in Patients Undergoing Non-Urgent PCI[NCT00751231]Phase 2652 participants (Actual)Interventional2008-12-31Completed
Randomized, Double-Blind, Active-Controlled, Multicenter Trial of Abciximab And Bivalirudin in Patients With Non-ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Interventions (ISAR-REACT-4)[NCT00373451]Phase 41,721 participants (Actual)Interventional2006-07-31Completed
Secondary Prevention of Small Subcortical Strokes (SPS3) Trial[NCT00059306]Phase 33,020 participants (Actual)Interventional2003-02-28Completed
Multi-Center Registry Trial of EXCEL Biodegradable Polymer Drug-Eluting Stent[NCT00331578]Phase 42,077 participants (Actual)Interventional2006-06-30Completed
The Effect of Glucocorticoid Therapy on Left Ventricular Remodelling in Acute ST-segment Elevation Myocardial Infarction (RECONSIDER)[NCT03371784]Phase 2/Phase 377 participants (Actual)Interventional2018-03-08Active, not recruiting
Double Randomization of a Monitoring Adjusted Antiplatelet Treatment Versus a Common Antiplatelet Treatment for DES Implantation, and a Interruption Versus Continuation of Double Antiplatelet Therapy, One Year After Stenting[NCT00827411]Phase 42,500 participants (Actual)Interventional2009-01-31Completed
Randomized Comparison of Platelet Function Monitoring to Adjust Antiplatelet Therapy Versus a Common Antiplatelet Treatment for Intracranial Aneurysm Stent-assisted Coiling[NCT02224131]Phase 41,856 participants (Anticipated)Interventional2015-01-31Not yet recruiting
ASS-Nonresponse Following Cardiac Surgery as Assessed With Multiple Electrode Aggregometry[NCT01824147]400 participants (Actual)Observational2013-08-31Completed
Routine Or Selective Stress Testing After Revascularization: ROSSTAR Trial RCT Outline[NCT03067402]1,100 participants (Anticipated)Interventional2017-03-20Not yet recruiting
Register of Cardiovascular Complications Among People Living With HIV[NCT02453919]800 participants (Anticipated)Observational [Patient Registry]2010-02-28Recruiting
Mechanism Based Resistance to Aspirin[NCT00948987]Phase 1400 participants (Actual)Interventional2004-09-30Completed
TBTC Study 24: A Non-Comparative Study of the Efficacy of a Largely-Intermittent, Six-Month Tuberculosis Treatment Regimen Among Patients Who Will Not Receive Isoniazid Due to Initial Isoniazid Resistance or Intolerance[NCT00023374]98 participants (Actual)Interventional2000-08-31Completed
Platelet Inhibition in the Acute Phase of ST-segment Elevation Myocardial Infarction[NCT01144819]46 participants (Actual)Observational2009-10-31Completed
[NCT01584791]Phase 4148 participants (Actual)Interventional2010-10-31Completed
On-treatment PLAtelet Reactivity-guided Therapy Modification FOR ST-segment Elevation Myocardial Infarction (PLATFORM)[NCT01739556]Phase 3242 participants (Actual)Interventional2015-06-30Terminated (stopped due to An interim analysis showed that there is no difference in the primary endpoint, given the small number of events in the groups examined.)
Influence of the Compression Method After Transradial Catheterization in Radial Artery[NCT02697526]274 participants (Actual)Interventional2007-01-31Completed
A Double-Blind, Randomized Comparison Between Two Different Clopidogrel Maintenance Doses After Percutaneous Coronary Intervention (ISAR-CHOICE-2)[NCT00140465]Phase 460 participants (Actual)Interventional2004-10-31Completed
Early and Long-Term Outcome of Elective Stenting of the Infarct-Related Artery in Patients With Viability in the Infarct-Area Early After Acute Myocardial Infarction. The VIAMI-Trial.[NCT00149591]300 participants Interventional2001-04-30Active, not recruiting
Approaches to Chronic Occlusions With Sirolimus Stents-Cypher (ACROSS-Cypher) Total Occlusion Study of Coronary Arteries 4 Trial[NCT00378612]Phase 3200 participants (Actual)Interventional2005-06-30Completed
Prospective Pilot Study- Does Mean Platelet Volume Change With Clopidogrel in Patients With Stable Angina Undergoing Percutaneous Coronary Intervention?[NCT02550301]100 participants (Anticipated)Observational2015-09-30Not yet recruiting
Gastrointestinal Ulceration in Patients on Dual Antiplatelet Therapy After Percutaneous Coronary Intervention[NCT00413309]30 participants (Anticipated)Interventional2006-04-30Completed
Platelet Function in Resuscitated Patients[NCT02914795]99 participants (Actual)Observational2015-06-30Completed
Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of the Glycoprotein IIb/IIIa Inhibition With Abciximab in Patients With ACS Undergoing Coronary Stenting After Pretreatment With a High Loading Dose of Clopidogrel (ISAR-REACT-2)[NCT00133003]Phase 42,022 participants (Actual)Interventional2003-03-31Completed
Biological Efficacy of Clopidogrel 600 mg Loading Dose Followed by 75 mg Maintenance Dose After Implantation of Drug-eluting Stents in Patients With Diabetes Mellitus or Metabolic Syndrome (SPACE)[NCT00298428]159 participants (Actual)Interventional2006-05-31Completed
Revascularization With Paclitaxel-coated Balloon Angioplasty Versus Drug-eluting Stenting in Acute Myocardial Infarction - a Randomized Controlled Trial.[NCT02219802]120 participants (Anticipated)Interventional2014-08-31Not yet recruiting
Chewing Clopidogrel in Addition to Regular Oral Clopidogrel Treatment to Improve Platelets Aggregation in Patient With NON ST ELEVATION MI[NCT00889044]Phase 330 participants (Anticipated)Interventional2009-04-30Recruiting
Optimizing the Anticoagulation Regimen of Enoxaparin During Percutaneous Coronary Intervention[NCT03145675]Phase 4378 participants (Actual)Interventional2017-05-12Completed
Anti-Xa Assay Correlation to the Efficacy and Safety of Enoxaparin in the Treatment of Pulmonary Embolism[NCT02977013]42 participants (Actual)Observational2013-08-31Completed
A Comparison of Drug Eluting and Bare Metal Stents With or Without Abciximab in ST Segment Elevation Myocardial Infarction The Eindhoven Reperfusion Study[NCT00986050]Phase 4907 participants (Actual)Interventional2006-01-31Completed
A Pilot Study of The Effects of a Single High Dose Bolus Tirofiban in Diabetic Patients Undergoing Elective Percutaneous Coronary Intervention[NCT00407771]Phase 444 participants (Anticipated)Interventional2007-11-30Not yet recruiting
REduction of Myocardial Necrosis Achieved With Nose-dive Manual Thrombus Aspiration[NCT01342848]76 participants (Actual)Observational2011-03-31Completed
The Efficacy and Safety of Proton Pump Inhibitor ( in Patients With Moderate Bleeding Risk and Coronary Artery Disease Undergoing Percutaneous Coronary: A Randomised, Open ,Compared With Control[NCT05820048]Phase 4300 participants (Anticipated)Interventional2023-05-01Not yet recruiting
Aspirin Non-responsiveness and Clopidogrel Endpoint Trial.[NCT00222261]Phase 41,001 participants (Actual)Interventional2003-04-30Completed
Maintenance Of aNtiplatElet Therapy in Patients With Coronary Stenting Undergoing Surgery[NCT03445273]1,800 participants (Anticipated)Observational [Patient Registry]2018-11-21Not yet recruiting
Ongoing WARfarin and Coronary STENTing. A Multi-center, Prospective Registry on Antithrombotic Treatment.[NCT00722319]1,000 participants (Anticipated)Observational2009-03-31Active, not recruiting
Clopidogrel Or Metoprolol in Myocardial Infarction Trial[NCT00222573]Phase 446,000 participants Interventional1999-07-31Completed
Warfarin After Anterior ST-Elevation Myocardial Infarction[NCT00662467]20 participants (Actual)Interventional2006-11-30Completed
Antiplatelet Therapy in Acute Mild-Moderate Ischemic Stroke (ATAMIS): a Parallel Randomized, Open-label, Multicenter, Prospective Study[NCT02869009]Phase 33,000 participants (Actual)Interventional2016-11-30Completed
Prospective, Single-Arm, Multi-Centre, Observational Registry to Further Validate Safety and Efficacy of the Nobori DES in Real-World Patients[NCT01261273]18,000 participants (Actual)Observational2010-08-25Completed
BIOTRONIK-Safety and Clinical PerFormance of the Drug ELuting Orsiro Stent in the Treatment of Subjects With de Novo Coronary Artery Lesions-VI[NCT02870985]Phase 3440 participants (Anticipated)Interventional2015-07-31Recruiting
Which Early ST Elevation Myocardial Infarction Therapy? The WEST Study[NCT00121446]Phase 2/Phase 3300 participants Interventional2003-07-31Completed
Polypill Strategy for Evidence-Based Management of Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention in an Underserved Patient Population[NCT05514938]Phase 260 participants (Anticipated)Interventional2022-11-30Recruiting
Phase 4 Study of Randomized Comparison Among Oral Rapamycin Plus Bare Metal Stents Versus Drug Eluting Stents in de Novo Coronary Lesions.[NCT00552669]Phase 4200 participants (Actual)Interventional2006-01-31Completed
Personalized Patient Data and Behavioral Nudges to Improve Adherence to Chronic Cardiovascular Medications (The Nudge Study)[NCT03973931]9,501 participants (Actual)Interventional2019-07-01Active, not recruiting
Are Serial Electrocardiograms Additive to SeriAl Second-generations Troponins in Predicting Acute CoronAry Syndromes in PatienTs With Undifferentiated cHest Pain (ASAP CATH) Study[NCT01953276]382 participants (Anticipated)Observational2013-01-31Completed
Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis.[NCT00360386]Phase 2110 participants Interventional2004-03-31Completed
Clopidogrel Hyper-Responsiveness: Incidence and Associated Outcomes in Patients With Cerebral Aneurysms[NCT05945563]208 participants (Anticipated)Observational [Patient Registry]2023-01-17Recruiting
An Exploratory Study Investigating the Use of the Lutonix Paclitaxel-Coated Balloon in Conjunction With Bare Metal Stenting in Patients With De Novo Coronary Lesions.[NCT00934752]Phase 1/Phase 224 participants (Actual)Interventional2009-07-31Completed
A Multicenter, Open-labeled, Randomized Controlled Trial Comparing Three 2nd Generation Drug-Eluting Stents in Real-World Practice[NCT01397175]1,960 participants (Actual)Interventional2013-01-16Terminated (stopped due to Slow enrollment)
A Prospective Optical Coherence Tomography Study on Completeness of Strut Coverage and Vessel Wall Response at 3-6 and 9 Months Following Paclitaxel Eluting Stent Implantation in Multivessel Coronary Artery Disease[NCT00704145]Phase 430 participants (Anticipated)Interventional2007-11-30Completed
Vessel Injury in Relation With Strut Thickness Assessed by OCT (VISTA): A Comparison of Vascular Injury Induced by a Polymer Free Sirolimus and Probucol Eluting Stent and a Biodegradable-polymer Biolimus-eluting Stent[NCT03026465]Phase 450 participants (Actual)Interventional2017-02-16Completed
In-Vivo Vascular Response of Sirolimus-,Paclitaxel- and Zotarolimus-Eluting Stents in Long Lesions Requiring Overlapping. A Prospective, Randomized, Controlled Study Using Optical Coherence Tomography[NCT00693030]Phase 477 participants (Anticipated)Interventional2006-08-31Recruiting
The Optical Coherence Tomography Drug Eluting Stent Investigation(OCTDESI)[NCT00776204]60 participants (Actual)Interventional2008-05-31Completed
Frequency Domain Imaging to Determine Stent Strut Coverage and Duration of Anti-Platelet Treatment After Endeavor Stent Placement[NCT01219894]0 participants (Actual)Observational2010-11-30Withdrawn (stopped due to Number of patients to meet individual IDE requirements was not obtained.)
Effect of TCFA on Neointimal Coverage After EXCEL Biodegradable Polymer-coated Sirolimus-eluting Stents Implantation at 9 Months Follow-up: Evaluated by Optical Coherence Tomography and Fractional Flow Reserve[NCT02384837]33 participants (Actual)Observational2014-12-31Completed
Optical Frequency Domain Imaging (OFDI) Determined Stent Strut Coverage and Plaque Morphology After RESOLUTE Stent Placement in Non-Insulin Dependent Diabetics Presenting With Acute Coronary Syndrome (ACS)[NCT01794949]8 participants (Actual)Interventional2013-09-30Completed
A Prospective, Multicentre, Randomized, Open Label, Blinded Endpoint, Phase 3 Trial to Assess the Safety and Efficacy of Prophylactic TicagrelOr With Acetylsalicylic Acid Versus CLopidogrel With Acetylsalicylic Acid in the Development of Cerebrovascular E[NCT02989558]Phase 390 participants (Actual)Interventional2016-12-31Completed
P2Y12 Inhibitors Utilization in Bifurcation and Chronic Total Occlusion PCI With Biologically Active Stents (P2BiTO) Registry[NCT01967615]4,500 participants (Actual)Observational2015-01-31Completed
Platelet Inhibition With Ticagrelor 60 mg Versus Ticagrelor 90 mg Twice Daily in Elderly Patients With Acute Coronary Syndrome (ACS)[NCT04739384]Phase 350 participants (Actual)Interventional2021-04-01Completed
The Role of the P2Y12 Receptor in Tissue Factor Induced Coagulation[NCT01099566]Phase 420 participants (Actual)Interventional2009-11-30Completed
Influence Of Omeprazole On The Anti-Platelet Action Of Clopidogrel Associated To Aspirin: Double-Blind Randomized Trial Against Placebo[NCT00349661]Phase 3120 participants (Anticipated)Interventional2006-06-30Completed
Study of Optimal Clopidogrel Duration in Patients Receiving Drug Eluting Stents (SCORE Trial)[NCT00781573]167 participants (Actual)Interventional2008-09-11Completed
Pragmatic Randomized Controlled Trial Comparing Treatment Effectiveness of Guideline Indicated Anti-platelet Therapy for Acute Coronary Syndrome in Patients With Chronic Kidney Disease[NCT03150667]Phase 4220 participants (Anticipated)Interventional2017-04-10Recruiting
ReAssessment of Anti-Platelet Therapy Using an InDividualized Strategy Based on GENetic Evaluation (The RAPID GENE Study)[NCT01184300]Phase 2/Phase 3200 participants (Actual)Interventional2010-08-31Completed
Improvements of Hand Function in Chronic Stroke Related to Upper Arm Anesthesia[NCT00006414]12 participants Observational2000-10-31Completed
A Multicenter, Randomized Trial Evaluating 30-day and 6-month Clinical Outcomes With Three Different Treatment Strategies (Coronary Angioplasty + Abciximab, Intracoronary Stent + Abciximab, and Intracoronary Stent + Placebo) in Patients Undergoing Percuta[NCT00271401]Phase 32,399 participants (Actual)Interventional1996-07-31Completed
Gemini Angioplasty and Arterial Measurement Evaluation (GAAME) An Evaluation of the Metricath Gemini System, a Percutaneous Interventional Device Intended to Make Arterial Lumen Measurements and Perform Percutaneous Transluminal Angioplasty Dilations.[NCT00399646]Phase 2145 participants (Actual)Interventional2005-11-30Completed
Induction of Mucosal Tolerance to E-Selectin for the Secondary Prevention of Stroke[NCT00012454]Phase 260 participants Interventional2001-03-31Terminated
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Number of Participants With Non Coronary Artery Bypass Graft-Related (Non CABG-related) Thrombolysis in Myocardial Infarction (TIMI) Clinically Significant Bleeding Events

Non CABG-related TIMI clinically significant bleeding events are sum of non CABG-related TIMI major bleeding events, TIMI minor bleeding events and TIMI bleeding events requiring medical attention. Major: any symptomatic intracranial bleeding: clinically overt signs of hemorrhage with hemoglobin (Hb) drop of greater than or equal to (>=)5 gram per deciliter (g/dl) (or absolute drop in hematocrit of >=15%) and fatal bleeding (results in death within 7 days); Minor: clinically overt sign of hemorrhage with Hb drop of 3 - <5 g/dl (or drop in hematocrit of 9 - <15%); requiring medical attention: bleeding event that required medical, surgical treatment/laboratory evaluation and did not meet criteria for major/minor bleeding event. (NCT02293395)
Timeframe: From start of study treatment until follow-up (up to 390 days)

Interventionparticipants (Number)
Rivaroxaban 2.5 mg Twice Daily (BID)80
Acetylsalicylic Acid 100 mg Once Daily (OD)74

Composite of Ischemic Stroke, Myocardial Infarction, Death From Ischemic Vascular Causes, or Major Hemorrhage

Secondary efficacy outcome: Number of participants with ischemic stroke, myocardial infarction, death from ischemic vascular causes, or major hemorrhage (NCT00991029)
Timeframe: Up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel141
Placebo167

Composite of Ischemic Stroke, Myocardial Infarction, or Death From Ischemic Vascular Causes

Primary efficacy outcome: Number of Participants with Ischemic Stroke, Myocardial Infarction, or Death From Ischemic Vascular Causes (NCT00991029)
Timeframe: Up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel121
Placebo160

Death From Any Cause

Other safety outcome: Number of Participants with Death from any cause (NCT00991029)
Timeframe: up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel18
Placebo12

Death From Ischemic Vascular Causes

Secondary efficacy outcome: Number of participants with Death from ischemic vascular causes (NCT00991029)
Timeframe: Up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel6
Placebo4

Hemorrhagic Stroke

Other safety outcome: Number of participants with Hemorrhagic stroke (NCT00991029)
Timeframe: up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel5
Placebo3

Ischemic or Hemorrhagic Stroke

Secondary efficacy outcome: Number of participants with Ischemic or hemorrhagic stroke (NCT00991029)
Timeframe: Up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel116
Placebo156

Ischemic Stroke

Secondary efficacy outcome:Number of participants with Ischemic stroke (NCT00991029)
Timeframe: Up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel112
Placebo155

Major Hemorrhage

Primary safety outcome: Number of Participants with major hemorrhage (NCT00991029)
Timeframe: Up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel23
Placebo10

Major Hemorrhage Other Than Intracranial Hemorrhage

Other safety outcome: Number of Participants with Major hemorrhage other than intracranial hemorrhage (NCT00991029)
Timeframe: up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel17
Placebo7

Minor Hemorrhage

Other safety outcome:Number of Participants with Minor hemorrhage (NCT00991029)
Timeframe: up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel40
Placebo13

Myocardial Infarction

Secondary efficacy outcome: Number of participants with Myocardial infarction (NCT00991029)
Timeframe: Up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel10
Placebo7

Other Symptomatic Intracranial Hemorrhage

Other safety outcome: Number of participants with other symptomatic intracranial hemorrhage (NCT00991029)
Timeframe: up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel2
Placebo0

Symptomatic Intracerebral Hemorrhage

Other safety outcome: Number of participants with Symptomatic intracerebral hemorrhage (NCT00991029)
Timeframe: up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel2
Placebo2

Number of Participants With a Bleeding Academic Research Consortium (BARC) 3 or 5 Bleeding

"BARC definition. We only considered BARC 3 or 5 for this secondary safety endpoint.~Type 3: Clinical, laboratory, and/or imaging evidence of bleeding with:~Type 3a:~Overt bleeding + Hb drop of 3 to < 5 g/dL (provided Hb drop is related to bleed)~Any transfusion with overt bleeding~Type 3b:~Overt bleeding + Hb drop ≥5 g/dL (provided Hb drop is related to bleed)~Cardiac tamponade~Bleeding requiring surgical intervention (excluding dental/nasal/skin/haemorrhoid)~Bleeding requiring intravenous vasoactive agents~Type 3c:~Intracranial haemorrhage (does not include microbleeds or haemorrhagic transformation, does include intraspinal)~Subcategories confirmed by autopsy or imaging or lumbar puncture~Intraocular bleed compromising vision. Type 5: Fatal bleeding~Type 5a:~• Probable fatal bleeding; no autopsy or imaging confirmation but clinically suspicious~Type 5b:~Definite fatal bleeding; overt bleeding or autopsy or imaging confirmation" (NCT01813435)
Timeframe: 2 year

InterventionParticipants (Count of Participants)
Experimental Treatment Strategy163
Reference Treatment Strategy169

Number of Participants With a Composite of All-cause Mortality or Non-fatal New Q-wave Myocardial Infarction (MI)

Number of Participants with a composite of all-cause mortality or non-fatal new Q-wave MI up to 2 years post randomisation. (NCT01813435)
Timeframe: 2 year

InterventionParticipants (Count of Participants)
Experimental Treatment Strategy304
Reference Treatment Strategy349

Number of Participants With a Composite of All-cause Mortality, Stroke, or New Q-wave Myocardial Infarction

shown are the first event per event type for each patient only. Multiple events of the same type within the same patient are disregarded (NCT01813435)
Timeframe: 2-year

InterventionParticipants (Count of Participants)
Experimental Treatment Strategy362
Reference Treatment Strategy416

Number of Participants With a Definite Stent Thrombosis

(NCT01813435)
Timeframe: 2 year

InterventionParticipants (Count of Participants)
Experimental Treatment Strategy64
Reference Treatment Strategy64

Number of Participants With a Myocardial Revascularisation

(NCT01813435)
Timeframe: 2 year

InterventionParticipants (Count of Participants)
Experimental Treatment Strategy739
Reference Treatment Strategy793

Number of Participants With a Stroke

(NCT01813435)
Timeframe: 2 year

InterventionParticipants (Count of Participants)
Experimental Treatment Strategy80
Reference Treatment Strategy82

Number of Participants With All-cause Mortality

(NCT01813435)
Timeframe: 2-year

InterventionParticipants (Count of Participants)
Experimental Treatment Strategy224
Reference Treatment Strategy253

Number of Participants With Myocardial Infarction

(NCT01813435)
Timeframe: 2 year

InterventionParticipants (Count of Participants)
Experimental Treatment Strategy248
Reference Treatment Strategy250

Number of Participants With New Q-wave Myocardial Infarction

(NCT01813435)
Timeframe: 2-year

InterventionParticipants (Count of Participants)
Experimental Treatment Strategy83
Reference Treatment Strategy103

Number of Patients With All Cause Death and Non-fatal Stroke

This is a key secondary endpoint. The number of observed patients with all cause death and non-fatal stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)50
Primary PCI (Group B)43

Number of Patients With All Cause Death and Shock

This is a key secondary endpoint. The number of observed patients with all cause death and shock within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)59
Primary PCI (Group B)73

Number of Patients With All Cause Death and Shock and CHF

This is a key secondary endpoint. The number of observed patients with all cause death and shock and CHF within 30 days was reported. (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)100
Primary PCI (Group B)123

Number of Patients With All Cause Death and Shock and CHF and Reinfarction and Disabling Stroke

This is a key secondary endpoint. The number of observed patients with all cause death and shock and CHF and reinfarction and disabling stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)117
Primary PCI (Group B)135

Number of Patients With All Cause Death and Shock and Reinfarction

This is a key secondary endpoint. The number of observed patients with all cause death and shock and reinfarction within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)77
Primary PCI (Group B)85

Number of Patients With All Cause Mortality

This is a key secondary endpoint. The number of observed patients with all cause mortality within 30 days was reported. (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)43
Primary PCI (Group B)42

Number of Patients With All-cause Mortality, Cardiogenic Shock, Congestive Heart Failure and Recurrent Myocardial Infarction Within 30 Days for FAS.

The number of observed patients with all-cause mortality, cardiogenic shock, congestive heart failure (CHF) and recurrent myocardial infarction within 30 days was reported for full analysis set (FAS). (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)116
Primary PCI (Group B)135

Number of Patients With Cardiac Mortality

This is a key secondary endpoint. The number of observed patients with cardiac mortality within 30 days was reported. (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)31
Primary PCI (Group B)32

Number of Patients With Cardiogenic Shock

This is a key secondary endpoint. The number of observed patients with cardiogenic shock within 30 days was reported. (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)41
Primary PCI (Group B)56

Number of Patients With Congestive Heart Failure (CHF)

This is a key secondary endpoint. The number of observed patients with congestive heart failure (CHF) within 30 days was reported. (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)57
Primary PCI (Group B)72

Number of Patients With Intracranial Haemorrhage

This is a key secondary endpoint. The number of observed patients with intracranial haemorrhage within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)9
Primary PCI (Group B)2

Number of Patients With Ischaemic Stroke

This is a key secondary endpoint. The number of observed patients with ischaemic stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)6
Primary PCI (Group B)3

Number of Patients With Major Non-intracranial Bleeds Including Blood Transfusions

This is a key secondary endpoint. The number of observed patients with major non-intracranial bleeds including blood transfusions within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)61
Primary PCI (Group B)45

Number of Patients With Minor Non-intracranial Bleeds

This is a key secondary endpoint. The number of observed patients with minor non-intracranial bleeds within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)206
Primary PCI (Group B)191

Number of Patients With Recurrent Myocardial Infarction (Reinfarction)

This is a key secondary endpoint. The number of observed patients with recurrent myocardial infarction (reinfarction) within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)23
Primary PCI (Group B)21

Number of Patients With Rehospitalisation for Cardiac Reasons

This is a key secondary endpoint. The number of observed patients with rehospitalisation for cardiac reasons within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)45
Primary PCI (Group B)41

Number of Patients With Rehospitalisation for Non-cardiac Reasons

This is a key secondary endpoint. The number of observed patients with rehospitalisation for non-cardiac reasons within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)19
Primary PCI (Group B)11

Number of Patients With Serious Repeat Target Vessel Revascularization

This is a key secondary endpoint. The number of observed patients with serious repeat target vessel revascularization within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)1
Primary PCI (Group B)2

Number of Patients With Serious Resuscitated Ventricular Fibrillation

This is a key secondary endpoint. The number of observed patients with serious resuscitated ventricular fibrillation within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)32
Primary PCI (Group B)38

Number of Patients With Serious Resuscitated Ventricular Fibrillation in Association With Invasive Procedures

This is a key secondary endpoint. The number of observed patients with serious resuscitated ventricular fibrillation in association with invasive procedures (occurring at any time during catheterisation or urgent/elective PCI) within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)10
Primary PCI (Group B)29

Number of Patients With Total Disabling Stroke

This is a key secondary endpoint. The number of observed patients with total disabling stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)2
Primary PCI (Group B)0

Number of Patients With Total Fatal Stroke

This is a key secondary endpoint. The number of observed patients with total fatal stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)7
Primary PCI (Group B)4

Number of Patients With Total Non-disabling Stroke

This is a key secondary endpoint. The number of observed patients with total non-disabling stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)8
Primary PCI (Group B)1

Number of Patients With Total Non-intracranial Bleeds

This is a key secondary endpoint. The number of observed patients with total non-intracranial bleeds within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)267
Primary PCI (Group B)236

Number of Patients With Total Stroke (All Types)

This is a key secondary endpoint. The number of observed patients with total stroke (all types) within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)15
Primary PCI (Group B)5

Percentage of Participants With a Composite Endpoint of All-cause Death, MI, or Stroke

The percentage of participants is the total number of participants experiencing an all-cause death, nonfatal MI, or nonfatal stroke divided by number of participants in the treatment arm. Endpoint events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)

Interventionpercentage of participants with an event (Number)
Prasugrel: <75 Years of Age10.61
Prasugrel: 75 Years of Age or Older27.04
Clopidogrel: <75 Years of Age11.12
Clopidogrel: 75 Years of Age or Older26.83

Percentage of Participants With a Composite Endpoint of Cardiovascular (CV) Death, Myocardial Infarction (MI), or Stroke

The percentage of participants is the total number of participants experiencing a CV death, nonfatal MI, or nonfatal stroke divided by number of participants in the treatment arm multiplied by 100. Endpoint events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)

Interventionpercentage of participants with an event (Number)
Prasugrel: <75 Years of Age10.06
Prasugrel: 75 Years of Age or Older24.64
Clopidogrel: <75 Years of Age10.96
Clopidogrel: 75 Years of Age or Older24.13

Percentage of Participants With a Composite Endpoint of CV Death and MI

The percentage of participants is the total number of participants experiencing a CV death or nonfatal MI divided by number of participants in the treatment arm. Endpoint events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)

Interventionpercentage of participants with an event (Number)
Prasugrel: <75 Years of Age9.61
Prasugrel: 75 Years of Age or Older22.53
Clopidogrel: <75 Years of Age10.21
Clopidogrel: 75 Years of Age or Older22.69

Percentage of Participants With a Composite Endpoint of CV Death, MI, Stroke, or Re-hospitalization for Recurrent Unstable Angina (UA)

The percentage of participants is the total number of participants experiencing a CV death, nonfatal MI, nonfatal stroke or re-hospitalization for a recurrent UA divided by number of participants in the treatment arm. Endpoints events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)

Interventionpercentage of participants with an event (Number)
Prasugrel: <75 Years of Age12.13
Prasugrel: 75 Years of Age or Older26.27
Clopidogrel: <75 Years of Age12.83
Clopidogrel: 75 Years of Age or Older25.67

Biomarker Measurements of Inflammation/Hemodynamic Stress: Brain Natriuretic Peptide (BNP)

Brain natriuretic peptide (BNP) is secreted by the ventricles of the heart in response to hemodynamic stress and is a biomarker associated with increased CV risk. Results are presented as geometric least squares means (Geometric LS means). Geometric LS means were adjusted for treatment + baseline value + clopidogrel status at randomization. (NCT00699998)
Timeframe: Day 30 and 6 Months

,,,
Interventionpicograms per milliliter (pg/mL) (Geometric Mean)
Day 306 Months (n=725, 125, 701, 174)
Clopidogrel: <75 Years of Age319.345250.982
Clopidogrel: 75 Years of Age or Older951.359722.750
Prasugrel: <75 Years of Age313.494253.434
Prasugrel: 75 Years of Age or Older1082.396770.132

Biomarker Measurements of Inflammation/Hemodynamic Stress: C-Reactive Protein (CRP)

C-Reactive Protein (CRP) is a biomarker associated with inflammation and increased CV risk. Results are presented as geometric least squares means (Geometric LS means). Geometric LS means were adjusted for treatment + baseline value + clopidogrel status at randomization. (NCT00699998)
Timeframe: Day 30 and Month 6

,,,
Interventionmilligrams per liter (mg/L) (Geometric Mean)
Day 306 Months (n=755, 143, 745, 178)
Clopidogrel: <75 Years of Age2.2872.149
Clopidogrel: 75 Years of Age or Older2.2261.543
Prasugrel: <75 Years of Age2.3302.272
Prasugrel: 75 Years of Age or Older2.4411.593

Economic and Quality of Life Outcomes

Seattle Angina Questionnaire (SAQ) is a validated, disease-specific questionnaire containing 11 questions (Q) yielding 5 summary scales related to angina: physical limitations, angina stability, angina frequency, treatment satisfaction and disease perception. In this study only angina frequency and the physical limitations scales were assessed. Anginal Frequency was assessed using Q3 and Q4 which consists of a Likert scale ranging from 1 to 6 (higher values equals better quality of life) to assess how often a patient is having symptoms now. Physical limitations was assessed using Q1 which contains 9 items each assessed via Likert scale ranging from 1 to 6 (higher values equals better quality of life) to assess how much a participant's condition is hampering their ability to do what they want to do. Scale scores are transformed to a 0-100 by subtracting the lowest possible score, dividing by the range of the scale, and multiplying by 100. Higher values equal better quality of life. (NCT00699998)
Timeframe: Baseline and follow-up (24 months)

,
Interventionunits on a scale (Mean)
Baseline, physical limitationsBaseline, angina frequency24 Months, physical limitations (n=420, 412)24 Months, angina frequency (n=420, 412)
Clopidogrel67.073.174.589.5
Prasugrel67.873.675.189.7

Genotyping Related to Drug Metabolism

Variation in the genes encoding the cytochrome P450 (CYP) enzymes (CYP2C19) can reduce the ability to metabolize clopidogrel and a reduced platelet response and have been associated with increased rates of CV events including CV death. Participants were classified as extensive metabolizers (EM); reduced metabolizers (RM); or unknown (UNK) metabolizers based on their CYP2C19 genotype. Possible extensive metabolizer (EM) phenotypes include EM=extensive metabolizer, UM=ultra-rapid metabolizer, and EM (non-UM) that are not UM. Possible reduced metabolizer (RM) phenotypes include IM=intermediate metabolizer and PM=poor metabolizer. Genotypes associated with each predicted phenotype are presented; predicted phenotype is presented first followed by the genotype. Percentage=(number of participants with the predicted phenotype and genotype divided by the total number of participants per arm) multiplied by 100. (NCT00699998)
Timeframe: Baseline

,,,
Interventionpercentage participants with geneotype (Number)
UM, *1/*17UM, *17/*17EM (non-UM), *1/*1IM, *1/*2IM, *1/*3IM, *1/*4IM, *1/*6IM, *1/*8PM, *2/*2PM, *2/*3PM, *2/*4PM, *2/*6PM, *2/*8PM, *3/*3UNK, *1/*10UNK, *1/*13UNK, *1/*9UNK, *1/*9, *9/*17UNK, *13/*17UNK, *2/*13UNK, *2/*17UNK, *2/*9UNK, *3/*17UNK, *4/*17UNK, *4/*9UNK, *6/*17UNK, *8/*17UNK, *9/*17UNK, Undefined genotype
Clopidogrel: <75 Years of Age25.15.435.719.80.50.10.00.44.30.30.20.00.00.20.10.00.00.00.00.06.80.10.00.20.00.00.10.00.5
Clopidogrel: 75 Years of Age or Older21.84.341.219.70.60.30.20.33.80.30.20.00.00.00.00.00.00.00.00.06.20.00.30.00.00.20.00.00.6
Prasugrel: <75 Years of Age24.05.138.818.60.80.40.00.13.90.30.00.00.00.00.00.00.10.00.00.06.30.00.10.20.00.00.20.00.7
Prasugrel: 75 Years of Age or Older25.03.642.118.30.60.00.20.52.20.20.20.00.00.00.00.20.20.00.00.06.10.00.00.20.00.00.00.00.6

Platelet Aggregation Measures

Platelet aggregation was measured by as measured by Accumetrics Verify Now™ P2Y12. Results were reported in P2Y12 Reaction Units (PRU). PRU represents the rate and extent of adenosine (ADP)-stimulated platelet aggregation. Lower values indicate greater P2Y12 platelet inhibition and lower platelet activity and aggregation. ANCOVA Model was used and values were corrected for treatment + baseline value + clopidogrel status at randomization. (NCT00699998)
Timeframe: Day 30 and 12 Months

,,,
InterventionP2Y12 Reaction Units (PRU) (Least Squares Mean)
Day 30Month 12 (n=386, 76, 400, 103)
Clopidogrel: <75 Years of Age193.489199.003
Clopidogrel: 75 Years of Age or Older200.285181.360
Prasugrel: <75 Years of Age93.28094.529
Prasugrel: 75 Years of Age or Older151.872135.096

Summary of All Deaths

All deaths, regardless of possible relatedness, with the exception of 1 event, were adjudicated by the Clinical Endpoint Committee (CEC) and are reported in this table. The 1 event which was not adjudicated was a result of the revocation of consent by the participant prior to their death. Deaths possibly related to study drug in the opinion of the investigator are also contained in the Serious Adverse Event (SAE) module. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)

,,,
Interventionparticipants (Number)
Congestive Heart FailureCardiogenic ShockCardiac RuptureMyocardial InfarctionDysrhythmiaStent ThrombosisDirectly Related to Revascularization-CABG or PCIIntracranial HemorrhageNon-Hemorrhagic StrokeSudden death due to cardiovascular eventPulmonary EmbolismStroke, unknown typeOther Cardiovascular EventCardiovascular event, unknown typeAccidentalTraumaHemorrhage, not intracranialInfectionMalignancySuicideOther Non-Cardiovascular eventCause unknown (nonadjudicated event)
Clopidogrel: <75 Years of Age13100246014470200451001614080
Clopidogrel: 75 Years of Age or Older2390213011343101451141711060
Prasugrel: <75 Years of Age1080165012475006401211414180
Prasugrel: 75 Years of Age or Older214124201143911141031217041

Number of Subjects Reaching the Composite Endpoint of All-Cause Death, Nonfatal Myocardial Infarction (MI), or Nonfatal Stroke

The endpoint in this measure is a combination of all-cause death, nonfatal MI, or nonfatal stroke. Results are reported for the All ACS population. (NCT00097591)
Timeframe: Randomization up to 15 months

InterventionParticipants (Number)
Prasugrel692
Clopidogrel822

Number of Subjects Reaching the Composite Endpoint of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, or Rehospitalization for Cardiac Ischemic Events

The endpoint in this measure is a combination of CV death, nonfatal MI, nonfatal stroke, or rehospitalization for cardiac ischemic events. Results are reported for the All ACS population. (NCT00097591)
Timeframe: Randomization up to 15 months

InterventionParticipants (Number)
Prasugrel797
Clopidogrel938

Number of Subjects Reaching the Composite Endpoint of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), or Nonfatal Stroke

The endpoint in this measure is a combination of CV death, nonfatal MI, or nonfatal stroke. Results are reported for the All ACS population for the 30 and 90 day periods. (NCT00097591)
Timeframe: Randomization to 30 days; randomization to 90 days

,
InterventionParticipants (Number)
All ACS (Through 30 days)All ACS (Through 90 days)
Clopidogrel502573
Prasugrel389462

Number of Subjects Reaching the Composite Endpoint of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), or Nonfatal Stroke

The endpoint in this measure is a combination of CV death, nonfatal MI, or nonfatal stroke. The data is presented by the study population, which is represented as follows: 1) subjects who presented with unstable angina and non-ST-segment elevation myocardial infarction (UA/NSTEMI), 2) subjects who presented with ST segment elevation myocardial infarction (STEMI), and 3) all subjects with acute coronary syndromes (ACS) (i.e. all subjects with UA/NSTEMI or STEMI). (NCT00097591)
Timeframe: Randomization up to 15 months

,
InterventionParticipants (Number)
UA/NSTEMI (n=5044, n=5030)STEMI (n=1769, n=1765)All ACS (n=6813, n=6795)
Clopidogrel565216781
Prasugrel469174643

Number of Subjects Reaching the Composite Endpoint of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), or Urgent Target Vessel Revascularization (UTVR)

The endpoint in this measure is a combination of CV death, nonfatal MI, or UTVR. Results are reported for the All ACS subject population for the 30 and 90 day periods. (NCT00097591)
Timeframe: Randomization to 30 days; randomization to 90 days

,
InterventionParticipants (Number)
All ACS (Through 30 days)All ACS (Through 90 days)
Clopidogrel504588
Prasugrel399472

Number of Treated Subjects With Non-Coronary Artery Bypass Graft (CABG) Related Thrombolysis In Myocardial Infarction (TIMI) Study Group Major and Minor Bleeding Events

TIMI classification for major and minor bleeding in the subset of subjects who did not undergo a coronary artery bypass operation (CABG) were defined as follows: Major bleeding: any intracranial hemorrhage (ICH) OR any clinically overt bleeding (including bleeding evident on imaging studies) associated with a fall in hemoglobin (Hgb) of ≥5 grams/deciliter (gm/dL)from baseline. Minor Bleeding: any clinically overt bleeding associated with a fall in Hgb of ≥3 gm/dL but <5 gm/dL from baseline. Major bleeding events were further examined as events that were deemed life threatening and/or fatal. (NCT00097591)
Timeframe: First dose of study drug up to 15 months (while at risk)

,
InterventionParticipants (Number)
TIMI Major or Minor BleedingTIMI Major BleedingTIMI Major Bleeding - Life-threatening (LT)LT - FatalLT - Symptomatic intracranial hemorrage (ICH)LT - Requiring inotropesLT - Requiring surgical interventionLT - Requiring transfusion (>=4 units)TIMI Minor Bleeding
Clopidogrel2311115651781930125
Prasugrel303146852119211945164

Number of Participants With BARC Type 2, 3, or 5

Number of participants with first occurrence of clinically relevant bleeding episode, defined as Bleeding Academic Research Consortium (BARC) Types 2, 3 or 5 bleeding. BARC bleeding types range from 0 (no bleeding) to 5 (fatal bleeding). (NCT02270242)
Timeframe: 12 months after randomization

InterventionParticipants (Count of Participants)
Placebo + Ticagrelor141
Aspirin + Ticagrelor250

Number of Participants With Ischemic Episode

Number of participants with first occurrence of confirmed all-cause death, non-fatal myocardial infarction or stroke. (NCT02270242)
Timeframe: 12 months after randomization

InterventionParticipants (Count of Participants)
Placebo + Ticagrelor135
Aspirin + Ticagrelor137

Composite Endpoint of Cardiac Death and Myocardial Infarction (Not Clearly Attributable to a Non-target Vessel)

(NCT00752128)
Timeframe: 12 Months

Interventionpercentage of participants (Number)
Cardiac Death or Target Vessel MI4.2

Overall Stent Thrombosis, Defined as Definite and Probable Stent Thrombosis, According to the Academic Research Consortium (ARC) Definition

(NCT00752128)
Timeframe: 12 Months

Interventionpercentage of participants (Number)
Overall Stent Thrombosis (Definite and Probable-ARC)0.9

Death

(NCT00726453)
Timeframe: 12 months

Interventionpercentage of participants (Number)
Primary Enrollment Group1.3

Major Adverse Cardiac Event (MACE)

Major Adverse Cardiac Event (MACE) composite endpoint and each individual component (death, Target Vessel MI (Q wave and non-Q wave), emergent coronary bypass surgery (CABG), or clinically-driven repeat Target Lesion Revascularization (TLR) by percutaneous or surgical methods). (NCT00726453)
Timeframe: 12 months

Interventionpercentage of participants (Number)
Primary Enrollment Group5.5

Stent Thrombosis (ST)

Stent Thrombosis (ST) (as determined by historic and ARC definitions). (NCT00726453)
Timeframe: 12 months

Interventionpercentage of participants (Number)
Primary Enrollment Group0.1

Target Lesion Failure (TLF)

Target Lesion Failure (TLF) at 12 months post-procedure, defined as Cardiac Death, Target Vessel Myocardial Infarction (TVMI) (Q wave and non-Q wave) or clinically-driven Target Lesion Revascularization (TLR) by percutaneous or surgical methods. (NCT00726453)
Timeframe: 12 Months

Interventionpercentage of participants (Number)
Primary Enrollment Group4.7

Target Vessel Failure (TVF)

Target Vessel Failure (TVF) composite endpoint and each individual component (Cardiac Death, Target Vessel MI, or clinically-driven Target Vessel Revascularization (TVR) by percutaneous or surgical methods). (NCT00726453)
Timeframe: 12 months

Interventionpercentage of participants (Number)
Primary Enrollment Group6.3

Target Vessel MI

Target Vessel MI (as determined by extended historical and ARC definitions). (NCT00726453)
Timeframe: 12 months

Interventionpercentage of eligible participants (Number)
Primary Enrollment Group1.4

In-stent Late Lumen Loss (LLL)

The difference between the post-procedure immediate minimal lumen diameter (MLD) and follow up angigraphy MLD (NCT00927940)
Timeframe: Post procedure, 8 Months

Interventionmm (Mean)
Zotarolimus Eluting Stent0.13

Percent of Patient With Target Lesion Failure(Major Secondary Endpoint)

Major Secondary Endpoint Target lesion fature (TLF) is defined as cardiac death, target vessel myocardial infarction(Q wave and non-Q wave), or clinically-driven target lesion revascularization (TLR) by percutaneous or surgical methods. (NCT00927940)
Timeframe: 12 months

Interventionpercentage of participants with TLF (Number)
Zotarolims Eluting Stent4.0

In-Stent Percent Diameter Stenosis

In Stent Percent Diameter Stenosis at thirteen months. In Stent Percent Diameter Stenosis: measured percent of diameter stenosis at the region of the stent (calculated as 100x(RVD-MLD)/RVD using the mean values from 2 orthogonal views by QCA. RVD (Reference Vessel Diameter): average of normal segments within 10mm proximal and distal to target lesion from 2 orthogonal views using QCA. MLD (Minimal Lumen Diameter): average of 2 orthogonal views of the narrowest point wihtin the area of assessment. MLD measured during QCA by the angiographic core laboratory. (NCT00617084)
Timeframe: 13 Months

InterventionPercentage diameter stenosis (Mean)
1. Resolute - 12-13 Months21.65
2. XIENCE V - 12-13 Months19.76

Target Lesion Failure

Percentage of participants that had either Cardiac Death, Myocardial Infarction (not clearly attributable to a non-target vessel)or Target Lesion Revascularization (TLR, clinically indicated) after one year. MI: Q MI if new pathological Q waves and chest pain, non Q MI if CK elevated more than two times normal, troponin elevated more than normal, according to ARC definitions. TLR, clinically indicated if associated with ischemic symptoms and angiographic min lumen diameter bigger than fifty percent by QCA or without symptoms and min lumen diameter bigger than seventy percent. Measure average. (NCT00617084)
Timeframe: 12 months

Interventionpercentage of participants (Number)
1. Resolute - 12-13 Months8.2
2. XIENCE V - 12-13 Months8.3

Participants With Any Event From the Composite of All-cause Mortality, MI, and Stroke

Participants with death from any cause, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal of consent or date of scheduled withdrawal from therapy. ITT analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months

InterventionParticipants (Number)
TICAGRELOR901
CLOPIDOGREL1065

Participants With Any Event From the Composite of Death From Vascular Causes, MI (Including Silent), Stroke, Recurrent Ischemia, Transient Ischemic Attack (TIA) and Other Arterial Thrombotic Events.

Participants with death from vascular causes, MI, stroke, recurrent ischemia, or other thrombotic events. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT analysis of whole population. Events were adjudicated. (NCT00391872)
Timeframe: Randomization up to 12 months

InterventionParticipants (Number)
TICAGRELOR1290
CLOPIDOGREL1456

Participants With Any Event From the Composite of Death From Vascular Causes, MI, and Stroke for the Subgroup of Patients With Intent for Invasive Management at Randomization

Participants with death from vascular causes, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT analysis of intent for invasive management population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months

InterventionParticipants (Number)
TICAGRELOR569
CLOPIDOGREL668

Participants With Any Event From the Composite of Death From Vascular Causes, Myocardial Infarction (MI), and Stroke

Participants with death from vascular causes, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. Intention To Treat (ITT) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months

InterventionParticipants (Number)
TICAGRELOR864
CLOPIDOGREL1014

Participants With Any Major Bleeding Event

Participants with major (fatal/life-threatening or other) bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months

InterventionParticipants (Number)
TICAGRELOR961
CLOPIDOGREL929

Participants With Coronary Artery Bypass Graft (CABG) Major Bleeding

Participants with a major CABG-related bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. All CABG surgeries were submitted for adjudication by an endpoint committee as potential bleeds. (NCT00391872)
Timeframe: First dosing up to 12 months

InterventionParticipants (Number)
TICAGRELOR619
CLOPIDOGREL654

Participants With Coronary Artery Bypass Graft (CABG) Major Fatal/Life-threatening Bleeding

Number of participants with a major fatal/life-threatening CABG-related bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. All CABG surgeries were submitted for adjudication by an endpoint committee as potential bleeds. (NCT00391872)
Timeframe: First dosing up to 12 months

InterventionParticipants (Number)
TICAGRELOR329
CLOPIDOGREL341

Participants With Death From Any Cause

Participants with death from any cause. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months

InterventionParticipants (Number)
TICAGRELOR399
CLOPIDOGREL506

Participants With Death From Vascular Causes

Participants with death from vascular causes. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months

InterventionParticipants (Number)
TICAGRELOR353
CLOPIDOGREL442

Participants With Major or Minor Bleeding

Participants with major (fatal/life-threatening or other) or minor bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months

InterventionParticipants (Number)
TICAGRELOR1339
CLOPIDOGREL1215

Participants With MI Event

Participants with MI event. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months

InterventionParticipants (Number)
TICAGRELOR504
CLOPIDOGREL593

Participants With Non-CABG (Coronary Artery Bypass Graft) Related Major Bleeding

Participants with non CABG related major (fatal/life-threatening or other) bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months

InterventionParticipants (Number)
TICAGRELOR362
CLOPIDOGREL306

Participants With Non-procedural Major Bleeding

Participants with non-procedural major bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months

InterventionParticipants (Number)
TICAGRELOR235
CLOPIDOGREL180

Participants With Stroke

Participants with stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months

InterventionParticipants (Number)
TICAGRELOR125
CLOPIDOGREL106

Participants With Ventricular Pauses of Greater Than or Equal to 3 Seconds in Patients Monitored by Holter 24 Hour ECG Recorders for 1 Week at 1 Month Following Randomization

Number of participants who were observed to have at least 1 ventricular pause of at least 3 seconds. Population is all patients who were observed over 2 week-long periods. Pauses were flagged algorithmically and confirmed by TIMI cardiologists. (NCT00391872)
Timeframe: 1-week period following randomization

InterventionParticipants (Number)
TICAGRELOR21
CLOPIDOGREL16

Participants With Ventricular Pauses of Greater Than or Equal to 3 Seconds in Patients Monitored by Holter 24-hour ECG Recorders for 1 Week Following Randomization

Number of participants who were observed to have at least 1 ventricular pause of at least 3 seconds. Population is all patients who were observed over 2 week-long periods. Pauses were flagged algorithmically and confirmed by Thrombolysis in Myocardial Infarction (TIMI) group cardiologists. (NCT00391872)
Timeframe: 1-week period following randomization

InterventionParticipants (Number)
TICAGRELOR84
CLOPIDOGREL51

1st Composite Clinical Endpoint

death/MI/stroke/urgent revascularization/stent thrombosis. Adjudicated events except death (NCT01347580)
Timeframe: during the 30 days of treatment

Interventionpatients (Number)
Pre-hospital Ticagrelor41
In-hospital Ticagrelor42

2nd Composite Clinical Endpoint

Death/MI/urgent revascularization. Adjudicated events except death (NCT01347580)
Timeframe: within 30 days of study

Interventionpatients (Number)
Pre-hospital Ticagrelor39
In-hospital Ticagrelor34

Definite Stent Thrombosis

Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation. It is an adjudicated endpoint (NCT01347580)
Timeframe: during 30 days of treatment

Interventionpatients (Number)
Pre-hospital Ticagrelor2
In-hospital Ticagrelor11

Major Bleeds After 48 Hours

non CABG related bleeds (PLATO definition) include life threatening and other major bleedings (NCT01347580)
Timeframe: after 48hours post-first dose

Interventionpatients (Number)
Pre-hospital Ticagrelor11
In-hospital Ticagrelor11

Major Bleeds Within 48 Hours

non CABG related bleeds, (PLATO definition) include Life threatening and other major bleeds (NCT01347580)
Timeframe: within 48 hours of first dose

Interventionpatients (Number)
Pre-hospital Ticagrelor16
In-hospital Ticagrelor15

Minor and Major Bleedings Within 48 Hours

non CABG related bleeds (PLATO definition) (NCT01347580)
Timeframe: within 48 hours of first dose

Interventionpatients (Number)
Pre-hospital Ticagrelor24
In-hospital Ticagrelor24

Minor and Major Bleeds After 48 Hours

non CABG related bleeds (PLATO definition) (NCT01347580)
Timeframe: after 48 hours post first dose

Interventionpatients (Number)
Pre-hospital Ticagrelor18
In-hospital Ticagrelor16

ST Segment Elevation Resolution Post-PCI >= 70%

ST segment elevation resolution post PCI >=70% is defined as complete resolution (NCT01347580)
Timeframe: Between baseline and ECG 60 mn post-PCI

Interventionpatients (Number)
Pre-hospital Ticagrelor410
In-hospital Ticagrelor390

ST-segment Elevation Resolution Pre PCI ≥70% (Co-primary Endpoint)

ST segment elevation resolution is the mean ST elevation pre-hospital minus the mean STelevation pre-PCI divided by the mean ST elevation pre-hospital. It is expressed as a percentage and split in 2 categories , complete (≥70%) versus incomplete (<70%) resolution. (NCT01347580)
Timeframe: Between baseline and PCI

Interventionpatients (Number)
Pre-hospital Ticagrelor102
In-hospital Ticagrelor102

Thrombolysis In Myocardial Infarction (TIMI) Flow Grade 3 of MI Culprit Vessel at Initial Angiography (Co-primary Endpoint)

(TIMI) flow grade classification is used to assess coronary blood flow in acute coronary syndromes. grade 0:no reperfusion, grade 1: penetration without perfusion, grade 2: Partial reperfusion, grade 3: complete perfusion. (NCT01347580)
Timeframe: At initial angiography, pre PCI

Interventionpatients (Number)
Pre-hospital Ticagrelor143
In-hospital Ticagrelor145

Thrombotic Bail-out With GPIIb/IIIa Inhibitors at Initial PCI

Glycoprotein (GP) IIb/IIIa inhibitors are often used as a rescue or bailout therapy to manage complications arising during percutaneous coronary intervention. (NCT01347580)
Timeframe: during PCI

Interventionpatients (Number)
Pre-hospital Ticagrelor78
In-hospital Ticagrelor100

TIMI Flow Grade 3 Post -PCI

TIMI) flow grade 3 is complete perfusion post-PCI. (NCT01347580)
Timeframe: at coroangiography post-PCI

Interventionpatients (Number)
Pre-hospital Ticagrelor625
In-hospital Ticagrelor630

Any Bleeding Event

"Bleeding classified by the TIMI hemorrhage classification scheme:~Minor: any clinically overt sign of hemorrhage (including imaging) that is associated with a hemoglobin drop of 3 to < 5 g/dL~Major: (1) if it is intracranial, or (2) clinically significant overt signs of hemorrhage associated with a drop inhemoglobin of > 5 g/dL" (NCT01515345)
Timeframe: 30days

Interventionparticipants (Number)
Standard Therapy17
Individualized Therapy9

Definite Stent Thrombosis

"The angiographic or pathological confirmation of stent thrombosis is called definite stent thrombosis" (NCT01515345)
Timeframe: 30 days

Interventionparticipants (Number)
Standard Therapy1
Individualized Therapy0

Probable Stent Thrombosis

"Probable stent thrombosis is considered to have occurred in case of~any unexplained death within the first 30 days.~any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause, irrespective of the time after the index procedure" (NCT01515345)
Timeframe: 30days

Interventionparticipants (Number)
Standard Therapy2
Individualized Therapy0

Factors Associated With Initial ADP Receptor Inhibitor Selection at Enrollment: Duke Coronary Artery Disease (CAD) Index

The Duke CAD Index is a validated composite measure of angiographic burden, which assigns prognostic weights 1 through 100. Higher scores indicate greater angiographic burden and are associated with poorer prognosis. (NCT01088503)
Timeframe: Day 0 (study enrollment)

Interventionunits on a scale (Mean)
Prasugrel40.36
Other41.87

Factors Associated With Initial ADP Receptor Inhibitor Selection at Enrollment: Pre-Procedure Hemoglobin

(NCT01088503)
Timeframe: Day 0 (study enrollment)

Interventiongrams/deciliter (g/dL) (Mean)
Prasugrel14.59
Other14

Percentage of Participants With Definite or Probable Stent Thrombosis (ST) Events

Academic Research Consortium (ARC) criteria were used to define ST. Definite ST is angiographic or pathologic confirmation of partial or total thrombotic occlusion within the peri-stent region, and at least 1 of the following additional criteria: acute ischemic symptoms; ischemic electrocardiogram changes; elevated cardiac biomarkers. Probable ST is any unexplained death within 30 days of stent implantation; any MI, which is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of ST and in the absence of any other obvious cause. Events that occurred more than 7 days after medication was switched or discontinued were excluded from the analysis. Observed (unadjusted) percentages of participants with ST events are presented. Kaplan-Meier analysis was used to estimate the percentage of participants with a definite or probable ST event. (NCT01088503)
Timeframe: Baseline through 15 months

Interventionpercentage of participants (Number)
Prasugrel1.35
Clopidogrel1.79

Percentage of Participants With MACE and Who Had No Prior History of Transient Ischemic Attack (TIA)/Stroke, Weigh ≥60 Kilograms (kg), and Are Age <75 Years

MACE is defined as a composite of all-cause death, MI, stroke, or unplanned coronary revascularization. Events that occurred more than 7 days after medication was switched or discontinued were excluded from the analysis. Observed (unadjusted) percentages of participants with MACE, as well as the statistical analyses adjusted for baseline cohort differences, are presented. Percentage of participant = (number of participants with events / number of participants treated) * 100. (NCT01088503)
Timeframe: Baseline through 12 months

Interventionpercentage of participants (Number)
Prasugrel12.67
Clopidogrel15.89

Percentage of Participants With Major Adverse Cardiovascular Events (MACE)

MACE is defined as a composite of all-cause death, myocardial infarction (MI), stroke, or unplanned coronary revascularization. Events that occurred more than 7 days after medication was switched or discontinued were excluded from the analysis. Observed (unadjusted) percentages of participants with MACE, as well as the statistical analyses adjusted for baseline cohort differences, are presented. Percentage of participants = (number of participants with events in 12 months/ number of participants treated) * 100. (NCT01088503)
Timeframe: Baseline through 12 months

Interventionpercentage of participants (Number)
Prasugrel13.14
Clopidogrel17.12

Factors Associated With Initial Adenosine Diphosphate (ADP) Receptor Inhibitor Selection at Enrollment

Factors are drug-eluting stent (DES) vs. bare metal stent (BMS) placement, other (no stent) vs. BMS, STEMI, other race, cardiogenic shock occurred within 24 hours, male, European Quality of Life Questionnaire-5 Dimension Health State Score (EQ-5D) - United States (US) Index =1 vs. <1, married, diabetes, and other vs. BMS placement. The EQ-5D US index is a participant-rated, health-related, quality-of-life instrument based on US population. Scores range from -0.11 to 1.0 with 1.0 = perfect health. (NCT01088503)
Timeframe: Day 0 (study enrollment)

,
Interventionparticipants (Number)
Received DESReceived only BMSSTEMIOther Race (Non-Caucasian)Cardiogenic Shock on PresentationMale ParticipantsEQ-5D US index = 1 vs. <1Married ParticipantsParticipant has DiabetesNo BMS or DES
Other62822491450810491766342387356012472331
Prasugrel236567218313657924511516204476786

Percentage of Participants With Cumulative Severe or Moderate Bleeding Events

Bleeding events were collected utilizing the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) definition of bleeding. Non-coronary artery bypass grafting (CABG)-related GUSTO severe or life-threatening bleeding is any intracranial hemorrhage (ICH) OR any bleeding event resulting in substantial hemodynamic compromise requiring treatment. Non-CABG-related GUSTO moderate bleeding is any bleeding event resulting in the need for transfusion that is not considered a GUSTO severe or life-threatening bleed. Additional bleeding events are fatal bleeding or ICH, or any non -fatal surgical-related bleeding events leading to ≥4 units of red cell transfusion. Observed (unadjusted) percentages of participants with bleeding events, as well as the statistical analyses adjusted for baseline cohort differences, are presented. Percentage of participants = (number of participants with events / number of participants treated) * 100. (NCT01088503)
Timeframe: Baseline, 1, 6, 12 and 15 months

,
Interventionpercentage of participants (Number)
Baseline1 month6 months12 months15 months
Clopidogrel0.451.622.773.864.21
Prasugrel0.541.221.932.723.10

Percentage of Participants With MACE Over 1, 6 and 15 Months

MACE is defined as a composite of all-cause death, MI, stroke, or unplanned coronary revascularization. Events that occurred more than 7 days after medication was switched or discontinued were excluded from the analysis. Observed (unadjusted) percentages of participants with MACE are presented. Kaplan-Meier analysis was used to estimate the percentage of participants with a MACE event. (NCT01088503)
Timeframe: Baseline through 1, 6 and 15 months

,
Interventionpercentage of participants (Number)
1 month6 months15 months
Clopidogrel5.4012.0419.13
Prasugrel4.639.6414.26

Incidence of Major Bleeding (GUSTO Classification, Severe and Moderate Bleeding Combined) for Randomized Subjects

(NCT01069003)
Timeframe: Placebo and Thienopyridine 12 - 30 months; Surveillance Arm (0 - 24 months)

InterventionPercentage of participants (Number)
Placebo Arm1.8
Thienopyridine Therapy2.0
Surveillance Arm4.8

Percentage of Participants of Incidence of ARC Definite or Probable Stent Thrombosis (ST) for Randomized Subjects

"All definite and probable Stent Thrombosis (ST) are adjudicated by an independent committee according to the definition based on Academic Research Consortium (ARC)~Definite is defined as angiographic or pathologic confirmation of partial or total thrombotic occlusion within the peri-stent region and at least 1 of the following: Acute ischemic symptoms, Ischemic ECG changes, Elevated cardiac biomarkers~Probable defined as any unexplained death within the first 30 days of procedure and any myocardial infarction, which is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause" (NCT01069003)
Timeframe: Placebo and Thienopyridine 12 - 30 months; Surveillance Arm (0 - 24 months)

Interventionpercentage of participants (Number)
Placebo Arm1.0
Thienopyridine Therapy0.5
Surveillance Arm2.4

Percentage of Participants With Composite of All Death, Target Vessel Myocardial Infarction (MI) and Stroke (Defined as MACCE) for Randomized Subjects

(NCT01069003)
Timeframe: Placebo and Thienopyridine 12 - 30 months; Surveillance Arm (0 - 24 months)

InterventionPercentage of participants (Number)
Placebo Arm4.3
Thienopyridine Therapy4.8
Surveillance Arm16.9

The Composite Incidence of All-cause Mortality, Myocardial Infarction (MI), Ischemia-driven Revascularization (IDR) and Stent Thrombosis (ST)

Clinical Events Committee (CEC)-adjudicated results (modified intent-to-treat [mITT] population) (NCT01156571)
Timeframe: 48 hours after randomization

Interventionparticipants (Number)
Cangrelor Treatment Arm257
Clopidogrel Treatment Arm322

Incidence of Major/Minor Non-coronary Artery Bypass Graft (CABG)-Related Hemorrhage by Clinical Relevant Criteria - GUSTO Severe/Life-threatening, Moderate and Mild

GUSTO = Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries trial (NCT01156571)
Timeframe: 48 hours after randomization

,
Interventionparticipants (Number)
GUSTO severe/life threateningGUSTO moderateGUSTO severe or moderateTIMI majorTIMI minorTIMI major or minorAny blood transfusion
Cangrelor Treatment Arm92231591425
Clopidogrel Treatment Arm6131953816

Individual Incidence of Stent Thrombosis (ST), Death, Myocardial Infarction (MI) and Ischemia-driven Revascularization (IDR)

CEC-adjudicated results (mITT population) (NCT01156571)
Timeframe: 48 hours after randomization

,
Interventionparticipants (Number)
Stent ThrombosisDeathMI (myocardial infarction)IDR (ischemia-driven revascularization)
Cangrelor Treatment Arm461820728
Clopidogrel Treatment Arm741825538

Number of Participants With Cardiovascular Death or Thromboembolic Event

Composite of CV-death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism (per adjudication). (NCT02556203)
Timeframe: Through study completion, on average 16 months

InterventionParticipants (Count of Participants)
Rivaroxaban (Xarelto, BAY59-7939)83
Antiplatelet68

Number of Participants With Composite Bleeding Endpoint of BARC (Bleeding Academic Research Consortium) 2, 3, or 5 Bleeds

Composite of BARC 2,3 or 5 bleedings (NCT02556203)
Timeframe: Through study completion, on average 16 months

InterventionParticipants (Count of Participants)
Rivaroxaban (Xarelto, BAY59-7939)148
Antiplatelet85

Number of Participants With Death or First Thromboembolic Event (DTE)

Death or first adjudicated thromboembolic event (DTE), defined as composite of all-cause death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism. (NCT02556203)
Timeframe: Through study completion, on average 14 months

InterventionParticipants (Count of Participants)
Rivaroxaban (Xarelto, BAY59-7939)68
Antiplatelet63

Number of Participants With Death or First Thromboembolic Event (DTE)

Death or first adjudicated thromboembolic event (DTE), defined as composite of all-cause death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism. (NCT02556203)
Timeframe: Through study completion, on average 16 months

InterventionParticipants (Count of Participants)
Rivaroxaban (Xarelto, BAY59-7939)105
Antiplatelet78

Number of Participants With ISTH (International Society on Thrombosis and Haemostasis) Major Bleeds

ISTH major bleeds (NCT02556203)
Timeframe: Through study completion, on average 16 months

InterventionParticipants (Count of Participants)
Rivaroxaban (Xarelto, BAY59-7939)49
Antiplatelet30

Number of Participants With Net-clinical Benefit

The net-clinical-benefit defined as the adjudicated composite of all-cause death, any stroke, myocardial infarction, symptomatic valve thrombosis, pulmonary embolism, deep vein thrombosis, non-CNS systemic embolism (efficacy); VARC life-threatening, disabling and VARC major bleeds (safety). (NCT02556203)
Timeframe: Through study completion, on average 16 months

InterventionParticipants (Count of Participants)
Rivaroxaban (Xarelto, BAY59-7939)137
Antiplatelet100

Number of Participants With Primary Bleeding Event (PBE)

PBE is defined according to VARC (Valve Academic Research Consortium) definitions as the adjudicated composite of: Life-threatening, disabling or major bleeding. (NCT02556203)
Timeframe: Through study completion, on average 16 months

InterventionParticipants (Count of Participants)
Rivaroxaban (Xarelto, BAY59-7939)46
Antiplatelet31

Number of Participants With TIMI (Thrombolysis In Myocardial Infarction) Major / Minor Bleeds

Composite of TIMI major and minor bleedings (NCT02556203)
Timeframe: Through study completion, on average 16 months

InterventionParticipants (Count of Participants)
Rivaroxaban (Xarelto, BAY59-7939)42
Antiplatelet24

5-year Composite Endpoint of All-cause Mortality, Non-fatal Myocardial Infarction, and Stroke

median 3.8 years of follow-up (NCT00086450)
Timeframe: Measured at Year 5

Interventionpercentage of participants (Number)
Percutaneous Coronary Intervention26.6
Coronary Artery Bypass Graft18.7

All-cause Mortality

(NCT00086450)
Timeframe: Measured at Year 5

Interventionpercentage of participants (Number)
Percutaneous Coronary Intervention16.3
Coronary Artery Bypass Graft10.9

Major MACCE Rates, Including the First of One of the Following: Death, Myocardial Infarction, Stroke, or Repeat Revascularization

(NCT00086450)
Timeframe: Measured at Year 1

Interventionpercentage of participants (Number)
Percutaneous Coronary Intervention16.8
Coronary Artery Bypass Graft11.8

Rates of Individual MACCE Endpoints

Major adverse cardiovascular and cerebrovascular events (NCT00086450)
Timeframe: Measured at Day 30

Interventionpercentage of participants (Number)
Percutaneous Coronary Intervention4.8
Coronary Artery Bypass Graft5.2

Definite or Probable Stent Thrombosis (ST) - Propensity Matched DES vs. BMS

Secondary powered endpoint (NCT00977938)
Timeframe: 33 months (0-33 months post-index procedure)

Interventionpercentage of patients (Number)
Propensity-matched DES1.70
Propensity-matched BMS2.61

Definite or Probable Stent Thrombosis (ST) - Randomized BMS ITT

ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)

Interventionpercentage of patients (KM estimate) (Number)
BMS 30-month DAPT0.50
BMS 12-month DAPT1.11

Definite or Probable Stent Thrombosis (ST) - Randomized BMS ITT

ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)

Interventionpercentage of patients (KM estimate) (Number)
BMS 30-month DAPT0.50
BMS 12-month DAPT1.11

Definite or Probable Stent Thrombosis (ST) - Randomized DES ITT

ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)

Interventionpercentage of patients (KM estimate) (Number)
DES 30-month DAPT0.69
DES 12-month DAPT1.45

Definite or Probable Stent Thrombosis (ST) - Randomized DES ITT

The coprimary efficacy endpoints were the cumulative incidence of MACCE and the cumulative incidence of definite or probable ST within randomized DES ITT patients between 12 and 30 months post procedure. ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)

Interventionpercentage of patients (KM estimate) (Number)
DES 30-month DAPT0.40
DES 12-month DAPT1.35

GUSTO Severe or Moderate Bleeding - Randomized BMS ITT

Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)

Interventionpercentage of patients (Number)
BMS 30-month DAPT2.03
BMS 12-month DAPT0.90

GUSTO Severe or Moderate Bleeding - Randomized BMS ITT

Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)

Interventionpercentage of patients (Number)
BMS 30-month DAPT2.09
BMS 12-month DAPT1.05

GUSTO Severe or Moderate Bleeding - Randomized DES ITT

Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)

Interventionpercentage of patients (Number)
DES 30-month DAPT2.74
DES 12-month DAPT1.88

GUSTO Severe or Moderate Bleeding - Randomized DES ITT

The primary safety endpoint was moderate or severe bleeding within randomized DES ITT patients between 12 and 30 months post procedure. Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)

Interventionpercentage of patients (Number)
DES 30-month DAPT2.53
DES 12-month DAPT1.57

MACCE (Death, Myocardial Infarction or Stroke) - Propensity Matched DES vs. BMS

Secondary powered endpoint (NCT00977938)
Timeframe: 33 months (0-33 months post-index procedure)

Interventionpercentage of patients (Number)
Propensity-matched DES11.37
Propensity-matched BMS13.24

MACCE (Death, Myocardial Infarction or Stroke) - Randomized BMS ITT

(NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)

Interventionpercentage of patients (KM estimate) (Number)
BMS 30-month DAPT4.04
BMS 12-month DAPT4.69

MACCE (Death, Myocardial Infarction or Stroke) - Randomized BMS ITT

(NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)

Interventionpercentage of patients (KM estimate) (Number)
BMS 30-month DAPT4.68
BMS 12-month DAPT5.48

MACCE (Death, Myocardial Infarction or Stroke) - Randomized DES ITT

(NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)

Interventionpercentage of patients (KM estimate) (Number)
DES 30-month DAPT5.62
DES 12-month DAPT6.49

MACCE (Death, Myocardial Infarction or Stroke) - Randomized DES ITT

The coprimary efficacy endpoints were the cumulative incidence of MACCE and the cumulative incidence of ARC definite or probable stent thrombosis within randomized DES ITT patients between 12 and 30 months post procedure. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)

Interventionpercentage of patients (KM estimate) (Number)
DES 30-month DAPT4.34
DES 12-month DAPT5.92

Area Under Curve of Serial Cardiac Biomarkers

An area under the curve of serial levels of Troponin I and creatine kinase-MB isoenzyme during 36 hours (NCT03114995)
Timeframe: 0,6,12,18,24,30,36 hours

,,
InterventionHours*ng/ml (Median)
Troponin Icreatine kinase-MB isoenzyme
Control C1 (High Platelet Reactivity - no Tirofiban)38.092.7
Control C2 (Low Platelet Reactivity - no Tirofiban)121.4185.6
Group A (High Platelet Reactivity - Tirofiban)197.2252.5

Percentage of Participants With Periprocedural Myonecrosis

"Percentage of participants with periprocedural myonecrosis under the criteria described below.~When the cardiac biomarkers before the procedure were within the 99th percentile upper reference limit (URL), more than a 5-fold elevation in the URL within 12 hours after percutaneous coronary intervention (PCI) was defined as periprocedural myonecrosis. If the cardiac biomarker level was already above the 99th percentile URL before the procedure and the trend was stationary or decreasing, a ≥20% increase compared to the previous level was considered periprocedural myonecrosis. If the trend was still increasing, the levels at the post-6 hour and 12-hour were compared to determine periprocedural myonecrosis." (NCT03114995)
Timeframe: 0,6,12,18,24,30,36 hours

,,
InterventionParticipants (Count of Participants)
Troponin Icreatine kinase-MB isoenzyme
Control C1 (High Platelet Reactivity - no Tirofiban)1510
Control C2 (Low Platelet Reactivity - no Tirofiban)2625
Group A (High Platelet Reactivity - Tirofiban)1611

Composite Outcome of Stroke, Myocardial Infarction (MI), or Vascular Death (Antiplatelet Comparison Only)

Number of patients with any of stroke, myocardial infarction, vascular death (NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years

InterventionParticipants (Number)
Aspirin + Extended Release Dipyridamole1333
Clopidogrel1333

Composite Outcome of Stroke, Myocardial Infarction, Vascular Death, or New or Worsening Congestive Heart Failure (CHF) (Telmisartan vs. Placebo Only)

Number of patients with any of stroke, myocardial infarction, vascular death, or new or worsening congestive heart failure (NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years

InterventionParticipants (Number)
Telmisartan1367
Placebo1463

Number of Patients With First Recurrent Stroke of Any Type, Fatal or Nonfatal (Antiplatelet Comparison Only)

(NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years

InterventionParticipants (Number)
Aspirin + Extended Release Dipyridamole916
Clopidogrel898

Number of Patients With First Recurrent Stroke of Any Type, Fatal or Nonfatal (Telmisartan vs. Placebo Only)

(NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years

InterventionParticipants (Number)
Telmisartan880
Placebo934

Number of Patients With New Onset of Diabetes (Telmisartan vs. Placebo Only)

(NCT00153062)
Timeframe: Randomization to final patient contact

InterventionParticipants (Number)
Telmisartan125
Placebo151

First Occurrence of CV Death / MI / Stroke - Interaction Clopidogrel Treatment Regimen and ASA Dose Level

(NCT00335452)
Timeframe: 30 days

Interventionparticipants (Number)
Clopidogrel 300/75/75 mg + ASA Low Dose267
Clopidogrel 300/75/75 mg + ASA High Dose290
Clopidogrel 600/150/75 mg + ASA Low Dose282
Clopidogrel 600/150/75 mg + ASA High Dose240

First Occurrence of CV Death / MI / Stroke - ASA Dose Comparison

(NCT00335452)
Timeframe: 30 days

,
Interventionparticipants (Number)
CV death/MI/Stroke- CV death- MI (fatal or not)- Stroke (fatal or not)
Clopidogrel + ASA High Dose52721125165
Clopidogrel + ASA Low Dose54623126055

First Occurrence of CV Death / MI / Stroke - Clopidogrel Treatment Regimen Comparison

"The primary endpoint is the first occurrence of any of the following events:~Cardiovascular death (any death with a clear cardiovascular or unknown cause),~Myocardial Infarction (diagnosis of new Myocardial Infarction (MI) - nonfatal or fatal)~Stroke (presence of a new focal neurologic deficit thought to be vascular in origin, with signs or symptoms lasting more than 24 hours - nonfatal or fatal)~reported between the randomization and Day 30 (inclusive), and validated by the blinded Event Adjudication Committee (EAC)." (NCT00335452)
Timeframe: 30 days

,
Interventionparticipants (Number)
CV death/MI/Stroke- CV death- MI (fatal or not)- Stroke (fatal or not)
Clopidogrel 300/75/75 mg + ASA55722227461
Clopidogrel 600/150/75 mg + ASA52222623759

First Occurrence of CV Death / MI / Stroke - Clopidogrel Treatment Regimen Comparison in PCI Subgroup

(NCT00335452)
Timeframe: 30 days

,
Interventionparticipants (Number)
CV death/MI/Stroke- CV death- MI (fatal or not)- Stroke (fatal or not)
Clopidogrel 300/75/75 mg + ASA39213222535
Clopidogrel 600/150/75 mg + ASA33013017228

Occurrence of Major Bleeding - ASA Dose Level Comparison

(NCT00335452)
Timeframe: 30 days

,
Interventionparticipants (Number)
Major bleeding- Severe bleeding- Major but not severe bleeding
Clopidogrel + ASA High Dose28221673
Clopidogrel + ASA Low Dose28521574

Occurrence of Major Bleeding - Clopidogrel Dose Regimen Comparison

Major bleeding is defined as any severe bleeding (associated with any of the following: death, leading to a drop in hemoglobin ≥ 5 g/dl, significant hypotension with the need for inotropic agents, symptomatic intracranial hemorrhage, requirement for surgery or for a transfusion ≥ 4 units of red blood cells or equivalent whole blood) and other major bleeding (significantly disabling bleeding, or intraocular bleeding leading to significant loss of vision or bleeding requiring transfusion of 2-3 units of red blood cells or equivalent whole blood) after validation by the independent EAC. (NCT00335452)
Timeframe: 30 days

,
Interventionparticipants (Number)
Major bleeding- Severe bleeding- Major but not severe bleeding
Clopidogrel 300/75/75 mg + ASA25519565
Clopidogrel 600/150/75 mg + ASA31323683

Occurrence of Stent Thrombosis - Clopidogrel Treatment Regimen Comparison

This includes definite stent thrombosis (confirmed by angiography or evidence of recent thrombus determined at autopsy or by examination of tissue retrieved following thrombectomy) and probable stent thrombosis (unexplained death having occurred after intracoronary stenting or, MI related to acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any obvious cause) after validation by the EAC. (NCT00335452)
Timeframe: 30 days

,
Interventionparticipants (Number)
Stent trombosis- Definite- Probable
Clopidogrel 300/75/75 mg + ASA20011189
Clopidogrel 600/150/75 mg + ASA1355877

Number of Participants With Healed Peptic Ulcer

Follow-up endoscopy was performed at the end of the 6th month (NCT02418312)
Timeframe: 6 months

Interventionparticipants (Number)
Histamine-2 Receptor Antagonist Group106
Placebo Group101

Number of Participants With Ulcer Recurrence

Follow-up endoscopy was performed at the end of the 6th month (NCT02551744)
Timeframe: six month

Interventionparticipants (Number)
Proton Pump Inhibitor Group1
Histamine-2 Receptor Antagonist Group7

Adjudicated Major Bleedings

The number of participants with at least one major bleeding, validated by the Event Adjudication Committee are counted over the duration of the follow-up (including after permanent discontinuation of the study drug). (NCT00249873)
Timeframe: expected median follow-up of approximately 3 years

Interventionparticipants (Number)
Clopidogrel + ASA251
Placebo + ASA162

Death From Any Cause (Cardiovascular and Noncardiovascular)

The considered event is death from any cause. The analysis is performed on the time from randomization to this event. Numbers of patients with the event over the duration of the follow-up are presented by arm group. (NCT00249873)
Timeframe: expected median follow-up of approximately 3 years

Interventionparticipants (Number)
Clopidogrel + ASA825
Placebo + ASA841

Occurrence of Stroke

The event is the occurence of stroke (nonfatal or fatal, ischemic, hemorrhagic or of uncertain type) after validation of the Event Adjudication Committee . The analysis is performed on the time from randomization to the occurrence of this event. Numbers of patients with the event over the duration of the follow-up are presented by arm group. (NCT00249873)
Timeframe: expected median follow-up of approximately 3 years

Interventionparticipants (Number)
Clopidogrel + ASA296
Placebo + ASA408

First Occurence of Any Component of the Composite of Stroke, Non-Central Nervous System (Non-CNS) Systemic Embolism, Myocardial Infarction or Vascular Death as Per Adjudication

"The primary event is the first occurence of any adjudicated component of the following cluster over the duration of follow-up :~stroke (nonfatal or fatal)~myocardial infarction (nonfatal or fatal)~non-CNS systemic embolism~vascular death~The primary efficacy analysis is performed on the time from randomization to this primary event. Numbers of patients with the composite event over the duration of the follow-up are presented by arm group." (NCT00249873)
Timeframe: expected median follow-up of approximately 3 years

,
Interventionparticipants (Number)
All components- Myocardial Infarction (fatal or not)- Stroke (fatal or not)- Non-CNS systemic embolism- Vascular death
Clopidogrel + ASA8328428550413
Placebo + ASA92410539148380

All-cause Death

Time to first occurence of All-cause death. The number of participants with events was reported. (NCT02291419)
Timeframe: up to 6 months. The planned duration of treatment was one year but the study was terminated after 6 months.

InterventionParticipants (Count of Participants)
Ticagrelor0
Aspirin0

Cardiovascular Death

Time to first occurence of Cardiovascular death. The number of patients with events was reported. (NCT02291419)
Timeframe: Up to 6 months. The planned duration of treatment was one year but the study was terminated after 6 months.

InterventionParticipants (Count of Participants)
Ticagrelor0
Aspirin0

Major Adverse Cardiovascular Events

Time to first occurence of the composite of Cardiovascular Death, Non-fatal Myocardial Infarction, Coronary Revascularization or Non-fatal Stroke. The number of patients with events is reported. (NCT02291419)
Timeframe: up to 6 months. The planned duration of treatment was one year but the study was terminated after 6 months.

InterventionParticipants (Count of Participants)
Ticagrelor0
Aspirin0

Non-fatal Myocardial Infarction or Coronary Revascularization

Time to first occurence of Non-fatal myocardial infarction or coronary revascularization. The number of participants with events was reported. (NCT02291419)
Timeframe: up to 6 months. The planned duration of treatment was one year but the study was terminated after 6 months.

InterventionParticipants (Count of Participants)
Ticagrelor0
Aspirin0

Non-fatal Stroke

Time to first occurence of Non-fatal stroke. The number of participants with events was reported. (NCT02291419)
Timeframe: up to 6 months. The planned duration of treatment was one year but the study was terminated after 6 months.

InterventionParticipants (Count of Participants)
Ticagrelor0
Aspirin0

The Number of Participants With Bleeding According to Bleeding Academic Research Consortium (BARC) Definitions

(NCT02291419)
Timeframe: up to 6 months. The planned duration of treatment was one year but the study was terminated after 6 months.

InterventionParticipants (Count of Participants)
Ticagrelor0
Aspirin0

Pharmacology Arm - Major Adverse Cardiovascular Events

Number of participants with major adverse cardiovascular events (death, reinfarction, target-vessel revascularization for ischemia, and stroke) (NCT00433966)
Timeframe: 3 years

InterventionParticipants (Count of Participants)
Pharmacology Arm - Bivalirudin379
Pharmacology Arm - Unfractionated Heparin377

Pharmacology Arm - Major Adverse Cardiovascular Events

Number of participants with major adverse cardiovascular events (death, reinfarction, target-vessel revascularization for ischemia, and stroke) (NCT00433966)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Pharmacology Arm - Bivalirudin98
Pharmacology Arm - Unfractionated Heparin99

Pharmacology Arm - Major Adverse Ischemic Cardiac Events and Major Bleeding Events

Number of participants with major adverse cardiovascular events (death, reinfarction, target-vessel revascularization for ischemia, and stroke) and major bleeding (bleeding adjudicated as not related to coronary artery bypass grafting). (NCT00433966)
Timeframe: 30 Days

InterventionParticipants (Count of Participants)
Pharmacology Arm - Bivalirudin166
Pharmacology Arm - Unfractionated Heparin218

Pharmacology Arm - Non-Coronary Artery Bypass Grafting-Related Major Bleeding

Number of participants with major bleeding (bleeding adjudicated as not related to coronary artery bypass grafting) (NCT00433966)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Pharmacology Arm - Bivalirudin89
Pharmacology Arm - Unfractionated Heparin149

Stent Arm - Death, Reinfarction, Stroke, or Stent Thrombosis

Number of Participants With Death, Reinfarction, Stroke, or Stent Thrombosis (NCT00433966)
Timeframe: 1 year

InterventionParticipants (Count of Participants)
Stent Arm - Paclitaxel-Eluting Stent181
Stent Arm - Bare Metal Stent59

Stent Arm - Ischemic Target Lesion Revascularization

Number of Participants With Ischemic Target Lesion Revascularization (NCT00433966)
Timeframe: 1 year

InterventionParticipants (Count of Participants)
Stent Arm - Paclitaxel-Eluting Stent98
Stent Arm - Bare Metal Stent54

Stent Arm - Segment Binary Angiographic Restenosis

Number of Participants With Segment Binary Angiographic Restenosis (13-month Angiographic Subset). (NCT00433966)
Timeframe: 13 months

InterventionParticipants (Count of Participants)
Stent Arm - Paclitaxel-Eluting Stent102
Stent Arm - Bare Metal Stent76

Incidence of Abrupt Closure, Threatened Abrupt Closure, Need for Urgent Coronary Artery Bypass Graft (CABG) Surgery, or Unsuccessful Procedure During the Index PCI

(a patient could have multiple procedural events) (NCT00305162)
Timeframe: during index PCI

Interventionparticipants (Number)
Cangrelor Arm127
Clopidogrel Arm141

Incidence of ACUITY Major Bleeding

Major bleeding (non-CABG-related) - Safety population (NCT00305162)
Timeframe: randomization through 48 hours after randomization

Interventionparticipants (Number)
Cangrelor Arm151
Clopidogrel Arm120

Incidence of ACUITY Major Bleeding (Without Hematoma >/= 5 cm)

excludes ACUITY major bleeding for which the only qualifying event was hematoma >/= 5 cm (NCT00305162)
Timeframe: randomization through 48 hours after randomization

Interventionparticipants (Number)
Cangrelor Arm78
Clopidogrel Arm65

Incidence of All Cause Mortality

(excluding STEMI) (NCT00305162)
Timeframe: randomization through 1 year after randomization

Interventionparticipants (Number)
Cangrelor Arm116
Clopidogrel Arm120

Incidence of All-cause Mortality

(NCT00305162)
Timeframe: randomization through 30 days after randomization

Interventionparticipants (Number)
Cangrelor Arm34
Clopidogrel Arm29

Incidence of All-cause Mortality and MI

(composite incidence) (NCT00305162)
Timeframe: randomization through 48 hours after randomization

Interventionparticipants (Number)
Cangrelor Arm285
Clopidogrel Arm261

Incidence of All-cause Mortality or MI

(composite incidence) (NCT00305162)
Timeframe: randomization through 30 days after randomization

Interventionparticipants (Number)
Cangrelor Arm321
Clopidogrel Arm298

Incidence of All-cause Mortality, MI or IDR

(composite incidence) (NCT00305162)
Timeframe: randomization through 30 days after randomization

Interventionparticipants (Number)
Cangrelor Arm343
Clopidogrel Arm327

Incidence of All-cause Mortality, Myocardial Infarction (MI), and Ischemia-driven Revascularization (IDR)

(composite incidence) (NCT00305162)
Timeframe: randomization through 48 hours after randomization

Interventionparticipants (Number)
Cangrelor Arm290
Clopidogrel Arm276

Incidence of GUSTO Severe / Life-threatening Bleeding

Major bleeding (non-CABG-related) - Safety population (NCT00305162)
Timeframe: randomization through 48 hours after randomization

Interventionparticipants (Number)
Cangrelor Arm10
Clopidogrel Arm11

Incidence of IDR

(NCT00305162)
Timeframe: randomization through 30 days after randomization

Interventionparticipants (Number)
Cangrelor Arm44
Clopidogrel Arm52

Incidence of MI

(NCT00305162)
Timeframe: randomization through 30 days after randomization

Interventionparticipants (Number)
Cangrelor Arm297
Clopidogrel Arm276

Incidence of Stroke

(NCT00305162)
Timeframe: randomization through 30 days after randomization

Interventionparticipants (Number)
Cangrelor Arm5
Clopidogrel Arm7

Incidence of Thrombolysis in Myocardial Infarction (TIMI) Major Bleeding

Major bleeding (non-CABG-related) - Safety population (NCT00305162)
Timeframe: randomization through 48 hours after randomization

Interventionparticipants (Number)
Cangrelor Arm19
Clopidogrel Arm14

Individual Incidence of All-cause Mortality

(NCT00305162)
Timeframe: randomization through 48 hours after randomization

Interventionparticipants (Number)
Cangrelor Arm8
Clopidogrel Arm5

Individual Incidence of IDR

(NCT00305162)
Timeframe: randomization through 48 hours after randomization

Interventionparticipants (Number)
Cangrelor Arm13
Clopidogrel Arm23

Incidence of Stroke

"Stroke is defined as a sudden, focal neurological defect resulting from a cerebrovascular cause that is not reversible within 24 hours and not due to a readily identifiable cause such as a tumor or trauma. All suspected strokes were reviewed and adjudicated by the Clinical Events Committee (CEC) who considered all clinically relevant information and imaging studies to classify all strokes as:~primary hemorrhagic - stroke with focal collections of intracranial blood~ischemic cerebral infarction - stroke without focal collections of intracranial blood~infarction with hemorrhagic conversion - cerebral infarction with blood thought to represent hemorrhagic conversion and not primary bleeding~uncertain - no imaging or autopsy data are available." (NCT00305162)
Timeframe: randomization through 48 hours after randomization

,
Interventionparticipants (Number)
primary hemorrhagicinfarction with hemorrhagic conversioncerebral infarctionuncertain type
Cangrelor Arm1050
Clopidogrel Arm0070

Device Time

This is one of the Device and Procedure-Related Endpoints. Device Time is defined as the time the Steerable Guide Catheter is placed in the intra-atrial septum until the time the MitraClip Delivery System (CDS) is retracted into the Steerable Guide Catheter. Device Time is shorter in duration than Procedure Time because it does not include the time required to perform transseptal access into the left atrium. (NCT01301625)
Timeframe: At day 0 (on the day of index procedure)

InterventionMinutes (Mean)
MitraClip Implant91.2

Fluoroscopy Duration

This is one of the Device and Procedure-Related Endpoints. Mean fluoroscopy duration during the MitraClip procedure. (NCT01301625)
Timeframe: At day 0 (on the day of index procedure)

InterventionMinutes (Mean)
MitraClip Implant41.2

Number of Participants With Acute Procedural Success Rate

Defined as successful MitraClip implantation with resulting MR of 2+ or less. (NCT01301625)
Timeframe: At day 0 (on the day of index procedure)

InterventionParticipants (Count of Participants)
MitraClip Implant39

Percentage of Participants Experiencing Death (Kaplan-Meier Analysis)

"Clinical Endpoint.~Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.)~Non-cardiac death is defined as a death not due to cardiac causes (as defined above)." (NCT01301625)
Timeframe: 12 months

Interventionpercentage of participants (Number)
MitraClip Implant8.3

Percentage of Participants Experiencing Death (Kaplan-Meier Analysis)

"Clinical Endpoint.~Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.)~Non-cardiac death is defined as a death not due to cardiac causes (as defined above)." (NCT01301625)
Timeframe: 30 days

Interventionpercentage of participants (Number)
MitraClip Implant0.0

Percentage of Participants Experiencing Death (Kaplan-Meier Analysis)

"Clinical Endpoint.~Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.)~Non-cardiac death is defined as a death not due to cardiac causes (as defined above)." (NCT01301625)
Timeframe: 6 months

Interventionpercentage of participants (Number)
MitraClip Implant6.1

Percentage of Participants Experiencing Death (Kaplan-Meier Analysis)

"Clinical Endpoint.~Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.)~Non-cardiac death is defined as a death not due to cardiac causes (as defined above)." (NCT01301625)
Timeframe: Baseline

Interventionpercentage of participants (Number)
MitraClip Implant0.0

Percentage of Participants Experiencing Freedom From Death and Congestive Heart Failure (Kaplan-Meier Curve Analysis)

"Death: Defined as all causes of death for the primary safety Major Adverse Event (MAE) Endpoint.~Death is further divided into 2 categories:~A. Cardiac death is defined as death due to any of the following:~Acute myocardial infarction~Cardiac perforation/pericardial tamponade~Arrhythmia or conduction abnormality~Stroke within 30 days of the procedure or stroke suspected of being related to the procedure~Death due to any complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery~Any death for which a cardiac cause cannot be excluded. B. Non-cardiac death is defined as a death not due to cardiac causes (as defined above).~Congestive Heart Failure (CHF): Defined as a documented diagnosis of CHF on the hospital admission report or discharge summary." (NCT01301625)
Timeframe: 6 months

Interventionpercentage of participants (Number)
MitraClip Implant91.5

Percentage of Participants Experiencing Freedom From Death and Congestive Heart Failure (Kaplan-Meier Curve Analysis)

"Death: Defined as all causes of death for the primary safety Major Adverse Event (MAE) Endpoint.~Death is further divided into 2 categories:~A. Cardiac death is defined as death due to any of the following:~Acute myocardial infarction~Cardiac perforation/pericardial tamponade~Arrhythmia or conduction abnormality~Stroke within 30 days of the procedure or stroke suspected of being related to the procedure~Death due to any complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery~Any death for which a cardiac cause cannot be excluded.~B. Non-cardiac death is defined as a death not due to cardiac causes (as defined above).~Congestive Heart Failure (CHF): Defined as a documented diagnosis of CHF on the hospital admission report or discharge summary." (NCT01301625)
Timeframe: 12 months

Interventionpercentage of participants (Number)
MitraClip Implant85.3

Percentage of Participants Experiencing Freedom From Death and Congestive Heart Failure (Kaplan-Meier Curve Analysis)

"Death: Defined as all causes of death for the primary safety Major Adverse Event (MAE) Endpoint.~Death is further divided into 2 categories:~A. Cardiac death is defined as death due to any of the following:~Acute myocardial infarction~Cardiac perforation/pericardial tamponade~Arrhythmia or conduction abnormality~Stroke within 30 days of the procedure or stroke suspected of being related to the procedure~Death due to any complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery~Any death for which a cardiac cause cannot be excluded.~B. Non-cardiac death is defined as a death not due to cardiac causes (as defined above).~Congestive Heart Failure (CHF): Defined as a documented diagnosis of CHF on the hospital admission report or discharge summary." (NCT01301625)
Timeframe: 30 days

Interventionpercentage of participants (Number)
MitraClip Implant96.1

Percentage of Participants Experiencing Freedom From Death and Congestive Heart Failure (Kaplan-Meier Curve Analysis)

"Death: Defined as all causes of death for the primary safety Major Adverse Event (MAE) Endpoint.~Death is further divided into 2 categories:~A. Cardiac death is defined as death due to any of the following:~Acute myocardial infarction~Cardiac perforation/pericardial tamponade~Arrhythmia or conduction abnormality~Stroke within 30 days of the procedure or stroke suspected of being related to the procedure~Death due to any complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery~Any death for which a cardiac cause cannot be excluded.~B. Non-cardiac death is defined as a death not due to cardiac causes (as defined above).~Congestive Heart Failure (CHF): Defined as a documented diagnosis of CHF on the hospital admission report or discharge summary." (NCT01301625)
Timeframe: Baseline

Interventionpercentage of participants (Number)
MitraClip Implant100

Post-procedure Hospital Stay

This is the Economic data reported to support the MitraClip System economic analysis. It is defined as the mean duration of time that patients spent in hospital following the MitraClip procedure. (NCT01301625)
Timeframe: Post index procedure within 30 days

InterventionDays (Mean)
MitraClip Implant3.4

Post-procedure Intensive Care Unit (ICU)/Critical Care Unit (CCU)/Post-anesthesia Care Unit (PACU) Duration

ICU and hospital stay is defined as the mean duration of time that patients spent in the ICU (Intensive Care Unit)/ CCU (Cardiac Care Unit)/ PACU (Post-Anesthesia Care Unit) following the MitraClip procedure. (NCT01301625)
Timeframe: Post index procedure within 30 days

InterventionHours (Mean)
MitraClip Implant62.1

Procedure Time

This is one of the Device and Procedure-Related Endpoints. Procedure Time is defined as the time elapsed from the start of the transseptal procedure to the time the Steerable Guide Catheter is removed. (NCT01301625)
Timeframe: At day 0 (on the day of index procedure)

InterventionMinutes (Mean)
MitraClip Implant133.5

Six Minute Walking Distance

The six-minute walk test (6MWT) measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. It is a measure of a patient's exercise capacity. (NCT01301625)
Timeframe: 12 months

InterventionMeters (Mean)
MitraClip Implant329.9

Six Minute Walking Distance

The six-minute walk test (6MWT) measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. It is a measure of a patient's exercise capacity. (NCT01301625)
Timeframe: 30 days

InterventionMeters (Mean)
MitraClip Implant297.3

Six Minute Walking Distance

The six-minute walk test (6MWT) measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. It is a measure of a patient's exercise capacity. (NCT01301625)
Timeframe: 6 months

InterventionMeters (Mean)
MitraClip Implant324.3

Six Minute Walking Distance

The six-minute walk test (6MWT) measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. It is a measure of a patient's exercise capacity. (NCT01301625)
Timeframe: Baseline

InterventionMeters (Mean)
MitraClip Implant271.0

Total Contrast Volume

This is one of the Device and Procedure-Related Endpoints. (NCT01301625)
Timeframe: At day 0 (on the day of index procedure)

InterventionMilliliters (Mean)
MitraClip Implant10.6

Change in Minnesota Living With Heart Failure (MLWHF) Quality of Life (QOL) Score From Baseline to 12 Months

"The Minnesota Living with Heart Failure Questionnaire(MLHFQ) is comprised of 21 questions.The response for each question ranges from 0(no affect on the patient's living) to 5(affected the patient's life very much during the past month).The total score for the 21 items can range from 0-105.A lower&higher MLHFQ score indicates less effect of heart failure&the worse impact of heart failure on a patient's QOL,respectively.Although the MLHFQ incorporates relevant aspects of the key dimensions of QOL (physical and emotional),the questionnaire was not designed to measure any particular dimension separately.The total score should be taken as the best measure of how heart failure and treatments impact QOL.~The total score is the sum of a)the physical dimension,measured using 8 questions (possible subscale score range 0-40) b)the emotional dimension,measured using 5 questions(possible subscale score from 0-25)&c) other factors,measured using 8 questions (possible subscale score from 0-40)." (NCT01301625)
Timeframe: 12 months

Interventionscores on a scale (Mean)
Baseline12 monthsDifference (12 months - Baseline)
MitraClip Implant51.130.2-20.9

Change in Minnesota Living With Heart Failure (MLWHF) Quality of Life (QOL) Score From Baseline to 30 Days

"The Minnesota Living with Heart Failure Questionnaire(MLHFQ) is comprised of 21 questions.The response for each question ranges from 0(no affect on the patient's living) to 5(affected the patient's life very much during the past month).The total score for the 21 items can range from 0-105.A lower&higher MLHFQ score indicates less effect of heart failure&the worse impact of heart failure on a patient's QOL,respectively.Although the MLHFQ incorporates relevant aspects of the key dimensions of QOL (physical and emotional),the questionnaire was not designed to measure any particular dimension separately.The total score should be taken as the best measure of how heart failure and treatments impact QOL.~The total score is the sum of a)the physical dimension,measured using 8 questions (possible subscale score range 0-40) b)the emotional dimension,measured using 5 questions(possible subscale score from 0-25)&c) other factors,measured using 8 questions (possible subscale score from 0-40)." (NCT01301625)
Timeframe: 30 days

Interventionscores on a scale (Mean)
Baseline30 daysDifference (30 days - Baseline)
MitraClip Implant50.426.4-24.0

Change in Minnesota Living With Heart Failure (MLWHF) Quality of Life (QOL) Score From Baseline to 6 Months

"The Minnesota Living with Heart Failure Questionnaire(MLHFQ) is comprised of 21 questions.The response for each question ranges from 0(no affect on the patient's living) to 5(affected the patient's life very much during the past month).The total score for the 21 items can range from 0-105.A lower&higher MLHFQ score indicates less effect of heart failure&the worse impact of heart failure on a patient's QOL,respectively.Although the MLHFQ incorporates relevant aspects of the key dimensions of QOL (physical and emotional),the questionnaire was not designed to measure any particular dimension separately.The total score should be taken as the best measure of how heart failure and treatments impact QOL.~The total score is the sum of a)the physical dimension,measured using 8 questions (possible subscale score range 0-40) b)the emotional dimension,measured using 5 questions(possible subscale score from 0-25)&c) other factors,measured using 8 questions (possible subscale score from 0-40)." (NCT01301625)
Timeframe: 6 months

Interventionscores on a scale (Mean)
Baseline6 monthsDifference (6 months - Baseline)
MitraClip Implant49.528.0-21.5

Duration of Rehospitalization

(NCT01301625)
Timeframe: 30 days

InterventionDays (Mean)
All re-hospitalizationsHeart Failure-related re-hospitalizationsOther cardiac-related re-hospitalizationsOther non-cardiac-related re-hospitalizations
MitraClip Implant8.418.382.877.44

Left Atrial Volume

Left atrial volume is assessed by echocardiography. Using the single plane method of disks, the left atrial volume is derived by planimetry in the 4-chamber view at end-systole. (NCT01301625)
Timeframe: At Baseline and 12 Months

Interventionml (Mean)
Baseline12 Months
MitraClip Implant148.5132.4

Left Atrial Volume

Left atrial volume is assessed by echocardiography. Using the single plane method of disks, the left atrial volume is derived by planimetry in the 4-chamber view at end-systole. (NCT01301625)
Timeframe: At Baseline and 30 Days

Interventionml (Mean)
Baseline30 Days
MitraClip Implant140.4138.8

Left Atrial Volume

Left atrial volume is assessed by echocardiography. Using the single plane method of disks, the left atrial volume is derived by planimetry in the 4-chamber view at end-systole. (NCT01301625)
Timeframe: At Baseline and Discharge (≤7 days of index procedure)

Interventionml (Mean)
BaselineDischarge
MitraClip Implant141.7141.8

Left Ventricle End Diastolic Volume (LVEDV)

Left Ventricular end-diastolic volume (LVEDV) as determined by the core echo laboratory. Left Ventricular end-diastolic volume (LVEDV) measured using 2-dimensional echocardiography. The endocardium is traced at end-diastole (frame before mitral valve closure or maximum cavity dimension) in the 2- and 4-chamber views to calculate volumes. (NCT01301625)
Timeframe: At Baseline and 12 months

Interventionml (Mean)
Baseline12 Months
MitraClip Implant161.1150.1

Left Ventricle End Diastolic Volume (LVEDV)

Left Ventricular end-diastolic volume (LVEDV) as determined by the core echo laboratory. Left Ventricular end-diastolic volume (LVEDV) measured using 2-dimensional echocardiography. The endocardium is traced at end-diastole (frame before mitral valve closure or maximum cavity dimension) in the 2- and 4-chamber views to calculate volumes. (NCT01301625)
Timeframe: At Baseline and 30 Days

Interventionml (Mean)
Baseline30 Days
MitraClip Implant152.9148.2

Left Ventricle End Diastolic Volume (LVEDV)

Left Ventricular end-diastolic volume (LVEDV) as determined by the core echo laboratory. Left Ventricular end-diastolic volume (LVEDV) measured using 2-dimensional echocardiography. The endocardium is traced at end-diastole (frame before mitral valve closure or maximum cavity dimension) in the 2- and 4-chamber views to calculate volumes. (NCT01301625)
Timeframe: At Baseline and Discharge (≤7 days of index procedure)

InterventionMilliliters (Mean)
BaselineDischarge
MitraClip Implant158.2151.3

Left Ventricular Ejection Fraction (LVEF)

Left ventricular ejection fraction is assessed by transthoracic echocardiography according to Simpson's rule (biplane method of disks). (NCT01301625)
Timeframe: At Baseline and 12 months

Interventionpercent (Mean)
Baseline12 Months
MitraClip Implant46.947.4

Left Ventricular Ejection Fraction (LVEF)

Left ventricular ejection fraction is assessed by transthoracic echocardiography according to Simpson's rule (biplane method of disks). (NCT01301625)
Timeframe: At Baseline and 30 Days

Interventionpercent (Mean)
Baseline30 Days
MitraClip Implant48.446.5

Left Ventricular Ejection Fraction (LVEF)

Left ventricular ejection fraction is assessed by transthoracic echocardiography according to Simpson's rule (biplane method of disks). (NCT01301625)
Timeframe: At Baseline and Discharge (≤7 days of index procedure)

Interventionpercent (Mean)
BaselineDischarge
MitraClip Implant47.244.6

Left Ventricular End Systolic Volume (LVESV)

Left Ventricular end-systolic volume (LVESV) as determined by the core echo laboratory. Left Ventricular end-systolic volume (LVESV) measured using 2-dimensional echocardiography. The endocardium is traced at end-systole (frame prior to mitral valve opening or the minimum cavity area) in the 2- and 4-chamber views to calculate volumes. (NCT01301625)
Timeframe: At Baseline and 12 months

Interventionml (Mean)
Baseline12 Months
MitraClip Implant97.891.7

Left Ventricular End Systolic Volume (LVESV)

Left Ventricular end-systolic volume (LVESV) as determined by the core echo laboratory. Left Ventricular end-systolic volume (LVESV) measured using 2-dimensional echocardiography. The endocardium is traced at end-systole (frame prior to mitral valve opening or the minimum cavity area) in the 2- and 4-chamber views to calculate volumes. (NCT01301625)
Timeframe: At Baseline and 30 Days

Interventionml (Mean)
Baseline30 Days
MitraClip Implant88.589.0

Left Ventricular End Systolic Volume (LVESV)

Left Ventricular end-systolic volume (LVESV) as determined by the core echo laboratory. Left Ventricular end-systolic volume (LVESV) measured using 2-dimensional echocardiography. The endocardium is traced at end-systole (frame prior to mitral valve opening or the minimum cavity area) in the 2- and 4-chamber views to calculate volumes. (NCT01301625)
Timeframe: At Baseline and Discharge (≤7 days of index procedure)

InterventionMilliliter (Mean)
BaselineDischarge
MitraClip Implant93.393.2

Left Ventricular Internal Diameter End Diastole (LVIDd)

LVIDd is the measurements of the left ventricular internal dimension at end-diastole and normally corresponds to the largest cardiac dimension. LVIDd is measured by transthoracic echocardiography and the results are interpreted by the study's echocardiography core laboratory. (NCT01301625)
Timeframe: At Baseline and 12 Months

Interventioncm (Mean)
Baseline12 Months
MitraClip Implant6.05.7

Left Ventricular Internal Diameter End Diastole (LVIDd)

LVIDd is the measurements of the left ventricular internal dimension at end-diastole and normally corresponds to the largest cardiac dimension. LVIDd is measured by transthoracic echocardiography and the results are interpreted by the study's echocardiography core laboratory. (NCT01301625)
Timeframe: At Baseline and 30 Days

Interventioncm (Mean)
Baseline30 Days
MitraClip Implant5.95.7

Left Ventricular Internal Diameter End Diastole (LVIDd)

LVIDd is the measurements of the left ventricular internal dimension at end-diastole and normally corresponds to the largest cardiac dimension. LVIDd is measured by transthoracic echocardiography and the results are interpreted by the study's echocardiography core laboratory. (NCT01301625)
Timeframe: At Baseline and Discharge (≤7 days of index procedure)

Interventioncm (Mean)
BaselineDischarge
MitraClip Implant5.95.7

Left Ventricular Internal Diameter End Systole (LVIDs)

LVIDs is the measurements of the left ventricular internal dimension at end-systole and normally corresponds to the smallest cardiac dimension. LVIDs is measured by transthoracic echocardiography and the results are interpreted by the study's echocardiography core laboratory. (NCT01301625)
Timeframe: At Baseline and 12 Months

Interventioncm (Mean)
Baseline12 Months
MitraClip Implant4.64.5

Left Ventricular Internal Diameter End Systole (LVIDs)

LVIDs is the measurements of the left ventricular internal dimension at end-systole and normally corresponds to the smallest cardiac dimension. LVIDs is measured by transthoracic echocardiography and the results are interpreted by the study's echocardiography core laboratory. (NCT01301625)
Timeframe: At Baseline and 30 Days

Interventioncm (Mean)
Baseline30 Days
MitraClip Implant4.54.5

Left Ventricular Internal Diameter End Systole (LVIDs)

LVIDs is the measurements of the left ventricular internal dimension at end-systole and normally corresponds to the smallest cardiac dimension. LVIDs is measured by transthoracic echocardiography and the results are interpreted by the study's echocardiography core laboratory. (NCT01301625)
Timeframe: At Baseline and Discharge (≤7 days of index procedure)

Interventioncm (Mean)
BaselineDischarge
MitraClip Implant4.54.4

Mitral Valve Area (MVA) by Pressure Half-time (PHT)

Measure of the area of the mitral valve orifice using transthoracic echocardiography. The pressure half time method is used to assess the presence and severity of mitral stenosis. Results are interpreted by the study's echocardiography core laboratory. (NCT01301625)
Timeframe: At Baseline and 12 Months

Interventioncm^2 (Mean)
Baseline12 Months
MitraClip Implant3.82.3

Mitral Valve Area (MVA) by Pressure Half-time (PHT)

Measure of the area of the mitral valve orifice using transthoracic echocardiography. The pressure half time method is used to assess the presence and severity of mitral stenosis. Results are interpreted by the study's echocardiography core laboratory. (NCT01301625)
Timeframe: At Baseline and 30 Days

Interventioncm^2 (Mean)
Baseline30 Days
MitraClip Implant3.52.3

Mitral Valve Area (MVA) by Pressure Half-time (PHT)

Measure of the area of the mitral valve orifice using transthoracic echocardiography. The pressure half time method is used to assess the presence and severity of mitral stenosis. Results are interpreted by the study's echocardiography core laboratory. (NCT01301625)
Timeframe: At Baseline and Discharge (≤7 days of index procedure)

Interventioncm^2 (Mean)
BaselineDischarge
MitraClip Implant3.52.4

Mitral Valve Mean Gradient

Mitral valve mean gradient is defined as the mean pressure gradients across the mitral valve as measured by echocardiography. (NCT01301625)
Timeframe: At Baseline and 12 Months

InterventionmmHg (Mean)
Baseline12 Months
MitraClip Implant2.33.4

Mitral Valve Mean Gradient

Mitral valve mean gradient is defined as the mean pressure gradients across the mitral valve as measured by echocardiography. (NCT01301625)
Timeframe: At Baseline and 30 Days

InterventionmmHg (Mean)
Baseline30 Days
MitraClip Implant2.33.5

Mitral Valve Mean Gradient

Mitral valve mean gradient is defined as the mean pressure gradients across the mitral valve as measured by echocardiography. (NCT01301625)
Timeframe: At Baseline and Discharge (≤7 days of index procedure)

InterventionmmHg (Mean)
BaselineDischarge
MitraClip Implant2.33.7

Number of Participants at Discharge Facility

This is the economic data reported to support the MitraClip System economic analysis. (NCT01301625)
Timeframe: < or = 12 days

InterventionParticipants (Count of Participants)
HomeHome with home health careSkilled nursing facilityNursing homeDeathOther
MitraClip Implant7041021

Number of Participants With 0, 1, 2, and 3 MitraClip Devices Implanted

This is one of the Device and Procedure-Related Endpoints. Implant Rate is defined as the rate of successful delivery and deployment of MitraClip device implant(s) with echocardiographic evidence of leaflet approximation and retrieval of the delivery catheter. (NCT01301625)
Timeframe: Day 0 (On the day of procedure)

InterventionParticipants (Count of Participants)
0 Mitra Clip devices1 Mitra Clip devices2 Mitra Clip devices3 Mitra Clip devices
MitraClip Implant141351

Number of Participants With Mitral Valve Surgery

Mital Valve Surgery Post-MitraClip Procedure; Surgery Types includes Replacement and Repair. (NCT01301625)
Timeframe: 30 days of Post-MitraClip Procedure

InterventionParticipants (Count of Participants)
Recurring mitral regurgitationDevice failure
MitraClip Implant11

Number of Participants With MR Severity

"Mitral regurgitation severity was determined based on the American Society of Echocardiography (ASE) Recommendations for Evaluation of The Severity of Native Valvular Regurgitation with Two-Dimensional and Doppler Echocardiography. MR severity was scored using the integrative method based on qualitative and quantitative echocardiographic parameters as described in the ASE guidelines.Site-assessed mitral regurgitation severity using echocardiography.~MR severity was graded as follows: 0: None, 1+: Mild, 2+: Moderate, 3+: Moderate-to-Severe, 4+: Severe." (NCT01301625)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
0: None1+:Mild2+: Moderate3+: Moderate-to-Severe4+: SevereNot Evaluable
MitraClip Implant21515730

Number of Participants With MR Severity

"Mitral regurgitation severity was determined based on the American Society of Echocardiography (ASE) Recommendations for Evaluation of The Severity of Native Valvular Regurgitation with Two-Dimensional and Doppler Echocardiography. MR severity was scored using the integrative method based on qualitative and quantitative echocardiographic parameters as described in the ASE guidelines.Site-assessed mitral regurgitation severity using echocardiography.~MR severity was graded as follows: 0: None, 1+: Mild, 2+: Moderate, 3+: Moderate-to-Severe, 4+: Severe." (NCT01301625)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
0: None1+:Mild2+: Moderate3+: Moderate-to-Severe4+: SevereNot Evaluable
MitraClip Implant126251250

Number of Participants With MR Severity

"Mitral regurgitation severity was determined based on the American Society of Echocardiography (ASE) Recommendations for Evaluation of The Severity of Native Valvular Regurgitation with Two-Dimensional and Doppler Echocardiography. MR severity was scored using the integrative method based on qualitative and quantitative echocardiographic parameters as described in the ASE guidelines.Site-assessed mitral regurgitation severity using echocardiography.~MR severity was graded as follows: 0: None, 1+: Mild, 2+: Moderate, 3+: Moderate-to-Severe, 4+: Severe." (NCT01301625)
Timeframe: 6 months

InterventionParticipants (Count of Participants)
0: None1+:Mild2+: Moderate3+: Moderate-to-Severe4+: SevereNot Evaluable
MitraClip Implant020241240

Number of Participants With MR Severity

"Mitral regurgitation severity was determined based on the American Society of Echocardiography (ASE) Recommendations for Evaluation of The Severity of Native Valvular Regurgitation with Two-Dimensional and Doppler Echocardiography. MR severity was scored using the integrative method based on qualitative and quantitative echocardiographic parameters as described in the ASE guidelines.Site-assessed mitral regurgitation severity using echocardiography.~MR severity was graded as follows: 0: None, 1+: Mild, 2+: Moderate, 3+: Moderate-to-Severe, 4+: Severe." (NCT01301625)
Timeframe: At discharge (≤7 days of index procedure)

InterventionParticipants (Count of Participants)
0: None1+:Mild2+: Moderate3+: Moderate-to-Severe4+: SevereNot Evaluable
MitraClip Implant13822931

Number of Participants With MR Severity

"Mitral regurgitation severity was determined based on the American Society of Echocardiography (ASE) Recommendations for Evaluation of The Severity of Native Valvular Regurgitation with Two-Dimensional and Doppler Echocardiography. MR severity was scored using the integrative method based on qualitative and quantitative echocardiographic parameters as described in the ASE guidelines.Site-assessed mitral regurgitation severity using echocardiography.~MR severity was graded as follows: 0: None, 1+: Mild, 2+: Moderate, 3+: Moderate-to-Severe, 4+: Severe." (NCT01301625)
Timeframe: Baseline

InterventionParticipants (Count of Participants)
0: None1+:Mild2+: Moderate3+: Moderate-to-Severe4+: SevereNot Evaluable
MitraClip Implant00022550

Number of Participants With Second Intervention to Place an Additional MitraClip Device

Second MitraClip device interventions are reported by Abbott Vascular personnel on Procedural Observation Forms. A second MitraClip device intervention is a good option for patients with MR following placement of the original MitraClip device. (NCT01301625)
Timeframe: Through 12 months

InterventionParticipants (Count of Participants)
Recurring mitral regurgitationSingle leaflet device attachment (SLDA)
MitraClip Implant21

Percentage of Participants With New York Heart Association (NYHA) Class

"Class I Patients with cardiac disease but without resulting limitations of physical activity;~Class II Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain;~Class III Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain;~Class IV Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased." (NCT01301625)
Timeframe: 12 months

Interventionpercentage of participants (Number)
NYHA INYHA IINYHA IIINYHA IV
MitraClip Implant52.542.52.52.5

Percentage of Participants With New York Heart Association (NYHA) Class

"Class I Patients with cardiac disease but without resulting limitations of physical activity;~Class II Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain;~Class III Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain;~Class IV Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased." (NCT01301625)
Timeframe: 30 days

Interventionpercentage of participants (Number)
NYHA INYHA IINYHA IIINYHA IV
MitraClip Implant36.244.915.92.9

Percentage of Participants With New York Heart Association (NYHA) Class

"Class I Patients with cardiac disease but without resulting limitations of physical activity;~Class II Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain;~Class III Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain;~Class IV Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased." (NCT01301625)
Timeframe: 6 months

Interventionpercentage of participants (Number)
NYHA INYHA IINYHA IIINYHA IV
MitraClip Implant33.356.78.31.7

Percentage of Participants With New York Heart Association (NYHA) Class

"Class I Patients with cardiac disease but without resulting limitations of physical activity;~Class II Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain;~Class III Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain;~Class IV Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased." (NCT01301625)
Timeframe: Baseline

Interventionpercentage of participants (Number)
NYHA INYHA IINYHA IIINYHA IV
MitraClip Implant2.626.951.319.2

Rate of Patients Rehospitalized

Defined as re-admission of patients to the hospital following discharge from the Clip procedure. (NCT01301625)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
All re-hospitalizationsHeart Failure-related re-hospitalizationsOther cardiac-related re-hospitalizationsOther non-cardiac-related re-hospitalizations
MitraClip Implant35101122

Regurgitant Fraction

Regurgitant fraction as determined by the core echo laboratory. Regurgitant fraction is defined as the regurgitant volume divided by the forward stroke volume through the regurgitant valve. (NCT01301625)
Timeframe: At Baseline and 12 Months

InterventionPercentage (Mean)
Baseline12 Months
MitraClip Implant44.636.8

Regurgitant Fraction

Regurgitant fraction as determined by the core echo laboratory. Regurgitant fraction is defined as the regurgitant volume divided by the forward stroke volume through the regurgitant valve. (NCT01301625)
Timeframe: At Baseline and 30 Days

InterventionPercentage (Mean)
Baseline30 Days
MitraClip Implant40.515.2

Regurgitant Fraction

Regurgitant fraction as determined by the core echo laboratory. Regurgitant fraction is defined as the regurgitant volume divided by the forward stroke volume through the regurgitant valve. (NCT01301625)
Timeframe: At Baseline and Discharge (≤7 days of index procedure)

InterventionPercentage (Mean)
BaselineDischarge
MitraClip Implant38.925.8

Regurgitant Volume

Regurgitant volume as determined by the core echo laboratory. In the presence of regurgitation of one valve, without any intracardiac shunt, the flow through the affected valve is larger than through other competent valves. The difference between the two represents the regurgitant volume. (NCT01301625)
Timeframe: At Baseline and 12 Months

Interventionml (Mean)
Baseline12 Months
MitraClip Implant49.873.3

Regurgitant Volume

Regurgitant volume as determined by the core echo laboratory. In the presence of regurgitation of one valve, without any intracardiac shunt, the flow through the affected valve is larger than through other competent valves. The difference between the two represents the regurgitant volume. (NCT01301625)
Timeframe: At Baseline and 30 Days

Interventionml (Mean)
Baseline30 Days
MitraClip Implant61.925.6

Regurgitant Volume

Regurgitant volume as determined by the core echo laboratory. In the presence of regurgitation of one valve, without any intracardiac shunt, the flow through the affected valve is larger than through other competent valves. The difference between the two represents the regurgitant volume. (NCT01301625)
Timeframe: At Baseline and Discharge (≤7 days of index procedure)

Interventionml (Mean)
BaselineDischarge
MitraClip Implant55.525.1

Number of Participants With Cumulative Clinical Endpoint of Death and Stent Thrombosis

(NCT02914795)
Timeframe: 7 days

InterventionParticipants (Count of Participants)
Non-resuscitated Myocardial Infarction0
Resuscitated Myocardial Infarction3

Platelet Inhibition Measured With Optical Aggregometry

Median (Inter-Quartile Range) Collagen AUC values on Day 3 measured with optical aggregometry The more light signal is detected, the better thrombocyte function is. (NCT02914795)
Timeframe: day 3

InterventionAU*min (Median)
Non-resuscitated Myocardial Infarction109
Resuscitated Myocardial Infarction253.8

Differences in Costs Between Two Revascularization Strategies for de Novo Coronary Lesions.

Overall costs expressed in US dollars at 18 months of follow up between Oral Sirolimus Plus BMS vs DES implantation in denovo coronary lesions. (NCT00552669)
Timeframe: Follow up will be conducted by the coordinating Center at 18 months of follow up

InterventionUS dollars (Mean)
Oral Sirolimus + Bare Metal Stent5483
Drug Eluting Stents7658.2

Target Vessel Revascularization (TVR)

Efficacy end point was TVR as revasacularization of the treated vessel. (NCT00552669)
Timeframe: 18 months

Interventionvessels (Number)
Oral Sirolimus + Bare Metal Stent14
Drug Eluting Stents15

Major Adverse Cardiovascular Events (MACCE)

Death from any cause, myocardial infarction and stroke. Safety was analyzed as MACCE (major adverse cardiovascular events) including death, MI and stroke. (NCT00552669)
Timeframe: 18 Months

,
Interventionparticipants (Number)
MACCEDeathAcute Myocardial InfarctionStroke
Drug Eluting Stents15791
Oral Sirolimus + Bare Metal Stent9360

Percent Stent Coverage

Assessment of vascular healing 6 months after Resolute Integrity placement in non-diabetic patients and patients with non-insulin dependent diabetes presenting with acute coronary syndrome (ACS) using optical frequency domain imaging (OFDI). Vascular healing will be measured by percent covered stents as determined by OFDI. A higher percentage of stent coverage indicates increased endothelial regrowth, which is an essential component for the maintenance of long-term luminal patency. (NCT01794949)
Timeframe: 6 months

,
InterventionParticipants (Count of Participants)
85% up to 90% stent coverage90% up to 95% stent coverage95% or greater percent stent coverage
NIDDM Patients Receiving the Resolute Stent010
Non-diabetic Patients Receiving the Resolute Stent131

Reviews

238 reviews available for ticlopidine and Myocardial Infarction

ArticleYear
Influence of individual proton pump inhibitors on clinical outcomes in patients receiving clopidogrel following percutaneous coronary intervention.
    Medicine, 2021, Dec-30, Volume: 100, Issue:52

    Topics: Clopidogrel; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation

2021
Monotherapy with a P2Y
    Lancet (London, England), 2020, 05-09, Volume: 395, Issue:10235

    Topics: Aged; Aspirin; Atherosclerosis; Cerebrovascular Disorders; Clopidogrel; Coronary Disease; Female; He

2020
Effect of CYP2C19 Genotype on Ischemic Outcomes During Oral P2Y
    JACC. Cardiovascular interventions, 2021, 04-12, Volume: 14, Issue:7

    Topics: Cytochrome P-450 CYP2C19; Genotype; Humans; Middle Aged; Myocardial Infarction; Platelet Aggregation

2021
Outcomes of a multi-ethnic Asian population on combined treatment with clopidogrel and omeprazole in 12,440 patients.
    Journal of thrombosis and thrombolysis, 2021, Volume: 52, Issue:3

    Topics: Asian People; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Ethnicity; Humans; Myocardia

2021
Risk of Early Adverse Events After Clopidogrel Discontinuation in Patients Undergoing Short-Term Dual Antiplatelet Therapy: An Individual Participant Data Analysis.
    JACC. Cardiovascular interventions, 2017, 08-28, Volume: 10, Issue:16

    Topics: Aged; Aspirin; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Drug Administration Schedule;

2017
Cangrelor in Percutaneous Coronary Intervention: Current Status and Perspectives.
    Journal of cardiovascular pharmacology and therapeutics, 2018, Volume: 23, Issue:1

    Topics: Adenosine Monophosphate; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Corona

2018
Triple therapy: worth the risk?
    Minerva medica, 2018, Volume: 109, Issue:5

    Topics: Anticoagulants; Aspirin; Clopidogrel; Drug Synergism; Drug Therapy, Combination; Factor Xa Inhibitor

2018
Prehospital treatment of ST-segment elevated myocardial infarction patients.
    Future cardiology, 2013, Volume: 9, Issue:2

    Topics: Antithrombins; Clopidogrel; Electrocardiography; Emergency Medical Services; Hirudins; Humans; Myoca

2013
Dual anti-platelet therapy after coronary artery bypass grafting: is there any benefit? A systematic review and meta-analysis.
    Journal of cardiac surgery, 2013, Volume: 28, Issue:2

    Topics: Angina Pectoris; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Graft Occl

2013
Impact of proton pump inhibitor therapy on the efficacy of clopidogrel in the CAPRIE and CREDO trials.
    Journal of the American Heart Association, 2013, Jan-15, Volume: 2, Issue:1

    Topics: Aged; Aryl Hydrocarbon Hydroxylases; Brain Ischemia; Chi-Square Distribution; Clopidogrel; Cytochrom

2013
Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy.
    The Canadian journal of cardiology, 2013, Volume: 29, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel;

2013
Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: a meta-analysis based on 23,035 subjects.
    Archives of cardiovascular diseases, 2013, Volume: 106, Issue:10

    Topics: Aryl Hydrocarbon Hydroxylases; Chi-Square Distribution; Clopidogrel; Coronary Thrombosis; Cytochrome

2013
Cangrelor versus clopidogrel in percutaneous coronary intervention: a systematic review and meta-analysis.
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2014, Mar-20, Volume: 9, Issue:11

    Topics: Adenosine Monophosphate; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Perc

2014
Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy for patients undergoing PCI: a meta-analysis of randomized trials with adjusted indirect comparisons.
    Current medical research and opinion, 2014, Volume: 30, Issue:1

    Topics: Aspirin; Cilostazol; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Hemorrhage; Humans

2014
Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes.
    The Cochrane database of systematic reviews, 2013, Oct-18, Issue:10

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Fibrinolytic Agent

2013
Ticagrelor for acute coronary syndromes.
    Expert review of cardiovascular therapy, 2013, Volume: 11, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Animals; Clinical Trials, Phase III as Topic; Clopidogrel; Human

2013
Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes.
    The Cochrane database of systematic reviews, 2013, Nov-08, Issue:11

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Fibrinolytic Agents; Hemorrhage; H

2013
[Differentiated antiplatelet therapy for acute coronary syndromes].
    Deutsche medizinische Wochenschrift (1946), 2014, Volume: 139, Issue:4

    Topics: Acute Coronary Syndrome; Adenosine; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Hemorrh

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials.
    Atherosclerosis, 2014, Volume: 233, Issue:2

    Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Administration, Oral; Clopidogrel; Coro

2014
Pharmacokinetic evaluation of prasugrel for the treatment of myocardial infarction.
    Expert opinion on drug metabolism & toxicology, 2014, Volume: 10, Issue:4

    Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Myocardial Infarction; Percutaneous Coronary Intervent

2014
Effects of P2Y12 receptor inhibition in patients with ST-segment elevation myocardial infarction.
    The American journal of cardiology, 2014, Jun-15, Volume: 113, Issue:12

    Topics: Administration, Oral; Aged; Clopidogrel; Combined Modality Therapy; Dose-Response Relationship, Drug

2014
Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials.
    Journal of thrombosis and thrombolysis, 2015, Volume: 39, Issue:1

    Topics: Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; M

2015
[Dual platelet inhibitors in intensive care units].
    Medizinische Klinik, Intensivmedizin und Notfallmedizin, 2014, Volume: 109, Issue:6

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Germany; Guideline Adherence; Hemorrhage; Hum

2014
Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease.
    Annals of medicine, 2014, Volume: 46, Issue:7

    Topics: Adenosine; Aspirin; Asymptomatic Diseases; Cilostazol; Clopidogrel; Fibrinolytic Agents; Humans; Int

2014
Dual versus single antiplatelet therapy in patients undergoing transcatheter aortic valve replacement: a systematic review and meta-analysis.
    Heart, lung & circulation, 2015, Volume: 24, Issue:2

    Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Myocardial Infarc

2015
Management of acute coronary syndrome in the hospital: a focus on ACCF/AHA guideline updates to oral antiplatelet therapy.
    Hospital practice (1995), 2014, Volume: 42, Issue:3

    Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aspirin; Body Weight; Clopidogrel; Humans; Myocardi

2014
Outcome comparison of 600 mg versus 300 mg loading dose of clopidogrel for patients with ST-elevation myocardial infarction: a meta-analysis.
    Postgraduate medicine, 2014, Volume: 126, Issue:5

    Topics: Aged; Clopidogrel; Dose-Response Relationship, Drug; Female; Hemorrhage; Humans; Male; Middle Aged;

2014
Meta-analysis appraising high maintenance dose clopidogrel in patients who underwent percutaneous coronary intervention with and without high on-clopidogrel platelet reactivity.
    The American journal of cardiology, 2015, Mar-01, Volume: 115, Issue:5

    Topics: Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Mainte

2015
[Anticoagulant therapy in secondary prevention of coronary events].
    Vnitrni lekarstvi, 2014, Volume: 60, Issue:12

    Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine

2014
Novel oral P2Y12 inhibitor prasugrel vs. clopidogrel in patients with acute coronary syndrome: evidence based on 6 studies.
    Medical science monitor : international medical journal of experimental and clinical research, 2015, Apr-20, Volume: 21

    Topics: Acute Coronary Syndrome; Administration, Oral; Clopidogrel; Evidence-Based Medicine; Hemorrhage; Hum

2015
Comparison of Dual-antiplatelet Therapy to Mono-antiplatelet Therapy After Transcatheter Aortic Valve Implantation: Systematic Review and Meta-analysis.
    The Canadian journal of cardiology, 2015, Volume: 31, Issue:6

    Topics: Aged; Aged, 80 and over; Aortic Valve Stenosis; Aspirin; Clopidogrel; Drug Therapy, Combination; Fem

2015
Thrombocytopenia in acute coronary syndromes: etiologies and proposed management.
    The Canadian journal of cardiology, 2015, Volume: 31, Issue:6

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Therapy, Combina

2015
Switching from Clopidogrel to Prasugrel in patients undergoing PCI: A meta-analytic overview.
    Platelets, 2016, Volume: 27, Issue:2

    Topics: Acute Coronary Syndrome; Clopidogrel; Drug Substitution; Hemorrhage; Humans; Myocardial Infarction;

2016
Among antithrombotic agents, prasugrel, but not ticagrelor, is associated with reduced 30 day mortality in patients with ST-elevated myocardial infarction.
    International journal of cardiology, 2015, Sep-15, Volume: 195

    Topics: Adenosine; Clopidogrel; Electrocardiography; Female; Humans; Male; Middle Aged; Myocardial Infarctio

2015
Early P2Y12 inhibition in ST-segment elevation myocardial infarction: Bridging the gap.
    American heart journal, 2015, Volume: 170, Issue:1

    Topics: Adenosine; Clopidogrel; Early Medical Intervention; Humans; Myocardial Infarction; Percutaneous Coro

2015
Ticagrelor, prasugrel, or clopidogrel in ST-segment elevation myocardial infarction: which one to choose?
    Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:13

    Topics: Adenosine; Aspirin; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation; Pl

2015
Current Evidence on Platelet P2Y12 Receptor Inhibitors: Is There Still a Role for Clopidogrel in 2015?
    The Canadian journal of cardiology, 2015, Volume: 31, Issue:12

    Topics: Acute Coronary Syndrome; Adenosine; Algorithms; Angioplasty, Balloon, Coronary; Clopidogrel; Humans;

2015
Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials.
    European heart journal, 2016, Jan-21, Volume: 37, Issue:4

    Topics: Adenosine; Adult; Aged; Clopidogrel; Drug Therapy, Combination; Humans; Long-Term Care; Middle Aged;

2016
Recurrent acute coronary syndrome and restenosis after percutaneous coronary intervention in a patient with idiopathic thrombocytopenic purpura: a case report and literature review.
    BMC cardiovascular disorders, 2015, Sep-18, Volume: 15

    Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Clopidogrel; Coronary Angiography; Drug-Elut

2015
Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2015, Oct-01, Volume: 72, Issue:19

    Topics: Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Half-Life; Hemorrhage; Humans; L

2015
Efficacy and safety analysis of new P2Y12 inhibitors versus clopidogrel in patients with percutaneous coronary intervention: a meta-analysis.
    Current medical research and opinion, 2015, Volume: 31, Issue:12

    Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Corona

2015
Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54.
    Heart (British Cardiac Society), 2016, 05-15, Volume: 102, Issue:10

    Topics: Adenosine; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Hemorrhage

2016
Intensified Antiplatelet Treatment Reduces Major Cardiac Events in Patients with Clopidogrel Low Response: A Meta-analysis of Randomized Controlled Trials.
    Chinese medical journal, 2016, Apr-20, Volume: 129, Issue:8

    Topics: Cardiovascular Diseases; Clopidogrel; Humans; Myocardial Infarction; Percutaneous Coronary Intervent

2016
[Meta-analysis of the combination of warfarin and clopidogrel after coronary stenting in patients with indications for chronic oral anticoagulation].
    Zhonghua yi xue za zhi, 2016, May-10, Volume: 96, Issue:17

    Topics: Administration, Oral; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Hemorrhage; Humans;

2016
Pharmacokinetics and pharmacodynamics of oral P2Y12 inhibitors during the acute phase of a myocardial infarction: A systematic review.
    Thrombosis research, 2016, Volume: 143

    Topics: Adenosine; Administration, Oral; Clopidogrel; Humans; Myocardial Infarction; Percutaneous Coronary I

2016
Management of Antiplatelet Allergy After Cardiac Stenting.
    JAMA dermatology, 2016, 10-01, Volume: 152, Issue:10

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Drug Administration Schedule; Drug Eruptions; Drug-Elut

2016
Long-Term P2Y12-Receptor Antagonists in Post-Myocardial Infarction Patients: Facing a New Trilemma?
    Journal of the American College of Cardiology, 2016, 09-13, Volume: 68, Issue:11

    Topics: Adenosine; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hy

2016
Contemporary management of ST-segment elevation myocardial infarction.
    Internal and emergency medicine, 2016, Volume: 11, Issue:8

    Topics: Analgesics; Clopidogrel; Humans; Morphine; Myocardial Infarction; Percutaneous Coronary Intervention

2016
A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis.
    Cardiovascular revascularization medicine : including molecular interventions, 2017, Volume: 18, Issue:2

    Topics: Adenosine; Adenosine Monophosphate; Clopidogrel; Humans; Myocardial Infarction; Network Meta-Analysi

2017
Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients.
    European heart journal, 2017, 04-07, Volume: 38, Issue:14

    Topics: Acute Coronary Syndrome; Analysis of Variance; Aspirin; Blood Vessel Prosthesis Implantation; Clopid

2017
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
    Lancet (London, England), 2017, 03-11, Volume: 389, Issue:10073

    Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H

2017
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
    Lancet (London, England), 2017, 03-11, Volume: 389, Issue:10073

    Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H

2017
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
    Lancet (London, England), 2017, 03-11, Volume: 389, Issue:10073

    Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H

2017
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
    Lancet (London, England), 2017, 03-11, Volume: 389, Issue:10073

    Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H

2017
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
    Lancet (London, England), 2017, 03-11, Volume: 389, Issue:10073

    Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H

2017
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
    Lancet (London, England), 2017, 03-11, Volume: 389, Issue:10073

    Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H

2017
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
    Lancet (London, England), 2017, 03-11, Volume: 389, Issue:10073

    Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H

2017
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
    Lancet (London, England), 2017, 03-11, Volume: 389, Issue:10073

    Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H

2017
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
    Lancet (London, England), 2017, 03-11, Volume: 389, Issue:10073

    Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H

2017
The year in interventional cardiology.
    Journal of the American College of Cardiology, 2008, Jun-17, Volume: 51, Issue:24

    Topics: Acute Coronary Syndrome; American Heart Association; Angioplasty, Balloon, Coronary; Clopidogrel; Co

2008
Revascularization treatment recommendations based on atherosclerotic disease distribution: coronary artery bypass grafting versus stenting.
    Current atherosclerosis reports, 2008, Volume: 10, Issue:5

    Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Bypass; Coronary Arter

2008
Pre-procedural C-reactive protein levels and clinical outcomes after percutaneous coronary interventions with and without abciximab: pooled analysis of four ISAR trials.
    Heart (British Cardiac Society), 2009, Volume: 95, Issue:2

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Biomarkers; C-Reactive Prot

2009
Impact of pretreatment with clopidogrel on initial patency and outcome in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a systematic review.
    Circulation, 2008, Oct-28, Volume: 118, Issue:18

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Coronary Thrombosis; Electro

2008
[Acute intervention for ST-elevation myocardial infarction].
    Deutsche medizinische Wochenschrift (1946), 2008, Volume: 133 Suppl 8

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Bypass; History, 20th Century; Humans;

2008
Antiplatelet therapy after endovascular intervention: does combination therapy really work and what is the optimum duration of therapy?
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2009, Jul-01, Volume: 74 Suppl 1

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Vessel Prosthesis Implantation; Cardiovascular Diseas

2009
Antiplatelet therapy in percutaneous coronary intervention: integration of prasugrel into clinical practice.
    Critical pathways in cardiology, 2009, Volume: 8, Issue:1

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therap

2009
Clopidogrel in acute coronary syndromes.
    BMJ (Clinical research ed.), 2009, Apr-14, Volume: 338

    Topics: Acute Coronary Syndrome; Clopidogrel; Drug-Eluting Stents; Hemorrhage; Humans; Myocardial Infarction

2009
Critical review of prasugrel for formulary decision makers.
    Journal of managed care pharmacy : JMCP, 2009, Volume: 15, Issue:4

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Drug Interactions; Formularies, Hospital as Topic; Huma

2009
Diabetes mellitus: a prothrombotic state implications for outcomes after coronary revascularization.
    Vascular health and risk management, 2009, Volume: 5, Issue:1

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Angiography; C

2009
Use of clopidogrel in the reduction of myocardial damage during percutaneous coronary intervention.
    Vascular health and risk management, 2009, Volume: 5, Issue:1

    Topics: Angioplasty, Balloon, Coronary; Biomarkers; Clopidogrel; Creatine Kinase, MB Form; Drug Administrati

2009
[New approach to interventional cardiology treatment with personalized medicine].
    Przeglad lekarski, 2008, Volume: 65, Issue:12

    Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspi

2008
Bedside evaluation of thienopyridine antiplatelet therapy.
    Circulation, 2009, May-19, Volume: 119, Issue:19

    Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Clinical Trials as Topic; Cl

2009
Peri-procedural platelet function and platelet inhibition in percutaneous coronary intervention.
    JACC. Cardiovascular interventions, 2008, Volume: 1, Issue:2

    Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Disease; Drug

2008
Improving outcomes in patients undergoing percutaneous coronary intervention: role of prasugrel.
    Vascular health and risk management, 2009, Volume: 5, Issue:1

    Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thrombosis; Dia

2009
A new generation of antiplatelet agents.
    Current opinion in cardiology, 2009, Volume: 24, Issue:4

    Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation I

2009
Evidence for using clopidogrel alone or in addition to aspirin in post coronary artery bypass surgery patients.
    The American journal of cardiology, 2009, Jun-15, Volume: 103, Issue:12

    Topics: Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Restenosis; Drug Therapy, Combination; Electr

2009
Improving adjunctive pharmacotherapy for primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: beyond the HORIZONS-AMI trial.
    Reviews in cardiovascular medicine, 2009,Spring, Volume: 10, Issue:2

    Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Chemotherapy, Adjuvant; Clopidogrel; Drug Therapy, C

2009
Challenges in oral antiplatelet therapy: ST-segment elevation myocardial infarction.
    The American journal of cardiology, 2009, Sep-07, Volume: 104, Issue:5 Suppl

    Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Administration Sche

2009
Platelet-directed therapies and coronary artery bypass grafting.
    The American journal of cardiology, 2009, Sep-07, Volume: 104, Issue:5 Suppl

    Topics: Aspirin; Clopidogrel; Coronary Artery Bypass; Humans; Myocardial Infarction; Platelet Aggregation In

2009
Current controversies in the pharmacogenomics of clopidogrel.
    Progress in cardiovascular nursing, 2009, Volume: 24, Issue:3

    Topics: Clopidogrel; Confidence Intervals; Coronary Artery Disease; Genotype; Humans; Myocardial Infarction;

2009
Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients.
    The Cochrane database of systematic reviews, 2009, Oct-07, Issue:4

    Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation I

2009
Platelet monitoring for PCI: is it really necessary?
    Hamostaseologie, 2009, Volume: 29, Issue:4

    Topics: Blood Coagulation; Blood Platelets; Clopidogrel; Coronary Disease; Humans; Monitoring, Physiologic;

2009
Dual antiplatelet therapy in coronary artery disease: a case-based approach.
    Cleveland Clinic journal of medicine, 2009, Volume: 76, Issue:11

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery

2009
[Acute coronary syndrome in patients with carbohydrate metabolic disturbances (a review)].
    Terapevticheskii arkhiv, 2009, Volume: 81, Issue:10

    Topics: Acute Coronary Syndrome; Blood Glucose; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogr

2009
Current standings of the proton pump inhibitor and clopidogrel co-therapy: review on an evolving field with the eyes of the gastroenterologist.
    Digestion, 2010, Volume: 81, Issue:1

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Interactions; Dr

2010
Acute myocardial infarction in a patient with post-splenectomy thrombocytosis: a case report and review of literature.
    Cardiology journal, 2010, Volume: 17, Issue:1

    Topics: Adult; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Follow-Up Studies; Humans; Male; Myocar

2010
Combined mechanical and pharmacological approach to a thrombus-containing lesion.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2010, May-01, Volume: 75, Issue:6

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Coronary Angiography; Corona

2010
Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. BET 1: Adding clopidogrel to standard treatment for acute myocardial infarction.
    Emergency medicine journal : EMJ, 2010, Volume: 27, Issue:3

    Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Emergency Service, Hospital; Evidence-Based Emergen

2010
Management of antiplatelet therapy during acute percutaneous coronary intervention: new strategies and therapeutics.
    Annals of the Academy of Medicine, Singapore, 2010, Volume: 39, Issue:3

    Topics: Adenosine; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Therapy, Combination; Electrocardiograp

2010
[Discontinuation of treatment with platelet aggregation inhibitors in surgical patients with cardiac stents].
    Ugeskrift for laeger, 2010, Mar-15, Volume: 172, Issue:11

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Loss, Surgical; Clopidogrel; Coronary Thrombosis; Dru

2010
Therapy for ST-segment elevation myocardial infarction patients who present late or are ineligible for reperfusion therapy.
    Journal of the American College of Cardiology, 2010, May-04, Volume: 55, Issue:18

    Topics: Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitors; Clopidogrel; Comorbidity;

2010
The year in interventional cardiology.
    Journal of the American College of Cardiology, 2010, May-18, Volume: 55, Issue:20

    Topics: Adenosine; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Coronary Angiograp

2010
Strategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE): updated standing orders for ST-segment elevation myocardial infarction and unstable angina/non-ST-segment elevation myocardial infarction.
    Critical pathways in cardiology, 2010, Volume: 9, Issue:2

    Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Clopidogr

2010
Impact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
    Heart (British Cardiac Society), 2011, Volume: 97, Issue:2

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Dose-Response Relationship, Dr

2011
Clinical Inquiries: Which drugs should post-MI patients routinely receive?
    The Journal of family practice, 2010, Volume: 59, Issue:9

    Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atorvastatin; Clopidogrel; Eplerenone; Heptanoic

2010
Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes.
    The Cochrane database of systematic reviews, 2010, Sep-08, Issue:9

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Fibrinolytic Agents; Hemorrhage; H

2010
Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis.
    American heart journal, 2010, Volume: 160, Issue:3

    Topics: Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Human

2010
[Thienopyridines in the treatment and prevention of cardiovascular diseases. Part V. Combination of clopidogrel and acetylsalicylic acid in the treatment of stable patients with atherothrombotic cardiovascular diseases].
    Kardiologiia, 2010, Volume: 50, Issue:5

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Arteriosclerosis; Aspirin; Cardiovascular D

2010
Cytochrome P450 2C19 polymorphism is associated with poor clinical outcomes in coronary artery disease patients treated with clopidogrel.
    Molecular biology reports, 2011, Volume: 38, Issue:3

    Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Human

2011
Review article: combination of clopidogrel and proton pump inhibitors: implications for clinicians.
    Journal of cardiovascular pharmacology and therapeutics, 2010, Volume: 15, Issue:4

    Topics: Aryl Hydrocarbon Hydroxylases; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Cytoc

2010
Contemporary management of coronary heart disease.
    The journal of the Royal College of Physicians of Edinburgh, 2010, Volume: 40, Issue:1

    Topics: Acute Coronary Syndrome; Administration, Oral; Angina Pectoris; Angioplasty, Balloon, Coronary; Anti

2010
Antiplatelet therapy after placement of a drug-eluting stent: a review of efficacy and safety studies.
    Clinical therapeutics, 2010, Volume: 32, Issue:14

    Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Huma

2010
[ST-elevation myocardial infarction: reperfusion strategy based on the results from large clinical trials].
    Giornale italiano di cardiologia (2006), 2010, Volume: 11, Issue:10 Suppl 1

    Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Clopidogrel; Fibrinolytic Agents; Guidelines as Topi

2010
[Prasugrel for acute and long-term treatment of patients with acute coronary syndromes: what is state-of-the-art?].
    Deutsche medizinische Wochenschrift (1946), 2011, Volume: 136, Issue:15

    Topics: Acute Coronary Syndrome; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Electroca

2011
[Myocardial infarction: Role of new antiplatelet agents].
    Presse medicale (Paris, France : 1983), 2011, Volume: 40, Issue:6

    Topics: Adenosine; Adenosine Monophosphate; Administration, Oral; Clinical Trials as Topic; Clopidogrel; Com

2011
Safety of clopidogrel being continued until the time of coronary artery bypass grafting in patients with acute coronary syndrome: a meta-analysis of 34 studies.
    European heart journal, 2011, Volume: 32, Issue:23

    Topics: Acute Coronary Syndrome; Blood Transfusion; Clopidogrel; Coronary Artery Bypass; Critical Care; Fema

2011
Benefits and risks of using clopidogrel before coronary artery bypass surgery: systematic review and meta-analysis of randomized trials and observational studies.
    The Journal of thoracic and cardiovascular surgery, 2012, Volume: 143, Issue:3

    Topics: Blood Transfusion; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Coronary Artery Di

2012
Prasugrel vs. ticagrelor in acute coronary syndromes: which one to choose?
    Wiener klinische Wochenschrift, 2011, Volume: 123, Issue:15-16

    Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Piperazi

2011
A meta-analysis of impact of proton pump inhibitors on antiplatelet effect of clopidogrel.
    Cardiovascular therapeutics, 2012, Volume: 30, Issue:5

    Topics: Acute Coronary Syndrome; Clopidogrel; Data Interpretation, Statistical; Drug Interactions; Endpoint

2012
Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis.
    Health technology assessment (Winchester, England), 2011, Volume: 15, Issue:31

    Topics: Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Clopidogrel; Cost-Benefit Analysis; Delayed-Ac

2011
Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data.
    Journal of the American College of Cardiology, 2011, Nov-01, Volume: 58, Issue:19

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Inf

2011
[Decreasing incidence of stent thrombosis].
    Annales de cardiologie et d'angeiologie, 2011, Volume: 60, Issue:6

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Drug Therap

2011
Antiplatelet agents and anticoagulants for hypertension.
    The Cochrane database of systematic reviews, 2011, Dec-07, Issue:12

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Clopidogrel; Humans; Hypertension;

2011
Antiplatelet therapy in patients with ST-elevation myocardial infarction undergoing myocardial revascularisation: beyond clopidogrel.
    Current medical research and opinion, 2012, Volume: 28, Issue:2

    Topics: Adenosine; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Myocardial Revascularization; Pip

2012
Unstable angina and non-ST elevation myocardial infarction.
    American journal of respiratory and critical care medicine, 2012, May-01, Volume: 185, Issue:9

    Topics: Acute Coronary Syndrome; Adenosine; Angina, Unstable; Anticoagulants; Aspirin; Clopidogrel; Coronary

2012
Recent advances in the pharmacogenetics of clopidogrel.
    Human genetics, 2012, Volume: 131, Issue:5

    Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System

2012
Effects of combined aspirin and clopidogrel therapy on cardiovascular outcomes: a systematic review and meta-analysis.
    PloS one, 2012, Volume: 7, Issue:2

    Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocar

2012
A brief review of the past and future of platelet P2Y12 antagonist.
    Coronary artery disease, 2012, Volume: 23, Issue:6

    Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clopidogrel; Coronary Artery Disease; H

2012
Antiplatelet therapy beyond 2012: role of personalized medicine.
    Polskie Archiwum Medycyny Wewnetrznej, 2012, Volume: 122, Issue:6

    Topics: Adenosine; Clopidogrel; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors;

2012
Importance of potent P2Y(12) receptor blockade in acute myocardial infarction: focus on prasugrel.
    Expert opinion on pharmacotherapy, 2012, Volume: 13, Issue:12

    Topics: Clopidogrel; Costs and Cost Analysis; Drug Interactions; Humans; Myocardial Infarction; Piperazines;

2012
Effect of addition of clopidogrel to aspirin on mortality: systematic review of randomized trials.
    Stroke, 2012, Volume: 43, Issue:8

    Topics: Adult; Aged; Aspirin; Cause of Death; Cerebral Hemorrhage; Clopidogrel; Data Interpretation, Statist

2012
Cilostazol-based triple antiplatelet therapy compared to dual antiplatelet therapy in patients with coronary stent implantation: a meta-analysis of 5,821 patients.
    Cardiology, 2012, Volume: 122, Issue:3

    Topics: Acute Coronary Syndrome; Aspirin; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantation; Cil

2012
Acute ST-elevation myocardial infarction.
    Current opinion in critical care, 2012, Volume: 18, Issue:5

    Topics: Abciximab; Antibodies, Monoclonal; Clopidogrel; Coronary Angiography; Drug-Eluting Stents; Hemodynam

2012
Impact of antiplatelet therapy in heart disease.
    Advances in cardiology, 2012, Volume: 47

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillatio

2012
Clopidogrel in coronary artery disease: update 2012.
    Advances in cardiology, 2012, Volume: 47

    Topics: Adenosine; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Humans; Myocard

2012
Bleeding and the use of antiplatelet agents in the management of acute coronary syndromes and atrial fibrillation.
    Advances in cardiology, 2012, Volume: 47

    Topics: Acute Coronary Syndrome; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Clopidogrel; Hemorr

2012
Primary prevention of ischaemic cardiovascular disorders with antiplatelet agents.
    Handbook of experimental pharmacology, 2012, Issue:210

    Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Humans; Ischemia; Myocardia

2012
Reducing adverse effects of proton pump inhibitors.
    American family physician, 2012, Jul-01, Volume: 86, Issue:1

    Topics: Anemia, Iron-Deficiency; Clopidogrel; Clostridioides difficile; Critical Care; Diarrhea; Drug Intera

2012
Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
    Thrombosis and haemostasis, 2013, Volume: 109, Issue:1

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Thrombosis; Female; Humans; Intracra

2013
Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
    JAMA, 2012, Dec-19, Volume: 308, Issue:23

    Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Artery Disease; Endpoint Determination; Hemorrhage; H

2012
Drug interactions in the treatment of depression in patients with ischemic heart disease.
    The Journal of clinical psychiatry, 2012, Volume: 73, Issue:12

    Topics: Aged; Antidepressive Agents; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Comorbidity; Cytoc

2012
Controversies in the use & implementation of drug-eluting stent technology.
    The Indian journal of medical research, 2012, Volume: 136, Issue:6

    Topics: Absorbable Implants; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coated Materials, Biocompa

2012
Combination antiplatelet therapy: implications for pharmacists.
    Pharmacotherapy, 2002, Volume: 22, Issue:10

    Topics: Adult; Aspirin; Clopidogrel; Coronary Restenosis; Drug Therapy, Combination; Eptifibatide; Female; H

2002
Spontaneous multivessel coronary artery dissection in a long-distance runner successfully treated with oral antiplatelet therapy.
    The Journal of invasive cardiology, 2002, Volume: 14, Issue:11

    Topics: Adult; Aortic Dissection; Aspirin; Clopidogrel; Coronary Aneurysm; Exercise; Female; Humans; Myocard

2002
[Secondary and primary prevention of coronary heart disease: platelet aggregation inhibitors and anticoagulants].
    Zeitschrift fur Kardiologie, 2002, Volume: 91 Suppl 2

    Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Dose-Respon

2002
[Treatment strategy of unstable angina and non-ST-segment elevation myocardial infarction].
    Medicina (Kaunas, Lithuania), 2002, Volume: 38 Suppl 2

    Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Clopidogrel; Coronary Angiography;

2002
2002 update to the ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: implications for emergency department practice.
    Annals of emergency medicine, 2003, Volume: 41, Issue:3

    Topics: American Heart Association; Angina, Unstable; Anticoagulants; Cardiology; Child; Clopidogrel; Electr

2003
Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention.
    Journal of the American College of Cardiology, 2003, Feb-19, Volume: 41, Issue:4 Suppl S

    Topics: Acute Disease; Administration, Oral; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clop

2003
Appropriate antiplatelet and antithrombotic therapy in patients with acute coronary syndromes: recent updates to the ACC/AHA guidelines.
    The Journal of invasive cardiology, 2002, Volume: 14 Suppl E

    Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopid

2002
Aspirin and clopidogrel in patients with ACS undergoing PCI: CURE and PCI-CURE.
    The Journal of invasive cardiology, 2003, Volume: 15 Suppl B

    Topics: Adult; Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Administration Schedule; D

2003
[Anti thrombotic therapy after coronary thrombolysis].
    Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61 Suppl 4

    Topics: Anticoagulants; Aspirin; Coronary Restenosis; Drug Therapy, Combination; Fibrinolytic Agents; Hepari

2003
[Anticoagulant, antiplatelet agents].
    Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61 Suppl 4

    Topics: Anticoagulants; Aspirin; Death, Sudden, Cardiac; Dipyridamole; Drug Therapy, Combination; Heparin; H

2003
Clopidogrel in acute coronary syndromes (unstable angina and non-Q-wave myocardial infarction).
    Drugs of today (Barcelona, Spain : 1998), 2003, Volume: 39, Issue:4

    Topics: Angina, Unstable; Clinical Trials as Topic; Clopidogrel; Humans; Myocardial Infarction; Platelet Agg

2003
[Clopidogrel: background information and use in clinical practice].
    Ugeskrift for laeger, 2003, Apr-28, Volume: 165, Issue:18

    Topics: Arteriosclerosis; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Fibrinol

2003
Emergency management of hemorrhagic complications in the era of glycoprotein IIb/IIIa receptor antagonists, clopidogrel, low molecular weight heparin, and third-generation fibrinolytic agents.
    Current cardiology reports, 2003, Volume: 5, Issue:4

    Topics: Acute Disease; Angina, Unstable; Clopidogrel; Emergency Medical Services; Fibrinolytic Agents; Hemor

2003
[Update cardiology 2001/2002-part II. From unstable coronary syndrome to terminal heart failure].
    Medizinische Klinik (Munich, Germany : 1983), 2003, Jun-15, Volume: 98, Issue:6

    Topics: Abciximab; Acute Disease; Adrenergic beta-Antagonists; Angina, Unstable; Antibodies, Monoclonal; Ant

2003
The role of platelets and platelet inhibition in acute myocardial infarction.
    Coronary artery disease, 2003, Volume: 14, Issue:5

    Topics: Animals; Aspirin; Blood Platelets; Clopidogrel; Fibrinolytic Agents; Humans; Membrane Glycoproteins;

2003
[Stent thrombosis in patients with myocardial infarction].
    Kardiologiia, 2003, Volume: 43, Issue:2

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Coronary Thrombosis; Fibrinolytic Age

2003
Current management of non-ST-segment-elevation acute coronary syndrome: reconciling the results of randomized controlled trials.
    European heart journal, 2003, Volume: 24, Issue:17

    Topics: Anticoagulants; Clopidogrel; Coronary Disease; Echocardiography, Stress; Heparin, Low-Molecular-Weig

2003
[Antiplatelet drugs in prevention and treatment of coronary heart disease: aspirin is obligatory, quite sufficient, and safe].
    Kardiologiia, 2003, Volume: 43, Issue:6

    Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Intera

2003
Treatment of unstable angina pectoris/non-ST-segment elevation myocardial infarction in elderly patients.
    The journals of gerontology. Series A, Biological sciences and medical sciences, 2003, Volume: 58, Issue:10

    Topics: Adrenergic beta-Antagonists; Aged; Angina, Unstable; Angiotensin-Converting Enzyme Inhibitors; Antic

2003
Role of antiplatelet drugs in the prevention of cardiovascular events.
    Thrombosis research, 2003, Jun-15, Volume: 110, Issue:5-6

    Topics: Aspirin; Benzamidines; Clopidogrel; Coronary Artery Disease; Humans; Myocardial Infarction; Oximes;

2003
Recent clinical trial results with antiplatelet therapy: implications in stroke prevention.
    Cerebrovascular diseases (Basel, Switzerland), 2004, Volume: 17 Suppl 3

    Topics: Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Humans; Myocardial Infarction; Pla

2004
Clopidogrel's role in the management of atherosclerotic disease: a focus on acute coronary syndromes.
    Expert review of cardiovascular therapy, 2003, Volume: 1, Issue:4

    Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Arteriosclerosis; Aspirin; Clinical Trials as Topi

2003
Acute coronary syndromes in women: is treatment different? Should it be?
    Current cardiology reports, 2004, Volume: 6, Issue:4

    Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Bypass; Female; Fibri

2004
P2Y12, a new platelet ADP receptor, target of clopidogrel.
    Seminars in vascular medicine, 2003, Volume: 3, Issue:2

    Topics: Adenosine Diphosphate; Angina, Unstable; Animals; Blood Platelets; Clopidogrel; Down-Regulation; Hum

2003
Combined antithrombotic therapy for acute coronary syndrome.
    Seminars in vascular medicine, 2003, Volume: 3, Issue:2

    Topics: Administration, Oral; Angina, Unstable; Anticoagulants; Aspirin; Clopidogrel; Coronary Thrombosis; D

2003
Antithrombotic treatment of NSTEMI/UAP. The interaction with PCI.
    Scandinavian cardiovascular journal : SCJ, 2004, Volume: 38, Issue:1

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combin

2004
Comparison of cilostazol and ticlopidine for one-month effectiveness and safety after elective coronary stenting.
    Cardiovascular drugs and therapy, 2004, Volume: 18, Issue:3

    Topics: Administration, Oral; Aspirin; Cilostazol; Coronary Restenosis; Coronary Stenosis; Coronary Vessels;

2004
Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention.
    Circulation, 2004, Aug-24, Volume: 110, Issue:8

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Bl

2004
Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
    Chest, 2004, Volume: 126, Issue:3 Suppl

    Topics: Antithrombins; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Artery D

2004
Thrombolysis and adjunctive therapy in acute myocardial infarction: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
    Chest, 2004, Volume: 126, Issue:3 Suppl

    Topics: Aspirin; Clopidogrel; Contraindications; Drug Therapy, Combination; Electrocardiography; Evidence-Ba

2004
Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass grafts: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
    Chest, 2004, Volume: 126, Issue:3 Suppl

    Topics: Aspirin; Clopidogrel; Contraindications; Coronary Artery Bypass; Coronary Disease; Dose-Response Rel

2004
[Cardiovascular risk in diabetes--diagnostic and therapeutic aspects].
    MMW Fortschritte der Medizin, 2004, Sep-02, Volume: 146, Issue:35-36

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitors; Antibodies, Mon

2004
Stroke: advances in therapy.
    The Lancet. Neurology, 2005, Volume: 4, Issue:1

    Topics: Aspirin; Carotid Stenosis; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Drug Thera

2005
Controversies of oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention.
    Seminars in thrombosis and hemostasis, 2004, Volume: 30, Issue:6

    Topics: Administration, Oral; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Drug Synergi

2004
[Antithrombotic therapy after myocardial infarction: arguments for the use of acetylsalicylic acid and coumarin derivatives].
    Nederlands tijdschrift voor geneeskunde, 2005, Jan-08, Volume: 149, Issue:2

    Topics: Anticoagulants; Aspirin; Clopidogrel; Coumarins; Death, Sudden, Cardiac; Fibrinolytic Agents; Humans

2005
[Antithrombotic therapy during percutaneous coronary interventions].
    Nederlands tijdschrift voor geneeskunde, 2005, Apr-23, Volume: 149, Issue:17

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Fibrinolyti

2005
Clopidogrel in acute coronary syndrome: when, how much, how long?
    Zeitschrift fur Kardiologie, 2005, Volume: 94, Issue:6

    Topics: Acute Disease; Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Disease; D

2005
Meta-analysis of trials comparing oral anticoagulation and aspirin versus dual antiplatelet therapy after coronary stenting. Clues for the management of patients with an indication for long-term anticoagulation undergoing coronary stenting.
    Cardiology, 2005, Volume: 104, Issue:2

    Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary

2005
CLARITY about the use of clopidogrel in patients with acute coronary syndromes and myocardial infarction.
    Expert opinion on pharmacotherapy, 2005, Volume: 6, Issue:10

    Topics: Acute Disease; Clopidogrel; Coronary Disease; Humans; Multicenter Studies as Topic; Myocardial Infar

2005
[Prevention of periprocedural myocardial damage in patients undergoing percutaneous coronary intervention].
    Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology, 2005, Volume: 6, Issue:9

    Topics: Actuarial Analysis; Adenosine; Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Anticholestere

2005
Clopidogrel in acute coronary heart disease.
    The American heart hospital journal, 2005,Fall, Volume: 3, Issue:4

    Topics: Acute Disease; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Humans; Myocardial Inf

2005
Emerging drugs in peripheral arterial disease.
    Expert opinion on emerging drugs, 2006, Volume: 11, Issue:1

    Topics: Administration, Oral; Anticoagulants; Arterial Occlusive Diseases; Arteries; Aspirin; Clopidogrel; D

2006
[Secondary prevention of acute coronary syndromes: are we following correctly the guidelines?].
    Giornale italiano di cardiologia (2006), 2006, Volume: 7, Issue:3

    Topics: Acute Disease; Adrenergic beta-Antagonists; Algorithms; Angina, Unstable; Angiotensin-Converting Enz

2006
[Anti-platelet drugs (aspirin, ticlopidine, etc)].
    Nihon rinsho. Japanese journal of clinical medicine, 2006, Volume: 64, Issue:4

    Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Humans; Meta-An

2006
[Adding aspirin to clopidogrel in secondary prevention of ischemic stroke: no significant benefits. Results of the Match study].
    Presse medicale (Paris, France : 1983), 2006, Volume: 35, Issue:4 Pt 2

    Topics: Aspirin; Cerebral Infarction; Clopidogrel; Drug Therapy, Combination; Follow-Up Studies; Hemorrhage;

2006
The year in non-ST-segment elevation acute coronary syndromes.
    Journal of the American College of Cardiology, 2006, Jul-18, Volume: 48, Issue:2

    Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Atorvastatin; Biomarkers; Clopidogrel; Coronary Ve

2006
Clopidogrel in ST-elevation myocardial infarction patients undergoing percutaneous coronary intervention.
    Expert opinion on pharmacotherapy, 2006, Volume: 7, Issue:12

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inh

2006
Current developments in anti-platelet therapy.
    Wiener medizinische Wochenschrift (1946), 2006, Volume: 156, Issue:17-18

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cerebral Infarction; Clopidogrel; Drug Resistance;

2006
Narrative review: reperfusion strategies for ST-segment elevation myocardial infarction.
    Annals of internal medicine, 2006, Oct-17, Volume: 145, Issue:8

    Topics: Aged; Algorithms; Clopidogrel; Contraindications; Drug Therapy, Combination; Electrocardiography; Fe

2006
Clopidogrel response variability, resistance, or both?
    The American journal of cardiology, 2006, Nov-20, Volume: 98, Issue:10A

    Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Resistance; Humans; Myocardial Infarction; Plat

2006
Aspirin resistance or variable response or both?
    The American journal of cardiology, 2006, Nov-20, Volume: 98, Issue:10A

    Topics: Aspirin; Clopidogrel; Drug Resistance; Humans; Myocardial Infarction; Platelet Aggregation Inhibitor

2006
[Antithrombotic treatment of acute coronary syndromes without ST-segment elevation].
    Deutsche medizinische Wochenschrift (1946), 2006, Nov-24, Volume: 131, Issue:47 Suppl 7

    Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Clopidogrel; Eptifibatide; Fibrinolytic Agents; Humans;

2006
[Antiplatelet agents--problem for cardiac surgeon].
    Kardiologia polska, 2006, Volume: 64, Issue:11

    Topics: Anticoagulants; Aspirin; Coronary Thrombosis; Dipyridamole; Fibrinolytic Agents; Humans; Myocardial

2006
Evolving management of ST-segment elevation myocardial infarction: update on recent data.
    The American journal of cardiology, 2006, Dec-18, Volume: 98, Issue:12A

    Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Fibrinolytic Agents; Heparin;

2006
[Acute myocardial infarction: what is new?].
    Annales de cardiologie et d'angeiologie, 2005, Volume: 54, Issue:6

    Topics: Acute Disease; Algorithms; Angioplasty, Balloon, Coronary; Anticoagulants; Clinical Trials as Topic;

2005
Platelet P2 receptors: old and new targets for antithrombotic drugs.
    Expert review of cardiovascular therapy, 2007, Volume: 5, Issue:1

    Topics: Adenosine; Adenosine Monophosphate; Angina, Unstable; Animals; Blood Platelets; Clopidogrel; Coronar

2007
Clopidogrel bisulfate: in ST-segment elevation myocardial infarction.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2006, Volume: 6, Issue:6

    Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Drug Therapy

2006
The relationship of platelet reactivity to the occurrence of post-stenting ischemic events: emergence of a new cardiovascular risk factor.
    Reviews in cardiovascular medicine, 2006, Volume: 7 Suppl 4

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Therapy; Dr

2006
Accelerating time to reperfusion in acute myocardial infarction: prehospital and emergency department strategies, systems of care, and pharmacologic interventions.
    Reviews in cardiovascular medicine, 2006, Volume: 7 Suppl 4

    Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Blood Platelet

2006
Clinical update on the therapeutic use of clopidogrel: treatment of acute ST-segment elevation myocardial infarction (STEMI).
    Vascular health and risk management, 2006, Volume: 2, Issue:4

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Coro

2006
Contemporary issues in clopidogrel therapy: new evidence shaping clinical practice.
    Pharmacotherapy, 2007, Volume: 27, Issue:4

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Dose-Response Relationship, Drug; Electrocardiography;

2007
Antiplatelet therapy for atherothrombotic disease: an update for the primary care physician.
    Mayo Clinic proceedings, 2007, Volume: 82, Issue:5

    Topics: Anticoagulants; Aspirin; Atherosclerosis; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial

2007
Should EDTA chelation therapy be used instead of long-term clopidogrel plus aspirin to treat patients at risk from drug-eluting stents?
    Alternative medicine review : a journal of clinical therapeutic, 2007, Volume: 12, Issue:2

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Chelating Agents; Clopidogrel; Drug Implants; Edetic Acid;

2007
The role of clopidogrel in revascularized and nonrevascularized patients with acute coronary syndromes.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2007, Volume: 7, Issue:3

    Topics: Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Bypass

2007
Optimizing platelet P2Y12 inhibition for patients undergoing PCI.
    Cardiovascular drug reviews, 2007,Summer, Volume: 25, Issue:2

    Topics: Adenosine; Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clinica

2007
Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease.
    Vascular medicine (London, England), 2007, Volume: 12, Issue:2

    Topics: Angina, Unstable; Aspirin; Atherosclerosis; Biomarkers; Blood Platelets; Clopidogrel; Humans; Inflam

2007
Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: a meta-analysis of randomized trials.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2007, Volume: 7, Issue:4

    Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans

2007
Antithrombotic therapy and the transition to the catheterization laboratory in UA/NSTEMI.
    Minerva cardioangiologica, 2007, Volume: 55, Issue:5

    Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Th

2007
Platelet function monitoring in patients with coronary artery disease.
    Journal of the American College of Cardiology, 2007, Nov-06, Volume: 50, Issue:19

    Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Disease; Drug Resis

2007
Facilitated PCI: rationale, current evidence, open questions, and future directions.
    Journal of cardiovascular pharmacology, 2008, Volume: 51, Issue:1

    Topics: Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Fibrinolytic Agents; Humans;

2008
Antiplatelet therapy with clopidogrel and aspirin in vascular diseases: clinical evidence for and against the combination.
    Expert opinion on pharmacotherapy, 2008, Volume: 9, Issue:3

    Topics: Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Clopidogrel; Coronary Disease; Drug The

2008
[Gp IIb/IIIa receptor antagonists in acute coronary syndromes with no ST elevation].
    Archives des maladies du coeur et des vaisseaux, 2007, Volume: 100, Issue:12

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Clopidogrel; Hirudins; Huma

2007
Do patients with acute myocardial infarction benefit from treatment with clopidogrel?
    The Journal of emergency medicine, 2008, Volume: 34, Issue:4

    Topics: Adult; Clopidogrel; Emergency Medical Services; Evidence-Based Medicine; Humans; Male; Myocardial In

2008
[Drug-eluting stent thrombosis and its pharmacological prevention].
    Kardiologiia, 2007, Volume: 47, Issue:7

    Topics: Aspirin; Clopidogrel; Death, Sudden, Cardiac; Drug-Eluting Stents; Fibrinolytic Agents; Humans; Inci

2007
ST-elevation myocardial infarction: the role of adjunctive antiplatelet therapy.
    The American journal of emergency medicine, 2008, Volume: 26, Issue:2

    Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Clopidogrel; Electrocardiography; Eptifibatide; Fibrinol

2008
[Antithrombotic therapy after percutanous coronary intervention with stenting].
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2008, Feb-14, Volume: 128, Issue:4

    Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Drug-Eluting Stents; Fibrinoly

2008
Translational therapeutics at the platelet vascular interface. Summary.
    Arteriosclerosis, thrombosis, and vascular biology, 2008, Volume: 28, Issue:3

    Topics: Angina, Unstable; Animals; Aspirin; Blood Platelets; Clopidogrel; Disease Models, Animal; Drug Evalu

2008
Recent developments in acute coronary syndromes.
    Clinical medicine (London, England), 2008, Volume: 8, Issue:1

    Topics: Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Antithromb

2008
Clopidogrel use in coronary heart disease and percutaneous coronary intervention.
    Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 2008, Volume: 56, Issue:4

    Topics: Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Drug Intera

2008
Chronic antithrombotic therapy in post-myocardial infarction patients.
    Cardiology clinics, 2008, Volume: 26, Issue:2

    Topics: Anticoagulants; Aspirin; Azetidines; Benzylamines; Clopidogrel; Humans; Myocardial Infarction; Perip

2008
Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromes.
    Clinical cardiology, 2008, Volume: 31, Issue:3 Suppl 1

    Topics: Abciximab; Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin;

2008
Cyclic nucleotides, prostaglandins, and ischemic heart disease.
    Advances in cyclic nucleotide and protein phosphorylation research, 1984, Volume: 17

    Topics: 6-Ketoprostaglandin F1 alpha; Animals; Arteriosclerosis; Coronary Disease; Diet, Atherogenic; Myocar

1984
[Platelet anti-aggregant drugs and ischemic cardiopathy: evaluation of the effect on platelet aggregation and on antithrombin III].
    Bollettino della Societa italiana di cardiologia, 1981, Volume: 26, Issue:8

    Topics: Adult; Anticoagulants; Antithrombin III; Arrhythmias, Cardiac; Clofibrate; Dipyridamole; Female; Hum

1981
Medical treatment for stroke prevention.
    Annals of internal medicine, 1994, Jul-01, Volume: 121, Issue:1

    Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Ischemic Attack, Transient; Myocard

1994
Strategies for preventing stroke.
    Current opinion in neurology and neurosurgery, 1993, Volume: 6, Issue:1

    Topics: Adult; Aged; Aspirin; Blood Pressure; Cerebrovascular Disorders; Endarterectomy, Carotid; Female; Hu

1993
Confusion in reperfusion. Problems in the clinical development of antithrombotic drugs.
    Circulation, 1997, Feb-18, Volume: 95, Issue:4

    Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Cerebrovascular Disorders; Drug Therapy, Combination; Fi

1997
Platelet activation and inhibition in unstable coronary syndromes.
    The American journal of cardiology, 1997, Sep-04, Volume: 80, Issue:5A

    Topics: Angina, Unstable; Aspirin; Humans; Myocardial Infarction; Platelet Activation; Platelet Aggregation

1997
[Post myocardial infarction management].
    Revue medicale de Bruxelles, 1997, Volume: 18, Issue:4

    Topics: Aftercare; Anticholesteremic Agents; Antioxidants; Atorvastatin; Chromans; Clopidogrel; Diet, Fat-Re

1997
Beyond aspirin.
    Harvard heart letter : from Harvard Medical School, 1998, Volume: 8, Issue:10

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thrombosis; Humans; Myocardial Infarc

1998
Choosing the most appropriate treatment for stable angina. Safety considerations.
    Drug safety, 1998, Volume: 19, Issue:1

    Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Aspiri

1998
The results of CAPRIE, IST and CAST. Clopidogrel vs. Aspirin in Patients at Risk of Ischaemic Events. International Stroke Trial. Chinese Acute Stroke Trial.
    Thrombosis research, 1998, Sep-15, Volume: 92, Issue:1 Suppl 1

    Topics: Aspirin; Cerebrovascular Disorders; Clopidogrel; Double-Blind Method; Humans; Ischemia; Myocardial I

1998
Evolution of improved antithrombotic and antiplatelet agents: genesis of the Comparison of Abciximab Complications with Hirulog [and back-Up Abciximab] Events Trial (CACHET).
    The American journal of cardiology, 1998, Oct-22, Volume: 82, Issue:8B

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Antithrombins; As

1998
Results of the CAPRIE trial: efficacy and safety of clopidogrel. Clopidogrel versus aspirin in patients at risk of ischaemic events.
    Vascular medicine (London, England), 1998, Volume: 3, Issue:3

    Topics: Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clopidogrel; Follow-Up Studies; Humans; Myocar

1998
Antiplatelet drugs in secondary prevention after acute myocardial infarction.
    Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology, 1998, Volume: 17, Issue:12

    Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation

1998
Ticlopidine and clopidogrel.
    Circulation, 1999, Oct-12, Volume: 100, Issue:15

    Topics: Adenosine Diphosphate; Adenylyl Cyclase Inhibitors; Adenylyl Cyclases; Angina, Unstable; Aspirin; Bo

1999
[Intervention therapy of acute coronary syndrome].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 1999, Sep-10, Volume: 88, Issue:9

    Topics: Abciximab; Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal;

1999
[Acute complications of coronary angioplasty: prevention and management].
    Archives des maladies du coeur et des vaisseaux, 1999, Volume: 92, Issue:11 Suppl

    Topics: Angioplasty, Balloon, Coronary; Coronary Artery Bypass; Coronary Disease; Coronary Thrombosis; Human

1999
Antiplatelet and anticoagulant therapy in the secondary prevention of ischemic heart disease.
    The Medical clinics of North America, 2000, Volume: 84, Issue:1

    Topics: Anticoagulants; Aspirin; Clopidogrel; Coronary Disease; Humans; Myocardial Infarction; Platelet Aggr

2000
Beyond heparin and aspirin: new treatments for unstable angina and non-Q-wave myocardial infarction.
    Archives of internal medicine, 2000, Mar-27, Volume: 160, Issue:6

    Topics: Angina, Unstable; Antithrombins; Clopidogrel; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Hi

2000
Value of antiplatelet therapy in preventing thrombotic events in generalized vascular disease.
    Clinical cardiology, 2000, Volume: 23 Suppl 6

    Topics: Arteriosclerosis; Clopidogrel; Eptifibatide; Humans; Myocardial Infarction; Peptides; Platelet Aggre

2000
The future of antiplatelet therapy: optimizing management in patients with acute coronary syndrome.
    Clinical cardiology, 2000, Volume: 23 Suppl 6

    Topics: Angina, Unstable; Clopidogrel; Humans; Myocardial Infarction; Platelet Activation; Platelet Aggregat

2000
New recommendations from the 1999 American College of Cardiology/American Heart Association acute myocardial infarction guidelines.
    The Annals of pharmacotherapy, 2001, Volume: 35, Issue:5

    Topics: Adrenergic beta-Antagonists; Aged; American Heart Association; Angioplasty, Balloon, Coronary; Cardi

2001
[Acute coronary syndromes: an update. I. Pathogenesis and drug therapy].
    Herz, 2001, Volume: 26, Issue:2

    Topics: Acute Disease; Administration, Oral; Adrenergic beta-Antagonists; Angina, Unstable; Anticoagulants;

2001
Platelet glycoprotein IIb/IIIa blockers for percutaneous coronary revascularization, and unstable angina and non-ST-segment elevation myocardial infarction.
    The Cochrane database of systematic reviews, 2001, Issue:4

    Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Fibrinolytic Agents; Heparin; Humans; Myo

2001
[Antithrombotic treatment protocols in interventional cardiology].
    Archives des maladies du coeur et des vaisseaux, 2001, Volume: 94, Issue:11 Suppl

    Topics: Aspirin; Clopidogrel; Drug Resistance; Enoxaparin; Fibrinolytic Agents; Heparin; Humans; Myocardial

2001
From CURE to MATCH: ADP receptor antagonists as the treatment of choice for high-risk atherothrombotic patients.
    Cerebrovascular diseases (Basel, Switzerland), 2002, Volume: 13 Suppl 1

    Topics: Angina, Unstable; Aspirin; Clopidogrel; Drug Therapy, Combination; Heparin; Humans; Intracranial Art

2002
Persistence of the prothrombotic state after acute coronary syndromes: implications for treatment.
    American heart journal, 2002, Volume: 143, Issue:2

    Topics: Angina, Unstable; Aspirin; Clopidogrel; Coronary Thrombosis; Heparin, Low-Molecular-Weight; Humans;

2002
The use of antithrombotic drugs in older people.
    Minerva medica, 2002, Volume: 93, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Fibrinolytic Agents; Heparin; Heparin, Low-Molecular-Weight; Humans; Myo

2002
[Modern therapy in acute coronary syndrome].
    Medizinische Klinik (Munich, Germany : 1983), 2002, Apr-15, Volume: 97, Issue:4

    Topics: Angina, Unstable; Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Di

2002
Aspirin and other platelet-active drugs. The relationship between dose, effectiveness, and side effects.
    Chest, 1992, Volume: 102, Issue:4 Suppl

    Topics: Anticoagulants; Aspirin; Cerebrovascular Disorders; Dipyridamole; Dose-Response Relationship, Drug;

1992
Ticlopidine, a new antithrombotic drug: but is it better than aspirin for longterm use?
    Journal of neurology, neurosurgery, and psychiatry, 1990, Volume: 53, Issue:3

    Topics: Aspirin; Cerebrovascular Disorders; Humans; Ischemic Attack, Transient; Myocardial Infarction; Rando

1990
[Thrombosis in various diseases: myocardial infarct].
    Nihon rinsho. Japanese journal of clinical medicine, 1986, Volume: 44, Issue:5

    Topics: Angioplasty, Balloon; Aspirin; Dipyridamole; Humans; Myocardial Infarction; Platelet Aggregation; Th

1986
Clinical trials evaluating platelet-modifying drugs in patients with atherosclerotic cardiovascular disease and thrombosis.
    Circulation, 1986, Volume: 73, Issue:2

    Topics: Anticoagulants; Aspirin; Blood Platelets; Blood Vessel Prosthesis; Cardiovascular Diseases; Clinical

1986

Trials

413 trials available for ticlopidine and Myocardial Infarction

ArticleYear
Blunting periprocedural myocardial necrosis: Rationale and design of the randomized ALPHEUS study.
    American heart journal, 2020, Volume: 225

    Topics: Aged; Clopidogrel; Coronary Angiography; Coronary Disease; Humans; Myocardial Infarction; Percutaneo

2020
Prospective partially randomized comparison of clopidogrel loading versus maintenance dosing to prevent periprocedural myocardial infarction after stenting for stable angina pectoris: Results from the "Method of Clopidogrel Pre-treatment Undergoing Conven
    International journal of clinical pharmacology and therapeutics, 2020, Volume: 58, Issue:10

    Topics: Angina, Stable; Clopidogrel; Coronary Angiography; Humans; Myocardial Infarction; Percutaneous Coron

2020
Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
    Lancet (London, England), 2017, May-06, Volume: 389, Issue:10081

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Double-Blind M

2017
Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study.
    JACC. Cardiovascular interventions, 2017, 05-08, Volume: 10, Issue:9

    Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Double-Blind Method; Drug

2017
Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomi
    JACC. Cardiovascular interventions, 2017, 07-10, Volume: 10, Issue:13

    Topics: Aged; Aged, 80 and over; Aortic Valve; Aspirin; Balloon Valvuloplasty; Canada; Clopidogrel; Drug The

2017
Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomi
    JACC. Cardiovascular interventions, 2017, 07-10, Volume: 10, Issue:13

    Topics: Aged; Aged, 80 and over; Aortic Valve; Aspirin; Balloon Valvuloplasty; Canada; Clopidogrel; Drug The

2017
Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomi
    JACC. Cardiovascular interventions, 2017, 07-10, Volume: 10, Issue:13

    Topics: Aged; Aged, 80 and over; Aortic Valve; Aspirin; Balloon Valvuloplasty; Canada; Clopidogrel; Drug The

2017
Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomi
    JACC. Cardiovascular interventions, 2017, 07-10, Volume: 10, Issue:13

    Topics: Aged; Aged, 80 and over; Aortic Valve; Aspirin; Balloon Valvuloplasty; Canada; Clopidogrel; Drug The

2017
Cangrelor reduces the risk of ischemic complications in patients with single-vessel and multi-vessel disease undergoing percutaneous coronary intervention: Insights from the CHAMPION PHOENIX trial.
    American heart journal, 2017, Volume: 188

    Topics: Adenosine Monophosphate; Administration, Oral; Aged; Cause of Death; Clopidogrel; Coronary Angiograp

2017
Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention.
    Annals of internal medicine, 2017, Jul-04, Volume: 167, Issue:1

    Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Administration Sc

2017
Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention.
    Annals of internal medicine, 2017, Jul-04, Volume: 167, Issue:1

    Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Administration Sc

2017
Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention.
    Annals of internal medicine, 2017, Jul-04, Volume: 167, Issue:1

    Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Administration Sc

2017
Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention.
    Annals of internal medicine, 2017, Jul-04, Volume: 167, Issue:1

    Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Administration Sc

2017
Morphological and pharmacological determinants of peri-procedural myocardial infarction following elective stent implantation: Optical coherence tomography sub-analysis of the PRASFIT-Elective study.
    Journal of cardiology, 2017, Volume: 70, Issue:6

    Topics: Aged; Aspirin; Clopidogrel; Creatine Kinase, MB Form; Double-Blind Method; Elective Surgical Procedu

2017
Dual Antiplatelet Therapy for 6 Versus 18 Months After Biodegradable Polymer Drug-Eluting Stent Implantation.
    JACC. Cardiovascular interventions, 2017, 06-26, Volume: 10, Issue:12

    Topics: Absorbable Implants; Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; D

2017
6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin: Final Results of the ITALIC Trial (Is There a Life for DES After Discontinuation of Clopidogrel).
    JACC. Cardiovascular interventions, 2017, 06-26, Volume: 10, Issue:12

    Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Administration Schedu

2017
Validation of the DAPT score in patients randomized to 6 or 12 months clopidogrel after predominantly second-generation drug-eluting stents.
    Thrombosis and haemostasis, 2017, 10-05, Volume: 117, Issue:10

    Topics: Aged; Aspirin; Clinical Decision-Making; Clopidogrel; Coronary Disease; Coronary Thrombosis; Decisio

2017
Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin (from CHAMPION PHOENIX).
    The American journal of cardiology, 2017, Oct-01, Volume: 120, Issue:7

    Topics: Adenosine Monophosphate; Aged; Anticoagulants; Clopidogrel; Dose-Response Relationship, Drug; Double

2017
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
    Lancet (London, England), 2017, Oct-14, Volume: 390, Issue:10104

    Topics: Acute Coronary Syndrome; Clopidogrel; Drug Administration Schedule; Drug Monitoring; Europe; Female;

2017
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
    Lancet (London, England), 2017, Oct-14, Volume: 390, Issue:10104

    Topics: Acute Coronary Syndrome; Clopidogrel; Drug Administration Schedule; Drug Monitoring; Europe; Female;

2017
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
    Lancet (London, England), 2017, Oct-14, Volume: 390, Issue:10104

    Topics: Acute Coronary Syndrome; Clopidogrel; Drug Administration Schedule; Drug Monitoring; Europe; Female;

2017
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
    Lancet (London, England), 2017, Oct-14, Volume: 390, Issue:10104

    Topics: Acute Coronary Syndrome; Clopidogrel; Drug Administration Schedule; Drug Monitoring; Europe; Female;

2017
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
    Lancet (London, England), 2017, Oct-14, Volume: 390, Issue:10104

    Topics: Acute Coronary Syndrome; Clopidogrel; Drug Administration Schedule; Drug Monitoring; Europe; Female;

2017
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
    Lancet (London, England), 2017, Oct-14, Volume: 390, Issue:10104

    Topics: Acute Coronary Syndrome; Clopidogrel; Drug Administration Schedule; Drug Monitoring; Europe; Female;

2017
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
    Lancet (London, England), 2017, Oct-14, Volume: 390, Issue:10104

    Topics: Acute Coronary Syndrome; Clopidogrel; Drug Administration Schedule; Drug Monitoring; Europe; Female;

2017
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
    Lancet (London, England), 2017, Oct-14, Volume: 390, Issue:10104

    Topics: Acute Coronary Syndrome; Clopidogrel; Drug Administration Schedule; Drug Monitoring; Europe; Female;

2017
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
    Lancet (London, England), 2017, Oct-14, Volume: 390, Issue:10104

    Topics: Acute Coronary Syndrome; Clopidogrel; Drug Administration Schedule; Drug Monitoring; Europe; Female;

2017
Cangrelor compared with clopidogrel in patients with prior myocardial infarction - Insights from the CHAMPION trials.
    International journal of cardiology, 2018, Jan-01, Volume: 250

    Topics: Adenosine Monophosphate; Aged; Clopidogrel; Double-Blind Method; Female; Humans; Male; Middle Aged;

2018
Risk of discontinuation of clopidogrel after 1 month following bare-metal stents: a propensity-score adjusted comparison with continued administration of clopidogrel after drug-eluting stents.
    Journal of thrombosis and thrombolysis, 2018, Volume: 45, Issue:3

    Topics: Aged; Clopidogrel; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Mortality; Myocardial Inf

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Randomized Comparison of Strut Coverage between Ticagrelor and Clopidogrel in Acute Myocardial Infarction at 3-Month Optical Coherence Tomography.
    Yonsei medical journal, 2018, Volume: 59, Issue:5

    Topics: Adenosine; Aged; Clopidogrel; Coronary Angiography; Drug-Eluting Stents; Female; Humans; Male; Middl

2018
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
    Lancet (London, England), 2018, 09-15, Volume: 392, Issue:10151

    Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy,

2018
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
    Lancet (London, England), 2018, 09-15, Volume: 392, Issue:10151

    Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy,

2018
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
    Lancet (London, England), 2018, 09-15, Volume: 392, Issue:10151

    Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy,

2018
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
    Lancet (London, England), 2018, 09-15, Volume: 392, Issue:10151

    Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy,

2018
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
    Lancet (London, England), 2018, 09-15, Volume: 392, Issue:10151

    Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy,

2018
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
    Lancet (London, England), 2018, 09-15, Volume: 392, Issue:10151

    Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy,

2018
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
    Lancet (London, England), 2018, 09-15, Volume: 392, Issue:10151

    Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy,

2018
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
    Lancet (London, England), 2018, 09-15, Volume: 392, Issue:10151

    Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy,

2018
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
    Lancet (London, England), 2018, 09-15, Volume: 392, Issue:10151

    Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy,

2018
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
    Lancet (London, England), 2018, 09-15, Volume: 392, Issue:10151

    Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy,

2018
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
    Lancet (London, England), 2018, 09-15, Volume: 392, Issue:10151

    Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy,

2018
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
    Lancet (London, England), 2018, 09-15, Volume: 392, Issue:10151

    Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy,

2018
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
    Lancet (London, England), 2018, 09-15, Volume: 392, Issue:10151

    Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy,

2018
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
    Lancet (London, England), 2018, 09-15, Volume: 392, Issue:10151

    Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy,

2018
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
    Lancet (London, England), 2018, 09-15, Volume: 392, Issue:10151

    Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy,

2018
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
    Lancet (London, England), 2018, 09-15, Volume: 392, Issue:10151

    Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy,

2018
Pretreatment with antiplatelet drugs improves the cardiac function after myocardial infarction without reperfusion in a mouse model.
    Cardiology journal, 2021, Volume: 28, Issue:1

    Topics: Animals; Humans; Hydrogen Peroxide; Mice; Mice, Inbred C57BL; Myocardial Infarction; Percutaneous Co

2021
Efficacy and safety of 12 versus 48 months of dual antiplatelet therapy after implantation of a drug-eluting stent: the OPTImal DUAL antiplatelet therapy (OPTIDUAL) trial: study protocol for a randomized controlled trial.
    Trials, 2013, Feb-21, Volume: 14

    Topics: Aspirin; Clinical Protocols; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; D

2013
Quantification of the effect of clopidogrel on enzymatic infarct size related to a percutaneous coronary intervention in patients with acute coronary syndromes: insights from the CHAMPION percutaneous coronary intervention trial.
    Coronary artery disease, 2013, Volume: 24, Issue:4

    Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Creatine Kinase, MB Form; Female; Humans; Logistic Model

2013
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
    The New England journal of medicine, 2013, Apr-11, Volume: 368, Issue:15

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination;

2013
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
    The New England journal of medicine, 2013, Apr-11, Volume: 368, Issue:15

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination;

2013
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
    The New England journal of medicine, 2013, Apr-11, Volume: 368, Issue:15

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination;

2013
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
    The New England journal of medicine, 2013, Apr-11, Volume: 368, Issue:15

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination;

2013
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
    The New England journal of medicine, 2013, Apr-11, Volume: 368, Issue:15

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination;

2013
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
    The New England journal of medicine, 2013, Apr-11, Volume: 368, Issue:15

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination;

2013
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
    The New England journal of medicine, 2013, Apr-11, Volume: 368, Issue:15

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination;

2013
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
    The New England journal of medicine, 2013, Apr-11, Volume: 368, Issue:15

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination;

2013
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
    The New England journal of medicine, 2013, Apr-11, Volume: 368, Issue:15

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination;

2013
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
    The New England journal of medicine, 2013, Apr-11, Volume: 368, Issue:15

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination;

2013
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
    The New England journal of medicine, 2013, Apr-11, Volume: 368, Issue:15

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination;

2013
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
    The New England journal of medicine, 2013, Apr-11, Volume: 368, Issue:15

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination;

2013
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
    The New England journal of medicine, 2013, Apr-11, Volume: 368, Issue:15

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination;

2013
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
    The New England journal of medicine, 2013, Apr-11, Volume: 368, Issue:15

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination;

2013
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
    The New England journal of medicine, 2013, Apr-11, Volume: 368, Issue:15

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination;

2013
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
    The New England journal of medicine, 2013, Apr-11, Volume: 368, Issue:15

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination;

2013
Cost-effectiveness of ticagrelor versus clopidogrel for the prevention of atherothrombotic events in adult patients with acute coronary syndrome in Germany.
    Clinical research in cardiology : official journal of the German Cardiac Society, 2013, Volume: 102, Issue:6

    Topics: Acute Coronary Syndrome; Adenosine; Adult; Atherosclerosis; Clopidogrel; Cost-Benefit Analysis; Deci

2013
Relationship between postoperative clopidogrel use and subsequent angiographic and clinical outcomes following coronary artery bypass grafting.
    Journal of thrombosis and thrombolysis, 2013, Volume: 36, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Angiography; Coronary Art

2013
[Prevention of non-acute stent thrombosis after drug-eluting stent implantation].
    Zhonghua wei zhong bing ji jiu yi xue, 2013, Volume: 25, Issue:5

    Topics: Aspirin; Clopidogrel; Drug-Eluting Stents; Female; Humans; Male; Myocardial Infarction; Platelet Agg

2013
Incidence and outcome of high on-treatment platelet reactivity in patients with non-ST elevation acute coronary syndromes undergoing percutaneous coronary intervention (from the VIP [VerifyNow and Inhibition of Platelet Reactivity] study).
    The American journal of cardiology, 2013, Sep-15, Volume: 112, Issue:6

    Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Angiography; Death, Sudden, Cardiac; Electrocar

2013
Quantitative ST-depression in acute coronary syndromes: the PLATO electrocardiographic substudy.
    The American journal of medicine, 2013, Volume: 126, Issue:8

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Cardiovascular Diseases; Clopidogrel; Cohort Studies; Elec

2013
Short-term follow-up of tirofiban as alternative therapy for urgent surgery patients with an implanted coronary drug-eluting stent after ST-elevation myocardial infarction.
    Coronary artery disease, 2013, Volume: 24, Issue:6

    Topics: Aged; Aspirin; China; Clopidogrel; Drug Administration Schedule; Drug Substitution; Drug Therapy, Co

2013
Comparison of pre-hospital 600 mg or 900 mg vs. peri-interventional 300 mg clopidogrel in patients with ST-elevation myocardial infarction undergoing primary coronary angioplasty. The Load&Go randomized trial.
    International journal of cardiology, 2013, Oct-12, Volume: 168, Issue:5

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Dose-Response Relationship,

2013
Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial.
    Lancet (London, England), 2013, Aug-17, Volume: 382, Issue:9892

    Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Clopidogrel; Coronary Angiography; Female; Humans;

2013
Implementation of contemporary oral antiplatelet treatment guidelines in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a report from the GReek AntiPlatelet rEgistry (GRAPE).
    International journal of cardiology, 2013, Oct-15, Volume: 168, Issue:6

    Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aged; Clopidogrel; Combined Modality Thera

2013
CYP2C19 poor metabolizer is associated with clinical outcome of clopidogrel therapy in acute myocardial infarction but not stable angina.
    Circulation. Cardiovascular genetics, 2013, Volume: 6, Issue:5

    Topics: Adult; Aged; Alleles; Angina, Stable; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 C

2013
Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-plate
    JACC. Cardiovascular interventions, 2013, Volume: 6, Issue:9

    Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy,

2013
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial.
    European heart journal, 2014, Volume: 35, Issue:4

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Embolism; Fema

2014
Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibit
    Journal of the American College of Cardiology, 2014, Jan-28, Volume: 63, Issue:3

    Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind

2014
Short- versus long-term duration of dual antiplatelet therapy in patients treated for in-stent restenosis: a PRODIGY trial substudy (Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia).
    Journal of the American College of Cardiology, 2014, Feb-18, Volume: 63, Issue:6

    Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Restenosis; Female; Humans; Italy; Male; Mid

2014
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
    JAMA, 2013, Dec-18, Volume: 310, Issue:23

    Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Sc

2013
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
    JAMA, 2013, Dec-18, Volume: 310, Issue:23

    Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Sc

2013
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
    JAMA, 2013, Dec-18, Volume: 310, Issue:23

    Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Sc

2013
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
    JAMA, 2013, Dec-18, Volume: 310, Issue:23

    Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Sc

2013
Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarctio
    JACC. Cardiovascular interventions, 2013, Volume: 6, Issue:12

    Topics: Acute Coronary Syndrome; Aged; Calcium Channel Blockers; Clopidogrel; Double-Blind Method; Drug Inte

2013
Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment
    JACC. Cardiovascular interventions, 2014, Volume: 7, Issue:1

    Topics: Aged, 80 and over; Chi-Square Distribution; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; D

2014
Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment
    JACC. Cardiovascular interventions, 2014, Volume: 7, Issue:1

    Topics: Aged, 80 and over; Chi-Square Distribution; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; D

2014
Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment
    JACC. Cardiovascular interventions, 2014, Volume: 7, Issue:1

    Topics: Aged, 80 and over; Chi-Square Distribution; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; D

2014
Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment
    JACC. Cardiovascular interventions, 2014, Volume: 7, Issue:1

    Topics: Aged, 80 and over; Chi-Square Distribution; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; D

2014
Clinical implications and correlates of Q waves in patients with ST-elevation myocardial infarction treated with fibrinolysis: observations from the CLARITY-TIMI 28 trial.
    Clinical cardiology, 2014, Volume: 37, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Circulation; Coronary Thrombosis; Creatin

2014
Von Willebrand factor antigen predicts response to double dose of aspirin and clopidogrel by PFA-100 in patients undergoing primary angioplasty for ST elevation myocardial infarction.
    TheScientificWorldJournal, 2013, Volume: 2013

    Topics: ADAM Proteins; ADAMTS13 Protein; Aged; Aspirin; Clopidogrel; Female; Follow-Up Studies; Humans; Male

2013
Efficacy and safety of tirofiban-supported primary percutaneous coronary intervention in patients pretreated with 600 mg clopidogrel: results of propensity analysis using the Clinical Center of Serbia STEMI Register.
    European heart journal. Acute cardiovascular care, 2014, Volume: 3, Issue:1

    Topics: Aged; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Electrocardiography;

2014
Outcomes in patients with ST-segment elevation acute myocardial infarction treated with clopidogrel versus prasugrel (from the INFUSE-AMI trial).
    The American journal of cardiology, 2014, May-01, Volume: 113, Issue:9

    Topics: Antithrombins; Clopidogrel; Coronary Angiography; Electrocardiography; Female; Hirudins; Humans; Mal

2014
Comparison of prasugrel and bivalirudin vs clopidogrel and heparin in patients with ST-segment elevation myocardial infarction: Design and rationale of the Bavarian Reperfusion Alternatives Evaluation (BRAVE) 4 trial.
    Clinical cardiology, 2014, Volume: 37, Issue:5

    Topics: Anticoagulants; Clopidogrel; Drug Therapy, Combination; Female; Heparin; Hirudins; Humans; Male; Myo

2014
The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial.
    European heart journal, 2014, Jun-14, Volume: 35, Issue:23

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Dose-Response Relationship, Drug; Double-Blin

2014
Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial.
    European heart journal, 2014, Aug-14, Volume: 35, Issue:31

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Hemorrhage; Humans; Kaplan-Meier Esti

2014
Impact of preoperative fibrinogen concentration on postoperative outcome in patients who received dual antiplatelet therapy in proximity to off-pump coronary bypass surgery.
    Circulation journal : official journal of the Japanese Circulation Society, 2014, Volume: 78, Issue:7

    Topics: Aged; Blood Loss, Surgical; Clopidogrel; Coronary Artery Bypass, Off-Pump; Female; Fibrinogen; Human

2014
Prospective validation of the Bleeding Academic Research Consortium classification in the all-comer PRODIGY trial.
    European heart journal, 2014, Oct-01, Volume: 35, Issue:37

    Topics: Administration, Oral; Aged; Aspirin; Clopidogrel; Epidemiologic Methods; Female; Hemorrhage; Humans;

2014
Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study.
    Circulation journal : official journal of the Japanese Circulation Society, 2014, Volume: 78, Issue:7

    Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Asian People; Aspirin; Clopidogrel; Drug Th

2014
Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction.
    European heart journal, 2014, Sep-07, Volume: 35, Issue:34

    Topics: Aged; Anticoagulants; Clopidogrel; Coronary Angiography; Coronary Stenosis; Drug Therapy, Combinatio

2014
Clinical outcomes for prasugrel versus clopidogrel in patients with unstable angina or non-ST-elevation myocardial infarction: an analysis from the TRITON-TIMI 38 trial.
    European heart journal. Acute cardiovascular care, 2014, Volume: 3, Issue:4

    Topics: Angina, Unstable; Clopidogrel; Double-Blind Method; Female; Hemorrhage; Humans; Male; Middle Aged; M

2014
Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial.
    European journal of preventive cardiology, 2015, Volume: 22, Issue:6

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Female; Hemorrhage; Huma

2015
Comparing the effect of clopidogrel versus ticagrelor on coronary microvascular dysfunction in acute coronary syndrome patients (TIME trial): study protocol for a randomized controlled trial.
    Trials, 2014, May-01, Volume: 15

    Topics: Acute Coronary Syndrome; Adenosine; Clinical Protocols; Clopidogrel; Coronary Circulation; Coronary

2014
High clopidogrel dose in patients with chronic kidney disease having clopidogrel resistance after percutaneous coronary intervention.
    Angiology, 2015, Volume: 66, Issue:4

    Topics: Aged; China; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Administration Schedule

2015
Prasugrel versus clopidogrel in patients with ST-segment elevation myocardial infarction according to timing of percutaneous coronary intervention: a TRITON-TIMI 38 subgroup analysis (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Plate
    JACC. Cardiovascular interventions, 2014, Volume: 7, Issue:6

    Topics: Aged; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Femal

2014
Platelet reactivity and cardiovascular events after percutaneous coronary intervention in patients with stable coronary artery disease: the Stent Thrombosis In Belgium (STIB) trial.
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2014, Volume: 10, Issue:2

    Topics: Aged; Angina, Stable; Aspirin; Belgium; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coron

2014
CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients-Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study.
    American heart journal, 2014, Volume: 168, Issue:1

    Topics: Adult; Aged; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Electrocardiograp

2014
CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients-Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study.
    American heart journal, 2014, Volume: 168, Issue:1

    Topics: Adult; Aged; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Electrocardiograp

2014
CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients-Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study.
    American heart journal, 2014, Volume: 168, Issue:1

    Topics: Adult; Aged; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Electrocardiograp

2014
CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients-Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study.
    American heart journal, 2014, Volume: 168, Issue:1

    Topics: Adult; Aged; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Electrocardiograp

2014
Monitoring the efficacy of ADP inhibitor treatment in patients with acute STEMI post-PCI by VASP-P flow cytometry assay.
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2015, Volume: 21, Issue:4

    Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Aged, 80 and over; Aspirin; Blood Platelets; C

2015
Applying novel methods to assess clinical outcomes: insights from the TRILOGY ACS trial.
    European heart journal, 2015, Feb-07, Volume: 36, Issue:6

    Topics: Aged; Angina, Unstable; Clopidogrel; Endpoint Determination; Humans; Middle Aged; Myocardial Infarct

2015
An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel.
    Current medical research and opinion, 2014, Volume: 30, Issue:11

    Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Bypass; Drug Ad

2014
Prehospital ticagrelor in ST-segment elevation myocardial infarction.
    The New England journal of medicine, 2014, Sep-11, Volume: 371, Issue:11

    Topics: Adenosine; Aged; Anticoagulants; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Therap

2014
Prehospital ticagrelor in ST-segment elevation myocardial infarction.
    The New England journal of medicine, 2014, Sep-11, Volume: 371, Issue:11

    Topics: Adenosine; Aged; Anticoagulants; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Therap

2014
Prehospital ticagrelor in ST-segment elevation myocardial infarction.
    The New England journal of medicine, 2014, Sep-11, Volume: 371, Issue:11

    Topics: Adenosine; Aged; Anticoagulants; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Therap

2014
Prehospital ticagrelor in ST-segment elevation myocardial infarction.
    The New England journal of medicine, 2014, Sep-11, Volume: 371, Issue:11

    Topics: Adenosine; Aged; Anticoagulants; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Therap

2014
Prehospital ticagrelor in ST-segment elevation myocardial infarction.
    The New England journal of medicine, 2014, Sep-11, Volume: 371, Issue:11

    Topics: Adenosine; Aged; Anticoagulants; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Therap

2014
Prehospital ticagrelor in ST-segment elevation myocardial infarction.
    The New England journal of medicine, 2014, Sep-11, Volume: 371, Issue:11

    Topics: Adenosine; Aged; Anticoagulants; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Therap

2014
Prehospital ticagrelor in ST-segment elevation myocardial infarction.
    The New England journal of medicine, 2014, Sep-11, Volume: 371, Issue:11

    Topics: Adenosine; Aged; Anticoagulants; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Therap

2014
Prehospital ticagrelor in ST-segment elevation myocardial infarction.
    The New England journal of medicine, 2014, Sep-11, Volume: 371, Issue:11

    Topics: Adenosine; Aged; Anticoagulants; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Therap

2014
Prehospital ticagrelor in ST-segment elevation myocardial infarction.
    The New England journal of medicine, 2014, Sep-11, Volume: 371, Issue:11

    Topics: Adenosine; Aged; Anticoagulants; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Therap

2014
Prehospital ticagrelor in ST-segment elevation myocardial infarction.
    The New England journal of medicine, 2014, Sep-11, Volume: 371, Issue:11

    Topics: Adenosine; Aged; Anticoagulants; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Therap

2014
Prehospital ticagrelor in ST-segment elevation myocardial infarction.
    The New England journal of medicine, 2014, Sep-11, Volume: 371, Issue:11

    Topics: Adenosine; Aged; Anticoagulants; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Therap

2014
Prehospital ticagrelor in ST-segment elevation myocardial infarction.
    The New England journal of medicine, 2014, Sep-11, Volume: 371, Issue:11

    Topics: Adenosine; Aged; Anticoagulants; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Therap

2014
Prehospital ticagrelor in ST-segment elevation myocardial infarction.
    The New England journal of medicine, 2014, Sep-11, Volume: 371, Issue:11

    Topics: Adenosine; Aged; Anticoagulants; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Therap

2014
Prehospital ticagrelor in ST-segment elevation myocardial infarction.
    The New England journal of medicine, 2014, Sep-11, Volume: 371, Issue:11

    Topics: Adenosine; Aged; Anticoagulants; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Therap

2014
Prehospital ticagrelor in ST-segment elevation myocardial infarction.
    The New England journal of medicine, 2014, Sep-11, Volume: 371, Issue:11

    Topics: Adenosine; Aged; Anticoagulants; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Therap

2014
Prehospital ticagrelor in ST-segment elevation myocardial infarction.
    The New England journal of medicine, 2014, Sep-11, Volume: 371, Issue:11

    Topics: Adenosine; Aged; Anticoagulants; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Therap

2014
MULTInational non-interventional study of patients with ST-segment elevation myocardial infarction treated with PRimary Angioplasty and Concomitant use of upstream antiplatelet therapy with prasugrel or clopidogrel--the European MULTIPRAC Registry.
    European heart journal. Acute cardiovascular care, 2015, Volume: 4, Issue:3

    Topics: Acute Coronary Syndrome; Aged; Antithrombins; Clopidogrel; Drug Therapy, Combination; Europe; Female

2015
Relationship between ABCB1 polymorphisms, thromboelastography and risk of bleeding events in clopidogrel-treated patients with ST-elevation myocardial infarction.
    Thrombosis research, 2014, Volume: 134, Issue:5

    Topics: Aged; ATP Binding Cassette Transporter, Subfamily B; Clopidogrel; Female; Hemorrhage; Humans; Male;

2014
Point-of-care measurements of platelet inhibition after clopidogrel loading in patients with acute coronary syndrome: comparison of generic and branded clopidogrel bisulfate.
    Clinical therapeutics, 2014, Nov-01, Volume: 36, Issue:11

    Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Drugs, Generic; Female; Humans; Male; M

2014
Switching from generic to brand clopidogrel in male patients after ST-elevated myocardial infarction.
    Cardiology, 2014, Volume: 129, Issue:2

    Topics: Adenosine Diphosphate; Aspirin; Clopidogrel; Drug Substitution; Drug Therapy, Combination; Drugs, Ge

2014
Prasugrel, a third-generation P2Y12 receptor antagonist, in patients with coronary artery disease undergoing elective percutaneous coronary intervention.
    Circulation journal : official journal of the Japanese Circulation Society, 2014, Volume: 78, Issue:12

    Topics: Aged; Brain Ischemia; Clopidogrel; Combined Modality Therapy; Coronary Disease; Cytochrome P-450 CYP

2014
Tradeoff between bleeding and stent thrombosis in different dual antiplatelet therapy regimes: Importance of case fatality rates and effective treatment durations.
    American heart journal, 2014, Volume: 168, Issue:5

    Topics: Aged; Angina Pectoris; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Drug-El

2014
Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial.
    American heart journal, 2014, Volume: 168, Issue:6

    Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Drug Monitoring; Drug Therapy, Combination; Electrocardi

2014
Comparison of prasugrel and clopidogrel-treated patients with acute coronary syndrome undergoing percutaneous coronary intervention: A propensity score-matched analysis of the Acute Myocardial Infarction in Switzerland (AMIS)-Plus Registry.
    European heart journal. Acute cardiovascular care, 2016, Volume: 5, Issue:1

    Topics: Acute Coronary Syndrome; Acute Disease; Aged; Aged, 80 and over; Clopidogrel; Female; Humans; Male;

2016
ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting.
    European heart journal, 2015, May-21, Volume: 36, Issue:20

    Topics: Aged; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Drug Administration Schedule; Drug-

2015
Double-blind, randomized, prospective comparison of loading doses of 600 mg clopidogrel versus 60 mg prasugrel in patients with acute ST-segment elevation myocardial infarction scheduled for primary percutaneous intervention: the ETAMI trial (early thieno
    JACC. Cardiovascular interventions, 2015, Volume: 8, Issue:1 Pt B

    Topics: Aged; Biomarkers; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Coronary Vessels; Double-Bl

2015
Ticagrelor versus high dose clopidogrel in ST-segment elevation myocardial infarction patients with high platelet reactivity post fibrinolysis.
    Journal of thrombosis and thrombolysis, 2015, Volume: 40, Issue:3

    Topics: Adenosine; Aged; Blood Platelets; Clopidogrel; Female; Fibrinolysis; Hemorrhage; Humans; Male; Middl

2015
Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]).
    JACC. Cardiovascular interventions, 2015, Volume: 8, Issue:3

    Topics: Adenosine Monophosphate; Aged; Anticoagulants; Chi-Square Distribution; Clopidogrel; Coronary Artery

2015
Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After
    European heart journal, 2015, May-21, Volume: 36, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combinat

2015
Generic Clopidogrel Besylate in the Secondary Prevention of Atherothrombotic Events: A 6-month Follow-up of a Randomised Clinical Trial.
    Current vascular pharmacology, 2015, Volume: 13, Issue:6

    Topics: Aged; Aged, 80 and over; Clopidogrel; Drugs, Generic; Female; Follow-Up Studies; Hemorrhage; Humans;

2015
Generic Clopidogrel Besylate in the Secondary Prevention of Atherothrombotic Events: A 6-month Follow-up of a Randomised Clinical Trial.
    Current vascular pharmacology, 2015, Volume: 13, Issue:6

    Topics: Aged; Aged, 80 and over; Clopidogrel; Drugs, Generic; Female; Follow-Up Studies; Hemorrhage; Humans;

2015
Generic Clopidogrel Besylate in the Secondary Prevention of Atherothrombotic Events: A 6-month Follow-up of a Randomised Clinical Trial.
    Current vascular pharmacology, 2015, Volume: 13, Issue:6

    Topics: Aged; Aged, 80 and over; Clopidogrel; Drugs, Generic; Female; Follow-Up Studies; Hemorrhage; Humans;

2015
Generic Clopidogrel Besylate in the Secondary Prevention of Atherothrombotic Events: A 6-month Follow-up of a Randomised Clinical Trial.
    Current vascular pharmacology, 2015, Volume: 13, Issue:6

    Topics: Aged; Aged, 80 and over; Clopidogrel; Drugs, Generic; Female; Follow-Up Studies; Hemorrhage; Humans;

2015
Safety profile of prasugrel and clopidogrel in patients with acute coronary syndromes in Switzerland.
    Heart (British Cardiac Society), 2015, Volume: 101, Issue:11

    Topics: Adolescent; Adult; Aged; Cerebrovascular Disorders; Clopidogrel; Drug-Eluting Stents; Female; Guidel

2015
Safety profile of prasugrel and clopidogrel in patients with acute coronary syndromes in Switzerland.
    Heart (British Cardiac Society), 2015, Volume: 101, Issue:11

    Topics: Adolescent; Adult; Aged; Cerebrovascular Disorders; Clopidogrel; Drug-Eluting Stents; Female; Guidel

2015
Safety profile of prasugrel and clopidogrel in patients with acute coronary syndromes in Switzerland.
    Heart (British Cardiac Society), 2015, Volume: 101, Issue:11

    Topics: Adolescent; Adult; Aged; Cerebrovascular Disorders; Clopidogrel; Drug-Eluting Stents; Female; Guidel

2015
Safety profile of prasugrel and clopidogrel in patients with acute coronary syndromes in Switzerland.
    Heart (British Cardiac Society), 2015, Volume: 101, Issue:11

    Topics: Adolescent; Adult; Aged; Cerebrovascular Disorders; Clopidogrel; Drug-Eluting Stents; Female; Guidel

2015
Intrinsic platelet reactivity before start with clopidogrel as predictor for on-clopidogrel platelet function and long-term clinical outcome.
    Thrombosis and haemostasis, 2015, Volume: 114, Issue:1

    Topics: Aged; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug Resistance; Female; Germa

2015
A prospective randomized evaluation of a pharmacogenomic approach to antiplatelet therapy among patients with ST-elevation myocardial infarction: the RAPID STEMI study.
    The pharmacogenomics journal, 2016, Volume: 16, Issue:1

    Topics: Aged; ATP Binding Cassette Transporter, Subfamily B; Clopidogrel; Cytochrome P-450 CYP2C19; Female;

2016
[Midterm follow-up outcomes of ticagrelor on acute ST segment elevation myocardial infarction undergoing emergency percutaneous coronary intervention].
    Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 2015, Jun-18, Volume: 47, Issue:3

    Topics: Adenosine; Clopidogrel; Follow-Up Studies; Humans; Myocardial Infarction; Percutaneous Coronary Inte

2015
Impact of chronic kidney disease on long-term ischemic and bleeding outcomes in medically managed patients with acute coronary syndromes: Insights from the TRILOGY ACS Trial.
    European heart journal. Acute cardiovascular care, 2016, Volume: 5, Issue:6

    Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Creatinine; Female; Hemorrhage; Humans; Kaplan-Meier Est

2016
Antiplatelet efficacy of P2Y12 inhibitors (prasugrel, ticagrelor, clopidogrel) in patients treated with mild therapeutic hypothermia after cardiac arrest due to acute myocardial infarction.
    Journal of thrombosis and thrombolysis, 2016, Volume: 41, Issue:4

    Topics: Adenosine; Aged; Clopidogrel; Female; Heart Arrest; Humans; Hypothermia, Induced; Male; Middle Aged;

2016
Ticagrelor overcomes high platelet reactivity in patients with acute myocardial infarction or coronary artery in-stent restenosis: a randomized controlled trial.
    Scientific reports, 2015, Sep-09, Volume: 5

    Topics: Adenosine; Aged; Clopidogrel; Coronary Angiography; Coronary Restenosis; Female; Follow-Up Studies;

2015
Study design and rationale for Optimal aNtiplatelet pharmacotherapy guided by bedSIDE genetic or functional TESTing in elective percutaneous coronary intervention patients (ONSIDE TEST): a prospective, open-label, randomised parallel-group multicentre tri
    Kardiologia polska, 2016, Volume: 74, Issue:4

    Topics: Adolescent; Adult; Aged; Clopidogrel; Cytochrome P-450 CYP2C19; Humans; Middle Aged; Myocardial Infa

2016
Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome -- randomized, double-blind, phase III PHILO study.
    Circulation journal : official journal of the Japanese Circulation Society, 2015, Volume: 79, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Asian People; Clopidogrel; Double-Blind Method; Female; He

2015
Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome -- randomized, double-blind, phase III PHILO study.
    Circulation journal : official journal of the Japanese Circulation Society, 2015, Volume: 79, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Asian People; Clopidogrel; Double-Blind Method; Female; He

2015
Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome -- randomized, double-blind, phase III PHILO study.
    Circulation journal : official journal of the Japanese Circulation Society, 2015, Volume: 79, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Asian People; Clopidogrel; Double-Blind Method; Female; He

2015
Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome -- randomized, double-blind, phase III PHILO study.
    Circulation journal : official journal of the Japanese Circulation Society, 2015, Volume: 79, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Asian People; Clopidogrel; Double-Blind Method; Female; He

2015
Long-term outcomes for women versus men with unstable angina/non-ST-segment elevation myocardial infarction managed medically without revascularization: insights from the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acu
    American heart journal, 2015, Volume: 170, Issue:4

    Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Clopidogrel; Coronary Angiography; Double-Blind Met

2015
The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX.
    European heart journal, 2016, Apr-07, Volume: 37, Issue:14

    Topics: Adenosine Monophosphate; Aged; Clopidogrel; Coronary Thrombosis; Double-Blind Method; Female; Femora

2016
Platelet function and coagulation in patients with STEMI and peri-interventional clopidogrel plus heparin vs. prasugrel plus bivalirudin therapy (BRAVE 4 substudy).
    Thrombosis research, 2016, Volume: 137

    Topics: Antithrombins; Clopidogrel; Drug Therapy, Combination; Female; Heparin; Hirudins; Humans; Male; Midd

2016
ADP receptor antagonists in patients with acute myocardial infarction complicated by cardiogenic shock: a post hoc IABP-SHOCK II trial subgroup analysis.
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2016, Dec-10, Volume: 12, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Female; Humans; Male; Middle Aged; Myo

2016
P-Glycoprotein Polymorphism C3435T Is Associated with Dose-Adjusted Clopidogrel and 2-Oxo-Clopidogrel Concentration.
    Pharmacology, 2016, Volume: 97, Issue:3-4

    Topics: Adult; Aged; Aged, 80 and over; ATP Binding Cassette Transporter, Subfamily B; Clopidogrel; Cross-Se

2016
Pre-PCI medication using clopidogrel and ticagrelor in the treatment of patients with acute myocardial infarction.
    European review for medical and pharmacological sciences, 2015, Volume: 19, Issue:23

    Topics: Adenosine; Aged; Clopidogrel; Combined Modality Therapy; Drug Administration Schedule; Female; Human

2015
Outcomes of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy: A Comparison of Clopidogrel Versus Prasugrel From the TRANSLATE-ACS Study.
    JACC. Cardiovascular interventions, 2015, Dec-21, Volume: 8, Issue:14

    Topics: Administration, Oral; Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Co

2015
Ticagrelor vs clopidogrel followed by ticagrelor re-loading in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: A randomized, pharmacodynamic comparison.
    Platelets, 2016, Volume: 27, Issue:5

    Topics: Adenosine; Biomarkers; Blood Platelets; Clopidogrel; Electrocardiography; Myocardial Infarction; Per

2016
Implications of ischaemic area at risk and mode of reperfusion in ST-elevation myocardial infarction.
    Heart (British Cardiac Society), 2016, Volume: 102, Issue:7

    Topics: Aged; Clopidogrel; Comparative Effectiveness Research; Electrocardiography; Enoxaparin; Female; Huma

2016
Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention.
    Heart (British Cardiac Society), 2016, Volume: 102, Issue:8

    Topics: Adenosine; Aged; Clopidogrel; Combined Modality Therapy; Dose-Response Relationship, Drug; Double-Bl

2016
Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention.
    Heart (British Cardiac Society), 2016, Volume: 102, Issue:8

    Topics: Adenosine; Aged; Clopidogrel; Combined Modality Therapy; Dose-Response Relationship, Drug; Double-Bl

2016
Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention.
    Heart (British Cardiac Society), 2016, Volume: 102, Issue:8

    Topics: Adenosine; Aged; Clopidogrel; Combined Modality Therapy; Dose-Response Relationship, Drug; Double-Bl

2016
Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention.
    Heart (British Cardiac Society), 2016, Volume: 102, Issue:8

    Topics: Adenosine; Aged; Clopidogrel; Combined Modality Therapy; Dose-Response Relationship, Drug; Double-Bl

2016
Comparison of the influence of ticagrelor and clopidogrel on inflammatory biomarkers and vascular endothelial function for patients with ST-segment elevation myocardial infarction receiving emergency percutaneous coronary intervention: study protocol for
    Trials, 2016, Feb-11, Volume: 17

    Topics: Adenosine; Biomarkers; C-Reactive Protein; CD40 Ligand; Clinical Protocols; Clopidogrel; Endothelium

2016
Effectiveness of platelet inhibition on major adverse cardiac events in non-cardiac surgery after percutaneous coronary intervention: a prospective cohort study.
    British journal of anaesthesia, 2016, Volume: 116, Issue:4

    Topics: Aged; Aspirin; Cardiomyopathy, Dilated; Clopidogrel; Cohort Studies; Female; Heart Diseases; Humans;

2016
Spontaneous MI After Non-ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization: The TRILOGY ACS Trial.
    Journal of the American College of Cardiology, 2016, Mar-22, Volume: 67, Issue:11

    Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Angiography; Dose-Response Relationshi

2016
Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY trial.
    American heart journal, 2016, Volume: 174

    Topics: Administration, Oral; Aged; Aspirin; Clopidogrel; Coronary Vessels; Drug Therapy, Combination; Elect

2016
Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy.
    Journal of the American College of Cardiology, 2016, Apr-12, Volume: 67, Issue:14

    Topics: Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyspepsia;

2016
Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients.
    Heart (British Cardiac Society), 2016, 08-01, Volume: 102, Issue:15

    Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Double-Blind Method; Drug Administration Schedu

2016
Salts of Clopidogrel: Investigation to Ensure Clinical Equivalence: A 12-Month Randomized Clinical Trial.
    Journal of cardiovascular pharmacology and therapeutics, 2016, Volume: 21, Issue:6

    Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Clopidogrel; Drug Compounding; Drugs, Generic; Fem

2016
Salts of Clopidogrel: Investigation to Ensure Clinical Equivalence: A 12-Month Randomized Clinical Trial.
    Journal of cardiovascular pharmacology and therapeutics, 2016, Volume: 21, Issue:6

    Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Clopidogrel; Drug Compounding; Drugs, Generic; Fem

2016
Salts of Clopidogrel: Investigation to Ensure Clinical Equivalence: A 12-Month Randomized Clinical Trial.
    Journal of cardiovascular pharmacology and therapeutics, 2016, Volume: 21, Issue:6

    Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Clopidogrel; Drug Compounding; Drugs, Generic; Fem

2016
Salts of Clopidogrel: Investigation to Ensure Clinical Equivalence: A 12-Month Randomized Clinical Trial.
    Journal of cardiovascular pharmacology and therapeutics, 2016, Volume: 21, Issue:6

    Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Clopidogrel; Drug Compounding; Drugs, Generic; Fem

2016
Adjunctive loading dose of cilostazol in preventing periprocedural myocardial infarction.
    Cardiovascular therapeutics, 2016, Volume: 34, Issue:4

    Topics: Aged; Aspirin; Biomarkers; Chi-Square Distribution; China; Cilostazol; Clopidogrel; Drug Administrat

2016
Association Between Very Low Levels of High-Density Lipoprotein Cholesterol and Long-term Outcomes of Patients With Acute Coronary Syndrome Treated Without Revascularization: Insights From the TRILOGY ACS Trial.
    Clinical cardiology, 2016, Volume: 39, Issue:6

    Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Biomarkers; Cholesterol, HDL; Clopidogrel;

2016
Design and rationale for the Effects of Ticagrelor and Clopidogrel in Patients with Peripheral Artery Disease (EUCLID) trial.
    American heart journal, 2016, Volume: 175

    Topics: Adenosine; Aged; Ankle Brachial Index; Clopidogrel; Disease Progression; Female; Humans; Male; Middl

2016
6-Month Versus 12-Month Dual-Antiplatelet Therapy Following Long Everolimus-Eluting Stent Implantation: The IVUS-XPL Randomized Clinical Trial.
    JACC. Cardiovascular interventions, 2016, 07-25, Volume: 9, Issue:14

    Topics: Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Thrombosis; Drug Administration Schedule; Drug

2016
Risks and Benefits of Dual Antiplatelet Therapy Beyond 12 Months After Coronary Stenting: A Prospective Randomized Cohort Study.
    Medicine, 2016, Volume: 95, Issue:22

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography;

2016
Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
    American heart journal, 2016, Volume: 177

    Topics: Abciximab; Acute Coronary Syndrome; Adenosine; Aged; Antibodies, Monoclonal; Aspirin; Cardiovascular

2016
Rationale and design of the Affordability and Real-world Antiplatelet Treatment Effectiveness after Myocardial Infarction Study (ARTEMIS): A multicenter, cluster-randomized trial of P2Y12 receptor inhibitor copayment reduction after myocardial infarction.
    American heart journal, 2016, Volume: 177

    Topics: Adenosine; Clopidogrel; Cost Sharing; Drug Costs; Financial Support; Health Care Costs; Health Expen

2016
[The use of prasugrel in STEMI and NSTEMI: TRITON TIMI 38 study and subgroup analyses].
    Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2015, Volume: 43 Suppl 2

    Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors

2015
[TRILOGY-ACS and ACCOAST trial from an expert's perspective].
    Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2015, Volume: 43 Suppl 2

    Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Prasugrel Hydrochlo

2015
Safety and efficacy of policosanol in patients with high on-treatment platelet reactivity after drug-eluting stent implantation: two-year follow-up results.
    Cardiovascular therapeutics, 2016, Volume: 34, Issue:5

    Topics: Acute Coronary Syndrome; Aged; Aspirin; China; Clopidogrel; Drug Therapy, Combination; Drug-Eluting

2016
Rationale and design of the SAFE-A study: SAFety and Effectiveness trial of Apixaban use in association with dual antiplatelet therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention.
    Journal of cardiology, 2017, Volume: 69, Issue:4

    Topics: Aspirin; Atrial Fibrillation; Blood Transfusion; Clopidogrel; Drug Therapy, Combination; Drug-Elutin

2017
Dual Antiplatelet Therapy and Outcomes in Patients With Atrial Fibrillation and Acute Coronary Syndromes Managed Medically Without Revascularization: Insights From the TRILOGY ACS Trial.
    Clinical cardiology, 2016, Volume: 39, Issue:9

    Topics: Acute Coronary Syndrome; Aged; Aspirin; Atrial Fibrillation; Chi-Square Distribution; Clopidogrel; D

2016
Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition).
    Circulation, 2016, Sep-06, Volume: 134, Issue:10

    Topics: Adenosine Monophosphate; Aged; Clopidogrel; Disease Management; Double-Blind Method; Female; Humans;

2016
Implications of different criteria for percutaneous coronary intervention-related myocardial infarction on study results of three large phase III clinical trials: The CHAMPION experience.
    European heart journal. Acute cardiovascular care, 2018, Volume: 7, Issue:2

    Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Aged; Dose-Response Relationship, Drug; Double-Bli

2018
Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial.
    American heart journal, 2016, Volume: 178

    Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Cause of Death; Clopidogrel; Coronary Artery Disease; D

2016
Impact of Sex on 2-Year Clinical Outcomes in Patients Treated With 6-Month or 24-Month Dual-Antiplatelet Therapy Duration: A Pre-Specified Analysis From the PRODIGY Trial.
    JACC. Cardiovascular interventions, 2016, 09-12, Volume: 9, Issue:17

    Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; C

2016
Clinical outcomes of dual antiplatelet therapy after implantation of drug-eluting stents in patients with different cardiovascular risk factors.
    Clinical research in cardiology : official journal of the German Cardiac Society, 2017, Volume: 106, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Death, Sudden, Cardiac; Dose-Response Relations

2017
Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial.
    JACC. Cardiovascular interventions, 2016, 09-26, Volume: 9, Issue:18

    Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Aged; Angina, Stable; Chi-Square Distribution; Clo

2016
A comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization: Design and rationale of the randomized Elderly-ACS 2 study.
    American heart journal, 2016, Volume: 181

    Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Drug Therapy

2016
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
    American heart journal, 2017, Volume: 184

    Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy,

2017
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
    American heart journal, 2017, Volume: 184

    Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy,

2017
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
    American heart journal, 2017, Volume: 184

    Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy,

2017
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
    American heart journal, 2017, Volume: 184

    Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy,

2017
Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy).
    Circulation, 2017, May-02, Volume: 135, Issue:18

    Topics: Acute Coronary Syndrome; Aged; Angina, Stable; Aspirin; Clopidogrel; Coronary Thrombosis; Double-Bli

2017
Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel (3T/2R). Rationale for the study and protocol design.
    Cardiovascular drugs and therapy, 2008, Volume: 22, Issue:4

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Clopidogrel; Double-Blind Method; Drug Resistan

2008
Long-term cost-effectiveness of clopidogrel in STEMI patients.
    International journal of cardiology, 2009, Jul-10, Volume: 135, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Cost-Benefit Analysis; Decision Trees; Double-Blind Method; Female; Huma

2009
Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial.
    European heart journal, 2008, Volume: 29, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Female; Hemorrhage; Huma

2008
Bivalirudin versus unfractionated heparin during percutaneous coronary intervention.
    The New England journal of medicine, 2008, Aug-14, Volume: 359, Issue:7

    Topics: Aged; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Clopidogrel

2008
Bivalirudin versus unfractionated heparin during percutaneous coronary intervention.
    The New England journal of medicine, 2008, Aug-14, Volume: 359, Issue:7

    Topics: Aged; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Clopidogrel

2008
Bivalirudin versus unfractionated heparin during percutaneous coronary intervention.
    The New England journal of medicine, 2008, Aug-14, Volume: 359, Issue:7

    Topics: Aged; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Clopidogrel

2008
Bivalirudin versus unfractionated heparin during percutaneous coronary intervention.
    The New England journal of medicine, 2008, Aug-14, Volume: 359, Issue:7

    Topics: Aged; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Clopidogrel

2008
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
    The New England journal of medicine, 2008, Sep-18, Volume: 359, Issue:12

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia;

2008
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
    The New England journal of medicine, 2008, Sep-18, Volume: 359, Issue:12

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia;

2008
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
    The New England journal of medicine, 2008, Sep-18, Volume: 359, Issue:12

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia;

2008
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
    The New England journal of medicine, 2008, Sep-18, Volume: 359, Issue:12

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia;

2008
Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial I
    Circulation, 2008, Oct-14, Volume: 118, Issue:16

    Topics: Administration, Oral; Aged; Clopidogrel; Coronary Thrombosis; Diabetes Mellitus, Type 1; Diabetes Me

2008
Use of and inhospital outcomes after early clopidogrel therapy in patients not undergoing an early invasive strategy for treatment of non-ST-segment elevation myocardial infarction: results from Can Rapid risk stratification of Unstable angina patients Su
    American heart journal, 2008, Volume: 156, Issue:3

    Topics: Aged; Aged, 80 and over; Angina, Unstable; Clopidogrel; Electrocardiography; Female; Hemorrhage; Hos

2008
Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study.
    European heart journal, 2009, Volume: 30, Issue:8

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Death, Sudden, Cardiac; Double-Blind Method; F

2009
Tirofiban optimizes platelet inhibition for immediate percutaneous coronary intervention in high-risk acute coronary syndromes.
    Thrombosis and haemostasis, 2008, Volume: 100, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease

2008
Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy.
    American heart journal, 2008, Volume: 156, Issue:6

    Topics: Acute Coronary Syndrome; Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopi

2008
Immediate versus deferred coronary angioplasty in non-ST-segment elevation acute coronary syndromes.
    Heart (British Cardiac Society), 2009, Volume: 95, Issue:10

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Female; Humans; Incid

2009
Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.
    Lancet (London, England), 2009, Jan-24, Volume: 373, Issue:9660

    Topics: Adult; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450

2009
Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.
    Lancet (London, England), 2009, Jan-24, Volume: 373, Issue:9660

    Topics: Adult; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450

2009
Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.
    Lancet (London, England), 2009, Jan-24, Volume: 373, Issue:9660

    Topics: Adult; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450

2009
Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.
    Lancet (London, England), 2009, Jan-24, Volume: 373, Issue:9660

    Topics: Adult; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450

2009
Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.
    Lancet (London, England), 2009, Jan-24, Volume: 373, Issue:9660

    Topics: Adult; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450

2009
Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.
    Lancet (London, England), 2009, Jan-24, Volume: 373, Issue:9660

    Topics: Adult; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450

2009
Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.
    Lancet (London, England), 2009, Jan-24, Volume: 373, Issue:9660

    Topics: Adult; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450

2009
Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.
    Lancet (London, England), 2009, Jan-24, Volume: 373, Issue:9660

    Topics: Adult; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450

2009
Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.
    Lancet (London, England), 2009, Jan-24, Volume: 373, Issue:9660

    Topics: Adult; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450

2009
Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.
    Lancet (London, England), 2009, Jan-24, Volume: 373, Issue:9660

    Topics: Adult; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450

2009
Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.
    Lancet (London, England), 2009, Jan-24, Volume: 373, Issue:9660

    Topics: Adult; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450

2009
Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.
    Lancet (London, England), 2009, Jan-24, Volume: 373, Issue:9660

    Topics: Adult; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450

2009
Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.
    Lancet (London, England), 2009, Jan-24, Volume: 373, Issue:9660

    Topics: Adult; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450

2009
Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.
    Lancet (London, England), 2009, Jan-24, Volume: 373, Issue:9660

    Topics: Adult; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450

2009
Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.
    Lancet (London, England), 2009, Jan-24, Volume: 373, Issue:9660

    Topics: Adult; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450

2009
Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.
    Lancet (London, England), 2009, Jan-24, Volume: 373, Issue:9660

    Topics: Adult; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450

2009
Iron-induced platelet aggregation measurement: a novel method to measure platelet function in stenting for ST segment elevation myocardial infarction.
    European journal of clinical investigation, 2009, Volume: 39, Issue:2

    Topics: Aged; Aspirin; Clopidogrel; Feasibility Studies; Female; Humans; Iron; Male; Middle Aged; Myocardial

2009
Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: effects on platelet function, thrombelastographic indexes, and their relation to periprocedural infarction results of the CLEAR PLATELETS-2 (Clopidogrel with Eptifibatide to
    Journal of the American College of Cardiology, 2009, Feb-24, Volume: 53, Issue:8

    Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Blood Coagulation; Bloo

2009
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
    Lancet (London, England), 2009, Feb-28, Volume: 373, Issue:9665

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met

2009
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
    Lancet (London, England), 2009, Feb-28, Volume: 373, Issue:9665

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met

2009
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
    Lancet (London, England), 2009, Feb-28, Volume: 373, Issue:9665

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met

2009
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
    Lancet (London, England), 2009, Feb-28, Volume: 373, Issue:9665

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met

2009
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
    Lancet (London, England), 2009, Feb-28, Volume: 373, Issue:9665

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met

2009
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
    Lancet (London, England), 2009, Feb-28, Volume: 373, Issue:9665

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met

2009
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
    Lancet (London, England), 2009, Feb-28, Volume: 373, Issue:9665

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met

2009
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
    Lancet (London, England), 2009, Feb-28, Volume: 373, Issue:9665

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met

2009
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
    Lancet (London, England), 2009, Feb-28, Volume: 373, Issue:9665

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met

2009
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
    Lancet (London, England), 2009, Feb-28, Volume: 373, Issue:9665

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met

2009
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
    Lancet (London, England), 2009, Feb-28, Volume: 373, Issue:9665

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met

2009
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
    Lancet (London, England), 2009, Feb-28, Volume: 373, Issue:9665

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met

2009
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
    Lancet (London, England), 2009, Feb-28, Volume: 373, Issue:9665

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met

2009
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
    Lancet (London, England), 2009, Feb-28, Volume: 373, Issue:9665

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met

2009
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
    Lancet (London, England), 2009, Feb-28, Volume: 373, Issue:9665

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met

2009
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
    Lancet (London, England), 2009, Feb-28, Volume: 373, Issue:9665

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met

2009
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
    Lancet (London, England), 2009, Feb-28, Volume: 373, Issue:9665

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met

2009
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
    Lancet (London, England), 2009, Feb-28, Volume: 373, Issue:9665

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met

2009
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
    Lancet (London, England), 2009, Feb-28, Volume: 373, Issue:9665

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met

2009
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
    Lancet (London, England), 2009, Feb-28, Volume: 373, Issue:9665

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met

2009
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
    Lancet (London, England), 2009, Feb-28, Volume: 373, Issue:9665

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met

2009
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
    Lancet (London, England), 2009, Feb-28, Volume: 373, Issue:9665

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met

2009
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
    Lancet (London, England), 2009, Feb-28, Volume: 373, Issue:9665

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met

2009
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
    Lancet (London, England), 2009, Feb-28, Volume: 373, Issue:9665

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met

2009
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
    Lancet (London, England), 2009, Feb-28, Volume: 373, Issue:9665

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met

2009
Antiplatelet therapy in percutaneous coronary intervention: integration of prasugrel into clinical practice.
    Critical pathways in cardiology, 2009, Volume: 8, Issue:1

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therap

2009
Temporal relation between Clopidogrel cessation and stent thrombosis after drug-eluting stent implantation.
    The American journal of cardiology, 2009, Mar-15, Volume: 103, Issue:6

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Female;

2009
The safety and efficacy of clopidogrel versus ticlopidine in Japanese stroke patients: combined results of two Phase III, multicenter, randomized clinical trials.
    Journal of neurology, 2009, Volume: 256, Issue:6

    Topics: Aged; Brain Infarction; Clopidogrel; Double-Blind Method; Female; Follow-Up Studies; Humans; Inciden

2009
Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial.
    Circulation, 2009, Mar-31, Volume: 119, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Chronic Disease; Clopidogrel; Death; Double-Blind Method; F

2009
Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial.
    Circulation, 2009, Apr-14, Volume: 119, Issue:14

    Topics: Abciximab; Aged; Angioplasty, Balloon; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Antic

2009
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
    The New England journal of medicine, 2009, May-14, Volume: 360, Issue:20

    Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb

2009
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
    The New England journal of medicine, 2009, May-14, Volume: 360, Issue:20

    Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb

2009
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
    The New England journal of medicine, 2009, May-14, Volume: 360, Issue:20

    Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb

2009
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
    The New England journal of medicine, 2009, May-14, Volume: 360, Issue:20

    Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb

2009
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
    The New England journal of medicine, 2009, May-14, Volume: 360, Issue:20

    Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb

2009
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
    The New England journal of medicine, 2009, May-14, Volume: 360, Issue:20

    Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb

2009
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
    The New England journal of medicine, 2009, May-14, Volume: 360, Issue:20

    Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb

2009
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
    The New England journal of medicine, 2009, May-14, Volume: 360, Issue:20

    Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb

2009
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
    The New England journal of medicine, 2009, May-14, Volume: 360, Issue:20

    Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb

2009
Interaction between cigarette smoking and clinical benefit of clopidogrel.
    Journal of the American College of Cardiology, 2009, Apr-14, Volume: 53, Issue:15

    Topics: Aged; Clopidogrel; Electrocardiography; Female; Humans; Logistic Models; Male; Middle Aged; Myocardi

2009
Efficacy of clopidrogel on reperfusion and high-sensitivity C-reactive protein in patients with acute myocardial infarction.
    Mediators of inflammation, 2009, Volume: 2009

    Topics: Aspirin; C-Reactive Protein; Clopidogrel; Coronary Circulation; Creatine Kinase, MB Form; Drug Thera

2009
Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease.
    Journal of the American College of Cardiology, 2009, May-12, Volume: 53, Issue:19

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Confidence Intervals; Coronary Angiography; Coron

2009
Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial.
    European heart journal, 2009, Volume: 30, Issue:14

    Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Cell Adhesion Molecu

2009
Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardi
    Circulation, 2009, Jun-02, Volume: 119, Issue:21

    Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Biomarkers; Clopidogrel;

2009
Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and U
    JACC. Cardiovascular interventions, 2008, Volume: 1, Issue:6

    Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagula

2008
The effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention: a BRIEF-PCI (Brief Infusion of Intravenous Eptifibatide Following Successful Percutaneous Coronary Intervention) trial substudy.
    JACC. Cardiovascular interventions, 2008, Volume: 1, Issue:6

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease

2008
The FDA prasugrel review: adjudication of myocardial infarction controversy.
    Cardiology, 2009, Volume: 114, Issue:2

    Topics: Acute Coronary Syndrome; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Ad

2009
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
    Circulation, 2009, Jun-30, Volume: 119, Issue:25

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Thera

2009
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
    Circulation, 2009, Jun-30, Volume: 119, Issue:25

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Thera

2009
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
    Circulation, 2009, Jun-30, Volume: 119, Issue:25

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Thera

2009
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
    Circulation, 2009, Jun-30, Volume: 119, Issue:25

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Thera

2009
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
    Circulation, 2009, Jun-30, Volume: 119, Issue:25

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Thera

2009
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
    Circulation, 2009, Jun-30, Volume: 119, Issue:25

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Thera

2009
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
    Circulation, 2009, Jun-30, Volume: 119, Issue:25

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Thera

2009
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
    Circulation, 2009, Jun-30, Volume: 119, Issue:25

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Thera

2009
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
    Circulation, 2009, Jun-30, Volume: 119, Issue:25

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Thera

2009
A randomised study comparing the antiplatelet and antiinflammatory effect of clopidogrel 150 mg/day versus 75 mg/day in patients with ST-segment elevation acute myocardial infarction and poor responsiveness to clopidogrel: results from the DOUBLE study.
    Thrombosis research, 2010, Volume: 125, Issue:4

    Topics: Anterior Wall Myocardial Infarction; Anti-Inflammatory Agents; C-Reactive Protein; Cell Adhesion Mol

2010
Stent thrombosis up to 3 years after stenting for ST-segment elevation myocardial infarction versus for stable angina--comparison of the effects of drug-eluting versus bare-metal stents.
    American heart journal, 2009, Volume: 158, Issue:2

    Topics: Angina Pectoris; Clopidogrel; Drug-Eluting Stents; Endpoint Determination; Humans; Myocardial Infarc

2009
Relation between myocardial infarct size and ventricular tachyarrhythmia among patients with preserved left ventricular ejection fraction following fibrinolytic therapy for ST-segment elevation myocardial infarction.
    The American journal of cardiology, 2009, Aug-15, Volume: 104, Issue:4

    Topics: Aged; Clopidogrel; Creatine Kinase, MB Form; Female; Humans; Incidence; Male; Middle Aged; Myocardia

2009
The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Pla
    Journal of the American College of Cardiology, 2009, Aug-18, Volume: 54, Issue:8

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Therapy, Combinatio

2009
Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction.
    Journal of thrombosis and haemostasis : JTH, 2009, Volume: 7, Issue:10

    Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Thrombosis; Dis

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Long term efficacy of abciximab bolus-only compared to abciximab bolus and infusion after transradial coronary stenting.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2009, Dec-01, Volume: 74, Issue:7

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coron

2009
Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.
    Journal of the American College of Cardiology, 2009, Sep-29, Volume: 54, Issue:14

    Topics: Acute Coronary Syndrome; Age Factors; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Clopidog

2009
Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: results from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial.
    Journal of the American College of Cardiology, 2009, Oct-06, Volume: 54, Issue:15

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon; Anticoagulants; Clopidogrel; Confidence Interva

2009
Impact of final activated clotting time after transradial coronary stenting with maximal antiplatelet therapy.
    The American journal of cardiology, 2009, Nov-01, Volume: 104, Issue:9

    Topics: Abciximab; Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoag

2009
Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction.
    The American journal of cardiology, 2009, Nov-15, Volume: 104, Issue:10

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Angiography; C

2009
Platelet inhibition with cangrelor in patients undergoing PCI.
    The New England journal of medicine, 2009, Dec-10, Volume: 361, Issue:24

    Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Administration, Oral; Aged; Angioplasty, Balloon,

2009
Platelet inhibition with cangrelor in patients undergoing PCI.
    The New England journal of medicine, 2009, Dec-10, Volume: 361, Issue:24

    Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Administration, Oral; Aged; Angioplasty, Balloon,

2009
Platelet inhibition with cangrelor in patients undergoing PCI.
    The New England journal of medicine, 2009, Dec-10, Volume: 361, Issue:24

    Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Administration, Oral; Aged; Angioplasty, Balloon,

2009
Platelet inhibition with cangrelor in patients undergoing PCI.
    The New England journal of medicine, 2009, Dec-10, Volume: 361, Issue:24

    Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Administration, Oral; Aged; Angioplasty, Balloon,

2009
Primary percutaneous coronary angioplasty with and without eptifibatide in ST-segment elevation myocardial infarction: a safety and efficacy study of integrilin-facilitated versus primary percutaneous coronary intervention in ST-segment elevation myocardi
    Circulation. Cardiovascular interventions, 2009, Volume: 2, Issue:4

    Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiograp

2009
Low postoperative dose of aprotinin reduces bleeding and is safe in patients receiving clopidogrel before coronary artery bypass surgery. A prospective randomized study.
    Interactive cardiovascular and thoracic surgery, 2010, Volume: 10, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Aprotinin; Blood Transfusion; Cerebrovascular Disorders; Clopidogrel

2010
Extent of ST-segment resolution after fibrinolysis adds improved risk stratification to clinical risk score for ST-segment elevation myocardial infarction.
    American heart journal, 2010, Volume: 159, Issue:1

    Topics: Adult; Aged; Clopidogrel; Confidence Intervals; Coronary Angiography; Coronary Circulation; Dose-Res

2010
Evaluation of platelet inhibition by tirofiban in patients stratified according to aspirin and clopidogrel responsiveness: the 3T/2R (Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel).
    Journal of the American College of Cardiology, 2010, Jan-19, Volume: 55, Issue:3

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cohort Studies; Drug Resistance; Humans; Myoca

2010
Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: Results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patie
    Circulation. Cardiovascular interventions, 2010, Feb-01, Volume: 3, Issue:1

    Topics: Adenosine Diphosphate; Aged; Aspirin; Blood Platelets; Blood Vessel Prosthesis Implantation; Cells,

2010
Cardioprotective effects of ischemic postconditioning in patients treated with primary percutaneous coronary intervention, evaluated by magnetic resonance.
    Circulation. Cardiovascular interventions, 2010, Feb-01, Volume: 3, Issue:1

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiotonic Agents; Chemotherapy, Adjuvant; Clopidogrel; Di

2010
Cardioprotective effects of ischemic postconditioning in patients treated with primary percutaneous coronary intervention, evaluated by magnetic resonance.
    Circulation. Cardiovascular interventions, 2010, Feb-01, Volume: 3, Issue:1

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiotonic Agents; Chemotherapy, Adjuvant; Clopidogrel; Di

2010
Cardioprotective effects of ischemic postconditioning in patients treated with primary percutaneous coronary intervention, evaluated by magnetic resonance.
    Circulation. Cardiovascular interventions, 2010, Feb-01, Volume: 3, Issue:1

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiotonic Agents; Chemotherapy, Adjuvant; Clopidogrel; Di

2010
Cardioprotective effects of ischemic postconditioning in patients treated with primary percutaneous coronary intervention, evaluated by magnetic resonance.
    Circulation. Cardiovascular interventions, 2010, Feb-01, Volume: 3, Issue:1

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiotonic Agents; Chemotherapy, Adjuvant; Clopidogrel; Di

2010
Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial.
    Journal of thrombosis and thrombolysis, 2010, Volume: 30, Issue:2

    Topics: Aged; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Embolism; Feasibility Studies

2010
Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation.
    JAMA, 2010, Feb-24, Volume: 303, Issue:8

    Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Myocardial Infarction

2010
Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation.
    JAMA, 2010, Feb-24, Volume: 303, Issue:8

    Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Myocardial Infarction

2010
Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation.
    JAMA, 2010, Feb-24, Volume: 303, Issue:8

    Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Myocardial Infarction

2010
Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation.
    JAMA, 2010, Feb-24, Volume: 303, Issue:8

    Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Myocardial Infarction

2010
Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation.
    JAMA, 2010, Feb-24, Volume: 303, Issue:8

    Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Myocardial Infarction

2010
Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation.
    JAMA, 2010, Feb-24, Volume: 303, Issue:8

    Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Myocardial Infarction

2010
Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation.
    JAMA, 2010, Feb-24, Volume: 303, Issue:8

    Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Myocardial Infarction

2010
Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation.
    JAMA, 2010, Feb-24, Volume: 303, Issue:8

    Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Myocardial Infarction

2010
Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation.
    JAMA, 2010, Feb-24, Volume: 303, Issue:8

    Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Myocardial Infarction

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
    Lancet (London, England), 2010, Feb-27, Volume: 375, Issue:9716

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo

2010
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
    The New England journal of medicine, 2010, Apr-15, Volume: 362, Issue:15

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc

2010
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
    The New England journal of medicine, 2010, Apr-15, Volume: 362, Issue:15

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc

2010
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
    The New England journal of medicine, 2010, Apr-15, Volume: 362, Issue:15

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc

2010
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
    The New England journal of medicine, 2010, Apr-15, Volume: 362, Issue:15

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc

2010
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
    The New England journal of medicine, 2010, Apr-15, Volume: 362, Issue:15

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc

2010
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
    The New England journal of medicine, 2010, Apr-15, Volume: 362, Issue:15

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc

2010
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
    The New England journal of medicine, 2010, Apr-15, Volume: 362, Issue:15

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc

2010
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
    The New England journal of medicine, 2010, Apr-15, Volume: 362, Issue:15

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc

2010
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
    The New England journal of medicine, 2010, Apr-15, Volume: 362, Issue:15

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc

2010
Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial.
    JACC. Cardiovascular interventions, 2010, Volume: 3, Issue:3

    Topics: Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Chi-Square Distribution; Clopidogrel; Coronary A

2010
Clopidogrel reloading in patients undergoing percutaneous coronary intervention on chronic clopidogrel therapy: results of the ARMYDA-4 RELOAD (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) randomized trial.
    European heart journal, 2010, Volume: 31, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Biomarkers; Clopidogrel; Coronary Aneurysm; Double-Blind Metho

2010
Impact of early abciximab administration on myocardial reperfusion in patients with ST-segment elevation myocardial infarction pretreated with 600 mg of clopidogrel before percutaneous coronary intervention.
    Journal of thrombosis and thrombolysis, 2010, Volume: 30, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Clopidogrel

2010
Contemporary incidence and predictors of major adverse cardiac events after saphenous vein graft intervention with embolic protection (an AMEthyst trial substudy).
    The American journal of cardiology, 2010, Apr-15, Volume: 105, Issue:8

    Topics: Aged; Clopidogrel; Coronary Angiography; Coronary Stenosis; Drug-Eluting Stents; Embolism; Female; H

2010
Smoking at least 10 cigarettes per day increases platelet inhibition by clopidogrel in patients with ST-segment-elevation myocardial infarction.
    Thrombosis research, 2010, Volume: 126, Issue:4

    Topics: Adult; Aged; Blood Platelets; Clopidogrel; Female; Humans; Male; Myocardial Infarction; Platelet Agg

2010
Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data.
    Journal of thrombosis and haemostasis : JTH, 2010, Volume: 8, Issue:8

    Topics: Aged; Angina, Unstable; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cohort Studies; Cytochrome P-450

2010
Impact of chronic antiplatelet therapy before hospitalization on ischemic and bleeding events in invasively managed patients with acute coronary syndromes: the ACUITY trial.
    European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology, 2011, Volume: 18, Issue:1

    Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Chi-Square Distribution; Clopidogrel; Drug A

2011
Randomized controlled trial of dual antiplatelet therapy in patients undergoing surgery for critical limb ischemia.
    Annals of surgery, 2010, Volume: 252, Issue:1

    Topics: Aged; Amputation, Surgical; Aspirin; Clopidogrel; Double-Blind Method; Female; Flow Cytometry; Hemor

2010
Early dynamic risk stratification with baseline troponin levels and 90-minute ST-segment resolution to predict 30-day cardiovascular mortality in ST-segment elevation myocardial infarction: analysis from CLopidogrel as Adjunctive ReperfusIon TherapY (CLAR
    American heart journal, 2010, Volume: 159, Issue:6

    Topics: Clopidogrel; Dose-Response Relationship, Drug; Electrocardiography; Female; Follow-Up Studies; Human

2010
One-year clinical outcomes with abciximab in acute myocardial infarction: results of the BRAVE-3 randomized trial.
    Clinical research in cardiology : official journal of the German Cardiac Society, 2010, Volume: 99, Issue:12

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Double-Blind M

2010
The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study.
    American heart journal, 2010, Volume: 160, Issue:1

    Topics: Aged; Aspirin; Cardiac Catheterization; Cause of Death; Clopidogrel; Drug Therapy, Combination; Elec

2010
The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study.
    American heart journal, 2010, Volume: 160, Issue:1

    Topics: Aged; Aspirin; Cardiac Catheterization; Cause of Death; Clopidogrel; Drug Therapy, Combination; Elec

2010
The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study.
    American heart journal, 2010, Volume: 160, Issue:1

    Topics: Aged; Aspirin; Cardiac Catheterization; Cause of Death; Clopidogrel; Drug Therapy, Combination; Elec

2010
The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study.
    American heart journal, 2010, Volume: 160, Issue:1

    Topics: Aged; Aspirin; Cardiac Catheterization; Cause of Death; Clopidogrel; Drug Therapy, Combination; Elec

2010
The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study.
    American heart journal, 2010, Volume: 160, Issue:1

    Topics: Aged; Aspirin; Cardiac Catheterization; Cause of Death; Clopidogrel; Drug Therapy, Combination; Elec

2010
The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study.
    American heart journal, 2010, Volume: 160, Issue:1

    Topics: Aged; Aspirin; Cardiac Catheterization; Cause of Death; Clopidogrel; Drug Therapy, Combination; Elec

2010
The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study.
    American heart journal, 2010, Volume: 160, Issue:1

    Topics: Aged; Aspirin; Cardiac Catheterization; Cause of Death; Clopidogrel; Drug Therapy, Combination; Elec

2010
The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study.
    American heart journal, 2010, Volume: 160, Issue:1

    Topics: Aged; Aspirin; Cardiac Catheterization; Cause of Death; Clopidogrel; Drug Therapy, Combination; Elec

2010
The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study.
    American heart journal, 2010, Volume: 160, Issue:1

    Topics: Aged; Aspirin; Cardiac Catheterization; Cause of Death; Clopidogrel; Drug Therapy, Combination; Elec

2010
Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage
    American heart journal, 2010, Volume: 160, Issue:1

    Topics: Administration, Oral; Aged; Angina, Unstable; Clopidogrel; Dose-Response Relationship, Drug; Double-

2010
Clopidogrel pretreatment in ST-elevation myocardial infarction patients transferred for percutaneous coronary intervention.
    American heart journal, 2010, Volume: 160, Issue:1

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Coronary Restenosis; Dose-Respons

2010
Prehospital high-dose tirofiban in patients undergoing primary percutaneous intervention. The AGIR-2 study.
    Archives of cardiovascular diseases, 2010, Volume: 103, Issue:5

    Topics: Ambulances; Angioplasty, Balloon, Coronary; Biomarkers; Clopidogrel; Coronary Angiography; Coronary

2010
[Glycoprotein IIb-IIIa antagonist Monafram in primary angioplasty of patients with acute coronary syndrome without st segment elevation].
    Kardiologiia, 2010, Volume: 50, Issue:6

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clop

2010
Effectiveness of in-laboratory high-dose clopidogrel loading versus routine pre-load in patients undergoing percutaneous coronary intervention: results of the ARMYDA-5 PRELOAD (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) ra
    Journal of the American College of Cardiology, 2010, Aug-10, Volume: 56, Issue:7

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Female; Humans; Male; Myocardial

2010
Study design and rationale of 'Influence of Cilostazol-based triple anti-platelet therapy on ischemic complication after drug-eluting stent implantation (CILON-T)' study: A multicenter randomized trial evaluating the efficacy of Cilostazol on ischemic vas
    Trials, 2010, Aug-24, Volume: 11

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Brain Ischemia; Cilostazol; Clinical Protocols; Clopidogrel

2010
ISAR-REACT 3A: a study of reduced dose of unfractionated heparin in biomarker negative patients undergoing percutaneous coronary intervention.
    European heart journal, 2010, Volume: 31, Issue:20

    Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Clopidogrel; Deat

2010
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
    The New England journal of medicine, 2010, Sep-02, Volume: 363, Issue:10

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo

2010
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
    The New England journal of medicine, 2010, Sep-02, Volume: 363, Issue:10

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo

2010
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
    The New England journal of medicine, 2010, Sep-02, Volume: 363, Issue:10

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo

2010
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
    The New England journal of medicine, 2010, Sep-02, Volume: 363, Issue:10

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo

2010
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
    The New England journal of medicine, 2010, Sep-02, Volume: 363, Issue:10

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo

2010
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
    The New England journal of medicine, 2010, Sep-02, Volume: 363, Issue:10

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo

2010
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
    The New England journal of medicine, 2010, Sep-02, Volume: 363, Issue:10

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo

2010
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
    The New England journal of medicine, 2010, Sep-02, Volume: 363, Issue:10

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo

2010
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
    The New England journal of medicine, 2010, Sep-02, Volume: 363, Issue:10

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo

2010
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
    The New England journal of medicine, 2010, Sep-02, Volume: 363, Issue:10

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo

2010
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
    The New England journal of medicine, 2010, Sep-02, Volume: 363, Issue:10

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo

2010
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
    The New England journal of medicine, 2010, Sep-02, Volume: 363, Issue:10

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo

2010
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
    The New England journal of medicine, 2010, Sep-02, Volume: 363, Issue:10

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo

2010
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
    The New England journal of medicine, 2010, Sep-02, Volume: 363, Issue:10

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo

2010
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
    The New England journal of medicine, 2010, Sep-02, Volume: 363, Issue:10

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo

2010
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
    The New England journal of medicine, 2010, Sep-02, Volume: 363, Issue:10

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo

2010
The efficacy and safety of clopidogrel in vascular surgery patients with immediate postoperative asymptomatic troponin T release for the prevention of late cardiac events: Rationale and design of the Dutch Echocardiographic Cardiac Risk Evaluation Applyin
    American heart journal, 2010, Volume: 160, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Echocardiography, Stress; Humans; Myo

2010
Prehospital triple antiplatelet therapy in patients with acute ST elevation myocardial infarction leads to better platelet aggregation inhibition and clinical outcome than dual antiplatelet therapy.
    Heart (British Cardiac Society), 2010, Volume: 96, Issue:22

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Drug Therapy,

2010
Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) tr
    Journal of the American College of Cardiology, 2010, Oct-26, Volume: 56, Issue:18

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Resistance; Elec

2010
Troponin-positive, MB-negative patients with non-ST-elevation myocardial infarction: An undertreated but high-risk patient group: Results from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network-Get With Th
    American heart journal, 2010, Volume: 160, Issue:5

    Topics: Aged; Aged, 80 and over; Antithrombins; Biomarkers; Clopidogrel; Coronary Angiography; Creatine Kina

2010
Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON is
    Journal of the American College of Cardiology, 2011, Jan-18, Volume: 57, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Coronary Disease; Drug Therapy, Combination;

2011
Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON is
    Journal of the American College of Cardiology, 2011, Jan-18, Volume: 57, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Coronary Disease; Drug Therapy, Combination;

2011
Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON is
    Journal of the American College of Cardiology, 2011, Jan-18, Volume: 57, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Coronary Disease; Drug Therapy, Combination;

2011
Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON is
    Journal of the American College of Cardiology, 2011, Jan-18, Volume: 57, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Coronary Disease; Drug Therapy, Combination;

2011
Safety of clopidogrel in older patients: a nonrandomized, parallel-group, controlled, two-centre study.
    Drugs & aging, 2011, Feb-01, Volume: 28, Issue:2

    Topics: Acute Coronary Syndrome; Administration, Cutaneous; Age Factors; Aged; Angioplasty, Balloon, Coronar

2011
Impact of reduced glomerular filtration rate on outcomes in patients with ST-segment elevation myocardial infarction undergoing fibrinolysis: a CLARITY-TIMI 28 analysis.
    Journal of thrombosis and thrombolysis, 2011, Volume: 31, Issue:4

    Topics: Adolescent; Adult; Aged; Clopidogrel; Coronary Angiography; Female; Fibrinolysis; Glomerular Filtrat

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Omeprazole, but not pantoprazole, reduces the antiplatelet effect of clopidogrel: a randomized clinical crossover trial in patients after myocardial infarction evaluating the clopidogrel-PPIs drug interaction.
    European journal of gastroenterology & hepatology, 2011, Volume: 23, Issue:5

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Blood Platelets; Clopidogrel; Cross-Over Studies; Dru

2011
Long-term reduction of mortality in the 4-year follow up of tirofiban therapy in elective percutaneous coronary interventions (TOPSTAR) trial.
    The Journal of invasive cardiology, 2011, Volume: 23, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; Drug Therapy, Combi

2011
High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention.
    Heart (British Cardiac Society), 2011, Volume: 97, Issue:12

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Atherosclerosis; Clopidogrel; Drug Therapy, Combinati

2011
Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction.
    Circulation, 2011, Apr-26, Volume: 123, Issue:16

    Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Antithrombins; Clopidogrel; Coronary Restenosi

2011
Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype.
    JACC. Cardiovascular interventions, 2011, Volume: 4, Issue:4

    Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin;

2011
High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2).
    JACC. Cardiovascular interventions, 2011, Volume: 4, Issue:4

    Topics: Adenosine Diphosphate; Adult; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopido

2011
Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial.
    European heart journal, 2011, Volume: 32, Issue:22

    Topics: Acute Coronary Syndrome; Aged; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Dose-

2011
A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab wi
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2011, Jun-01, Volume: 77, Issue:7

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Antithrombi

2011
Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel--Thrombolysis in Myocardial Infarction 38 (TRITON-
    Circulation, 2011, Jun-14, Volume: 123, Issue:23

    Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged

2011
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
    Circulation, 2011, Aug-02, Volume: 124, Issue:5

    Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal

2011
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
    Circulation, 2011, Aug-02, Volume: 124, Issue:5

    Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal

2011
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
    Circulation, 2011, Aug-02, Volume: 124, Issue:5

    Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal

2011
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
    Circulation, 2011, Aug-02, Volume: 124, Issue:5

    Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal

2011
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
    Circulation, 2011, Aug-02, Volume: 124, Issue:5

    Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal

2011
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
    Circulation, 2011, Aug-02, Volume: 124, Issue:5

    Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal

2011
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
    Circulation, 2011, Aug-02, Volume: 124, Issue:5

    Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal

2011
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
    Circulation, 2011, Aug-02, Volume: 124, Issue:5

    Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal

2011
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
    Circulation, 2011, Aug-02, Volume: 124, Issue:5

    Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal

2011
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
    Circulation, 2011, Aug-02, Volume: 124, Issue:5

    Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal

2011
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
    Circulation, 2011, Aug-02, Volume: 124, Issue:5

    Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal

2011
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
    Circulation, 2011, Aug-02, Volume: 124, Issue:5

    Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal

2011
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
    Circulation, 2011, Aug-02, Volume: 124, Issue:5

    Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal

2011
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
    Circulation, 2011, Aug-02, Volume: 124, Issue:5

    Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal

2011
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
    Circulation, 2011, Aug-02, Volume: 124, Issue:5

    Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal

2011
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
    Circulation, 2011, Aug-02, Volume: 124, Issue:5

    Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal

2011
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
    Circulation, 2011, Aug-02, Volume: 124, Issue:5

    Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal

2011
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
    Circulation, 2011, Aug-02, Volume: 124, Issue:5

    Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal

2011
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
    Circulation, 2011, Aug-02, Volume: 124, Issue:5

    Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal

2011
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
    Circulation, 2011, Aug-02, Volume: 124, Issue:5

    Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal

2011
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
    Circulation, 2011, Aug-02, Volume: 124, Issue:5

    Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal

2011
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
    Circulation, 2011, Aug-02, Volume: 124, Issue:5

    Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal

2011
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
    Circulation, 2011, Aug-02, Volume: 124, Issue:5

    Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal

2011
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
    Circulation, 2011, Aug-02, Volume: 124, Issue:5

    Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal

2011
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
    Circulation, 2011, Aug-02, Volume: 124, Issue:5

    Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal

2011
Residual platelet reactivity after clopidogrel loading in patients with ST-elevation myocardial infarction undergoing an unexpectedly delayed primary percutaneous coronary intervention. - Impact on intracoronary thrombus burden and myocardial perfusion-.
    Circulation journal : official journal of the Japanese Circulation Society, 2011, Volume: 75, Issue:9

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Circulation; Co

2011
Combined clopidogrel and proton pump inhibitor therapy is associated with higher cardiovascular event rates after percutaneous coronary intervention: a report from the BASKET trial.
    Journal of internal medicine, 2012, Volume: 271, Issue:3

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Interactio

2012
Higher efficacy of pre-hospital tirofiban with longer pre-treatment time to primary PCI: protection for the negative impact of time delay.
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2011, Volume: 7, Issue:4

    Topics: Aged; Ambulances; Angioplasty, Balloon, Coronary; Aspirin; Chi-Square Distribution; Clopidogrel; Cor

2011
Relationship between clopidogrel-induced platelet P2Y12 inhibition and stent thrombosis or myocardial infarction after percutaneous coronary intervention-a case-control study.
    American heart journal, 2011, Volume: 162, Issue:2

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Co

2011
Inhibitory interaction between calcium channel blocker and clopidogrel. -Efficacy of cilostazol to overcome it-.
    Circulation journal : official journal of the Japanese Circulation Society, 2011, Volume: 75, Issue:11

    Topics: Aged; Brain Ischemia; Calcium Channel Blockers; Cilostazol; Clopidogrel; Death; Drug Antagonism; Dru

2011
Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial.
    Circulation, 2011, Sep-06, Volume: 124, Issue:10

    Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Drug-Eluting Stents; Female; Follow-Up

2011
Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial.
    Circulation, 2011, Sep-06, Volume: 124, Issue:10

    Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Drug-Eluting Stents; Female; Follow-Up

2011
Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial.
    Circulation, 2011, Sep-06, Volume: 124, Issue:10

    Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Drug-Eluting Stents; Female; Follow-Up

2011
Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial.
    Circulation, 2011, Sep-06, Volume: 124, Issue:10

    Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Drug-Eluting Stents; Female; Follow-Up

2011
Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial.
    Circulation, 2011, Sep-06, Volume: 124, Issue:10

    Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Drug-Eluting Stents; Female; Follow-Up

2011
Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial.
    Circulation, 2011, Sep-06, Volume: 124, Issue:10

    Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Drug-Eluting Stents; Female; Follow-Up

2011
Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial.
    Circulation, 2011, Sep-06, Volume: 124, Issue:10

    Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Drug-Eluting Stents; Female; Follow-Up

2011
Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial.
    Circulation, 2011, Sep-06, Volume: 124, Issue:10

    Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Drug-Eluting Stents; Female; Follow-Up

2011
Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial.
    Circulation, 2011, Sep-06, Volume: 124, Issue:10

    Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Drug-Eluting Stents; Female; Follow-Up

2011
Coronary stenting with the Genous™ Bio-Engineered R Stent™ in elderly patients.
    Circulation journal : official journal of the Japanese Circulation Society, 2011, Volume: 75, Issue:11

    Topics: Age Factors; Aged; Angioplasty, Balloon, Coronary; Blood Vessel Prosthesis; Clopidogrel; Death; Fema

2011
Outcome comparison of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results from the ARMYDA-6 MI (Antiplatelet therapy for Reduction of MYocar
    Journal of the American College of Cardiology, 2011, Oct-04, Volume: 58, Issue:15

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Inf

2011
CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients.
    Circulation. Cardiovascular interventions, 2011, Oct-01, Volume: 4, Issue:5

    Topics: Adult; Aryl Hydrocarbon Hydroxylases; Aryldialkylphosphatase; Biomarkers, Pharmacological; Clopidogr

2011
CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients.
    Circulation. Cardiovascular interventions, 2011, Oct-01, Volume: 4, Issue:5

    Topics: Adult; Aryl Hydrocarbon Hydroxylases; Aryldialkylphosphatase; Biomarkers, Pharmacological; Clopidogr

2011
CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients.
    Circulation. Cardiovascular interventions, 2011, Oct-01, Volume: 4, Issue:5

    Topics: Adult; Aryl Hydrocarbon Hydroxylases; Aryldialkylphosphatase; Biomarkers, Pharmacological; Clopidogr

2011
CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients.
    Circulation. Cardiovascular interventions, 2011, Oct-01, Volume: 4, Issue:5

    Topics: Adult; Aryl Hydrocarbon Hydroxylases; Aryldialkylphosphatase; Biomarkers, Pharmacological; Clopidogr

2011
Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable.
    Annals of internal medicine, 2011, Nov-01, Volume: 155, Issue:9

    Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial

2011
Evaluating the safety of very short-term (10 days) dual antiplatelet therapy after Genous™ bio-engineered R stent™ implantation: the multicentre pilot Genous trial.
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2011, Volume: 7, Issue:7

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Stenosis;

2011
Cystatin C and estimated glomerular filtration rate as predictors for adverse outcome in patients with ST-elevation and non-ST-elevation acute coronary syndromes: results from the Platelet Inhibition and Patient Outcomes study.
    Clinical chemistry, 2012, Volume: 58, Issue:1

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Biomarkers; C-Reactive Protein; Clopidogrel; Creatinine; C

2012
The effect of pre-hospital glycoprotein IIb-IIIa inhibitors on angiographic outcome in STEMI patients who are candidates for primary PCI.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2012, May-01, Volume: 79, Issue:6

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Circulati

2012
ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial: insights from the ECG substudy.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Electrocardio

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Efficacy and safety of a high loading dose of clopidogrel administered prehospitally to improve primary percutaneous coronary intervention in acute myocardial infarction: the randomized CIPAMI trial.
    Clinical research in cardiology : official journal of the German Cardiac Society, 2012, Volume: 101, Issue:4

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Emergency Medical Services; Femal

2012
Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial.
    Circulation, 2012, Feb-28, Volume: 125, Issue:8

    Topics: Adenosine; Aged; Clopidogrel; Double-Blind Method; Female; Humans; Male; Middle Aged; Myocardial Inf

2012
Net clinical benefit of prehospital glycoprotein IIb/IIIa inhibitors in patients with ST-elevation myocardial infarction and high risk of bleeding: effect of tirofiban in patients at high risk of bleeding using CRUSADE bleeding score.
    The Journal of invasive cardiology, 2012, Volume: 24, Issue:3

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypas

2012
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
    Circulation, 2012, Apr-24, Volume: 125, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels

2012
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
    Circulation, 2012, Apr-24, Volume: 125, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels

2012
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
    Circulation, 2012, Apr-24, Volume: 125, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels

2012
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
    Circulation, 2012, Apr-24, Volume: 125, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels

2012
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
    Circulation, 2012, Apr-24, Volume: 125, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels

2012
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
    Circulation, 2012, Apr-24, Volume: 125, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels

2012
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
    Circulation, 2012, Apr-24, Volume: 125, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels

2012
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
    Circulation, 2012, Apr-24, Volume: 125, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels

2012
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
    Circulation, 2012, Apr-24, Volume: 125, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels

2012
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
    Circulation, 2012, Apr-24, Volume: 125, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels

2012
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
    Circulation, 2012, Apr-24, Volume: 125, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels

2012
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
    Circulation, 2012, Apr-24, Volume: 125, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels

2012
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
    Circulation, 2012, Apr-24, Volume: 125, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels

2012
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
    Circulation, 2012, Apr-24, Volume: 125, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels

2012
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
    Circulation, 2012, Apr-24, Volume: 125, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels

2012
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
    Circulation, 2012, Apr-24, Volume: 125, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels

2012
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
    Circulation, 2012, Apr-24, Volume: 125, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels

2012
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
    Circulation, 2012, Apr-24, Volume: 125, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels

2012
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
    Circulation, 2012, Apr-24, Volume: 125, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels

2012
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
    Circulation, 2012, Apr-24, Volume: 125, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels

2012
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
    Circulation, 2012, Apr-24, Volume: 125, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels

2012
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
    Circulation, 2012, Apr-24, Volume: 125, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels

2012
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
    Circulation, 2012, Apr-24, Volume: 125, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels

2012
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
    Circulation, 2012, Apr-24, Volume: 125, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels

2012
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
    Circulation, 2012, Apr-24, Volume: 125, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels

2012
Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOppin
    JACC. Cardiovascular interventions, 2012, Volume: 5, Issue:3

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Administration Schedule;

2012
The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study.
    European heart journal, 2012, Volume: 33, Issue:17

    Topics: Aryl Hydrocarbon Hydroxylases; Atherosclerosis; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genot

2012
[Changes in coagulation and fibrinolysis in the patients with coronary heart disease in acute period and effect of drug intervention].
    Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue, 2012, Volume: 24, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Aspirin; Blood Coagulation; Case-Control Studies;

2012
Baseline Q waves as a prognostic modulator in patients with ST-segment elevation: insights from the PLATO trial.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2012, Jul-10, Volume: 184, Issue:10

    Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Biomarkers; Clopidogrel; Creatin

2012
Lessons from platelet inhibition and patient outcomes.
    Current opinion in cardiology, 2012, Volume: 27, Issue:4

    Topics: Acute Coronary Syndrome; Adenosine; Blood Platelets; Clopidogrel; Confidence Intervals; Humans; Myoc

2012
Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack.
    Circulation, 2012, Jun-12, Volume: 125, Issue:23

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Brain Ischemia; Clopidogrel; Female; Humans; Intracranial

2012
Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial.
    American heart journal, 2012, Volume: 163, Issue:5

    Topics: Adenosine Monophosphate; Adult; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiogra

2012
A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PC
    Circulation. Cardiovascular interventions, 2012, Volume: 5, Issue:3

    Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Canada; Clopidogrel; Disease-Free Survival; Do

2012
Predictors of high on-treatment platelet reactivity early after clopidogrel loading in ST-elevation myocardial infarction.
    Circulation journal : official journal of the Japanese Circulation Society, 2012, Volume: 76, Issue:9

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Blood Platelets; Clopidogrel; Female; Humans; Male; M

2012
Prognostic value of a high on-clopidogrel treatment platelet reactivity in bivalirudin versus abciximab treated non-ST-segment elevation myocardial infarction patients. ISAR-REACT 4 (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action fo
    Journal of the American College of Cardiology, 2012, Jul-31, Volume: 60, Issue:5

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Antithrombi

2012
Clopidogrel trial in patients with elective percutaneous coronary intervention for stable angina and old myocardial infarction (CLEAN).
    International heart journal, 2012, Volume: 53, Issue:2

    Topics: Adult; Aged; Angina, Stable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality

2012
P2Y12 platelet reactivity after thrombolytic therapy for ST-segment elevation myocardial infarction.
    Thrombosis research, 2012, Volume: 130, Issue:3

    Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Fibrinolytic Agents; Humans; Male; Middle A

2012
Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study.
    European heart journal, 2013, Volume: 34, Issue:3

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Cost-Benefit Analysis; Female; Humans; Life E

2013
Antiplatelet effect of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: an analysis of the ARMYDA-6 MI (Antiplatelet therapy for Reduction of MYo
    International journal of cardiology, 2012, Oct-18, Volume: 160, Issue:3

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Dose-Response Relationship, Drug; Humans; International

2012
Pantoprazole significantly interferes with antiplatelet effect of clopidogrel: results of a pilot randomized trial.
    International journal of cardiology, 2013, Sep-01, Volume: 167, Issue:5

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Clopidogrel; Drug Interactions; Female; Humans; Male;

2013
Triple vs. dual antiplatelet therapy in patients with acute myocardial infarction and renal dysfunction.
    Circulation journal : official journal of the Japanese Circulation Society, 2012, Volume: 76, Issue:10

    Topics: Aged; Aged, 80 and over; Aspirin; Cilostazol; Clopidogrel; Disease-Free Survival; Drug Therapy, Comb

2012
The impact of smoking on the antiplatelet action of clopidogrel in non-ST-elevation myocardial infarction patients: results from the ISAR-REACT 4 platelet substudy.
    Journal of thrombosis and haemostasis : JTH, 2012, Volume: 10, Issue:10

    Topics: Aged; Aged, 80 and over; Clopidogrel; Female; Germany; Humans; Male; Middle Aged; Myocardial Infarct

2012
Angiographic and platelet reactivity outcomes with prasugrel 60 mg pretreatment and clopidogrel 600 mg pretreatment in primary percutaneous coronary intervention.
    Journal of thrombosis and thrombolysis, 2012, Volume: 34, Issue:4

    Topics: Adult; Aged; Asian People; Clopidogrel; Cohort Studies; Coronary Thrombosis; Female; Humans; Male; M

2012
Influence of omeprazole and famotidine on the antiplatelet effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes: a prospective, randomized, multicenter study.
    Circulation journal : official journal of the Japanese Circulation Society, 2012, Volume: 76, Issue:11

    Topics: Acute Coronary Syndrome; Aged; Anti-Ulcer Agents; Aspirin; Blood Platelets; Clopidogrel; Drug Antago

2012
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.
    The New England journal of medicine, 2012, Oct-04, Volume: 367, Issue:14

    Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Doub

2012
Prasugrel versus high dose clopidogrel to overcome early high on clopidogrel platelet reactivity in patients with ST elevation myocardial infarction.
    Cardiovascular drugs and therapy, 2012, Volume: 26, Issue:5

    Topics: Aged; Blood Platelets; Clopidogrel; Dose-Response Relationship, Drug; Female; Humans; Male; Middle A

2012
Impact of Clopidogrel loading dose in patients with chronic kidney disease undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.
    The American journal of cardiology, 2012, Dec-01, Volume: 110, Issue:11

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopidogrel; Dose-Response Relationship, Dr

2012
Microvascular effect of intracoronary eptifibatide in acute myocardial infarction.
    Cardiology, 2012, Volume: 123, Issue:1

    Topics: Adolescent; Adult; Clopidogrel; Coronary Angiography; Echocardiography; Electrocardiography; Eptifib

2012
Clopidogrel two doses comparative 1-year assessment of safety and efficacy (COMPASS) study in Japanese patients with ischemic stroke.
    Cerebrovascular diseases (Basel, Switzerland), 2012, Volume: 34, Issue:3

    Topics: Age Factors; Aged; Asian People; Body Weight; Clopidogrel; Dose-Response Relationship, Drug; Double-

2012
Lack of association between clopidogrel responsiveness tested using point-of-care assay and prognosis of patients with coronary artery disease.
    Journal of thrombosis and thrombolysis, 2013, Volume: 36, Issue:1

    Topics: Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Disease-Free Survival; Female; Follow

2013
Randomized comparison of new dual-antiplatelet therapy (aspirin, prasugrel) and triple-antiplatelet therapy (aspirin, clopidogrel, cilostazol) using P2Y12 point-of-care assay in patients with STEMI undergoing primary PCI.
    International journal of cardiology, 2013, Sep-20, Volume: 168, Issue:1

    Topics: Adult; Aged; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Midd

2013
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
    JAMA, 2012, Nov-07, Volume: 308, Issue:17

    Topics: Acute Coronary Syndrome; Age Factors; Aged; Angina, Unstable; Aspirin; Body Weight; Clopidogrel; Fem

2012
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
    JAMA, 2012, Nov-07, Volume: 308, Issue:17

    Topics: Acute Coronary Syndrome; Age Factors; Aged; Angina, Unstable; Aspirin; Body Weight; Clopidogrel; Fem

2012
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
    JAMA, 2012, Nov-07, Volume: 308, Issue:17

    Topics: Acute Coronary Syndrome; Age Factors; Aged; Angina, Unstable; Aspirin; Body Weight; Clopidogrel; Fem

2012
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
    JAMA, 2012, Nov-07, Volume: 308, Issue:17

    Topics: Acute Coronary Syndrome; Age Factors; Aged; Angina, Unstable; Aspirin; Body Weight; Clopidogrel; Fem

2012
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
    The New England journal of medicine, 2012, Nov-29, Volume: 367, Issue:22

    Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans;

2012
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
    The New England journal of medicine, 2012, Nov-29, Volume: 367, Issue:22

    Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans;

2012
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
    The New England journal of medicine, 2012, Nov-29, Volume: 367, Issue:22

    Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans;

2012
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
    The New England journal of medicine, 2012, Nov-29, Volume: 367, Issue:22

    Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans;

2012
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
    The New England journal of medicine, 2012, Nov-29, Volume: 367, Issue:22

    Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans;

2012
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
    The New England journal of medicine, 2012, Nov-29, Volume: 367, Issue:22

    Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans;

2012
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
    The New England journal of medicine, 2012, Nov-29, Volume: 367, Issue:22

    Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans;

2012
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
    The New England journal of medicine, 2012, Nov-29, Volume: 367, Issue:22

    Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans;

2012
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
    The New England journal of medicine, 2012, Nov-29, Volume: 367, Issue:22

    Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans;

2012
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
    The New England journal of medicine, 2012, Nov-29, Volume: 367, Issue:22

    Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans;

2012
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
    The New England journal of medicine, 2012, Nov-29, Volume: 367, Issue:22

    Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans;

2012
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
    The New England journal of medicine, 2012, Nov-29, Volume: 367, Issue:22

    Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans;

2012
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
    The New England journal of medicine, 2012, Nov-29, Volume: 367, Issue:22

    Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans;

2012
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
    The New England journal of medicine, 2012, Nov-29, Volume: 367, Issue:22

    Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans;

2012
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
    The New England journal of medicine, 2012, Nov-29, Volume: 367, Issue:22

    Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans;

2012
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
    The New England journal of medicine, 2012, Nov-29, Volume: 367, Issue:22

    Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans;

2012
Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin.
    Circulation, 2013, Jan-22, Volume: 127, Issue:3

    Topics: Administration, Oral; Adolescent; Adult; Aspirin; Clopidogrel; Cross-Over Studies; Cyclooxygenase 1;

2013
Increased platelet aggregation and turnover in the acute phase of ST-elevation myocardial infarction.
    Platelets, 2013, Volume: 24, Issue:7

    Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Cohort Studies; Female; Humans; Male; Middle Aged; Myoc

2013
Increased platelet aggregation and turnover in the acute phase of ST-elevation myocardial infarction.
    Platelets, 2013, Volume: 24, Issue:7

    Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Cohort Studies; Female; Humans; Male; Middle Aged; Myoc

2013
Increased platelet aggregation and turnover in the acute phase of ST-elevation myocardial infarction.
    Platelets, 2013, Volume: 24, Issue:7

    Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Cohort Studies; Female; Humans; Male; Middle Aged; Myoc

2013
Increased platelet aggregation and turnover in the acute phase of ST-elevation myocardial infarction.
    Platelets, 2013, Volume: 24, Issue:7

    Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Cohort Studies; Female; Humans; Male; Middle Aged; Myoc

2013
Efficacy and safety of low-dose clopidogrel in Japanese patients after drug-eluting stent implantation: a randomized pilot trial.
    Heart and vessels, 2014, Volume: 29, Issue:1

    Topics: Aged; Asian People; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy

2014
Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Clopidogrel; Female; Humans; Ischemic A

2013
Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY).
    European heart journal, 2013, Volume: 34, Issue:12

    Topics: Aged; Clopidogrel; Coronary Restenosis; Coronary Vessels; Drug Administration Schedule; Drug Therapy

2013
Comparison of antiplatelet efficacy and tolerability of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients after percutaneous coronary intervention: a prospective, multicenter, randomized, open-label, phase IV, noninfe
    Clinical therapeutics, 2013, Volume: 35, Issue:1

    Topics: Aged; Blood Platelets; Cerebrovascular Disorders; Chi-Square Distribution; Clopidogrel; Coronary Art

2013
Rationale and design of the on-treatment PLAtelet Reactivity-Guided Therapy Modification FOR ST-Segment Elevation Myocardial Infarction (PLATFORM) randomized trial.
    Journal of interventional cardiology, 2013, Volume: 26, Issue:3

    Topics: Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infarction; Percutane

2013
Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus.
    The American journal of cardiology, 2002, Sep-15, Volume: 90, Issue:6

    Topics: Aged; Aspirin; Clopidogrel; Diabetes Complications; Diabetes Mellitus; Diabetic Angiopathies; Endpoi

2002
Effectiveness of clopidogrel versus aspirin in preventing acute myocardial infarction in patients with symptomatic atherothrombosis (CAPRIE trial).
    The American journal of cardiology, 2002, Oct-01, Volume: 90, Issue:7

    Topics: Age Factors; Aged; Aspirin; Clopidogrel; Creatinine; Diabetes Mellitus; Female; Humans; Male; Massac

2002
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
    JAMA, 2002, Nov-20, Volume: 288, Issue:19

    Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho

2002
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
    JAMA, 2002, Nov-20, Volume: 288, Issue:19

    Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho

2002
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
    JAMA, 2002, Nov-20, Volume: 288, Issue:19

    Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho

2002
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
    JAMA, 2002, Nov-20, Volume: 288, Issue:19

    Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho

2002
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
    JAMA, 2002, Nov-20, Volume: 288, Issue:19

    Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho

2002
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
    JAMA, 2002, Nov-20, Volume: 288, Issue:19

    Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho

2002
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
    JAMA, 2002, Nov-20, Volume: 288, Issue:19

    Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho

2002
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
    JAMA, 2002, Nov-20, Volume: 288, Issue:19

    Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho

2002
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
    JAMA, 2002, Nov-20, Volume: 288, Issue:19

    Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho

2002
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
    JAMA, 2002, Nov-20, Volume: 288, Issue:19

    Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho

2002
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
    JAMA, 2002, Nov-20, Volume: 288, Issue:19

    Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho

2002
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
    JAMA, 2002, Nov-20, Volume: 288, Issue:19

    Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho

2002
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
    JAMA, 2002, Nov-20, Volume: 288, Issue:19

    Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho

2002
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
    JAMA, 2002, Nov-20, Volume: 288, Issue:19

    Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho

2002
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
    JAMA, 2002, Nov-20, Volume: 288, Issue:19

    Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho

2002
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
    JAMA, 2002, Nov-20, Volume: 288, Issue:19

    Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho

2002
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
    JAMA, 2002, Nov-20, Volume: 288, Issue:19

    Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho

2002
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
    JAMA, 2002, Nov-20, Volume: 288, Issue:19

    Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho

2002
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
    JAMA, 2002, Nov-20, Volume: 288, Issue:19

    Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho

2002
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
    JAMA, 2002, Nov-20, Volume: 288, Issue:19

    Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho

2002
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
    JAMA, 2002, Nov-20, Volume: 288, Issue:19

    Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho

2002
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
    JAMA, 2002, Nov-20, Volume: 288, Issue:19

    Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho

2002
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
    JAMA, 2002, Nov-20, Volume: 288, Issue:19

    Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho

2002
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
    JAMA, 2002, Nov-20, Volume: 288, Issue:19

    Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho

2002
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
    JAMA, 2002, Nov-20, Volume: 288, Issue:19

    Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho

2002
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
    JAMA, 2002, Nov-20, Volume: 288, Issue:19

    Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho

2002
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
    JAMA, 2002, Nov-20, Volume: 288, Issue:19

    Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho

2002
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
    JAMA, 2002, Nov-20, Volume: 288, Issue:19

    Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho

2002
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
    JAMA, 2002, Nov-20, Volume: 288, Issue:19

    Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho

2002
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
    JAMA, 2002, Nov-20, Volume: 288, Issue:19

    Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho

2002
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
    JAMA, 2002, Nov-20, Volume: 288, Issue:19

    Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho

2002
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
    JAMA, 2002, Nov-20, Volume: 288, Issue:19

    Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho

2002
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
    JAMA, 2002, Nov-20, Volume: 288, Issue:19

    Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho

2002
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
    JAMA, 2002, Nov-20, Volume: 288, Issue:19

    Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho

2002
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
    JAMA, 2002, Nov-20, Volume: 288, Issue:19

    Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho

2002
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
    JAMA, 2002, Nov-20, Volume: 288, Issue:19

    Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho

2002
Early and late effects of clopidogrel in patients with acute coronary syndromes.
    Circulation, 2003, Feb-25, Volume: 107, Issue:7

    Topics: Acute Disease; Angina, Unstable; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combinatio

2003
Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial.
    Circulation, 2003, Aug-26, Volume: 108, Issue:8

    Topics: Angioplasty, Balloon, Coronary; Atorvastatin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450

2003
Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study.
    Circulation, 2003, Oct-07, Volume: 108, Issue:14

    Topics: Acute Disease; Angina, Unstable; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Double-Blin

2003
Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET).
    Journal of the American College of Cardiology, 2003, Oct-01, Volume: 42, Issue:7

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Combined Mo

2003
[Non ST elevation acute coronary syndrome. Some characteristics of coagulation and von Willebrand factor during short term use of ticlopidine or clopidogrel].
    Kardiologiia, 2003, Volume: 43, Issue:10

    Topics: Acute Disease; Adult; Angina, Unstable; Anticoagulants; Aspirin; Blood Coagulation; Clopidogrel; Dat

2003
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
Eptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel. Results of the platelet activity extinction in non-Q-wave myocardial infarction with aspirin, clopidogrel
    Journal of the American College of Cardiology, 2004, Jan-21, Volume: 43, Issue:2

    Topics: Aged; Aspirin; Clopidogrel; Drug Synergism; Drug Therapy, Combination; Enoxaparin; Eptifibatide; Fem

2004
Leukocyte count as an independent predictor of recurrent ischemic events.
    Stroke, 2004, Volume: 35, Issue:5

    Topics: Aspirin; Biomarkers; Brain Ischemia; Cause of Death; Clopidogrel; Female; Humans; Inflammation; Leuk

2004
Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome.
    Journal of the American College of Cardiology, 2004, Jun-02, Volume: 43, Issue:11

    Topics: Adenosine Diphosphate; Aspirin; Blood Platelets; CD40 Ligand; Clopidogrel; Enzyme-Linked Immunosorbe

2004
Comparison between ticlopidine and clopidogrel in patients with ST-segment elevation myocardial infarction treated with coronary stenting.
    Thrombosis and haemostasis, 2004, Volume: 91, Issue:6

    Topics: Aged; Clopidogrel; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocar

2004
Comparison of cilostazol and ticlopidine for one-month effectiveness and safety after elective coronary stenting.
    Cardiovascular drugs and therapy, 2004, Volume: 18, Issue:3

    Topics: Administration, Oral; Aspirin; Cilostazol; Coronary Restenosis; Coronary Stenosis; Coronary Vessels;

2004
Lack of efficacy of clopidogrel pre-treatment in the prevention of myocardial damage after elective stent implantation.
    Journal of the American College of Cardiology, 2004, Jul-07, Volume: 44, Issue:1

    Topics: Aged; Angioplasty, Balloon, Coronary; Biomarkers; Blood Vessel Prosthesis Implantation; Clopidogrel;

2004
Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin.
    Circulation, 2004, Jul-27, Volume: 110, Issue:4

    Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Cardiac Catheter

2004
Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin.
    Circulation, 2004, Jul-27, Volume: 110, Issue:4

    Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Cardiac Catheter

2004
Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin.
    Circulation, 2004, Jul-27, Volume: 110, Issue:4

    Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Cardiac Catheter

2004
Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin.
    Circulation, 2004, Jul-27, Volume: 110, Issue:4

    Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Cardiac Catheter

2004
Treatment of left anterior descending coronary artery disease with sirolimus-eluting stents.
    Circulation, 2004, Jul-27, Volume: 110, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Cohort Studies; Coronary

2004
[First experience of clopidogrel application in the treatment of acute myocardial infarction with ST-elevation].
    Terapevticheskii arkhiv, 2004, Volume: 76, Issue:6

    Topics: Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Electrocardiography;

2004
Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction.
    Journal of the American College of Cardiology, 2004, Sep-15, Volume: 44, Issue:6

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Combined Modal

2004
Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel.
    Circulation, 2004, Dec-14, Volume: 110, Issue:24

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Arter

2004
A randomized comparison of the effects of aspirin and clopidogrel on thrombotic risk factors and C-reactive protein following myocardial infarction: the CADET trial.
    Journal of thrombosis and haemostasis : JTH, 2004, Volume: 2, Issue:11

    Topics: Aged; Aspirin; Biomarkers; Blood Coagulation Factors; Blood Viscosity; C-Reactive Protein; Clopidogr

2004
The cost-effectiveness of the use of clopidogrel in acute coronary syndromes in five countries based upon the CURE study.
    European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology, 2004, Volume: 11, Issue:6

    Topics: Angina, Unstable; Canada; Clopidogrel; Cost-Benefit Analysis; Europe; Health Care Costs; Hospitaliza

2004
Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization.
    Journal of the American College of Cardiology, 2004, Dec-07, Volume: 44, Issue:11

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
Lack of clopidogrel-CYP3A4 statin interaction in patients with acute coronary syndrome.
    Heart (British Cardiac Society), 2005, Volume: 91, Issue:1

    Topics: Aged; Angina, Unstable; Clopidogrel; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug In

2005
One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrel.
    European heart journal, 2005, Volume: 26, Issue:14

    Topics: Abciximab; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagu

2005
Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
    Circulation, 2005, Mar-08, Volume: 111, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Coronary; Cardiovascular Agen

2005
Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
    Circulation, 2005, Mar-08, Volume: 111, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Coronary; Cardiovascular Agen

2005
Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
    Circulation, 2005, Mar-08, Volume: 111, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Coronary; Cardiovascular Agen

2005
Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
    Circulation, 2005, Mar-08, Volume: 111, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Coronary; Cardiovascular Agen

2005
Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
    Circulation, 2005, Mar-08, Volume: 111, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Coronary; Cardiovascular Agen

2005
Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
    Circulation, 2005, Mar-08, Volume: 111, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Coronary; Cardiovascular Agen

2005
Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
    Circulation, 2005, Mar-08, Volume: 111, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Coronary; Cardiovascular Agen

2005
Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
    Circulation, 2005, Mar-08, Volume: 111, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Coronary; Cardiovascular Agen

2005
Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
    Circulation, 2005, Mar-08, Volume: 111, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Coronary; Cardiovascular Agen

2005
Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty)
    Circulation, 2005, Apr-26, Volume: 111, Issue:16

    Topics: Aged; Angioplasty, Balloon, Coronary; Biomarkers; Clopidogrel; Creatine Kinase; Dose-Response Relati

2005
Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty)
    Circulation, 2005, Apr-26, Volume: 111, Issue:16

    Topics: Aged; Angioplasty, Balloon, Coronary; Biomarkers; Clopidogrel; Creatine Kinase; Dose-Response Relati

2005
Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty)
    Circulation, 2005, Apr-26, Volume: 111, Issue:16

    Topics: Aged; Angioplasty, Balloon, Coronary; Biomarkers; Clopidogrel; Creatine Kinase; Dose-Response Relati

2005
Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty)
    Circulation, 2005, Apr-26, Volume: 111, Issue:16

    Topics: Aged; Angioplasty, Balloon, Coronary; Biomarkers; Clopidogrel; Creatine Kinase; Dose-Response Relati

2005
Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty)
    Circulation, 2005, Apr-26, Volume: 111, Issue:16

    Topics: Aged; Angioplasty, Balloon, Coronary; Biomarkers; Clopidogrel; Creatine Kinase; Dose-Response Relati

2005
Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty)
    Circulation, 2005, Apr-26, Volume: 111, Issue:16

    Topics: Aged; Angioplasty, Balloon, Coronary; Biomarkers; Clopidogrel; Creatine Kinase; Dose-Response Relati

2005
Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty)
    Circulation, 2005, Apr-26, Volume: 111, Issue:16

    Topics: Aged; Angioplasty, Balloon, Coronary; Biomarkers; Clopidogrel; Creatine Kinase; Dose-Response Relati

2005
Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty)
    Circulation, 2005, Apr-26, Volume: 111, Issue:16

    Topics: Aged; Angioplasty, Balloon, Coronary; Biomarkers; Clopidogrel; Creatine Kinase; Dose-Response Relati

2005
Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty)
    Circulation, 2005, Apr-26, Volume: 111, Issue:16

    Topics: Aged; Angioplasty, Balloon, Coronary; Biomarkers; Clopidogrel; Creatine Kinase; Dose-Response Relati

2005
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar

2005
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar

2005
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar

2005
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar

2005
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar

2005
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar

2005
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar

2005
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar

2005
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar

2005
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar

2005
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar

2005
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar

2005
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar

2005
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar

2005
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar

2005
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar

2005
Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation.
    Journal of the American College of Cardiology, 2005, Mar-15, Volume: 45, Issue:6

    Topics: Acute Disease; Aged; Clopidogrel; Coronary Disease; Cost-Benefit Analysis; Electrocardiography; Fema

2005
Comparison of cilostazol and clopidogrel after successful coronary stenting.
    The American journal of cardiology, 2005, Apr-01, Volume: 95, Issue:7

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Coronary Restenosis; Female;

2005
[Safety and efficacy of dalteparin administration for elective percutaneous interventions in patients pre-treated with aspirin and ticlopidine].
    Przeglad lekarski, 2004, Volume: 61, Issue:12

    Topics: Adolescent; Adult; Aged; Angioplasty, Balloon; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dal

2004
Comparative inhibitory effects of cilostazol and ticlopidine on subacute stent thrombosis and platelet function in acute myocardial infarction patients with percutaneous coronary intervention.
    International heart journal, 2005, Volume: 46, Issue:1

    Topics: Aged; Aspirin; Cilostazol; Drug Therapy, Combination; Female; Humans; Incidence; Male; Myocardial In

2005
Comparison of two strategies for the management of antiplatelet therapy during urgent surgery.
    The Annals of thoracic surgery, 2005, Volume: 80, Issue:1

    Topics: Aged; Angina, Unstable; Aprotinin; Aspirin; Clopidogrel; Coronary Artery Bypass; Female; Hemostatics

2005
Effect of clopidogrel plus aspirin on tissue perfusion and coronary flow in patients with ST-segment elevation myocardial infarction: a new reperfusion strategy.
    American heart journal, 2005, Volume: 149, Issue:6

    Topics: Aged; Aspirin; Clopidogrel; Coronary Circulation; Drug Therapy, Combination; Electrocardiography; Fe

2005
A randomized trial comparing clopidogrel versus ticlopidine therapy in patients undergoing infarct artery stenting for acute myocardial infarction with abciximab as adjunctive therapy.
    American heart journal, 2005, Volume: 150, Issue:2

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents, Non-Steroidal; Antibodies

2005
Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) tria
    Journal of the American College of Cardiology, 2005, Sep-06, Volume: 46, Issue:5

    Topics: Aspirin; Cardiac Catheterization; Clopidogrel; Cost-Benefit Analysis; Drug Therapy, Combination; Fem

2005
Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study.
    JAMA, 2005, Sep-14, Volume: 294, Issue:10

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Female; Humans; Male; Middle Aged; Myoca

2005
Effects of tirofiban plus clopidogrel versus clopidogrel plus provisional abciximab on biomarkers of myocardial necrosis in patients with non-ST-elevation acute coronary syndromes treated with early aggressive approach. Results of the CLOpidogrel, upstrea
    American heart journal, 2005, Volume: 150, Issue:3

    Topics: Abciximab; Acute Disease; Aged; Angina, Unstable; Antibodies, Monoclonal; Clopidogrel; Creatine Kina

2005
A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
    American heart journal, 2005, Volume: 150, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Brain Ischemia; Cardiovascular Diseases; Clopidogrel; Coronary Disea

2005
Impact of heparin neutralization by protamine on restenosis after coronary stent implantation.
    International journal of cardiology, 2005, Oct-20, Volume: 105, Issue:1

    Topics: Aged; Angina Pectoris; Anticoagulants; Aspirin; Blood Vessel Prosthesis Implantation; Coronary Reste

2005
Effects of clopidogrel on the rebound hypercoagulable state after heparin discontinuation in patients with acute coronary syndromes.
    Journal of the American College of Cardiology, 2005, Oct-18, Volume: 46, Issue:8

    Topics: Acute Disease; Angina, Unstable; Anticoagulants; Antithrombin III; Clopidogrel; Heparin; Humans; Myo

2005
Could clopidogrel's platelet inhibition be enhanced by an increased loading dose and eptifibatide?
    Nature clinical practice. Cardiovascular medicine, 2005, Volume: 2, Issue:7

    Topics: Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Eptifibatide; Flow Cytomet

2005
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
    Lancet (London, England), 2005, Nov-05, Volume: 366, Issue:9497

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio

2005
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
    Lancet (London, England), 2005, Nov-05, Volume: 366, Issue:9497

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio

2005
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
    Lancet (London, England), 2005, Nov-05, Volume: 366, Issue:9497

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio

2005
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
    Lancet (London, England), 2005, Nov-05, Volume: 366, Issue:9497

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio

2005
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
    Lancet (London, England), 2005, Nov-05, Volume: 366, Issue:9497

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio

2005
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
    Lancet (London, England), 2005, Nov-05, Volume: 366, Issue:9497

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio

2005
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
    Lancet (London, England), 2005, Nov-05, Volume: 366, Issue:9497

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio

2005
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
    Lancet (London, England), 2005, Nov-05, Volume: 366, Issue:9497

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio

2005
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
    Lancet (London, England), 2005, Nov-05, Volume: 366, Issue:9497

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio

2005
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
    Lancet (London, England), 2005, Nov-05, Volume: 366, Issue:9497

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio

2005
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
    Lancet (London, England), 2005, Nov-05, Volume: 366, Issue:9497

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio

2005
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
    Lancet (London, England), 2005, Nov-05, Volume: 366, Issue:9497

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio

2005
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
    Lancet (London, England), 2005, Nov-05, Volume: 366, Issue:9497

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio

2005
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
    Lancet (London, England), 2005, Nov-05, Volume: 366, Issue:9497

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio

2005
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
    Lancet (London, England), 2005, Nov-05, Volume: 366, Issue:9497

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio

2005
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
    Lancet (London, England), 2005, Nov-05, Volume: 366, Issue:9497

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio

2005
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
    Lancet (London, England), 2005, Nov-05, Volume: 366, Issue:9497

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio

2005
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
    Lancet (London, England), 2005, Nov-05, Volume: 366, Issue:9497

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio

2005
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
    Lancet (London, England), 2005, Nov-05, Volume: 366, Issue:9497

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio

2005
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
    Lancet (London, England), 2005, Nov-05, Volume: 366, Issue:9497

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio

2005
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
    Lancet (London, England), 2005, Nov-05, Volume: 366, Issue:9497

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio

2005
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
    Lancet (London, England), 2005, Nov-05, Volume: 366, Issue:9497

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio

2005
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
    Lancet (London, England), 2005, Nov-05, Volume: 366, Issue:9497

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio

2005
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
    Lancet (London, England), 2005, Nov-05, Volume: 366, Issue:9497

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio

2005
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
    Lancet (London, England), 2005, Nov-05, Volume: 366, Issue:9497

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio

2005
Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 Trial.
    Circulation, 2005, Dec-20, Volume: 112, Issue:25

    Topics: Adolescent; Adult; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Drug Thera

2005
Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study.
    American heart journal, 2005, Volume: 150, Issue:6

    Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Bypass; Coronary Dise

2005
[Indirect comparison of changes of parameters of hemostasis during short-term use of ticlopidine and clopidogrel in patients with non-ST elevation acute coronary syndrome].
    Kardiologiia, 2005, Volume: 45, Issue:12

    Topics: Anticoagulants; Aspirin; Clopidogrel; Electrocardiography; Enoxaparin; Fibrinolysis; Fibrinolytic Ag

2005
Effect of aspirin plus clopidogrel on inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome.
    Chinese medical journal, 2006, Jan-05, Volume: 119, Issue:1

    Topics: Adult; Aged; Angina, Unstable; Aspirin; C-Reactive Protein; Clopidogrel; Drug Therapy, Combination;

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial.
    JAMA, 2006, Apr-05, Volume: 295, Issue:13

    Topics: Abciximab; Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogre

2006
Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial.
    JAMA, 2006, Apr-05, Volume: 295, Issue:13

    Topics: Abciximab; Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogre

2006
Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial.
    JAMA, 2006, Apr-05, Volume: 295, Issue:13

    Topics: Abciximab; Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogre

2006
Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial.
    JAMA, 2006, Apr-05, Volume: 295, Issue:13

    Topics: Abciximab; Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogre

2006
Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial.
    JAMA, 2006, Apr-05, Volume: 295, Issue:13

    Topics: Abciximab; Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogre

2006
Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial.
    JAMA, 2006, Apr-05, Volume: 295, Issue:13

    Topics: Abciximab; Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogre

2006
Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial.
    JAMA, 2006, Apr-05, Volume: 295, Issue:13

    Topics: Abciximab; Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogre

2006
Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial.
    JAMA, 2006, Apr-05, Volume: 295, Issue:13

    Topics: Abciximab; Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogre

2006
Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial.
    JAMA, 2006, Apr-05, Volume: 295, Issue:13

    Topics: Abciximab; Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogre

2006
Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial.
    JAMA, 2006, Apr-05, Volume: 295, Issue:13

    Topics: Abciximab; Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogre

2006
Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial.
    JAMA, 2006, Apr-05, Volume: 295, Issue:13

    Topics: Abciximab; Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogre

2006
Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial.
    JAMA, 2006, Apr-05, Volume: 295, Issue:13

    Topics: Abciximab; Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogre

2006
Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial.
    JAMA, 2006, Apr-05, Volume: 295, Issue:13

    Topics: Abciximab; Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogre

2006
Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial.
    JAMA, 2006, Apr-05, Volume: 295, Issue:13

    Topics: Abciximab; Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogre

2006
Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial.
    JAMA, 2006, Apr-05, Volume: 295, Issue:13

    Topics: Abciximab; Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogre

2006
Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial.
    JAMA, 2006, Apr-05, Volume: 295, Issue:13

    Topics: Abciximab; Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogre

2006
Single high-dose bolus tirofiban with high-loading-dose clopidogrel in primary coronary angioplasty.
    Heart and vessels, 2006, Volume: 21, Issue:2

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarctio

2006
Can clopidogrel and aspirin lower mortality in patients with acute myocardial infarction?
    Nature clinical practice. Cardiovascular medicine, 2006, Volume: 3, Issue:4

    Topics: Aged; Aspirin; Clopidogrel; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administrat

2006
Is delayed facilitated percutaneous coronary intervention better than immediate in reperfused myocardial infarction? Six months follow up findings.
    Journal of thrombosis and thrombolysis, 2006, Volume: 21, Issue:2

    Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Clopidogrel; Combined Modality Therapy; Female

2006
A comparison of dual vs. triple antiplatelet therapy in patients with non-ST-segment elevation acute coronary syndrome: results of the ELISA-2 trial.
    European heart journal, 2006, Volume: 27, Issue:12

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Drug Combinations; Enzymes; Female; Humans; Male;

2006
A comparison of pharmacologic therapy with/without timely coronary intervention vs. primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST (Which Early ST-elevation myocardial infarction Therapy) study.
    European heart journal, 2006, Volume: 27, Issue:13

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Drug

2006
[Therapy of acute mayocardial infarction: COMMIT (Clopidogrel and Metoprolol Infarction Trial)].
    Der Internist, 2006, Volume: 47, Issue:7

    Topics: Administration, Oral; Antihypertensive Agents; China; Clopidogrel; Drug Combinations; Humans; Metopr

2006
The role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST-segment elevation myocardial infarction: the ECG CLARITY-TIMI 28 Study.
    Journal of the American College of Cardiology, 2006, Jul-04, Volume: 48, Issue:1

    Topics: Aged; Clopidogrel; Coronary Circulation; Double-Blind Method; Electrocardiography; Female; Hospital

2006
Angiographically evident thrombus following fibrinolytic therapy is associated with impaired myocardial perfusion in STEMI: a CLARITY-TIMI 28 substudy.
    European heart journal, 2006, Volume: 27, Issue:17

    Topics: Adolescent; Adult; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Double-Bli

2006
Randomized comparison of the effects of ASA plus clopidogrel versus ASA alone on early platelet activation in acute coronary syndromes with elevated high-sensitivity C-reactive protein and soluble CD40 ligand levels.
    Clinical therapeutics, 2006, Volume: 28, Issue:6

    Topics: Acute Disease; Aged; Angina, Unstable; Aspirin; C-Reactive Protein; CD40 Ligand; Clopidogrel; Dose-R

2006
[Effectiveness and safety of clopidogrel bisulfate in complex therapy of patients with acute coronary syndrome with ST segment elevation].
    Kardiologiia, 2006, Volume: 46, Issue:7

    Topics: Acute Disease; Angina Pectoris, Variant; Clopidogrel; Echocardiography; Female; Humans; Male; Middle

2006
Erythrocyte deformability and white blood cell count are associated with aspirin resistance in high-risk vascular patients.
    Clinical hemorheology and microcirculation, 2006, Volume: 35, Issue:1-2

    Topics: Aged; Angina, Unstable; Aspirin; Bleeding Time; Blood Viscosity; Clopidogrel; Drug Resistance; Eryth

2006
A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) t
    Journal of the American College of Cardiology, 2006, Sep-05, Volume: 48, Issue:5

    Topics: Acute Disease; Adenosine Diphosphate; Aged; Biomarkers; Clopidogrel; Dose-Response Relationship, Dru

2006
A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) t
    Journal of the American College of Cardiology, 2006, Sep-05, Volume: 48, Issue:5

    Topics: Acute Disease; Adenosine Diphosphate; Aged; Biomarkers; Clopidogrel; Dose-Response Relationship, Dru

2006
A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) t
    Journal of the American College of Cardiology, 2006, Sep-05, Volume: 48, Issue:5

    Topics: Acute Disease; Adenosine Diphosphate; Aged; Biomarkers; Clopidogrel; Dose-Response Relationship, Dru

2006
A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) t
    Journal of the American College of Cardiology, 2006, Sep-05, Volume: 48, Issue:5

    Topics: Acute Disease; Adenosine Diphosphate; Aged; Biomarkers; Clopidogrel; Dose-Response Relationship, Dru

2006
Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infar
    American heart journal, 2006, Volume: 152, Issue:4

    Topics: Acute Disease; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Dose-Response Re

2006
The role of aspirin resistance on outcome in patients with acute coronary syndrome and the effect of clopidogrel therapy in the prevention of major cardiovascular events.
    Journal of thrombosis and thrombolysis, 2006, Volume: 22, Issue:2

    Topics: Angina, Unstable; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Resistance; Female; Follow-Up

2006
Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting.
    Journal of the American College of Cardiology, 2006, Oct-03, Volume: 48, Issue:7

    Topics: Aged; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Electrocardiography; F

2006
Efficacy and safety of clopidogrel 600 mg administered pre-hospitally to improve primary percutaneous coronary intervention in patients with acute myocardial infarction (CIPAMI): study rationale and design.
    Cardiology, 2007, Volume: 108, Issue:4

    Topics: Adult; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Drug Administration Sch

2007
Naproxen treatment prevents periprocedural inflammatory response but not myocardial injury after percutaneous coronary intervention.
    Thrombosis research, 2007, Volume: 119, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; C-Reactive P

2007
Prehospital fibrinolysis with dual antiplatelet therapy in ST-elevation acute myocardial infarction: a substudy of the randomized double blind CLARITY-TIMI 28 trial.
    Journal of thrombosis and thrombolysis, 2007, Volume: 23, Issue:3

    Topics: Aged; Ambulances; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emergency Me

2007
Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents.
    Journal of the American College of Cardiology, 2006, Dec-19, Volume: 48, Issue:12

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug Deli

2006
Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents.
    Journal of the American College of Cardiology, 2006, Dec-19, Volume: 48, Issue:12

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug Deli

2006
Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents.
    Journal of the American College of Cardiology, 2006, Dec-19, Volume: 48, Issue:12

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug Deli

2006
Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents.
    Journal of the American College of Cardiology, 2006, Dec-19, Volume: 48, Issue:12

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug Deli

2006
Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents.
    Journal of the American College of Cardiology, 2006, Dec-19, Volume: 48, Issue:12

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug Deli

2006
Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents.
    Journal of the American College of Cardiology, 2006, Dec-19, Volume: 48, Issue:12

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug Deli

2006
Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents.
    Journal of the American College of Cardiology, 2006, Dec-19, Volume: 48, Issue:12

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug Deli

2006
Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents.
    Journal of the American College of Cardiology, 2006, Dec-19, Volume: 48, Issue:12

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug Deli

2006
Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents.
    Journal of the American College of Cardiology, 2006, Dec-19, Volume: 48, Issue:12

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug Deli

2006
Clopidogrel bisulfate: in ST-segment elevation myocardial infarction: a viewpoint by Jeffrey W Moses.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2006, Volume: 6, Issue:6

    Topics: Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine

2006
Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; results from the ESPRIT trial.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2007, Jul-01, Volume: 70, Issue:1

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combi

2007
Clinical relevance of aspirin resistance in patients with stable coronary artery disease: a prospective follow-up study (PROSPECTAR).
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2007, Volume: 18, Issue:2

    Topics: Aged; Angina Pectoris; Aspirin; Clopidogrel; Coronary Artery Disease; Death; Drug Resistance; Female

2007
A novel enoxaparin regime for ST elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: a WEST sub-study.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2007, Volume: 70, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Canada; Clopidogrel; Corona

2007
Benefits and risks of clopidogrel pretreatment before coronary artery bypass grafting in patients with ST-elevation myocardial infarction treated with fibrinolytics in CLARITY-TIMI 28.
    Journal of thrombosis and thrombolysis, 2007, Volume: 24, Issue:2

    Topics: Aged; Clopidogrel; Coronary Artery Bypass; Double-Blind Method; Female; Hemorrhage; Humans; Male; Mi

2007
[Influence of the double antiplatelet therapy on patency of the occluded artery after acute myocardial infarction with ST-segment elevation].
    Vojnosanitetski pregled, 2007, Volume: 64, Issue:2

    Topics: Adult; Aged; Aspirin; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; Electrocardiogra

2007
Relation between impaired antiplatelet response to clopidogrel and possible pleiotropic effects.
    Journal of thrombosis and thrombolysis, 2007, Volume: 24, Issue:3

    Topics: Aged; Aspirin; Blood Platelets; C-Reactive Protein; Clopidogrel; Drug Resistance; Female; Humans; In

2007
Comparison of three-year clinical outcome of sirolimus- and paclitaxel-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction (from the RESEARCH and T-SEARCH Registries).
    The American journal of cardiology, 2007, Apr-15, Volume: 99, Issue:8

    Topics: Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel; Cohort Studies; Coronary Restenosis; El

2007
Comparison of two antiplatelet regimens (aspirin alone versus aspirin + ticlopidine or clopidogrel) after intracoronary implantation of a carbofilm-coated stent.
    The American journal of cardiology, 2007, Apr-15, Volume: 99, Issue:8

    Topics: Aspirin; Carbon; Cause of Death; Clopidogrel; Coated Materials, Biocompatible; Coronary Disease; Cor

2007
[The effect of different loading doses of clopidogrel on platelet aggregation].
    Zhonghua nei ke za zhi, 2007, Volume: 46, Issue:2

    Topics: Adult; Aged; Angina, Unstable; Clopidogrel; Dose-Response Relationship, Drug; Female; Humans; Male;

2007
Renal function and outcomes in acute coronary syndrome: impact of clopidogrel.
    European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology, 2007, Volume: 14, Issue:2

    Topics: Aged; Angina, Unstable; Clopidogrel; Coronary Disease; Creatinine; Double-Blind Method; Female; Glom

2007
Platelet function in clopidogrel-treated patients with acute coronary syndrome.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2007, Volume: 18, Issue:4

    Topics: Aged; Blood Platelets; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; P-Sele

2007
Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial.
    Journal of the American College of Cardiology, 2007, May-15, Volume: 49, Issue:19

    Topics: Aged; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studie

2007
Efficacy and safety of enoxaparin versus unfractionated heparin in patients with ST-segment elevation myocardial infarction also treated with clopidogrel.
    Journal of the American College of Cardiology, 2007, Jun-12, Volume: 49, Issue:23

    Topics: Aged; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; Female; Fibrinolytic

2007
[Absence of benefit with triple antiaggregation in acute non persistent ST segment elevation myocardial infarction in patients not subjected to early interventionism].
    Medicina intensiva, 2007, Volume: 31, Issue:4

    Topics: Aged; Aspirin; Clopidogrel; Electrocardiography; Female; Humans; Male; Middle Aged; Myocardial Infar

2007
Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: long-term results of the DIABETES trial.
    European heart journal, 2007, Volume: 28, Issue:16

    Topics: Aged; Aspirin; Blood Vessel Prosthesis; Clopidogrel; Coronary Restenosis; Coronary Stenosis; Death,

2007
Association of interleukin-10 level with increased 30-day mortality in patients with ST-segment elevation acute myocardial infarction undergoing primary coronary intervention.
    Circulation journal : official journal of the Japanese Circulation Society, 2007, Volume: 71, Issue:7

    Topics: Aged; Angioplasty, Balloon; Clopidogrel; Cohort Studies; Electrocardiography; Female; Humans; Interl

2007
Optimal platelet inhibition in patients undergoing PCI: data from the Multicenter Registry of High-Risk Percutaneous Coronary Intervention and Adequate Platelet Inhibition (MR PCI) study.
    American heart journal, 2007, Volume: 154, Issue:2

    Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Clopidogrel; Eptifibatide; Humans; Myocardial Infa

2007
An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial.
    European heart journal, 2007, Volume: 28, Issue:18

    Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Clopidogrel; Disease-Free Survival; Drug Th

2007
The paclitaxel-eluting Coroflex Please stent pilot study (PECOPS I) : the one-year clinical follow-up.
    Clinical research in cardiology : official journal of the German Cardiac Society, 2007, Volume: 96, Issue:11

    Topics: Aged; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Death; Drug-Eluting Stents; Female;

2007
ExTRACT-TIMI 25 trial: clarifying the role of enoxaparin in patients with ST-elevation myocardial infarction receiving fibrinolysis.
    Expert review of cardiovascular therapy, 2007, Volume: 5, Issue:5

    Topics: Adult; Age Factors; Aged; Clopidogrel; Double-Blind Method; Enoxaparin; Female; Fibrinolytic Agents;

2007
Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.
    Journal of the American College of Cardiology, 2007, Nov-06, Volume: 50, Issue:19

    Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Clopidogrel; Dose-Response Relationship, Drug;

2007
Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.
    Journal of the American College of Cardiology, 2007, Nov-06, Volume: 50, Issue:19

    Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Clopidogrel; Dose-Response Relationship, Drug;

2007
Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.
    Journal of the American College of Cardiology, 2007, Nov-06, Volume: 50, Issue:19

    Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Clopidogrel; Dose-Response Relationship, Drug;

2007
Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.
    Journal of the American College of Cardiology, 2007, Nov-06, Volume: 50, Issue:19

    Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Clopidogrel; Dose-Response Relationship, Drug;

2007
Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.
    Journal of the American College of Cardiology, 2007, Nov-06, Volume: 50, Issue:19

    Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Clopidogrel; Dose-Response Relationship, Drug;

2007
Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.
    Journal of the American College of Cardiology, 2007, Nov-06, Volume: 50, Issue:19

    Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Clopidogrel; Dose-Response Relationship, Drug;

2007
Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.
    Journal of the American College of Cardiology, 2007, Nov-06, Volume: 50, Issue:19

    Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Clopidogrel; Dose-Response Relationship, Drug;

2007
Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.
    Journal of the American College of Cardiology, 2007, Nov-06, Volume: 50, Issue:19

    Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Clopidogrel; Dose-Response Relationship, Drug;

2007
Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.
    Journal of the American College of Cardiology, 2007, Nov-06, Volume: 50, Issue:19

    Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Clopidogrel; Dose-Response Relationship, Drug;

2007
Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.
    Journal of the American College of Cardiology, 2007, Nov-06, Volume: 50, Issue:19

    Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Clopidogrel; Dose-Response Relationship, Drug;

2007
Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.
    Journal of the American College of Cardiology, 2007, Nov-06, Volume: 50, Issue:19

    Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Clopidogrel; Dose-Response Relationship, Drug;

2007
Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.
    Journal of the American College of Cardiology, 2007, Nov-06, Volume: 50, Issue:19

    Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Clopidogrel; Dose-Response Relationship, Drug;

2007
Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.
    Journal of the American College of Cardiology, 2007, Nov-06, Volume: 50, Issue:19

    Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Clopidogrel; Dose-Response Relationship, Drug;

2007
Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.
    Journal of the American College of Cardiology, 2007, Nov-06, Volume: 50, Issue:19

    Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Clopidogrel; Dose-Response Relationship, Drug;

2007
Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.
    Journal of the American College of Cardiology, 2007, Nov-06, Volume: 50, Issue:19

    Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Clopidogrel; Dose-Response Relationship, Drug;

2007
Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.
    Journal of the American College of Cardiology, 2007, Nov-06, Volume: 50, Issue:19

    Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Clopidogrel; Dose-Response Relationship, Drug;

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Cilostazol could ameliorate platelet responsiveness to clopidogrel in patients undergoing primary percutaneous coronary intervention.
    Circulation journal : official journal of the Japanese Circulation Society, 2007, Volume: 71, Issue:12

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Blood Platelets; CD40 Antigens; Cilostazo

2007
Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial
    Circulation, 2007, Dec-18, Volume: 116, Issue:25

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Cross-Over Studies; Fe

2007
Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial
    Circulation, 2007, Dec-18, Volume: 116, Issue:25

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Cross-Over Studies; Fe

2007
Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial
    Circulation, 2007, Dec-18, Volume: 116, Issue:25

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Cross-Over Studies; Fe

2007
Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial
    Circulation, 2007, Dec-18, Volume: 116, Issue:25

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Cross-Over Studies; Fe

2007
Effects of pretreatment with clopidogrel on nonemergent percutaneous coronary intervention after fibrinolytic administration for ST-segment elevation myocardial infarction: a Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarct
    American heart journal, 2008, Volume: 155, Issue:1

    Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Double-Blind Me

2008
One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: results of the ISAR-REACT 2 randomized trial.
    European heart journal, 2008, Volume: 29, Issue:4

    Topics: Abciximab; Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Cl

2008
Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study.
    Journal of the American College of Cardiology, 2008, Jan-22, Volume: 51, Issue:3

    Topics: Aged; Angioplasty, Balloon, Coronary; Cell Adhesion Molecules; Clopidogrel; Double-Blind Method; Dru

2008
Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study.
    Journal of the American College of Cardiology, 2008, Jan-22, Volume: 51, Issue:3

    Topics: Aged; Angioplasty, Balloon, Coronary; Cell Adhesion Molecules; Clopidogrel; Double-Blind Method; Dru

2008
Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study.
    Journal of the American College of Cardiology, 2008, Jan-22, Volume: 51, Issue:3

    Topics: Aged; Angioplasty, Balloon, Coronary; Cell Adhesion Molecules; Clopidogrel; Double-Blind Method; Dru

2008
Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study.
    Journal of the American College of Cardiology, 2008, Jan-22, Volume: 51, Issue:3

    Topics: Aged; Angioplasty, Balloon, Coronary; Cell Adhesion Molecules; Clopidogrel; Double-Blind Method; Dru

2008
Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study.
    Journal of the American College of Cardiology, 2008, Jan-22, Volume: 51, Issue:3

    Topics: Aged; Angioplasty, Balloon, Coronary; Cell Adhesion Molecules; Clopidogrel; Double-Blind Method; Dru

2008
Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study.
    Journal of the American College of Cardiology, 2008, Jan-22, Volume: 51, Issue:3

    Topics: Aged; Angioplasty, Balloon, Coronary; Cell Adhesion Molecules; Clopidogrel; Double-Blind Method; Dru

2008
Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study.
    Journal of the American College of Cardiology, 2008, Jan-22, Volume: 51, Issue:3

    Topics: Aged; Angioplasty, Balloon, Coronary; Cell Adhesion Molecules; Clopidogrel; Double-Blind Method; Dru

2008
Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study.
    Journal of the American College of Cardiology, 2008, Jan-22, Volume: 51, Issue:3

    Topics: Aged; Angioplasty, Balloon, Coronary; Cell Adhesion Molecules; Clopidogrel; Double-Blind Method; Dru

2008
Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study.
    Journal of the American College of Cardiology, 2008, Jan-22, Volume: 51, Issue:3

    Topics: Aged; Angioplasty, Balloon, Coronary; Cell Adhesion Molecules; Clopidogrel; Double-Blind Method; Dru

2008
Patients with non-ST-elevation acute coronary syndromes undergoing coronary artery bypass grafting in the modern era of antithrombotic therapy.
    American heart journal, 2008, Volume: 155, Issue:2

    Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Artery Bypass; Electrocardiography; Enoxaparin;

2008
Association of blood glucose with angiographic and clinical outcomes among patients with ST-segment elevation myocardial infarction (from the CLARITY-TIMI-28 study).
    The American journal of cardiology, 2008, Feb-01, Volume: 101, Issue:3

    Topics: Blood Glucose; Clopidogrel; Coronary Angiography; Female; Hospital Mortality; Humans; Hyperglycemia;

2008
Association of impaired thrombolysis in myocardial infarction myocardial perfusion grade with ventricular tachycardia and ventricular fibrillation following fibrinolytic therapy for ST-segment elevation myocardial infarction.
    Journal of the American College of Cardiology, 2008, Feb-05, Volume: 51, Issue:5

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Circulati

2008
Sirolimus-eluting stents versus bare-metal stents in patients with ST-segment elevation myocardial infarction: 9-month angiographic and intravascular ultrasound results and 12-month clinical outcome results from the MISSION! Intervention Study.
    Journal of the American College of Cardiology, 2008, Feb-12, Volume: 51, Issue:6

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Clopidog

2008
Association between baseline neutrophil count, clopidogrel therapy, and clinical and angiographic outcomes in patients with ST-elevation myocardial infarction receiving fibrinolytic therapy.
    European heart journal, 2008, Volume: 29, Issue:8

    Topics: Clopidogrel; Coronary Angiography; Epidemiologic Methods; Female; Humans; Leukocyte Count; Male; Mid

2008
Effects of coronary prestenting platelet inhibition on coronary poststenting inflammation.
    Journal of cardiovascular pharmacology, 2008, Volume: 51, Issue:3

    Topics: Aged; alpha 1-Antitrypsin; Clopidogrel; Drug Administration Schedule; Female; Humans; Inflammation;

2008
Effect of tirofiban plus clopidogrel and aspirin on primary percutaneous coronary intervention via transradial approach in patients with acute myocardial infarction.
    Chinese medical journal, 2008, Mar-20, Volume: 121, Issue:6

    Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Therapy, Combination; Female

2008
The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
    American heart journal, 2008, Volume: 155, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Fema

2008
Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomi
    Lancet (London, England), 2008, Apr-19, Volume: 371, Issue:9621

    Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Fe

2008
Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study.
    Journal of the American College of Cardiology, 2008, Apr-08, Volume: 51, Issue:14

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Cell Adhesion Molecules; Clopidogrel;

2008
Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study.
    Journal of the American College of Cardiology, 2008, Apr-08, Volume: 51, Issue:14

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Cell Adhesion Molecules; Clopidogrel;

2008
Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study.
    Journal of the American College of Cardiology, 2008, Apr-08, Volume: 51, Issue:14

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Cell Adhesion Molecules; Clopidogrel;

2008
Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study.
    Journal of the American College of Cardiology, 2008, Apr-08, Volume: 51, Issue:14

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Cell Adhesion Molecules; Clopidogrel;

2008
Clopidogrel pre-treatment in stable angina: for all patients > 6 h before elective coronary angiography or only for angiographically selected patients a few minutes before PCI? A randomized multicentre trial PRAGUE-8.
    European heart journal, 2008, Volume: 29, Issue:12

    Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Blood Loss, Surgical; Chronic Disease; Clopid

2008
Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolys
    Journal of the American College of Cardiology, 2008, May-27, Volume: 51, Issue:21

    Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Com

2008
[Aftercare of heart infarct patients to reduce the risk of a subsequent infarction].
    Nederlands tijdschrift voor geneeskunde, 1983, Apr-16, Volume: 127, Issue:16

    Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Clinical Trials as Top

1983
Registry of prospective clinical trials--fifth report.
    Thrombosis and haemostasis, 1982, Dec-27, Volume: 48, Issue:3

    Topics: Aspirin; Clinical Trials as Topic; Coronary Artery Bypass; Coronary Disease; Dipyridamole; Double-Bl

1982
Coronary stent placement in patients with acute myocardial infarction: comparison of clinical and angiographic outcome after randomization to antiplatelet or anticoagulant therapy.
    Journal of the American College of Cardiology, 1997, Volume: 29, Issue:1

    Topics: Anticoagulants; Aspirin; Coronary Angiography; Coronary Disease; Female; Follow-Up Studies; Heparin;

1997
Aspirin plus either dipyridamole or ticlopidine is effective in preventing recurrent myocardial infarction. Secondary Prevention Group.
    Japanese circulation journal, 1997, Volume: 61, Issue:1

    Topics: Aged; Aspirin; Dipyridamole; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Mid

1997
Major benefit from antiplatelet therapy for patients at high risk for adverse cardiac events after coronary Palmaz-Schatz stent placement: analysis of a prospective risk stratification protocol in the Intracoronary Stenting and Antithrombotic Regimen (ISA
    Circulation, 1997, Apr-15, Volume: 95, Issue:8

    Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cardiovascular Diseases; Combined Modality

1997
Early versus late coronary stenting following acute myocardial infarction: results of the STENTIM I Study (French Registry of Stenting in Acute Myocardial Infarction).
    Catheterization and cardiovascular diagnosis, 1997, Volume: 42, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Feasibility Studies; Female

1997
Wiktor stent for treatment of chronic total coronary artery occlusions: short- and long-term clinical and angiographic results from a large multicenter experience.
    Journal of the American College of Cardiology, 1998, Volume: 31, Issue:2

    Topics: Analysis of Variance; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Catheterization, Peri

1998
PAMI (Primary Angioplasty in Myocardial Infarction) Stent Pilot Trial.
    Clinical cardiology, 1998, Volume: 21, Issue:2

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Drug Therapy, Combination; Follow-Up Studies; Humans; Myoca

1998
The STIMS trial: the ticlopidine experience and its clinical applications. Swedish Ticlopidine Multicenter Study.
    Vascular medicine (London, England), 1996, Volume: 1, Issue:2

    Topics: Cerebrovascular Disorders; Female; Humans; Intermittent Claudication; Male; Myocardial Infarction; P

1996
One-month results of coronary stenting in patients > or = 75 years of age.
    The American journal of cardiology, 1998, Jul-01, Volume: 82, Issue:1

    Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Drug Therapy, Combination; Female; He

1998
Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.
    Lancet (London, England), 1998, Jul-11, Volume: 352, Issue:9122

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Coronary Disease; Corona

1998
Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.
    Lancet (London, England), 1998, Jul-11, Volume: 352, Issue:9122

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Coronary Disease; Corona

1998
Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.
    Lancet (London, England), 1998, Jul-11, Volume: 352, Issue:9122

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Coronary Disease; Corona

1998
Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.
    Lancet (London, England), 1998, Jul-11, Volume: 352, Issue:9122

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Coronary Disease; Corona

1998
The results of CAPRIE, IST and CAST. Clopidogrel vs. Aspirin in Patients at Risk of Ischaemic Events. International Stroke Trial. Chinese Acute Stroke Trial.
    Thrombosis research, 1998, Sep-15, Volume: 92, Issue:1 Suppl 1

    Topics: Aspirin; Cerebrovascular Disorders; Clopidogrel; Double-Blind Method; Humans; Ischemia; Myocardial I

1998
Results of the CAPRIE trial: efficacy and safety of clopidogrel. Clopidogrel versus aspirin in patients at risk of ischaemic events.
    Vascular medicine (London, England), 1998, Volume: 3, Issue:3

    Topics: Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clopidogrel; Follow-Up Studies; Humans; Myocar

1998
Safety and efficacy of ticlopidine for only 2 weeks after successful intracoronary stent placement.
    Circulation, 1999, Jan-19, Volume: 99, Issue:2

    Topics: Abciximab; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Coronary Disease; Drug Administra

1999
Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
    The New England journal of medicine, 1999, Jul-29, Volume: 341, Issue:5

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Combined Modality Therapy; Corona

1999
Clopidogrel-rt-PA-heparin combination in the treatment of acute myocardial infarction.
    Seminars in thrombosis and hemostasis, 1999, Volume: 25 Suppl 2

    Topics: Administration, Oral; Adult; Aged; Clopidogrel; Drug Therapy, Combination; Female; Fibrinolytic Agen

1999
Comparison of cilostazol versus ticlopidine therapy after stent implantation.
    The American journal of cardiology, 1999, Sep-01, Volume: 84, Issue:5

    Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Coronary Disease; Coronary Thrombo

1999
Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events.
    Drug safety, 1999, Volume: 21, Issue:4

    Topics: Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clopidogrel; Double-Blind Method; Gastrointest

1999
Impact of cilostazol on clinical and angiographic outcome after primary stenting for acute myocardial infarction.
    The American journal of cardiology, 1999, Nov-01, Volume: 84, Issue:9

    Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Coronary Angiography; Female; Fibr

1999
Changes in levels of factor VII and protein S after acute myocardial infarction: effects of low-dose warfarin.
    Thrombosis research, 1999, Nov-01, Volume: 96, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antigens; Aspirin; Brain Ischemia; Death, Sudden, Ca

1999
Usefulness of cilostazol versus ticlopidine in coronary artery stenting.
    The American journal of cardiology, 1999, Dec-15, Volume: 84, Issue:12

    Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Cilostazol; Coronary Angiograp

1999
[Aspirin vs ticlid and their combination in patients with acute myocardial infarction].
    Klinicheskaia meditsina, 2000, Volume: 78, Issue:1

    Topics: Aged; Aspirin; Blood Platelets; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocar

2000
Antiplatelet is superior to anticoagulant treatment after coronary stenting: fewer coronary and other events within 30 days after stenting.
    Angiology, 2000, Volume: 51, Issue:4

    Topics: Acenocoumarol; Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coron

2000
Increased platelet aggregability in response to shear stress in acute myocardial infarction and its inhibition by combined therapy with aspirin and cilostazol after coronary intervention.
    The American journal of cardiology, 2000, May-01, Volume: 85, Issue:9

    Topics: Aged; Aspirin; Cilostazol; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial

2000
Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators.
    American heart journal, 2000, Volume: 140, Issue:1

    Topics: Aspirin; Brain Ischemia; Cause of Death; Clopidogrel; Confidence Intervals; Double-Blind Method; Fem

2000
Final results of the Can Routine Ultrasound Influence Stent Expansion (CRUISE) study.
    Circulation, 2000, Aug-01, Volume: 102, Issue:5

    Topics: Aspirin; Coronary Angiography; Coronary Disease; Coronary Vessels; Coumarins; Female; Fibrinolytic A

2000
Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: enhanced inhibitory effects of combination therapy.
    Journal of the American College of Cardiology, 2000, Volume: 36, Issue:3

    Topics: Adenosine Diphosphate; Adult; Aged; Antigens, CD; Aspirin; Blood; Clopidogrel; Collagen; Dose-Respon

2000
Rationale, design and organization of the Second Chinese Cardiac Study (CCS-2): a randomized trial of clopidogrel plus aspirin, and of metoprolol, among patients with suspected acute myocardial infarction. Second Chinese Cardiac Study (CCS-2) Collaborativ
    Journal of cardiovascular risk, 2000, Volume: 7, Issue:6

    Topics: Adrenergic beta-Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; D

2000
A safe and effective regimen without heparin therapy after successful primary coronary stenting in patients with acute myocardial infarction.
    Japanese heart journal, 2000, Volume: 41, Issue:6

    Topics: Aged; Aspirin; Combined Modality Therapy; Coronary Angiography; Coronary Thrombosis; Coronary Vessel

2000
Ticlopidine versus aspirin after myocardial infarction (STAMI) trial.
    Journal of the American College of Cardiology, 2001, Volume: 37, Issue:5

    Topics: Adult; Aged; Aspirin; Cause of Death; Double-Blind Method; Female; Follow-Up Studies; Humans; Male;

2001
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
    Lancet (London, England), 2001, Aug-18, Volume: 358, Issue:9281

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F

2001
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
    Lancet (London, England), 2001, Aug-18, Volume: 358, Issue:9281

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F

2001
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
    Lancet (London, England), 2001, Aug-18, Volume: 358, Issue:9281

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F

2001
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
    Lancet (London, England), 2001, Aug-18, Volume: 358, Issue:9281

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F

2001
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
    Lancet (London, England), 2001, Aug-18, Volume: 358, Issue:9281

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F

2001
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
    Lancet (London, England), 2001, Aug-18, Volume: 358, Issue:9281

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F

2001
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
    Lancet (London, England), 2001, Aug-18, Volume: 358, Issue:9281

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F

2001
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
    Lancet (London, England), 2001, Aug-18, Volume: 358, Issue:9281

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F

2001
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
    Lancet (London, England), 2001, Aug-18, Volume: 358, Issue:9281

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F

2001
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
    Lancet (London, England), 2001, Aug-18, Volume: 358, Issue:9281

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F

2001
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
    Lancet (London, England), 2001, Aug-18, Volume: 358, Issue:9281

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F

2001
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
    Lancet (London, England), 2001, Aug-18, Volume: 358, Issue:9281

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F

2001
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
    Lancet (London, England), 2001, Aug-18, Volume: 358, Issue:9281

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F

2001
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
    Lancet (London, England), 2001, Aug-18, Volume: 358, Issue:9281

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F

2001
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
    Lancet (London, England), 2001, Aug-18, Volume: 358, Issue:9281

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F

2001
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
    Lancet (London, England), 2001, Aug-18, Volume: 358, Issue:9281

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F

2001
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
    Lancet (London, England), 2001, Aug-18, Volume: 358, Issue:9281

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F

2001
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
    Lancet (London, England), 2001, Aug-18, Volume: 358, Issue:9281

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F

2001
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
    Lancet (London, England), 2001, Aug-18, Volume: 358, Issue:9281

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F

2001
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
    Lancet (London, England), 2001, Aug-18, Volume: 358, Issue:9281

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F

2001
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
    Lancet (London, England), 2001, Aug-18, Volume: 358, Issue:9281

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F

2001
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
    Lancet (London, England), 2001, Aug-18, Volume: 358, Issue:9281

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F

2001
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
    Lancet (London, England), 2001, Aug-18, Volume: 358, Issue:9281

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F

2001
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
    Lancet (London, England), 2001, Aug-18, Volume: 358, Issue:9281

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F

2001
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
    Lancet (London, England), 2001, Aug-18, Volume: 358, Issue:9281

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F

2001
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
    Lancet (London, England), 2001, Aug-18, Volume: 358, Issue:9281

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F

2001
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
    Lancet (London, England), 2001, Aug-18, Volume: 358, Issue:9281

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F

2001
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
    Lancet (London, England), 2001, Aug-18, Volume: 358, Issue:9281

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F

2001
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
    Lancet (London, England), 2001, Aug-18, Volume: 358, Issue:9281

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F

2001
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
    Lancet (London, England), 2001, Aug-18, Volume: 358, Issue:9281

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F

2001
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
    Lancet (London, England), 2001, Aug-18, Volume: 358, Issue:9281

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F

2001
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
    Lancet (London, England), 2001, Aug-18, Volume: 358, Issue:9281

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F

2001
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
    Lancet (London, England), 2001, Aug-18, Volume: 358, Issue:9281

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F

2001
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
    Lancet (London, England), 2001, Aug-18, Volume: 358, Issue:9281

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F

2001
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
    Lancet (London, England), 2001, Aug-18, Volume: 358, Issue:9281

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F

2001
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
    Lancet (London, England), 2001, Aug-18, Volume: 358, Issue:9281

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F

2001
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
    Lancet (London, England), 2001, Aug-18, Volume: 358, Issue:9281

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F

2001
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
    Lancet (London, England), 2001, Aug-18, Volume: 358, Issue:9281

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F

2001
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
    Lancet (London, England), 2001, Aug-18, Volume: 358, Issue:9281

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F

2001
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
    Lancet (London, England), 2001, Aug-18, Volume: 358, Issue:9281

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F

2001
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
    Lancet (London, England), 2001, Aug-18, Volume: 358, Issue:9281

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F

2001
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
    Lancet (London, England), 2001, Aug-18, Volume: 358, Issue:9281

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F

2001
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
    Lancet (London, England), 2001, Aug-18, Volume: 358, Issue:9281

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F

2001
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
    Lancet (London, England), 2001, Aug-18, Volume: 358, Issue:9281

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F

2001
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
    Lancet (London, England), 2001, Aug-18, Volume: 358, Issue:9281

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F

2001
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
    Lancet (London, England), 2001, Aug-18, Volume: 358, Issue:9281

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F

2001
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
    Lancet (London, England), 2001, Aug-18, Volume: 358, Issue:9281

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F

2001
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
    Lancet (London, England), 2001, Aug-18, Volume: 358, Issue:9281

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F

2001
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
    Lancet (London, England), 2001, Aug-18, Volume: 358, Issue:9281

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F

2001
Insights from CURE: using clopidogrel on top of standard therapy.
    Cerebrovascular diseases (Basel, Switzerland), 2002, Volume: 13 Suppl 1

    Topics: Aged; Angina, Unstable; Aspirin; Clopidogrel; Double-Blind Method; Female; Follow-Up Studies; Hepari

2002
Clopidogrel: a CURE in acute coronary syndromes?
    Expert opinion on pharmacotherapy, 2002, Volume: 3, Issue:3

    Topics: Acute Disease; Aged; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; Female; Hemorrhage

2002
Efficacy of ticlopidine in the prevention of thromboembolic events in patients with VVI pacemakers.
    Pacing and clinical electrophysiology : PACE, 1991, Volume: 14, Issue:2 Pt 1

    Topics: Aged; Cerebrovascular Disorders; Extremities; Female; Follow-Up Studies; Humans; Incidence; Italy; M

1991
Ticlopidine treatment for patients with unstable angina at rest. A further analysis of the study of ticlopidine in unstable angina. Studio della Ticlopidina nell'Angina Instabile Group.
    European heart journal, 1991, Volume: 12 Suppl G

    Topics: Aged; Angina, Unstable; Humans; Male; Middle Aged; Myocardial Infarction; Rest; Ticlopidine

1991
Ticlopidine, a new antithrombotic drug: but is it better than aspirin for longterm use?
    Journal of neurology, neurosurgery, and psychiatry, 1990, Volume: 53, Issue:3

    Topics: Aspirin; Cerebrovascular Disorders; Humans; Ischemic Attack, Transient; Myocardial Infarction; Rando

1990
Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study.
    Journal of internal medicine, 1990, Volume: 227, Issue:5

    Topics: Aged; Cerebrovascular Disorders; Coronary Disease; Female; Humans; Intermittent Claudication; Ischem

1990
The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke.
    Lancet (London, England), 1989, Jun-03, Volume: 1, Issue:8649

    Topics: Aged; Canada; Cause of Death; Cerebrovascular Disorders; Cohort Studies; Drug Administration Schedul

1989
Clinical trials evaluating platelet-modifying drugs in patients with atherosclerotic cardiovascular disease and thrombosis.
    Circulation, 1986, Volume: 73, Issue:2

    Topics: Anticoagulants; Aspirin; Blood Platelets; Blood Vessel Prosthesis; Cardiovascular Diseases; Clinical

1986
The effect of ticlopidine on platelet functions in acute myocardial infarction. A double blind controlled trial.
    Thrombosis and haemostasis, 1985, Jun-24, Volume: 53, Issue:3

    Topics: Adult; Aged; Anticoagulants; Blood Coagulation; Blood Platelets; Clinical Trials as Topic; Collagen;

1985

Other Studies

934 other studies available for ticlopidine and Myocardial Infarction

ArticleYear
Letter: proton pump inhibitors and risk of myocardial infarction.
    Alimentary pharmacology & therapeutics, 2022, Volume: 55, Issue:1

    Topics: Humans; Myocardial Infarction; Proton Pump Inhibitors; Ticlopidine

2022
Clinical and Pharmacological Parameters Determine Relapse During Clopidogrel Treatment of Acute Coronary Syndrome.
    Journal of clinical pharmacology, 2022, Volume: 62, Issue:6

    Topics: Acute Coronary Syndrome; Aspirin; Calcium Channel Blockers; Clopidogrel; Coronary Artery Disease; Cy

2022
Cost Utility of Prasugrel in Postangioplasty Diabetic Patients.
    Value in health regional issues, 2022, Volume: 30

    Topics: Clopidogrel; Diabetes Mellitus; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhi

2022
Impact of continued clopidogrel use on outcomes of patients undergoing carotid endarterectomy.
    Journal of vascular surgery, 2023, Volume: 78, Issue:2

    Topics: Aged; Aspirin; Carotid Stenosis; Clopidogrel; Endarterectomy, Carotid; Female; Humans; Male; Myocard

2023
Contemporary use of guideline-based higher potency P2Y12 receptor inhibitor therapy in patients with moderate-to-high risk non-ST-segment elevation myocardial infarction: Results from the Canadian ACS reflective II cross-sectional study.
    Clinical cardiology, 2021, Volume: 44, Issue:6

    Topics: Canada; Cross-Sectional Studies; Humans; Myocardial Infarction; Non-ST Elevated Myocardial Infarctio

2021
Proton Pump Inhibitor and Clopidogrel Use After Percutaneous Coronary Intervention and Risk of Major Cardiovascular Events.
    Cardiovascular drugs and therapy, 2022, Volume: 36, Issue:6

    Topics: Clopidogrel; Cohort Studies; Coronary Disease; Humans; Myocardial Infarction; Percutaneous Coronary

2022
On-clopidogrel platelet reactivity as predictor for long-term clinical outcome in patients after planned discontinuation of clopidogrel.
    Thrombosis and haemostasis, 2017, 07-26, Volume: 117, Issue:8

    Topics: Aged; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Administration Schedule; Drug

2017
Optimizing dual antiplatelet therapy duration after myocardial infarction: evidence-based, precision, or personalized medicine?
    European heart journal, 2017, 04-07, Volume: 38, Issue:14

    Topics: Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors;

2017
[Contemporary use of ticagrelor in patients with acute coronary syndrome after discharge].
    Zhonghua yi xue za zhi, 2017, Apr-18, Volume: 97, Issue:15

    Topics: Acute Coronary Syndrome; Adenosine; Humans; Myocardial Infarction; Patient Discharge; Platelet Aggre

2017
Association of measured platelet reactivity with changes in P2Y
    American heart journal, 2017, Volume: 187

    Topics: Aged; Blood Platelets; Brain Ischemia; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; M

2017
Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes.
    American heart journal, 2017, Volume: 186

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Fibrinolytic Agents; Hemorrhage; Huma

2017
Prevalence, Management, and Long-Term (6-Year) Outcomes of Atrial Fibrillation Among Patients Receiving Drug-Eluting Coronary Stents.
    JACC. Cardiovascular interventions, 2017, 06-12, Volume: 10, Issue:11

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Chi-Square Distribution; Clopidogrel; Coronary A

2017
Antiplatelet Therapy and Clinical Outcomes Following Myocardial Infarction Among Patients in a U.S. Employer-Based Insurance Database.
    Journal of managed care & specialty pharmacy, 2017, Volume: 23, Issue:6

    Topics: Adolescent; Adult; Aged; Clopidogrel; Databases, Factual; Female; Humans; Male; Medicare; Middle Age

2017
Comparison of the Antiplatelet Effects of Once and Twice Daily Low-Dose Ticagrelor and Clopidogrel After Percutaneous Coronary Intervention.
    The American journal of cardiology, 2017, Jul-15, Volume: 120, Issue:2

    Topics: Adenosine; Aged; Clopidogrel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug T

2017
APpropriateness Assessment in Antiplatelet THerapY (APATHY) registry: Insight from current clinical practice.
    International journal of cardiology, 2017, Oct-01, Volume: 244

    Topics: Aged; Aged, 80 and over; Clopidogrel; Female; Humans; Male; Myocardial Infarction; Percutaneous Coro

2017
Comparison of prasugrel versus clopidogrel in Korean patients with acute myocardial infarction undergoing successful revascularization.
    Journal of cardiology, 2018, Volume: 71, Issue:1

    Topics: Aged; Asian People; Calcium Channel Blockers; Clopidogrel; Female; Hemorrhage; Hospitalization; Huma

2018
Cost-effectiveness analysis of 30-month vs 12-month dual antiplatelet therapy with clopidogrel and aspirin after drug-eluting stents in patients with acute coronary syndrome.
    Clinical cardiology, 2017, Volume: 40, Issue:10

    Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Computer Simulation; Coronary Thrombosis; Cost-Benefi

2017
Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the PROMETHEUS Study.
    JACC. Cardiovascular interventions, 2017, 10-23, Volume: 10, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Chi-Square Distribution; Clopidogrel; Coronary Thr

2017
Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents: 2-Year Results of a Prospective, Multicenter Registry Study.
    JACC. Cardiovascular interventions, 2017, 08-28, Volume: 10, Issue:16

    Topics: Aged; Aspirin; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Thrombosis; Drug Resi

2017
Antiplatelet treatment in diabetic patients with acute coronary syndrome undergoing percutaneous coronary intervention: a GReek AntiPlatElet registry substudy.
    Coronary artery disease, 2018, Volume: 29, Issue:1

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Case-Control Studies; Clopidogrel; Cohort Studies; Comorbi

2018
Recurrent Cardiovascular Events Despite Antiplatelet Therapy in a Patient with Polycythemia Vera and Accelerated Platelet Turnover.
    The American journal of case reports, 2017, Sep-01, Volume: 18

    Topics: Adenosine; Brain Infarction; Clopidogrel; Drug Therapy, Combination; Humans; Male; Middle Aged; Myoc

2017
Safety and efficacy of prasugrel in East Asian patients with acute coronary syndromes.
    Journal of cardiology, 2018, Volume: 71, Issue:2

    Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors

2018
Safety and Necessity of Antiplatelet Therapy on Patients Underwent Endovascular Aortic Repair with Both Stanford Type B Aortic Dissection and Coronary Heart Disease.
    Chinese medical journal, 2017, Oct-05, Volume: 130, Issue:19

    Topics: Adult; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Disease; Female; Hemorrhage; Human

2017
Risk stratification with the DAPT score: Carefully read the instructions and use as intended.
    Thrombosis and haemostasis, 2017, 10-05, Volume: 117, Issue:10

    Topics: Aspirin; Drug Therapy, Combination; Drug-Eluting Stents; Myocardial Infarction; Percutaneous Coronar

2017
Clopidogrel or ticagrelor in acute coronary syndrome patients treated with newer-generation drug-eluting stents: CHANGE DAPT.
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2017, Nov-20, Volume: 13, Issue:10

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery D

2017
Clinical characteristics and outcomes of patients with coronary artery spasm who initially presented with acute myocardial infarction.
    Coronary artery disease, 2018, Volume: 29, Issue:1

    Topics: Adult; Aged; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Dise

2018
[Clinical effectiveness and safety of ticagrelor in patients after PCI because of acute non ST segment elevation myocardial infarction].
    Zhonghua yi xue za zhi, 2017, Nov-21, Volume: 97, Issue:43

    Topics: Adenosine; Aspirin; China; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platel

2017
Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China.
    European journal of clinical pharmacology, 2018, Volume: 74, Issue:4

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Asian People; Chi-Square Distribution; China; Clinical Dec

2018
A clinical risk score to identify patients at high risk of very late stent thrombosis.
    Journal of interventional cardiology, 2018, Volume: 31, Issue:2

    Topics: Aspirin; Case-Control Studies; Female; Hemorrhage; Humans; Long Term Adverse Effects; Male; Middle A

2018
Nonsteroidal anti-inflammatory drug choice and adverse outcomes in clopidogrel users: A retrospective cohort study.
    PloS one, 2018, Volume: 13, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Brain Ischemia;

2018
Panax quinquefolius saponins combined with dual antiplatelet drug therapy alleviate gastric mucosal injury and thrombogenesis through the COX/PG pathway in a rat model of acute myocardial infarction.
    PloS one, 2018, Volume: 13, Issue:3

    Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aspirin; Blood Platelets; Clopidogrel; Cyclooxygenase 2; Gast

2018
Single and dual antiplatelet therapy in elderly patients of medically managed myocardial infarction.
    BMC geriatrics, 2018, 04-05, Volume: 18, Issue:1

    Topics: Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Drug Therapy, Combination; Electrocardiogra

2018
Acute myocardial infarction occurring while on chronic clopidogrel therapy ('clopidogrel failure') is associated with high incidence of clopidogrel poor responsiveness and stent thrombosis.
    PloS one, 2018, Volume: 13, Issue:4

    Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Female; Humans; Male; Middle Aged; My

2018
Platelet Function Analyzer-200 P2Y Results Are Predictive of the Risk of Major Adverse Cardiac Events in Korean Patients Receiving Clopidogrel Therapy Following Acute Coronary Syndrome.
    Annals of laboratory medicine, 2018, Volume: 38, Issue:5

    Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Female; Humans; Male; Middle Aged; Myoc

2018
Individual long-term variation of platelet reactivity in patients with dual antiplatelet therapy after myocardial infarction.
    Platelets, 2019, Volume: 30, Issue:5

    Topics: Adult; Aged; Blood Platelets; Clopidogrel; Electrocardiography; Female; Follow-Up Studies; Humans; M

2019
Secondary Stroke Prophylaxis with Clopidogrel Produces Sufficient Antiplatelet Response.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2018, Volume: 27, Issue:10

    Topics: Aged; Clopidogrel; Denmark; Drug Resistance; Female; Humans; Ischemic Attack, Transient; Male; Medic

2018
Comparison of the Effects of Ticagrelor and Clopidogrel on Inflammatory Factors, Vascular Endothelium Functions and Short-Term Prognosis in Patients with Acute ST-Segment Elevation Myocardial Infarction Undergoing Emergency Percutaneous Coronary Intervent
    Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2018, Volume: 48, Issue:1

    Topics: Adenosine; Adult; Aged; Biomarkers; C-Reactive Protein; Clopidogrel; Endothelium, Vascular; Female;

2018
Aspirin Plus Clopidogrel vs Aspirin Alone for Preventing Cardiovascular Events Among Patients at High Risk for Cardiovascular Events.
    JAMA, 2018, 08-14, Volume: 320, Issue:6

    Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocar

2018
The association between clopidogrel and 2-oxo-clopidogrel plasma levels and the long-term clinical outcome after acute myocardial infarction
.
    International journal of clinical pharmacology and therapeutics, 2019, Volume: 57, Issue:2

    Topics: Clopidogrel; Humans; Ischemia; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet A

2019
Efficacy of Antiplatelet Agent Usage for Primary and Secondary Prevention in Dialysis Patients: a Nationwide Data Survey and Propensity Analysis.
    Cardiovascular drugs and therapy, 2019, Volume: 33, Issue:4

    Topics: Aspirin; Clopidogrel; Cohort Studies; Female; Humans; Male; Middle Aged; Myocardial Infarction; Plat

2019
Adherence to Antiplatelet Therapy after Coronary Intervention among Patients with Myocardial Infarction Attending Vietnam National Heart Institute.
    BioMed research international, 2019, Volume: 2019

    Topics: Adult; Aspirin; Clopidogrel; Cross-Sectional Studies; Female; Heart; Humans; Income; Male; Medicatio

2019
Long-term outcome after angiographically proven coronary stent thrombosis.
    The American journal of cardiology, 2013, May-01, Volume: 111, Issue:9

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Drug-E

2013
Cardiac magnetic resonance detection of left ventricular thrombus in acute myocardial infarction.
    Acute cardiac care, 2013, Volume: 15, Issue:1

    Topics: Aged; Anticoagulants; Aspirin; Clopidogrel; Cohort Studies; Drug Therapy, Combination; Echocardiogra

2013
Duration of dual antiplatelet therapy after implantation of the first-generation and second-generation drug-eluting stents.
    Coronary artery disease, 2013, Volume: 24, Issue:3

    Topics: Aged; Aspirin; Cardiovascular Agents; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease;

2013
Low prevalence of clopidogrel and acetylsalicylic acid resistance in patients with acute myocardial infarction and pantoprazole treatment in everyday practice.
    International journal of cardiology, 2013, Sep-20, Volume: 168, Issue:1

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug

2013
Correlation of platelet reactivity and C-reactive protein levels to occurrence of peri-procedural myocardial infarction in patients undergoing percutaneous coronary intervention (from the ARMYDA-CRP study).
    The American journal of cardiology, 2013, Jun-15, Volume: 111, Issue:12

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Biomarkers; C-Reactive Protein; Clopi

2013
CYP2C19 phenotype, stent thrombosis, myocardial infarction, and mortality in patients with coronary stent placement in a Chinese population.
    PloS one, 2013, Volume: 8, Issue:3

    Topics: Aged; Alleles; Aryl Hydrocarbon Hydroxylases; Asian People; Clopidogrel; Cytochrome P-450 CYP2C19; F

2013
Questions and answers on treating acute myocardial infarction.
    The Journal of invasive cardiology, 2004, Volume: Suppl

    Topics: Cardiac Catheterization; Clopidogrel; Decision Making; Humans; Myocardial Infarction; Platelet Aggre

2004
Thrombocytosis as a potential cause of a very late stent thrombosis in the left main coronary artery.
    Kardiologia polska, 2013, Volume: 71, Issue:3

    Topics: Adult; Clopidogrel; Coronary Angiography; Coronary Stenosis; Coronary Thrombosis; Drug-Eluting Stent

2013
Antiplatelet therapy. Cangrelor succeeds, at last, in PCI.
    Nature reviews. Cardiology, 2013, Volume: 10, Issue:6

    Topics: Adenosine Monophosphate; Administration, Intravenous; Administration, Oral; Blood Platelets; Clopido

2013
Clopidogrel pretreatment in primary percutaneous coronary intervention: prevalence of high on-treatment platelet reactivity and impact on preprocedural patency of the infarct-related artery.
    Thrombosis and haemostasis, 2013, Volume: 110, Issue:1

    Topics: Arteries; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Corona

2013
Newly identified synergy between clopidogrel and calcium-channel blockers for blood pressure regulation possibly involves CYP2C19 rs4244285.
    International journal of cardiology, 2013, Oct-03, Volume: 168, Issue:3

    Topics: Adult; Aged; Angina, Unstable; Aryl Hydrocarbon Hydroxylases; Blood Pressure; Calcium Channel Blocke

2013
Abciximab bolus with optional infusion in intervention for ST-elevation myocardial infarction.
    Scandinavian cardiovascular journal : SCJ, 2013, Volume: 47, Issue:4

    Topics: Abciximab; Aged; Aged, 80 and over; Antibodies, Monoclonal; Clopidogrel; Coronary Thrombosis; Cost S

2013
ED administration of thienopyridines in non-ST-segment elevation myocardial infarction: results from the NCDR.
    The American journal of emergency medicine, 2013, Volume: 31, Issue:7

    Topics: Aged; Clopidogrel; Drug Administration Schedule; Emergency Service, Hospital; Female; Hemorrhage; Ho

2013
Should alcohol be considered a minor protective factor for unprovoked venous thromboembolism?
    Thrombosis and haemostasis, 2013, Volume: 110, Issue:1

    Topics: Arteries; Clopidogrel; Female; Humans; Male; Myocardial Infarction; Percutaneous Coronary Interventi

2013
Modern antiplatelet management of coronary artery bypass patients: a role of platelet function testing in decision making.
    Journal of thrombosis and thrombolysis, 2014, Volume: 37, Issue:3

    Topics: Coronary Angiography; Coronary Artery Bypass; Female; Humans; Male; Myocardial Infarction; Platelet

2014
Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention.
    Journal of the American College of Cardiology, 2013, Sep-10, Volume: 62, Issue:11

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopido

2013
Predictors of myocardial infarction after an acute coronary syndrome with clopidogrel and prasugrel.
    The American journal of emergency medicine, 2013, Volume: 31, Issue:8

    Topics: Acute Coronary Syndrome; Clopidogrel; Follow-Up Studies; Humans; Myocardial Infarction; Piperazines;

2013
Upstream antiactivation antiplatelet therapy: first, do no harm. Then consider doing some good.
    The American journal of emergency medicine, 2013, Volume: 31, Issue:9

    Topics: Emergency Service, Hospital; Female; Humans; Male; Myocardial Infarction; Piperazines; Platelet Aggr

2013
[Relevance of CYP2C19 2 regarding platelet reactivity in patients with acute coronary syndrome treated with clopidogrel].
    Medicina clinica, 2014, Jul-07, Volume: 143, Issue:1

    Topics: Acute Coronary Syndrome; Aged; Alleles; Angina, Unstable; Aryldialkylphosphatase; Biotransformation;

2014
The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation.
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2013, Volume: 9, Issue:3

    Topics: Acute Coronary Syndrome; Aged; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subf

2013
Use of clopidogrel and proton pump inhibitors after a serious acute coronary event: risk of coronary events and peptic ulcer bleeding.
    Thrombosis and haemostasis, 2013, Volume: 110, Issue:5

    Topics: Aged; Aged, 80 and over; Case-Control Studies; Clopidogrel; Cohort Studies; Coronary Vessels; Drug I

2013
Optimal anticoagulation during off pump coronary artery bypass in patients recently exposed to clopidogrel.
    Yonsei medical journal, 2013, Volume: 54, Issue:5

    Topics: Age Factors; Aged; Anastomosis, Surgical; Blood Loss, Surgical; Blood Transfusion; Clopidogrel; Coro

2013
Impact of the CYP2C19*17 polymorphism on the clinical outcome of clopidogrel therapy in Asian patients undergoing percutaneous coronary intervention.
    Pharmacogenetics and genomics, 2013, Volume: 23, Issue:10

    Topics: Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Administration S

2013
A comparative study of bivalirudin plus clopidogrel versus bivalirudin plus prasugrel in primary angioplasty using propensity score matching.
    Journal of interventional cardiology, 2013, Volume: 26, Issue:5

    Topics: Angioplasty; Antithrombins; Clopidogrel; Cohort Studies; Drug Combinations; Female; Hirudins; Humans

2013
TRILOGY ACS: prasugrel of benefit only after angiography?
    Lancet (London, England), 2013, Aug-17, Volume: 382, Issue:9892

    Topics: Angina, Unstable; Clopidogrel; Female; Humans; Male; Myocardial Infarction; Piperazines; Platelet Ag

2013
Pharmacodynamic effect of clopidogrel in patients undergoing transcatheter aortic valve implantation.
    BioMed research international, 2013, Volume: 2013

    Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aortic Valve; Blood Platelets; Blood Vessel Prosth

2013
Acute myocardial infarction in pregnancy following unlicensed use of methylenedioxymethamphetamine ('Ecstasy').
    Scottish medical journal, 2013, Volume: 58, Issue:3

    Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic Uptake Inhibitors; Adult; Aspirin; Bisoprolol; Ch

2013
Antiplatelet effect of thienopyridine (clopidogrel or prasugrel) pretreatment in patients undergoing primary percutaneous intervention for ST elevation myocardial infarction.
    The American journal of cardiology, 2013, Nov-15, Volume: 112, Issue:10

    Topics: Clopidogrel; Coronary Angiography; Dose-Response Relationship, Drug; Drug Therapy, Combination; Elec

2013
Efficacy and safety of aspirin, clopidogrel, and warfarin after coronary artery stenting in Korean patients with atrial fibrillation.
    Heart and vessels, 2014, Volume: 29, Issue:5

    Topics: Aged; Anticoagulants; Asian People; Aspirin; Atrial Fibrillation; Blood Coagulation; Clopidogrel; Co

2014
Effects of clopidogrel on mortality, cardiovascular and bleeding outcomes in patients with chronic kidney disease - data from Taiwan acute coronary syndrome full spectrum registry.
    PloS one, 2013, Volume: 8, Issue:8

    Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Female; Hemorrhage; Humans; Kaplan-Me

2013
Stratified reporting of high sensitivity troponin I assay is associated with suboptimal management of patients with acute coronary syndrome and intermediate troponin elevation.
    Journal of clinical laboratory analysis, 2013, Volume: 27, Issue:5

    Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Clopidogrel; Cohort Studies; Coronary Angiography; Fe

2013
Comparison of the degree of platelet aggregation inhibition with prasugrel versus clopidogrel and clinical outcomes in patients with unprotected left main disease treated with everolimus-eluting stents.
    The American journal of cardiology, 2013, Dec-15, Volume: 112, Issue:12

    Topics: Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Everolimus; Fema

2013
Predictors of 1-year outcomes in the Taiwan Acute Coronary Syndrome Full Spectrum Registry.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2014, Volume: 113, Issue:11

    Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug-Eluting Stents; Female; Follow-Up Studies;

2014
[The CHAMPION PHOENIX study].
    Giornale italiano di cardiologia (2006), 2013, Volume: 14, Issue:10

    Topics: Adenosine Monophosphate; Clopidogrel; Coronary Restenosis; Coronary Stenosis; Coronary Thrombosis; D

2013
[Primary angioplasty in a patient with acute inferior myocardial infarction: the unexpected trap].
    Giornale italiano di cardiologia (2006), 2013, Volume: 14, Issue:10

    Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aortography; Aspirin; Cardiac Catheterization; Clopi

2013
[What kind of antiplatelet treatment in acute coronary syndrome?--Intensive antiplatelet treatment only for patients with invasive strategy].
    Deutsche medizinische Wochenschrift (1946), 2013, Volume: 138, Issue:45

    Topics: Angina, Unstable; Female; Humans; Male; Myocardial Infarction; Piperazines; Platelet Aggregation Inh

2013
Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
    Thrombosis and haemostasis, 2014, Volume: 111, Issue:2

    Topics: Adenosine; Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Drug Design; Female; Germany; Huma

2014
Discontinuation of secondary prevention medication after myocardial infarction - the role of general practitioners and patients.
    Swiss medical weekly, 2013, Volume: 143

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angio

2013
Monitoring persistent platelet reactivity in patients with unprotected left main stenting.
    Journal of interventional cardiology, 2013, Volume: 26, Issue:6

    Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inh

2013
Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease.
    JACC. Cardiovascular interventions, 2013, Volume: 6, Issue:11

    Topics: Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Biotransformation; Clopidogrel; Coronary Artery Diseas

2013
Platelet and leukocyte ROS production and lipoperoxidation are associated with high platelet reactivity in Non-ST elevation myocardial infarction (NSTEMI) patients on dual antiplatelet treatment.
    Atherosclerosis, 2013, Volume: 231, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Cell Separation; Clopidogrel; Drug Adminis

2013
Disbalance between mortality and non-fatal vascular events in the CHAMPION-PHOENIX trial: the cangrelor efficacy challenge.
    Thrombosis and haemostasis, 2014, Volume: 111, Issue:1

    Topics: Adenosine Monophosphate; Blood Platelets; Clopidogrel; Data Interpretation, Statistical; Humans; Myo

2014
A patient with HIV and tuberculosis with diminished clopidogrel response.
    International journal of STD & AIDS, 2014, Volume: 25, Issue:7

    Topics: Antitubercular Agents; Clopidogrel; Drug Interactions; Drug Resistance; HIV Infections; HIV Protease

2014
High on clopidogrel treatment platelet reactivity is frequent in acute and rare in elective stenting and can be functionally overcome by switch of therapy.
    Thrombosis research, 2014, Volume: 133, Issue:2

    Topics: Aged; Blood Platelets; Clopidogrel; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial

2014
Impact of mild hypothermia on platelet responsiveness to aspirin and clopidogrel: an in vitro pharmacodynamic investigation.
    Journal of cardiovascular translational research, 2014, Volume: 7, Issue:1

    Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Female;

2014
Risk factors for acute gastrointestinal bleeding following myocardial infarction in veteran patients who are prescribed clopidogrel.
    Journal of digestive diseases, 2014, Volume: 15, Issue:4

    Topics: Acute Disease; Age Factors; Aged; Anticoagulants; Chronic Disease; Clopidogrel; Female; Gastrointest

2014
Residual thrombin generation potential is inversely linked to the occurrence of atherothrombotic events in patients with peripheral arterial disease.
    European journal of clinical investigation, 2014, Volume: 44, Issue:3

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Blood Platelets; Cardiovascular Diseases; Clopidogrel

2014
Increased risk for developing major adverse cardiovascular events in stented Chinese patients treated with dual antiplatelet therapy after concomitant use of the proton pump inhibitor.
    PloS one, 2014, Volume: 9, Issue:1

    Topics: Aged; Angioplasty, Balloon, Coronary; Asian People; Aspirin; Clopidogrel; Drug Combinations; Female;

2014
Cost-effectiveness of optimal use of acute myocardial infarction treatments and impact on coronary heart disease mortality in China.
    Circulation. Cardiovascular quality and outcomes, 2014, Volume: 7, Issue:1

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitor

2014
Antiplatelet therapy in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: a retrospective observational study of prasugrel and clopidogrel.
    Cardiovascular therapeutics, 2014, Volume: 32, Issue:1

    Topics: Adult; Aged; Clopidogrel; Electrocardiography; Female; Hospital Mortality; Humans; Male; Middle Aged

2014
Reply to Rubino et al.
    European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 2014, Volume: 46, Issue:2

    Topics: Aspirin; Coronary Artery Bypass; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation I

2014
Immune thrombocytopenic purpura and myocardial infarction: a dilemma of management.
    The Israel Medical Association journal : IMAJ, 2013, Volume: 15, Issue:12

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Disease Management; Fema

2013
Temporary adjunctive cilostazol vs clopidogrel loading for ST-segment elevation acute myocardial infarction.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2014, Volume: 14, Issue:2

    Topics: Acute Disease; Aged; Cilostazol; Clopidogrel; Electrocardiography; Female; Humans; Male; Middle Aged

2014
Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study.
    Circulation, 2014, Apr-15, Volume: 129, Issue:15

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Cohort Studies;

2014
Spontaneous omental bleeding in the setting of dual anti-platelet therapy with ticagrelor.
    Heart, lung & circulation, 2014, Volume: 23, Issue:4

    Topics: Adenosine; Aged; Aspirin; Clopidogrel; Gastrointestinal Hemorrhage; Humans; Male; Myocardial Infarct

2014
Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel.
    Journal of the American College of Cardiology, 2014, Mar-25, Volume: 63, Issue:11

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel; Combined

2014
Positive clinical response to clopidogrel is independent of paraoxonase 1 Q192R and CYP2C19 genetic variants.
    Journal of clinical pharmacology, 2014, Volume: 54, Issue:8

    Topics: Aged; Alleles; Angina Pectoris; Aryldialkylphosphatase; Aspirin; Clopidogrel; Cohort Studies; Corona

2014
Factor XIII Val34Leu polymorphism and recurrent myocardial infarction in patients with coronary artery disease.
    Journal of thrombosis and thrombolysis, 2014, Volume: 38, Issue:3

    Topics: Adult; Aged; Amino Acid Substitution; Aspirin; Clopidogrel; Coronary Artery Disease; Factor XIII; Fe

2014
Association of upstream clopidogrel administration and myocardial reperfusion assessed by cardiac magnetic resonance imaging in patients with ST-elevation myocardial infarction.
    European heart journal. Acute cardiovascular care, 2014, Volume: 3, Issue:2

    Topics: Aged; Cardiac Catheterization; Clopidogrel; Female; Humans; Magnetic Resonance Angiography; Male; Mi

2014
Impact of preoperative antiplatelet therapy on in-hospital outcomes after coronary artery bypass grafting.
    European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 2014, Volume: 46, Issue:2

    Topics: Aspirin; Coronary Artery Bypass; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation I

2014
Clopidogrel resistance in diabetic patient with acute myocardial infarction due to stent thrombosis.
    The American journal of emergency medicine, 2014, Volume: 32, Issue:5

    Topics: Aged, 80 and over; Aspirin; Clopidogrel; Coronary Angiography; Diabetes Mellitus, Type 2; Drug Resis

2014
Cilostazol in acute myocardial infarction: new tricks for an old drug?
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2014, Volume: 14, Issue:2

    Topics: Cilostazol; Clopidogrel; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitor

2014
Estimating the effects of time-varying exposures in observational studies using Cox models with stabilized weights adjustment.
    Pharmacoepidemiology and drug safety, 2014, Volume: 23, Issue:8

    Topics: Clopidogrel; Confounding Factors, Epidemiologic; Drug-Eluting Stents; Electronic Health Records; Hem

2014
Safer heart-attack prevention for seniors with revised drug regimen. Half the normal dose of prasugrel, a lifesaving medication, is just as effective as the larger dose, and reduces risk of serious side effects.
    DukeMedicine healthnews, 2013, Volume: 19, Issue:11

    Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Middle Aged; Myocardial Infarction; P

2013
Point-of-care testing of clopidogrel-mediated platelet inhibition and risk for cardiovascular events after coronary angiography with or without percutaneous coronary intervention.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2014, Volume: 25, Issue:6

    Topics: Adenosine Diphosphate; Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Angiography; Female; Hu

2014
Triple versus dual antiplatelet therapy after percutaneous coronary intervention for coronary bifurcation lesions: results from the COBIS (COronary BIfurcation Stent) II Registry.
    Heart and vessels, 2015, Volume: 30, Issue:4

    Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy,

2015
We need to do better for patients with non-ST-segment elevation acute coronary syndrome who are managed without revascularization.
    Journal of the American College of Cardiology, 2014, Jun-03, Volume: 63, Issue:21

    Topics: Angina, Unstable; Clopidogrel; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inh

2014
Comparative effectiveness of clopidogrel in medically managed patients with unstable angina and non-ST-segment elevation myocardial infarction.
    Journal of the American College of Cardiology, 2014, Jun-03, Volume: 63, Issue:21

    Topics: Aged; Angina, Unstable; Clopidogrel; Cohort Studies; Disease Management; Female; Follow-Up Studies;

2014
A cautionary tale on the use of antiplatelet treatment following TURP.
    BMJ case reports, 2014, Apr-04, Volume: 2014

    Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Hematuria; Humans; Male; Myoca

2014
Controversies in acute cardiovascular care.
    European heart journal, 2014, Volume: 35, Issue:9

    Topics: Adenosine; Clinical Trials as Topic; Clopidogrel; Emergency Medical Services; Humans; Myocardial Inf

2014
Early clopidogrel versus prasugrel use among contemporary STEMI and NSTEMI patients in the US: insights from the National Cardiovascular Data Registry.
    Journal of the American Heart Association, 2014, Apr-14, Volume: 3, Issue:2

    Topics: Aged; Clopidogrel; Drug Administration Schedule; Drug Utilization Review; Female; Guideline Adherenc

2014
Subacute bioresorbable vascular scaffold thrombosis: a report of 2 cases.
    Heart and vessels, 2015, Volume: 30, Issue:4

    Topics: Absorbable Implants; Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Stenosis;

2015
Cytochrome p450 gene variants, race, and mortality among clopidogrel-treated patients after acute myocardial infarction.
    Circulation. Cardiovascular genetics, 2014, Volume: 7, Issue:3

    Topics: Adult; Aged; Black People; Clopidogrel; Cohort Studies; Cytochrome P-450 CYP1A2; Cytochrome P-450 CY

2014
Thrombotic and bleeding events after coronary stenting according to clopidogrel and aspirin platelet reactivity: VerifyNow French Registry (VERIFRENCHY).
    Archives of cardiovascular diseases, 2014, Volume: 107, Issue:4

    Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Female; France; Hemorrha

2014
Pharmacologic strategy for one repeated stent thrombosis patient with hyporesponsiveness to standard dual antiplatelet therapy.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2015, Volume: 114, Issue:10

    Topics: Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Electrocardiography; Huma

2015
Acute coronary thrombosis and multiple coronary aneurysms in a 22-year-old man with the human immunodeficiency virus.
    Texas Heart Institute journal, 2014, Volume: 41, Issue:2

    Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Aneurysm; Coronary An

2014
Development of a multiplex and cost-effective genotype test toward more personalized medicine for the antiplatelet drug clopidogrel.
    International journal of molecular sciences, 2014, May-05, Volume: 15, Issue:5

    Topics: Asian People; Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Genotyping Techniques; Humans; Multip

2014
Delay in filling first clopidogrel prescription after coronary stenting is associated with an increased risk of death and myocardial infarction.
    Journal of the American Heart Association, 2014, May-28, Volume: 3, Issue:3

    Topics: Aged; Clopidogrel; Drug-Eluting Stents; Female; Humans; Male; Medication Adherence; Middle Aged; Myo

2014
Improving outcomes with bivalirudin in primary percutaneous coronary intervention.
    European heart journal, 2014, Sep-07, Volume: 35, Issue:34

    Topics: Anticoagulants; Clopidogrel; Heparin; Hirudins; Humans; Male; Myocardial Infarction; Peptide Fragmen

2014
Posttreatment platelet reactivity on clopidogrel is associated with the risk of adverse events after off-pump coronary artery bypass.
    American heart journal, 2014, Volume: 167, Issue:6

    Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Cohort Studies; Coronary Artery Bypass, Off-Pump; Coron

2014
The quality of antiplatelet and anticoagulant medication administration among ST-segment elevation myocardial infarction patients transferred for primary percutaneous coronary intervention.
    American heart journal, 2014, Volume: 167, Issue:6

    Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Cohort Studies; Early Me

2014
Cholesterol embolization syndrome with an atypical proximal presentation simulating calciphylaxis.
    JAMA dermatology, 2014, Volume: 150, Issue:8

    Topics: Aspirin; Back; Buttocks; Calciphylaxis; Cardiac Catheterization; Clopidogrel; Diagnosis, Differentia

2014
Risk and benefit of dual antiplatelet treatment among non-revascularized myocardial infarction patients in different age groups.
    European heart journal. Acute cardiovascular care, 2017, Volume: 6, Issue:6

    Topics: Age Distribution; Age Factors; Aged; Aspirin; Cause of Death; Clopidogrel; Denmark; Drug Therapy, Co

2017
Uncovering the shroud on antiplatelet therapy for patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.
    JACC. Cardiovascular interventions, 2014, Volume: 7, Issue:6

    Topics: Clopidogrel; Electrocardiography; Female; Humans; Male; Myocardial Infarction; Percutaneous Coronary

2014
Early ambulance initiation versus in-hospital initiation of high dose clopidogrel in ST-segment elevation myocardial infarction.
    Thrombosis and haemostasis, 2014, Sep-02, Volume: 112, Issue:3

    Topics: Aged; Clopidogrel; Cohort Studies; Electrocardiography; Emergency Medical Services; Emergency Servic

2014
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
    Lancet (London, England), 2015, 01-31, Volume: 385, Issue:9966

    Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor

2015
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
    Lancet (London, England), 2015, 01-31, Volume: 385, Issue:9966

    Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor

2015
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
    Lancet (London, England), 2015, 01-31, Volume: 385, Issue:9966

    Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor

2015
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
    Lancet (London, England), 2015, 01-31, Volume: 385, Issue:9966

    Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor

2015
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
    Lancet (London, England), 2015, 01-31, Volume: 385, Issue:9966

    Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor

2015
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
    Lancet (London, England), 2015, 01-31, Volume: 385, Issue:9966

    Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor

2015
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
    Lancet (London, England), 2015, 01-31, Volume: 385, Issue:9966

    Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor

2015
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
    Lancet (London, England), 2015, 01-31, Volume: 385, Issue:9966

    Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor

2015
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
    Lancet (London, England), 2015, 01-31, Volume: 385, Issue:9966

    Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor

2015
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
    Lancet (London, England), 2015, 01-31, Volume: 385, Issue:9966

    Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor

2015
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
    Lancet (London, England), 2015, 01-31, Volume: 385, Issue:9966

    Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor

2015
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
    Lancet (London, England), 2015, 01-31, Volume: 385, Issue:9966

    Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor

2015
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
    Lancet (London, England), 2015, 01-31, Volume: 385, Issue:9966

    Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor

2015
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
    Lancet (London, England), 2015, 01-31, Volume: 385, Issue:9966

    Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor

2015
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
    Lancet (London, England), 2015, 01-31, Volume: 385, Issue:9966

    Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor

2015
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
    Lancet (London, England), 2015, 01-31, Volume: 385, Issue:9966

    Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor

2015
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
    Lancet (London, England), 2015, 01-31, Volume: 385, Issue:9966

    Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor

2015
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
    Lancet (London, England), 2015, 01-31, Volume: 385, Issue:9966

    Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor

2015
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
    Lancet (London, England), 2015, 01-31, Volume: 385, Issue:9966

    Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor

2015
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
    Lancet (London, England), 2015, 01-31, Volume: 385, Issue:9966

    Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor

2015
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
    Lancet (London, England), 2015, 01-31, Volume: 385, Issue:9966

    Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor

2015
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
    Lancet (London, England), 2015, 01-31, Volume: 385, Issue:9966

    Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor

2015
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
    Lancet (London, England), 2015, 01-31, Volume: 385, Issue:9966

    Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor

2015
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
    Lancet (London, England), 2015, 01-31, Volume: 385, Issue:9966

    Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor

2015
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
    Lancet (London, England), 2015, 01-31, Volume: 385, Issue:9966

    Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor

2015
Clinical outcomes associated with proton pump inhibitor use among clopidogrel-treated patients within CYP2C19 genotype groups following acute myocardial infarction.
    The pharmacogenomics journal, 2015, Volume: 15, Issue:1

    Topics: Adult; Aged; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genotype; Humans; Male; Middle Aged; Myo

2015
Chronic treatment with ticagrelor limits myocardial infarct size: an adenosine and cyclooxygenase-2-dependent effect.
    Arteriosclerosis, thrombosis, and vascular biology, 2014, Volume: 34, Issue:9

    Topics: 6-Ketoprostaglandin F1 alpha; Adenosine; Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor An

2014
An atypical presentation of an extremely late stent thrombosis after more than 7 years (2634 days) of DES implantation in a patient without obvious risk factors on regular dual antiplatelet therapy.
    BMJ case reports, 2014, Jul-15, Volume: 2014

    Topics: Aspirin; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Drug Therapy, Combination; Drug-Elu

2014
Real-world observations with prasugrel compared to clopidogrel in acute coronary syndrome patients treated with percutaneous coronary intervention in the United States.
    Current medical research and opinion, 2014, Volume: 30, Issue:11

    Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Hemorrhage; Hospitalization; Humans; Male; Middl

2014
In-hospital switching between clopidogrel and prasugrel among patients with acute myocardial infarction treated with percutaneous coronary intervention: insights into contemporary practice from the national cardiovascular data registry.
    Circulation. Cardiovascular interventions, 2014, Volume: 7, Issue:4

    Topics: Acute Disease; Age Factors; Aged; Clopidogrel; Drug Substitution; Female; Humans; Male; Middle Aged;

2014
Optimizing human apyrase to treat arterial thrombosis and limit reperfusion injury without increasing bleeding risk.
    Science translational medicine, 2014, Aug-06, Volume: 6, Issue:248

    Topics: Adenosine Diphosphate; Animals; Apyrase; Clopidogrel; Coronary Circulation; Dogs; Fibrinolysis; Hemo

2014
Clopidogrel discontinuation within the first year after coronary drug-eluting stent implantation: an observational study.
    BMC cardiovascular disorders, 2014, Aug-13, Volume: 14

    Topics: Aged; Clopidogrel; Coronary Thrombosis; Denmark; Drug Administration Schedule; Drug Prescriptions; D

2014
Residual platelet reactivity after clopidogrel loading in ST-elevation myocardial infarction patients undergoing a delayed catheterization. Impact on long term clinical events.
    International journal of cardiology, 2014, Oct-20, Volume: 176, Issue:3

    Topics: Aged; Blood Platelets; Cardiac Catheterization; Clopidogrel; Female; Follow-Up Studies; Humans; Long

2014
Global platelet hyperreactivity and elevated C-reactive protein levels predict long term mortality in STEMI patients.
    Thrombosis research, 2014, Volume: 134, Issue:4

    Topics: Aged; Aspirin; Blood Platelets; C-Reactive Protein; Clopidogrel; Female; Follow-Up Studies; Humans;

2014
Reanalysis or redefinition of the hypothesis?
    European heart journal, 2015, Feb-07, Volume: 36, Issue:6

    Topics: Angina, Unstable; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasu

2015
Benefit of clopidogrel therapy in patients with myocardial infarction and chronic kidney disease-a Danish nation-wide cohort study.
    Journal of the American Heart Association, 2014, Aug-21, Volume: 3, Issue:4

    Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Case-Control Studies; Clopidogrel; Cohort Studies;

2014
Effects of new regional cooperative rescue model on patients with ST-elevation myocardial infarction.
    International journal of cardiology, 2014, Dec-15, Volume: 177, Issue:2

    Topics: Aged; Aspirin; Clopidogrel; Electrocardiography; Emergency Medical Services; Female; Follow-Up Studi

2014
Clopidogrel prescription filling delays and cardiovascular outcomes in a pharmacy system integrating inpatient and outpatient care: insights from the Veterans Affairs CART Program.
    American heart journal, 2014, Volume: 168, Issue:3

    Topics: Adult; Aged; Clopidogrel; Female; Hospitals, Veterans; Humans; Male; Middle Aged; Myocardial Infarct

2014
Validation of acute myocardial infarction cases in the national health insurance research database in taiwan.
    Journal of epidemiology, 2014, Volume: 24, Issue:6

    Topics: Aged; Aged, 80 and over; Aspirin; Clinical Coding; Clopidogrel; Cross-Sectional Studies; Databases,

2014
Prasugrel vs clopidogrel in cardiogenic shock patients undergoing primary PCI for acute myocardial infarction. Results of the ISAR-SHOCK registry.
    Thrombosis and haemostasis, 2014, Volume: 112, Issue:6

    Topics: Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Coronary Thrombosis; Female; Germany; Hemorrh

2014
Time-related changes in determinants of antiplatelet effect of clopidogrel in patients after myocardial infarction.
    European journal of pharmacology, 2014, Nov-05, Volume: 742

    Topics: Adenosine Diphosphate; Aged; Clopidogrel; Female; Follow-Up Studies; Humans; Male; Medication Adhere

2014
Changes in thrombus composition and profilin-1 release in acute myocardial infarction.
    European heart journal, 2015, Apr-21, Volume: 36, Issue:16

    Topics: Analysis of Variance; Blood Platelets; Clopidogrel; Coronary Thrombosis; Female; Fibrinogen; Humans;

2015
Clopidogrel bioactivation and risk of bleeding in patients cotreated with angiotensin-converting enzyme inhibitors after myocardial infarction: a proof-of-concept study.
    Clinical pharmacology and therapeutics, 2014, Volume: 96, Issue:6

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Biotransformation; Carboxylic Ester Hydrolases; Clop

2014
Assessment of the prophylactic role of aspirin and/or clopidogrel on experimentally induced acute myocardial infarction in hypercholesterolemic rats.
    Drugs in R&D, 2014, Volume: 14, Issue:4

    Topics: Animals; Aspirin; C-Reactive Protein; Cholesterol; Clopidogrel; Creatine Kinase; Diet, High-Fat; Dru

2014
Impact of gene polymorphisms, platelet reactivity, and the SYNTAX score on 1-year clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention: the GEPRESS study.
    JACC. Cardiovascular interventions, 2014, Volume: 7, Issue:10

    Topics: Acute Coronary Syndrome; Aged; Biotransformation; Blood Platelets; Clopidogrel; Coronary Angiography

2014
Does baseline hematocrit influence the assays of on-treatment platelet reactivity to clopidogrel?
    American heart journal, 2014, Volume: 168, Issue:4

    Topics: Aged; Blood Platelets; Clopidogrel; Elective Surgical Procedures; Female; Follow-Up Studies; Hematoc

2014
Spontaneous coronary artery dissection: a complete resolution with medical treatment.
    BMJ case reports, 2014, Oct-15, Volume: 2014

    Topics: Adult; Aspirin; Clopidogrel; Coronary Angiography; Coronary Vessel Anomalies; Fibrinolytic Agents; H

2014
Very late bioresorbable vascular scaffold thrombosis following discontinuation of antiplatelet therapy.
    European heart journal, 2015, Feb-07, Volume: 36, Issue:6

    Topics: Absorbable Implants; Adenosine; Adult; Aspirin; Blood Vessel Prosthesis; Clopidogrel; Graft Occlusio

2015
Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry.
    BMJ open, 2014, Oct-31, Volume: 4, Issue:10

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets;

2014
Roles of the red cell distribution width and neutrophil/lymphocyte ratio in predicting thrombolysis failure in patients with an ST-segment elevation myocardial infarction.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2015, Volume: 26, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; Electrocardiography; Er

2015
Stent thrombosis is the primary cause of ST-segment elevation myocardial infarction following coronary stent implantation: a five year follow-up of the SORT OUT II study.
    PloS one, 2014, Volume: 9, Issue:11

    Topics: Aged; Angina, Stable; Clopidogrel; Cohort Studies; Drug-Eluting Stents; Female; Follow-Up Studies; H

2014
Tailored antiplatelet therapy in a patient with ITP and clopidogrel resistance.
    Thrombosis and haemostasis, 2015, Volume: 113, Issue:3

    Topics: Adenosine; Clopidogrel; Coronary Thrombosis; Drug Resistance; Drug Substitution; Humans; Male; Middl

2015
Web Exclusives. The consult guys--balancing the medication portfolio 5 years after a heart attack.
    Annals of internal medicine, 2014, 12-16, Volume: 161, Issue:12

    Topics: Adrenergic beta-1 Receptor Antagonists; Aspirin; Clopidogrel; Drug Therapy, Combination; Evidence-Ba

2014
In-hospital switching between adenosine diphosphate receptor inhibitors in patients with acute myocardial infarction treated with percutaneous coronary intervention: Insights into contemporary practice from the TRANSLATE-ACS study.
    European heart journal. Acute cardiovascular care, 2015, Volume: 4, Issue:6

    Topics: Adenosine; Aged; Clopidogrel; Drug Substitution; Female; Humans; Kaplan-Meier Estimate; Male; Middle

2015
A pharmacodynamic comparison of 5 anti-platelet protocols in patients with ST-elevation myocardial infarction undergoing primary PCI.
    BMC cardiovascular disorders, 2014, Dec-16, Volume: 14

    Topics: Adenosine; Aged; Blood Platelets; Clinical Protocols; Clopidogrel; Drug Administration Schedule; Ele

2014
Discrepancies in assessment of adherence to antiplatelet treatment after myocardial infarction.
    Pharmacology, 2015, Volume: 95, Issue:1-2

    Topics: Adenosine Diphosphate; Clopidogrel; Female; Humans; Male; Medication Adherence; Middle Aged; Myocard

2015
Acute coronary syndromes and coronary intervention.
    European heart journal, 2015, Feb-07, Volume: 36, Issue:6

    Topics: Angina, Unstable; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasu

2015
Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent in patients with acute myocardial infarction.
    International journal of cardiology, 2015, Mar-15, Volume: 183

    Topics: Absorbable Implants; Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Everolimu

2015
Serial changes of mean platelet volume in relation to Killip Class in patients with acute myocardial infarction and primary percutaneous coronary intervention.
    Thrombosis research, 2015, Volume: 135, Issue:4

    Topics: Acute Disease; Clopidogrel; Echocardiography; Female; Humans; Male; Mean Platelet Volume; Middle Age

2015
How should I treat subacute stent thrombosis in the context of brain haemorrhage with abciximab?
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2015, Volume: 10, Issue:10

    Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Cerebral Hemorrhage; Clopidogrel; Embolic Protection Dev

2015
Thrombotic complications associated with early and late nonadherence to dual antiplatelet therapy.
    JACC. Cardiovascular interventions, 2015, Volume: 8, Issue:3

    Topics: Aged; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; D

2015
Plasma fibrin clot phenotype independently affects intracoronary thrombus ultrastructure in patients with acute myocardial infarction.
    Thrombosis and haemostasis, 2015, Volume: 113, Issue:6

    Topics: Aged; Aspirin; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Thrombosis; Coronary

2015
Optimal antiplatelet therapy in out-hospital cardiac arrest patients treated by primary percutaneous coronary intervention.
    Resuscitation, 2015, Volume: 90

    Topics: Female; Heart Arrest; Humans; Hypothermia, Induced; Male; Myocardial Infarction; Percutaneous Corona

2015
Aspirin 'resistance': impact on no-reflow, platelet and inflammatory biomarkers in diabetics after ST-segment elevation myocardial infarction.
    Cardiology, 2015, Volume: 131, Issue:1

    Topics: Aged; Aspirin; Biomarkers; Clopidogrel; Diabetes Complications; Drug Resistance; Female; Humans; Inf

2015
Impact of prolonged dual antiplatelet therapy after acute myocardial infarction on 5-year mortality in the FAST-MI 2005 registry.
    International journal of cardiology, 2015, Volume: 187

    Topics: Aged; Aspirin; Clopidogrel; Drug-Eluting Stents; Female; Humans; Male; Myocardial Infarction; Platel

2015
Dual antiplatelet therapy after acute coronary syndrome: a cardiologist-based optimal decision.
    Heart (British Cardiac Society), 2015, Volume: 101, Issue:11

    Topics: Female; Humans; Male; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Purinergi

2015
Delayed clopidogrel transit during myocardial infarction evident on angiography.
    The Journal of invasive cardiology, 2015, Volume: 27, Issue:5

    Topics: Administration, Oral; Clopidogrel; Coronary Angiography; Dose-Response Relationship, Drug; Electroca

2015
The impact of therapeutic hypothermia on on-treatment platelet reactivity and clinical outcome in cardiogenic shock patients undergoing primary PCI for acute myocardial infarction: Results from the ISAR-SHOCK registry.
    Thrombosis research, 2015, Volume: 136, Issue:1

    Topics: Acute Disease; Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Female; Humans; Hypothermia, I

2015
A population-based study of the drug interaction between clopidogrel and angiotensin converting enzyme inhibitors.
    British journal of clinical pharmacology, 2015, Volume: 80, Issue:4

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Case-Control Studies; Clopidogrel; Databases, Factua

2015
Cardioembolic acute myocardial infarction associated with apical ballooning: Considerations.
    International journal of cardiology, 2015, Aug-01, Volume: 192

    Topics: Aged, 80 and over; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Echocardiog

2015
Very late bioresorbable vascular scaffold thrombosis: a new clinical entity.
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2015, May-19, Volume: 11, Issue:1

    Topics: Absorbable Implants; Aged, 80 and over; Anterior Wall Myocardial Infarction; Brachytherapy; Clopidog

2015
ACP Journal Club. Review: In patients having PCI, high-dose clopidogrel reduces major cardiac events vs standard-dose clopidogrel.
    Annals of internal medicine, 2015, May-19, Volume: 162, Issue:10

    Topics: Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors;

2015
Unfractionated heparin-clopidogrel combination in ST-elevation myocardial infarction not receiving reperfusion therapy.
    Atherosclerosis, 2015, Volume: 241, Issue:1

    Topics: Aged; Anticoagulants; Clopidogrel; Drug Therapy, Combination; Enoxaparin; Europe; Female; Fibrinolyt

2015
Prehospital administration of P2Y12 inhibitors and early coronary reperfusion in primary PCI: an observational comparative study.
    Thrombosis and haemostasis, 2015, Aug-31, Volume: 114, Issue:3

    Topics: Adenosine; Aged; Clopidogrel; Coronary Angiography; Coronary Circulation; Drug Administration Schedu

2015
Pre-treatment with dual antiplatelet therapy in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention.
    Internal medicine journal, 2015, Volume: 45, Issue:10

    Topics: Acute Coronary Syndrome; Aged; Aspirin; Australia; Clopidogrel; Female; Hemorrhage; Humans; Logistic

2015
Ticagrelor protects the heart against reperfusion injury and improves remodeling after myocardial infarction.
    Arteriosclerosis, thrombosis, and vascular biology, 2015, Volume: 35, Issue:8

    Topics: Adenosine; Administration, Oral; Animals; Apoptosis; Cardiotonic Agents; Clopidogrel; Disease Models

2015
Proton Pump Inhibitor Usage and the Risk of Myocardial Infarction in the General Population.
    PloS one, 2015, Volume: 10, Issue:6

    Topics: Adult; Clopidogrel; Humans; Middle Aged; Myocardial Infarction; Prospective Studies; Proton Pump Inh

2015
Assessing the Quality of Care for Patients With Acute Myocardial Infarction in China.
    Clinical cardiology, 2015, Volume: 38, Issue:6

    Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; China; Clopido

2015
Lights and Shadows of Antiplatelet Therapy in Primary Percutaneous Coronary Intervention.
    JACC. Cardiovascular interventions, 2015, Volume: 8, Issue:7

    Topics: Female; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platel

2015
Reply: Lights and Shadows of Antiplatelet Therapy in Primary Percutaneous Coronary Intervention.
    JACC. Cardiovascular interventions, 2015, Volume: 8, Issue:7

    Topics: Female; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platel

2015
Interaction of Panax quinquefolius Saponin and Dual Antiplatelets on Vascular Endothelial Function in Rats with Acute Myocardial Infarction.
    BioMed research international, 2015, Volume: 2015

    Topics: Animals; Aspirin; Clopidogrel; Coronary Vessels; Endothelial Cells; Humans; Male; Myocardial Infarct

2015
Temporal Changes of Platelet Reactivity After Coronary Stenting-A Thing to Think About.
    The American journal of cardiology, 2015, Sep-01, Volume: 116, Issue:5

    Topics: Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors;

2015
Clinical outcomes of multiple chronic total occlusions in coronary arteries according to three therapeutic strategies: Bypass surgery, percutaneous intervention and medication.
    International journal of cardiology, 2015, Oct-15, Volume: 197

    Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Bypass;

2015
Cytochrome P450 CYP 2C19*2 Associated with Adverse 1-Year Cardiovascular Events in Patients with Acute Coronary Syndrome.
    PloS one, 2015, Volume: 10, Issue:7

    Topics: Activation, Metabolic; Acute Coronary Syndrome; Aged; Alleles; Angina Pectoris; Aspirin; Clopidogrel

2015
National Quality Assessment of Early Clopidogrel Therapy in Chinese Patients With Acute Myocardial Infarction (AMI) in 2006 and 2011: Insights From the China Patient-Centered Evaluative Assessment of Cardiac Events (PEACE)-Retrospective AMI Study.
    Journal of the American Heart Association, 2015, Jul-10, Volume: 4, Issue:7

    Topics: Aged; Asian People; China; Clopidogrel; Drug Administration Schedule; Female; Healthcare Disparities

2015
Safety of Prasugrel Loading Doses in Patients Pre-Loaded With Clopidogrel in the Setting of Primary Percutaneous Coronary Intervention: Results of a Nonrandomized Observational Study.
    JACC. Cardiovascular interventions, 2015, Volume: 8, Issue:8

    Topics: Aged; Clopidogrel; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Myoc

2015
Safety of Prasugrel Loading Doses in Patients Pre-Loaded With Clopidogrel in the Setting of Primary Percutaneous Coronary Intervention: Results of a Nonrandomized Observational Study.
    JACC. Cardiovascular interventions, 2015, Volume: 8, Issue:8

    Topics: Aged; Clopidogrel; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Myoc

2015
Safety of Prasugrel Loading Doses in Patients Pre-Loaded With Clopidogrel in the Setting of Primary Percutaneous Coronary Intervention: Results of a Nonrandomized Observational Study.
    JACC. Cardiovascular interventions, 2015, Volume: 8, Issue:8

    Topics: Aged; Clopidogrel; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Myoc

2015
Safety of Prasugrel Loading Doses in Patients Pre-Loaded With Clopidogrel in the Setting of Primary Percutaneous Coronary Intervention: Results of a Nonrandomized Observational Study.
    JACC. Cardiovascular interventions, 2015, Volume: 8, Issue:8

    Topics: Aged; Clopidogrel; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Myoc

2015
Outcomes with prolonged clopidogrel therapy after coronary stenting in patients with chronic kidney disease.
    Heart (British Cardiac Society), 2015, Volume: 101, Issue:19

    Topics: Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Drug Administration Schedule; Drug-El

2015
Comparing prasugrel to twice daily clopidogrel post percutaneous coronary intervention in a Veterans Affairs population.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2015, Sep-01, Volume: 72, Issue:17 Suppl 2

    Topics: Aged; Cardiovascular Diseases; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardia

2015
Proton Pump Inhibitors and Myocardial Infarction.
    Gastroenterology, 2015, Volume: 149, Issue:4

    Topics: Humans; Myocardial Infarction; Proton Pump Inhibitors; Ticlopidine

2015
Independent Predictors of Major Adverse Events following Coronary Stenting over 28 Months of Follow-Up.
    Cardiology, 2015, Volume: 132, Issue:3

    Topics: Acute Coronary Syndrome; Adult; Aged; Aspirin; Case-Control Studies; Clopidogrel; Coronary Angiograp

2015
Does clopidogrel affect the efficacy of myocardial perfusion imaging?
    Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 2016, Volume: 23, Issue:4

    Topics: Clopidogrel; Humans; Myocardial Infarction; Myocardial Perfusion Imaging; Ticlopidine; Treatment Out

2016
Age- and Gender-related Disparities in Primary Percutaneous Coronary Interventions for Acute ST-segment elevation Myocardial Infarction.
    PloS one, 2015, Volume: 10, Issue:9

    Topics: Age Factors; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Female; Geriatrics; Hospitals; Humans; M

2015
Effects of prasugrel pretreatment on angiographic myocardial perfusion parameters in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Coronary artery disease, 2015, Volume: 26, Issue:8

    Topics: Aged; Aspirin; Case-Control Studies; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; F

2015
Changes in platelet function independent of pharmacotherapy following coronary intervention in non-ST-elevation myocardial infarction patients.
    Atherosclerosis, 2015, Volume: 243, Issue:1

    Topics: 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid; Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Bl

2015
Personalized ADP-receptor inhibition strategy and outcomes following primary PCI for STEMI (PASTOR study).
    International journal of cardiology, 2016, Jan-01, Volume: 202

    Topics: Aged; Antithrombins; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutan

2016
Prior chronic clopidogrel therapy is associated with increased adverse events and early stent thrombosis.
    Thrombosis and haemostasis, 2016, Volume: 115, Issue:2

    Topics: Acute Coronary Syndrome; Aged; Cardiovascular Diseases; Clopidogrel; Comorbidity; Coronary Artery By

2016
Japanese postmarketing surveillance of clopidogrel in patients with non-ST-segment elevation acute coronary syndrome, stable angina, old myocardial infarction, and ST-segment elevation myocardial infarction after percutaneous coronary intervention in a re
    Cardiovascular intervention and therapeutics, 2016, Volume: 31, Issue:2

    Topics: Acute Coronary Syndrome; Adolescent; Adult; Aged; Angina, Stable; Asian People; Clopidogrel; Female;

2016
A tablet of clopidogrel remaining in the lower esophagus after primary percutaneous coronary intervention for acute myocardial infarction.
    Endoscopy, 2015, Volume: 47 Suppl 1 UCTN

    Topics: Aged; Clopidogrel; Combined Modality Therapy; Esophagus; Female; Humans; Myocardial Infarction; Perc

2015
Safety of prasugrel in real-world patients with ST-segment elevation myocardial infarction: 1-year results from a prospective observational study (Bleeding and Myocardial Infarction Study).
    Archives of cardiovascular diseases, 2016, Volume: 109, Issue:1

    Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans

2016
[A case review: About a STEMI in the very elderly].
    Annales de cardiologie et d'angeiologie, 2015, Volume: 64, Issue:6

    Topics: Aged, 80 and over; Aging; Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents, Non-Steroidal; A

2015
Switching from prasugrel to clopidogrel based on Cytochrome P450 2C19 genotyping in East Asian patients stabilized after acute myocardial infarction.
    Platelets, 2016, Volume: 27, Issue:4

    Topics: Aged; Alleles; Asian People; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Substituti

2016
CYP2C19 and CES1 polymorphisms and efficacy of clopidogrel and aspirin dual antiplatelet therapy in patients with symptomatic intracranial atherosclerotic disease.
    Journal of neurosurgery, 2016, Volume: 124, Issue:6

    Topics: Aged; Aspirin; Carboxylic Ester Hydrolases; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Gene Freq

2016
Determinants of pre-hospital pharmacological intervention and its association with outcome in acute myocardial infarction.
    Scandinavian journal of trauma, resuscitation and emergency medicine, 2015, Dec-01, Volume: 23

    Topics: Adrenergic beta-Antagonists; Aged; Analgesics, Opioid; Anticoagulants; Aspirin; Clopidogrel; Electro

2015
Is Proton Pump Inhibitor Use Associated With Risk of Myocardial Infarction?
    Gastroenterology, 2016, Volume: 150, Issue:2

    Topics: Humans; Myocardial Infarction; Proton Pump Inhibitors; Ticlopidine

2016
Reply.
    Gastroenterology, 2016, Volume: 150, Issue:2

    Topics: Humans; Myocardial Infarction; Proton Pump Inhibitors; Ticlopidine

2016
Ticagrelor in Triple Antithrombotic Therapy: Predictors of Ischemic and Bleeding Complications.
    Clinical cardiology, 2016, Volume: 39, Issue:1

    Topics: Adenosine; Chi-Square Distribution; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination

2016
Clopidogrel Versus Aspirin as an Antiplatelet Monotherapy After 12-Month Dual-Antiplatelet Therapy in the Era of Drug-Eluting Stents.
    Circulation. Cardiovascular interventions, 2016, Volume: 9, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug-Eluting Stents; Female; Humans; I

2016
Spontaneous coronary artery dissection in the presence of myocardial bridge causing myocardial infarction: an insight into mechanism.
    International journal of cardiology, 2016, Mar-01, Volume: 206

    Topics: Adult; Aspirin; Atorvastatin; Clopidogrel; Coronary Angiography; Coronary Vessel Anomalies; Female;

2016
Clopidogrel Use as Single Antiplatelet Therapy in Outpatients with Stable Coronary Artery Disease: Prevalence, Correlates and Association with Prognosis (from the CORONOR Study).
    Cardiology, 2016, Volume: 134, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Endovascular Procedures; F

2016
Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease.
    The American journal of medicine, 2016, Volume: 129, Issue:6

    Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity;

2016
Usefulness of Intravascular Ultrasound for Predicting Risk of Intraprocedural Stent Thrombosis.
    The American journal of cardiology, 2016, Mar-15, Volume: 117, Issue:6

    Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Humans; Japan; Male;

2016
Likelihood ratio meta-analysis: New motivation and approach for an old method.
    Contemporary clinical trials, 2016, Volume: 47

    Topics: Aspirin; Bayes Theorem; Clopidogrel; Data Interpretation, Statistical; Humans; Hydroxymethylglutaryl

2016
Prevalence and risk factors of clopidogrel non-response among Saudi patients undergoing coronary angiography.
    Saudi medical journal, 2016, Volume: 37, Issue:2

    Topics: Adult; Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Angiography; Coronary Artery Disease; C

2016
Clopidogrel, prasugrel or ticagrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
    Internal medicine journal, 2016, Volume: 46, Issue:5

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Australia; Clopidogrel; Comorbidity; Fe

2016
Antiplatelet Therapy of Cilostazol or Sarpogrelate with Aspirin and Clopidogrel after Percutaneous Coronary Intervention: A Retrospective Cohort Study Using the Korean National Health Insurance Claim Database.
    PloS one, 2016, Volume: 11, Issue:3

    Topics: Aspirin; Cilostazol; Clopidogrel; Drug-Related Side Effects and Adverse Reactions; Hemorrhage; Human

2016
Outcomes According to Cardiac Catheterization Referral and Clopidogrel Use Among Medicare Patients With Non-ST-Segment Elevation Myocardial Infarction Discharged Without In-hospital Revascularization.
    Journal of the American Heart Association, 2016, Mar-14, Volume: 5, Issue:3

    Topics: Age Factors; Aged; Aged, 80 and over; Cardiac Catheterization; Clopidogrel; Coronary Angiography; Co

2016
Save the Unlucky Unrevascularized Acute Coronary Syndrome Patient.
    Journal of the American College of Cardiology, 2016, Mar-22, Volume: 67, Issue:11

    Topics: Acute Coronary Syndrome; Aspirin; Electrocardiography; Female; Humans; Male; Myocardial Infarction;

2016
Dual Antiplatelet Therapy Beyond 1 Year Postinfarction: The Time Has Come and We're Beginning to Know Who Will Benefit.
    Revista espanola de cardiologia (English ed.), 2016, Volume: 69, Issue:5

    Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Myocard

2016
Pharmacogenetics of Clopidogrel: An Unresolved Issue.
    Circulation. Cardiovascular genetics, 2016, Volume: 9, Issue:2

    Topics: Clopidogrel; Cytochrome P-450 CYP2C19; Electrocardiography; Genotype; Humans; Male; Middle Aged; Myo

2016
[Relationship between ATP-binding cassette subfamily B member 1 and cytochrome P450 2C19 polymorphisms and the effect of clopidogrel post percutaneous coronary intervention in patients with acute coronary syndrome].
    Zhonghua xin xue guan bing za zhi, 2016, Apr-24, Volume: 44, Issue:4

    Topics: Acute Coronary Syndrome; Alleles; Angina Pectoris; ATP Binding Cassette Transporter, Subfamily B; Cl

2016
Comparison of short-term clinical outcomes between ticagrelor versus clopidogrel in patients with acute myocardial infarction undergoing successful revascularization; from Korea Acute Myocardial Infarction Registry-National Institute of Health.
    International journal of cardiology, 2016, Jul-15, Volume: 215

    Topics: Adenosine; Clopidogrel; Female; Hemorrhage; Hospitalization; Humans; Male; Myocardial Infarction; Pe

2016
Continued vorapaxar versus withdrawed clopidogrel both on top of low dose aspirin in patients undergoing heart surgery: A call for randomized trial.
    International journal of cardiology, 2016, Jul-15, Volume: 215

    Topics: Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Female; Humans; Lactones; Mal

2016
Mortality in primary angioplasty patients starting antiplatelet therapy with prehospital prasugrel or clopidogrel: a 1-year follow-up from the European MULTIPRAC Registry.
    Vascular health and risk management, 2016, Volume: 12

    Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Administration Schedul

2016
Hospital Variation in Premature Clopidogrel Discontinuation After Drug-Eluting Stent Placement in the Veterans Affairs (VA) Healthcare System.
    Journal of the American Heart Association, 2016, 05-05, Volume: 5, Issue:5

    Topics: Aftercare; Aged; Cardiology; Cause of Death; Clopidogrel; Coronary Artery Disease; Deprescriptions;

2016
Individualized Modeling Approach for DAPT Duration: Vision or Confusion?
    Journal of the American College of Cardiology, 2016, 05-17, Volume: 67, Issue:19

    Topics: Drug Therapy, Combination; Drug-Eluting Stents; Myocardial Infarction; Percutaneous Coronary Interve

2016
Initiation and persistence with dual antiplatelet therapy after acute myocardial infarction: a Danish nationwide population-based cohort study.
    BMJ open, 2016, 05-12, Volume: 6, Issue:5

    Topics: Adenosine; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Cohort Studies; Denmark; Drug Prescription

2016
Interaction of CYP2C19, P2Y12, and GPIIIa Variants Associates With Efficacy of Clopidogrel and Adverse Events on Patients With Ischemic Stroke.
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2017, Volume: 23, Issue:7

    Topics: Aged; Aged, 80 and over; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genetic Variation; Humans; I

2017
A State Transition Model for Health Outcomes Associated with Vorapaxar Treatment as an Add-on to Standard Care Antiplatelet Therapy in the Prevention of Thrombotic Events for Patients with a Recent Myocardial Infarction.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2016, Volume: 16, Issue:4

    Topics: Aspirin; Cardiovascular System; Clopidogrel; Hemorrhage; Humans; Lactones; Myocardial Infarction; Pl

2016
[Retrospective cohort study for the impact on readmission of patients with ischemic stroke after treatment of aspirin plus clopidogrel or aspirin mono-therapy].
    Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 2016, Jun-18, Volume: 48, Issue:3

    Topics: Aspirin; Beijing; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction;

2016
Relationship between diabetes, platelet reactivity, and the SYNTAX score to one-year clinical outcome in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention.
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2016, Jun-20, Volume: 12, Issue:3

    Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Blood Platelets; C

2016
The Impact of Timing of Ischemic and Hemorrhagic Events on Mortality After Percutaneous Coronary Intervention: The ADAPT-DES Study.
    JACC. Cardiovascular interventions, 2016, 07-25, Volume: 9, Issue:14

    Topics: Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; D

2016
Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registry.
    European heart journal, 2016, Nov-21, Volume: 37, Issue:44

    Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation

2016
CASE 11-2016 Perioperative Coronary Thrombosis in a Patient With Multiple Second-Generation Drug-Eluting Stents: Is It Time for a Paradigm Shift?
    Journal of cardiothoracic and vascular anesthesia, 2016, Volume: 30, Issue:6

    Topics: Analgesics, Opioid; Anti-Arrhythmia Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopid

2016
Concomitant Use of Proton Pump Inhibitors and Clopidogrel Is Not Associated with Adverse Outcomes after Ischemic Stroke in Chinese Population.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2016, Volume: 25, Issue:12

    Topics: Aged; Aged, 80 and over; Brain Ischemia; China; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P-

2016
Extended Dual Antiplatelet Therapy in Patients With Prior Myocardial Infarction.
    JAMA cardiology, 2016, 09-01, Volume: 1, Issue:6

    Topics: Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine

2016
Head to Head Comparison of Two Point-of-care Platelet Function Tests Used for Assessment of On-clopidogrel Platelet Reactivity in Chinese Acute Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention.
    Chinese medical journal, 2016, 10-05, Volume: 129, Issue:19

    Topics: Adenosine Diphosphate; Aged; Aspirin; Blood Platelets; China; Clopidogrel; Female; Humans; Male; Mid

2016
Increased Platelet-leukocyte Aggregates Are Associated With Myocardial No-reflow in Patients With ST Elevation Myocardial Infarction.
    The American journal of the medical sciences, 2016, Volume: 352, Issue:3

    Topics: Aspirin; Blood Platelets; Clopidogrel; Coronary Angiography; Coronary Circulation; Coronary Thrombos

2016
Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2017, Jun-01, Volume: 89, Issue:7

    Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Administration Schedule; Drug Antagonism; Drug

2017
Early Cessation of Adenosine Diphosphate Receptor Inhibitors Among Acute Myocardial Infarction Patients Treated With Percutaneous Coronary Intervention: Insights From the TRANSLATE-ACS Study (Treatment With Adenosine Diphosphate Receptor Inhibitors: Longi
    Circulation. Cardiovascular interventions, 2016, Volume: 9, Issue:11

    Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Drug Administration Schedule; Drug Costs; Female; Health

2016
Protective Effects of Ticagrelor on Myocardial Injury After Infarction.
    Circulation, 2016, Nov-29, Volume: 134, Issue:22

    Topics: Adenosine; Animals; Blood Platelets; Cardiotonic Agents; Clopidogrel; Cyclooxygenase 2; Myocardial I

2016
Single versus double antiplatelet therapy in patients undergoing coronary artery bypass grafting with coronary endarterectomy: mid-term results and clinical implications.
    Interactive cardiovascular and thoracic surgery, 2017, 02-01, Volume: 24, Issue:2

    Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Drug Therapy, Combinati

2017
Impact of Proton Pump Inhibitor Use on the Comparative Effectiveness and Safety of Prasugrel Versus Clopidogrel: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acu
    Journal of the American Heart Association, 2016, 10-21, Volume: 5, Issue:10

    Topics: Acute Coronary Syndrome; Aftercare; Aged; Cardiovascular Diseases; Clopidogrel; Comparative Effectiv

2016
Baseline characteristics, adenosine diphosphate receptor inhibitor treatment patterns, and in-hospital outcomes of myocardial infarction patients undergoing percutaneous coronary intervention in the prospective Canadian Observational AntiPlatelet sTudy (C
    American heart journal, 2016, Volume: 181

    Topics: Adenosine; Adult; Aged; Aged, 80 and over; Canada; Clopidogrel; Drug Substitution; Emergency Medical

2016
Long-term outcomes in patients with acute coronary syndromes related to prolonging dual antiplatelet therapy more than 12 months after coronary stenting.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2017, Jun-01, Volume: 89, Issue:7

    Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Databases, Factual; Drug Administration Schedul

2017
Long-term versus short-term dual antiplatelet therapy was similarly associated with a lower risk of death, stroke, or infarction in patients with acute coronary syndrome regardless of underlying kidney disease.
    Kidney international, 2017, Volume: 91, Issue:1

    Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Creatinine; Drug Therapy, Co

2017
Longitudinal treatment patterns with ADP receptor inhibitors after myocardial infarction: Insights from the Canadian Observational AntiPlatelet sTudy.
    International journal of cardiology, 2017, Feb-01, Volume: 228

    Topics: Adenosine; Aged; Canada; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; F

2017
Tutorial on statistical considerations on subgroup analysis in confirmatory clinical trials.
    Statistics in medicine, 2017, 04-15, Volume: 36, Issue:8

    Topics: Aspirin; Clopidogrel; Data Interpretation, Statistical; Humans; Models, Statistical; Myocardial Infa

2017
Impact of an Interaction Between Clopidogrel and Selective Serotonin Reuptake Inhibitors.
    The American journal of cardiology, 2017, 02-15, Volume: 119, Issue:4

    Topics: Aged; Cerebral Hemorrhage; Clopidogrel; Cohort Studies; Cytochrome P-450 CYP2C19 Inhibitors; Databas

2017
Switching of adenosine diphosphate receptor inhibitor after hospital discharge among myocardial infarction patients: Insights from the Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after
    American heart journal, 2017, Volume: 183

    Topics: Adenosine; Adenosine Diphosphate; Aged; Cardiovascular Diseases; Clopidogrel; Drug Substitution; Fem

2017
Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention.
    Circulation. Cardiovascular interventions, 2017, Volume: 10, Issue:1

    Topics: Adenosine Monophosphate; Aged; Brain Ischemia; Chi-Square Distribution; Clopidogrel; Coronary Artery

2017
Dual Antiplatelet Therapy Versus Aspirin Monotherapy in Diabetics With Multivessel Disease Undergoing CABG: FREEDOM Insights.
    Journal of the American College of Cardiology, 2017, Jan-17, Volume: 69, Issue:2

    Topics: Acute Coronary Syndrome; Aged; Aspirin; Cause of Death; Clopidogrel; Diabetic Angiopathies; Drug The

2017
Effect of Clopidogrel by Smoking Status on Secondary Stroke Prevention.
    Circulation, 2017, 01-17, Volume: 135, Issue:3

    Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Datasets as Topic; Drug Therapy, Combination; Humans

2017
Clopidogrel and ischemic stroke outcomes by smoking status: Smoker's paradox?
    Journal of the neurological sciences, 2017, Feb-15, Volume: 373

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Plat

2017
Dual Antiplatelet Therapy and Clinical Outcomes after Coronary Drug-Eluting Stent Implantation in Patients on Hemodialysis.
    Clinical journal of the American Society of Nephrology : CJASN, 2017, 02-07, Volume: 12, Issue:2

    Topics: Aged; Aspirin; Brain Ischemia; Case-Control Studies; Clopidogrel; Coronary Artery Disease; Drug Ther

2017
Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
    Circulation. Cardiovascular interventions, 2017, Volume: 10, Issue:2

    Topics: Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; D

2017
A randomized clinical trial comparing long-term clopidogrel vs aspirin monotherapy beyond dual antiplatelet therapy after drug-eluting coronary stent implantation: Design and rationale of the Harmonizing Optimal Strategy for Treatment of coronary artery s
    American heart journal, 2017, Volume: 185

    Topics: Acute Coronary Syndrome; Aspirin; Cause of Death; Clopidogrel; Coronary Stenosis; Drug Therapy, Comb

2017
State transition model: vorapaxar added to standard antiplatelet therapy to prevent thrombosis post myocardial infarction or peripheral artery disease.
    Current medical research and opinion, 2017, Volume: 33, Issue:9

    Topics: Aspirin; Clopidogrel; Female; Hemorrhage; Humans; Lactones; Male; Middle Aged; Myocardial Infarction

2017
Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease: Analysis From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
    Circulation. Cardiovascular interventions, 2017, Volume: 10, Issue:3

    Topics: Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; D

2017
2007 focused update to the ACC/AHA guidelines for the management of patients with ST-segment elevation myocardial infarction: implications for emergency department practice.
    Annals of emergency medicine, 2008, Volume: 52, Issue:4

    Topics: Angioplasty, Balloon, Coronary; Cardiology; Clopidogrel; Emergency Service, Hospital; Enoxaparin; Ev

2008
Long-term outcomes by clopidogrel duration and stent type in a diabetic population with de novo coronary artery lesions.
    Journal of the American College of Cardiology, 2008, Jun-10, Volume: 51, Issue:23

    Topics: Clopidogrel; Coronary Artery Disease; Diabetes Mellitus; Disease Progression; Drug-Eluting Stents; F

2008
The evolution of thienopyridine therapy clopidogrel duration, diabetes, and drug-eluting stents.
    Journal of the American College of Cardiology, 2008, Jun-10, Volume: 51, Issue:23

    Topics: Clopidogrel; Coronary Artery Disease; Diabetes Mellitus; Disease Progression; Drug-Eluting Stents; H

2008
Relation of low response to clopidogrel assessed with point-of-care assay to periprocedural myonecrosis in patients undergoing elective coronary stenting for stable angina pectoris.
    The American journal of cardiology, 2008, Jun-15, Volume: 101, Issue:12

    Topics: Aged; Angina Pectoris; Aspirin; Clopidogrel; Confidence Intervals; Elective Surgical Procedures; Fem

2008
2007 Guideline update for unstable angina/non-ST-segment elevation myocardial infarction: focus on antiplatelet and anticoagulant therapies.
    The Annals of pharmacotherapy, 2008, Volume: 42, Issue:7

    Topics: American Heart Association; Angina, Unstable; Anticoagulants; Clopidogrel; Drug-Eluting Stents; Enox

2008
Comparison of stent thrombosis, myocardial infarction, and mortality following drug-eluting versus bare-metal stent coronary intervention in patients with diabetes mellitus.
    The American journal of cardiology, 2008, Jul-15, Volume: 102, Issue:2

    Topics: Aged; Aspirin; Clopidogrel; Denmark; Diabetes Complications; Drug-Eluting Stents; Female; Humans; Ma

2008
Reversible clopidogrel resistance due to right ventricular myocardial infarction: risk factor of recurrent stent thrombosis?
    Clinical research in cardiology : official journal of the German Cardiac Society, 2008, Volume: 97, Issue:11

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug R

2008
Hydrolysis of adenine nucleotides in platelets from patients with acute myocardial infarction.
    Clinical biochemistry, 2008, Volume: 41, Issue:14-15

    Topics: Adenine Nucleotides; Adenosine Diphosphate; Adenosine Monophosphate; Adenosine Triphosphate; Aspirin

2008
Effectiveness of reloading to overcome clopidogrel nonresponsiveness in patients with acute myocardial infarction.
    The American journal of cardiology, 2008, Sep-01, Volume: 102, Issue:5

    Topics: Blood Platelets; Clopidogrel; Dose-Response Relationship, Drug; Electrocardiography; Female; Fibrino

2008
Acute arthritis associated with loading dose of clopidogrel.
    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2008, Volume: 14, Issue:4

    Topics: Aged; Arthritis; Clopidogrel; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors;

2008
Clopidogrel treatment and the MEND-CABG II trial.
    JAMA, 2008, Sep-03, Volume: 300, Issue:9

    Topics: Clopidogrel; Coronary Artery Bypass; Humans; Myocardial Infarction; Myocardial Reperfusion Injury; P

2008
Survival benefit with concomitant oral platelet therapy after coronary angiography and before ad hoc percutaneous coronary intervention.
    Mayo Clinic proceedings, 2008, Volume: 83, Issue:9

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Coronary Angiography;

2008
Survival benefit with concomitant clopidogrel and glycoprotein IIb/IIIa inhibitor therapy at ad hoc percutaneous coronary intervention.
    Mayo Clinic proceedings, 2008, Volume: 83, Issue:9

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Confidence Intervals;

2008
Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors.
    Journal of the American College of Cardiology, 2008, Sep-16, Volume: 52, Issue:12

    Topics: Clopidogrel; Drug Interactions; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet A

2008
Recurrent myocardial infarction in a young football player with antithrombin III deficiency.
    Cardiology journal, 2008, Volume: 15, Issue:5

    Topics: Angioplasty, Balloon, Coronary; Antithrombin III Deficiency; Clopidogrel; Coronary Angiography; Drug

2008
[Severe myocardial infarction due to late and very late stent thrombosis after coronary artery stenting with drug-eluting stents].
    Deutsche medizinische Wochenschrift (1946), 2008, Volume: 133, Issue:40

    Topics: Aged; Aspirin; Cardiac Catheterization; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Crea

2008
Initiation and persistence with clopidogrel treatment after acute myocardial infarction: a nationwide study.
    British journal of clinical pharmacology, 2008, Volume: 66, Issue:6

    Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Confidence Intervals; Denmark; Female; Hum

2008
Unprotected left main coronary artery bifurcation stenosis: impact of plaque debulking prior to single sirolimus-eluting stent implantation.
    The Journal of invasive cardiology, 2008, Volume: 20, Issue:10

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Vessel

2008
Treatment of patients with cardiogenic shock in the setting of acute myocardial infarction. Case reports.
    Georgian medical news, 2008, Issue:162

    Topics: Aged; Angioplasty, Balloon; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carbazoles; Carvedilol

2008
Outcomes after percutaneous coronary intervention in contemporary Australian practice: insights from a large multicentre registry.
    The Medical journal of Australia, 2008, Oct-20, Volume: 189, Issue:8

    Topics: Acute Coronary Syndrome; Adult; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Comorbidity; Drug

2008
Optimizing clopidogrel therapy before stent implantation: should clinical setting be taken into account?
    Journal of the American College of Cardiology, 2008, Oct-14, Volume: 52, Issue:16

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Cohort Studies; Coronary Angiography; Coronary Stenosis

2008
ExTRACT-TIMI 25 in perspective: key lessons regarding enoxaparin as an adjunct to fibrinolytic therapy.
    Journal of thrombosis and thrombolysis, 2009, Volume: 27, Issue:1

    Topics: Aged; Anticoagulants; Clopidogrel; Combined Modality Therapy; Comorbidity; Disease-Free Survival; Dr

2009
Cardiovascular outcomes after a change in prescription policy for clopidogrel.
    The New England journal of medicine, 2008, Oct-23, Volume: 359, Issue:17

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Co

2008
[Acute coronary syndrome -- long term protection by dual thrombocyte aggregation inhibition during twelve months].
    MMW Fortschritte der Medizin, 2008, Oct-16, Volume: 150, Issue:42

    Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials

2008
Patterns of upstream antiplatelet therapy use before primary percutaneous coronary intervention for acute ST-elevation myocardial infarction (from the CRUSADE National Quality Improvement Initiative).
    The American journal of cardiology, 2008, Nov-15, Volume: 102, Issue:10

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Inf

2008
Clopidogrel under scrutiny.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2008, Dec-01, Volume: 72, Issue:7

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Drug Therap

2008
Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: results from the CADILLAC trial.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2008, Dec-01, Volume: 72, Issue:7

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coron

2008
Increased morning ADP-dependent platelet aggregation persists despite dual antiplatelet therapy in patients with first ST-segment elevation myocardial infarction: Preliminary report.
    Cardiology journal, 2008, Volume: 15, Issue:6

    Topics: Abciximab; Aged; Antibodies, Monoclonal; Anticoagulants; Circadian Rhythm; Clopidogrel; Dose-Respons

2008
Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy.
    The American journal of cardiology, 2008, Dec-15, Volume: 102, Issue:12

    Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Disease-Free Survival; D

2008
A cost-utility analysis of clopidogrel in patients with ST elevation acute coronary syndromes in the UK.
    International journal of cardiology, 2010, Apr-30, Volume: 140, Issue:3

    Topics: Aspirin; Clopidogrel; Cost-Benefit Analysis; Drug Costs; Follow-Up Studies; Humans; Markov Chains; M

2010
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Genetic determinants of response to clopidogrel and cardiovascular events.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte

2009
Clopidogrel, genetics, and drug responsiveness.
    The New England journal of medicine, 2009, Jan-22, Volume: 360, Issue:4

    Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Cardiovascular Diseases; Clopidogrel; Cytoch

2009
Clopidogrel use in ST-elevation myocardial infarction (STEMI).
    The Journal of emergency medicine, 2010, Volume: 39, Issue:2

    Topics: Catheter Ablation; Clopidogrel; Electrocardiography; Emergency Service, Hospital; Humans; Myocardial

2010
A population-based study of the drug interaction between proton pump inhibitors and clopidogrel.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2009, Mar-31, Volume: 180, Issue:7

    Topics: Age Distribution; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Case-Control Studies; Clo

2009
A population-based study of the drug interaction between proton pump inhibitors and clopidogrel.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2009, Mar-31, Volume: 180, Issue:7

    Topics: Age Distribution; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Case-Control Studies; Clo

2009
A population-based study of the drug interaction between proton pump inhibitors and clopidogrel.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2009, Mar-31, Volume: 180, Issue:7

    Topics: Age Distribution; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Case-Control Studies; Clo

2009
A population-based study of the drug interaction between proton pump inhibitors and clopidogrel.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2009, Mar-31, Volume: 180, Issue:7

    Topics: Age Distribution; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Case-Control Studies; Clo

2009
A population-based study of the drug interaction between proton pump inhibitors and clopidogrel.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2009, Mar-31, Volume: 180, Issue:7

    Topics: Age Distribution; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Case-Control Studies; Clo

2009
A population-based study of the drug interaction between proton pump inhibitors and clopidogrel.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2009, Mar-31, Volume: 180, Issue:7

    Topics: Age Distribution; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Case-Control Studies; Clo

2009
A population-based study of the drug interaction between proton pump inhibitors and clopidogrel.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2009, Mar-31, Volume: 180, Issue:7

    Topics: Age Distribution; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Case-Control Studies; Clo

2009
A population-based study of the drug interaction between proton pump inhibitors and clopidogrel.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2009, Mar-31, Volume: 180, Issue:7

    Topics: Age Distribution; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Case-Control Studies; Clo

2009
A population-based study of the drug interaction between proton pump inhibitors and clopidogrel.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2009, Mar-31, Volume: 180, Issue:7

    Topics: Age Distribution; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Case-Control Studies; Clo

2009
Prognosis of patients suffering an acute coronary syndrome while already under chronic clopidogrel therapy.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2009, Jun-01, Volume: 73, Issue:7

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo

2009
Essential thrombocythemia: a case of acute ST-segment elevation myocardial infarction in a young female.
    Clinical cardiology, 2009, Volume: 32, Issue:2

    Topics: Adult; Age Factors; Antisickling Agents; Aspirin; Clopidogrel; Coronary Angiography; Female; Fibrino

2009
Facts and controversies of aspirin and clopidogrel therapy.
    American heart journal, 2009, Volume: 157, Issue:3

    Topics: Acute Coronary Syndrome; Aspirin; Atherosclerosis; Blood Platelets; Brain Ischemia; Clopidogrel; Dos

2009
Ischaemia versus bleeding: the art of clinical decision-making.
    Lancet (London, England), 2009, Feb-28, Volume: 373, Issue:9665

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Decision Making; Hemorrhage; H

2009
Focus on adjunctive pharmacotherapy to improve outcomes of percutaneous coronary intervention.
    The Journal of invasive cardiology, 2009, Volume: 21, Issue:3

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Chemotherapy, Adjuvant;

2009
Successful clopidogrel desensitization after drug-eluting stent implantation.
    The Journal of invasive cardiology, 2009, Volume: 21, Issue:3

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Desensitization, Immunologic; Drug-Eluting Ste

2009
Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis.
    The American journal of cardiology, 2009, Mar-15, Volume: 103, Issue:6

    Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Thromb

2009
Clopidogrel pretreatment before primary percutaneous coronary stenting in patients with acute ST-segment elevation myocardial infarction: comparison of high loading dose (600 mg) versus low loading dose (300 mg).
    Coronary artery disease, 2009, Volume: 20, Issue:2

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Drug Administration Sche

2009
Clopidogrel for preventing cardiovascular events.
    The Mount Sinai journal of medicine, New York, 2009, Volume: 76, Issue:2

    Topics: Aspirin; Clopidogrel; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Evidence-Based Medicine;

2009
Novel antiplatelet strategies in acute coronary syndromes.
    Cleveland Clinic journal of medicine, 2009, Volume: 76 Suppl 1

    Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clinical Trials, Phase III as Topic; Clopidogrel; Hu

2009
Very late drug-eluting stent thrombosis after nonsteroidal anti-inflammatory drug treatment despite dual antiplatelet therapy.
    The Canadian journal of cardiology, 2009, Volume: 25, Issue:4

    Topics: Adult; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thrombosis; Cyclooxygenase Inh

2009
Cytochrome P450 2C19 polymorphism and clopidogrel after MI.
    Lancet (London, England), 2009, Apr-04, Volume: 373, Issue:9670

    Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Heterozygote; Humans

2009
Cytochrome P450 2C19 polymorphism and clopidogrel after MI.
    Lancet (London, England), 2009, Apr-04, Volume: 373, Issue:9670

    Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Follow-Up Studies; Heterozygot

2009
Cytochrome P450 2C19 polymorphism and clopidogrel after MI.
    Lancet (London, England), 2009, Apr-04, Volume: 373, Issue:9670

    Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Humans; Liver; Myocardial Infa

2009
Dual antiplatelet therapy after percutaneous coronary intervention with stent implantation in patients taking chronic oral anticoagulation.
    JACC. Cardiovascular interventions, 2008, Volume: 1, Issue:1

    Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosi

2008
Effective platelet inhibition by aspirin and clopidogrel: where are we now?
    Heart (British Cardiac Society), 2009, Volume: 95, Issue:10

    Topics: Aspirin; Clopidogrel; Coronary Disease; Humans; Myocardial Infarction; Platelet Aggregation Inhibito

2009
Antithrombotic therapy for the prevention of reinfarction after reperfusion therapy: the price of success.
    Revista espanola de cardiologia, 2009, Volume: 62, Issue:5

    Topics: China; Clinical Trials as Topic; Clopidogrel; Electrocardiography; Fibrinolytic Agents; Heparin; Hum

2009
Acknowledging a failed strategy.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2009, Jun-01, Volume: 73, Issue:7

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogr

2009
Clopidogrel. More on proton pump inhibitors.
    BMJ (Clinical research ed.), 2009, May-20, Volume: 338

    Topics: Clopidogrel; Drug Combinations; Humans; Myocardial Infarction; Proton Pump Inhibitors; Recurrence; R

2009
Stent thrombosis, clinical events, and influence of prolonged clopidogrel use after placement of drug-eluting stent data from an observational cohort study of drug-eluting versus bare-metal stents.
    JACC. Cardiovascular interventions, 2008, Volume: 1, Issue:5

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Cohort Studies; Coronary Artery Disease; Drug Adm

2008
Impact of combining proton pump inhibitors and clopidogrel.
    The American journal of cardiology, 2009, Jun-01, Volume: 103, Issue:11

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Interactions; Drug Therap

2009
Prasugrel STEMI subgroup analysis.
    Lancet (London, England), 2009, May-30, Volume: 373, Issue:9678

    Topics: Clopidogrel; Data Interpretation, Statistical; Electrocardiography; Humans; Myocardial Infarction; P

2009
Prasugrel STEMI subgroup analysis.
    Lancet (London, England), 2009, May-30, Volume: 373, Issue:9678

    Topics: Clopidogrel; Data Interpretation, Statistical; Drug Administration Schedule; Electrocardiography; Hu

2009
Prasugrel STEMI subgroup analysis.
    Lancet (London, England), 2009, May-30, Volume: 373, Issue:9678

    Topics: Aspirin; Clopidogrel; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction;

2009
Risks of proton-pump inhibitors: what every doctor should know. Comment.
    The Medical journal of Australia, 2009, Jun-01, Volume: 190, Issue:11

    Topics: Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Gastric Acid; Gastric Mucosa; Hu

2009
Can we override clopidogrel resistance?
    Circulation, 2009, Jun-02, Volume: 119, Issue:21

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Biotransformation; Clo

2009
Future of oral antiplatelet therapy: four challenged hypotheses.
    Thrombosis and haemostasis, 2009, Volume: 101, Issue:6

    Topics: Adenosine; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Cost-Benefit Analysis; Hemorr

2009
Saving lives, money and resources: drug and CABG/PCI use after myocardial infarction in a Swedish record-linkage study.
    The European journal of health economics : HEPAC : health economics in prevention and care, 2010, Volume: 11, Issue:2

    Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Ant

2010
Interaction between clopidogrel and proton pump inhibitors.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2009, Jun-09, Volume: 180, Issue:12

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Case-Control Studies; Clopidogrel; Drug Interactions; Drug

2009
Interaction between clopidogrel and proton pump inhibitors.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2009, Jun-09, Volume: 180, Issue:12

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Case-Control Studies; Clopidogrel; Drug Interactions; Drug

2009
Tailored medical and interventional therapy against recurrent stent thrombosis after drug-eluting stenting.
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2010, Volume: 16, Issue:5

    Topics: Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Thrombosis; Drug-Eluting Stents; Humans; Male

2010
Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Circulation, 2009, Jun-30, Volume: 119, Issue:25

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Combined Modality Therapy; C

2009
ACC/AHA guideline update for the management of ST-segment elevation myocardial infarction.
    American family physician, 2009, Jun-15, Volume: 79, Issue:12

    Topics: Antihypertensive Agents; Aspirin; Catheter Ablation; Clopidogrel; Combined Modality Therapy; Electro

2009
Dual antiplatelet therapy for more than 12 months after percutaneous coronary intervention: insights from the Guthrie PCI Registry.
    Heart (British Cardiac Society), 2009, Volume: 95, Issue:19

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; D

2009
Aspirin for heart attack, stroke prevention. When benefits outweigh risks: four new studies help clarify who should--and who shouldn't--take the drug.
    DukeMedicine healthnews, 2009, Volume: 15, Issue:6

    Topics: Aspirin; Clopidogrel; Contraindications; Drug Interactions; Drug Therapy, Combination; Female; Gastr

2009
Drug-eluting coronary stents: many meta-analyses, little benefit.
    Prescrire international, 2009, Volume: 18, Issue:100

    Topics: Angina, Unstable; Angioplasty, Balloon; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Co

2009
[Clopidogrel plus proton pump inhibitor: is infarct risk increased? (interview by Dr. Thomas Meissner)].
    MMW Fortschritte der Medizin, 2009, Jun-04, Volume: 151, Issue:23

    Topics: Clopidogrel; Drug Interactions; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet A

2009
Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period.
    European heart journal, 2009, Volume: 30, Issue:22

    Topics: Aged; Blood Vessel Prosthesis; Clopidogrel; Coronary Angiography; Drug-Eluting Stents; Female; Graft

2009
A caution on Plavix and PPIs.
    The Johns Hopkins medical letter health after 50, 2009, Volume: 21, Issue:5

    Topics: Clopidogrel; Drug Interactions; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Prot

2009
Clinical impact of early clopidogrel discontinuation following acute myocardial infarction hospitalization or stent implantation: analysis in a single integrated health network.
    Current medical research and opinion, 2009, Volume: 25, Issue:9

    Topics: Aged; Algorithms; Cardiovascular Surgical Procedures; Clopidogrel; Cohort Studies; Coronary Disease;

2009
Clinical impact of early clopidogrel discontinuation following acute myocardial infarction hospitalization or stent implantation: analysis in a nationally representative managed-care population.
    Current medical research and opinion, 2009, Volume: 25, Issue:9

    Topics: Aged; Algorithms; Cardiovascular Surgical Procedures; Clopidogrel; Cohort Studies; Coronary Disease;

2009
Letter by Ryding et al regarding article, "Impact of pretreatment with clopidogrel on initial patency and outcome in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a systematic review".
    Circulation, 2009, Jul-28, Volume: 120, Issue:4

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Humans; Meta-Analysis as Topic; Myocardial Infarction;

2009
Right ventricular function in ST elevation myocardial infarction: effect of reperfusion.
    Clinical and investigative medicine. Medecine clinique et experimentale, 2009, Aug-01, Volume: 32, Issue:4

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Clopidogrel;

2009
New coating stent design for patients with high-risk coronary lesions for thrombotic events: early and long-term results of the Camouflage registry.
    The Journal of invasive cardiology, 2009, Volume: 21, Issue:8

    Topics: Aged; Argentina; Clopidogrel; Coated Materials, Biocompatible; Coronary Angiography; Coronary Diseas

2009
Drug-specific thienopyridine resistance in patient with recurrent coronary stent thrombosis.
    The Journal of invasive cardiology, 2009, Volume: 21, Issue:8

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Drug Resistance; Humans; Male; Mid

2009
Usefulness of pretreatment with high-dose clopidogrel in patients undergoing primary angioplasty for ST-elevation myocardial infarction.
    The American journal of cardiology, 2009, Aug-15, Volume: 104, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Cohort Studies; Dose-Response Relationship, Drug;

2009
Acute myocardial infarction associated with pregnancy successfully treated with percutaneous coronary intervention.
    Internal medicine (Tokyo, Japan), 2009, Volume: 48, Issue:16

    Topics: Adult; Angioplasty, Balloon, Coronary; Cesarean Section; Clopidogrel; Female; Humans; Infant, Newbor

2009
Percutaneous coronary intervention in a patient with factor XI deficiency.
    The Journal of invasive cardiology, 2009, Volume: 21, Issue:9

    Topics: Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Factor XI Deficiency; Human

2009
Risk of adverse clinical outcomes with concomitant use of clopidogrel and proton pump inhibitors following percutaneous coronary intervention.
    Digestive diseases and sciences, 2010, Volume: 55, Issue:7

    Topics: Angioplasty, Balloon, Coronary; Chi-Square Distribution; Clopidogrel; Cohort Studies; Drug Interacti

2010
Early stent thrombosis in patients undergoing primary coronary stenting for acute myocardial infarction: incidence, a simple risk score, and prognosis.
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2010, Volume: 16, Issue:1

    Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Female; Humans; Incid

2010
Headache as the sole presenting symptom of acute myocardial infarction.
    The Journal of the Association of Physicians of India, 2009, Volume: 57

    Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Aspirin; Atorvastatin; Clopidogrel; Headac

2009
Clopidogrel plus aspirin in atrial fibrillation.
    The New England journal of medicine, 2009, Sep-24, Volume: 361, Issue:13

    Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Embolism; Humans; Myocardial I

2009
Desensitization to clopidogrel: a growing need.
    Allergy, 2010, Volume: 65, Issue:2

    Topics: Aspirin; Cardiac Catheterization; Clopidogrel; Desensitization, Immunologic; Drug Therapy, Combinati

2010
Hunting for the "sweet spot" in P2Y12 receptor blockade.
    Journal of the American College of Cardiology, 2009, Oct-06, Volume: 54, Issue:15

    Topics: Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2 Receptor

2009
Clinical benefit of early reperfusion therapy in patients with ST-elevation myocardial infarction usually excluded from randomized clinical trials (results from the Maximal Individual Therapy in Acute Myocardial Infarction Plus [MITRA Plus] registry).
    The American journal of cardiology, 2009, Oct-15, Volume: 104, Issue:8

    Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clopidogrel; E

2009
Routine early angioplasty after fibrinolysis.
    The New England journal of medicine, 2009, Oct-08, Volume: 361, Issue:15

    Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy;

2009
[Prasugrel or clopidogrel in patients with coronary intervention].
    Der Internist, 2009, Volume: 50, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Bypass; Double-Blind Method; Endpoint

2009
Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.
    Prescrire international, 2009, Volume: 18, Issue:103

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogr

2009
A comparison of the VASP index between patients with hemodynamically complicated and uncomplicated acute myocardial infarction.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2010, Feb-01, Volume: 75, Issue:2

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Biomarkers; Blood Platelets; Case-Control S

2010
Letter by Kan et al regarding Article, "randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart failure (WATCH) trial".
    Circulation, 2009, Nov-17, Volume: 120, Issue:20

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Chronic Disease; Clopidogrel; Death; Double-Blind Method; F

2009
Therapeutic innovations, diminishing returns, and control rate preservation.
    JAMA, 2009, Nov-25, Volume: 302, Issue:20

    Topics: Angioplasty, Balloon, Coronary; Biomarkers; Cardiovascular Agents; Clopidogrel; Diagnosis, Different

2009
There is no place like home after successful percutaneous coronary intervention.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2009, Dec-01, Volume: 74, Issue:7

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coronary Ar

2009
Concomitant use of clopidogrel and proton pump inhibitors or cimetidine after acute myocardial infarction would increase the risk of re-infarction.
    The American journal of gastroenterology, 2009, Volume: 104, Issue:12

    Topics: Alleles; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Cimetidine; Clopidogrel; Cytochrome P-450

2009
Stent thrombosis: a poor man's disease?
    The Israel Medical Association journal : IMAJ, 2009, Volume: 11, Issue:9

    Topics: Acute Disease; Aged; Angioplasty, Balloon, Coronary; Chi-Square Distribution; Clopidogrel; Cohort St

2009
A regional system for delivery of primary percutaneous coronary intervention in ST-elevation myocardial infarction: STEMI-St. Cloud.
    The Journal of invasive cardiology, 2009, Volume: 21, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Delivery of He

2009
Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data.
    Lancet (London, England), 2009, Dec-12, Volume: 374, Issue:9706

    Topics: Adult; Aged; Aspirin; Clopidogrel; Denmark; Drug Therapy, Combination; Female; Follow-Up Studies; He

2009
Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data.
    Lancet (London, England), 2009, Dec-12, Volume: 374, Issue:9706

    Topics: Adult; Aged; Aspirin; Clopidogrel; Denmark; Drug Therapy, Combination; Female; Follow-Up Studies; He

2009
Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data.
    Lancet (London, England), 2009, Dec-12, Volume: 374, Issue:9706

    Topics: Adult; Aged; Aspirin; Clopidogrel; Denmark; Drug Therapy, Combination; Female; Follow-Up Studies; He

2009
Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data.
    Lancet (London, England), 2009, Dec-12, Volume: 374, Issue:9706

    Topics: Adult; Aged; Aspirin; Clopidogrel; Denmark; Drug Therapy, Combination; Female; Follow-Up Studies; He

2009
The PLATO trial: do you believe in magic?
    European heart journal, 2010, Volume: 31, Issue:7

    Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials, Phase III as Topic; Clopidogrel; Humans; Intrac

2010
Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasug
    Circulation, 2010, Jan-05, Volume: 121, Issue:1

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Cos

2010
Antiplatelet drugs for patients at high cardiovascular risk. Aspirin generally remains the best choice.
    Prescrire international, 2009, Volume: 18, Issue:104

    Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Atrial Fibrillation; Brain Ischemia; Clini

2009
Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual antiplatelet therapy after drug-eluting stents should be continued for more than one year and preferably indefinitely.
    Circulation. Cardiovascular interventions, 2008, Volume: 1, Issue:3

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis;

2008
Clopidogrel for the hot patient.
    Circulation. Cardiovascular interventions, 2009, Volume: 2, Issue:6

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; C-Reactive Protein; Clopidogrel; Drug Therapy,

2009
Relationship between baseline inflammatory markers, antiplatelet therapy, and adverse cardiac events after percutaneous coronary intervention: an analysis from the clopidogrel for the reduction of events during observation trial.
    Circulation. Cardiovascular interventions, 2009, Volume: 2, Issue:6

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; C-Reactive Protein; Clopidogrel; Double-B

2009
Improved clinical outcome after acute myocardial infarction in hospitals participating in a Swedish quality improvement initiative.
    Circulation. Cardiovascular quality and outcomes, 2009, Volume: 2, Issue:5

    Topics: Aged; Clopidogrel; Female; Fibrinolytic Agents; Follow-Up Studies; Guideline Adherence; Hemorrhage;

2009
Ticagrelor versus clopidogrel in acute coronary syndromes.
    The New England journal of medicine, 2009, Dec-10, Volume: 361, Issue:24

    Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Coronary Artery Bypass; Hemorrhage; Humans; Myocard

2009
[Antiplatelet therapy and urgent surgical procedures. Acute appendicitis two days after stent implantation--a case report].
    Kardiologia polska, 2009, Volume: 67, Issue:12

    Topics: Appendicitis; Clopidogrel; Coronary Thrombosis; Dobutamine; Humans; Intraoperative Complications; Ma

2009
Cost-effectiveness of clopidogrel in STEMI patients in the Netherlands: a model based on the CLARITY trial.
    Current medical research and opinion, 2010, Volume: 26, Issue:3

    Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Costs and Cost Analysis; Female; Humans; Male; Model

2010
Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials.
    European heart journal, 2010, Volume: 31, Issue:6

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Meta-Analys

2010
Anxiety is a better predictor of platelet reactivity in coronary artery disease patients than depression.
    European heart journal, 2010, Volume: 31, Issue:13

    Topics: Adenosine Diphosphate; Aged; Angina, Unstable; Anxiety Disorders; Aspirin; Clopidogrel; Cross-Sectio

2010
Efficacy of high-dose clopidogrel treatment (600 mg) less than two hours before percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes.
    The American journal of cardiology, 2010, Feb-01, Volume: 105, Issue:3

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Electrocardiography; Fem

2010
Duration of clopidogrel treatment and risk of mortality and recurrent myocardial infarction among 11 680 patients with myocardial infarction treated with percutaneous coronary intervention: a cohort study.
    BMC cardiovascular disorders, 2010, Jan-29, Volume: 10

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Cohort Studies; Denmark; Female; Follow-Up Studie

2010
HORIZONS-AMI.
    Lancet (London, England), 2010, Jan-30, Volume: 375, Issue:9712

    Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Clopidogrel; Heparin; Hirudins; Humans; Myocardial I

2010
Safety and efficacy of clopidogrel treatment in Japanese patients undergoing drug-eluting stent implantation.
    Journal of cardiology, 2010, Volume: 55, Issue:1

    Topics: Aged; Clopidogrel; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Myocardial Infarction; Pla

2010
Efficacy of modified dual antiplatelet therapy combined with warfarin following percutaneous coronary intervention with drug-eluting stents.
    The Journal of invasive cardiology, 2010, Volume: 22, Issue:2

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Combi

2010
Lack of outcome benefit and clopidogrel "resistance." The TRITON trial challenge.
    Thrombosis and haemostasis, 2010, Volume: 103, Issue:2

    Topics: Acute Coronary Syndrome; Clopidogrel; Drug Approval; Drug Resistance; Humans; Myocardial Infarction;

2010
High residual platelet reactivity after clopidogrel: extent of coronary atherosclerosis and periprocedural myocardial infarction in patients with stable angina undergoing percutaneous coronary intervention.
    JACC. Cardiovascular interventions, 2010, Volume: 3, Issue:1

    Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Coronary Angiog

2010
VerifyNow and VASP phosphorylation assays give similar results for patients receiving clopidogrel, but they do not always correlate with platelet aggregation.
    Platelets, 2010, Volume: 21, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Cell Adhesion Molecules; Clopidogrel; Female; Humans; Male; Microfil

2010
Antiplatelet therapy with clopidogrel or ticlopidine reduces intimal hyperplasia in an animal model of experimental arterial injury.
    Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology, 2010, Volume: 10, Issue:1

    Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Animals; Arteries; Cell Division; Clopidogrel; Cor

2010
The impact of treatment with omeprazole on the effectiveness of clopidogrel drug therapy during the first year after successful coronary stenting.
    The Canadian journal of cardiology, 2010, Volume: 26, Issue:2

    Topics: Administration, Oral; Angina, Unstable; Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel;

2010
Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry).
    American heart journal, 2010, Volume: 159, Issue:2

    Topics: Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Female; Follow-Up

2010
Antiplatelet therapy after percutaneous coronary intervention: Should another regimen be "TAPT?".
    Circulation. Cardiovascular interventions, 2010, Feb-01, Volume: 3, Issue:1

    Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chemotherapy, Adjuvant; Cilostazol; C

2010
Multivariate-adjusted pharmacoepidemiologic analyses of confidential information pooled from multiple health care utilization databases.
    Pharmacoepidemiology and drug safety, 2010, Volume: 19, Issue:8

    Topics: Anti-Ulcer Agents; Clopidogrel; Confidentiality; Databases, Factual; Female; Humans; Male; Meta-Anal

2010
Long-term effectiveness and safety of sirolimus stent implantation for coronary in-stent restenosis results of the TRUE (Tuscany Registry of sirolimus for unselected in-stent restenosis) registry at 4 years.
    Journal of the American College of Cardiology, 2010, Feb-16, Volume: 55, Issue:7

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Restenosis; Coronary

2010
Clinical relevance of clopidogrel unresponsiveness during elective coronary stenting: experience with the point-of-care platelet function assay-100 C/ADP.
    American heart journal, 2010, Volume: 159, Issue:3

    Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Vessels;

2010
Clopidogrel use and clinical events after drug-eluting stent implantation: findings from the HealthCore Integrated Research Database.
    American heart journal, 2010, Volume: 159, Issue:3

    Topics: Aged; Clopidogrel; Cohort Studies; Databases, Factual; Drug Administration Schedule; Drug-Eluting St

2010
Cost-effectiveness analysis of short-term clopidogrel therapy for ST elevation myocardial infarction.
    Critical pathways in cardiology, 2010, Volume: 9, Issue:1

    Topics: Adolescent; Adult; Aged; Clopidogrel; Cost-Benefit Analysis; Diagnosis-Related Groups; Female; Hospi

2010
Acute myocardial infarction related to very late sirolimus-eluting stent thrombosis 6 months after discontinuation of dual antiplatelet therapy.
    Journal of cardiovascular medicine (Hagerstown, Md.), 2011, Volume: 12, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Angiogra

2011
The loading dose of clopidogrel in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty.
    The American journal of emergency medicine, 2010, Volume: 28, Issue:3

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon; Aspirin; Clopidogrel; Humans; Myocardial Infarction;

2010
Delays of event adjudication in the TRITON trial.
    Cardiology, 2010, Volume: 115, Issue:3

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Cerebral Infarction; Clopidogrel; Coronary

2010
Recurrence of acute myocardial infarction in patients discharged on clopidogrel and a proton pump inhibitor after stent placement for acute myocardial infarction.
    Clinical cardiology, 2010, Volume: 33, Issue:3

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Angioplasty, Balloon, Coronary; Anti-Ulcer Agents; Clopidog

2010
Platelet inhibition with cangrelor.
    The New England journal of medicine, 2010, Mar-18, Volume: 362, Issue:11

    Topics: Adenosine Monophosphate; Administration, Oral; Angioplasty, Balloon, Coronary; Clopidogrel; Humans;

2010
Point-of-care assessment of platelet reactivity after clopidogrel to predict myonecrosis in patients undergoing percutaneous coronary intervention.
    JACC. Cardiovascular interventions, 2010, Volume: 3, Issue:3

    Topics: Aged; Angioplasty, Balloon, Coronary; Biomarkers; Blood Platelets; Clopidogrel; Coronary Artery Dise

2010
Increased mortality associated with low use of clopidogrel in patients with heart failure and acute myocardial infarction not undergoing percutaneous coronary intervention: a nationwide study.
    Journal of the American College of Cardiology, 2010, Mar-30, Volume: 55, Issue:13

    Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Denmark; Female; Heart Failure; Humans; Ma

2010
Clopidogrel and heart failure survival: missed opportunity or wrong turn?
    Journal of the American College of Cardiology, 2010, Mar-30, Volume: 55, Issue:13

    Topics: Clopidogrel; Denmark; Heart Failure; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors;

2010
Acute coronary syndrome and severe haemophilia: an unusual association with challenging treatment.
    Thrombosis and haemostasis, 2010, Volume: 103, Issue:6

    Topics: Acute Coronary Syndrome; Anticoagulants; Clopidogrel; Coagulants; Comorbidity; Coronary Angiography;

2010
Adverse events after stopping clopidogrel in post-acute coronary syndrome patients: Insights from a large integrated healthcare delivery system.
    Circulation. Cardiovascular quality and outcomes, 2010, Volume: 3, Issue:3

    Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Clopidog

2010
If I take the blood thinner Plavix, should I avoid using Prilosec or other heartburn medications?
    Mayo Clinic women's healthsource, 2010, Volume: 14, Issue:5

    Topics: Anti-Ulcer Agents; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Health Knowledge, Atti

2010
Non-invasive coronary flow reserve after successful primary angioplasty for acute anterior myocardial infarction is an independent predictor of left ventricular adverse remodelling.
    European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology, 2010, Volume: 11, Issue:8

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Echocardiography; Female; Fractional Flow Rese

2010
Delays in filling clopidogrel prescription after hospital discharge and adverse outcomes after drug-eluting stent implantation: implications for transitions of care.
    Circulation. Cardiovascular quality and outcomes, 2010, Volume: 3, Issue:3

    Topics: Cardiovascular Diseases; Chemotherapy, Adjuvant; Clopidogrel; Drug-Eluting Stents; Female; Follow-Up

2010
Relationship between chronic obstructive pulmonary disease and in-hospital management and outcomes in patients with acute myocardial infarction.
    Kardiologia polska, 2010, Volume: 68, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Comorbidity; Female; Health Services Accessibility; Hospital Mortality;

2010
[Thrombosis of pharmacoactive coronary endoprothesis after stopping antiplatelet treatment].
    La Tunisie medicale, 2010, Volume: 88, Issue:1

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Cholecystectomy, Laparoscopic; Cholecystolithiasis; Clopido

2010
Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor.
    Archives of internal medicine, 2010, Apr-26, Volume: 170, Issue:8

    Topics: Age Factors; Aged; Aged, 80 and over; Case-Control Studies; Clopidogrel; Cohort Studies; Confidence

2010
Thrombus too big for pharmacology alone?
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2010, May-01, Volume: 75, Issue:6

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Coronary Thrombosis; Humans;

2010
Increased risk of bleeding in patients on clopidogrel therapy after drug-eluting stents implantation: insights from the HMO Research Network-Stent Registry (HMORN-stent).
    Circulation. Cardiovascular interventions, 2010, Jun-01, Volume: 3, Issue:3

    Topics: Aged; Clopidogrel; Comorbidity; Drug-Eluting Stents; Female; Follow-Up Studies; Health Maintenance O

2010
[Interview with Prof. Franz-Joseph Krozingen: Interventional cardiology on the success course].
    MMW Fortschritte der Medizin, 2010, Apr-01, Volume: 152, Issue:13

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Cardiology; Clinical Trials as Topic; Clopi

2010
Clinician-patient discord: exploring differences in perspectives for discontinuing clopidogrel.
    European journal of cardiovascular nursing, 2011, Volume: 10, Issue:1

    Topics: Aged; Attitude of Health Personnel; Attitude to Health; Clopidogrel; Communication; Comorbidity; Dru

2011
[Experience of treatment of patients with myocardial infarction without raise of ST segment on ECG of high risk of cardiocomplications by method of coronary angioplasty].
    Voenno-meditsinskii zhurnal, 2010, Volume: 331, Issue:1

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Elect

2010
[Interview with Prof. Uwe Zeymer, Ludwgshaven Clinic. Infarct register reveals high "loss ratios" in treatment (interview by Sonja Bohm)].
    MMW Fortschritte der Medizin, 2010, May-20, Volume: 152, Issue:20

    Topics: Aspirin; Clopidogrel; Drug Administration Schedule; Drug Combinations; Follow-Up Studies; Germany; G

2010
Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden: a lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulations.
    Applied health economics and health policy, 2010, Volume: 8, Issue:4

    Topics: Aged; Aspirin; Atherosclerosis; Clopidogrel; Cost-Benefit Analysis; Female; Humans; Male; Markov Cha

2010
[Managing myocardial infarct in general practice].
    Praxis, 2010, Jul-07, Volume: 99, Issue:14

    Topics: Acute Coronary Syndrome; Algorithms; Angina, Unstable; Anticoagulants; Atorvastatin; Blood Chemical

2010
[The problems of antiaggregant therapy of patients with acute myocardial infarction. Experience with the use of clopidogrel].
    Kardiologiia, 2010, Volume: 50, Issue:7

    Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Drugs, Generic; Electrocardiography; Health Care Co

2010
Risk of drug-eluting stent thrombosis in patients receiving proton pump inhibitors.
    Thrombosis and haemostasis, 2010, Volume: 104, Issue:3

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Chi-Square Distribution; Clopidogrel; Comorbidity; Co

2010
Duration of clopidogrel therapy with drug-eluting stents.
    The New England journal of medicine, 2010, 07-29, Volume: 363, Issue:5

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Schedule

2010
Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model.
    Thrombosis and haemostasis, 2010, Volume: 104, Issue:3

    Topics: Adenosine; Animals; Bleeding Time; Blood Coagulation; Clopidogrel; Coronary Circulation; Coronary Th

2010
Pattern of clopidogrel use in hospitalized patients receiving percutaneous coronary interventions.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2010, Sep-01, Volume: 67, Issue:17

    Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Coro

2010
Comparison of platelet reactivity and periprocedural outcomes in patients with versus without diabetes mellitus and treated with clopidogrel and percutaneous coronary intervention.
    The American journal of cardiology, 2010, Sep-01, Volume: 106, Issue:5

    Topics: Aged; Angioplasty, Balloon, Coronary; Case-Control Studies; Clopidogrel; Cohort Studies; Coronary St

2010
[Registries of myocardial infarction in Germany. Consequences for drug therapy of patients with acute ST elevation myocardial infarction].
    Der Internist, 2010, Volume: 51, Issue:10

    Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angina, Unstable; Angioplasty, Balloon, Corona

2010
Mid-term outcomes of patients with PCI prior to CABG in comparison to patients with primary CABG.
    Vascular health and risk management, 2010, Aug-09, Volume: 6

    Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Case-Control Studies; Clopidogrel; Coronary

2010
Letter by Serebruany regarding article, "Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the Trial to Assess Improvement in Therapeutic Outcomes by O
    Circulation, 2010, Aug-24, Volume: 122, Issue:8

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Cost-Benefit Analysis; Humans;

2010
General thoracic surgery is safe in patients taking clopidogrel (Plavix).
    The Journal of thoracic and cardiovascular surgery, 2010, Volume: 140, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Alabama; Angioplasty, Balloon, Coronary; Blood Loss, Surgical; Case-

2010
Atorvastatin for reduction of myocardial damage during angioplasty trials.
    Journal of cardiovascular medicine (Hagerstown, Md.), 2010, Volume: 11, Issue:10

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents; Atorvastatin; Clo

2010
Frequency and risk of noncardiac surgery after drug-eluting stent implantation.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2011, Jun-01, Volume: 77, Issue:7

    Topics: Aged; Angioplasty, Balloon, Coronary; Chi-Square Distribution; Clopidogrel; Drug-Eluting Stents; Fem

2011
Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry).
    American heart journal, 2010, Volume: 160, Issue:3

    Topics: Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Humans; Myocardial

2010
Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events.
    American heart journal, 2010, Volume: 160, Issue:3

    Topics: Aged; Alleles; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Biotransformation; Car

2010
Duration of clopidogrel therapy with drug-eluting stents.
    The New England journal of medicine, 2010, 07-29, Volume: 363, Issue:5

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Schedule

2010
Acute and subacute stent thrombosis after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: incidence, predictors and clinical outcome.
    Journal of thrombosis and haemostasis : JTH, 2010, Volume: 8, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Female; Humans; Incidence; Male; Middle Aged; Myo

2010
Conflicting evidence surrounding the clopidogrel and proton pump inhibitor drug interaction.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Clopidogrel; Coronary Restenosis; Drug Interactions; Drug Therapy, Combination; Humans; Myocardial I

2010
Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study.
    Annals of internal medicine, 2010, Sep-21, Volume: 153, Issue:6

    Topics: Adult; Cardiovascular Diseases; Clopidogrel; Cohort Studies; Drug Interactions; Drug Therapy, Combin

2010
Conflicting evidence: what's a clinician to do?
    Annals of internal medicine, 2010, Sep-21, Volume: 153, Issue:6

    Topics: Cardiovascular Diseases; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Evidence-Based M

2010
Increased use of acid-suppressing drugs before the occurrence of ischemic events: a potential source of confounding in recent observational studies.
    Pharmacotherapy, 2010, Volume: 30, Issue:10

    Topics: Adult; Aged; Angina, Unstable; Cardiovascular Diseases; Clopidogrel; Cohort Studies; Confounding Fac

2010
Outcomes related to antiplatelet or anticoagulation use in patients undergoing carotid endarterectomy.
    Annals of vascular surgery, 2011, Volume: 25, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Chi-Square Distribution; Clopidogrel; Endar

2011
[Does dual antiplatelet therapy always require gastroprotection? Tailored medical therapy should prevail over the generalized prescription of proton pump inhibitors in patients on dual antiplatelet therapy].
    Giornale italiano di cardiologia (2006), 2010, Volume: 11, Issue:6

    Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Elect

2010
Cytochrome P450 2C19 polymorphism, suboptimal reperfusion and all-cause mortality in patients with acute myocardial infarction.
    Cardiology, 2010, Volume: 117, Issue:2

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 C

2010
Acute myocardial infarction and renal infarction in a bodybuilder using anabolic steroids.
    Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2010, Volume: 38, Issue:4

    Topics: Adult; Anabolic Agents; Angiography; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopid

2010
Three-month dual antiplatelet therapy after implantation of zotarolimus-eluting stents: the DATE (Duration of Dual Antiplatelet Therapy AfterImplantation of Endeavor Stent) registry.
    Circulation journal : official journal of the Japanese Circulation Society, 2010, Volume: 74, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Chi-Square Distribution; Clopi

2010
Letter by Lozano et al regarding article, "Increased risk of bleeding in patients on clopidogrel therapy after drug-eluting stents implantation: insights from the HMO Research Network-Stent Registry (HMORN-stent)".
    Circulation. Cardiovascular interventions, 2010, Volume: 3, Issue:5

    Topics: Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Humans; Myocardial Infarction; Postoperat

2010
Comparison of platelet P2Y(12) ADP receptor-mediated pathway inhibition in triple versus dual antiplatelet therapy as assessed by VASP-phosphorylation in Japanese patients undergoing coronary stenting.
    International heart journal, 2010, Volume: 51, Issue:5

    Topics: Aged; Angioplasty, Balloon, Coronary; Blood Proteins; Cell Adhesion Molecules; Cilostazol; Clopidogr

2010
[Effect of duration of clopidogrel use on clinical follow-up outcomes in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention].
    Zhonghua yi xue za zhi, 2010, Jun-22, Volume: 90, Issue:24

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Drug-Eluting Stents; Female; Follow-Up Studies; H

2010
Frequency of left ventricular thrombus in patients with anterior wall acute myocardial infarction treated with percutaneous coronary intervention and dual antiplatelet therapy.
    The American journal of cardiology, 2010, Nov-01, Volume: 106, Issue:9

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Chi-Square Distribution; Clopidogrel; Combined Modali

2010
Frequency of left ventricular thrombus in patients with anterior wall acute myocardial infarction treated with percutaneous coronary intervention and dual antiplatelet therapy.
    The American journal of cardiology, 2010, Nov-01, Volume: 106, Issue:9

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Chi-Square Distribution; Clopidogrel; Combined Modali

2010
Frequency of left ventricular thrombus in patients with anterior wall acute myocardial infarction treated with percutaneous coronary intervention and dual antiplatelet therapy.
    The American journal of cardiology, 2010, Nov-01, Volume: 106, Issue:9

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Chi-Square Distribution; Clopidogrel; Combined Modali

2010
Frequency of left ventricular thrombus in patients with anterior wall acute myocardial infarction treated with percutaneous coronary intervention and dual antiplatelet therapy.
    The American journal of cardiology, 2010, Nov-01, Volume: 106, Issue:9

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Chi-Square Distribution; Clopidogrel; Combined Modali

2010
Comparison of 600 versus 300-mg Clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary coronary angioplasty.
    The American journal of cardiology, 2010, Nov-01, Volume: 106, Issue:9

    Topics: Aged; Angioplasty, Balloon, Coronary; Chi-Square Distribution; Clopidogrel; Combined Modality Therap

2010
Peak cardiac troponin-T level, scintigraphic myocardial infarct size and one-year prognosis in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction.
    The American journal of cardiology, 2010, Nov-01, Volume: 106, Issue:9

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Clopidogrel; Combined Modality Therapy; Creatin

2010
Role of intramural platelet thrombus in the pathogenesis of wall rupture and intra-ventricular thrombosis following acute myocardial infarction.
    Thrombosis and haemostasis, 2011, Volume: 105, Issue:2

    Topics: Animals; Aspirin; Blood Platelets; Clopidogrel; Disease Models, Animal; Hemodynamics; Inflammation;

2011
Clinical impact of enhanced inhibition of P2Y12-mediated platelet aggregation in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.
    Hospital practice (1995), 2010, Volume: 38, Issue:4

    Topics: Adenosine; Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Moda

2010
Risk of recurrent myocardial infarction with the concomitant use of clopidogrel and proton pump inhibitors.
    Alimentary pharmacology & therapeutics, 2011, Volume: 33, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Case-Control Studies; Clopidogrel; Combined Modality The

2011
Coprescription of clopidogrel and proton pump inhibitors.
    BMJ (Clinical research ed.), 2010, Nov-18, Volume: 341

    Topics: Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Aggregation Inhibito

2010
Impact of cytochrome P450 2C19*2 polymorphism on intra-stent thrombus after drug-eluting stent implantation in Japanese patients receiving clopidogrel.
    Circulation journal : official journal of the Japanese Circulation Society, 2011, Volume: 75, Issue:1

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Asian People; Cardiovascular Ag

2011
[Evidence-based management of ST-segment elevation myocardial infarction (STEMI). Latest guidelines of the European Society of Cardiology (ESC) 2010].
    Herz, 2010, Volume: 35, Issue:8

    Topics: Aftercare; Anticoagulants; Cardiovascular Agents; Clopidogrel; Combined Modality Therapy; Contraindi

2010
An algorithm for use of prasugrel (effient) in patients undergoing cardiac catheterization and percutaneous coronary intervention.
    Critical pathways in cardiology, 2010, Volume: 9, Issue:4

    Topics: Angioplasty, Balloon, Coronary; Cardiac Catheterization; Clinical Protocols; Clinical Trials as Topi

2010
Hybrid revascularization, comprising coronary artery bypass graft with exclusive arterial conduits followed by early drug-eluting stent implantation, in multivessel coronary artery disease.
    Archives of cardiovascular diseases, 2010, Volume: 103, Issue:10

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Case-Control Studies; Chi-Square Distribution; Clopid

2010
What is the optimal duration of triple anti-platelet therapy in patients with acute myocardial infarction undergoing drug-eluting stent implantation?
    Journal of cardiology, 2011, Volume: 57, Issue:1

    Topics: Aspirin; Cilostazol; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Female; Follow-Up Studie

2011
[Acute myocardial infarction: importance of the networking in the initial management].
    Revue medicale suisse, 2010, Nov-17, Volume: 6, Issue:271

    Topics: Clopidogrel; Humans; Information Services; Myocardial Infarction; Myocardial Revascularization; Plat

2010
Dosing of clopidogrel and aspirin in acute coronary syndromes.
    The New England journal of medicine, 2010, 12-16, Volume: 363, Issue:25

    Topics: Acute Coronary Syndrome; Algorithms; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clop

2010
Concomitant use of proton pump inhibitors and clopidogrel in patients with coronary, cerebrovascular, or peripheral artery disease in the factores de Riesgo y ENfermedad Arterial (FRENA) registry.
    Journal of cardiovascular pharmacology, 2011, Volume: 57, Issue:1

    Topics: Aged; Cerebrovascular Disorders; Clopidogrel; Contraindications; Coronary Artery Disease; Drug Inter

2011
Clinical and angiographic outcomes with sirolimus-eluting stent for coronary bifurcation lesions. The J-PMS study.
    Circulation journal : official journal of the Japanese Circulation Society, 2011, Volume: 75, Issue:2

    Topics: Angioplasty; Aspirin; Calcinosis; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Coro

2011
Frequency and location of yellow and disrupted coronary plaques in patients as detected by angioscopy.
    Circulation journal : official journal of the Japanese Circulation Society, 2011, Volume: 75, Issue:3

    Topics: Acute Coronary Syndrome; Aged; Angioscopy; Aspirin; Clopidogrel; Coronary Artery Disease; Disease Pr

2011
What you need to know about Clopidogrel. This drug helps to prevent the blood clots that can cause heart attacks and stroke.
    Heart advisor, 2009, Volume: 12, Issue:8

    Topics: Clopidogrel; Health Knowledge, Attitudes, Practice; Heart Diseases; Humans; Myocardial Infarction; P

2009
Clopidogrel Resistance: case reports of CYP2C19 gene variants in suspected coronary stent thrombosis.
    Heart, lung & circulation, 2011, Volume: 20, Issue:10

    Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Stenosis; Cytochrome P-450 CYP2C19; Drug Resist

2011
Calcium-channel blockers do not alter the clinical efficacy of clopidogrel after myocardial infarction: a nationwide cohort study.
    Journal of the American College of Cardiology, 2011, Jan-25, Volume: 57, Issue:4

    Topics: Aged; Calcium Channel Blockers; Cause of Death; Clopidogrel; Cohort Studies; Confidence Intervals; D

2011
Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocard
    Circulation, 2011, Feb-08, Volume: 123, Issue:5

    Topics: Aged; Aged, 80 and over; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cohort Studies; Cytochrome P-45

2011
Comparison of 600 versus 300-mg clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary coronary angioplasty.
    The American journal of cardiology, 2011, Feb-15, Volume: 107, Issue:4

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Electrocardiography; Heart Conduction System; Humans; M

2011
Recurrent myocardial infarction due to one subacute and two very late thrombotic events of drug-eluting stent associated with clopidogrel resistance.
    The Journal of invasive cardiology, 2011, Volume: 23, Issue:2

    Topics: Adult; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Drug

2011
Has the ClOpidogrel and Metoprolol in Myocardial Infarction Trial (COMMIT) of early β-blocker use in acute coronary syndromes impacted on clinical practice in Canada? Insights from the Global Registry of Acute Coronary Events (GRACE).
    American heart journal, 2011, Volume: 161, Issue:2

    Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Canada; Clopidogrel;

2011
Standard versus high loading doses of clopidogrel in Asian ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention: insights from the Korea Acute Myocardial Infarction Registry.
    American heart journal, 2011, Volume: 161, Issue:2

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarctio

2011
Impact of smoking on acute phase outcomes of myocardial infarction.
    Coronary artery disease, 2011, Volume: 22, Issue:4

    Topics: Acute Disease; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Drug-Eluting Stents; Female; Human

2011
Total occlusion of aortic arch in a 62-year-old man presenting with acute myocardial infarction.
    Journal of cardiovascular medicine (Hagerstown, Md.), 2011, Volume: 12, Issue:6

    Topics: Angioplasty, Balloon, Coronary; Aorta, Thoracic; Aortic Diseases; Clopidogrel; Coronary Angiography;

2011
Safety of clopidogrel and proton pump inhibitors in patients undergoing drug-eluting stent implantation.
    Coronary artery disease, 2011, Volume: 22, Issue:3

    Topics: Acute Coronary Syndrome; Aged; Blood Vessel Prosthesis Implantation; Clopidogrel; Cohort Studies; Co

2011
Efficacy of post-operative clopidogrel treatment in patients revascularized with coronary artery bypass grafting after myocardial infarction.
    Journal of the American College of Cardiology, 2011, Mar-08, Volume: 57, Issue:10

    Topics: Aged; Clopidogrel; Combined Modality Therapy; Comorbidity; Coronary Artery Bypass; Denmark; Female;

2011
An initial experiment with personalized antiplatelet therapy: the GRAVITAS trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationship, Dr

2011
Temporal trends and practice variations in clopidogrel loading doses in patients with non-ST-segment elevation myocardial infarction, from the National Cardiovascular Data Registry.
    American heart journal, 2011, Volume: 161, Issue:4

    Topics: Aged; Aged, 80 and over; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Plat

2011
Efficacy and safety of clopidogrel after PCI with stenting in patients on oral anticoagulants with acute coronary syndrome.
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2011, Volume: 6, Issue:9

    Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Anticoagulants;

2011
Relation between clopidogrel discontinuation and early cardiovascular events after percutaneous coronary intervention with drug-eluting stents.
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2011, Volume: 6, Issue:9

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; District of Columbia; Drug Administration Schedul

2011
Impaired inhibition of P2Y(12) by clopidogrel is a major determinant of cardiac death in diabetes mellitus patients treated by percutaneous coronary intervention.
    Atherosclerosis, 2011, Volume: 217, Issue:2

    Topics: Aged; Angioplasty, Balloon, Coronary; Cell Adhesion Molecules; Chi-Square Distribution; Clopidogrel;

2011
Gastrointestinal bleeding and outcomes after percutaneous coronary intervention for ST-segment elevation myocardial infarction.
    American journal of critical care : an official publication, American Association of Critical-Care Nurses, 2011, Volume: 20, Issue:3

    Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Female; Gastrointestinal Hemor

2011
Optimizing of thienopyridine therapy by multiple electrode platelet aggregometry in clopidogrel low responders undergoing PCI.
    Clinical research in cardiology : official journal of the German Cardiac Society, 2011, Volume: 100, Issue:10

    Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Cerebrovascula

2011
The impact of noncardiac surgery on selection of a revascularization strategy.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2011, Jun-01, Volume: 77, Issue:7

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Drug-Eluting Stents; Humans; Myocardial Infarction; Pat

2011
Diurnal variation in platelet inhibition by clopidogrel.
    Platelets, 2011, Volume: 22, Issue:8

    Topics: Adenosine Diphosphate; Aged; Blood Platelets; Circadian Rhythm; Clopidogrel; Female; Humans; Male; M

2011
Effect of clopidogrel pretreatment on ischemic complications of percutaneous coronary intervention among bivalirudin-treated patients (from the EVENT registry).
    The American journal of cardiology, 2011, Jun-15, Volume: 107, Issue:12

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Antithrombins; Clopidogrel; Female; H

2011
Early determination of clopidogrel responsiveness by platelet reactivity indexidentifies patients at risk for cardiovascular events after myocardial infarction.
    Thrombosis and haemostasis, 2011, Volume: 106, Issue:1

    Topics: Aged; Clopidogrel; Disease Progression; Drug Resistance; Early Diagnosis; Female; Flow Cytometry; Hu

2011
Effects of platelet and inflammatory system activation on outcomes in diabetic patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention.
    Kardiologia polska, 2011, Volume: 69, Issue:6

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; Diabetes Complicati

2011
Standard- vs high-dose clopidogrel after percutaneous coronary intervention.
    JAMA, 2011, Jun-22, Volume: 305, Issue:24

    Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascular Diseases; Clopidogrel;

2011
Standard- vs high-dose clopidogrel after percutaneous coronary intervention.
    JAMA, 2011, Jun-22, Volume: 305, Issue:24

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Dose-Response Relationship, Drug; Hemorrhage; Humans; M

2011
Percutaneous coronary intervention of unprotected left main coronary artery disease as culprit lesion in patients with acute myocardial infarction.
    JACC. Cardiovascular interventions, 2011, Volume: 4, Issue:6

    Topics: Aged; Angioplasty; Bundle-Branch Block; Clopidogrel; Confidence Intervals; Coronary Artery Disease;

2011
A complex case of angulated and bifurcated lesion facilitated by excimer laser coronary angioplasty.
    Journal of interventional cardiology, 2011, Volume: 24, Issue:6

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Stenosis; Hu

2011
Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    European heart journal, 2011, Volume: 32, Issue:23

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Female; Graft Occlusion, Vascular; Hemor

2011
Massive thrombus burden with recurrence of intracoronary thrombosis early after stenting and delayed onset of prasugrel action in a patient with ST-elevation myocardial infarction and cardiac shock.
    Thrombosis and haemostasis, 2011, Volume: 106, Issue:3

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiopulmonary Resuscitation; Catecholamines; Clopidogrel; Co

2011
Comparison of efficacy and safety of a standard versus a loading dose of clopidogrel for acute myocardial infarction in patients ≥ 75 years of age (from the FAST-MI registry).
    The American journal of cardiology, 2011, Sep-15, Volume: 108, Issue:6

    Topics: Aged; Aged, 80 and over; Analysis of Variance; Blood Transfusion; Clopidogrel; Female; France; Hemor

2011
Late bare-metal stent thrombosis in a patient with Crohn's disease.
    Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology, 2011, Volume: 11, Issue:5

    Topics: Adult; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Crohn Disease; Humans; Male; Myocardial

2011
Reduced antiplatelet therapy after drug-eluting stenting: multicenter Janus Flex carbostent implantation with short dual antiplatelet treatment for 2 or 6 months-MATRIX study.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2012, Sep-01, Volume: 80, Issue:3

    Topics: Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; D

2012
Standard versus high loading doses of clopidogrel in Asian patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: insights from the Korea Acute Myocardial Infarction Registry.
    American heart journal, 2011, Volume: 162, Issue:1

    Topics: Angioplasty, Balloon, Coronary; Asian People; Clopidogrel; Dose-Response Relationship, Drug; Electro

2011
PCI and clopidogrel: antiplatelet responsiveness and patient characteristics.
    Acta cardiologica, 2011, Volume: 66, Issue:3

    Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Cell Adhesion Molecules; Clopidogrel; Drug Resistance;

2011
Clopidogrel use throughout pregnancy in a patient with a drug-eluting coronary stent.
    Obstetrics and gynecology, 2011, Volume: 118, Issue:2 Pt 2

    Topics: Adult; Cesarean Section; Clopidogrel; Cocaine; Drug-Eluting Stents; Female; Humans; Infant, Newborn;

2011
Dose-related effect of statins in venous thrombosis risk reduction.
    The American journal of medicine, 2011, Volume: 124, Issue:9

    Topics: Aged; Aspirin; Atherosclerosis; Cerebral Infarction; Clopidogrel; Cohort Studies; Cross-Sectional St

2011
Non-cardiac surgery in patients with coronary stents: the RECO study.
    Heart (British Cardiac Society), 2011, Volume: 97, Issue:19

    Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Cerebr

2011
Non-cardiac surgery in patients with coronary stents: the RECO study.
    Heart (British Cardiac Society), 2011, Volume: 97, Issue:19

    Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Cerebr

2011
Non-cardiac surgery in patients with coronary stents: the RECO study.
    Heart (British Cardiac Society), 2011, Volume: 97, Issue:19

    Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Cerebr

2011
Non-cardiac surgery in patients with coronary stents: the RECO study.
    Heart (British Cardiac Society), 2011, Volume: 97, Issue:19

    Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Cerebr

2011
Recent trends in Australian percutaneous coronary intervention practice: insights from the Melbourne Interventional Group registry.
    The Medical journal of Australia, 2011, Aug-01, Volume: 195, Issue:3

    Topics: Age Factors; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Australia; Clopidogrel; Comorb

2011
Sensitive troponin I assay in patients with suspected acute coronary syndrome.
    JAMA, 2011, Aug-03, Volume: 306, Issue:5

    Topics: Acute Coronary Syndrome; Clopidogrel; Creatinine; Humans; Myocardial Infarction; Myocardial Ischemia

2011
Influence of platelet reactivity on outcome of patients with acute myocardial infarction undergoing primary angioplasty.
    Circulation journal : official journal of the Japanese Circulation Society, 2011, Volume: 75, Issue:9

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Female; Humans; Male; Myocardial I

2011
Clopidogrel after coronary artery bypass graft surgery: insufficient evidence.
    Journal of the American College of Cardiology, 2011, Aug-30, Volume: 58, Issue:10

    Topics: Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine

2011
The unknown effect of clopidogrel resistance in dual antiplatelet therapies after coronary artery bypass grafting.
    Journal of the American College of Cardiology, 2011, Aug-30, Volume: 58, Issue:10

    Topics: Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine

2011
Clopidogrel discontinuation after acute coronary syndromes: frequency, predictors and associations with death and myocardial infarction--a hospital registry-primary care linked cohort (MINAP-GPRD).
    European heart journal, 2011, Volume: 32, Issue:19

    Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Clopidogrel; Cohort Studies; Death, Sudden,

2011
Three-year clinical outcome with the Endeavor™ zotarolimus-eluting stent in primary percutaneous coronary intervention for ST elevation myocardial infarction: the Endeavor™ primary PCI study (E-PPCI).
    Journal of interventional cardiology, 2011, Volume: 24, Issue:6

    Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Confidence Intervals; Drug-Elu

2011
Desperate times, desperate measures: rotablating dissections in acute myocardial infarction.
    The Journal of invasive cardiology, 2011, Volume: 23, Issue:9

    Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aortic Dissection; Aspirin; Atherectomy, Coron

2011
Use of prasugrel in a patient with clopidogrel hypersensitivity.
    The Annals of pharmacotherapy, 2011, Volume: 45, Issue:10

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Drug Hypersensitivity; Humans; Male; Middle Aged; Myoca

2011
Letter by Hnid and Chtioui regarding article, "Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of
    Circulation, 2011, Sep-13, Volume: 124, Issue:11

    Topics: Aryl Hydrocarbon Hydroxylases; Female; Humans; Male; Myocardial Infarction; Proton Pump Inhibitors;

2011
The use of ticagrelor in a patient at increased risk of stent thrombosis resistant to multiple thienopyridines.
    Cardiology, 2011, Volume: 119, Issue:2

    Topics: Adenosine; Aged, 80 and over; Cardiac Catheterization; Clopidogrel; Drug-Eluting Stents; Humans; Mal

2011
Effect of paraoxonase-1 polymorphism on clinical outcomes in patients treated with clopidogrel after an acute myocardial infarction.
    Clinical pharmacology and therapeutics, 2011, Volume: 90, Issue:4

    Topics: Aged; Aged, 80 and over; Aryldialkylphosphatase; Clopidogrel; Female; Follow-Up Studies; Genotype; H

2011
Clopidogrel pre-treatment is associated with reduced in-hospital mortality in primary percutaneous coronary intervention for acute ST-elevation myocardial infarction.
    European heart journal, 2011, Volume: 32, Issue:23

    Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Austria; Clopidogrel; Female; Hospital Mortali

2011
Residual platelet reactivity after aspirin and clopidogrel treatment predicts 2-year major cardiovascular events in patients undergoing percutaneous coronary intervention.
    European journal of internal medicine, 2011, Volume: 22, Issue:5

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug T

2011
High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.
    JAMA, 2011, Sep-21, Volume: 306, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angioplasty; Aspirin; Clopidogrel; Death; Fema

2011
High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.
    JAMA, 2011, Sep-21, Volume: 306, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angioplasty; Aspirin; Clopidogrel; Death; Fema

2011
High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.
    JAMA, 2011, Sep-21, Volume: 306, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angioplasty; Aspirin; Clopidogrel; Death; Fema

2011
High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.
    JAMA, 2011, Sep-21, Volume: 306, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angioplasty; Aspirin; Clopidogrel; Death; Fema

2011
Applying platelet function testing in clinical practice: what are the unmet needs?
    JAMA, 2011, Sep-21, Volume: 306, Issue:11

    Topics: Acute Coronary Syndrome; Clopidogrel; Cohort Studies; Death; Humans; Myocardial Infarction; Platelet

2011
Aborted myocardial infarction in a patient with rapid progression of Wellens syndrome.
    The Journal of emergency medicine, 2012, Volume: 43, Issue:3

    Topics: Aspirin; Clopidogrel; Coronary Stenosis; Early Diagnosis; Electrocardiography; Humans; Male; Middle

2012
Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2011, Nov-08, Volume: 183, Issue:16

    Topics: Adrenal Cortex Hormones; Age Factors; Aged; Anemia; Angioplasty; Anticoagulants; Antihypertensive Ag

2011
Use of early clopidogrel by reperfusion strategy among patients presenting with ST-segment elevation myocardial infarction.
    Circulation. Cardiovascular quality and outcomes, 2011, Nov-01, Volume: 4, Issue:6

    Topics: Administration, Cutaneous; Aged; Angioplasty; Clopidogrel; Coronary Vessels; Electrocardiography; Fe

2011
Platelet response to standard aspirin and clopidogrel treatment correlates with long-term outcome in patients with acute ST-elevation myocardial infarction.
    International journal of cardiology, 2011, Dec-01, Volume: 153, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Clopidogrel; Drug Therapy, Combination; Fe

2011
Unraveling the pharmacogenetics of clopidogrel: the paraoxonase-1 controversy.
    Circulation. Cardiovascular interventions, 2011, Oct-01, Volume: 4, Issue:5

    Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Humans; Male; Myocardi

2011
Leucocytoclastic vasculitis associated with clopidogrel.
    Cutaneous and ocular toxicology, 2012, Volume: 31, Issue:2

    Topics: Clopidogrel; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Puri

2012
Safety and efficacy of a pharmaco-invasive reperfusion strategy in rural ST-elevation myocardial infarction patients with expected delays due to long-distance transfers.
    European heart journal, 2012, Volume: 33, Issue:10

    Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Emergency T

2012
Selecting the optimal stroke prevention therapy in atrial fibrillation.
    Annals of internal medicine, 2011, Nov-01, Volume: 155, Issue:9

    Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhib

2011
Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin.
    Circulation. Cardiovascular interventions, 2011, Dec-01, Volume: 4, Issue:6

    Topics: Aged; Alleles; Aryl Hydrocarbon Hydroxylases; Asia, Eastern; Asian People; Aspirin; Blood Platelets;

2011
The HEART study: a real-world experience using the CID Chrono Carbostent in primary and rescue PCI.
    Journal of cardiovascular medicine (Hagerstown, Md.), 2012, Volume: 13, Issue:12

    Topics: Aged; Aspirin; Chi-Square Distribution; Chromium Alloys; Clopidogrel; Coated Materials, Biocompatibl

2012
Concomitant use of clopidogrel and proton pump inhibitors is not associated with major adverse cardiovascular events following coronary stent implantation.
    Alimentary pharmacology & therapeutics, 2012, Volume: 35, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Catheter Ablation; Clopidogrel; Cohort Studies; Cytochrome P-450 Enz

2012
High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study.
    European heart journal, 2012, Volume: 33, Issue:10

    Topics: Acute Coronary Syndrome; Adult; Age Factors; Aged; Aged, 80 and over; Clopidogrel; Cross-Sectional S

2012
PON1 Q192R and clopidogrel: a case of the winner's curse or inadequate replication?
    Clinical pharmacology and therapeutics, 2011, Volume: 90, Issue:6

    Topics: Aryldialkylphosphatase; Cardiovascular Diseases; Female; Genetic Association Studies; Genetic Variat

2011
Unveiling the mysteries of clopidogrel metabolism and efficacy.
    Clinical pharmacology and therapeutics, 2011, Volume: 90, Issue:6

    Topics: Aryldialkylphosphatase; Cardiovascular Diseases; Female; Genetic Association Studies; Genetic Variat

2011
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
    JAMA, 2011, Nov-16, Volume: 306, Issue:19

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure;

2011
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
    JAMA, 2011, Nov-16, Volume: 306, Issue:19

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure;

2011
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
    JAMA, 2011, Nov-16, Volume: 306, Issue:19

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure;

2011
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
    JAMA, 2011, Nov-16, Volume: 306, Issue:19

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure;

2011
[Clopidogrel induced thrombotic thrombocytopenic purpura].
    La Revue de medecine interne, 2011, Volume: 32, Issue:12

    Topics: Clopidogrel; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Purp

2011
Clinical outcomes following coronary stenting in Japanese patients treated with and without proton pump inhibitor.
    Circulation journal : official journal of the Japanese Circulation Society, 2012, Volume: 76, Issue:1

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Asian People; Aspirin; Clopidogrel; Coronar

2012
The relevance of P2Y(12)-receptor gene variation for the outcome of clopidogrel-treated patients undergoing elective coronary stent implantation: a clinical follow-up.
    Thrombosis and haemostasis, 2012, Volume: 107, Issue:1

    Topics: Adenosine Diphosphate; Aged; Aspirin; Clopidogrel; Female; Follow-Up Studies; Genetic Variation; Hum

2012
Bleeding complications in primary percutaneous coronary intervention of ST-elevation myocardial infarction in a radial center.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2012, Jan-01, Volume: 79, Issue:1

    Topics: Abciximab; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidog

2012
PPI co-therapy did not adversely affect outcomes in clopidogrel users.
    Alimentary pharmacology & therapeutics, 2012, Volume: 35, Issue:2

    Topics: Cytochrome P-450 Enzyme Inhibitors; Female; Gastroesophageal Reflux; Humans; Male; Myocardial Infarc

2012
High residual platelet reactivity and thrombotic events.
    JAMA, 2011, Dec-21, Volume: 306, Issue:23

    Topics: Acute Coronary Syndrome; Female; Humans; Male; Myocardial Infarction; Platelet Adhesiveness; Platele

2011
Predicting clopidogrel response using DNA samples linked to an electronic health record.
    Clinical pharmacology and therapeutics, 2012, Volume: 91, Issue:2

    Topics: Aged; Aryl Hydrocarbon Hydroxylases; Aryldialkylphosphatase; ATP Binding Cassette Transporter, Subfa

2012
Myocardial infarction in an young patient associated with oral contraceptive, smoking and elevated cholesterol level.
    Archives of gynecology and obstetrics, 2012, Volume: 285, Issue:6

    Topics: Abortion, Induced; Adult; Anticholesteremic Agents; Anticoagulants; Atorvastatin; Clopidogrel; Contr

2012
Effect of individual proton pump inhibitors on cardiovascular events in patients treated with clopidogrel following coronary stenting: results from the Ibaraki Cardiac Assessment Study Registry.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2012, Oct-01, Volume: 80, Issue:4

    Topics: Aged; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Drug Interactions; Female; Gast

2012
Effect size of ticagrelor over clopidogrel in the Platelet Inhibition and Patient Outcomes (PLATO) trial: from statistics to clinical judgment.
    Journal of cardiovascular medicine (Hagerstown, Md.), 2012, Volume: 13, Issue:2

    Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopid

2012
Beneficial impact of prolonged dual antiplatelet therapy after drug-eluting stent implantation.
    Journal of interventional cardiology, 2012, Volume: 25, Issue:6

    Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Male; Middle A

2012
CYP2C19 and clopidogrel response: more than validation in the real world.
    Clinical pharmacology and therapeutics, 2012, Volume: 91, Issue:2

    Topics: Clopidogrel; Databases, Nucleic Acid; Electronic Health Records; Female; Humans; Male; Myocardial In

2012
Extension of Kaplan-Meier methods in observational studies with time-varying treatment.
    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2012, Volume: 15, Issue:1

    Topics: Age Factors; Aged; Clopidogrel; Comorbidity; Confounding Factors, Epidemiologic; Coronary Artery Dis

2012
Toward a therapeutic window for antiplatelet therapy in the elderly.
    European heart journal, 2012, Volume: 33, Issue:10

    Topics: Acute Coronary Syndrome; Clopidogrel; Female; Humans; Male; Myocardial Infarction; Piperazines; Plat

2012
Successful use of glycoprotein IIb/IIIa inhibitor, heparin, and IABP during PCI in a post-neurosurgical patient with STEMI and cardiogenic shock due to very late bare-metal stent thrombosis.
    The Journal of invasive cardiology, 2012, Volume: 24, Issue:2

    Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Heparin; Humans; Intra-Aortic

2012
[The GRAVITAS study].
    Giornale italiano di cardiologia (2006), 2012, Volume: 13, Issue:1

    Topics: Algorithms; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Administration Schedule; Drug-Eluting

2012
[Perioperative management of antiplatelet therapy in thoracic surgery. A survey of German hospitals].
    Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2012, Volume: 83, Issue:6

    Topics: Arterial Occlusive Diseases; Aspirin; Attitude of Health Personnel; Brain Ischemia; Clopidogrel; Com

2012
Spontaneous remission after a year of romiplostim in an adult patient with refractory primary immune thrombocytopenia.
    Annals of hematology, 2012, Volume: 91, Issue:9

    Topics: Antibodies, Monoclonal, Murine-Derived; Anticoagulants; Aspirin; Clopidogrel; Drug Resistance; Hemor

2012
Serotonin antagonism improves platelet inhibition in clopidogrel low-responders after coronary stent placement: an in vitro pilot study.
    PloS one, 2012, Volume: 7, Issue:2

    Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Humans; In Vitro Techn

2012
High on-treatment platelet reactivity by ADP and increased risk of MACE in good clopidogrel metabolizers.
    Platelets, 2012, Volume: 23, Issue:8

    Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Alleles; Aryl Hydroc

2012
Time-dependent changes of myeloperoxidase in relation to in-hospital mortality in patients with the first anterior ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention.
    Clinical biochemistry, 2012, Volume: 45, Issue:7-8

    Topics: Aged; Angioplasty; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Blood Chemical Analysis; Clo

2012
A high loading dose of clopidogrel reduces myocardial infarct size in patients undergoing primary percutaneous coronary intervention: a magnetic resonance imaging study.
    American heart journal, 2012, Volume: 163, Issue:3

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Dose-Response Relationship, Drug; Female; Humans;

2012
[Letter to Kardiologia Polska concerning optimal treatment of myocardial infarction].
    Kardiologia polska, 2012, Volume: 70, Issue:2

    Topics: Adenosine; Clopidogrel; Cost-Benefit Analysis; Humans; Models, Theoretical; Myocardial Infarction; P

2012
[Optimal antiplatelet and antithrombotic therapy in patients with ST elevation myocardial infarction].
    Kardiologia polska, 2012, Volume: 70, Issue:2

    Topics: Abciximab; Adenosine; Antibodies, Monoclonal; Clopidogrel; Drug Therapy, Combination; Fibrinolytic A

2012
Are the results of a regional ST-elevation myocardial infarction system reproducible?
    The American journal of cardiology, 2012, Jun-01, Volume: 109, Issue:11

    Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clinical Protocols; Clop

2012
Comparison of early outcomes after primary stenting in Japanese patients with acute myocardial infarction between clopidogrel and ticlopidine in concomitant use with proton-pump inhibitor.
    Journal of cardiology, 2012, Volume: 60, Issue:1

    Topics: Aged; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Myocardial Infarction; Platelet

2012
Usefulness of C-reactive protein as a marker of early post-infarct left ventricular systolic dysfunction.
    Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2012, Volume: 61, Issue:7

    Topics: Aged; Angioplasty, Balloon, Coronary; Anti-Arrhythmia Agents; Antihypertensive Agents; Aspirin; Biom

2012
Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel.
    Pharmacotherapy, 2012, Volume: 32, Issue:4

    Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Cardiovascular Diseases; Clopidogrel; Comput

2012
Individualised PPI prescription in patients on combination antiplatelet therapy and upper gastrointestinal events after percutaneous coronary intervention: a cohort study.
    Wiener medizinische Wochenschrift (1946), 2012, Volume: 162, Issue:3-4

    Topics: Acute Coronary Syndrome; Adrenal Cortex Hormones; Adverse Drug Reaction Reporting Systems; Aged; Ang

2012
Safety and effectiveness of antithrombotic strategies in older adult patients with atrial fibrillation and non-ST elevation myocardial infarction.
    American heart journal, 2012, Volume: 163, Issue:4

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity; Dose-Response Relat

2012
Dual antiplatelet therapy after myocardial infarction and percutaneous coronary intervention: analysis of patient adherence using a French health insurance reimbursement database.
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2012, Volume: 7, Issue:12

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cohort Studies; Databases, Factual; Drug

2012
Clopidogrel response up to six months after acute myocardial infarction.
    The American journal of cardiology, 2012, Aug-01, Volume: 110, Issue:3

    Topics: Aspirin; Clopidogrel; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; P

2012
Biological efficacy of a 600 mg loading dose of clopidogrel in ST-elevation myocardial infarction.
    Thrombosis and haemostasis, 2012, Volume: 108, Issue:1

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Animals; Clinical Protocols; Clopidog

2012
Effect of glycemic control on response to antiplatelet therapy in patients with diabetes mellitus and ST-segment elevation myocardial infarction.
    The American journal of cardiology, 2012, Aug-01, Volume: 110, Issue:3

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Glucose; Clopidogrel; Diabetic Cardiomyopathies; Elec

2012
Multiple gene polymorphisms predisposing to the prothrombotic state in an adolescent with acute myocardial infarction.
    Cardiovascular journal of Africa, 2012, Apr-12, Volume: 23, Issue:3

    Topics: Adolescent; Anticoagulants; Aspirin; Cholesterol Ester Transfer Proteins; Clopidogrel; Coronary Angi

2012
Very late thrombosis of a paclitaxel-eluting stent after 72 months in a patient on dual anti-platelet therapy.
    Cardiovascular journal of Africa, 2012, Apr-12, Volume: 23, Issue:3

    Topics: Aspirin; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Echocardiography; Electrocardiograph

2012
Clopidogrel use and hospital quality in medically managed patients with non-ST-segment-elevation myocardial infarction.
    Circulation. Cardiovascular quality and outcomes, 2012, Jul-01, Volume: 5, Issue:4

    Topics: Aged; Aged, 80 and over; Chi-Square Distribution; Clopidogrel; Drug Utilization; Female; Guideline A

2012
Dramatic effect of early clopidogrel administration in reducing mortality and MACE rates in ACS patients. Data from the Swiss registry AMIS-Plus.
    Swiss medical weekly, 2012, Volume: 142

    Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aspirin; Cardiac Catheterization; Clopidogr

2012
Peripartum management of dual antiplatelet therapy and neuraxial labor analgesia after bare metal stent insertion for acute myocardial infarction.
    Anesthesia and analgesia, 2012, Volume: 115, Issue:3

    Topics: Adult; Analgesia, Obstetrical; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Eptifibatide; F

2012
Duration of dual antiplatelet therapy and long-term clinical outcome after coronary drug-eluting stent implantation: landmark analyses from the CREDO-Kyoto PCI/CABG Registry Cohort-2.
    Circulation. Cardiovascular interventions, 2012, Volume: 5, Issue:3

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Chi-Square Distribution; Clopidogrel; Cohort Studies;

2012
Prolonged clopidogrel use after bare metal and drug-eluting stent placement: the Veterans Administration drug-eluting stent study.
    Circulation. Cardiovascular interventions, 2012, Volume: 5, Issue:3

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Thera

2012
Dual thienopyridine low-response to clopidogrel and prasugrel in a patient with STEMI, cardiogenic shock and early stent thrombosis is overcome by ticagrelor.
    Platelets, 2012, Volume: 23, Issue:5

    Topics: Adenosine; Aged; Cardiopulmonary Resuscitation; Clopidogrel; Humans; Myocardial Infarction; Piperazi

2012
Platelet reactivity and percutaneous coronary intervention: another clue in the quest for the Holy Grail of tailored antithrombotic therapy?
    Journal of the American College of Cardiology, 2012, Jul-31, Volume: 60, Issue:5

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Antithrombins; Cl

2012
High post-clopidogrel platelet reactivity assessed by a point-of-care assay predicts long-term clinical outcomes in patients with ST-segment elevation myocardial infarction who underwent primary coronary stenting.
    International journal of cardiology, 2013, Sep-01, Volume: 167, Issue:5

    Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Cohort Studies; Drug Therapy, Combination; Female; Huma

2013
Benefits and risks of using clopidogrel before coronary artery bypass surgery: a role of platelet function assessment.
    The Journal of thoracic and cardiovascular surgery, 2012, Volume: 144, Issue:1

    Topics: Coronary Artery Bypass; Coronary Artery Disease; Humans; Myocardial Infarction; Platelet Aggregation

2012
Cardioprotection by clopidogrel in acute ST-elevated myocardial infarction patients: a retrospective analysis.
    Basic research in cardiology, 2012, Volume: 107, Issue:4

    Topics: Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion Injury

2012
Sequential ADP-stimulated light transmission and multiple electrode aggregometry in patients taking aspirin and clopidogrel after non ST-elevation myocardial infarction.
    Scandinavian journal of clinical and laboratory investigation, 2012, Volume: 72, Issue:4

    Topics: Aged; Aspirin; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggre

2012
Combined clopidogrel and aspirin treatment up to surgery increases the risk of postoperative myocardial infarction, blood loss and reoperation for bleeding in patients undergoing coronary artery bypass grafting.
    European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 2013, Volume: 43, Issue:4

    Topics: Aged; Aspirin; Blood Transfusion; Chi-Square Distribution; Clopidogrel; Coronary Artery Bypass; Fema

2013
Amlodipine, clopidogrel and CYP3A5 genetic variability: effects on platelet reactivity and clinical outcomes after percutaneous coronary intervention.
    Heart (British Cardiac Society), 2012, Volume: 98, Issue:18

    Topics: Aged; Amlodipine; Angioplasty, Balloon, Coronary; Clopidogrel; Cytochrome P-450 CYP3A; Drug Interact

2012
The extent of P2Y12 inhibition by clopidogrel in diabetes mellitus patients with acute coronary syndrome is not related to glycaemic control: roles of white blood cell count and body weight.
    Thrombosis and haemostasis, 2012, Volume: 108, Issue:2

    Topics: Acute Coronary Syndrome; Aged; Body Weight; Clopidogrel; Diabetes Complications; Diabetes Mellitus;

2012
Clopidogrel and interaction with proton pump inhibitors: comparison between cohort and within person study designs.
    BMJ (Clinical research ed.), 2012, Jul-10, Volume: 345

    Topics: Aspirin; Clopidogrel; Cohort Studies; Data Collection; Drug Interactions; Humans; Multivariate Analy

2012
Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes.
    The American journal of medicine, 2012, Volume: 125, Issue:9

    Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inh

2012
Clopidogrel efficacy and cigarette smoking status.
    JAMA, 2012, Jun-20, Volume: 307, Issue:23

    Topics: Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 CYP1A2; Humans; Myocardial Infarction; Platel

2012
Clopidogrel discontinuation after myocardial infarction and risk of thrombosis: a nationwide cohort study.
    European heart journal, 2012, Volume: 33, Issue:20

    Topics: Adult; Aged; Clopidogrel; Denmark; Drug Administration Schedule; Epidemiologic Methods; Female; Graf

2012
A potent alternative to clopidogrel emerges. Prasugrel appears to lower heart attack risk for patients with acute coronary syndrome.
    Heart advisor, 2010, Volume: 13, Issue:5

    Topics: Acute Coronary Syndrome; Clopidogrel; Drug Dosage Calculations; Hemorrhage; Humans; Myocardial Infar

2010
Platelet activation and microvascular injury in patients with ST-segment elevation myocardial infarction.
    Kardiologia polska, 2012, Volume: 70, Issue:7

    Topics: Clopidogrel; Comorbidity; Coronary Angiography; Electrocardiography; Female; Humans; Magnetic Field

2012
Ticagrelor FDA approval issues revisited.
    Cardiology, 2012, Volume: 122, Issue:3

    Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials, Phase III as Topic; Clopidogrel; Dose-Response

2012
[CYP2C19 gene polymorphism in patients with myocardial infarction who use clopidogrel].
    Kardiologiia, 2012, Volume: 52, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Biotransformation; Clo

2012
Complex coronary lesions and rotational atherectomy: one hospital's experience.
    Journal of Zhejiang University. Science. B, 2012, Volume: 13, Issue:8

    Topics: Aged; Angiography; Aspirin; Atherectomy, Coronary; Cardiology; Clopidogrel; Comorbidity; Coronary Ar

2012
Simultaneous thromboses of two coronary arteries in a heavy smoker woman: a singular case of acute myocardial infarction.
    Minerva cardioangiologica, 2012, Volume: 60, Issue:4

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents, Non-Steroidal; Antibodies

2012
Effects of 600 mg versus 300 mg loading dose of clopidogrel in Asian patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: long-term follow-up study.
    Yonsei medical journal, 2012, Volume: 53, Issue:5

    Topics: Aged; Clopidogrel; Drug Administration Schedule; Drug-Eluting Stents; Female; Humans; Kaplan-Meier E

2012
Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study.
    Circulation, 2012, Sep-04, Volume: 126, Issue:10

    Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Atrial Fi

2012
Value of platelet pharmacogenetics in common clinical practice of patients with ST-segment elevation myocardial infarction.
    International journal of cardiology, 2013, Sep-10, Volume: 167, Issue:6

    Topics: Aged; Aged, 80 and over; Aryl Hydrocarbon Hydroxylases; Blood Platelets; Clopidogrel; Cohort Studies

2013
Failure of high-dose clopidogrel in recurrent stent thrombosis.
    Singapore medical journal, 2012, Volume: 53, Issue:8

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Drug-Eluting Stents; Humans; Male; Middle Aged; Myocard

2012
Clinical efficacy and safety of biodegradable polymer-based sirolimus-eluting stents in patients with diabetes mellitus insight from the 4-year results of the create study.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2013, Jun-01, Volume: 81, Issue:7

    Topics: Absorbable Implants; Aged; Aspirin; Cardiovascular Agents; Chi-Square Distribution; Clopidogrel; Cor

2013
Association of clopidogrel treatment with risk of mortality and cardiovascular events following myocardial infarction in patients with and without diabetes.
    JAMA, 2012, Sep-05, Volume: 308, Issue:9

    Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Case-Control Studies; Clopidogrel; Data Collection

2012
Antiplatelet therapy following myocardial infarction in patients with diabetes.
    JAMA, 2012, Sep-05, Volume: 308, Issue:9

    Topics: Cardiovascular Diseases; Clopidogrel; Diabetes Mellitus; Female; Humans; Male; Myocardial Infarction

2012
Letter by Fort and Plachetka regarding article, "association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from PLATO".
    Circulation, 2012, Sep-11, Volume: 126, Issue:11

    Topics: Adenosine; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Proton Pump

2012
Association of CYP2C19 genotype with periprocedural myocardial infarction after uneventful stent implantation in Chinese patients receiving clopidogrel pretreatment.
    Circulation journal : official journal of the Japanese Circulation Society, 2012, Volume: 76, Issue:12

    Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Aryl Hydrocarbon Hydroxylases; Asian People; B

2012
Intracoronary GP IIb/IIIa inhibitors: could eptifibatide be the new kid on the block?
    Cardiology, 2012, Volume: 123, Issue:1

    Topics: Clopidogrel; Eptifibatide; Female; Humans; Male; Myocardial Infarction; Myocardial Reperfusion; Pept

2012
Effect of exposure to evidence-based pharmacotherapy on outcomes after acute myocardial infarction in older adults.
    Journal of the American Geriatrics Society, 2012, Volume: 60, Issue:10

    Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angio

2012
Impact of clopidogrel resistance on ST-segment resolution and no-reflow in acute myocardial infarction with ST-elevation patients treated with a primary percutaneous coronary intervention.
    Coronary artery disease, 2012, Volume: 23, Issue:8

    Topics: Clopidogrel; Coronary Angiography; Coronary Circulation; Drug Resistance; Electrocardiography; Femal

2012
The impact of reducing cardiovascular medication copayments on health spending and resource utilization.
    Journal of the American College of Cardiology, 2012, Oct-30, Volume: 60, Issue:18

    Topics: Aged; Cardiology; Cardiovascular Diseases; Case-Control Studies; Clopidogrel; Cost Sharing; Drug The

2012
Limitations of using cardiac catheterization rates to assess the quality of care for patients with non-ST-segment elevation myocardial infarction.
    American heart journal, 2012, Volume: 164, Issue:4

    Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Aged, 80 and over; Aspirin; Cardiac Catheterization; C

2012
Predictors of early, late, and very late stent thrombosis after primary percutaneous coronary intervention with bare-metal and drug-eluting stents for ST-segment elevation myocardial infarction.
    JACC. Cardiovascular interventions, 2012, Volume: 5, Issue:10

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Confidence Intervals; Coronary Restenosis; Corona

2012
Antidepressant use, serotonin transporter affinity, and reinfarction among patients receiving clopidogrel: a population-based study.
    Pharmacoepidemiology and drug safety, 2012, Volume: 21, Issue:12

    Topics: Acute Disease; Aged; Aged, 80 and over; Antidepressive Agents; Case-Control Studies; Clopidogrel; Fe

2012
Effects of pre-hospital clopidogrel administration on early and late residual platelet reactivity in ST-segment elevation myocardial infarction patients undergoing primary intervention.
    Journal of thrombosis and haemostasis : JTH, 2013, Volume: 11, Issue:1

    Topics: Aged; Belgium; Blood Platelets; Clopidogrel; Coronary Thrombosis; Drug Administration Schedule; Emer

2013
[Platelet inhibition in clinical practice].
    Therapeutische Umschau. Revue therapeutique, 2012, Volume: 69, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Arterial Occlusive Diseases; Aspirin; Cerebral Infarction; Clo

2012
Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis.
    Journal of thrombosis and haemostasis : JTH, 2013, Volume: 11, Issue:1

    Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Cerebrovascular Disorders; Clopidogrel; Comp

2013
Discontinuation of long-term clopidogrel therapy is associated with death and myocardial infarction after saphenous vein graft percutaneous coronary intervention.
    Journal of the American College of Cardiology, 2012, Dec-11, Volume: 60, Issue:23

    Topics: Aged; California; Cause of Death; Clopidogrel; Drug Administration Schedule; Female; Follow-Up Studi

2012
A new generation of biodegradable polymer-coated sirolimus-eluting stents for the treatment of coronary artery disease: final 5-year clinical outcomes from the CREATE study.
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2012, Nov-22, Volume: 8, Issue:7

    Topics: Absorbable Implants; Aged; Aspirin; Cardiovascular Agents; China; Clopidogrel; Coronary Artery Disea

2012
Clopidogrel and aspirin administration management prior to coronary artery surgery requires an individual approach.
    European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 2013, Volume: 43, Issue:6

    Topics: Aspirin; Coronary Artery Bypass; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation I

2013
2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the
    Journal of the American College of Cardiology, 2012, Dec-18, Volume: 60, Issue:24

    Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Alcohol Drinking; Angina Pectoris; Body Weight

2012
2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the
    Journal of the American College of Cardiology, 2012, Dec-18, Volume: 60, Issue:24

    Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Alcohol Drinking; Angina Pectoris; Body Weight

2012
2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the
    Journal of the American College of Cardiology, 2012, Dec-18, Volume: 60, Issue:24

    Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Alcohol Drinking; Angina Pectoris; Body Weight

2012
2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the
    Journal of the American College of Cardiology, 2012, Dec-18, Volume: 60, Issue:24

    Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Alcohol Drinking; Angina Pectoris; Body Weight

2012
Pharmaceutical care for patients with acute myocardial infarction in Hungary.
    International journal of clinical pharmacology and therapeutics, 2013, Volume: 51, Issue:2

    Topics: Acute Disease; Adult; Aged; Aspirin; Clopidogrel; Comorbidity; Diabetes Mellitus; Drug Therapy, Comb

2013
Clopidogrel pretreatment of patients with ST-elevation myocardial infarction does not affect platelet reactivity after subsequent prasugrel-loading: platelet reactivity in an observational study.
    Platelets, 2013, Volume: 24, Issue:7

    Topics: Aged; Blood Platelets; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Pipera

2013
Current antiplatelet therapy for Japanese patients with ST elevation acute myocardial infarction: J-AMI registry.
    Cardiovascular intervention and therapeutics, 2013, Volume: 28, Issue:2

    Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Femal

2013
Platelet P2Y₁₂ blockers confer direct postconditioning-like protection in reperfused rabbit hearts.
    Journal of cardiovascular pharmacology and therapeutics, 2013, Volume: 18, Issue:3

    Topics: Adenosine Monophosphate; Animals; Cardiotonic Agents; Clopidogrel; Coronary Vessels; Female; Heart;

2013
Hospital case volume and appropriate prescriptions at hospital discharge after acute myocardial infarction: a nationwide assessment.
    Circulation. Cardiovascular quality and outcomes, 2013, Jan-01, Volume: 6, Issue:1

    Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clopidogrel; Drug Th

2013
Bioequivalence in the real world is a complex challenge: the case of clopidogrel.
    Journal of the American College of Cardiology, 2013, Feb-05, Volume: 61, Issue:5

    Topics: Aged; Aged, 80 and over; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Plat

2013
Exploring the reduction in myocardial infarctions in the PLATO trial: which patients benefited on ticagrelor vs. clopidogrel?
    International journal of cardiology, 2013, May-25, Volume: 165, Issue:3

    Topics: Adenosine; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P

2013
Elevated plasma fibrinogen rather than residual platelet reactivity after clopidogrel pre-treatment is associated with an increased ischemic risk during elective percutaneous coronary intervention.
    Journal of the American College of Cardiology, 2013, Jan-08, Volume: 61, Issue:1

    Topics: Aged; Blood Platelets; C-Reactive Protein; Clopidogrel; Coronary Artery Disease; Creatine Kinase, MB

2013
Treatment with clopidogrel after myocardial infarction.
    JAMA, 2012, Dec-19, Volume: 308, Issue:23

    Topics: Cardiovascular Diseases; Diabetes Mellitus; Female; Humans; Male; Myocardial Infarction; Platelet Ag

2012
Treatment with clopidogrel after myocardial infarction.
    JAMA, 2012, Dec-19, Volume: 308, Issue:23

    Topics: Cardiovascular Diseases; Diabetes Mellitus; Female; Humans; Male; Myocardial Infarction; Platelet Ag

2012
[Correlation between antiplatelet resistance and recurrent cardiac ischemic events of patients with acute myocardial infarction].
    Zhonghua yi xue za zhi, 2012, Oct-16, Volume: 92, Issue:38

    Topics: Aged; Aspirin; Clopidogrel; Drug Resistance; Electric Impedance; Female; Humans; Male; Middle Aged;

2012
Prasugrel versus clopidogrel for acute coronary syndromes.
    The New England journal of medicine, 2013, 01-10, Volume: 368, Issue:2

    Topics: Acute Coronary Syndrome; Angina, Unstable; Female; Humans; Male; Myocardial Infarction; Piperazines;

2013
Prasugrel versus clopidogrel for acute coronary syndromes.
    The New England journal of medicine, 2013, 01-10, Volume: 368, Issue:2

    Topics: Acute Coronary Syndrome; Angina, Unstable; Female; Humans; Male; Myocardial Infarction; Piperazines;

2013
Hirudin anticoagulation allows more rapid determination of P2Y₁₂ inhibition by the VerifyNow P2Y12 assay.
    Thrombosis and haemostasis, 2013, Volume: 109, Issue:3

    Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Antithrombins; Area Under Curve; Cations; Citrates; C

2013
Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications.
    The American journal of cardiology, 2013, Apr-01, Volume: 111, Issue:7

    Topics: Acute Coronary Syndrome; Alleles; Aryl Hydrocarbon Hydroxylases; Blood Platelets; Cell Adhesion Mole

2013
Acute myocardial infarction and heart block: a challenge to emergency physicians.
    BMJ case reports, 2013, Jan-25, Volume: 2013

    Topics: Aspirin; Clopidogrel; Electrocardiography; Enoxaparin; Fibrinolytic Agents; Heart Block; Humans; Mal

2013
Risk of adverse cardiovascular outcomes and all-cause mortality associated with concomitant use of clopidogrel and proton pump inhibitors in elderly patients.
    Current medical research and opinion, 2013, Volume: 29, Issue:4

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Case-Control Studies; Clopidogrel;

2013
Cardiovascular risk among patients on clopidogrel anti-platelet therapy after placement of drug-eluting stents is modified by genetic variants in both the CYP2C19 and ABCB1 genes.
    Thrombosis and haemostasis, 2013, Volume: 109, Issue:4

    Topics: Aged; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cass

2013
Effects of high loading dose of clopidogrel in ST elevated myocardial infarction treated with fibrinolytic agent.
    Clinical and investigative medicine. Medecine clinique et experimentale, 2013, Feb-01, Volume: 36, Issue:1

    Topics: Aged; C-Reactive Protein; Clopidogrel; Drug Administration Schedule; Electrocardiography; Female; Fi

2013
[Platelet antiaggregation treatment in the aftermath of GUSTO IV, TARGET, TACTICS, and CURE trials].
    Revista espanola de cardiologia, 2002, Volume: 55, Issue:7

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Clopidogrel; Coro

2002
[2002 Update of the Guidelines of the Spanish Society of Cardiology for Unstable Angina/Without ST-Segment Elevation Myocardial Infarction].
    Revista espanola de cardiologia, 2002, Volume: 55, Issue:6

    Topics: Angina, Unstable; Chest Pain; Clopidogrel; Electrocardiography; Heparin, Low-Molecular-Weight; Human

2002
[New US guidelines. Myocardial infarct is now treated more aggressively].
    MMW Fortschritte der Medizin, 2002, May-16, Volume: 144, Issue:20

    Topics: Angina, Unstable; Aspirin; Cerebral Infarction; Clopidogrel; Drug Therapy, Combination; Humans; Myoc

2002
Effect of loading with clopidogrel at the time of coronary stenting on platelet aggregation and glycoprotein IIb/IIIa expression and platelet-leukocyte aggregate formation.
    The American journal of cardiology, 2002, Aug-01, Volume: 90, Issue:3

    Topics: Blood Platelets; Cell Adhesion; Clopidogrel; Humans; Leukocytes; Myocardial Infarction; Pilot Projec

2002
Abciximab therapy improves 1-month survival rate in unselected patients with acute myocardial infarction undergoing routine infarct artery stent implantation.
    American heart journal, 2002, Volume: 144, Issue:2

    Topics: Abciximab; Aged; Antibodies, Monoclonal; Aspirin; Cohort Studies; Contraindications; Coronary Angiog

2002
Evidence-based risk stratification to target therapies in acute coronary syndromes.
    Circulation, 2002, Sep-24, Volume: 106, Issue:13

    Topics: Acute Disease; Angina Pectoris; Anticoagulants; Biomarkers; Cardiac Catheterization; Clopidogrel; Co

2002
ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidel
    Circulation, 2002, Oct-01, Volume: 106, Issue:14

    Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants;

2002
Large intracoronary thrombi with good TIMI flow during acute myocardial infarction: four cases of successful aggressive medical management in patients without angiographically detectable coronary atherosclerosis.
    Heart (British Cardiac Society), 2002, Volume: 88, Issue:5

    Topics: Abciximab; Adult; Antibodies, Monoclonal; Anticoagulants; Aspirin; Clopidogrel; Coronary Circulation

2002
[Indications of treatment with clopidogrel in the guidelines of the Spanish Society of Cardiology for unstable angina/non-ST-segment elevation acute myocardial infarction].
    Revista espanola de cardiologia, 2002, Volume: 55, Issue:11

    Topics: Angina, Unstable; Clopidogrel; Electrocardiography; Humans; Myocardial Infarction; Platelet Aggregat

2002
New treatment guidelines for unstable angina/non-ST-segment elevation myocardial infartion.
    The Annals of pharmacotherapy, 2002, Volume: 36, Issue:11

    Topics: Angina, Unstable; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Heparin, Low-Molecu

2002
[New guidelines in acute coronary syndrome. Clopidogrel for nine months is recommended].
    MMW Fortschritte der Medizin, 2002, Oct-03, Volume: 144, Issue:40

    Topics: Angina, Unstable; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Hum

2002
Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease.
    British journal of haematology, 2003, Volume: 120, Issue:1

    Topics: Blood Platelets; Cell Size; Clopidogrel; Coronary Disease; Humans; Myocardial Infarction; Platelet A

2003
[In acute coronary syndrome. Seize platelets with pliers].
    MMW Fortschritte der Medizin, 2002, Nov-07, Volume: 144, Issue:45

    Topics: Acute Disease; Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Cyclooxygenase Inhi

2002
Optimal treatment and current situation in reperfusion after thrombolysis for acute myocardial infarction.
    Annals of medicine, 2002, Volume: 34, Issue:7-8

    Topics: Adrenergic beta-Antagonists; Angioplasty; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia

2002
Aspirin, clopidogrel, or both for secondary prevention of coronary disease.
    The New England journal of medicine, 2003, Feb-06, Volume: 348, Issue:6

    Topics: Aspirin; Clopidogrel; Coronary Disease; Cost-Benefit Analysis; Data Interpretation, Statistical; Dru

2003
Pharmacological treatment of acute coronary syndromes.
    Professional nurse (London, England), 2003, Volume: 18, Issue:5

    Topics: Adrenergic beta-Antagonists; Angina, Unstable; Aspirin; Clopidogrel; Humans; Myocardial Infarction;

2003
Spontaneous hemarthrosis of the knee associated with clopidogrel and aspirin treatment.
    Zeitschrift fur Rheumatologie, 2003, Volume: 62, Issue:1

    Topics: Aged; Angina, Unstable; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Coagulation Tests; C

2003
Antiplatelet drug works better if used longer.
    Heart advisor, 2003, Volume: 6, Issue:2

    Topics: Angioplasty; Clopidogrel; Follow-Up Studies; Humans; Myocardial Infarction; Platelet Aggregation Inh

2003
[Anticoagulation and antiaggregation in cardiac patients].
    Therapeutische Umschau. Revue therapeutique, 2003, Volume: 60, Issue:1

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cardiovascular Diseases; Clinical Trials as Topic; Clo

2003
[Anticoagulation and antiaggregation in patients with peripheral arterial occlusive diseases].
    Therapeutische Umschau. Revue therapeutique, 2003, Volume: 60, Issue:1

    Topics: Administration, Oral; Angioplasty, Balloon; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Bl

2003
Introduction to "Optimizing management of non-ST-segment elevation acute coronary syndromes". Harmonizing advances in mechanical and pharmacologic intervention.
    Journal of the American College of Cardiology, 2003, Feb-19, Volume: 41, Issue:4 Suppl S

    Topics: Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Cardiac Catheterization; Clopidogre

2003
Statistical versus clinical significance of the CURE study in acute coronary syndromes.
    Journal of the American College of Cardiology, 2003, Apr-02, Volume: 41, Issue:7

    Topics: Angina, Unstable; Clinical Trials as Topic; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggr

2003
Case presentations and discussions.
    The Journal of invasive cardiology, 2003, Volume: 15 Suppl B

    Topics: Age Factors; Aged; Aged, 80 and over; Cardiac Catheterization; Chest Pain; Clopidogrel; Critical Car

2003
Acute coronary syndrome associated with coronary aneurysm: a case report.
    The Journal of the Oklahoma State Medical Association, 2003, Volume: 96, Issue:4

    Topics: Acute Disease; Aged; Aged, 80 and over; Cardiac Catheterization; Clopidogrel; Coronary Aneurysm; Cor

2003
[Acute coronary syndrome. The second platelet inhibitor is self-paid].
    MMW Fortschritte der Medizin, 2003, Jun-12, Volume: 145, Issue:24

    Topics: Acute Disease; Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Cost-Benefit Analys

2003
Timing of anti-platelet effect after oral aspirin administration in patients with sympathetic excitement.
    Circulation journal : official journal of the Japanese Circulation Society, 2003, Volume: 67, Issue:8

    Topics: Aged; Aspirin; Blood Platelets; Collagen; Coronary Angiography; Humans; Male; Middle Aged; Myocardia

2003
Clopidogrel is associated with better in-hospital and 30-day outcomes than ticlopidine after coronary stenting.
    The Canadian journal of cardiology, 2003, Volume: 19, Issue:9

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopidogrel; Coronary Stenosis; Dose-

2003
[Long-term therapy with clopidogrel in combination with ASA significantly reduces risk of death, myocardial infarct or stroke].
    Minerva medica, 2003, Volume: 94, Issue:2

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; H

2003
Ask the doctor. Almost every day I read how important it is for people with heart disease to take an aspirin. Unfortunately, I am allergic to aspirin. There must be others with the same problem. Are there viable alternatives to aspirin? It's discouraging
    Harvard heart letter : from Harvard Medical School, 2003, Volume: 13, Issue:12

    Topics: Aspirin; Clopidogrel; Drug Hypersensitivity; Fatty Acids, Omega-3; Humans; Myocardial Infarction; Pl

2003
[Acute myocardial infarction during pregnancy. Treatment with clopidogrel].
    Medicina clinica, 2003, Sep-06, Volume: 121, Issue:7

    Topics: Adult; Angioplasty, Balloon, Coronary; Clopidogrel; Female; Humans; Myocardial Infarction; Platelet

2003
Improving antithrombotic treatment in patients after myocardial infarction.
    Lancet (London, England), 2003, Sep-06, Volume: 362, Issue:9386

    Topics: Azetidines; Benzylamines; Clopidogrel; Fibrinolytic Agents; Glycine; Humans; Myocardial Infarction;

2003
Epidemiology of acute myocardial infarction in the Italian CCU network: the BLITZ study.
    European heart journal, 2003, Volume: 24, Issue:18

    Topics: Adult; Aged; Aged, 80 and over; Clopidogrel; Coronary Care Units; Emergency Medical Services; Female

2003
Platelet inhibition strategies in percutaneous coronary intervention: competition or coopetition?
    Journal of the American College of Cardiology, 2003, Oct-01, Volume: 42, Issue:7

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Combined Mo

2003
[Dual platelet inhibition with clopidogrel and ASS. Who profits from the combination?].
    MMW Fortschritte der Medizin, 2003, Jul-10, Volume: 145, Issue:27-28

    Topics: Acute Disease; Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Cyclooxygenase Inhi

2003
Beta brachytherapy of an old degenerated saphenous vein graft with occlusive in-stent restenosis.
    Italian heart journal : official journal of the Italian Federation of Cardiology, 2003, Volume: 4, Issue:9

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Beta Particles; Blood Vessel Prosthesis; Brachytherap

2003
Deep venous thrombosis, myocardial infarction, and occlusion of vascular access associated with heparin-induced thrombocytopenia in a diabetic hemodialysis patient.
    Clinical and experimental nephrology, 2003, Volume: 7, Issue:4

    Topics: Anticoagulants; Catheters, Indwelling; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Fi

2003
A feasibility study of the safety and efficacy of a combined clopidogrel and aspirin regimen following off-pump coronary artery bypass grafting.
    The heart surgery forum, 2003, Volume: 6, Issue:5

    Topics: Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Feasibility

2003
Antiplatelet therapy for ischemic heart disease.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopid

2004
Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events.
    Stroke, 2004, Volume: 35, Issue:2

    Topics: Aged; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Databases, Factual; Female; Hospitaliz

2004
Incidence, mechanism, predictors, and long-term prognosis of late stent malapposition after bare-metal stent implantation.
    Circulation, 2004, Feb-24, Volume: 109, Issue:7

    Topics: Aged; Aspirin; Atherectomy, Coronary; Catheterization; Cilostazol; Combined Modality Therapy; Corona

2004
[Interaction of statins with clopidogrel].
    Der Internist, 2004, Volume: 45, Issue:3

    Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Biotransformation; Cause of Death; Clinica

2004
Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation.
    American heart journal, 2004, Volume: 147, Issue:3

    Topics: Aged; Aged, 80 and over; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin;

2004
Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment.
    Journal of the American College of Cardiology, 2004, Mar-17, Volume: 43, Issue:6

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Creatine Kinase

2004
For how long should treatment with clopidogrel be continued after coronary stent implantation?
    Journal of the American College of Cardiology, 2004, Apr-07, Volume: 43, Issue:7

    Topics: Angioplasty, Balloon, Coronary; Blood Vessel Prosthesis Implantation; Clopidogrel; Combined Modality

2004
Subcutaneous enoxaparin with early invasive strategy in patients with acute coronary syndromes.
    American heart journal, 2004, Volume: 147, Issue:4

    Topics: Analysis of Variance; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Cardiac Cath

2004
2 drugs team up for protection. Old standby joins relative newcomer to battle heart disease.
    Heart advisor, 2003, Volume: 6, Issue:8

    Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Aggregation

2003
"Super aspirin" cuts risks after multiple cardiac events.
    Heart advisor, 2004, Volume: 7, Issue:4

    Topics: Aspirin; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Secondary Prev

2004
Detection of acutely impaired microvascular reperfusion after infarct angioplasty with magnetic resonance imaging.
    Circulation, 2004, May-04, Volume: 109, Issue:17

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Clopidog

2004
Antiplatelet therapy for ischemic heart disease.
    The New England journal of medicine, 2004, May-13, Volume: 350, Issue:20

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cost-Benefit Analysis; Drug Therapy, Combinati

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Long-term management of patients with unstable angina and non-ST-elevation MI.
    The Journal of family practice, 2004, Volume: 53, Issue:6

    Topics: Angina, Unstable; Aspirin; Clopidogrel; Evidence-Based Medicine; Humans; Hydroxymethylglutaryl-CoA R

2004
Different treatments and outcomes of consecutive patients with non-ST-elevation myocardial infarction depending on initial electrocardiographic changes (results of the Acute Coronary Syndromes [ACOS] Registry).
    The American journal of cardiology, 2004, Jun-15, Volume: 93, Issue:12

    Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converti

2004
[Antithrombotic treatment of acute coronary syndrome].
    Acta medica Croatica : casopis Hravatske akademije medicinskih znanosti, 2004, Volume: 58, Issue:2

    Topics: Anticoagulants; Aspirin; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors

2004
Clopidogrel-associated autoimmune thrombocytopenic purpura.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2004, Volume: 62, Issue:3

    Topics: Clopidogrel; Glucocorticoids; Humans; Male; Methylprednisolone; Middle Aged; Myocardial Infarction;

2004
Clopidogrel resistance marks recurrent risks.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Aged; Bibliometrics; Cardiology; Clopidogrel; Cohort Studies; Coronary Restenosis; Drug Resistance;

2004
Diminishing returns...and too many choices...the saga of pharmacologic therapy to reduce the complications of percutaneous coronary intervention.
    Journal of the American College of Cardiology, 2004, Jul-07, Volume: 44, Issue:1

    Topics: Angioplasty, Balloon, Coronary; Biomarkers; Blood Vessel Prosthesis Implantation; Clopidogrel; Coron

2004
Building evidence for early initiation of clopidogrel loading in non-ST-segment elevation acute coronary syndromes: going past the American College of Cardiology/American Heart Association guidelines.
    Annals of emergency medicine, 2004, Volume: 43, Issue:5

    Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Therapy, Combination; E

2004
A critical appraisal of the CURE trial: role of clopidogrel in non-ST-segment elevation acute coronary syndromes.
    The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique, 2004,Spring, Volume: 11, Issue:1

    Topics: Aspirin; Clopidogrel; Confidence Intervals; Humans; Myocardial Infarction; Randomized Controlled Tri

2004
Platelet function predicts myocardial damage in patients with acute myocardial infarction.
    Circulation, 2004, Sep-14, Volume: 110, Issue:11

    Topics: Abciximab; Adenosine Diphosphate; Aged; Antibodies, Monoclonal; Anticoagulants; Aspirin; Cardiovascu

2004
[Cost effectiveness of clopidogrel in acute coronary syndromes without ST-elevation (unstable angina, non-Q AMI)].
    Orvosi hetilap, 2004, Jun-06, Volume: 145, Issue:23

    Topics: Acute Disease; Angina, Unstable; Canada; Cardiology; Clopidogrel; Congresses as Topic; Cost-Benefit

2004
[Guidelines: acute coronary syndrome (ACS)].
    Zeitschrift fur Kardiologie, 2004, Volume: 93, Issue:8

    Topics: Acute Disease; Angina, Unstable; Clinical Trials as Topic; Clopidogrel; Coronary Angiography; Electr

2004
Simultaneous kissing stents (SKS) technique for treating bifurcation lesions in medium-to-large size coronary arteries.
    The American journal of cardiology, 2004, Oct-01, Volume: 94, Issue:7

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Biomarkers; Blood Vessel Pr

2004
[Antiplatelet strategies in the acute and chronic therapy of cardiovascular disease].
    Medizinische Klinik (Munich, Germany : 1983), 2004, Aug-15, Volume: 99 Suppl 1

    Topics: Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Humans; Long-Term Care; Myocar

2004
[Antiplatelet therapy in patients with peripheral arterial disease (PAD)].
    Medizinische Klinik (Munich, Germany : 1983), 2004, Aug-15, Volume: 99 Suppl 1

    Topics: Arterial Occlusive Diseases; Aspirin; Cause of Death; Cerebral Infarction; Clopidogrel; Coronary Art

2004
[Acute coronary syndrome, stroke, arterial occlusive disease. Bring the patients out of the danger zone!].
    MMW Fortschritte der Medizin, 2004, Volume: 146 Suppl 1

    Topics: Arterial Occlusive Diseases; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Emboli

2004
[Attack on many vascular fronts. Atherothrombosis trouble seldom comes alone].
    MMW Fortschritte der Medizin, 2004, Volume: 146 Suppl 1

    Topics: Aged; Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Clinical Trials as Topic; Clopidogrel;

2004
[Patients with arterial occlusive disease die of myocardial infarct or stroke. The dangerous sisters: arterial occlusive disease and coronary heart disease].
    MMW Fortschritte der Medizin, 2004, Volume: 146 Suppl 1

    Topics: Aged; Arterial Occlusive Diseases; Aspirin; Cause of Death; Clinical Trials as Topic; Clopidogrel; C

2004
[Combination is standard. Dual thrombocyte function inhibition in acute coronary syndrome].
    MMW Fortschritte der Medizin, 2004, Volume: 146 Suppl 1

    Topics: Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Humans;

2004
[Interview with Prof. Dr. H. J. Rupprecht about secondary prevention: what is the optimal thrombocyte function inhibition?].
    MMW Fortschritte der Medizin, 2004, Volume: 146 Suppl 1

    Topics: Angina, Unstable; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Long-Term Care; Myocardia

2004
Antiplatelet therapy.
    Nursing older people, 2004, Volume: 16, Issue:8

    Topics: Aged; Aspirin; Clopidogrel; Dipyridamole; Drug Interactions; Humans; Myocardial Infarction; Patient

2004
Development of a score to predict the need for coronary artery bypass graft surgery in patients with non-ST segment elevation acute coronary syndromes.
    The Annals of thoracic surgery, 2004, Volume: 78, Issue:6

    Topics: Aged; Angina, Unstable; Clopidogrel; Coronary Artery Bypass; Heart Failure; Humans; Logistic Models;

2004
Risk reduction with long-term clopidogrel following percutaneous coronary intervention.
    European heart journal, 2004, Volume: 25, Issue:23

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inh

2004
I've been taking aspirin daily for 25 years, and clopidogrel fro several years. In spite of this, I've had a number of heart attacks. You reported recently on people who can't benefit from aspirin, and I think I may be one of them. What should I do?
    Heart advisor, 2004, Volume: 7, Issue:11

    Topics: Aspirin; Blood Coagulation Disorders; Clopidogrel; Drug Resistance; Humans; Myocardial Infarction; P

2004
[Spleen rupture in myocardial infarction after administration of GP IIb-IIIa-antagonists].
    Deutsche medizinische Wochenschrift (1946), 2005, Jan-07, Volume: 130, Issue:1-2

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Echocardiography; Electrocardiogr

2005
A case of life-saving pharmacologic and mechanical coronary dethrombosis.
    Italian heart journal : official journal of the Italian Federation of Cardiology, 2004, Volume: 5, Issue:11

    Topics: Angioplasty, Balloon; Aspirin; Combined Modality Therapy; Coronary Angiography; Coronary Thrombosis;

2004
Predictors of mortality in patients with acute myocardial infarction and cardiogenic shock.
    Circulation journal : official journal of the Japanese Circulation Society, 2005, Volume: 69, Issue:1

    Topics: Angioplasty, Balloon; Aspirin; C-Reactive Protein; Cholesterol; Electrocardiography; Hormones; Human

2005
Elective percutaneous coronary intervention using broad-spectrum antiplatelet therapy (eptifibatide, clopidogrel, and aspirin) alone, without scheduled unfractionated heparin or other antithrombin therapy.
    American heart journal, 2005, Volume: 149, Issue:1

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combinat

2005
Economic effects of prolonged clopidogrel therapy after percutaneous coronary intervention.
    Journal of the American College of Cardiology, 2005, Feb-01, Volume: 45, Issue:3

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Cost-Benefit Analysis; Decision Support Technique

2005
Summaries for patients. Is it cost-effective to treat high-risk cardiac patients with clopidogrel plus aspirin as opposed to aspirin alone?
    Annals of internal medicine, 2005, Feb-15, Volume: 142, Issue:4

    Topics: Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Computer Simulation; Cost-Benefit A

2005
A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone.
    Annals of internal medicine, 2005, Feb-15, Volume: 142, Issue:4

    Topics: Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Computer Simulation; Cost-Benefit A

2005
Impact of combined pharmacologic treatment with clopidogrel and a statin on outcomes of patients with non-ST-segment elevation acute coronary syndromes: perspectives from a large multinational registry.
    European heart journal, 2005, Volume: 26, Issue:11

    Topics: Adolescent; Adult; Aged; Angina, Unstable; Aspirin; Clopidogrel; Drug Therapy, Combination; Female;

2005
Concurrent antiplatelet and fibrinolytic therapy.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial

2005
Repetitive profound thrombocytopenia after treatment with tirofiban: a case report.
    Cardiovascular drugs and therapy, 2004, Volume: 18, Issue:6

    Topics: Angioplasty, Balloon; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Drug Administration Schedul

2004
Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (ASpirin non-responsiveness and Clopidogrel Endpoint Trial) design.
    Scandinavian cardiovascular journal : SCJ, 2004, Volume: 38, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel;

2004
Who needs Plavix? This super aspirin is meant mainly for people at high risk of having a heart attack or stroke.
    Harvard heart letter : from Harvard Medical School, 2005, Volume: 15, Issue:7

    Topics: Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Assessment; Stroke

2005
Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction.
    Archives of internal medicine, 2005, Apr-11, Volume: 165, Issue:7

    Topics: Age Factors; Aged; Anticoagulants; Aspirin; Case-Control Studies; Clopidogrel; Cohort Studies; Drug

2005
Design and rationale of Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 trial.
    American heart journal, 2005, Volume: 149, Issue:2

    Topics: Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Multicente

2005
Cost-effectiveness of clopidogrel.
    PharmacoEconomics, 2004, Volume: 22 Suppl 4

    Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Cost-Benefit Analysis; Embolism, Cholesterol; Humans

2004
[Exercise-induced left arm pain and thrombocytosis].
    Praxis, 2005, Apr-13, Volume: 94, Issue:15

    Topics: Angioplasty, Balloon, Coronary; Bone Marrow Examination; Clopidogrel; Coronary Angiography; Coronary

2005
The value of clopidogrel administered postoperatively following a non-ST-segment elevation acute coronary syndrome.
    Chest, 2005, Volume: 127, Issue:6

    Topics: Clopidogrel; Coronary Artery Bypass; Coronary Disease; Dose-Response Relationship, Drug; Drug Admini

2005
The (variable) definition of benefit in the case of clopidogrel vs aspirin.
    Archives of internal medicine, 2005, Jun-13, Volume: 165, Issue:11

    Topics: Aspirin; Clopidogrel; Humans; Myocardial Infarction; Peripheral Vascular Diseases; Platelet Aggregat

2005
Ischemia-driven target vessel revascularization after-primary percutaneous coronary intervention: patients at risk and their outcomes.
    Journal of interventional cardiology, 2005, Volume: 18, Issue:3

    Topics: Angioplasty, Balloon, Coronary; Blood Vessel Prosthesis Implantation; Cineangiography; Clinical Tria

2005
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction.
    The New England journal of medicine, 2005, Jun-23, Volume: 352, Issue:25

    Topics: Aspirin; Clopidogrel; Coronary Circulation; Drug Therapy, Combination; Fibrinolytic Agents; Heparin;

2005
Enhancing reperfusion therapy for myocardial infarction with dual antiplatelet therapy: Breaking the glass ceiling.
    American heart journal, 2005, Volume: 149, Issue:6

    Topics: Aspirin; Clopidogrel; Coronary Circulation; Humans; Myocardial Infarction; Platelet Aggregation Inhi

2005
Cost of care for new-onset acute coronary syndrome patients who undergo coronary revascularization.
    The Journal of invasive cardiology, 2005, Volume: 17, Issue:6

    Topics: Acute Disease; Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Angina, Unstable; Clopidogrel;

2005
Plavix reduces death risk following a heart attack.
    Health news (Waltham, Mass.), 2005, Volume: 11, Issue:6

    Topics: Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Secondary Prevention; T

2005
Hospitals improve heart attack care. As compliance with guidelines improves, in-hospital deaths fall.
    Heart advisor, 2005, Volume: 8, Issue:4

    Topics: Aspirin; Cardiac Catheterization; Clopidogrel; Electrocardiography; Guideline Adherence; Hospital Mo

2005
Clopidogrel for percutaneous coronary revascularization: time for more pretreatment, retreatment, or both?
    JAMA, 2005, Sep-14, Volume: 294, Issue:10

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inh

2005
Stent thrombosis in patients treated with thienopyridines: clinical description of 10 cases.
    International journal of cardiovascular interventions, 2004, Volume: 6, Issue:3-4

    Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Clopidogrel; Cohort Studies; Female; Follow-

2004
Clinical outcomes and left ventricular function in diabetic patients with acute myocardial infarction treated by primary coronary angioplasty.
    International heart journal, 2005, Volume: 46, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Bypass; Dia

2005
Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone.
    Annals of internal medicine, 2005, Sep-20, Volume: 143, Issue:6

    Topics: Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Cost-Benefit Analysis; Drug Therapy

2005
Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone.
    Annals of internal medicine, 2005, Sep-20, Volume: 143, Issue:6

    Topics: Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Cost-Benefit Analysis; Drug Therapy

2005
Feasibility trial of carotid stenting with and without an embolus protection device.
    Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists, 2005, Volume: 12, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Vessel Prosthesis Implantation; Carotid Artery, Commo

2005
Antiplatelet therapy and the vascular tree.
    Heart (British Cardiac Society), 2006, Volume: 92, Issue:1

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Artery Dis

2006
ST-elevation myocardial infarction: New Zealand management guidelines.
    The New Zealand medical journal, 2005, Oct-07, Volume: 118, Issue:1223

    Topics: Aged; Aspirin; Biomarkers; Cardiology; Clopidogrel; Contraindications; Creatine Kinase; Drug Monitor

2005
Letter regarding article by Patti et al, "Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reductio
    Circulation, 2005, Oct-25, Volume: 112, Issue:17

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Bypass; Humans; Myocardial Infarction;

2005
Letter regarding article by Patti et al, "Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reductio
    Circulation, 2005, Oct-25, Volume: 112, Issue:17

    Topics: Clopidogrel; Coronary Artery Bypass; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors;

2005
Does combined clopidogrel and statin therapy benefit patients with non-ST-elevation myocardial infarction?
    Nature clinical practice. Cardiovascular medicine, 2005, Volume: 2, Issue:11

    Topics: Adult; Aged; Aspirin; Clopidogrel; Cohort Studies; Confidence Intervals; Coronary Angiography; Drug

2005
Myonecrosis after elective percutaneous coronary intervention: effect of clopidogrel-statin interaction.
    The Journal of invasive cardiology, 2005, Volume: 17, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Creatine Kinase, MB Form; Cytochrome P-450 CYP3A;

2005
The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention: a Swedish analysis of the CREDO trial.
    The European journal of health economics : HEPAC : health economics in prevention and care, 2005, Volume: 6, Issue:4

    Topics: Administration, Oral; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel;

2005
Something old, something new: beta blockers and clopidogrel in acute myocardial infarction.
    Lancet (London, England), 2005, Nov-05, Volume: 366, Issue:9497

    Topics: Adrenergic beta-Antagonists; Adult; Aged; China; Clopidogrel; Drug Therapy, Combination; Humans; Met

2005
Bleeding complications in elderly patients following acute myocardial infarction.
    Archives of internal medicine, 2005, Nov-14, Volume: 165, Issue:20

    Topics: Aged; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocardia

2005
[Effects of anti-platelet drugs on myocardial no-reflow after acute myocardial infarction and reperfusion: experiment with mini-swine model].
    Zhonghua yi xue za zhi, 2005, Aug-17, Volume: 85, Issue:31

    Topics: Animals; Clopidogrel; Coronary Circulation; Myocardial Infarction; Myocardial Reperfusion; Myocardia

2005
Case 6-2005 thoracotomy after myocardial infarction and intracoronary stenting: a balance between myocardial recovery and procedural risk.
    Journal of cardiothoracic and vascular anesthesia, 2005, Volume: 19, Issue:6

    Topics: Clopidogrel; Coronary Disease; Exercise Test; Female; Humans; Lung; Lung Neoplasms; Middle Aged; Myo

2005
Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation.
    American heart journal, 2006, Volume: 151, Issue:1

    Topics: Acute Disease; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Clopidogrel; Cost-Benefit Ana

2006
Drawbacks of nonrandomized trials in acute coronary syndromes.
    The American journal of cardiology, 2006, Jan-01, Volume: 97, Issue:1

    Topics: Angina, Unstable; Cardiac Catheterization; Clinical Trials as Topic; Clopidogrel; Coronary Angiograp

2006
Management of acute coronary syndromes.
    The New England journal of medicine, 2005, Dec-22, Volume: 353, Issue:25

    Topics: Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography;

2005
Management of acute coronary syndromes.
    The New England journal of medicine, 2005, Dec-22, Volume: 353, Issue:25

    Topics: Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography;

2005
Different effects of tirofiban and aspirin plus clopidogrel on myocardial no-reflow in a mini-swine model of acute myocardial infarction and reperfusion.
    Heart (British Cardiac Society), 2006, Volume: 92, Issue:8

    Topics: Animals; Aspirin; Clopidogrel; Coronary Circulation; Drug Therapy, Combination; Myocardial Infarctio

2006
Postoperative clopidogrel improves mid-term outcome after off-pump coronary artery bypass graft surgery: a prospective study.
    European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 2006, Volume: 29, Issue:2

    Topics: Aged; Anticoagulants; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Bypass, Off-Pum

2006
Clopidogrel and metoprolol in myocardial infarction.
    Lancet (London, England), 2006, Mar-11, Volume: 367, Issue:9513

    Topics: Adrenergic beta-Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Humans;

2006
Clopidogrel and metoprolol in myocardial infarction.
    Lancet (London, England), 2006, Mar-11, Volume: 367, Issue:9513

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Gastrointestinal Hemorrhage; Humans;

2006
Clopidogrel and metoprolol in myocardial infarction.
    Lancet (London, England), 2006, Mar-11, Volume: 367, Issue:9513

    Topics: Adrenergic beta-Antagonists; Clopidogrel; Humans; Metoprolol; Myocardial Infarction; Platelet Aggreg

2006
Embedded guideline information without patient specificity in a commercial emergency department computerized order-entry system.
    Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, 2006, Volume: 13, Issue:4

    Topics: Adrenergic beta-Antagonists; Angina, Unstable; Aspirin; Clopidogrel; Decision Support Systems, Clini

2006
Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry.
    Circulation, 2006, Mar-21, Volume: 113, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Di

2006
Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry.
    Circulation, 2006, Mar-21, Volume: 113, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Di

2006
Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry.
    Circulation, 2006, Mar-21, Volume: 113, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Di

2006
Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry.
    Circulation, 2006, Mar-21, Volume: 113, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Di

2006
Combined aspirin and clopidogrel resistance associated with recurrent coronary stent thrombosis.
    Clinical research in cardiology : official journal of the German Cardiac Society, 2006, Volume: 95, Issue:2

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Rest

2006
Clopidogrel to treat patients with non-ST-segment elevation acute coronary syndromes after hospital discharge.
    Archives of internal medicine, 2006, Apr-10, Volume: 166, Issue:7

    Topics: Aged; Angina, Unstable; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Plate

2006
Clopidogrel (Plavix) revisited.
    The Medical letter on drugs and therapeutics, 2006, Apr-10, Volume: 48, Issue:1232

    Topics: Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Humans; Myocardial Infarction; Plate

2006
[More modest use in secondary prevention, risky in primary prevention].
    MMW Fortschritte der Medizin, 2006, Apr-06, Volume: 148, Issue:14

    Topics: Arteriosclerosis; Aspirin; Cause of Death; Clopidogrel; Dose-Response Relationship, Drug; Double-Bli

2006
[Thrombosis of a coronary stent after discontinuing treatment with clopidogrel].
    Nederlands tijdschrift voor geneeskunde, 2006, Apr-15, Volume: 150, Issue:15

    Topics: Adult; Aged; Angina Pectoris; Aspirin; Clopidogrel; Female; Humans; Male; Myocardial Infarction; Pla

2006
[Optimisation of the myocardial infarction pharmacotherapy--important insights from the COMMIT Trial].
    Kardiologia polska, 2006, Volume: 64, Issue:2

    Topics: Antihypertensive Agents; Clopidogrel; Humans; Metoprolol; Myocardial Infarction; Platelet Aggregatio

2006
Catheter thrombosis during primary percutaneous coronary intervention for acute ST elevation myocardial infarction despite subcutaneous low-molecular-weight heparin, acetylsalicylic acid, clopidogrel and abciximab pretreatment.
    The Canadian journal of cardiology, 2006, May-01, Volume: 22, Issue:6

    Topics: Abciximab; Adult; Aged; Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents, Non-Steroidal; Ant

2006
Comment: mortality benefit of no-load clopidogrel in COMMIT: not a surprise.
    Journal of cardiovascular pharmacology and therapeutics, 2006, Volume: 11, Issue:1

    Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infarc

2006
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
    Circulation, 2006, Jun-20, Volume: 113, Issue:24

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clop

2006
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
    Circulation, 2006, Jun-20, Volume: 113, Issue:24

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clop

2006
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
    Circulation, 2006, Jun-20, Volume: 113, Issue:24

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clop

2006
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
    Circulation, 2006, Jun-20, Volume: 113, Issue:24

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clop

2006
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
    Circulation, 2006, Jun-20, Volume: 113, Issue:24

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clop

2006
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
    Circulation, 2006, Jun-20, Volume: 113, Issue:24

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clop

2006
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
    Circulation, 2006, Jun-20, Volume: 113, Issue:24

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clop

2006
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
    Circulation, 2006, Jun-20, Volume: 113, Issue:24

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clop

2006
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
    Circulation, 2006, Jun-20, Volume: 113, Issue:24

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clop

2006
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
    Circulation, 2006, Jun-20, Volume: 113, Issue:24

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clop

2006
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
    Circulation, 2006, Jun-20, Volume: 113, Issue:24

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clop

2006
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
    Circulation, 2006, Jun-20, Volume: 113, Issue:24

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clop

2006
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
    Circulation, 2006, Jun-20, Volume: 113, Issue:24

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clop

2006
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
    Circulation, 2006, Jun-20, Volume: 113, Issue:24

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clop

2006
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
    Circulation, 2006, Jun-20, Volume: 113, Issue:24

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clop

2006
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
    Circulation, 2006, Jun-20, Volume: 113, Issue:24

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clop

2006
Spontaneous or clopidogrel related recanalisation of a coronary artery.
    Heart (British Cardiac Society), 2006, Volume: 92, Issue:7

    Topics: Clopidogrel; Coronary Angiography; Coronary Stenosis; Humans; Male; Middle Aged; Myocardial Infarcti

2006
Plavix isn't for everyone. Adding Plavix to aspirin doesn't help people without heart disease.
    Harvard heart letter : from Harvard Medical School, 2006, Volume: 16, Issue:10

    Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infarc

2006
The obesity paradox in non-ST-segment elevation acute coronary syndromes: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart A
    American heart journal, 2006, Volume: 152, Issue:1

    Topics: Aged; Angina, Unstable; Body Mass Index; Clopidogrel; Female; Guideline Adherence; Humans; Hypolipid

2006
Acute clopidogrel use and outcomes in patients with non-ST-segment elevation acute coronary syndromes undergoing coronary artery bypass surgery.
    Journal of the American College of Cardiology, 2006, Jul-18, Volume: 48, Issue:2

    Topics: Aged; Angina, Unstable; Blood Transfusion; Clopidogrel; Coronary Artery Bypass; Female; Guideline Ad

2006
Documented subacute stent thrombosis within thirty days after stenting with sirolimus-eluting stent (Cypher) for acute myocardial infarction: a Japanese single center retrospective non-randomized study.
    Circulation journal : official journal of the Japanese Circulation Society, 2006, Volume: 70, Issue:8

    Topics: Aged; Aspirin; Coronary Restenosis; Coronary Thrombosis; Disease Progression; Female; Humans; Immuno

2006
COMMIT/CCS-2 studies.
    Lancet (London, England), 2006, Aug-19, Volume: 368, Issue:9536

    Topics: Adrenergic beta-Antagonists; Clopidogrel; Humans; Metoprolol; Myocardial Infarction; Platelet Aggreg

2006
Clinical policy: critical issues in the evaluation and management of adult patients with non-ST-segment elevation acute coronary syndromes.
    Annals of emergency medicine, 2006, Volume: 48, Issue:3

    Topics: Adult; Angina Pectoris; Biomarkers; Cardiology; Clopidogrel; Electrocardiography; Emergency Service,

2006
[Physicians and insurance may collaborate on therapy].
    MMW Fortschritte der Medizin, 2006, Aug-03, Volume: 148, Issue:31-32

    Topics: Aspirin; Clopidogrel; Contract Services; Cooperative Behavior; Cost-Benefit Analysis; Drug Costs; Fa

2006
Usefulness of clopidogrel in abolishing the increased risk of reinfarction associated with higher platelet counts in patients with ST-elevation myocardial infarction (results from CLARITY-TIMI 28).
    The American journal of cardiology, 2006, Sep-15, Volume: 98, Issue:6

    Topics: Aged; Clopidogrel; Electrocardiography; Female; Humans; Male; Middle Aged; Myocardial Infarction; Pl

2006
End-stage renal disease and drug-eluting stents: one small step forward.
    The Journal of invasive cardiology, 2006, Volume: 18, Issue:9

    Topics: Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Coronary Restenosis; Humans; I

2006
[Bleeding complications after treatment with clopidogrel and acetylsalicylic acid after acute coronary syndrome].
    Ugeskrift for laeger, 2006, Sep-18, Volume: 168, Issue:38

    Topics: Age Factors; Aged; Angina, Unstable; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Com

2006
Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE initiative.
    Archives of internal medicine, 2006, Oct-09, Volume: 166, Issue:18

    Topics: Adrenergic beta-Antagonists; Aged; Angina, Unstable; Angiotensin-Converting Enzyme Inhibitors; Antic

2006
Effect of clopidogrel on 1-year mortality in hospital survivors of acute ST-segment elevation myocardial infarction in clinical practice.
    European heart journal, 2006, Volume: 27, Issue:22

    Topics: Aged; Clopidogrel; Female; Hospital Mortality; Humans; Male; Middle Aged; Myocardial Infarction; Pla

2006
Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4).
    The American journal of cardiology, 2006, Nov-01, Volume: 98, Issue:9

    Topics: Aged; Aged, 80 and over; Analysis of Variance; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary

2006
Late thrombosis of drug-eluting stents after discontinuation of clopidogrel: report of two cases and review of the literature.
    Connecticut medicine, 2006, Volume: 70, Issue:8

    Topics: Aged, 80 and over; Aspirin; Clopidogrel; Coronary Thrombosis; Humans; Male; Middle Aged; Myocardial

2006
[Beneficial effect of a loading dose of 600 mg of clopidogrel on platelet parameters in patients admitted for acute coronary syndrome].
    Archives des maladies du coeur et des vaisseaux, 2006, Volume: 99, Issue:10

    Topics: Acute Disease; Angina, Unstable; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarcti

2006
Clopidogrel in patients with acute coronary syndromes: learning from clinical practice.
    Archives of internal medicine, 2006, Nov-13, Volume: 166, Issue:20

    Topics: Aged; Angina, Unstable; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Plate

2006
Nontraumatic spinal epidural hematoma associated with clopidogrel.
    Zentralblatt fur Neurochirurgie, 2006, Volume: 67, Issue:4

    Topics: Aged; Back Pain; Clopidogrel; Female; Hematoma, Epidural, Spinal; Humans; Hypertension; Magnetic Res

2006
A current problem in cardiology: very late thrombosis after implantation of sirolimus eluting stent.
    Cardiology, 2007, Volume: 108, Issue:4

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Huma

2007
Effect of clopidogrel plus aspirin on ST segments in patients with ST-elevation acute myocardial infarction.
    The American journal of cardiology, 2006, Dec-01, Volume: 98, Issue:11

    Topics: Aspirin; Clopidogrel; Electrocardiography; Female; Fibrinolytic Agents; Humans; Length of Stay; Logi

2006
Clopidogrel response variability and future therapies: clopidogrel: does one size fit all?
    Circulation, 2006, Nov-28, Volume: 114, Issue:22

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Chest Pain; Clopidogrel; Coronary Angiography; Electr

2006
[Promising efficacy of the sirolimus-eluting stent in patients with acute myocardial infarction].
    Journal of cardiology, 2006, Volume: 48, Issue:5

    Topics: Aged; Coronary Restenosis; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggreg

2006
Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation.
    JAMA, 2007, Jan-10, Volume: 297, Issue:2

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Drug Delivery Systems; F

2007
Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation.
    JAMA, 2007, Jan-10, Volume: 297, Issue:2

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Drug Delivery Systems; F

2007
Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation.
    JAMA, 2007, Jan-10, Volume: 297, Issue:2

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Drug Delivery Systems; F

2007
Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation.
    JAMA, 2007, Jan-10, Volume: 297, Issue:2

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Drug Delivery Systems; F

2007
[Acute coronary syndrome: when an indication for clopidogrel?].
    Deutsche medizinische Wochenschrift (1946), 2006, Dec-15, Volume: 131, Issue:50

    Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Clopidogrel; Humans; Myocardial Infarction; Platel

2006
Clinical trials update from the annual scientific session of the American College of Cardiology 2006.
    The American journal of cardiology, 2006, Dec-18, Volume: 98, Issue:12A

    Topics: Aspirin; Cardiac Catheterization; Cardiology; Clopidogrel; Coronary Artery Disease; Drug Therapy, Co

2006
Risk stratification for patients undergoing nonurgent percutaneous coronary intervention using N-terminal pro-B-type natriuretic peptide: a Clopidogrel for the Reduction of Events During Observation (CREDO) substudy.
    American heart journal, 2007, Volume: 153, Issue:1

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Female; Humans; Male; Middle Ag

2007
Platelet reactivity in patients with subacute stent thrombosis compared with non-stent-related acute myocardial infarction.
    American heart journal, 2007, Volume: 153, Issue:1

    Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Female; Flow Cytometry;

2007
Long-term cost-effectiveness of clopidogrel in patients with acute coronary syndrome without ST-segment elevation in Germany.
    The European journal of health economics : HEPAC : health economics in prevention and care, 2007, Volume: 8, Issue:1

    Topics: Acute Coronary Syndrome; Adult; Age Factors; Aged; Aspirin; Clopidogrel; Cost-Benefit Analysis; Elec

2007
Clopidogrel bisulfate: in ST-segment elevation myocardial infarction: a viewpoint by Steven R Steinhubl.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2006, Volume: 6, Issue:6

    Topics: Aged; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Contro

2006
Clopidogrel bisulfate in st-segment elevation myocardial infarction: a viewpoint by Deepak L Bhatt.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2006, Volume: 6, Issue:6

    Topics: Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled T

2006
High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes.
    Thrombosis and haemostasis, 2007, Volume: 97, Issue:2

    Topics: Acute Disease; Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Fe

2007
Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting.
    European heart journal, 2007, Volume: 28, Issue:6

    Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Blood Vessel Prosthesis; Clopidogrel;

2007
Variability in response to clopidogrel: where is the threshold for 'low response'?
    European heart journal, 2007, Volume: 28, Issue:4

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Humans; Myocardial Infarction; Platel

2007
Acute coronary syndromes, response to clopidogrel, and worsened cardiovascular outcomes: the hen and the egg dilemma.
    European heart journal, 2007, Volume: 28, Issue:5

    Topics: Clopidogrel; Death, Sudden, Cardiac; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors;

2007
Clopidogrel-mediated reduction of circulating tissue factor in patients with stable coronary artery disease.
    European journal of haematology, 2007, Volume: 78, Issue:4

    Topics: Adult; CD40 Ligand; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Myocard

2007
[Platelet responsiveness to clopidogrel in patients with coronary syndrome. Comparison of platelet aggregation induced by ADP and flow cytometric analysis of intraplatelet VASP phosphorylation].
    Annales de cardiologie et d'angeiologie, 2007, Volume: 56, Issue:1

    Topics: Adenosine Diphosphate; Aged; Aspirin; Blood Platelets; Blood Proteins; Cell Adhesion Molecules; Clop

2007
Ticlopidine could be an alternative therapy in the case of pharmacological resistance to clopidogrel: a report of three cases.
    Journal of thrombosis and haemostasis : JTH, 2007, Volume: 5, Issue:4

    Topics: Aged; Angina, Unstable; Cell Adhesion Molecules; Clopidogrel; Drug Resistance; Female; Flow Cytometr

2007
Primary percutaneous coronary intervention.
    The New England journal of medicine, 2007, Apr-12, Volume: 356, Issue:15

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Eplerenone; Humans; Mineralocorticoid Receptor Antagoni

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Endpoints in studies on myocardial infarction.
    Lancet (London, England), 2007, Apr-28, Volume: 369, Issue:9571

    Topics: Clopidogrel; Coronary Disease; Endpoint Determination; Humans; Myocardial Infarction; Platelet Aggre

2007
[Acute stent thrombosis due to resistance to clopidogrel ? A case report].
    Archives des maladies du coeur et des vaisseaux, 2007, Volume: 100, Issue:2

    Topics: Aged; Clopidogrel; Drug Resistance; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibi

2007
Late thrombosis of a drug-eluting stent during combined anti-platelet therapy in a clopidogrel nonresponsive diabetic patient: shall we routinely test platelet function?
    Thrombosis and haemostasis, 2007, Volume: 97, Issue:5

    Topics: Aged; Clopidogrel; Coronary Thrombosis; Coronary Vessels; Diabetic Angiopathies; Drug Resistance; Hu

2007
Increased incidence of stent thrombosis in patients with cocaine use.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2007, Jun-01, Volume: 69, Issue:7

    Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cocaine-Related Disorders; Co

2007
Managing acute coronary syndrome: evidence-based approaches.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2007, Jun-01, Volume: 64, Issue:11 Suppl 7

    Topics: Acute Disease; Angioplasty, Balloon, Coronary; Clinical Protocols; Clopidogrel; Coronary Disease; Dr

2007
[Treatment of intrastent restenosis by drug eluting stents: experience from one cardiology centre].
    Archives des maladies du coeur et des vaisseaux, 2007, Volume: 100, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Aspirin; Clopidogrel; Coronary Angiography; Coronar

2007
Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) multicenter registry.
    Circulation, 2007, Jun-26, Volume: 115, Issue:25

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Angi

2007
Comparison of drug-eluting stents with bare metal stents in unselected patients with acute myocardial infarction.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2007, Jul-01, Volume: 70, Issue:1

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cardiovascular Diseases; Clopidogrel; C

2007
Relationship between systolic pulsed wave tissue Doppler parameters and both invasive and noninvasive reperfusion criteria in patients with acute anterior myocardial infarction undergoing primary percutaneous coronary intervention.
    Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography, 2008, Volume: 21, Issue:1

    Topics: Adult; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Angiography; E

2008
[Anticoagulation in atrial fibrillation. ACTIVE Study (Arterial fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events)].
    Der Internist, 2007, Volume: 48, Issue:8

    Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Aspirin; Atrial Fibrillation; Bipheny

2007
Spontaneous coronary hematoma during systemic thrombolysis for acute myocardial infarction: intracoronary ultrasound findings, percutaneous coronary intervention and complications.
    Minerva cardioangiologica, 2007, Volume: 55, Issue:4

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Aneurysm; Drug Therapy, Combination;

2007
Treatment of acute myocardial infarction in pregnancy with coronary artery balloon angioplasty and stenting: use of tirofiban and clopidogrel.
    International journal of cardiology, 2008, Jul-21, Volume: 127, Issue:3

    Topics: Adult; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents;

2008
[After coronary intervention. Which platelet inhibitor for whom?].
    MMW Fortschritte der Medizin, 2007, Apr-05, Volume: 149, Issue:14

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coated Materials, Biocompatible; Coronary Dise

2007
Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: a European model based on the CLARITY and COMMIT trials.
    Clinical therapeutics, 2007, Volume: 29, Issue:6

    Topics: Aged; Clopidogrel; Cohort Studies; Cost-Benefit Analysis; Decision Support Techniques; Drug Utilizat

2007
[Suspected clopidogrel resistance associated with recurrent coronary stent thrombosis--a case report].
    Kardiologia polska, 2007, Volume: 65, Issue:7

    Topics: Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombos

2007
Clopidogrel: new indication. In combination with aspirin: marginal additional benefits.
    Prescrire international, 2007, Volume: 16, Issue:90

    Topics: Aspirin; Clinical Trials as Topic; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidi

2007
The lack of endothelization after drug-eluting stent implantation as a cause of fatal late stent thrombosis.
    Journal of thrombosis and thrombolysis, 2008, Volume: 26, Issue:2

    Topics: Angioplasty, Balloon, Coronary; Autopsy; Cardiovascular Agents; Clopidogrel; Coronary Angiography; D

2008
Relationship between microvascular resistance and perfusion in patients with reperfused acute myocardial infarction.
    Journal of interventional cardiology, 2007, Volume: 20, Issue:5

    Topics: Acute Disease; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Circulation; Coronary Stenosis;

2007
Effects of glycoprotein IIb/IIIa blockers.
    Heart (British Cardiac Society), 2007, Volume: 93, Issue:10

    Topics: Abciximab; Antibodies, Monoclonal; Clinical Trials as Topic; Clopidogrel; Humans; Immunoglobulin Fab

2007
Antiplatelet agents make a comeback in ST-elevation myocardial infarction.
    American heart journal, 2007, Volume: 154, Issue:4

    Topics: Adenosine; Antifibrinolytic Agents; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infar

2007
The impact of oral antiplatelet responsiveness on the long-term prognosis after coronary stenting.
    American heart journal, 2007, Volume: 154, Issue:4

    Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Creatine Kinase, MB Form; Drug Therapy, Combinatio

2007
Dual antiplatelet agent failure: a new syndrome or clinical nonentity?
    American heart journal, 2007, Volume: 154, Issue:4

    Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Drug Resistance; Drug Therapy, Combination; Female; Hum

2007
Clopidogrel in addition to aspirin reduces one-year major adverse cardiac and cerebrovascular events in unselected patients with non-ST segment elevation myocardial infarction.
    Acute cardiac care, 2008, Volume: 10, Issue:1

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Comorbidity; Drug Therapy, Combination;

2008
Guideline-based discharge therapy for unstable angina pectoris/non-ST elevation myocardial infarction.
    Clinical cardiology, 2007, Volume: 30, Issue:10

    Topics: Angina, Unstable; Aspirin; Clopidogrel; Electrocardiography; Humans; Hypolipidemic Agents; Myocardia

2007
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
    Journal of the American College of Cardiology, 2007, Oct-16, Volume: 50, Issue:16

    Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudde

2007
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
    Journal of the American College of Cardiology, 2007, Oct-16, Volume: 50, Issue:16

    Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudde

2007
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
    Journal of the American College of Cardiology, 2007, Oct-16, Volume: 50, Issue:16

    Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudde

2007
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
    Journal of the American College of Cardiology, 2007, Oct-16, Volume: 50, Issue:16

    Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudde

2007
Sweet and sticky: diabetic platelets, enhanced reactivity, and cardiovascular risk.
    Journal of the American College of Cardiology, 2007, Oct-16, Volume: 50, Issue:16

    Topics: Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudden, Car

2007
Temporal trends in antiplatelet/antithrombotic use in acute coronary syndromes and in-hospital major bleeding complications.
    The American journal of cardiology, 2007, Nov-01, Volume: 100, Issue:9

    Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Cardiac Catheteriza

2007
Clopidogrel and long-term outcomes after stent implantation for acute coronary syndrome.
    American heart journal, 2007, Volume: 154, Issue:5

    Topics: Blood Vessel Prosthesis Implantation; Clopidogrel; Female; Follow-Up Studies; Humans; Male; Middle A

2007
Clinical trials update from the European Society of Cardiology Congress in Vienna, 2007: PROSPECT, EVEREST, ARISE, ALOFT, FINESSE, Prague-8, CARESS in MI and ACUITY.
    Cardiovascular drugs and therapy, 2007, Volume: 21, Issue:6

    Topics: Abciximab; Acute Coronary Syndrome; Amides; Antibodies, Monoclonal; Benzazepines; Clinical Trials as

2007
Clopidogrel versus aspirin in patients with atherothrombosis: CAPRIE-based calculation of cost-effectiveness for Germany.
    Current medical research and opinion, 2008, Volume: 24, Issue:1

    Topics: Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Clopidogrel; Cohort Studies; Coronary Thrombosis;

2008
Expression of platelet surface receptors and early changes in platelet function in patients with STEMI treated with abciximab and clopidogrel versus clopidogrel alone.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2007, Volume: 7, Issue:6

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Drug Therap

2007
2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2008, Jan-01, Volume: 71, Issue:1

    Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin;

2008
Perioperative complications in patients with drug-eluting stents: a three-year audit at Geelong Hospital.
    Anaesthesia and intensive care, 2007, Volume: 35, Issue:6

    Topics: Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Humans; Intraoperative Complications; Male; M

2007
Aspirin + clopidogrel therapy: how does your care compare to the evidence?
    The Journal of family practice, 2008, Volume: 57, Issue:1

    Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination;

2008
Outcomes associated with combined antiplatelet and anticoagulant therapy.
    Chest, 2008, Volume: 133, Issue:4

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Disea

2008
Clopidogrel in addition to aspirin reduces in-hospital major cardiac and cerebrovascular events in unselected patients with acute ST segment elevation myocardial.
    Thrombosis and haemostasis, 2008, Volume: 99, Issue:1

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Cerebrovascular Disorders; Clopido

2008
Percutaneous coronary intervention without on site surgical back-up; two-years registry of a large Dutch community hospital.
    International journal of cardiology, 2009, Feb-06, Volume: 132, Issue:1

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Feasibility Studies; Female; Hospitals, Community; Huma

2009
Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome.
    JAMA, 2008, Feb-06, Volume: 299, Issue:5

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel; Cluster

2008
Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome.
    JAMA, 2008, Feb-06, Volume: 299, Issue:5

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel; Cluster

2008
Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome.
    JAMA, 2008, Feb-06, Volume: 299, Issue:5

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel; Cluster

2008
Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome.
    JAMA, 2008, Feb-06, Volume: 299, Issue:5

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel; Cluster

2008
Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome.
    JAMA, 2008, Feb-06, Volume: 299, Issue:5

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel; Cluster

2008
Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome.
    JAMA, 2008, Feb-06, Volume: 299, Issue:5

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel; Cluster

2008
Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome.
    JAMA, 2008, Feb-06, Volume: 299, Issue:5

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel; Cluster

2008
Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome.
    JAMA, 2008, Feb-06, Volume: 299, Issue:5

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel; Cluster

2008
Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome.
    JAMA, 2008, Feb-06, Volume: 299, Issue:5

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel; Cluster

2008
Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome.
    JAMA, 2008, Feb-06, Volume: 299, Issue:5

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel; Cluster

2008
Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome.
    JAMA, 2008, Feb-06, Volume: 299, Issue:5

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel; Cluster

2008
Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome.
    JAMA, 2008, Feb-06, Volume: 299, Issue:5

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel; Cluster

2008
Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome.
    JAMA, 2008, Feb-06, Volume: 299, Issue:5

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel; Cluster

2008
Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome.
    JAMA, 2008, Feb-06, Volume: 299, Issue:5

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel; Cluster

2008
Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome.
    JAMA, 2008, Feb-06, Volume: 299, Issue:5

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel; Cluster

2008
Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome.
    JAMA, 2008, Feb-06, Volume: 299, Issue:5

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel; Cluster

2008
Very late thrombosis in a bare metal stent: an under-recognized problem.
    The Canadian journal of cardiology, 2008, Volume: 24, Issue:2

    Topics: Aspirin; Clopidogrel; Coronary Angiography; Coronary Restenosis; Coronary Thrombosis; Humans; Male;

2008
Effect of clopidogrel pretreatment on angiographic and clinical outcomes in patients undergoing primary percutaneous coronary intervention for ST-elevation acute myocardial infarction.
    The American journal of cardiology, 2008, Feb-15, Volume: 101, Issue:4

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Coronary Circulation; Coronary St

2008
[Prasugrel versus clopidogrel. From the American Heart Association meeting, 2007].
    Revue medicale suisse, 2008, Feb-13, Volume: 4, Issue:144

    Topics: Clopidogrel; Congresses as Topic; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet A

2008
Glycoprotein IIb-IIIa inhibitors in the emergency department for patients with non-ST-elevation acute coronary syndromes: principles and practices.
    The Journal of emergency medicine, 2009, Volume: 36, Issue:2

    Topics: Acute Coronary Syndrome; Atherectomy; Clopidogrel; Emergency Service, Hospital; Hemorrhage; Humans;

2009
Prasugrel versus clopidogrel.
    The New England journal of medicine, 2008, Mar-20, Volume: 358, Issue:12

    Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platel

2008
Prasugrel versus clopidogrel.
    The New England journal of medicine, 2008, Mar-20, Volume: 358, Issue:12

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Hemorrhage; Humans; Myocardial

2008
Prasugrel versus clopidogrel.
    The New England journal of medicine, 2008, Mar-20, Volume: 358, Issue:12

    Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Humans; Monitoring, Physiologic; Myocardial Infarctio

2008
Monitoring the efficacy of antiplatelet therapy: all methods are equal, but some methods are more equal than others?
    American heart journal, 2008, Volume: 155, Issue:4

    Topics: Aspirin; Clopidogrel; Drug Monitoring; Drug Therapy, Combination; Humans; Myocardial Infarction; Pla

2008
Will measuring vasodilator-stimulated phosphoprotein phosphorylation help us optimize the loading dose of clopidogrel?
    Journal of the American College of Cardiology, 2008, Apr-08, Volume: 51, Issue:14

    Topics: Angioplasty, Balloon, Coronary; Cell Adhesion Molecules; Clopidogrel; Drug Resistance; Humans; Micro

2008
Acute stent thrombosis in a patient with giant cell arteritis.
    The Canadian journal of cardiology, 2008, Volume: 24, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Di

2008
Platelet activation and atherothrombosis.
    The New England journal of medicine, 2008, Apr-10, Volume: 358, Issue:15

    Topics: Acute Coronary Syndrome; Aspirin; Atherosclerosis; Clopidogrel; Drug Therapy, Combination; Humans; M

2008
[Antiplatelet treatment after acute and chronic ischemic heart and brain events is insufficient according to recommendations].
    Ugeskrift for laeger, 2008, Mar-31, Volume: 170, Issue:14

    Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Angina Pectoris; Angina, Unstable; Aspirin;

2008
What anti-thrombotic therapy is best with primary PCI for acute ST elevation myocardial infarction: how should the HORIZONS trial change current practice?
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2008, May-01, Volume: 71, Issue:6

    Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cardiovascular Diseases; Clopidogrel; Fibri

2008
Commentary for "Comparison of drug eluting stents with bare metal stents in unselected patients with acute myocardial infarction".
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2008, May-01, Volume: 71, Issue:6

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Humans; Metal

2008
Drug interaction with anti-mycobacterial treatment as a cause of clopidogrel resistance.
    Postgraduate medical journal, 2008, Volume: 84, Issue:990

    Topics: Abciximab; Aged; Antibiotics, Antitubercular; Antibodies, Monoclonal; Clopidogrel; Drug Interactions

2008
A perspective on the efficacy and safety of intensive antiplatelet therapy in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38.
    The American journal of cardiology, 2008, May-01, Volume: 101, Issue:9

    Topics: Clinical Trials, Phase III as Topic; Clopidogrel; Data Interpretation, Statistical; Dose-Response Re

2008
Excess rates of nonfatal myocardial infarction in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel (preventing clinical events or chasing enzymatic ghosts?).
    The American journal of cardiology, 2008, May-01, Volume: 101, Issue:9

    Topics: Clinical Trials, Phase III as Topic; Clopidogrel; Dose-Response Relationship, Drug; Female; Humans;

2008
Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction.
    Thrombosis research, 2008, Volume: 122, Issue:6

    Topics: Adult; Aged; Biological Availability; Clopidogrel; Electrocardiography; Female; Humans; Intestinal A

2008
Drug-eluting stent implantation for acute myocardial infarction during pregnancy with use of glycoprotein IIb/IIIa inhibitor, aspirin and clopidogrel.
    The Journal of invasive cardiology, 2008, Volume: 20, Issue:5

    Topics: Aspirin; Clopidogrel; Coronary Angiography; Drug-Eluting Stents; Electrocardiography; Female; Humans

2008
Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.
    Journal of the American College of Cardiology, 2008, May-20, Volume: 51, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 C

2008
Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.
    Journal of the American College of Cardiology, 2008, May-20, Volume: 51, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 C

2008
Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.
    Journal of the American College of Cardiology, 2008, May-20, Volume: 51, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 C

2008
Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.
    Journal of the American College of Cardiology, 2008, May-20, Volume: 51, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 C

2008
Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.
    Journal of the American College of Cardiology, 2008, May-20, Volume: 51, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 C

2008
Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.
    Journal of the American College of Cardiology, 2008, May-20, Volume: 51, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 C

2008
Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.
    Journal of the American College of Cardiology, 2008, May-20, Volume: 51, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 C

2008
Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.
    Journal of the American College of Cardiology, 2008, May-20, Volume: 51, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 C

2008
Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.
    Journal of the American College of Cardiology, 2008, May-20, Volume: 51, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 C

2008
Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.
    Journal of the American College of Cardiology, 2008, May-20, Volume: 51, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 C

2008
Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.
    Journal of the American College of Cardiology, 2008, May-20, Volume: 51, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 C

2008
Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.
    Journal of the American College of Cardiology, 2008, May-20, Volume: 51, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 C

2008
Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.
    Journal of the American College of Cardiology, 2008, May-20, Volume: 51, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 C

2008
Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.
    Journal of the American College of Cardiology, 2008, May-20, Volume: 51, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 C

2008
Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.
    Journal of the American College of Cardiology, 2008, May-20, Volume: 51, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 C

2008
Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.
    Journal of the American College of Cardiology, 2008, May-20, Volume: 51, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 C

2008
Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.
    Journal of the American College of Cardiology, 2008, May-20, Volume: 51, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 C

2008
Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.
    Journal of the American College of Cardiology, 2008, May-20, Volume: 51, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 C

2008
Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.
    Journal of the American College of Cardiology, 2008, May-20, Volume: 51, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 C

2008
Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.
    Journal of the American College of Cardiology, 2008, May-20, Volume: 51, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 C

2008
Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.
    Journal of the American College of Cardiology, 2008, May-20, Volume: 51, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 C

2008
Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.
    Journal of the American College of Cardiology, 2008, May-20, Volume: 51, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 C

2008
Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.
    Journal of the American College of Cardiology, 2008, May-20, Volume: 51, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 C

2008
Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.
    Journal of the American College of Cardiology, 2008, May-20, Volume: 51, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 C

2008
Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.
    Journal of the American College of Cardiology, 2008, May-20, Volume: 51, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 C

2008
For better or for worse: the future of antiplatelet therapy.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2008, Jun-01, Volume: 65, Issue:11

    Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Disease; Forecasting; Hemorrhage; Humans; Myocardial

2008
New horizons in cardiology.
    International journal of cardiology, 1984, Volume: 6, Issue:5

    Topics: Adult; Angina, Unstable; Anticoagulants; Coronary Disease; Coronary Vessels; Electrocardiography; Fe

1984
Antithrombotic effect of ticlopidine on occlusive thrombi of small coronary arteries in (NZWxBXSB)F1 male mice with myocardial infarction and systemic lupus erythematosus.
    Journal of cardiovascular pharmacology, 1995, Volume: 25, Issue:1

    Topics: Analysis of Variance; Animals; Antigen-Antibody Complex; Blood Urea Nitrogen; Coronary Disease; Coro

1995
An experimental myocardial infarction model in the rat and its properties.
    Japanese journal of pharmacology, 1995, Volume: 67, Issue:1

    Topics: Animals; Biphenyl Compounds; Clopidogrel; Coronary Vessels; Disease Models, Animal; Electrocardiogra

1995
Guidelines for medical treatment for stroke prevention. American College of Physicians.
    Annals of internal medicine, 1994, Jul-01, Volume: 121, Issue:1

    Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Ischemic Attack, Transient; Myocard

1994
Primary stent implantation without coumadin in acute myocardial infarction.
    Journal of the American College of Cardiology, 1996, Volume: 28, Issue:1

    Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Case-Control Studies; Coronary Angiography;

1996
CAPRIE trial.
    Lancet (London, England), 1997, Feb-01, Volume: 349, Issue:9048

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Humans; Myocardial Infarction; Peripheral Vascular Diseases; P

1997
CAPRIE trial.
    Lancet (London, England), 1997, Feb-01, Volume: 349, Issue:9048

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Humans; Myocardial Infarction; Peripheral Vascular Diseases; P

1997
Aspirin versus clopidogrel: the wrong question?
    Lancet (London, England), 1997, Mar-15, Volume: 349, Issue:9054

    Topics: Aspirin; Cerebrovascular Disorders; Clopidogrel; Humans; Ischemia; Myocardial Infarction; Platelet A

1997
Clopidogrel: a new safe and effective antiplatelet agent. But unanswered questions remain.
    The Medical journal of Australia, 1997, Aug-04, Volume: 167, Issue:3

    Topics: Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clopidogrel; Humans; Myocardial Infarction; Pl

1997
[Myocardial infarct, stroke and vascular events reduced by a third].
    Zeitschrift fur Kardiologie, 1997, Volume: 86, Issue:11 Suppl M

    Topics: Aspirin; Cerebrovascular Disorders; Clopidogrel; Humans; Myocardial Infarction; Peripheral Vascular

1997
Blocking platelets more: are we skating on thin ice?
    Heart (British Cardiac Society), 1998, Volume: 79, Issue:1

    Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Cerebrovascular Disorders; Clopidogrel; Humans; Immunogl

1998
[Acetylsalicylic acid in ischemic insult].
    Deutsche medizinische Wochenschrift (1946), 1998, Feb-27, Volume: 123, Issue:9

    Topics: Anticoagulants; Aspirin; Brain Ischemia; Drug Therapy, Combination; Humans; Myocardial Infarction; P

1998
Clinical safety and efficacy of clopidogrel--implications of the Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) study for future management of atherosclerotic disease.
    Clinical therapeutics, 1998, Volume: 20 Suppl B

    Topics: Arteriosclerosis; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Humans; Myocardial Infa

1998
Micro stent implantation in patients with acute myocardial infarction without anticoagulation: clinical experience with two different antithrombotic protocols.
    Catheterization and cardiovascular diagnosis, 1998, Volume: 44, Issue:2

    Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Blood Vessel Prosthesis Implantation; Coronary Angiograp

1998
[Wiktor coronary stent for elective placement with an antiaggregation regimen. WINE study. WINE Group Study].
    Revista espanola de cardiologia, 1998, Volume: 51, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Catheterization; Coronary Disease; Female;

1998
Aspirin and newer orally active antiplatelet agents in the treatment of the post-myocardial infarction patient.
    Journal of the American College of Cardiology, 1998, Volume: 32, Issue:4

    Topics: Administration, Oral; Aspirin; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhi

1998
Emergency coronary artery bypass grafting (CABG) after failed coronary artery intervention--caution regarding the combined use of aspirin, ticlopidine and abciximab.
    Australian and New Zealand journal of medicine, 1998, Volume: 28, Issue:4

    Topics: Abciximab; Adult; Angina Pectoris; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin;

1998
New antiplatelet agents.
    Australian and New Zealand journal of medicine, 1998, Volume: 28, Issue:4

    Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopid

1998
Coronary stenting in unstable angina: early and late clinical outcomes.
    The Canadian journal of cardiology, 1998, Volume: 14, Issue:9

    Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Bypass; Coronary Disease;

1998
The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-Q-wave myocardial infarctions.
    Journal of the American College of Cardiology, 1998, Volume: 32, Issue:5

    Topics: Blood Vessel Prosthesis Implantation; Coronary Disease; Drug Therapy, Combination; Female; Follow-Up

1998
Primary stent implantation for acute myocardial infarction during pregnancy: use of abciximab, ticlopidine, and aspirin.
    Catheterization and cardiovascular diagnosis, 1998, Volume: 45, Issue:3

    Topics: Abciximab; Adult; Antibodies, Monoclonal; Aspirin; Blood Vessel Prosthesis Implantation; Coronary An

1998
Procedural results and long-term clinical outcomes following coronary stenting in perimyocardial infarction syndromes.
    The American journal of cardiology, 1998, Nov-15, Volume: 82, Issue:10

    Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Disease-Free Survival; Female; Follow

1998
Coronary-artery stents--gauging, gorging, and gouging.
    The New England journal of medicine, 1998, Dec-03, Volume: 339, Issue:23

    Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Drug Therapy, Combination

1998
Coronary artery stent placement with postprocedural antiplatelet therapy in acute myocardial infarction.
    Coronary artery disease, 1998, Volume: 9, Issue:9

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Drug Therapy, Combination; Female; Hu

1998
[Quincke's edema during ticlopidine treatment].
    Presse medicale (Paris, France : 1983), 1999, Jan-09, Volume: 28, Issue:1

    Topics: Angioedema; Humans; Male; Middle Aged; Myocardial Infarction; Ticlopidine

1999
[Role of antiplatelet in the prevention and treatment of thrombotic diseases].
    Zhonghua nei ke za zhi, 1997, Volume: 36, Issue:5

    Topics: Aspirin; Cerebrovascular Disorders; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors;

1997
Clopidogrel: a novel antiplatelet agent.
    Hospital medicine (London, England : 1998), 1999, Volume: 60, Issue:5

    Topics: Adenosine Diphosphate; Aspirin; Clopidogrel; Humans; Ischemia; Myocardial Infarction; Platelet Aggre

1999
Effectiveness of aspirin and clopidogrel combination therapy in coronary stenting.
    The American journal of cardiology, 1999, Sep-15, Volume: 84, Issue:6

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Dise

1999
[Ticlopidine-induced cholestasis].
    Schweizerische medizinische Wochenschrift, 1999, Oct-02, Volume: 129, Issue:39

    Topics: Aged; Aged, 80 and over; Angina Pectoris; Aspirin; Chemical and Drug Induced Liver Injury; Cholestas

1999
[Creative mathematics with clopidogrel; exaggeration of the preventive effect by manufacturer].
    Nederlands tijdschrift voor geneeskunde, 1999, Dec-04, Volume: 143, Issue:49

    Topics: Advertising; Clopidogrel; Data Interpretation, Statistical; Drug Industry; Humans; Myocardial Infarc

1999
Generalizing the results of clinical trials to actual practice: the example of clopidogrel therapy for the prevention of vascular events. CAPRA (CAPRIE Actual Practice Rates Analysis) Study Group. Clopidogrel versus Aspirin in Patients at Risk of Ischaemi
    The American journal of medicine, 1999, Volume: 107, Issue:6

    Topics: Aged; Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; C

1999
Hemolytic uremic syndrome in a patient treated with clopidogrel.
    Annals of internal medicine, 2000, Jun-20, Volume: 132, Issue:12

    Topics: Aged; Clopidogrel; Hemolytic-Uremic Syndrome; Humans; Male; Myocardial Infarction; Platelet Aggregat

2000
What have We learned from ESPRIT? What will we learn from TARGET?
    The Journal of invasive cardiology, 2000, Volume: 12, Issue:6

    Topics: Abciximab; Antibodies, Monoclonal; Anticoagulants; Clopidogrel; Cohort Studies; Eptifibatide; Fibrin

2000
[ASA or clopidogrel?].
    Lakartidningen, 2000, May-31, Volume: 97, Issue:22

    Topics: Aspirin; Clopidogrel; Controlled Clinical Trials as Topic; Drug Costs; Humans; Myocardial Infarction

2000
[Clopidogrel].
    Deutsche medizinische Wochenschrift (1946), 2000, Aug-04, Volume: 125, Issue:31-32

    Topics: Arteriosclerosis; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Strok

2000
[Myocardial infarction, pregnancy and anesthesia].
    Annales francaises d'anesthesie et de reanimation, 2000, Volume: 19, Issue:7

    Topics: Adrenergic beta-Antagonists; Adult; Analgesia, Obstetrical; Analgesia, Patient-Controlled; Analgesic

2000
Flow cytometric monitoring of glycoprotein IIb/IIIa blockade and platelet function in patients with acute myocardial infarction receiving reteplase, abciximab, and ticlopidine: continuous platelet inhibition by the combination of abciximab and ticlopidine
    Circulation, 2000, Sep-26, Volume: 102, Issue:13

    Topics: Abciximab; Aged; Antibodies, Monoclonal; Blood Platelets; Female; Fibrinolytic Agents; Flow Cytometr

2000
Antiplatelet drugs in cardiovascular prevention: coronary events: acute phase and secondary prevention.
    Prescrire international, 2000, Volume: 9, Issue:47

    Topics: Angina, Unstable; Angioplasty; Anticoagulants; Aspirin; Cardiovascular Diseases; Clinical Trials as

2000
Antiplatelet drugs in cardiovascular prevention: coronary events and stroke: primary prevention.
    Prescrire international, 2000, Volume: 9, Issue:47

    Topics: Aspirin; Carotid Stenosis; Cost-Benefit Analysis; Diabetes Mellitus; Digestive System; Female; Human

2000
Isolated profound thrombocytopenia associated with clopidogrel.
    The Journal of invasive cardiology, 2000, Volume: 12, Issue:10

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Hypersensitivity; Follow-Up Studies; Humans;

2000
Decreasing mortality with primary percutaneous coronary intervention in patients with acute myocardial infarction: the Mayo Clinic experience from 1991 through 1997.
    Mayo Clinic proceedings, 2000, Volume: 75, Issue:10

    Topics: Abciximab; Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting

2000
Successful management of intractable coronary spasm with a coronary stent.
    Japanese circulation journal, 2000, Volume: 64, Issue:11

    Topics: Adult; Amlodipine; Aspirin; Calcium Channel Blockers; Cardiovascular Agents; Coronary Angiography; C

2000
[2 platelet inhibitors administered at the same time. Improved prognosis in myocardial infarct?]].
    MMW Fortschritte der Medizin, 2001, Jan-11, Volume: 143, Issue:1-2

    Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Aggregation

2001
Efficacy of heparin-coated stent in early setting of acute myocardial infarction.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2001, Volume: 52, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Coated Materials, Biocompatible; Cor

2001
Results of CURE trial for acute coronary syndrome.
    JAMA, 2001, Apr-11, Volume: 285, Issue:14

    Topics: Clopidogrel; Cost-Benefit Analysis; Humans; Myocardial Infarction; Myocardial Ischemia; Platelet Agg

2001
[Acute heart attacks. Prognosis can be further improved].
    MMW Fortschritte der Medizin, 2001, Apr-05, Volume: 143, Issue:14

    Topics: Adrenergic beta-Antagonists; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combinati

2001
[Optimal platelet inhibition therapy in unstable angina pectoris and after coronary interventions].
    Herz, 2001, Volume: 26 Suppl 1

    Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clinical Trials as Topic;

2001
CURE--clopidogrel's major advance.
    International journal of clinical practice, 2001, Volume: 55, Issue:3

    Topics: Aspirin; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; Humans; Myocardial Infarction; Plate

2001
Is ticlopidine more effective than aspirin in preventing adverse cardiovascular events after myocardial infarction (MI)?
    The Journal of family practice, 2001, Volume: 50, Issue:7

    Topics: Angina Pectoris; Aspirin; Double-Blind Method; Fibrinolytic Agents; Humans; Multicenter Studies as T

2001
Clopidogrel: new preparation. An alternative to aspirin.
    Prescrire international, 1999, Volume: 8, Issue:44

    Topics: Aspirin; Clinical Trials as Topic; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; S

1999
Late acute thrombosis after paclitaxel eluting stent implantation.
    Heart (British Cardiac Society), 2001, Volume: 86, Issue:3

    Topics: Acute Disease; Angiogenesis Inhibitors; Aspirin; Coronary Disease; Coronary Thrombosis; Drug Implant

2001
[Cost effectiveness of clopidogrel in secondary cardiovascular prevention: a cost-effectiveness analysis based on the Caprie Study].
    Praxis, 2001, Mar-29, Volume: 90, Issue:13

    Topics: Adult; Aged; Arterial Occlusive Diseases; Aspirin; Cerebral Hemorrhage; Cerebral Infarction; Clopido

2001
[Antithrombotic therapy of unstable angina pectoris].
    Duodecim; laaketieteellinen aikakauskirja, 1998, Volume: 114, Issue:15

    Topics: Angina, Unstable; Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Heparin; Humans; Myocardi

1998
Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein.
    The American journal of cardiology, 2001, Sep-15, Volume: 88, Issue:6

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; C-Reactive Protein; Clopidogrel; Female; Humans; Male

2001
Acute myocardial infarction 2000 treatment.
    Comprehensive therapy, 2001,Fall, Volume: 27, Issue:3

    Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Heparin; Humans; Myocardial In

2001
Coronary stent thrombosis: insights from the porcine coronary stent model.
    Thrombosis and haemostasis, 2001, Volume: 86, Issue:3

    Topics: Animals; Anticoagulants; Aspirin; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Coronary Vess

2001
[Clopidogrel in acute coronary syndromes with non-ST elevation. Clinical implications of the CURE trial].
    Revista espanola de cardiologia, 2001, Volume: 54, Issue:10

    Topics: Angina, Unstable; Aspirin; Clopidogrel; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Hu

2001
Case report: successful pregnancy and delivery after myocardial infarction and essential thrombocythemia treated with clopidrogel.
    Clinical and experimental obstetrics & gynecology, 2001, Volume: 28, Issue:4

    Topics: Adult; Clopidogrel; Coronary Artery Bypass; Female; Humans; Myocardial Infarction; Platelet Aggregat

2001
Clopidogrel--a myocardial infarction CURE?
    Intensive & critical care nursing, 2001, Volume: 17, Issue:6

    Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Aggregation

2001
[Massive rhabdomyolysis associated with the use of cerivastatin monotherapy].
    Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2001, Volume: 21, Issue:6

    Topics: Anticholesteremic Agents; Anuria; Clopidogrel; Coronary Artery Bypass; Humans; Hypercholesterolemia;

2001
Oral anticoagulation for acute coronary syndromes.
    Circulation, 2002, Mar-19, Volume: 105, Issue:11

    Topics: Administration, Oral; Aged; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Aspirin; Clopi

2002
The CURE trial: using clopidogrel in acute coronary syndromes without ST-segment elevation.
    Cleveland Clinic journal of medicine, 2002, Volume: 69, Issue:5

    Topics: Angina Pectoris; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Random

2002
[Risk improves effectiveness. Proper administration of platelet aggregation inhibitors].
    MMW Fortschritte der Medizin, 2002, Mar-14, Volume: 144, Issue:11

    Topics: Aspirin; Cerebral Infarction; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhib

2002
[Strategies for antiplatelet therapy-drug-fixed method and suppression-fixed method].
    Nihon rinsho. Japanese journal of clinical medicine, 1992, Volume: 50, Issue:2

    Topics: Aspirin; Cerebral Infarction; Dipyridamole; Drug Therapy, Combination; Humans; Myocardial Infarction

1992
[Antiplatelet therapy in cardiac diseases].
    Nihon rinsho. Japanese journal of clinical medicine, 1992, Volume: 50, Issue:2

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Bypass; Humans; Mitral Valve Prolapse; Myoc

1992
Ticlopidine for prevention of stroke.
    The Medical letter on drugs and therapeutics, 1992, Jul-10, Volume: 34, Issue:874

    Topics: Aspirin; Clinical Trials as Topic; Humans; Intracranial Embolism and Thrombosis; Myocardial Infarcti

1992
Effects of ticlopidine on erythrocyte aggregation in thrombotic disorders.
    Angiology, 1991, Volume: 42, Issue:9

    Topics: Aged; Diabetic Angiopathies; Dose-Response Relationship, Drug; Erythrocyte Aggregation; Female; Hexa

1991
Comparison of ticlopidine and aspirin for the prevention of stroke.
    The New England journal of medicine, 1990, Feb-08, Volume: 322, Issue:6

    Topics: Aspirin; Cerebrovascular Disorders; Cholesterol; Humans; Myocardial Infarction; Research Design; Tic

1990
Effects of exercise and ticlopidine on platelet function and prostanoids in patients with old myocardial infarction.
    Taiwan yi xue hui za zhi. Journal of the Formosan Medical Association, 1989, Volume: 88, Issue:8

    Topics: 6-Ketoprostaglandin F1 alpha; Aged; Blood Platelets; Female; Humans; Male; Middle Aged; Myocardial I

1989
[Advantages and shortcomings of platelet antiaggregants in the treatment of myocardial infarction].
    Terapevticheskii arkhiv, 1988, Volume: 60, Issue:8

    Topics: Aged; Aspirin; Drug Eruptions; Humans; Middle Aged; Myocardial Infarction; Platelet Aggregation; Pla

1988
Intracoronary thrombodynamics in the early phase of acute myocardial infarction.
    Japanese circulation journal, 1988, Volume: 52, Issue:7

    Topics: Animals; Blood Pressure; Coronary Circulation; Coronary Disease; Coronary Thrombosis; Death, Sudden;

1988
Thromboxane A2 synthesizing activity of platelets in coronary artery diseases.
    Japanese circulation journal, 1987, Volume: 51, Issue:4

    Topics: Adolescent; Adult; Aged; Angina Pectoris; Blood Platelets; Coronary Disease; Female; Humans; Male; M

1987
[Mode of action and clinical evaluation of platelet aggregation inhibitors].
    Revue medicale de Liege, 1987, May-15, Volume: 42, Issue:10

    Topics: Aspirin; Cerebrovascular Disorders; Dipyridamole; Graft Occlusion, Vascular; Humans; Ketanserin; Myo

1987